

Accuracy of clinical diagnosis of idiopathic Parkinson's
study of 100 cases.

Journal of Neurology, Neurosurgery and Psychiatry
55, 181-184

DOI: [10.1136/jnnp.55.3.181](https://doi.org/10.1136/jnnp.55.3.181)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The dopaminergic response in multiple system atrophy.. Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 1009-1013.	0.9	152
2	Hereditary Lewyâ€Body Parkinsonism and Evidence for a Genetic Etiology of Parkinson's Disease. Brain Pathology, 1992, 2, 309-320.	2.1	23
3	Lack of pyramidal tract signs in Parkinson's disease. Lancet, The, 1992, 340, 125.	6.3	3
4	Parkinson's disease: one illness or many syndromes?. Lancet, The, 1992, 339, 1263-1264.	6.3	8
5	Growth hormone response to clonidine in central and peripheral primary autonomic failure. Lancet, The, 1992, 340, 263-266.	6.3	48
6	Diffuse lewy body disease presenting with supranuclear gaze palsy, parkinsonism, and dementia: A case report. Movement Disorders, 1992, 7, 355-358.	2.2	73
7	Letters to the Editor. Movement Disorders, 1992, 7, 387-391.	2.2	11
8	The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it. Annals of Neurology, 1992, 32, 804-812.	2.8	876
10	The detection of preclinical Parkinson's disease: What is the role of positron emission tomography?. Movement Disorders, 1993, 8, 271-277.	2.2	44
11	Striatonigral degeneration with neurofibrillary tangles. Acta Neuropathologica, 1993, 86, 405-410.	3.9	9
12	Current Approaches in the Treatment of Parkinson's Disease. Annual Review of Medicine, 1993, 44, 431-440.	5.0	18
13	Selective anosmia in Parkinson's disease?. Lancet, The, 1993, 341, 435-436.	6.3	74
14	Functional imaging in relation to parkinsonian syndromes. Journal of the Neurological Sciences, 1993, 115, 1-17.	0.3	92
15	A Clinicopathologic Study of 100 Cases of Parkinson's Disease. Archives of Neurology, 1993, 50, 140-148.	4.9	881
16	Possible Time-dependent Sensitization to Xenobiotics: Self-reported Illness from Chemical Odors, Foods, and Opiate Drugs in an Older Adult Population. Archives of Environmental Health, 1993, 48, 315-327.	0.4	51
17	Accuracy of clinical diagnosis of idiopathic Parkinson's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 938-939.	0.9	54
18	Environmental Causation of Parkinson's Disease. Archives of Neurology, 1993, 50, 651-652.	4.9	16
20	Herpes simplex encephalitis in a patient with complex partial epilepsy: confirmation by the polymerase chain reaction with necropsy studies.. Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 937-938.	0.9	2

#	ARTICLE	IF	CITATIONS
21	Significance of Parkinsonian Manifestations in Essential Tremor. Canadian Journal of Neurological Sciences, 1993, 20, 114-117.	0.3	124
22	Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data.. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 278-284.	0.9	160
23	HMPAO SPECT in Parkinson's disease before and after levodopa: correlation with dopaminergic responsiveness.. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 180-185.	0.9	32
24	Parkinson's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 672-681.	0.9	335
25	Therapy of Patients With Parkinson's Disease. Archives of Neurology, 1994, 51, 754-756.	4.9	0
26	Motor response to levodopa in patients with parkinsonian motor fluctuations: a follow-up study over three years.. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 430-434.	0.9	37
27	Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study.. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 217-220.	0.9	58
28	Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT.. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 1047-1056.	0.9	198
29	Signs of Madness: Towards a Cognitive Account of the Clinical Features of Schizophrenia. Quarterly Journal of Experimental Psychology Section A: Human Experimental Psychology, 1994, 47, 497-516.	2.3	2
30	Genetic factors in the etiology of idiopathic Parkinson's disease. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1994, 8, 1-37.	1.2	36
31	Cerebrospinal fluid ferritin levels of patients with Parkinson's disease, Alzheimer's disease, and multiple system atrophy. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1994, 7, 109-114.	1.2	41
32	Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease. Acta Neuropathologica, 1994, 87, 269-276.	3.9	138
33	Hypokinesia of associated movement in Parkinson's disease: A symptom in early stages of the disease. Journal of Neurology, 1994, 241, 517-521.	1.8	17
34	Early onset Parkinson's disease: Are juvenile- and young-onset different?. Movement Disorders, 1994, 9, 539-544.	2.2	44
35	What is it? Case 2, 1994: Parkinsonism and cognitive impairment. Movement Disorders, 1994, 9, 679-686.	2.2	3
36	Comparison of clinical state, retrospective informant interview and the neuropathologic diagnosis of alzheimer's disease. International Journal of Geriatric Psychiatry, 1994, 9, 233-236.	1.3	33
37	Autosomal dominant Lewy body parkinsonism in a four-generation family. Annals of Neurology, 1994, 35, 59-64.	2.8	163
38	Alzheimer's disease and Lewy body disease: A comparative clinicopathological study. Annals of Neurology, 1994, 35, 81-88.	2.8	162

#	ARTICLE	IF	CITATIONS
39	Oxidative stress: Free radical production in neural degeneration. , 1994, 63, 37-122.		454
40	Diagnosis and treatment of parkinsonâ€™s disease in the elderly. Journal of General Internal Medicine, 1994, 9, 583-589.	1.3	5
41	Striatal, Accumbent, and Nigral Degeneration with Rosenthal Fibers, Presenting as Shy-Drager Syndrome. Neuropathology, 1994, 14, 67-71.	0.7	0
42	Platelet morphology in Parkinson's disease: An electron microscopic study. Journal of the Neurological Sciences, 1994, 122, 84-89.	0.3	20
43	Positron emission tomography and central neurotransmitter systems in movement disorders. Fundamental and Clinical Pharmacology, 1994, 8, 503-517.	1.0	8
44	Stability of cell size and nucleolar size in Lewy body containing neurons of substantia nigra in Parkinson's disease. Brain Research, 1994, 637, 339-341.	1.1	47
45	Striatonigral Degeneration: Iron Deposition in Putamen Correlates with the Slit-like Void Signal of Magnetic Resonance Imaging. Canadian Journal of Neurological Sciences, 1994, 21, 311-318.	0.3	61
46	Positron emission tomography: applications to the investigation of movement disorders. European Journal of Clinical Investigation, 1994, 24, 433-440.	1.7	0
47	Magnetic Resonance Imaging of Neurodegenerative Diseases. Journal of Neuroimaging, 1994, 4, 146-158.	1.0	16
48	Autonomic Failure, Depression and Anxiety in Parkinson's Disease. British Journal of Psychiatry, 1995, 166, 789-792.	1.7	65
49	The Results, Indications, and Physiology of Posteroventral Pallidotomy for Patients with Parkinson's Disease. Neurosurgery, 1995, 36, 1118-1127.	0.6	222
50	Apolipoprotein E genotype and Lewy body disease. Neurology, 1995, 45, 97-103.	1.5	92
51	Familial progressive supranuclear palsy. Brain, 1995, 118, 1095-1103.	3.7	98
52	Olfactory function in atypical parkinsonian syndromes. Acta Neurologica Scandinavica, 1995, 91, 247-250.	1.0	224
53	A prospective study of depression in French patients with Parkinson's disease. The Depar study. European Journal of Neurology, 1995, 2, 455-461.	1.7	4
54	Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Annals of Neurology, 1995, 37, 204-210.	2.8	171
55	Concentrations of amyloid ? protein in cerebrospinal fluid of patients with alzheimer's disease. Annals of Neurology, 1995, 37, 277-279.	2.8	87
56	The subacute levodopa test for evaluating long-duration response in parkinson's disease. Annals of Neurology, 1995, 38, 389-395.	2.8	60

#	ARTICLE	IF	CITATIONS
57	Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease. <i>Movement Disorders</i> , 1995, 10, 163-170.	2.2	21
58	Patterns of regional cerebral blood flow in corticobasal degeneration studied using HMPAO SPECT; comparison with Parkinson's disease and normal controls. <i>Movement Disorders</i> , 1995, 10, 179-187.	2.2	100
59	Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. <i>Movement Disorders</i> , 1995, 10, 250-256.	2.2	74
60	Screening Parkinson's disease: A validated questionnaire of high specificity and sensitivity. <i>Movement Disorders</i> , 1995, 10, 643-649.	2.2	74
61	Parkinsonism and dilatation of the perivascular spaces (Å%otat CriblÅ©) of the striatum: A clinical, magnetic resonance imaging, and pathological study. <i>Movement Disorders</i> , 1995, 10, 754-760.	2.2	38
62	Localized proton NMR spectroscopy in the striatum of patients with idiopathic parkinson's disease: a multicenter pilot study. <i>Magnetic Resonance in Medicine</i> , 1995, 33, 589-594.	1.9	91
63	Parkinson's disease â€” medical education and psychosocial aspects. <i>Patient Education and Counseling</i> , 1995, 26, 71-79.	1.0	31
64	CSF somatostatin increase in patients with early parkinsonian syndrome. <i>Journal of Neural Transmission Parkinson's Disease and Dementia Section</i> , 1995, 9, 189-196.	1.2	10
65	Progression of motor and cognitive impairment in Parkinson's disease. <i>Journal of Neurology</i> , 1995, 242, 535-540.	1.8	23
66	The classification and nomenclature of autonomic disorders â€” ending chaos, resolving conflict and hopefully achieving clarity. <i>Clinical Autonomic Research</i> , 1995, 5, 307-310.	1.4	44
68	Magnetic resonance spectroscopic study of parkinsonism related to boxing.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1995, 58, 688-691.	0.9	51
69	The impact of genetic and environmental factors on the pathobiology of Alzheimer's disease: a multifactorial disorder?. <i>International Review of Psychiatry</i> , 1995, 7, 361-383.	1.4	3
70	The Frequency and Associated Risk Factors for Dementia in Patients With Parkinson's Disease. <i>Archives of Neurology</i> , 1995, 52, 695-701.	4.9	268
71	Which factors predict cognitive decline in Parkinson's disease?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1995, 58, 51-55.	0.9	59
72	Clinicopathological study of 35 cases of multiple system atrophy.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1995, 58, 160-166.	0.9	229
73	Magnetic resonance spectroscopic study of parkinsonism related to boxing.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1995, 59, 561-562.	0.9	5
74	The relation between bradykinesia and excitability of the motor cortex assessed using transcranial magnetic stimulation in normal and parkinsonian subjects. <i>Electroencephalography and Clinical Neurophysiology - Electromyography and Motor Control</i> , 1995, 97, 169-178.	1.4	50
75	Is there a genetic susceptibility to idiopathic parkinsonism?. <i>Parkinsonism and Related Disorders</i> , 1995, 1, 73-84.	1.1	8

#	ARTICLE	IF	CITATIONS
76	Apomorphine in patients with Parkinson's disease. <i>Biomedicine and Pharmacotherapy</i> , 1995, 49, 197-209.	2.5	39
77	Contingent negative variation and movement-related cortical potentials in parkinsonism. <i>Electroencephalography and Clinical Neurophysiology</i> , 1995, 95, 346-349.	0.3	51
78	Concurrence of Alzheimer's disease, Parkinson's disease, diffuse Lewy body disease, and amyotrophic lateral sclerosis. <i>Journal of the Neurological Sciences</i> , 1995, 128, 219-224.	0.3	31
79	Levodopa-induced local cerebral blood flow changes in Parkinson's disease and related disorders. <i>Journal of the Neurological Sciences</i> , 1995, 128, 212-218.	0.3	36
80	Parkinson's disease and the environment in early life. <i>Journal of the Neurological Sciences</i> , 1995, 132, 201-206.	0.3	64
81	A clinical and genetic study of familial cases of Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 1995, 133, 164-172.	0.3	30
82	“Lewy body disease”: clinico-pathological correlations in 18 consecutive cases of Parkinson's disease with and without dementia. <i>Clinical Neurology and Neurosurgery</i> , 1995, 97, 13-22.	0.6	75
83	Movement-related potential measures of different modes of movement selection in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 1996, 140, 67-74.	0.3	25
84	The GTP-cyclohydrolase I gene in atypical Parkinsonian patients: a clinico-genetic study. <i>Journal of the Neurological Sciences</i> , 1996, 141, 27-32.	0.3	23
85	Prevalence of Parkinsonian Signs and Associated Mortality in a Community Population of Older People. <i>New England Journal of Medicine</i> , 1996, 334, 71-76.	13.9	607
86	Lewy bodies are located preferentially in limbic areas in diffuse Lewy body disease. <i>Neuroscience Letters</i> , 1996, 212, 111-114.	1.0	68
87	The human homologue of the weaver mouse gene in familial and sporadic Parkinson's disease. <i>Neuroscience</i> , 1996, 72, 877-879.	1.1	23
88	Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community. <i>Journal of Clinical Epidemiology</i> , 1996, 49, 637-641.	2.4	89
89	Proton magnetic resonance spectroscopy of the striatum in Parkinson's disease patients with motor response fluctuations. <i>Parkinsonism and Related Disorders</i> , 1996, 2, 63-67.	1.1	17
90	Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease. <i>Journal of Clinical Neuroscience</i> , 1996, 3, 52-60.	0.8	93
91	The significance of cortical pathology in progressive supranuclear palsy: Clinico-pathological data in 10 cases. <i>Brain</i> , 1996, 119, 1123-1136.	3.7	116
93	Parkinson's Disease. <i>Journal of Neurosurgery</i> , 1996, 85, 528-9.	0.9	0
94	Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. <i>Clinical Autonomic Research</i> , 1996, 6, 125-126.	1.4	322

#	ARTICLE	IF	CITATIONS
95	Progressive supranuclear palsy: a clinicopathological study of 21 cases. <i>Acta Neuropathologica</i> , 1996, 91, 427-431.	3.9	78
96	Comparison of cerebral atrophy evaluated by MRI in Parkinson's disease and multiple system atrophy. <i>European Journal of Neurology</i> , 1996, 3, 429-437.	1.7	0
97	Prevalence of a history of shaking in persons 65 years of age and older: Diagnostic and functional correlates. <i>Movement Disorders</i> , 1996, 11, 63-69.	2.2	70
98	Reliability of patient completion of the historical section of the unified Parkinson's disease rating scale. <i>Movement Disorders</i> , 1996, 11, 185-192.	2.2	72
99	Occupation, education, and Parkinson's disease: A case-control study in an Italian population. <i>Movement Disorders</i> , 1996, 11, 201-206.	2.2	43
100	Clinical course of patients with idiopathic Parkinson's disease. <i>Movement Disorders</i> , 1996, 11, 236-242.	2.2	93
101	Basal ganglia iron content in Parkinson's disease measured with magnetic resonance. <i>Movement Disorders</i> , 1996, 11, 243-249.	2.2	85
102	Sympathetic skin response and R-R interval variability in multiple system atrophy and idiopathic Parkinson's disease. <i>Movement Disorders</i> , 1996, 11, 268-272.	2.2	57
103	What is it? case 1, 1996: Rapidly progressive parkinsonism, incontinence, impotency, and levodopa-induced moaning in a patient with multiple myeloma. <i>Movement Disorders</i> , 1996, 11, 298-310.	2.2	18
104	Quantitative gait analysis in patients with vascular parkinsonism. <i>Movement Disorders</i> , 1996, 11, 501-508.	2.2	67
105	Dietary lipids and antioxidants in Parkinson's disease: A population-based, case-control study. <i>Annals of Neurology</i> , 1996, 39, 89-94.	2.8	263
106	Dynamic properties of horizontal and vertical eye movements in parkinsonian syndromes. <i>Annals of Neurology</i> , 1996, 39, 368-377.	2.8	182
107	Abnormalities of smooth eye and head movement control in parkinson's disease. <i>Annals of Neurology</i> , 1996, 39, 749-760.	2.8	61
108	Serotonin and the extrapyramidal system ? a neurological perspective. <i>Human Psychopharmacology</i> , 1996, 11, S95-S102.	0.7	6
109	Mitochondrial NADH dehydrogenase and CYP2D6 genotypes in Lewy-body Parkinsonism. <i>Journal of Neuroscience Research</i> , 1996, 44, 174-183.	1.3	41
110	Tremor and voluntary repetitive movement in Parkinson's disease: comparison before and after l-dopa with positron emission tomography. <i>Experimental Brain Research</i> , 1996, 107, 453-62.	0.7	32
111	Patient Characteristics, MRI Examination, and Dopaminergic Drug Response in Clinical Possible Parkinson's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1996, 9, 157-163.	1.2	1
112	Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996, 60, 634-637.	0.9	78

#	ARTICLE	IF	CITATIONS
113	Effects of Intravenous L-Dopa on P300 and Regional Cerebral Blood Flow in Parkinsonism. <i>International Journal of Neuroscience</i> , 1996, 85, 147-154.	0.8	27
114	Frequency of the apolipoprotein E epsilon 4 allele in a case-control study of early onset Parkinson's disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996, 61, 347-351.	0.9	35
115	A 61-Year-Old Man With Parkinson's Disease. <i>JAMA - Journal of the American Medical Association</i> , 1996, 275, 716.	3.8	6
116	Neuropsychological and psychiatric differences between Alzheimer's disease and Parkinson's disease with dementia.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996, 61, 381-387.	0.9	70
117	How far are we in understanding the cause of Parkinson's disease?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996, 61, 4-16.	0.9	63
118	Tachykinins, Neurotrophism and Neurodegenerative Diseases: A Critical Review on the Possible Role of Tachykinins in the Aetiology of CNS Diseases. <i>Reviews in the Neurosciences</i> , 1996, 7, 187-214.	1.4	30
119	Movement preparation in Parkinson's disease Time course and distribution of movement-related potentials in a movement precueing task. <i>Brain</i> , 1996, 119, 1689-1704.	3.7	66
120	Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. <i>Brain</i> , 1997, 120, 2187-2195.	3.7	209
121	Olfactory dysfunction in Parkinson's disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997, 62, 436-446.	0.9	327
122	Parkinson's disease.. <i>Postgraduate Medical Journal</i> , 1997, 73, 257-264.	0.9	16
123	Smoking and Parkinson's disease: a case-control study in Germany. <i>International Journal of Epidemiology</i> , 1997, 26, 328-339.	0.9	74
124	Motor and cognitive function in Lewy body dementia: comparison with Alzheimer's and Parkinson's diseases.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997, 62, 243-252.	0.9	185
125	Prevalence of orthostatic hypotension in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997, 63, 584-589.	0.9	306
127	Disturbed striatoprefrontal mediated visual behaviour in moderate to severe parkinsonian patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997, 63, 296-299.	0.9	46
128	Genetics of Parkinson's disease. <i>Human Molecular Genetics</i> , 1997, 6, 1687-1691.	1.4	128
129	Mortality From Parkinson Disease. <i>Archives of Neurology</i> , 1997, 54, 260-264.	4.9	155
130	Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. <i>Brain</i> , 1997, 120, 1541-1552.	3.7	132
131	What Is the Accuracy of the Clinical Diagnosis of Multiple System Atrophy?. <i>Archives of Neurology</i> , 1997, 54, 937.	4.9	222

#	ARTICLE	IF	CITATIONS
132	P3 Latency Change in Aging and Parkinson Disease. Archives of Neurology, 1997, 54, 296-302.	4.9	33
133	Transient Worsening of Parkinson's Disease after Cigarette Smoking.. Internal Medicine, 1997, 36, 651-653.	0.3	8
134	Measurement environment for diagnosing the Parkinson's disease. , 0, , .		0
135	Electrophysiological analysis of cognitive slowing in Parkinson's disease. Journal of the Neurological Sciences, 1997, 149, 47-56.	0.3	43
136	Dementia with Lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon mission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 609-614.	2.2	55
137	PARKINSON'S DISEASE. Psychiatric Clinics of North America, 1997, 20, 769-790.	0.7	33
138	Cognitive Functions in Major Depression and Parkinson Disease. Archives of Neurology, 1997, 54, 982-986.	4.9	138
139	Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment. Parkinsonism and Related Disorders, 1997, 3, 103-107.	1.1	58
140	Point of view: Dementia in Parkinson's disease. Parkinsonism and Related Disorders, 1997, 3, 151-158.	1.1	16
141	Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet, The, 1997, 350, 1136-1139.	6.3	121
142	Identification of Spanish familial Parkinson's disease and screening for the Ala53Thr mutation of the α -synuclein gene in early onset patients. Neuroscience Letters, 1997, 235, 57-60.	1.0	66
143	Lewy bodies and progressive dementia: A critical review and meta-analysis. Journal of the International Neuropsychological Society, 1997, 3, 179-194.	1.2	42
144	Learning manual pursuit tracking skills in patients with Parkinson's disease. Brain, 1997, 120, 1325-1337.	3.7	91
145	Association of the mitochondrial tRNA ^{A4336G} mutation with Alzheimer's and Parkinson's diseases. Neuropathology and Applied Neurobiology, 1997, 23, 315-321.	1.8	75
146	SPECT findings in Alzheimer's disease and Parkinson's disease with dementia. European Journal of Neurology, 1997, 4, 231-236.	1.7	0
147	Is the SF-36 health survey questionnaire suitable as a self-report measure of the health status of older adults with Parkinson's disease?. Quality of Life Research, 1997, 6, 0-0.	1.5	34
148	A dynamic model of motor basal ganglia functions. Biological Cybernetics, 1997, 76, 451-458.	0.6	16
149	Mitochondrial DNA polymorphisms in pathologically proven Parkinson's disease. Journal of Neurology, 1997, 244, 262-265.	1.8	50

#	ARTICLE	IF	CITATIONS
150	A 99m Tc-HMPAO single-photon emission computed tomography study of Lewy body disease. Journal of Neurology, 1997, 244, 349-359.	1.8	47
152	Is seborrhea a sign of autonomic impairment in Parkinson's disease?. Journal of Neural Transmission, 1997, 104, 1295-1304.	1.4	48
153	Psychoses: Diagnosis and treatment in the elderly. New Directions for Mental Health Services, 1997, 24, 53-70.	0.4	5
154	Is there a genetic susceptibility locus for Parkinson's disease on chromosome 22q13?. Annals of Neurology, 1997, 41, 813-817.	2.8	32
155	Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease. Movement Disorders, 1997, 12, 103-106.	2.2	46
156	Prevalence of Parkinson's disease in JunÃn, Buenos Aires province, Argentina. Movement Disorders, 1997, 12, 197-205.	2.2	77
157	Clinical and pharmacological differences in early- versus late-onset Parkinson's disease. Movement Disorders, 1997, 12, 277-284.	2.2	65
158	Dopa-responsive, nonprogressive, juvenile parkinsonism: Report of a case. Movement Disorders, 1997, 12, 453-456.	2.2	8
159	Sleep benefit in parkinson's disease. Movement Disorders, 1997, 12, 506-508.	2.2	77
160	The 476C>T common deletion is not increased in parkinsonian substantia nigra as shown by competitive polymerase chain reaction. Movement Disorders, 1997, 12, 639-645.	2.2	21
161	Proton magnetic resonance spectroscopy in Steele-Richardson-Olszewski syndrome. Movement Disorders, 1997, 12, 767-771.	2.2	88
162	Postprandial hypotension and parkinsonian state in parkinson's disease. Movement Disorders, 1997, 12, 877-884.	2.2	55
163	Unilateral parkinsonism following a large infarct in the territory of the lenticulostriate arteries. Movement Disorders, 1997, 12, 1086-1090.	2.2	34
164	Apolipoprotein E genotyping in patients with neurodegenerative diseases. Clinical Biochemistry, 1997, 30, 405-411.	0.8	5
165	Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. Clinical Pharmacology and Therapeutics, 1998, 64, 183-191.	2.3	41
166	Ala50Pro mutation in the gene encoding α -synuclein in Parkinson's disease. Nature Genetics, 1998, 18, 106-108.	9.4	3,711
167	Olfactory Evoked Responses and Identification Tests in Neurological Disease. Annals of the New York Academy of Sciences, 1998, 855, 608-615.	1.8	85
168	Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients. Acta Neurologica Scandinavica, 1998, 97, 295-299.	1.0	41

#	ARTICLE	IF	CITATIONS
169	EEG findings in patients with vascular parkinsonism. <i>Acta Neurologica Scandinavica</i> , 1998, 98, 243-247.	1.0	18
170	Early detection of Parkinson's disease through automatic movement evaluation. <i>IEEE Engineering in Medicine and Biology Magazine</i> , 1998, 17, 81-88.	1.1	16
171	Genetic dissection of familial Parkinson's disease. <i>Trends in Molecular Medicine</i> , 1998, 4, 438-444.	2.6	25
172	The role of spectroscopy in parkinsonism. <i>Movement Disorders</i> , 1998, 13, 2-4.	2.2	1,335
173	Depression in classic versus akinetic-rigid Parkinson's disease. <i>Movement Disorders</i> , 1998, 13, 29-33.	2.2	204
174	Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study. <i>Movement Disorders</i> , 1998, 13, 39-45.	2.2	262
175	Genetic aspects of Parkinson's disease. <i>Movement Disorders</i> , 1998, 13, 203-211.	2.2	38
176	Late components of the event-related potentials and their topography in Parkinson's disease. <i>Movement Disorders</i> , 1998, 13, 262-267.	2.2	28
177	Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. <i>Movement Disorders</i> , 1998, 13, 268-274.	2.2	105
178	¹²³ I-Î²-CIT and ¹²³ I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease. <i>Movement Disorders</i> , 1998, 13, 438-445.	2.2	48
179	Do visual-evoked potentials and spatiotemporal contrast sensitivity help to distinguish idiopathic Parkinson's disease and multiple system atrophy?. <i>Movement Disorders</i> , 1998, 13, 446-452.	2.2	26
180	Confirmation of the antidyskinetic effect of posteroventral pallidotomy by means of an intraoperative apomorphine test. <i>Movement Disorders</i> , 1998, 13, 533-535.	2.2	6
181	Normal frontal perfusion in patients with frozen gait. <i>Movement Disorders</i> , 1998, 13, 677-683.	2.2	38
182	Parkinsonism with HIV infection. <i>Movement Disorders</i> , 1998, 13, 684-689.	2.2	143
183	An akinetic-rigid syndrome, depression, and stereotypies in a young man. <i>Movement Disorders</i> , 1998, 13, 835-844.	2.2	6
184	Apolipoprotein E Îµ4 allele and progression of cortical Lewy body pathology in Parkinson's disease. <i>Acta Neuropathologica</i> , 1998, 95, 450-454.	3.9	38
185	Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease. <i>Acta Neuropathologica</i> , 1998, 95, 576-582.	3.9	121
186	The genetics of Parkinson's disease and parkinsonian syndromes. <i>Journal of Neurology</i> , 1998, 245, 625-633.	1.8	10

#	ARTICLE	IF	CITATIONS
187	Novel mutations of mitochondrial complex I in pathologically proven Parkinson disease. <i>Neurogenetics</i> , 1998, 1, 197-204.	0.7	76
188	Simplified neuropathological diagnosis of dementia with Lewy bodies. <i>Neuropathology and Applied Neurobiology</i> , 1998, 24, 195-201.	1.8	38
189	Analysis of the α -synuclein G209A mutation in familial Parkinson's disease. <i>Lancet, The</i> , 1998, 351, 37-38.	6.3	55
190	Methodological and Research Issues in the Evaluation of Biological Diagnostic Markers for Alzheimer's Disease. <i>Neurobiology of Aging</i> , 1998, 19, 121-123.	1.5	7
191	Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease. <i>Movement Disorders</i> , 1998, 13, 70-77.	2.2	137
192	Movement quality of repetitive self-paced single joint rapid arm movements on Parkinson's disease: acute effect of 1-dopa. <i>Parkinsonism and Related Disorders</i> , 1998, 4, 31-37.	1.1	4
193	BRIEF COMMUNICATION Mutation in the α -Synuclein Gene and Sporadic Parkinson's Disease, Alzheimer's Disease, and Dementia with Lewy Bodies. <i>Experimental Neurology</i> , 1998, 153, 164-166.	2.0	27
194	Genetic and environmental risk factors in Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 1998, 100, 15-26.	0.6	72
195	Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. <i>Journal of the Neurological Sciences</i> , 1998, 155, 60-67.	0.3	246
196	Clinical Pharmacology of Dopamine Agonists in Parkinson's Disease. <i>Drugs and Aging</i> , 1998, 13, 381-389.	1.3	25
197	Utility of the Apolipoprotein E Genotype in the Diagnosis of Alzheimer's Disease. <i>New England Journal of Medicine</i> , 1998, 338, 506-511.	13.9	530
198	Genetic Epidemiology of Parkinson's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1998, 11, 98-106.	1.2	38
199	Levodopa responsive parkinsonism in an adult with Huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1998, 65, 577-579.	0.9	52
200	Parkinsonian Features. <i>JAMA - Journal of the American Medical Association</i> , 1998, 280, 1654.	3.8	19
201	Verbal Fluency Task Affects Gait in Parkinson's Disease with Motor Freezing. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1998, 11, 181-185.	1.2	129
202	Clinical and Genetic Aspects of Progressive Supranuclear Palsy. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1998, 11, 107-114.	1.2	30
203	Neuropsychological prediction of dementia in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1998, 64, 178-183.	0.9	183
204	Cognitive Impairment Without Dementia in Parkinson's Disease. <i>Advances in Behavioral Biology</i> , 1998, , 343-350.	0.2	0

#	ARTICLE	IF	CITATIONS
205	Accuracy of the Clinical Diagnoses of Lewy Body Disease, Parkinson Disease, and Dementia With Lewy Bodies. Archives of Neurology, 1998, 55, 969.	4.9	325
206	Diagnosis and Epidemiology of Parkinson's Disease. CNS Spectrums, 1998, 3, 23-35.	0.7	1
207	Chapter 22 A new approach to the genetic analysis of nervous system diseases: Retrospective genotyping of archival brains. Progress in Brain Research, 1998, 117, 307-313.	0.9	1
208	A Review of Lewy Body Disease, an Emerging Concept of Cortical Dementia. Journal of Neuropsychiatry and Clinical Neurosciences, 1998, 10, 267-279.	0.9	58
209	Reliance on external cues for movement initiation in Parkinson's disease. Evidence from movement-related potentials. Brain, 1998, 121, 167-177.	3.7	163
210	Continuous Spinal Anesthesia for Hip Surgery in a Patient with Shy-Drager Syndrome. Anesthesia and Analgesia, 1998, 87, 396-399.	1.1	12
211	Continuous Spinal Anesthesia for Hip Surgery in a Patient with Shy-Drager Syndrome. Anesthesia and Analgesia, 1998, 87, 396-399.	1.1	12
212	Increased Basal Ganglia Iron in Striatonigral Degeneration: <i>In Vivo</i> Estimation with Magnetic Resonance. Canadian Journal of Neurological Sciences, 1998, 25, 44-47.	0.3	30
213	Cognitive Dysfunction and Impaired Organization of Complex Motility in Degenerative Parkinsonian Syndromes. Archives of Neurology, 1998, 55, 372.	4.9	73
214	Neuropathology of Movement Disorders. Neurosurgery Clinics of North America, 1998, 9, 237-262.	0.8	24
215	Targeted Expression of a Toxin Gene to D1 Dopamine Receptor Neurons by Cre-Mediated Site-Specific Recombination. Journal of Neuroscience, 1998, 18, 9845-9857.	1.7	63
216	Prospective comparative study of the evolution of probable Alzheimer's disease and Parkinson's disease dementia. Journal of the International Neuropsychological Society, 1998, 4, 279-284.	1.2	24
217	Etiology of parkinsonism in a Brazilian movement disorders clinic. Arquivos De Neuro-Psiquiatria, 1998, 56, 171-175.	0.3	30
218	Genetics, drugs and environmental factors in Parkinson's disease: a case-control study. Arquivos De Neuro-Psiquiatria, 1999, 57, 347-355.	0.3	39
219	The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson's disease by use of the CAMCOG neuropsychological test. Age and Ageing, 1999, 28, 39-43.	0.7	79
220	Measuring the impact of Parkinson's disease with the Parkinson's Disease Quality of Life questionnaire. Age and Ageing, 1999, 28, 341-346.	0.7	133
221	Mechanisms underlying gait disturbance in Parkinson's disease. Brain, 1999, 122, 1271-1282.	3.7	266
222	Improvement of levodopa induced dyskinesias by thalamic deep brain stimulation is related to slight variation in electrode placement: possible involvement of the centre median and parafascicularis complex. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 308-314.	0.9	109

#	ARTICLE	IF	CITATIONS
223	Progression of Parkinsonian Signs in Parkinson Disease. Archives of Neurology, 1999, 56, 334.	4.9	195
224	Evidence for cortical dysfunction in clinically non-demented patients with Parkinson's disease: a proton MR spectroscopy study. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 20-26.	0.9	59
225	Effect of interstimulus interval on visual P300 in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 497-503.	0.9	25
226	Affective symptoms in multiple system atrophy and Parkinson's disease: response to levodopa therapy. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 66, 541-544.	0.9	81
227	¹ H-MRS evidence of neurodegeneration and excess glutamate glutamine in ALS medulla. Neurology, 1999, 53, 71-71.	1.5	123
228	Dopamine D ₂ receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology, 1999, 53, 1425-1425.	1.5	116
229	The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 300-307.	0.9	309
230	PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson's disease. Neurology, 1999, 52, 1221-1221.	1.5	55
231	Clinical Correlates of Vascular Parkinsonism. Archives of Neurology, 1999, 56, 98.	4.9	278
232	Historical and Clinical Features of Psychogenic Tremor: a Review of 70 Cases. Canadian Journal of Neurological Sciences, 1999, 26, 190-195.	0.3	99
233	Differential Diagnosis of Parkinsonism. Canadian Journal of Neurological Sciences, 1999, 26, S1-S4.	0.3	7
234	Proprioceptive regulation of voluntary ankle movements, demonstrated using muscle vibration, is impaired by Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 504-510.	0.9	78
235	Impairment of EEG desynchronisation before and during movement and its relation to bradykinesia in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 66, 442-446.	0.9	53
236	A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. Neurology, 1999, 53, 1415-1415.	1.5	112
237	No Mutation of G209A in the Alpha-Synuclein Gene in Sporadic Parkinson's Disease among Taiwan Chinese. European Neurology, 1999, 41, 85-87.	0.6	19
238	¹²³ I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 189-194.	0.9	318
239	Progressive supranuclear palsy (Steele-Richardson-Olszewski disease). Postgraduate Medical Journal, 1999, 75, 579-584.	0.9	35
240	Accuracy of diagnosis in patients with presumed Parkinson's disease. Age and Ageing, 1999, 28, 99-102.	0.7	224

#	ARTICLE	IF	CITATIONS
241	SPECT imaging of pre- and postsynaptic dopaminergic alterations in <scp>l</scp> -dopaâ€™untreated PD. <i>Neurology</i> , 1999, 52, 1206-1206.	1.5	102
242	Re-emergent tremor of Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999, 67, 646-650.	0.9	256
243	Acute and chronic effects of anteromedial globus pallidus stimulation in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999, 67, 315-322.	0.9	37
244	Silver staining method for demonstrating Lewy bodies in Parkinsonâ€™s disease and argyrophilic oligodendrocytes in multiple system atrophy. <i>Journal of Neuroscience Methods</i> , 1999, 87, 111-115.	1.3	33
245	MRI evaluation of brain iron in earlier- and later-onset Parkinsonâ€™s disease and normal subjects. <i>Magnetic Resonance Imaging</i> , 1999, 17, 213-222.	1.0	196
246	Mitochondrial myopathies and encephalomyopathies. <i>European Journal of Clinical Investigation</i> , 1999, 29, 886-898.	1.7	36
247	Fluorodopa uptake and glucose metabolism in early stages of corticobasal degeneration. <i>Journal of Neurology</i> , 1999, 246, 1151-1158.	1.8	74
248	Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 171-182.	3.3	149
249	Exercise test in Parkinson's disease. <i>Clinical Autonomic Research</i> , 1999, 9, 129-134.	1.4	27
250	Contribution of Neurophysiological Guidance to Stereotactic Posteroventral Pallidotomy for Parkinson's Disease. <i>Acta Neurochirurgica</i> , 1999, 141, 1195-1201.	0.9	7
251	Clinical parkinsonism in dementia patients with substantia nigra Lewy bodies. <i>Journal of Neural Transmission</i> , 1999, 106, 47-57.	1.4	10
252	Analysis of the parkin deletion in sporadic and familial Parkinson's disease. <i>Journal of Neural Transmission</i> , 1999, 106, 159-163.	1.4	16
253	The \pm 1 -antichymotrypsin A-allele in German Parkinson disease patients. <i>Journal of Neural Transmission</i> , 1999, 106, 729-736.	1.4	11
254	Alpha-synuclein immunoreactive Lewy bodies and Lewy neurites in Parkinson's disease are detectable by an advanced silver-staining technique. <i>Acta Neuropathologica</i> , 1999, 98, 461-464.	3.9	39
255	Validation of a mail questionnaire for parkinsonism in two languages (German and Italian). <i>Journal of Neurology</i> , 1999, 246, 79-86.	1.8	31
256	Two novel point mutations of mitochondrial tRNA genes in histologically confirmed Parkinson disease. <i>Neurogenetics</i> , 1999, 2, 121-127.	0.7	43
257	New, Selective Catechol-O-Methyltransferase Inhibitors as Therapeutic Agents in Parkinsonâ€™s Disease. , 1999, 81, 1-36.		84
258	Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. <i>Annals of Neurology</i> , 1999, 45, 65-74.	2.8	255

#	ARTICLE	IF	CITATIONS
259	Enhanced lateral premotor activity during paradoxical gait in Parkinson's disease. <i>Annals of Neurology</i> , 1999, 45, 329-336.	2.8	214
260	Increased susceptibility to sporadic Parkinson's disease by a certain combined α -synuclein/apolipoprotein E genotype. <i>Annals of Neurology</i> , 1999, 45, 611-617.	2.8	273
261	A data-driven approach to the study of heterogeneity in idiopathic Parkinson's disease: identification of three distinct subtypes. <i>Movement Disorders</i> , 1999, 14, 10-20.	2.2	131
262	Nutritional and occupational factors influencing the risk of Parkinson's disease: A case-control study in southeastern Sweden. <i>Movement Disorders</i> , 1999, 14, 28-37.	2.2	218
263	Apomorphine induces changes in GPI spontaneous outflow in patients with parkinson's disease. <i>Movement Disorders</i> , 1999, 14, 45-49.	2.2	106
264	The vulnerability of nigral neurons to Parkinson's disease is unrelated to their intrinsic capacity for dopamine synthesis: An in situ hybridization study. <i>Movement Disorders</i> , 1999, 14, 206-218.	2.2	33
265	Worsening of levodopa-induced dyskinesias by motor and mental tasks. <i>Movement Disorders</i> , 1999, 14, 242-246.	2.2	38
266	Parkinsonism associated with Sjögren's syndrome: Three cases and a review of the literature. <i>Movement Disorders</i> , 1999, 14, 262-268.	2.2	51
267	Bradykinesia and impairment of EEG desynchronization in Parkinson's disease. <i>Movement Disorders</i> , 1999, 14, 423-429.	2.2	97
268	Phosphorus magnetic resonance spectroscopy in multiple system atrophy and Parkinson's disease. <i>Movement Disorders</i> , 1999, 14, 430-435.	2.2	64
269	Prevalence of Parkinson's disease in lower Aragon, Spain. <i>Movement Disorders</i> , 1999, 14, 596-604.	2.2	46
270	Evolution of motor fluctuations in Parkinson's disease: A longitudinal study over 6 years. <i>Movement Disorders</i> , 1999, 14, 605-611.	2.2	41
271	Motor cortex activation in Parkinson's disease: Dissociation of electrocortical and peripheral measures of response generation. <i>Movement Disorders</i> , 1999, 14, 790-799.	2.2	50
272	Environmental risk factors in Parkinson's disease. <i>Movement Disorders</i> , 1999, 14, 928-939.	2.2	110
273	Neuroendocrine responses to levodopa in multiple system atrophy (MSA). <i>Movement Disorders</i> , 1999, 14, 981-987.	2.2	24
274	Evaluation of a screening questionnaire for genetic studies of Parkinson's disease. , 1999, 88, 539-543.		99
276	Diagnostic Criteria for Parkinson Disease. <i>Archives of Neurology</i> , 1999, 56, 33.	4.9	2,626
277	Parkinson's disease " a multifactorial neurodegenerative disorder. <i>Journal of Neural Transmission Supplementum</i> , 1999, 56, 113-125.	0.5	45

#	ARTICLE	IF	CITATIONS
278	Central motor conduction time in Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 1999, 6, 17-19.	0.8	4
279	Astrocytes and microglia in the substantia nigra and caudate-putamen in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 1999, 5, 115-122.	1.1	41
280	Genetic predisposition plays a role in nigral cell death in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 1999, 5, 169-172.	1.1	1
281	Event-related potentials reveal memory deficits in Parkinson's disease. <i>Cognitive Brain Research</i> , 1999, 8, 165-172.	3.3	21
282	Neurogenetic correlates of Parkinson's disease: apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism. <i>Neuroscience Letters</i> , 1999, 266, 149-151.	1.0	41
283	The Ile93Met mutation in the ubiquitin carboxy-terminal-hydrolase-L1 gene is not observed in European cases with familial Parkinson's disease. <i>Neuroscience Letters</i> , 1999, 270, 1-4.	1.0	75
284	Exclusion of dominant mutations within the FTDP-17 locus on chromosome 17 for Parkinson's disease. <i>Neuroscience Letters</i> , 1999, 272, 140-142.	1.0	4
285	Apolipoprotein E polymorphisms and Parkinson's disease. <i>Neuroscience Letters</i> , 1999, 277, 83-86.	1.0	18
287	Atypical parkinsonism in the French West Indies. <i>Lancet, The</i> , 1999, 354, 1473.	6.3	1
288	Atypical parkinsonism in the French West Indies. <i>Lancet, The</i> , 1999, 354, 1474.	6.3	4
289	Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. <i>Lancet, The</i> , 1999, 354, 281-286.	6.3	224
290	Unilateral pallidotomy in Parkinson's disease: a randomised, single-blind, multicentre trial. <i>Lancet, The</i> , 1999, 354, 1665-1669.	6.3	167
291	Clinical Disorders of the Autonomic Nervous System Associated with Orthostatic Intolerance: An Overview of Classification, Clinical Evaluation, and Management. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1999, 22, 798-810.	0.5	104
292	CLINICAL MANIFESTATIONS OF PARKINSON'S DISEASE. <i>Medical Clinics of North America</i> , 1999, 83, 327-347.	1.1	43
293	Visual event-related potential changes at two different tasks in nondemented Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 1999, 164, 139-147.	0.3	21
294	Use of the GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson's disease and their carers in the community. <i>Age and Ageing</i> , 1999, 28, 35-38.	0.7	141
295	Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. <i>Neurology</i> , 1999, 53, 795-795.	1.5	444
296	Single-Photon Emission Computed Tomography of the Dopamine Transporter in Parkinsonism. <i>Journal of Neuroimaging</i> , 1999, 9, 223-228.	1.0	9

#	ARTICLE	IF	CITATIONS
297	Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. <i>Neurology</i> , 2000, 55, 1068-1069.	1.5	33
298	Striatal Dopamine Transporter Binding Assessed by [¹²³ I]IPT and Single Photon Emission Computed Tomography in Patients With Early Parkinson's Disease. <i>Archives of Neurology</i> , 2000, 57, 205.	4.9	78
299	Towards Neurotransplantation in Multiple System Atrophy: Clinical Rationale, Pathophysiological Basis, and Preliminary Experimental Evidence. <i>Cell Transplantation</i> , 2000, 9, 279-288.	1.2	37
300	The Effect of Amantadine on Levodopa-induced Dyskinesias in Parkinson's Disease: A Double-blind, Placebo-controlled Study. <i>Clinical Neuropharmacology</i> , 2000, 23, 82-85.	0.2	148
301	[¹²³ I] β -CIT binding and SPET compared with clinical diagnosis in parkinsonism. <i>Nuclear Medicine Communications</i> , 2000, 21, 417-424.	0.5	13
302	Correlation between Tapping and Inserting of Pegs in Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2000, 27, 311-315.	0.3	48
303	The utility of neuroSPECT imaging in the investigation of dementia and parkinsonism. <i>Irish Journal of Psychological Medicine</i> , 2000, 17, 96-99.	0.7	1
304	Anal sphincter EMG does not distinguish between multiple system atrophy and Parkinson's disease. <i>Movement Disorders</i> , 2000, 23, 731-734.		60
305	Quantitative electromyography of the external anal sphincter in Parkinson's disease and multiple system atrophy. <i>Muscle and Nerve</i> , 2000, 23, 1250-1256.	1.0	58
306	A single nucleotide polymorphism of dopamine transporter gene is associated with Parkinson's disease. <i>Annals of Neurology</i> , 2000, 47, 528-531.	2.8	39
307	Parkin is associated with actin filaments in neuronal and nonneuronal cells. <i>Annals of Neurology</i> , 2000, 48, 737-744.	2.8	75
308	The dopamine D2 receptor gene is a susceptibility locus for Parkinson's disease. <i>Movement Disorders</i> , 2000, 15, 120-126.	2.2	108
309	Objective quantification of resting and activated parkinsonian rigidity: A comparison of angular impulse and work scores. <i>Movement Disorders</i> , 2000, 15, 48-55.	2.2	61
310	Pallidotomy and quality of life in patients with parkinson's disease: An early study. <i>Movement Disorders</i> , 2000, 15, 65-70.	2.2	56
311	Postural and action myoclonus in patients with parkinsonian type multiple system atrophy. <i>Movement Disorders</i> , 2000, 15, 77-83.	2.2	70
312	Motor unit changes in sporadic idiopathic Parkinson's disease. <i>Movement Disorders</i> , 2000, 15, 238-243.	2.2	19
313	Accurate differentiation of parkinsonism and essential tremor using visual assessment of [¹²³ I]-FP-CIT SPECT imaging: The [¹²³ I]-FP-CIT study group. <i>Movement Disorders</i> , 2000, 15, 503-510.	2.2	650
314	Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: A two-year follow-up study of previously untreated patients. <i>Movement Disorders</i> , 2000, 15, 613-626.	2.2	148

#	ARTICLE	IF	CITATIONS
315	Disruption of spatial organization and interjoint coordination in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy. <i>Movement Disorders</i> , 2000, 15, 627-640.	2.2	28
316	The bradykinesia akinesia incoordination test (BRAIN TEST ₂ ^{1/2}), an objective and user-friendly means to evaluate patients with Parkinsonism. <i>Movement Disorders</i> , 2000, 15, 641-647.	2.2	49
317	The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa. <i>Movement Disorders</i> , 2000, 15, 862-868.	2.2	45
318	5-HT _{2C} receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. <i>Movement Disorders</i> , 2000, 15, 1064-1069.	2.2	62
319	Dilated perivascular spaces in the putamen and pallidum in patients with Parkinson's disease scheduled for pallidotomy: A comparison between MRI findings and clinical symptoms and signs. <i>Movement Disorders</i> , 2000, 15, 1139-1144.	2.2	32
320	[¹²³ I]-CIT spect in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. <i>Movement Disorders</i> , 2000, 15, 1158-1167.	2.2	201
321	Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy. <i>European Journal of Neurology</i> , 2000, 7, 661-665.	1.7	57
322	Juvenile Parkinsonism: a heterogeneous entity. <i>European Journal of Neurology</i> , 2000, 7, 467-471.	1.7	12
323	Loss of dopamine uptake sites and dopamine D ₂ receptors in striatonigral degeneration. <i>Brain Research</i> , 2000, 852, 228-232.	1.1	14
324	Progress in the clinical and molecular genetics of familial parkinsonism. <i>Neurogenetics</i> , 2000, 2, 207-218.	0.7	36
325	Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. <i>Brain</i> , 2000, 123, 2423-2431.	3.7	205
326	Redundant-signals effects on reaction time, response force, and movement-related potentials in Parkinson's disease. <i>Experimental Brain Research</i> , 2000, 130, 533-539.	0.7	36
327	Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 566-573.	3.3	158
328	Scintigraphic differentiation between two forms of primary dysautonomia early after onset of autonomic dysfunction: value of cardiac and pulmonary iodine-123 MIBG uptake. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 595-600.	3.3	69
329	Genetic influence on the development of Parkinson's disease. <i>Journal of Neurology</i> , 2000, 247, 1169-1174.	1.8	20
330	Lack of autonomic nervous dysfunction in progressive supranuclear palsy, a study of blood pressure variability. <i>Clinical Autonomic Research</i> , 2000, 10, 309-312.	1.4	14
331	Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. <i>Journal of Neural Transmission</i> , 2000, 107, 59-71.	1.4	197
332	L-Glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients. <i>Journal of Neural Transmission</i> , 2000, 107, 183-189.	1.4	51

#	ARTICLE	IF	CITATIONS
333	Measuring the progression of idiopathic Parkinson's disease with [123 I] Î²-CIT SPECT. Journal of Neural Transmission, 2000, 107, 543-552.	1.4	75
334	Inconsistency between severe substantia nigra degeneration with Lewy bodies and clinical parkinsonism in dementia patients: a cliniconeuropathological study. Acta Neuropathologica, 2000, 99, 511-516.	3.9	6
335	Lewy body and Alzheimer pathology in a family with the amyloid-Î² precursor protein APP717 gene mutation. Acta Neuropathologica, 2000, 100, 145-152.	3.9	62
336	Visual event-related potentials in progressive supranuclear palsy, corticobasal degeneration, striatonigral degeneration, and Parkinson's disease. Journal of Neurology, 2000, 247, 356-363.	1.8	33
337	Is clonidine growth hormone stimulation a good test to differentiate multiple system atrophy from idiopathic Parkinson's disease?. Journal of Neurology, 2000, 247, 853-856.	1.8	29
338	Hallucinations, REM sleep, and Parkinson's disease. Neurology, 2000, 55, 281-288.	1.5	461
339	Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 590-594.	0.9	68
340	Mitochondrial DNA mutations in complex I and tRNA genes in Parkinson's disease. Neurology, 2000, 54, 703-703.	1.5	101
341	Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors. Brain, 2000, 123, 733-745.	3.7	847
342	A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology, 2000, 54, 1596-1603.	1.5	354
343	Cognitive impairment in Parkinson's disease. International Review of Psychiatry, 2000, 12, 281-289.	1.4	13
344	Immunocytochemical, Ultrastructural and Neurochemical Evidences on Synaptogenesis and Dopamine Release of Rat Chromaffin Cells Co-Cultured with Striatal Neurons. Journal of Neuropathology and Experimental Neurology, 2000, 59, 170-174.	0.9	2
345	Computerized Posturography Analysis of Progressive Supranuclear Palsy. Archives of Neurology, 2000, 57, 1464-9.	4.9	58
346	The Evolution of Diagnosis in Early Parkinson Disease. Archives of Neurology, 2000, 57, 369.	4.9	207
347	Cortical dysfunction in non-demented Parkinson's disease patients: A combined 31P-MRS and 18FDG-PET study. Brain, 2000, 123, 340-352.	3.7	214
348	Effects of Bilateral Posteroventral Pallidotomy on Gait of Subjects With Parkinson Disease. Archives of Neurology, 2000, 57, 198.	4.9	40
349	Pharmacological treatment of Parkinson's disease. Postgraduate Medical Journal, 2000, 76, 602-610.	0.9	44
350	ORGANOCHLORINE INSECTICIDES IN SUBSTANTIA NIGRA IN PARKINSON'S DISEASE. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2000, 59, 229-234.	1.1	217

#	ARTICLE	IF	CITATIONS
351	The FAB. <i>Neurology</i> , 2000, 55, 1621-1626.	1.5	3,317
352	Validating a screening questionnaire for parkinsonism in Australia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 69, 117-120.	0.9	30
353	Mismatch between electrophysiologically defined and ventriculography based theoretical targets for posteroventral pallidotomy in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 69, 787-791.	0.9	11
354	Progressive supranuclear palsy. <i>Postgraduate Medical Journal</i> , 2000, 76, 333-336.	0.9	28
355	Progression of Hoehn and Yahr stages in parkinsonian disorders: A clinicopathologic study. <i>Neurology</i> , 2000, 55, 888-891.	1.5	107
356	Levodopa Withdrawal After Bilateral Subthalamic Nucleus Stimulation in Advanced Parkinson Disease. <i>Archives of Neurology</i> , 2000, 57, 983.	4.9	197
357	Neuropsychological follow up in patients with Parkinson's disease, striatonigral degeneration-type multisystem atrophy, and progressive supranuclear palsy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 69, 313-318.	0.9	111
358	What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 68, 434-440.	0.9	225
359	Parkinsonism and Epilepsy: Case Report and Reappraisal of an Old Question. <i>Epilepsy and Behavior</i> , 2000, 1, 128-130.	0.9	20
360	Proton magnetic resonance spectroscopy of patients with parkinsonism. <i>Brain Research Bulletin</i> , 2000, 52, 589-595.	1.4	76
361	Test-retest reliability of an epidemiological instrument for Parkinson's disease. <i>Journal of Clinical Epidemiology</i> , 2000, 53, 863-865.	2.4	10
362	Levodopa in plasma correlates with body weight of parkinsonian patients. <i>Parkinsonism and Related Disorders</i> , 2000, 6, 171-173.	1.1	54
363	Construction of freezing of gait questionnaire for patients with Parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2000, 6, 165-170.	1.1	669
364	Levodopa motor complications in Parkinson's disease. <i>Trends in Neurosciences</i> , 2000, 23, S2-S7.	4.2	393
365	Goal-directed secondary motor tasks: Their effects on gait in subjects with Parkinson disease. <i>Archives of Physical Medicine and Rehabilitation</i> , 2000, 81, 110-116.	0.5	190
366	Neuropsychiatric Aspects of Parkinson's Disease. <i>Psychosomatics</i> , 2000, 41, 15-23.	2.5	94
367	Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. <i>Brain</i> , 2000, 123, 1155-1160.	3.7	386
368	Prospects for the treatment of Parkinson's disease using neural grafts. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 889-902.	0.9	12

#	ARTICLE	IF	CITATIONS
369	Efectividad y seguridad de la palidotomía posteroventral en el tratamiento de la enfermedad de Parkinson avanzada. <i>Medicina Clínica</i> , 2000, 114, 205-208.	0.3	1
370	VOIDING DYSFUNCTION AND PARKINSON'S DISEASE: URODYNAMIC ABNORMALITIES AND URINARY SYMPTOMS. <i>Journal of Urology</i> , 2000, 164, 1640-1643.	0.2	202
371	The effect of transcranial magnetic stimulation on reaction time in progressive supranuclear palsy. <i>Clinical Neurophysiology</i> , 2000, 111, 2008-2013.	0.7	16
372	Parkinson's disease impairs the ability to change set quickly. <i>Journal of the Neurological Sciences</i> , 2000, 175, 57-70.	0.3	129
373	Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG SPECT. <i>Journal of the Neurological Sciences</i> , 2000, 175, 3-12.	0.3	229
374	Short-term motor improvement after sub-threshold 5-Hz repetitive transcranial magnetic stimulation of the primary motor hand area in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2000, 178, 91-94.	0.3	151
375	Choice reaction time after levodopa challenge in parkinsonian patients. <i>Journal of the Neurological Sciences</i> , 2000, 181, 98-103.	0.3	25
376	Delay of simple reaction time after levodopa intake. <i>Clinical Neurophysiology</i> , 2001, 112, 2133-2137.	0.7	24
377	Pharmacokinetic-Pharmacodynamic Relationship of Levodopa with and without Tolcapone in Patients with Parkinson's Disease. <i>Clinical Pharmacokinetics</i> , 2001, 40, 383-393.	1.6	34
378	Risk factors of Parkinson's disease in Indian patients. <i>Journal of the Neurological Sciences</i> , 2001, 190, 49-55.	0.3	116
379	The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 266-272.	2.2	230
380	SINGLE PHOTON EMISSION CT AND POSITRON EMISSION TOMOGRAPHY IN THE EVALUATION OF NEUROLOGIC DISEASE. <i>Radiologic Clinics of North America</i> , 2001, 39, 1007-1033.	0.9	15
382	The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. <i>Brain</i> , 2001, 124, 1438-1449.	3.7	226
383	The frissonant Mutant Mouse, a Model of Dopamino-Sensitive, Inherited Motor Syndrome. <i>Neurobiology of Disease</i> , 2001, 8, 447-458.	2.1	11
384	Plasma von Willebrand factor activities in vascular Parkinsonism: Comparison with Parkinson's disease. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2001, 10, 227-230.	0.7	4
385	Levodopa responsive Parkinsonism in adults with Angelman Syndrome. <i>Journal of Clinical Neuroscience</i> , 2001, 8, 421-422.	0.8	37
386	Olanzapine for the Treatment of Psychosis in Patients With Parkinson's Disease and Dementia. <i>Psychosomatics</i> , 2001, 42, 477-481.	2.5	44
387	A comparison of ¹⁸ F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease. <i>Neurology</i> , 2001, 56, 1195-1200.	1.5	76

#	ARTICLE	IF	CITATIONS
388	Comparative analysis of the gait disorder of normal pressure hydrocephalus and Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 70, 289-297.	0.9	286
389	Recognition memory in normal aging and Parkinson's disease: behavioral and electrophysiologic measures. <i>Cognitive Brain Research</i> , 2001, 11, 23-32.	3.3	23
390	Tolcapone increases plasma catecholamine levels in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2001, 7, 93-96.	1.1	17
391	Familial occurrence of Parkinson's disease in a community-based case-control study. <i>Parkinsonism and Related Disorders</i> , 2001, 7, 297-303.	1.1	20
392	Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease. <i>Neurophysiologie Clinique</i> , 2001, 31, 321-340.	1.0	58
393	Parkinson's disease. <i>Neurologic Clinics</i> , 2001, 19, 565-578.	0.8	30
394	Lumping and splitting the parkinson plus syndromes. <i>Neurologic Clinics</i> , 2001, 19, 607-627.	0.8	41
396	Syncope Resulting from Autonomic Insufficiency Syndromes Associated with Orthostatic Intolerance. <i>Medical Clinics of North America</i> , 2001, 85, 457-472.	1.1	22
397	Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. <i>Neurology</i> , 2001, 57, 1497-1499.	1.5	729
398	Health-Related Quality of Life and Healthcare Utilisation in Patients with Parkinson's Disease. <i>Pharmacoeconomics</i> , 2001, 19, 1013-1038.	1.7	105
399	Relationship of substantia nigra echogenicity and motor function in elderly subjects. <i>Neurology</i> , 2001, 56, 13-17.	1.5	193
400	5: Movement disorders I: Parkinsonism and the akinetic-rigid syndromes. <i>Medical Journal of Australia</i> , 2001, 174, 357-363.	0.8	2
401	Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years. <i>Nuclear Medicine Communications</i> , 2001, 22, 721-725.	0.5	64
402	Imaging of the dopaminergic system in parkinsonism with SPET. <i>Nuclear Medicine Communications</i> , 2001, 22, 819-827.	0.5	34
403	Methylphenidate Increases the Motor Effects of L-Dopa in Parkinson's Disease: A Pilot Study. <i>Clinical Neuropharmacology</i> , 2001, 24, 208-213.	0.2	45
404	The 141C Ins/Del polymorphism of the dopamine D2 receptor gene is not associated with either migraine or Parkinson's disease. <i>Psychiatric Genetics</i> , 2001, 11, 49-52.	0.6	34
405	Familial Progressive supranuclear Palsy. <i>Archives of Neurology</i> , 2001, 58, 1846.	4.9	42
406	Pilot Study of Prevalence of Parkinson's Disease in Australia. <i>Neuroepidemiology</i> , 2001, 20, 112-117.	1.1	18

#	ARTICLE	IF	CITATIONS
407	Chapter 9 Clinical Trials in Parkinson's Disease. Blue Books of Practical Neurology, 2001, , 173-199.	0.1	0
408	The optimal imaging time for [99Tcm]TRODAT-1/SPET in normal subjects and patients with Parkinson's disease. Nuclear Medicine Communications, 2001, 22, 151-154.	0.5	31
409	Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 1523-1528.	3.3	55
410	The parkin gene is not a major susceptibility locus for typical late-onset Parkinson's disease. Neurological Sciences, 2001, 22, 73-74.	0.9	6
411	[123 I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. Journal of Neural Transmission, 2001, 108, 1011-1019.	1.4	89
412	Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease. Journal of Neural Transmission, 2001, 108, 803-807.	1.4	65
413	Correlating rates of cerebral atrophy in Parkinson's disease with measures of cognitive decline. Journal of Neural Transmission, 2001, 108, 571-580.	1.4	72
414	Synchrony of rest tremor in multiple limbs in Parkinson's disease: evidence for multiple oscillators. Journal of Neural Transmission, 2001, 108, 287-296.	1.4	64
415	Freezing of gait in patients with advanced Parkinson's disease. Journal of Neural Transmission, 2001, 108, 53-61.	1.4	338
416	Dementia with Lewy bodies and Alzheimer's disease. Acta Neuropathologica, 2001, 102, 621-626.	3.9	38
417	Prospective assessment of falls in Parkinson's disease. Journal of Neurology, 2001, 248, 950-958.	1.8	714
418	CYP2D6*4 polymorphism is not associated with Parkinson's disease and has no protective role against Alzheimer's disease in the Korean population. Psychiatry and Clinical Neurosciences, 2001, 55, 373-377.	1.0	24
419	Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes. European Journal of Neurology, 2001, 8, 573-577.	1.7	80
420	Parkinson's and Migraine. Cephalalgia, 2001, 21, 706-707.	1.8	2
421	Mutations in the α -synuclein gene in Parkinson's disease among Indians. Acta Neurologica Scandinavica, 2001, 103, 120-122.	1.0	24
422	Vascular parkinsonism: a distinct, heterogeneous clinical entity. Acta Neurologica Scandinavica, 2001, 104, 63-67.	1.0	119
423	Cardiovascular effects of domperidone in patients with Parkinson's disease treated with apomorphine. Acta Neurologica Scandinavica, 2001, 104, 92-96.	1.0	14
424	Phenotypic characterisation of autosomal recessive PARK6-linked parkinsonism in three unrelated Italian families. Movement Disorders, 2001, 16, 999-1006.	2.2	65

#	ARTICLE	IF	CITATIONS
425	CYP2D6 polymorphism in Parkinson's disease: The Rotterdam study. <i>Movement Disorders</i> , 2001, 16, 290-293.	2.2	14
426	Cardiovascular reflex testing contributes to clinical evaluation and differential diagnosis of Parkinsonian syndromes. <i>Movement Disorders</i> , 2001, 16, 217-225.	2.2	73
427	69-Year-old man with gait disturbance and parkinsonism. <i>Movement Disorders</i> , 2001, 16, 548-561.	2.2	1
428	The tau A0 allele in Parkinson's disease. <i>Movement Disorders</i> , 2001, 16, 442-447.	2.2	61
429	Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. <i>Movement Disorders</i> , 2001, 16, 622-630.	2.2	587
430	Effect of sleep deprivation on motor performance in patients with Parkinson's disease. <i>Movement Disorders</i> , 2001, 16, 616-621.	2.2	34
431	Novel observations with FDOPA-PET imaging after early nigrostriatal damage. <i>Movement Disorders</i> , 2001, 16, 838-848.	2.2	35
432	Gastric emptying time and gastric motility in patients with Parkinson's disease. <i>Movement Disorders</i> , 2001, 16, 1041-1047.	2.2	249
433	Rigidity decreases resting tremor intensity in Parkinson's disease: A [¹²³ I]β-CIT SPECT study in early, nonmedicated patients. <i>Movement Disorders</i> , 2001, 16, 1033-1040.	2.2	25
434	Clinical features of parkinsonian patients with the β-synuclein (G209A) mutation. <i>Movement Disorders</i> , 2001, 16, 1007-1013.	2.2	83
435	Parkinson's disease is not associated with the combined β-synuclein/apolipoprotein E susceptibility genotype. <i>Annals of Neurology</i> , 2001, 49, 665-668.	2.8	66
436	Metabolic enzyme expression in dopaminergic neurons in Parkinson's disease: An in situ hybridization study. <i>Annals of Neurology</i> , 2001, 50, 142-149.	2.8	15
437	Case-control study of the extended tau gene haplotype in Parkinson's disease. <i>Annals of Neurology</i> , 2001, 50, 658-661.	2.8	54
438	Stroke and idiopathic Parkinson's disease: Does a shortage of dopamine offer protection against stroke?. <i>Movement Disorders</i> , 2001, 16, 119-123.	2.2	50
439	Loss of olfaction in de novo and treated Parkinson's disease: Possible implications for early diagnosis. <i>Movement Disorders</i> , 2001, 16, 41-46.	2.2	256
440	The auditory startle reaction in parkinsonian disorders. <i>Movement Disorders</i> , 2001, 16, 62-71.	2.2	93
441	Quality of life in Parkinson's disease: Greek translation and validation of the Parkinson's disease questionnaire (PDQ-39). <i>Quality of Life Research</i> , 2001, 10, 159-163.	1.5	32
442	Do P1 and N1 evoked by the ERP task reflect primary visual processing in Parkinson's disease?. <i>Documenta Ophthalmologica</i> , 2001, 102, 1-9.	1.0	29

#	ARTICLE	IF	CITATIONS
443	Evaluation of antiparkinsonian drugs in pharmacy records as a marker for Parkinson's disease. <i>International Journal of Clinical Pharmacy</i> , 2001, 23, 148-152.	1.4	28
444	Differential expression and tissue distribution of parkin isoforms during mouse development. <i>Developmental Brain Research</i> , 2001, 130, 173-181.	2.1	35
445	Serum Melanotransferrin, p97 as a Biochemical Marker of Alzheimer's Disease. <i>Neuropsychopharmacology</i> , 2001, 25, 84-90.	2.8	60
446	Neural transplantation therapies for Parkinson's and Huntington's diseases. <i>Drug Discovery Today</i> , 2001, 6, 575-582.	3.2	7
447	Performance on the PD test battery by relatives of patients with progressive supranuclear palsy. <i>Neurology</i> , 2001, 56, 25-30.	1.5	19
448	Outcome of unilateral pallidotomy in advanced Parkinson's disease: cohort study of 32 patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 71, 375-382.	0.9	39
449	Association of Single-Nucleotide Polymorphisms of the Tau Gene With Late-Onset Parkinson Disease. <i>JAMA - Journal of the American Medical Association</i> , 2001, 286, 2245.	3.8	171
450	Barriers to Treatment: The Unique Challenges for Physicians Providing Dementia Care. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2001, 14, 188-198.	1.2	24
451	Clinical phenotype in patients with alpha-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 70, 662-665.	0.9	57
452	Prospective study of hallucinations and delusions in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 70, 734-738.	0.9	295
453	Clinical Correlates of Action Tremor in Parkinson Disease. <i>Archives of Neurology</i> , 2001, 58, 1630.	4.9	111
454	Effects of Levodopa on Pulmonary Function in Parkinson's Disease. <i>Chest</i> , 2001, 119, 387-393.	0.4	73
455	Bilateral pallidotomy for treatment of Parkinson's disease induced corticobulbar syndrome and psychic akinesia avoidable by globus pallidus lesion combined with contralateral stimulation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 71, 611-614.	0.9	69
456	Prevalence and correlates of parkinsonism in patients with primary depression. <i>Neurology</i> , 2001, 57, 553-555.	1.5	16
457	The <i>parkin</i> gene is not involved in late-onset Parkinson's disease. <i>Neurology</i> , 2001, 57, 359-362.	1.5	48
458	Failed Suppression of Direct Visuomotor Activation in Parkinson's Disease. <i>Journal of Cognitive Neuroscience</i> , 2001, 13, 31-43.	1.1	143
459	Parkinsonism in Ontario. <i>Neurology</i> , 2001, 57, 2278-2282.	1.5	42
460	Genome-wide scan for Parkinson's disease. <i>Neurology</i> , 2001, 57, 1124-1126.	1.5	84

#	ARTICLE	IF	CITATIONS
461	Effect of Levodopa on Orthostatic and Postprandial Hypotension in Elderly Parkinsonian Patients. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2001, 56, M749-M755.	1.7	47
462	New mutation (R42P) of the parkin gene in the ubiquitinlike domain associated with parkinsonism. Neurology, 2001, 56, 463-466.	1.5	55
463	An algorithm (decision tree) for the management of Parkinson's disease (2001):. Neurology, 2001, 56, S1-S88.	1.5	565
464	Parkinson's disease, CYP2D6 polymorphism, and age. Neurology, 2001, 56, 1363-1370.	1.5	28
465	Demography and Epidemiology of Age-Associated Neuronal Impairment. , 2001, , 31-50.		2
466	Early Morning Off-Medication Dyskinesias, Dystonia, and Choreic Subtypes. Archives of Neurology, 2001, 58, 1379.	4.9	40
467	Complete Genomic Screen in Parkinson Disease. JAMA - Journal of the American Medical Association, 2001, 286, 2239.	3.8	257
468	Anosmia in dementia is associated with Lewy bodies rather than Alzheimer's pathology. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 739-743.	0.9	124
469	The Parkinson's Disease Activities of Daily Living Scale: a new simple and brief subjective measure of disability in Parkinson's disease. Clinical Rehabilitation, 2001, 15, 241-246.	1.0	88
470	The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. Human Molecular Genetics, 2001, 10, 1649-1656.	1.4	133
471	Nonmotor fluctuations in Parkinson's disease. Neurology, 2002, 59, 408-413.	1.5	601
472	The genetic basis of Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 363-370.	0.9	57
473	Parkinson's disease and sleepiness. Neurology, 2002, 58, 1019-1024.	1.5	518
474	Incidence and prediction of falls in Parkinson's disease: a prospective multidisciplinary study. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 721-725.	0.9	546
475	Increased risk of Parkinson's disease after depression. Neurology, 2002, 58, 1501-1504.	1.5	258
476	Linkage stratification and mutation analysis at the parkin locus identifies mutation positive Parkinson's disease families. Journal of Medical Genetics, 2002, 39, 489-492.	1.5	54
477	Two large British kindreds with familial Parkinson's disease: a clinico-pathological and genetic study. Brain, 2002, 125, 44-57.	3.7	28
478	Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. Brain, 2002, 125, 801-811.	3.7	157

#	ARTICLE	IF	CITATIONS
479	Global attentional-executive sequelae following surgical lesions to globus pallidus interna. <i>Brain</i> , 2002, 125, 562-574.	3.7	46
480	14-3-3 Proteins in Lewy Bodies in Parkinson Disease and Diffuse Lewy Body Disease Brains. <i>Journal of Neuropathology and Experimental Neurology</i> , 2002, 61, 245-253.	0.9	145
481	Subthalamic nucleus stimulation affects striato-anterior cingulate cortex circuit in a response conflict task: a PET study. <i>Brain</i> , 2002, 125, 1995-2004.	3.7	164
482	Where Does Parkinson Disease Pathology Begin in the Brain?. <i>Journal of Neuropathology and Experimental Neurology</i> , 2002, 61, 413-426.	0.9	640
483	Brain Magnetic Resonance Imaging in Multiple-System Atrophy and Parkinson Disease. <i>Archives of Neurology</i> , 2002, 59, 835-42.	4.9	134
484	Fluctuations in attention. <i>Neurology</i> , 2002, 59, 1714-1720.	1.5	278
485	Dissociation of Habit-Learning in Parkinson's and Cerebellar Disease. <i>Journal of Cognitive Neuroscience</i> , 2002, 14, 493-499.	1.1	67
486	Epidemiologic study of 203 sibling pairs with Parkinson's disease. <i>Neurology</i> , 2002, 58, 79-84.	1.5	99
487	Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 73, 134-140.	0.9	239
488	Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. <i>Neurology</i> , 2002, 58, 575-580.	1.5	232
489	Budipine Provides Additional Benefit in Patients With Parkinson Disease Receiving a Stable Optimum Dopaminergic Drug Regimen. <i>Archives of Neurology</i> , 2002, 59, 803.	4.9	30
490	Relative high frequency of the c.255delA parkin gene mutation in Spanish patients with autosomal recessive parkinsonism. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 73, 582-584.	0.9	28
491	Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 73, 517-523.	0.9	199
492	Neuroimaging in Dementia with Lewy Bodies: Metabolism, Neurochemistry, and Morphology. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2002, 15, 200-209.	1.2	36
493	The association of incident dementia with mortality in PD. <i>Neurology</i> , 2002, 59, 1708-1713.	1.5	263
496	Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 529-534.	5.7	176
497	Motor Circuitry Re-organization After Pallidotomy in Parkinson Disease. <i>Journal of Clinical Neurophysiology</i> , 2002, 19, 553-561.	0.9	10
498	Motor Response to Apomorphine in Patients With Parkinson's Disease With Long-Duration Response to Levodopa. <i>Clinical Neuropharmacology</i> , 2002, 25, 119-121.	0.2	2

#	ARTICLE	IF	CITATIONS
499	Clinical aspects of Parkinson disease. <i>Current Opinion in Neurology</i> , 2002, 15, 457-460.	1.8	69
500	Parkinsonian syndromes and differential diagnosis. <i>Current Opinion in Neurology</i> , 2002, 15, 461-466.	1.8	12
501	Tapping and Peg Insertion after Levodopa Intake in Treated and <i>de novo</i> Parkinsonian Patients. <i>Canadian Journal of Neurological Sciences</i> , 2002, 29, 73-77.	0.3	21
502	Neuromelanin in the Human Brain: A Review and Atlas of Pigmented Cells in the Substantia Nigra. <i>Archives of Physiology and Biochemistry</i> , 2002, 110, 257-369.	1.0	24
503	Familial Aggregation of Parkinson Disease. <i>Archives of Neurology</i> , 2002, 59, 848-50.	4.9	75
504	Modafinil for the Treatment of Daytime Sleepiness in Parkinson's Disease: A Double-blind, Randomized, Crossover, Placebo-controlled Polygraphic Trial. <i>Sleep</i> , 2002, 25, 62-66.	0.6	216
505	Familial Diffuse Lewy Body Disease, Eye Movement Abnormalities, and Distribution of Pathology. <i>Archives of Neurology</i> , 2002, 59, 464.	4.9	48
506	Body Weight Influences Pharmacokinetics of Levodopa in Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 2002, 25, 79-82.	0.2	71
507	Increased Red Blood Cell Polyamines in ALS and Parkinson's Disease. <i>Experimental Neurology</i> , 2002, 177, 515-520.	2.0	51
508	Expression of MMP-2, MMP-9, and MMP-1 and Their Endogenous Counterregulators TIMP-1 and TIMP-2 in Postmortem Brain Tissue of Parkinson's Disease. <i>Experimental Neurology</i> , 2002, 178, 13-20.	2.0	121
509	Lewy body-free nigral degeneration—a case report. <i>Journal of the Neurological Sciences</i> , 2002, 198, 97-100.	0.3	3
510	Abnormalities of rate-corrected QT intervals in Parkinson's disease—a comparison with multiple system atrophy and progressive supranuclear palsy. <i>Journal of the Neurological Sciences</i> , 2002, 199, 31-37.	0.3	61
511	The nature of the autonomic dysfunction in multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2002, 200, 1-10.	0.3	49
512	Neurophysiological correlate of clinical signs in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2002, 113, 792-805.	0.7	68
513	The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. <i>Brain</i> , 2002, 125, 861-870.	3.7	1,108
514	Olfactory function in Parkinsonian syndromes. <i>Journal of Clinical Neuroscience</i> , 2002, 9, 521-524.	0.8	156
515	PARK3 Influences Age at Onset in Parkinson Disease: A Genome Scan in the GenePD Study. <i>American Journal of Human Genetics</i> , 2002, 70, 1089-1095.	2.6	96
516	Age at Onset in Two Common Neurodegenerative Diseases Is Genetically Controlled. <i>American Journal of Human Genetics</i> , 2002, 70, 985-993.	2.6	291

#	ARTICLE	IF	CITATIONS
517	Genome Screen to Identify Susceptibility Genes for Parkinson Disease in a Sample without parkin Mutations. American Journal of Human Genetics, 2002, 71, 124-135.	2.6	162
518	Neurodegeneration, parkinsonian syndromes and autonomic failure. Autonomic Neuroscience: Basic and Clinical, 2002, 96, 50-58.	1.4	13
519	Dual SPECT of dopamine system using [99mTc]TRODAT-1 and [123I]IBZM in normal and 6-OHDA-lesioned formosan rock monkeys. Nuclear Medicine and Biology, 2002, 29, 561-567.	0.3	35
520	Motor unit number estimates in idiopathic Parkinson's disease. Parkinsonism and Related Disorders, 2002, 8, 161-164.	1.1	31
521	Quantification of the dopaminergic response in Parkinson's disease. Parkinsonism and Related Disorders, 2002, 8, 181-186.	1.1	23
522	Apomorphine delays simple reaction time in Parkinsonian patients. Parkinsonism and Related Disorders, 2002, 8, 357-360.	1.1	11
523	Kinetic tremor during tracking movements in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2002, 8, 361-368.	1.1	8
524	Parkinson's geneticsâ€”creating exciting new insights. Parkinsonism and Related Disorders, 2002, 8, 459-464.	1.1	7
525	Idiopathic Parkinsonâ€™s disease(s) may follow subclinical episodes of perivenous demyelination. Medical Hypotheses, 2002, 59, 762-769.	0.8	5
526	Parkinsonâ€™s Genetics: Molecular Insights for the New Millennium. NeuroToxicology, 2002, 23, 503-514.	1.4	19
527	The Tau H1 Haplotype is associated with Parkinson's disease in the Norwegian population. Neuroscience Letters, 2002, 322, 83-86.	1.0	68
528	Metabolic Alterations in Parkinson's Disease after Thalamotomy, as Revealed by 1H MR Spectroscopy. Korean Journal of Radiology, 2002, 3, 180.	1.5	12
529	Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain, 2002, 125, 789-800.	3.7	126
530	Intact artificial grammar learning in patients with cerebellar degeneration and advanced Parkinsonâ€™s disease. Neuropsychologia, 2002, 40, 1534-1540.	0.7	59
531	Motivation, reward, and Parkinson's disease: influence of dopatherapy. Neuropsychologia, 2002, 40, 2257-2267.	0.7	313
532	Selective changes in the levels of nicotinic acetylcholine receptor protein and of corresponding mRNA species in the brains of patients with Parkinsonâ€™s disease. Brain Research, 2002, 956, 358-366.	1.1	57
533	Progressive supranuclear palsy: where are we now?. Lancet Neurology, The, 2002, 1, 359-369.	4.9	140
534	Age at onset of Parkinson disease and apolipoprotein E genotypes. American Journal of Medical Genetics Part A, 2002, 107, 156-161.	2.4	61

#	ARTICLE	IF	CITATIONS
535	Park6-linked parkinsonism occurs in several european families. <i>Annals of Neurology</i> , 2002, 51, 14-18.	2.8	98
536	Combined effect of age and severity on the risk of dementia in Parkinson's disease. <i>Annals of Neurology</i> , 2002, 51, 722-729.	2.8	199
537	Applications of neural network analyses to in vivo 1H magnetic resonance spectroscopy of Parkinson disease patients. <i>Journal of Magnetic Resonance Imaging</i> , 2002, 16, 13-20.	1.9	28
538	Clinical-Pathological study of levodopa complications. <i>Movement Disorders</i> , 2002, 17, 289-296.	2.2	117
539	Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. <i>Movement Disorders</i> , 2002, 17, 303-312.	2.2	183
540	Phenotypic variability in a large kindred (Family LA) with deletions in the parkin gene. <i>Movement Disorders</i> , 2002, 17, 424-426.	2.2	27
541	Trunk movement in Parkinson's disease during rising from seated position. <i>Movement Disorders</i> , 2002, 17, 274-282.	2.2	56
542	Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory study. <i>Movement Disorders</i> , 2002, 17, 250-257.	2.2	55
543	Field validation of a method for population screening of parkinsonism. <i>Movement Disorders</i> , 2002, 17, 258-264.	2.2	17
544	Bilateral pallidotomy in Parkinson's disease: A retrospective study. <i>Movement Disorders</i> , 2002, 17, 533-538.	2.2	60
545	Repairing the brain in Parkinson's disease: Where next?. <i>Movement Disorders</i> , 2002, 17, 233-241.	2.2	35
546	[123I]β-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. <i>Movement Disorders</i> , 2002, 17, 518-523.	2.2	105
547	Diagnosing Parkinson's disease using videotaped neurological examinations: Validity and factors that contribute to incorrect diagnoses. <i>Movement Disorders</i> , 2002, 17, 513-517.	2.2	38
548	Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis. <i>Movement Disorders</i> , 2002, 17, 795-798.	2.2	73
549	Parkinsonism in multiple system atrophy: Natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease. <i>Movement Disorders</i> , 2002, 17, 701-709.	2.2	76
550	Genetics of parkinsonism. <i>Movement Disorders</i> , 2002, 17, 645-656.	2.2	107
551	Clinical correlates of the pathology underlying parkinsonism: A population perspective. <i>Movement Disorders</i> , 2002, 17, 910-916.	2.2	72
552	Effect of medication on EMG patterns in individuals with Parkinson's disease. <i>Movement Disorders</i> , 2002, 17, 950-960.	2.2	68

#	ARTICLE	IF	CITATIONS
553	Survival duration of Parkinson's disease patients living in Greece who carry the G209A α -synuclein mutation. <i>Movement Disorders</i> , 2002, 17, 847-848.	2.2	5
554	Diagnosing multiple system atrophy with greater accuracy: Combined analysis of the clonidine-growth hormone test and external anal sphincter electromyography. <i>Movement Disorders</i> , 2002, 17, 1242-1247.	2.2	25
555	Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease. <i>Movement Disorders</i> , 2002, 17, 1227-1234.	2.2	56
556	An imaging study of parkinsonism among African-Caribbean and Indian London communities. <i>Movement Disorders</i> , 2002, 17, 1321-1328.	2.2	15
557	Parkinson's disease and dementia with Lewy bodies: One disease or two?. <i>Movement Disorders</i> , 2002, 17, 1161-1165.	2.2	69
558	Memory and executive function impairment predict dementia in Parkinson's disease. <i>Movement Disorders</i> , 2002, 17, 1221-1226.	2.2	230
559	Application of the International Cooperative Ataxia Scale rating in multiple system atrophy. <i>Movement Disorders</i> , 2002, 17, 1248-1254.	2.2	48
560	Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 711-714.	3.3	53
561	Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2002, 109, 329-339.	1.4	250
562	A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. <i>Journal of Neural Transmission</i> , 2002, 109, 489-501.	1.4	53
563	Olfactory function in idiopathic Parkinson's disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. <i>Journal of Neural Transmission</i> , 2002, 109, 805-811.	1.4	140
564	Stimulation of growth-hormone release with clonidine does not distinguish individual cases of idiopathic Parkinson's disease from those with Striatonigral Degeneration. <i>Journal of Neurology</i> , 2002, 249, 1206-1210.	1.8	15
565	Tactile hallucinations in Parkinson's disease. <i>Journal of Neurology</i> , 2002, 249, 1699-1703.	1.8	82
566	Clinical features and laboratory findings for differentiating parkinsonian syndromes. <i>Journal of Neurology</i> , 2002, 249, 1-1.	1.8	7
567	Influence of benzodiazepines on antiparkinsonian drug treatment in levodopa users. <i>Acta Neurologica Scandinavica</i> , 2002, 105, 8-12.	1.0	10
568	Anti-GM1 ganglioside antibodies in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2002, 106, 54-57.	1.0	57
569	Vascular parkinsonism - neuropathological findings. <i>Acta Neurologica Scandinavica</i> , 2002, 105, 414-415.	1.0	17
570	Lack of association between an estrogen receptor 1 gene polymorphism and Parkinson's disease with dementia. <i>Acta Neurologica Scandinavica</i> , 2002, 106, 128-130.	1.0	20

#	ARTICLE	IF	CITATIONS
571	Beta-CIT-SPECT combined with UPDRS appears to distinguish different parkinsonian conditions. <i>Acta Neurologica Scandinavica</i> , 2002, 105, 5-7.	1.0	5
572	L-Dopa decreases cutaneous nociceptive inhibition of motor activity in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2002, 105, 196-201.	1.0	41
573	Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. <i>British Journal of Clinical Pharmacology</i> , 2002, 54, 168-170.	1.1	45
574	Parkinson's disease mimicking senile dementia of the Alzheimer type: a clinicopathological study of four autopsy cases. <i>Neuropathology</i> , 2002, 22, 77-84.	0.7	12
575	The differential diagnosis of Parkinson's disease. <i>European Journal of Neurology</i> , 2002, 9, 23-30.	1.7	193
576	Drug prescribing patterns in Parkinson's disease: a pharmacoepidemiological survey in a cohort of ambulatory patients. <i>Pharmacoepidemiology and Drug Safety</i> , 2002, 11, 149-157.	0.9	51
577	Comparison of Striatal Dopamine D2 Receptors in Parkinson's Disease and Progressive Supranuclear Palsy Patients Using [¹²³ I] Iodobenzofuran Single-Photon Emission Computed Tomography. <i>Journal of Neuroimaging</i> , 2002, 12, 316-324.	1.0	25
578	Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 1623-1629.	3.3	48
579	The heterogeneity of idiopathic Parkinson's disease. <i>Journal of Neurology</i> , 2002, 249, 138-145.	1.8	198
580	Anatomically standardised 99m Tc-ECD brain perfusion SPET allows accurate differentiation between healthy volunteers, multiple system atrophy and idiopathic Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 16-24.	3.3	51
581	Clinical and neuropathological correlates of Lewy body disease. <i>Acta Neuropathologica</i> , 2003, 105, 341-350.	3.9	83
582	Magnetization transfer changes of grey and white matter in Parkinson's disease. <i>Neuroradiology</i> , 2003, 45, 224-230.	1.1	44
583	Lewy bodies in Betz cells of the motor cortex in a patient with Parkinson's disease. <i>Acta Neuropathologica</i> , 2003, 105, 189-192.	3.9	9
584	Î±-Synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution—a pilot study. <i>Acta Neuropathologica</i> , 2003, 106, 191-202.	3.9	169
585	123I-loflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. <i>Neurological Sciences</i> , 2003, 24, 149-150.	0.9	146
586	Diagnostic criteria for Parkinson's disease. <i>Neurological Sciences</i> , 2003, 24, s23-s26.	0.9	21
587	Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD. <i>Journal of Neural Transmission</i> , 2003, 110, 151-169.	1.4	163
588	Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study. <i>Journal of Neural Transmission</i> , 2003, 110, 239-251.	1.4	56

#	ARTICLE	IF	CITATIONS
589	Influence of age, gender, education and dexterity on upper limb motor performance in Parkinsonian patients and healthy controls. <i>Journal of Neural Transmission</i> , 2003, 110, 885-897.	1.4	16
590	Differentiation of parkinsonian syndromes according to differences in executive functions. <i>Journal of Neural Transmission</i> , 2003, 110, 983-995.	1.4	57
591	Genes and parkinsonism. <i>Lancet Neurology</i> , The, 2003, 2, 221-228.	4.9	98
592	A linkage study of candidate loci in familial Parkinson's Disease. <i>BMC Neurology</i> , 2003, 3, 6.	0.8	14
593	Deep brain stimulation of the subthalamic nucleus does not increase the striatal dopamine concentration in parkinsonian humans. <i>Movement Disorders</i> , 2003, 18, 41-48.	2.2	146
594	Systematic review of incidence studies of Parkinson's disease. <i>Movement Disorders</i> , 2003, 18, 19-31.	2.2	467
595	Cerebrospinal fluid A β 42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. <i>Movement Disorders</i> , 2003, 18, 186-190.	2.2	118
596	Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. <i>Movement Disorders</i> , 2003, 18, 267-274.	2.2	191
597	Increased daytime sleepiness in Parkinson's disease: A questionnaire survey. <i>Movement Disorders</i> , 2003, 18, 319-323.	2.2	70
598	0.2-Hz repetitive transcranial magnetic stimulation has no add-on effects as compared to a realistic sham stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2003, 18, 382-388.	2.2	130
599	SCA2 may present as levodopa-responsive parkinsonism. <i>Movement Disorders</i> , 2003, 18, 425-429.	2.2	99
600	Olfaction in neurodegenerative disorder. <i>Movement Disorders</i> , 2003, 18, 364-372.	2.2	265
601	Reliability of reported age at onset for Parkinson's disease. <i>Movement Disorders</i> , 2003, 18, 275-279.	2.2	29
602	Dopamine D2 receptor TaqIA and TaqIB polymorphisms in Parkinson's disease. <i>Movement Disorders</i> , 2003, 18, 593-595.	2.2	27
603	Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. <i>Movement Disorders</i> , 2003, 18, 685-688.	2.2	198
604	Parkinson's disease is associated with hippocampal atrophy. <i>Movement Disorders</i> , 2003, 18, 784-790.	2.2	294
606	Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy Brain Bank. <i>Movement Disorders</i> , 2003, 18, 1018-1026.	2.2	155
607	Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. <i>Movement Disorders</i> , 2003, 18, 1132-1138.	2.2	153

#	ARTICLE	IF	CITATIONS
608	Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2003, 18, 1332-1337.	2.2	258
609	Unclassifiable parkinsonism in two European tertiary referral centres for movement disorders. <i>Movement Disorders</i> , 2003, 18, 1123-1131.	2.2	26
610	Diagnostic potential of acoustic startle reflex, acoustic blink reflex, and electro-oculography in progressive supranuclear palsy: A prospective study. <i>Movement Disorders</i> , 2003, 18, 1273-1279.	2.2	27
611	Parkinson's syndrome associated with neurofibrillary degeneration and tau pathologic findings. <i>Movement Disorders</i> , 2003, 18, 28-33.	2.2	59
612	Impact of genetic analysis on Parkinson's disease research. <i>Movement Disorders</i> , 2003, 18, 96-98.	2.2	17
613	Role of dopamine transporter imaging in the diagnosis of atypical tremor disorders. <i>Movement Disorders</i> , 2003, 18, S22-S27.	2.2	42
614	Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: A decision-analytic approach. <i>Movement Disorders</i> , 2003, 18, S52-S62.	2.2	33
615	Sweating dysfunction in Parkinson's disease. <i>Movement Disorders</i> , 2003, 18, 1459-1463.	2.2	146
616	Role of dopamine transporter imaging in routine clinical practice. <i>Movement Disorders</i> , 2003, 18, 1415-1423.	2.2	208
617	Monoamine oxidase B polymorphism, cigarette smoking and risk of Parkinson's disease: A study in an Asian population. <i>American Journal of Medical Genetics Part A</i> , 2003, 120B, 58-62.	2.4	28
618	Subthalamic nucleus stimulation affects a frontotemporal network: A PET study. <i>Annals of Neurology</i> , 2003, 54, 445-450.	2.8	147
619	Familial aggregation of early- and late-onset Parkinson's disease. <i>Annals of Neurology</i> , 2003, 54, 507-513.	2.8	96
620	Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. <i>Acta Neurologica Scandinavica</i> , 2003, 107, 252-255.	1.0	44
621	Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2003, 108, 368-373.	1.0	76
622	Involvement of precerebellar nuclei in multiple system atrophy. <i>Neuropathology and Applied Neurobiology</i> , 2003, 29, 60-76.	1.8	86
623	Orthostatic Hypotension: PACE - Pacing and Clinical Electrophysiology, 2003, 26, 892-901.	0.5	38
624	Camptocormia as a form of dystonia in Parkinson's disease. <i>European Journal of Neurology</i> , 2003, 10, 107-108.	1.7	42
625	Clinical characteristics of the alpha-synuclein mutation (G209A)-associated Parkinson's disease in comparison with other forms of familial Parkinson's disease in Greece. <i>European Journal of Neurology</i> , 2003, 10, 281-286.	1.7	23

#	ARTICLE	IF	CITATIONS
626	Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. <i>European Journal of Neurology</i> , 2003, 10, 399-406.	1.7	220
627	Therapeutic effect of repetitive transcranial magnetic stimulation on motor function in Parkinson's disease patients. <i>European Journal of Neurology</i> , 2003, 10, 567-572.	1.7	148
628	Alzheimer's Disease and Parkinson's Disease. <i>New England Journal of Medicine</i> , 2003, 348, 1356-1364.	13.9	1,161
629	Enfermedad de Parkinson: concepto, etiopatogenia, manifestaciones clínicas, historia natural, complicaciones, diagnóstico diferencial. <i>Medicine</i> , 2003, 8, 5081-5088.	0.0	0
630	Movement disorders. <i>Medical Clinics of North America</i> , 2003, 87, 771-791.	1.1	4
631	[18F]fluorodopa uptake in the upper brainstem measured with positron emission tomography correlates with decreased REM sleep duration in early Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2003, 105, 262-269.	0.6	41
632	Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. <i>Journal of the Neurological Sciences</i> , 2003, 216, 163-167.	0.3	183
633	Paired transcranial magnetic stimulation for the early diagnosis of corticobasal degeneration. <i>Clinical Neurophysiology</i> , 2003, 114, 272-278.	0.7	32
634	Usefulness of neurophysiologic techniques in stereotactic subthalamic nucleus stimulation for advanced Parkinson's disease. <i>Clinical Neurophysiology</i> , 2003, 114, 1793-1799.	0.7	27
635	Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson's disease. <i>NeuroImage</i> , 2003, 18, 416-422.	2.1	103
636	Risk of action tremor in relatives of tremor-dominant and postural instability gait disorder PD. <i>Neurology</i> , 2003, 61, 931-936.	1.5	65
637	Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. <i>Neurology</i> , 2003, 60, 790-795.	1.5	222
638	Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. <i>Experimental Neurology</i> , 2003, 183, 458-468.	2.0	132
639	Alpha synuclein promoter and risk of Parkinson's disease: microsatellite and allelic size variability. <i>Neuroscience Letters</i> , 2003, 336, 70-72.	1.0	61
640	Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson's disease. <i>Neuroscience Letters</i> , 2003, 339, 25-28.	1.0	36
641	Strong association between Saitohin gene polymorphism and tau haplotype in the Polish population. <i>Neuroscience Letters</i> , 2003, 348, 163-166.	1.0	21
642	Imaging studies in movement disorders. <i>Seminars in Nuclear Medicine</i> , 2003, 33, 105-113.	2.5	18
643	Significant Linkage of Parkinson Disease to Chromosome 2q36-37. <i>American Journal of Human Genetics</i> , 2003, 72, 1053-1057.	2.6	158

#	ARTICLE	IF	CITATIONS
644	Neuroleptic malignant syndrome-like, or "dopaminergic malignant syndrome" due to levodopa therapy withdrawal. Clinical features in 11 patients. <i>Parkinsonism and Related Disorders</i> , 2003, 9, 175-178.	1.1	47
645	Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension. <i>Parkinsonism and Related Disorders</i> , 2003, 9, 221-224.	1.1	21
646	The prevalence of Parkinson's disease in British Columbia, Canada, estimated by using drug tracer methodology. <i>Parkinsonism and Related Disorders</i> , 2003, 9, 233-238.	1.1	28
647	Early sensory information processes are enhanced on visual oddball and S1-S2 tasks in Parkinson's disease: a visual event-related potentials study. <i>Parkinsonism and Related Disorders</i> , 2003, 9, 329-340.	1.1	22
648	Current status of Parkinson's disease treatment in Korea. <i>Parkinsonism and Related Disorders</i> , 2003, 9, 99-104.	1.1	7
649	Mutation at the SCA17 locus is not a common cause of parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2003, 9, 317-320.	1.1	15
650	Neuropsychological changes after subthalamic nucleus stimulation: a 12 month follow-up in nine patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2003, 10, 73-79.	1.1	64
651	Cutaneous sympathetic function and cardiovascular function in patients with progressive supranuclear palsy and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2003, 10, 101-106.	1.1	25
652	Trastornos del movimiento. Concepto, epidemiología y clasificación. <i>Medicine</i> , 2003, 8, 5075-5080.	0.0	0
653	Levodopa-Induced Response Fluctuations in Patients with Parkinson's Disease. <i>CNS Drugs</i> , 2003, 17, 475-489.	2.7	36
654	Amantadine for dyskinesia in Parkinson's disease. <i>The Cochrane Library</i> , 2003, , CD003467.	1.5	63
655	Rationale for current therapies in Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 1747-1761.	0.9	49
656	Heterozygosity for a mutation in the <i>parkin</i> gene leads to later onset Parkinson disease. <i>Neurology</i> , 2003, 60, 796-801.	1.5	215
657	A haplotype at the <i>PARK3</i> locus influences onset age for Parkinson's disease. <i>Neurology</i> , 2003, 61, 1557-1561.	1.5	49
658	Autonomic nervous system testing may not distinguish multiple system atrophy from Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 56-60.	0.9	71
659	Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. <i>Neurology</i> , 2003, 60, 922-927.	1.5	258
660	Deep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson's disease patients previously reliant on apomorphine. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 170-174.	0.9	31
661	Tremor in Parkinson's disease and serotonergic dysfunction. <i>Neurology</i> , 2003, 60, 601-605.	1.5	277

#	ARTICLE	IF	CITATIONS
662	[123I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 294-298.	0.9	92
663	Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 175-182.	0.9	183
664	Detecting scaling in the period dynamics of multimodal signals: Application to Parkinsonian tremor. <i>Physical Review E</i> , 2003, 67, 031903.	0.8	26
665	Accuracy of family history data on Parkinson's disease. <i>Neurology</i> , 2003, 61, 18-23.	1.5	85
666	Orthostatic Hypotension in De Novo Parkinson Disease. <i>Archives of Neurology</i> , 2003, 60, 1400.	4.9	93
667	Positron Emission Tomography of Striatal Serotonin Transporters in Parkinson Disease. <i>Archives of Neurology</i> , 2003, 60, 1223-9.	4.9	128
668	Amantadine in Parkinson's disease. <i>The Cochrane Library</i> , 2003, , CD003468.	1.5	60
669	Cortical and subcortical blood flow effects of subthalamic nucleus stimulation in PD. <i>Neurology</i> , 2003, 61, 816-821.	1.5	181
670	<sc>Dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. <i>Neurology</i> , 2003, 60, 1750-1755.	1.5	146
671	Detection of Pathologic Prion Protein in the Olfactory Epithelium in Sporadic Creutzfeldt-Jakob Disease. <i>New England Journal of Medicine</i> , 2003, 348, 711-719.	13.9	142
672	Occipital hypoperfusion in Parkinson's disease without dementia: correlation to impaired cortical visual processing. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 419-422.	0.9	120
673	High-Dose Ropinirole in Advanced Parkinson's Disease With Severe Dyskinesias. <i>Clinical Neuropharmacology</i> , 2003, 26, 146-150.	0.2	37
674	99mTc-TRODAT-1 SPECT in healthy and 6-OHDA lesioned parkinsonian monkeys: comparison with 18F-FDOPA PET. <i>Nuclear Medicine Communications</i> , 2003, 24, 77-83.	0.5	9
675	The Contribution of Somatic Symptoms to the Diagnosis of Depressive Disorder in Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2003, 15, 74-77.	0.9	60
676	Therapies for depression in Parkinson's disease. <i>The Cochrane Library</i> , 2003, , CD003465.	1.5	67
677	Progressive supranuclear palsy. <i>British Journal of Hospital Medicine</i> , 2003, 64, 585-588.	0.3	3
678	Increased Muscle Activity During Rapid Eye Movement Sleep Correlates with Decrease of Striatal Presynaptic Dopamine Transporters. IPT and IBZM SPECT Imaging in Subclinical and Clinically Manifest Idiopathic REM Sleep Behavior Disorder, Parkinson's Disease, and Controls. <i>Sleep</i> , 2003, 26, 507-512.	0.6	245
679	The Incidence of Parkinson's Disease in the Netherlands: Results from a Longitudinal General Practice-Based Registration. <i>Neuroepidemiology</i> , 2003, 22, 311-312.	1.1	16

#	ARTICLE	IF	CITATIONS
682	Uma revisão sobre depressão como fator de risco na Doença de Parkinson e seu impacto na cognição. Revista De Psiquiatria Do Rio Grande Do Sul, 2004, 26, 52-60.	0.3	6
683	Avaliação da doença de Parkinson pela ressonância magnética. Radiologia Brasileira, 2004, 37, 83-90.	0.3	2
684	Subthalamic nucleus deep brain stimulation in a patient with levodopa-responsive multiple system atrophy. Journal of Neurosurgery, 2004, 100, 553-556.	0.9	53
685	Obesity and the Risk of Parkinson's Disease. American Journal of Epidemiology, 2004, 159, 547-555.	1.6	91
686	Sexual Dysfunction in Parkinson's Disease. Journal of Sex and Marital Therapy, 2004, 30, 95-105.	1.0	160
687	Olfactory function distinguishes vascular parkinsonism from Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1749-1752.	0.9	111
688	Clozapine improves dyskinesias in Parkinson disease. Neurology, 2004, 62, 381-388.	1.5	212
689	Early pathological changes in the parkinsonian brain demonstrated by diffusion tensor MRI. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 481-484.	0.9	204
690	Tau gene and Parkinson's disease: a case-control study and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 962-965.	0.9	112
691	(123I) Î²-CIT and Single-Photon Emission Computed Tomographic Imaging vs Clinical Evaluation in Parkinsonian Syndrome. Archives of Neurology, 2004, 61, 1224-9.	4.9	160
692	Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease. Neurology, 2004, 62, 1568-1572.	1.5	143
693	The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaGN study. Brain, 2004, 127, 550-560.	3.7	605
694	Case study: cerebrovascular parkinsonism with levodopa addiction. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1365-1366.	0.9	4
695	MDR1, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese. Journal of Medical Genetics, 2004, 41, e60-e60.	1.5	71
696	Effects of subthalamic nucleus stimulation and medication on resting and postural tremor in Parkinson's disease. Brain, 2004, 127, 2131-2143.	3.7	101
697	Cortical Lewy body disease. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 175-178.	0.9	15
698	Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology, 2004, 63, 293-300.	1.5	215
699	Alpha-synuclein haplotypes implicated in risk of Parkinson's disease. Neurology, 2004, 62, 128-131.	1.5	85

#	ARTICLE	IF	CITATIONS
700	Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain. <i>Neurology</i> , 2004, 62, 734-741.	1.5	165
701	Postural abnormalities to multidirectional stance perturbations in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 1245-1254.	0.9	225
702	Incidence of parkinsonism and Parkinson disease in a general population. <i>Neurology</i> , 2004, 63, 1240-1244.	1.5	333
703	Psychiatric comorbidity in a population of Parkinson's disease patients. <i>European Journal of Neurology</i> , 2004, 11, 315-320.	1.7	173
704	Pergolide mesylate can improve sexual dysfunction in patients with Parkinson's disease: the results of an open, prospective, 6-month follow-up. <i>European Journal of Neurology</i> , 2004, 11, 483-488.	1.7	34
705	A registry-based, case-control investigation of Parkinson's disease with and without cognitive impairment. <i>European Journal of Neurology</i> , 2004, 11, 347-351.	1.7	12
706	Genetic testing in spinocerebellar ataxia in Taiwan: expansions of trinucleotide repeats in SCA8 and SCA17 are associated with typical Parkinson's disease. <i>Clinical Genetics</i> , 2004, 65, 209-214.	1.0	81
707	Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease. <i>Pharmacogenomics Journal</i> , 2004, 4, 291-306.	0.9	32
708	Subthalamic Nucleus Stimulation Restores Glucose Metabolism in Associative and Limbic Cortices and in Cerebellum: Evidence from a FDG-PET Study in Advanced Parkinson's Disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2004, 24, 7-16.	2.4	192
709	Effect of intention and visual fixation disengagement on prosaccades in Parkinson's disease patients. <i>Neuropsychologia</i> , 2004, 42, 624-632.	0.7	18
710	Learning of ambiguous versus hybrid sequences by patients with Parkinson's disease. <i>Neuropsychologia</i> , 2004, 42, 1350-1357.	0.7	33
711	Functional brain imaging in the differential diagnosis of Parkinson's disease. <i>Lancet Neurology</i> , The, 2004, 3, 284-290.	4.9	66
712	Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease. <i>Lancet Neurology</i> , The, 2004, 3, 466-474.	4.9	62
713	Diagnostic issues in non-AD dementias. <i>Clinical Neuroscience Research</i> , 2004, 3, 363-374.	0.8	2
714	Sound lateralization in Parkinson's disease. <i>Cognitive Brain Research</i> , 2004, 21, 335-341.	3.3	22
715	Imaging of Brain Function Using SPECT. <i>Metabolic Brain Disease</i> , 2004, 19, 113-123.	1.4	44
716	The Scientific Basis for the Current Treatment of Parkinson's Disease. <i>Annual Review of Medicine</i> , 2004, 55, 41-60.	5.0	165
717	Oxidative Basis of Manganese Neurotoxicity. <i>Annals of the New York Academy of Sciences</i> , 2004, 1012, 129-141.	1.8	114

#	ARTICLE	IF	CITATIONS
718	Manganese-Induced Parkinsonism and Parkinson's Disease. <i>Annals of the New York Academy of Sciences</i> , 2004, 1012, 209-223.	1.8	423
719	Parkinson's disease: clinical aspects. <i>Cell and Tissue Research</i> , 2004, 318, 115-120.	1.5	117
720	Effects of bilateral subthalamic stimulation on sleep in Parkinson's disease. <i>Journal of Neurology</i> , 2004, 251, 214-218.	1.8	76
721	Prevalence of Parkinson's disease and other types of Parkinsonism. <i>Journal of Neurology</i> , 2004, 251, 340-345.	1.8	64
722	Orofacial apraxia in corticobasal degeneration, progressive supranuclear palsy, multiple system atrophy and Parkinson's disease. <i>Journal of Neurology</i> , 2004, 251, 1317-1323.	1.8	45
723	Lewy body-related α -synucleinopathy in the aged human brain. <i>Journal of Neural Transmission</i> , 2004, 111, 1219-1235.	1.4	243
724	Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study. <i>Journal of Neural Transmission</i> , 2004, 111, 1065-73.	1.4	45
725	Parkinsonism following striatal infarcts: incidence in a prospective stroke unit cohort. <i>Journal of Neural Transmission</i> , 2004, 111, 1473-1483.	1.4	44
726	Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2004, 111, 1447-1453.	1.4	100
727	The role of functional neuroimaging in the differential diagnosis of idiopathic Parkinson's disease and multiple system atrophy. <i>Clinical Autonomic Research</i> , 2004, 14, 84-91.	1.4	30
728	Significance of ^{123}I -MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: It can be a specific marker for Lewy body disease. <i>Annals of Nuclear Medicine</i> , 2004, 18, 453-461.	1.2	128
729	Reproducibility of dopamine transporter density measured with ^{123}I -FPCIT SPECT in normal control and Parkinson's disease patients. <i>Annals of Nuclear Medicine</i> , 2004, 18, 609-616.	1.2	28
730	Dopamine transporter SPECT using fast kinetic ligands: ^{123}I -FP-CIT versus $^{99\text{m}}\text{Tc}$ -TRODAT-1. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 1119-1127.	3.3	52
731	Usefulness of brain $^{99\text{m}}\text{Tc}$ -TRODAT-1 SPET for the evaluation of Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 155-161.	3.3	62
732	Differential response in choice reaction time following apomorphine based on prior dopaminergic treatment. <i>Acta Neurologica Scandinavica</i> , 2004, 109, 348-354.	1.0	5
733	The effect of vascular disease on late onset Parkinson's disease. <i>European Journal of Neurology</i> , 2004, 11, 231-235.	1.7	59
734	parkin mutation analysis in clinic patients with early-onset Parkinson's disease. <i>American Journal of Medical Genetics Part A</i> , 2004, 129A, 44-50.	2.4	49
735	The new mutation, E46K, of α -synuclein causes parkinson and Lewy body dementia. <i>Annals of Neurology</i> , 2004, 55, 164-173.	2.8	2,367

#	ARTICLE	IF	CITATIONS
736	A functional polymorphism regulating dopamine β -hydroxylase influences against Parkinson's disease. <i>Annals of Neurology</i> , 2004, 55, 443-446.	2.8	59
737	The gene responsible for PARK6 Parkinson's disease, PINK1, does not influence common forms of parkinsonism. <i>Annals of Neurology</i> , 2004, 56, 329-335.	2.8	38
738	Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. <i>International Journal of Geriatric Psychiatry</i> , 2004, 19, 1-8.	1.3	223
739	Exercise-induced dystonia as a preceding symptom of familial Parkinson's disease. <i>Movement Disorders</i> , 2004, 19, 228-230.	2.2	32
740	Assessing quality of life in Parkinson's disease: Can a short-form questionnaire be useful?. <i>Movement Disorders</i> , 2004, 19, 308-312.	2.2	45
741	Cerebrospinal fluid A β 242 levels in multiple system atrophy. <i>Movement Disorders</i> , 2004, 19, 238-240.	2.2	32
742	Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease. <i>Movement Disorders</i> , 2004, 19, 554-560.	2.2	63
743	Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease. <i>Movement Disorders</i> , 2004, 19, 571-579.	2.2	87
744	Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome. <i>Movement Disorders</i> , 2004, 19, 397-405.	2.2	488
745	Measurements of transcallosally mediated cortical inhibition for differentiating parkinsonian syndromes. <i>Movement Disorders</i> , 2004, 19, 518-528.	2.2	72
746	Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. <i>Movement Disorders</i> , 2004, 19, 630-640.	2.2	332
747	Evaluation of the role of Nurr1 in a large sample of familial Parkinson's disease. <i>Movement Disorders</i> , 2004, 19, 649-655.	2.2	33
748	Atypical parkinsonism and Annonaceae consumption in New Caledonia. <i>Movement Disorders</i> , 2004, 19, 603-604.	2.2	37
749	Parkinson's disease-like presentation of multiple system atrophy with poor response to STN stimulation: A clinicopathological case report. <i>Movement Disorders</i> , 2004, 19, 973-977.	2.2	46
750	Impact of dopamine transporter SPECT using ¹²³ I-lobflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. <i>Movement Disorders</i> , 2004, 19, 1175-1182.	2.2	269
751	Comparison of diffusion-weighted imaging and [¹²³ I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. <i>Movement Disorders</i> , 2004, 19, 1438-1445.	2.2	86
752	Distribution, type, and origin of Parkin mutations: Review and case studies. <i>Movement Disorders</i> , 2004, 19, 1146-1157.	2.2	219
753	Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease. <i>Movement Disorders</i> , 2004, 19, 1511-1515.	2.2	8

#	ARTICLE	IF	CITATIONS
754	Nurr1 mutational screen in Parkinson's disease. <i>Movement Disorders</i> , 2004, 19, 1503-1505.	2.2	18
755	Smoking and Parkinson's disease. <i>Movement Disorders</i> , 2004, 9, 207-212.	2.2	46
756	Treatment Benefit and Daily Drug Costs Associated with Treating Parkinson's Disease in a Parkinson's Disease Clinic. <i>CNS Drugs</i> , 2004, 18, 105-111.	2.7	20
758	Mutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews. <i>New England Journal of Medicine</i> , 2004, 351, 1972-1977.	13.9	559
759	Cardiac 123I-MIBG scintigraphy can assess the disease severity and phenotype of PD. <i>Journal of the Neurological Sciences</i> , 2004, 220, 105-111.	0.3	87
760	Noradrenergic mechanisms in neurodegenerative diseases: a theory. <i>Brain Research Reviews</i> , 2004, 45, 38-78.	9.1	380
761	Association of variations in monoamine oxidases A and B with Parkinson's disease subgroups. <i>Genomics</i> , 2004, 83, 454-460.	1.3	21
762	Hand rhythmic tapping and timing in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2004, 10, 143-148.	1.1	60
763	Association of a variation in the promoter region of the brain-derived neurotrophic factor gene with familial Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2004, 10, 213-219.	1.1	31
764	Visual object recognition deficits in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2004, 10, 227-233.	1.1	35
765	Caribbean parkinsonism and other atypical Parkinsonian disorders. <i>Parkinsonism and Related Disorders</i> , 2004, 10, S19-S26.	1.1	4
766	Parkinson's disease and thyroid dysfunction. <i>Parkinsonism and Related Disorders</i> , 2004, 10, 381-383.	1.1	41
767	Diagnostic accuracy of [99mTc]TRODAT-1 SPECT imaging in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2004, 10, 375-379.	1.1	52
768	Comparison of magnetic resonance imaging in subtypes of multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2004, 10, 363-368.	1.1	68
769	Differential involvement and heterogeneous phosphorylation of tau isoforms in progressive supranuclear palsy. <i>Molecular Brain Research</i> , 2004, 121, 95-101.	2.5	20
770	The E318G substitution in PSEN1 gene is not connected with Alzheimer's disease in a large Polish cohort. <i>Neuroscience Letters</i> , 2004, 357, 167-170.	1.0	13
771	Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease. <i>Neuroscience Letters</i> , 2004, 363, 284-287.	1.0	30
772	Genetic analysis of DJ-1 in a cohort Parkinson's disease patients of different ethnicity. <i>Neuroscience Letters</i> , 2004, 367, 109-112.	1.0	24

#	ARTICLE	IF	CITATIONS
773	Paraoxonase 1 (PON1) gene polymorphisms and Parkinson's disease in a Finnish population. <i>Neuroscience Letters</i> , 2004, 367, 168-170.	1.0	26
774	Transient arrest of psychogenic tremor induced by contralateral ballistic movements. <i>Neuroscience Letters</i> , 2004, 370, 135-139.	1.0	64
775	Analysis of MDR1 haplotypes in Parkinson's disease in a white population. <i>Neuroscience Letters</i> , 2004, 372, 240-244.	1.0	44
776	Post-stroke movement disorders: report of 56 patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 1568-1574.	0.9	232
777	<i>L</i> 1 (PARK7) mutations are less frequent than <i>Parkin</i> (PARK2) mutations in early-onset Parkinson disease. <i>Neurology</i> , 2004, 62, 389-394.	1.5	188
778	Abnormalities of prepulse inhibition do not depend on blink reflex excitability: a study in Parkinson's disease and Huntington's disease. <i>Clinical Neurophysiology</i> , 2004, 115, 1527-1536.	0.7	82
779	Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. <i>NeuroImage</i> , 2004, 21, 229-235.	2.1	143
780	Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. <i>NeuroImage</i> , 2004, 21, 1443-1451.	2.1	149
781	PET and SPECT functional imaging in Parkinson's disease. <i>Sleep Medicine</i> , 2004, 5, 201-206.	0.8	36
782	Neuropathological Substrates of Psychiatric Symptoms in Prospectively Studied Patients With Autopsy-Confirmed Dementia With Lewy Bodies. <i>American Journal of Psychiatry</i> , 2004, 161, 843-849.	4.0	130
783	Plasma Homocysteine Levels in Pergolide-Treated Parkinson Disease Patients. <i>Clinical Neuropharmacology</i> , 2004, 27, 163-165.	0.2	7
784	Lack of Familial Aggregation of Parkinson Disease and Alzheimer Disease. <i>Archives of Neurology</i> , 2004, 61, 1033-9.	4.9	36
785	Mood disorders in early Parkinson's disease. <i>Current Opinion in Psychiatry</i> , 2004, 17, 191-196.	3.1	9
786	Vascular parkinsonism. <i>Current Opinion in Neurology</i> , 2004, 17, 49-54.	1.8	37
788	Morning Glory Sign: A Particular MR Finding in Progressive Supranuclear Palsy. <i>Magnetic Resonance in Medical Sciences</i> , 2004, 3, 125-132.	1.1	93
789	Predictors of Impaired Daytime Sleep and Wakefulness in Patients With Parkinson Disease Treated With Older (Ergot) vs Newer (Nonergot) Dopamine Agonists. <i>Archives of Neurology</i> , 2004, 61, 97.	4.9	174
791	Association of N-acetyl transferase 2 gene polymorphism and slow acetylator phenotype with young onset and late onset Parkinson's disease among Indians. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 731-735.	0.7	16
792	Evaluation of Epidemiologic and Animal Data Associating Pesticides With Parkinson's Disease. <i>Journal of Occupational and Environmental Medicine</i> , 2005, 47, 1059-1087.	0.9	78

#	ARTICLE	IF	CITATIONS
793	The Relation Between Visual Hallucinations and Visual Evoked Potential in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2005, 28, 79-82.	0.2	27
794	How genetics research in Parkinson's disease is enhancing understanding of the common idiopathic forms of the disease. <i>Current Opinion in Neurology</i> , 2005, 18, 706-711.	1.8	62
795	Quetiapine for Insomnia in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2005, 28, 185-187.	0.2	75
796	Effects of Aging on the Regularity of Physiological Tremor. <i>Journal of Neurophysiology</i> , 2005, 93, 3064-3074.	0.9	90
797	Clinical, diagnostic, genetic and management issues in dementia with Lewy bodies. <i>Clinical Science</i> , 2005, 109, 343-354.	1.8	15
798	Causes and consequences of Parkinson's disease. <i>Nursing and Residential Care</i> , 2005, 7, 158-161.	0.1	2
799	N-isopropyl-p-123I Iodoamphetamine Single Photon Emission Computed Tomography Study of Parkinson's Disease with Dementia. <i>Internal Medicine</i> , 2005, 44, 1046-1050.	0.3	13
800	Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to l-dopa therapy. <i>European Journal of Neurology</i> , 2005, 12, 9-15.	1.7	38
801	Tyrosinase exacerbates dopamine toxicity but is not genetically associated with Parkinson's disease. <i>Journal of Neurochemistry</i> , 2005, 93, 246-256.	2.1	103
802	The Treatment of Patients with Parkinson's Disease: Who Cares?. <i>Practical Neurology</i> , 2005, 5, 66-67.	0.5	0
803	Differential progression of proprioceptive and visual information processing deficits in Parkinson's disease. <i>European Journal of Neuroscience</i> , 2005, 21, 239-248.	1.2	71
804	Relationships among impairment, disability, handicap, burden of care, economic expenses, event-related potentials and regional cerebral blood flow in Parkinson's disease. <i>Geriatrics and Gerontology International</i> , 2005, 5, 189-201.	0.7	0
805	Growth hormone response to arginine test distinguishes multiple system atrophy from Parkinson's disease and idiopathic late-onset cerebellar ataxia. <i>Clinical Endocrinology</i> , 2005, 62, 428-433.	1.2	24
806	PARK11 is not linked with Parkinson's disease in European families. <i>European Journal of Human Genetics</i> , 2005, 13, 193-197.	1.4	23
807	Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease?. <i>Acta Neurologica Scandinavica</i> , 2005, 111, 353-359.	1.0	28
808	Three-dimensional stereotactic surface projection study of orthostatic hypotension and brain perfusion image in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2005, 112, 36-41.	1.0	15
809	The prevalence of PD in a nutritionally deficient rural population in China. <i>Acta Neurologica Scandinavica</i> , 2005, 112, 29-35.	1.0	18
810	A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia. <i>Acta Psychiatrica Scandinavica</i> , 2005, 111, 403-409.	2.2	15

#	ARTICLE	IF	CITATIONS
811	Past tense formation and comprehension of passive sentences in Parkinson's disease: Evidence from Greek. <i>Brain and Language</i> , 2005, 94, 297-303.	0.8	34
812	Progressive supranuclear palsy: A systematic review. <i>Neurobiology of Disease</i> , 2005, 20, 179-186.	2.1	42
813	Memory for time intervals is impaired in left hemi-Parkinson patients. <i>Neuropsychologia</i> , 2005, 43, 1163-1167.	0.7	32
814	Lack of evidence for a genetic association between FGF20 and Parkinson's disease in Finnish and Greek patients. <i>BMC Neurology</i> , 2005, 5, 11.	0.8	37
815	parkin mutation dosage and the phenomenon of anticipation: a molecular genetic study of familial parkinsonism. <i>BMC Neurology</i> , 2005, 5, 4.	0.8	10
816	Medical healthcare use in Parkinson's disease: survey in a cohort of ambulatory patients in Italy. <i>BMC Health Services Research</i> , 2005, 5, 26.	0.9	20
817	Dementia in Parkinson's disease: a post-mortem study in a population of brain donors. <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 418-422.	1.3	39
818	Clinical and positron emission tomography of Parkinson's disease caused by LRRK2. <i>Annals of Neurology</i> , 2005, 57, 453-456.	2.8	105
819	Multiple regions of α -synuclein are associated with Parkinson's disease. <i>Annals of Neurology</i> , 2005, 57, 535-541.	2.8	223
820	Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. <i>Annals of Neurology</i> , 2005, 58, 630-634.	2.8	193
821	Common variants of LRRK2 are not associated with sporadic Parkinson's disease. <i>Annals of Neurology</i> , 2005, 58, 905-908.	2.8	53
822	Three-dimensional gait biomechanics in Parkinson's disease: Evidence for a centrally mediated amplitude regulation disorder. <i>Movement Disorders</i> , 2005, 20, 40-50.	2.2	196
823	Impact of the motor complications of Parkinson's disease on the quality of life. <i>Movement Disorders</i> , 2005, 20, 224-230.	2.2	463
824	Pilot association study of the β -glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity. <i>Movement Disorders</i> , 2005, 20, 100-103.	2.2	93
825	Sydney multicenter study of Parkinson's disease: Non-L-dopa-responsive problems dominate at 15 years. <i>Movement Disorders</i> , 2005, 20, 190-199.	2.2	967
826	Novel parkin mutations detected in patients with early-onset Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 424-431.	2.2	60
827	Force control and disease severity in Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 441-450.	2.2	59
828	FP-CIT and MIBG scintigraphy in early Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 552-561.	2.2	101

#	ARTICLE	IF	CITATIONS
829	Mosapride citrate, a novel 5-HT ₄ agonist and partial 5-HT ₃ antagonist, ameliorates constipation in parkinsonian patients. <i>Movement Disorders</i> , 2005, 20, 680-686.	2.2	174
830	Patient-perceived involvement and satisfaction in Parkinson's disease: Effect on therapy decisions and quality of life. <i>Movement Disorders</i> , 2005, 20, 616-619.	2.2	100
831	Progressive supranuclear palsy-like phenotype associated with bilateral hypoxic-ischemic striopallidal lesions. <i>Movement Disorders</i> , 2005, 20, 755-757.	2.2	14
832	Does cigarette smoking provide clinically significant neuroprotection among patients diagnosed with Parkinson's disease?. <i>Movement Disorders</i> , 2005, 20, 641-642.	2.2	3
833	Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: Report of a case series. <i>Movement Disorders</i> , 2005, 20, 873-877.	2.2	27
834	Identifying and distinguishing cases of parkinsonism and Parkinson's disease using ICD-9 CM codes and pharmacy data. <i>Movement Disorders</i> , 2005, 20, 964-970.	2.2	57
835	Emergency hospital admissions in idiopathic Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 1104-1108.	2.2	164
836	Bilateral stimulation of nucleus subthalamicus in advanced Parkinson's disease: No effects on, and of, autonomic dysfunction. <i>Movement Disorders</i> , 2005, 20, 976-981.	2.2	34
837	Mutation of the Parkin gene in a Persian family: Clinical progression over a 40-year period. <i>Movement Disorders</i> , 2005, 20, 887-890.	2.2	4
838	Three-dimensional stereotactic surface projection study of freezing of gait and brain perfusion image in Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 1272-1277.	2.2	60
839	Atypical unclassifiable parkinsonism on Guadeloupe: An environmental toxic hypothesis. <i>Movement Disorders</i> , 2005, 20, S114-S118.	2.2	29
840	Validity of a modified Parkinson's disease screening questionnaire in India: Effects of literacy of participants and medical training of screeners and implications for screening efforts in developing countries. <i>Movement Disorders</i> , 2005, 20, 1550-1556.	2.2	13
841	Abnormal sleep architecture is an early feature in the E46K familial synucleinopathy. <i>Movement Disorders</i> , 2005, 20, 1310-1315.	2.2	34
842	Suboptimal medication adherence in Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 1502-1507.	2.2	179
843	Corticobasal degeneration and Parkinson's disease assessed by HmPaO SPECT: The utility of factorial discriminant analysis. <i>Movement Disorders</i> , 2005, 20, 1431-1438.	2.2	17
844	Effect of levodopa on pain threshold in Parkinson's disease: A clinical and positron emission tomography study. <i>Movement Disorders</i> , 2005, 20, 1557-1563.	2.2	343
845	Osteoporosis in Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 1636-1640.	2.2	39
846	Differences in [99mTc]TRODAT-1 SPECT binding to dopamine transporters in patients with multiple system atrophy and Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 302-307.	3.3	31

#	ARTICLE	IF	CITATIONS
847	Early-stage [¹²³ I]β-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 689-695.	3.3	31
848	Does subthalamic nucleus stimulation affect the frontal limbic areas? A single-photon emission computed tomography study using a manual anatomical segmentation method. <i>Surgical and Radiologic Anatomy</i> , 2005, 27, 389-394.	0.6	15
851	Parkinsonism with excessive daytime sleepiness. <i>Journal of Neurology</i> , 2005, 252, 139-145.	1.8	115
852	Progression of parkinsonism in multiple system atrophy. <i>Journal of Neurology</i> , 2005, 252, 91-96.	1.8	55
853	High frequency stimulation of the subthalamic nucleus is efficacious in Parkin disease. <i>Journal of Neurology</i> , 2005, 252, 208-211.	1.8	40
854	Association study of the G258S transferrin gene polymorphism and Parkinson's disease in the Spanish population. <i>Journal of Neurology</i> , 2005, 252, 1269-1270.	1.8	10
855	Different clinical and evolutionary patterns in late idiopathic and vascular parkinsonism. <i>Journal of Neurology</i> , 2005, 252, 1045-1049.	1.8	51
856	Development and evaluation of the Parkinson Psychosis Questionnaire. <i>Journal of Neurology</i> , 2005, 252, 1060-1066.	1.8	53
857	Factors associated with drug-induced visual hallucinations in Parkinson's disease. <i>Journal of Neurology</i> , 2005, 252, 1223-1228.	1.8	74
858	Effect of bilateral subthalamic nucleus stimulation on balance and finger control in Parkinson's disease. <i>Journal of Neurology</i> , 2005, 252, 1487-1494.	1.8	33
859	Analysis of polyglutamine-coding repeats in the TATA-binding protein in different neurodegenerative diseases. <i>Journal of Neural Transmission</i> , 2005, 112, 539-546.	1.4	25
860	Combined ¹²³ I-FP-CIT and ¹²³ I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. <i>Journal of Neural Transmission</i> , 2005, 112, 677-692.	1.4	213
861	Efficacy of budipine and placebo in untreated patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2005, 112, 1015-1023.	1.4	8
862	Imaging of dopamine transporters and D2 receptors in vascular parkinsonism: a report of four cases. <i>Journal of Neural Transmission</i> , 2005, 112, 1355-1361.	1.4	21
863	Quality of life and gender identity in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2005, 112, 1511-1522.	1.4	27
864	Brain SPECT imaging in multiple system atrophy. <i>Journal of Neural Transmission</i> , 2005, 112, 1635-1645.	1.4	50
865	Metaiodobenzylguanidine (MIBG) uptake in Parkinson's disease also decreases at thyroid. <i>Annals of Nuclear Medicine</i> , 2005, 19, 225-229.	1.2	27
866	Low-Frequency MEG Activity and MRI Evaluation in Parkinson's Disease. <i>Brain Topography</i> , 2005, 18, 59-63.	0.8	27

#	ARTICLE	IF	CITATIONS
867	Exclusion of PINK1 as candidate gene for the late-onset form of Parkinson's disease in two European populations. <i>Journal of Negative Results in BioMedicine</i> , 2005, 4, 10.	1.4	10
869	123-I ioflupane (Datscan®) presynaptic nigrostriatal imaging in patients with movement disorders. <i>Brazilian Archives of Biology and Technology</i> , 2005, 48, 115-126.	0.5	6
870	Approach to the patient presenting with parkinsonism. , 2005, , 551-560.		0
871	Depression in Parkinson's disease: study of 60 cases. <i>Arquivos De Neuro-Psiquiatria</i> , 2005, 63, 766-771.	0.3	19
872	The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs. <i>Neurology</i> , 2005, 64, 1397-1403.	1.5	160
873	Family-based case-control study of cigarette smoking and Parkinson disease. <i>Neurology</i> , 2005, 64, 442-447.	1.5	66
874	Testing association between LRRK2 and Parkinson's disease and investigating linkage disequilibrium. <i>Journal of Medical Genetics</i> , 2005, 43, e09-e09.	1.5	32
875	New and reliable MRI diagnosis for progressive supranuclear palsy. <i>Neurology</i> , 2005, 64, 2050-2055.	1.5	345
876	"Applause sign" helps to discriminate PSP from FTD and PD. <i>Neurology</i> , 2005, 64, 2132-2133.	1.5	121
877	Cognitive status correlates with neuropathologic stage in Parkinson disease. <i>Neurology</i> , 2005, 64, 1404-1410.	1.5	509
878	Conséquences fonctionnelles de la sclérose en plaques et de la maladie de Parkinson. , 2005, , 527-531.		2
879	Sex Differences in Clinical and Genetic Determinants of Levodopa Peak-Dose Dyskinesias in Parkinson Disease. <i>Archives of Neurology</i> , 2005, 62, 601.	4.9	195
880	Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1217-1221.	0.9	137
881	The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. <i>Journal of Medical Genetics</i> , 2005, 42, e65-e65.	1.5	178
882	Effect of MDR1 Haplotype on Risk of Parkinson Disease. <i>Archives of Neurology</i> , 2005, 62, 460.	4.9	66
883	Neurocardiogenic Syncope and Related Disorders of Orthostatic Intolerance. <i>Circulation</i> , 2005, 111, 2997-3006.	1.6	182
884	Population genetic approaches to neurological disease: Parkinson's disease as an example. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2005, 360, 1573-1578.	1.8	4
885	Amino-Truncated Î²-Amyloid42 Peptides in Cerebrospinal Fluid and Prediction of Progression of Mild Cognitive Impairment. <i>Clinical Chemistry</i> , 2005, 51, 1650-1660.	1.5	82

#	ARTICLE	IF	CITATIONS
886	Prevalence of parkinsonism and relationship to exposure in a large sample of Alabama welders. <i>Neurology</i> , 2005, 64, 230-235.	1.5	173
887	How useful is [123I]Â-CIT SPECT in clinical practice?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1211-1216.	0.9	61
888	Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 77, 372-374.	0.9	43
889	Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. <i>Neurology</i> , 2005, 65, 247-252.	1.5	330
890	Vascular parkinsonism--an important cause of parkinsonism in older people. <i>Age and Ageing</i> , 2005, 34, 114-119.	0.7	108
892	Apomorphine: an overview of clinical use. <i>Aging Health</i> , 2005, 1, 193-202.	0.3	1
893	A systematic review of nutritional risk factors of Parkinson's disease. <i>Nutrition Research Reviews</i> , 2005, 18, 259-282.	2.1	40
894	Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. <i>Brain</i> , 2005, 128, 1314-1322.	3.7	905
895	Parkinson disease: Handedness predicts asymmetry. <i>Neurology</i> , 2005, 64, 1925-1930.	1.5	128
896	Motor Deficits, Exercise, and Parkinson's Disease. <i>Quest</i> , 2005, 57, 79-101.	0.8	7
897	Voxel-wise analysis of [123I]Â-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. <i>Brain</i> , 2005, 128, 1605-1612.	3.7	115
898	Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 77, 317-321.	0.9	162
899	Long duration asymmetrical postural tremor is likely to predict development of Parkinson's disease and not essential tremor: clinical follow up study of 13 cases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 115-117.	0.9	95
900	Nonlinear Progression of Parkinson Disease as Determined by Serial Positron Emission Tomographic Imaging of Striatal Fluorodopa F 18 Activity. <i>Archives of Neurology</i> , 2005, 62, 378.	4.9	268
901	Dopamine Transporter Positron Emission Tomography in Spinocerebellar Ataxias Type 1, 2, 3, and 6. <i>Archives of Neurology</i> , 2005, 62, 1280.	4.9	89
902	Differential impairment of spatial location memory in Huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1516-1519.	0.9	33
903	Early-onset parkinsonism associated with PINK1 mutations: Frequency, genotypes, and phenotypes. <i>Neurology</i> , 2005, 65, 87-95.	1.5	323
904	The sepiapterin reductase gene region reveals association in the PARK3 locus: analysis of familial and sporadic Parkinson's disease in European populations. <i>Journal of Medical Genetics</i> , 2005, 43, 557-562.	1.5	38

#	ARTICLE	IF	CITATIONS
905	Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 343-348.	0.9	462
906	Contribution of Aging to the Severity of Different Motor Signs in Parkinson Disease. Archives of Neurology, 2005, 62, 467.	4.9	88
907	Bilateral subthalamotomy in Parkinson's disease: initial and long-term response. Brain, 2005, 128, 570-583.	3.7	184
908	Management of Referred Deep Brain Stimulation Failures. Archives of Neurology, 2005, 62, 1250.	4.9	400
909	Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy. Brain, 2005, 128, 1259-1266.	3.7	133
910	Acute akinesia in Parkinson disease. Neurology, 2005, 64, 1162-1169.	1.5	91
911	Alpha-Synuclein Lesions in Normal Aging, Parkinson Disease, and Alzheimer Disease: Evidence from the Baltimore Longitudinal Study of Aging (BLSA). Journal of Neuropathology and Experimental Neurology, 2005, 64, 156-162.	0.9	134
912	A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet, The, 2005, 365, 415-416.	6.3	391
914	Diagnosis and Initial Management of Parkinson's Disease. New England Journal of Medicine, 2005, 353, 1021-1027.	13.9	285
915	Abnormal head nociceptive withdrawal reaction to facial nociceptive stimuli in Parkinson's disease. Clinical Neurophysiology, 2005, 116, 2091-2098.	0.7	32
916	Executive dysfunction in Parkinson's disease is associated with altered pallidal "frontal processing. NeuroImage, 2005, 25, 588-599.	2.1	78
917	FDG PET in the differential diagnosis of parkinsonian disorders. NeuroImage, 2005, 26, 912-921.	2.1	385
918	Identification of a Novel LRRK2 Mutation Linked to Autosomal Dominant Parkinsonism: Evidence of a Common Founder across European Populations. American Journal of Human Genetics, 2005, 76, 672-680.	2.6	524
919	[99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. Neurology, 2005, 64, 1716-1720.	1.5	150
920	Dementia in Parkinson disease: Functional imaging of cholinergic and dopaminergic pathways. Neurology, 2005, 65, 1716-1722.	1.5	340
921	Genetics of Parkinson's disease. Annals of Medicine, 2005, 37, 86-96.	1.5	67
922	Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. Brain, 2005, 128, 3000-3011.	3.7	247
923	Simultaneous Measurement of β -Amyloid(1-42), Total Tau, and Phosphorylated Tau (Thr181) in Cerebrospinal Fluid by the xMAP Technology. Clinical Chemistry, 2005, 51, 336-345.	1.5	400

#	ARTICLE	IF	CITATIONS
924	Cognitive profile of patients with newly diagnosed Parkinson disease. <i>Neurology</i> , 2005, 65, 1239-1245.	1.5	890
925	Unaltered α -synuclein blood levels in juvenile Parkinsonism with a parkin exon 4 deletion. <i>Neuroscience Letters</i> , 2005, 374, 189-191.	1.0	16
926	Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using ¹³ C-sodium octanoate breath test. <i>Neuroscience Letters</i> , 2005, 375, 170-173.	1.0	135
927	Analysis of SCA-2 and SCA-3 repeats in Parkinsonism: Evidence of SCA-2 expansion in a family with autosomal dominant Parkinson's disease. <i>Neuroscience Letters</i> , 2005, 382, 191-194.	1.0	33
928	Voxel based comparison of glucose metabolism in the differential diagnosis of the multiple system atrophy using statistical parametric mapping. <i>Neuroscience Research</i> , 2005, 52, 211-219.	1.0	43
929	Neurodegenerative disorders mimicking progressive supranuclear palsy: a report of three cases. <i>Journal of Clinical Neuroscience</i> , 2005, 12, 941-945.	0.8	8
930	Trunk sway measurements during stance and gait tasks in Parkinson's disease. <i>Gait and Posture</i> , 2005, 22, 240-249.	0.6	128
931	Brain 3D-SSP SPECT analysis in dementia with Lewy bodies, Parkinson's disease with and without dementia, and Alzheimer's disease. <i>Clinical Neurology and Neurosurgery</i> , 2005, 107, 396-403.	0.6	60
932	Atypical parkinsonism on Guadeloupe, comparison with the parkinsonism-dementia complex of Guam, and environmental toxic hypotheses. <i>Environmental Toxicology and Pharmacology</i> , 2005, 19, 407-413.	2.0	19
933	Direction-specific postural instability in subjects with Parkinson's disease. <i>Experimental Neurology</i> , 2005, 193, 504-521.	2.0	329
934	Parkinsonian action tremor: Interference with object manipulation and lacking levodopa response. <i>Experimental Neurology</i> , 2005, 194, 151-160.	2.0	34
935	Administration of selegiline is not associated with visual hallucinations in advanced Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 265-266.	1.1	3
936	Visual event-related potentials under different interstimulus intervals in Parkinson's disease: Relation to motor disability, WAIS-R, and regional cerebral blood flow. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 209-219.	1.1	13
937	Early-onset Parkinson's disease in a Chinese population: ^{99m} Tc-TRODAT-1 SPECT, Parkin gene analysis and clinical study. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 173-180.	1.1	37
938	Quality of life in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 221-226.	1.1	132
939	Brain perfusion differences between Parkinson's disease and multiple system atrophy with predominant parkinsonian features. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 227-232.	1.1	25
940	Psychometric characteristics of the Parkinson's disease questionnaire (PDQ-39) - Ecuadorian version. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 297-304.	1.1	23
941	The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: evidence from the results of an open, prospective, one-year trial. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 509-512.	1.1	29

#	ARTICLE	IF	CITATIONS
942	Prevalence of parkin gene mutations and variations in idiopathic Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 341-347.	1.1	14
943	Balance and fear of falling in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 427-433.	1.1	116
944	Correlates of excessive daytime sleepiness in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 441-448.	1.1	24
945	Cause, seasonality of death and co-morbidities in progressive supranuclear palsy (PSP). <i>Parkinsonism and Related Disorders</i> , 2005, 11, 459-463.	1.1	28
946	The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 521-522.	1.1	70
947	Activating transcription factor 2 expression in the adult human brain: Association with both neurodegeneration and neurogenesis. <i>Neuroscience</i> , 2005, 133, 437-451.	1.1	63
948	Rigidity and bradykinesia reduce interlimb coordination in Parkinsonian gait. <i>Archives of Physical Medicine and Rehabilitation</i> , 2005, 86, 183-189.	0.5	73
949	Metaiodobenzylguanidine (MIBG) scintigraphy at various parts of the body in Parkinson's disease and multiple system atrophy. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2005, 119, 56-60.	1.4	15
954	Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2005, 231, 35-39.	0.3	26
955	Role of [18F]-dopa PET imaging in assessing movement disorders. <i>Radiologic Clinics of North America</i> , 2005, 43, 93-106.	0.9	33
956	Characterization of Proteome of Human Cerebrospinal Fluid. <i>International Review of Neurobiology</i> , 2006, 73, 29-98.	0.9	28
957	Validity and Utility of a LRRK2 G2019S Mutation Test for the Diagnosis of Parkinson's Disease. <i>Genetic Testing and Molecular Biomarkers</i> , 2006, 10, 221-227.	1.7	32
958	A Case-Control Association Study of the 12 Single-Nucleotide Polymorphisms Implicated in Parkinson Disease by a Recent Genome Scan. <i>American Journal of Human Genetics</i> , 2006, 78, 1090-1092.	2.6	38
959	Conflicting Results Regarding the Semaphorin Gene (SEMA5A) and the Risk for Parkinson Disease. <i>American Journal of Human Genetics</i> , 2006, 78, 1082-1083.	2.6	50
960	Comparison of region-of-interest analysis and human observers in the diagnosis of Parkinson's disease using [99mTc]TRODAT-1 and SPECT. <i>Physics in Medicine and Biology</i> , 2006, 51, 575-585.	1.6	24
962	Progression of putaminal degeneration in multiple system atrophy: A serial diffusion MR study. <i>NeuroImage</i> , 2006, 31, 240-245.	2.1	98
963	Low frequency rTMS of the SMA transiently ameliorates peak-dose LID in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2006, 117, 1917-1921.	0.7	85
965	Parkinsonian Syndromes. <i>Clinics in Geriatric Medicine</i> , 2006, 22, 827-842.	1.0	9

#	ARTICLE	IF	CITATIONS
966	Brain SPECT analysis by 3D-SSP and phenotype of Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2006, 241, 67-72.	0.3	27
967	Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: Analysis with [123I]IPT single photon emission computed tomography. <i>Journal of the Neurological Sciences</i> , 2006, 244, 103-109.	0.3	34
968	The range and nature of sleep dysfunction in untreated Parkinson's disease (PD). A comparative controlled clinical study using the Parkinson's disease sleep scale and selective polysomnography. <i>Journal of the Neurological Sciences</i> , 2006, 248, 158-162.	0.3	99
969	Are dementia and depression in Parkinson's disease related?. <i>Journal of the Neurological Sciences</i> , 2006, 248, 138-142.	0.3	43
970	Vascular parkinsonism "an update. <i>Journal of the Neurological Sciences</i> , 2006, 248, 185-191.	0.3	61
971	Effects of acute tryptophan depletion on cognition, memory and motor performance in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2006, 248, 259-265.	0.3	13
972	Complex I polymorphisms, bigenomic heterogeneity, and family history in Virginians with Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2006, 247, 224-230.	0.3	21
973	Effects of transcranial direct current stimulation on working memory in patients with Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2006, 249, 31-38.	0.3	551
974	Is it Parkinson's disease, and if not, what is it?. <i>Practical Neurology</i> , 2006, 6, 154-165.	0.5	10
975	A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease. <i>New England Journal of Medicine</i> , 2006, 355, 896-908.	13.9	2,577
976	Stimulation of the caudal zona incerta is superior to stimulation of the subthalamic nucleus in improving contralateral parkinsonism. <i>Brain</i> , 2006, 129, 1732-1747.	3.7	471
977	Broadening a classic clinical triad: The hypokinetic motor disorder of normal pressure hydrocephalus also affects the hand. <i>Experimental Neurology</i> , 2006, 198, 81-87.	2.0	31
978	Camptocormia or Pisa syndrome in multiple system atrophy. <i>Clinical Neurology and Neurosurgery</i> , 2006, 108, 699-704.	0.6	43
979	The effect of depression on motor function and disease severity of Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2006, 108, 465-469.	0.6	53
980	LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?. <i>Trends in Molecular Medicine</i> , 2006, 12, 76-82.	3.5	86
981	Analysis of the PINK1 gene in a cohort of patients with sporadic early-onset parkinsonism in Taiwan. <i>Neuroscience Letters</i> , 2006, 394, 33-36.	1.0	37
982	Absence/rarity of commonly reported LRRK2 mutations in Indian Parkinson's disease patients. <i>Neuroscience Letters</i> , 2006, 409, 83-88.	1.0	75
983	Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. <i>Neuroscience Letters</i> , 2006, 404, 56-60.	1.0	56

#	ARTICLE	IF	CITATIONS
984	Association study of sporadic Parkinson's disease genetic risk factors in patients from Russia by APEX technology. <i>Neuroscience Letters</i> , 2006, 405, 212-216.	1.0	13
985	Mutations in DJ-1 are rare in familial Parkinson disease. <i>Neuroscience Letters</i> , 2006, 408, 209-213.	1.0	45
986	The diagnosis of manganese-induced parkinsonism. <i>NeuroToxicology</i> , 2006, 27, 340-346.	1.4	203
987	A rapid method for mass screening for parkinsonism. <i>NeuroToxicology</i> , 2006, 27, 357-361.	1.4	14
988	Vigilance troubles in Parkinson's disease: A subjective and objective polysomnographic study. <i>Sleep Medicine</i> , 2006, 7, 448-453.	0.8	70
989	The effects of visual rhythms and optic flow on stride patterns of patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 21-27.	1.1	57
990	Parkin mutations in familial and sporadic Parkinson's disease among Indians. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 239-245.	1.1	43
991	Wisconsin Card Sorting Test and brain perfusion imaging in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 273-278.	1.1	10
992	Does cardiac metaiodobenzylguanidine (MIBG) uptake in Parkinson's disease correlate with major autonomic symptoms?. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 284-288.	1.1	57
993	Anticipation of onset age in familial Parkinson's disease without SCA gene mutations. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 309-313.	1.1	3
994	Disruptions of the fornix fiber in parkinsonian patients with excessive daytime sleepiness. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 319-322.	1.1	27
995	Parkinson's disease and family history. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 399-409.	1.1	56
996	LRRK2 G2019S mutation and Parkinson's disease: A clinical, neuropsychological and neuropsychiatric study in a large Italian sample. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 410-419.	1.1	106
997	Progression patterns of neuronal loss and Lewy body pathology in the substantia nigra in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2006, 12, S92-S98.	1.1	26
998	Lewy body disease: Thalamic cholinergic activity related to dementia and parkinsonism. <i>Neurobiology of Aging</i> , 2006, 27, 433-438.	1.5	58
1001	Syndromic Approach to Parkinson's Disease: Role of Functional Imaging. <i>Journal of Clinical Neurology</i>		

#	ARTICLE	IF	CITATIONS
1004	Quality of life in a Brazilian sample of patients with Parkinson's disease and their caregivers. Revista Brasileira De Psiquiatria, 2006, 28, 209-211.	0.9	29

1005 Clinical Implications of Cardiac-MIBG SPECT in the Differentiation of Parkinsonian Syndromes. Journal

#	ARTICLE	IF	CITATIONS
1023	Placebo-controlled trial of riluzole in multiple system atrophy. <i>European Journal of Neurology</i> , 2006, 13, 1146-1148.	1.7	32
1024	Overactive bladder in Parkinson's disease: alteration of brainstem raphe detected by transcranial sonography. <i>European Journal of Neurology</i> , 2006, 13, 1291-1297.	1.7	18
1025	LRRK2 mutations in a clinic-based cohort of Parkinson's disease. <i>European Journal of Neurology</i> , 2006, 13, 1298-1301.	1.7	7
1026	Parkin gene variations in late-onset Parkinson's disease: comparison between Norwegian and German cohorts. <i>Acta Neurologica Scandinavica</i> , 2006, 113, 9-13.	1.0	23
1027	Dietary factors and smoking as risk factors for PD in a rural population in China: a nested case-control study. <i>Acta Neurologica Scandinavica</i> , 2006, 113, 278-281.	1.0	26
1028	Depression in Parkinson's disease - a review. <i>Acta Neurologica Scandinavica</i> , 2006, 113, 1-8.	1.0	215
1029	A systematic review of depression and mental illness preceding Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2006, 113, 211-220.	1.0	265
1030	Features associated with the development of hallucinations in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2006, 114, 239-243.	1.0	42
1031	The validity of a hyperventilation test for an investigation of autonomic failure: assessment in patients with multiple system atrophy and Parkinson's disease. <i>International Journal of Clinical Practice</i> , 2006, 60, 1542-1547.	0.8	6
1032	Clinical Lewy Body Syndromes. <i>Annals of the New York Academy of Sciences</i> , 2000, 920, 1-8.	1.8	44
1033	Predictors of gastric emptying in Parkinson's disease. <i>Neurogastroenterology and Motility</i> , 2006, 18, 369-375.	1.6	149
1034	Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. <i>European Journal of Human Genetics</i> , 2006, 14, 322-331.	1.4	152
1035	Chromosome 5 and Parkinson disease. <i>European Journal of Human Genetics</i> , 2006, 14, 1106-1110.	1.4	4
1036	Parkinson's Disease and Brain Mitochondrial Dysfunction: A Functional Phosphorus Magnetic Resonance Spectroscopy Study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2006, 26, 283-290.	2.4	89
1037	[11C]d-threo-methylphenidate PET in patients with Parkinson's disease and essential tremor. <i>Journal of Neural Transmission</i> , 2006, 113, 187-193.	1.4	38
1038	Analysis of the polymorphic prion protein gene codon 129 in idiopathic Parkinson's disease. <i>Journal of Neural Transmission</i> , 2006, 113, 331-337.	1.4	16
1039	Kinematic analysis of dopaminergic effects on skilled handwriting movements in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2006, 113, 609-623.	1.4	97
1040	Kinetic tremor in Parkinson's disease – an underrated symptom. <i>Journal of Neural Transmission</i> , 2006, 113, 845-853.	1.4	55

#	ARTICLE	IF	CITATIONS
1041	Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome. <i>Journal of Neural Transmission</i> , 2006, 113, 1177-1190.	1.4	33
1042	The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. <i>Journal of Neural Transmission</i> , 2006, 113, 1435-1439.	1.4	216
1043	Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2006, 113, 1441-1448.	1.4	50
1044	Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia. <i>Journal of Neural Transmission</i> , 2006, 113, 1787-1790.	1.4	20
1045	Feasibility of ² -deoxy- ² [¹⁸ F]fluoro- ² glucose- ² A85380 PET for imaging of human cardiac nicotinic acetylcholine receptors in vivo. <i>Clinical Research in Cardiology</i> , 2006, 95, 105-109.	1.5	24
1047	The place of perceptual analysis of dysarthria in the differential diagnosis of corticobasal degeneration and Parkinson's disease. <i>Journal of Neurology</i> , 2006, 253, 92-97.	1.8	12
1048	Levodopa availability improves with progression of Parkinson's disease. <i>Journal of Neurology</i> , 2006, 253, 1221-1226.	1.8	24
1049	End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease. <i>Journal of Neurology</i> , 2006, 253, 1633-1639.	1.8	26
1050	Myocardial ¹²³ I-MIBG scintigraphy in patients with PSP, CBD and MSA. <i>Journal of Neurology</i> , 2006, 253, iii35-iii40.	1.8	11
1051	Early-onset Parkinson's disease caused by a novel parkin mutation in a genetic isolate from north-eastern Brazil. <i>Neurogenetics</i> , 2006, 7, 13-19.	0.7	21
1052	A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. <i>Neurogenetics</i> , 2006, 7, 133-138.	0.7	255
1053	Genetic susceptibility to Parkinson's disease among South and North Indians: I. Role of polymorphisms in dopamine receptor and transporter genes and association of DRD4 120-bp duplication marker. <i>Neurogenetics</i> , 2006, 7, 223-229.	0.7	23
1054	Quantitative simultaneous ^{99m} Tc-ECD/ ¹²³ I-FP-CIT SPECT in Parkinson's disease and multiple system atrophy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 87-92.	3.3	50
1055	Comparative non-radioactive RT-PCR assay: An approach to study the neurosteroids biosynthetic pathway in humans. <i>Journal of Neuroscience Methods</i> , 2006, 153, 290-298.	1.3	7
1056	Initial treatment of parkinson's disease. <i>Current Treatment Options in Neurology</i> , 2006, 8, 224-235.	0.7	13
1057	Evaluation of basal ganglia haemodynamic changes with perfusion-weighted magnetic resonance imaging in patients with Parkinson's disease. <i>Radiologia Medica</i> , 2006, 111, 284-290.	4.7	2
1058	Preclinical diagnosis of parkinson's disease: Are we there yet?. <i>Current Neurology and Neuroscience Reports</i> , 2006, 6, 295-301.	2.0	51
1059	Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode. <i>General Hospital Psychiatry</i> , 2006, 28, 59-64.	1.2	35

#	ARTICLE	IF	CITATIONS
1060	Brain dopamine and kinematics of graphomotor functions. <i>Human Movement Science</i> , 2006, 25, 492-509.	0.6	55
1061	The impact of normal aging and Parkinson's disease on response preparation in task-switching behavior. <i>Brain Research</i> , 2006, 1114, 173-182.	1.1	27
1062	The diagnosis of Parkinson's disease. <i>Lancet Neurology, The</i> , 2006, 5, 75-86.	4.9	665
1063	Non-motor symptoms of Parkinson's disease: diagnosis and management. <i>Lancet Neurology, The</i> , 2006, 5, 235-245.	4.9	2,202
1064	Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. <i>Lancet Neurology, The</i> , 2006, 5, 572-577.	4.9	901
1065	Case-control studies in the genomic era: a clinician's guide. <i>Lancet Neurology, The</i> , 2006, 5, 701-707.	4.9	43
1066	The mystery of motor asymmetry in Parkinson's disease. <i>Lancet Neurology, The</i> , 2006, 5, 796-802.	4.9	308
1067	Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. <i>Neurobiology of Disease</i> , 2006, 23, 481-489.	2.1	105
1068	Patients with Parkinson's disease learn to control complex systems – an indication for intact implicit cognitive skill learning. <i>Neuropsychologia</i> , 2006, 44, 2445-2451.	0.7	31
1069	Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort. <i>BMC Neurology</i> , 2006, 6, 24.	0.8	78
1070	The frequency and validity of self-reported diagnosis of Parkinson's Disease in the UK elderly: MRC CFAS cohort. <i>BMC Neurology</i> , 2006, 6, 29.	0.8	14
1071	A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan. <i>BMC Neurology</i> , 2006, 6, 47.	0.8	83
1072	Neuropathology, tremor and electromyogram in rats exposed to manganese phosphate/sulfate mixture. <i>Journal of Applied Toxicology</i> , 2006, 26, 419-426.	1.4	10
1073	Orthostatic hypotension in Parkinson's disease: association with cognitive decline?. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 778-783.	1.3	97
1074	Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. <i>Movement Disorders</i> , 2006, 21, 45-49.	2.2	91
1075	HS1-BP3 gene variant is common in familial essential tremor. <i>Movement Disorders</i> , 2006, 21, 306-309.	2.2	27
1076	Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and parkin-linked Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 299-305.	2.2	18
1077	Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. <i>Movement Disorders</i> , 2006, 21, 332-336.	2.2	47

#	ARTICLE	IF	CITATIONS
1078	REM sleep behavior disorder, hallucinations, and cognitive impairment in Parkinson's disease. Movement Disorders, 2006, 21, 462-466.	2.2	118
1079	Subthalamic nucleus influences spatial orientation in extrapersonal space. Movement Disorders, 2006, 21, 354-361.	2.2	19
1080	Parkinson's disease and LRRK2: Frequency of a common mutation in U.S. movement disorder clinics. Movement Disorders, 2006, 21, 519-523.	2.2	84
1081	No correlation between the clinical severity of autonomic symptoms (SCOPA-AUT) and electrophysiological test abnormalities in advanced Parkinson's disease. Movement Disorders, 2006, 21, 430-431.	2.2	16
1082	Quantitative study of salivary secretion in Parkinson's disease. Movement Disorders, 2006, 21, 660-667.	2.2	112
1083	Hereditary spastic paraplegia associated with dopa-responsive parkinsonism. Movement Disorders, 2006, 21, 716-717.	2.2	16
1084	Parkinsonism and Parkinson's disease in the elderly: A community-based survey in Brazil (the Bambuí Tj ETQq0 0 0 rgBT /Overlock 10 T	2.2	194
1085	Blood donations, iron stores, and risk of Parkinson's disease. Movement Disorders, 2006, 21, 835-838.	2.2	34
1086	Topography of putaminal degeneration in multiple system atrophy: A diffusion magnetic resonance study. Movement Disorders, 2006, 21, 847-852.	2.2	62
1087	Association of the Tau haplotype with Parkinson's disease in the Greek population. Movement Disorders, 2006, 21, 1036-1039.	2.2	22
1088	Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease. Movement Disorders, 2006, 21, 983-988.	2.2	41
1089	Protein intake in Parkinsonian patients using the EPIC food frequency questionnaire. Movement Disorders, 2006, 21, 1229-1231.	2.2	37
1090	Cardiac 123I-MIBG scintigraphy in patients with essential tremor. Movement Disorders, 2006, 21, 1235-1238.	2.2	29
1091	Head tremor in Parkinson's disease. Movement Disorders, 2006, 21, 1245-1248.	2.2	60
1092	Minor depression and brain perfusion images in Parkinson's disease. Movement Disorders, 2006, 21, 1169-1174.	2.2	33
1093	Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia. Movement Disorders, 2006, 21, 1663-1666.	2.2	31
1094	What is the evidence for a premorbid parkinsonian personality: A systematic review. Movement Disorders, 2006, 21, 1066-1072.	2.2	144
1095	Clinical phenotype of subjects with Parkinson's disease and orthostatic hypotension: Autonomic symptom and demographic comparison. Movement Disorders, 2006, 21, 1851-1855.	2.2	61

#	ARTICLE	IF	CITATIONS
1096	Special low-protein foods ameliorate postprandial off in patients with advanced Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 1682-1687.	2.2	44
1097	Efficacy and safety of herbal medicines for idiopathic Parkinson's disease: A systematic review. <i>Movement Disorders</i> , 2006, 21, 1709-1715.	2.2	57
1098	Noninvasive cortical stimulation with transcranial direct current stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 1693-1702.	2.2	363
1099	NR4A2 genetic variation in sporadic Parkinson's disease: A genome-wide approach. <i>Movement Disorders</i> , 2006, 21, 1960-1963.	2.2	15
1100	Direct costs of managing Parkinson's disease in India: Concerns in a developing country. <i>Movement Disorders</i> , 2006, 21, 1755-1758.	2.2	25
1101	Predictive value of transcranial sonography in the diagnosis of Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 1763-1765.	2.2	59
1102	Correlation between cardiac ¹²³ I-MIBG and odor identification in patients with Parkinson's disease and multiple system atrophy. <i>Movement Disorders</i> , 2006, 21, 1975-1977.	2.2	76
1103	Neurofilament heavy-chain NfHSM135 in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes. <i>Movement Disorders</i> , 2006, 21, 2224-2227.	2.2	68
1104	Hypoperfusion of the visual pathway in Parkinsonian patients with visual hallucinations. <i>Movement Disorders</i> , 2006, 21, 2140-2144.	2.2	70
1105	Hypoperfusion of the auditory and prefrontal cortices in Parkinsonian patients with verbal hallucinations. <i>Movement Disorders</i> , 2006, 21, 2165-2169.	2.2	20
1106	Exploring an interaction of adenosine A2A receptor variability with coffee and tea intake in Parkinson's disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2006, 141B, 634-636.	1.1	15
1107	Clinical heterogeneity of α -synuclein gene duplication in Parkinson's disease. <i>Annals of Neurology</i> , 2006, 59, 298-309.	2.8	308
1108	UCHL-1 is not a Parkinson's disease susceptibility gene. <i>Annals of Neurology</i> , 2006, 59, 627-633.	2.8	123
1109	Interface between tauopathies and synucleinopathies: A tale of two proteins. <i>Annals of Neurology</i> , 2006, 59, 449-458.	2.8	240
1110	Genetics of Parkinson's disease and parkinsonism. <i>Annals of Neurology</i> , 2006, 60, 389-398.	2.8	281
1111	Transcranial sonography and [¹²³ I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. <i>Brain</i> , 2006, 129, 1188-1193.	3.7	124
1112	Visual recognition memory differentiates dementia with Lewy bodies and Parkinson's disease dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 738-741.	0.9	51
1113	Pesticides and Parkinson's Disease: Is There a Link?. <i>Environmental Health Perspectives</i> , 2006, 114, 156-164.	2.8	352

#	ARTICLE	IF	CITATIONS
1114	The DONPAD-study " Treatment of dementia in patients with Parkinson's disease with donepezil. , 2006, , 27-30.		16
1115	Growth Hormone Stimulation Tests in the Differential Diagnosis of Parkinson's Disease. Clinical Medicine and Research, 2006, 4, 322-325.	0.4	13
1116	Differential Diagnosis of Parkinson's Disease: A New Blood Test?. Clinical Medicine and Research, 2006, 4, 246-247.	0.4	4
1117	Causes of death in multiple system atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 327-329.	0.9	69
1118	Non-motor symptoms in Parkinson's disease: an underdiagnosed problem. Aging Health, 2006, 2, 967-982.	0.3	19
1119	Impaired Visual Acuity as a Risk Factor for Visual Hallucinations in Parkinson's Disease. Journal of Geriatric Psychiatry and Neurology, 2006, 19, 36-40.	1.2	74
1120	A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 465-469.	0.9	130
1121	Motor Score of the Unified Parkinson Disease Rating Scale as a Good Predictor of Lewy Body-Associated Neuronal Loss in the Substantia Nigra. Archives of Neurology, 2006, 63, 584.	4.9	276
1122	Artificial neural network classifier for the diagnosis of Parkinson's disease using [99mTc]TRODAT-1 and SPECT. Physics in Medicine and Biology, 2006, 51, 3057-3066.	1.6	36
1123	Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. Brain, 2006, 129, 538-542.	3.7	120
1124	Clinical correlates of levodopa-induced dopamine release in Parkinson disease: A PET study. Neurology, 2006, 67, 1612-1617.	1.5	173
1125	Occupational titles as risk factors for Parkinson's disease. Occupational Medicine, 2006, 57, 50-56.	0.8	32
1126	Frontal Assessment Battery and Brain Perfusion Image in Parkinson's Disease. Journal of Geriatric Psychiatry and Neurology, 2006, 19, 41-45.	1.2	39
1127	Association of Tau Haplotype-Tagging Polymorphisms with Parkinson's Disease in Diverse Ethnic Parkinson's Disease Cohorts. Neurodegenerative Diseases, 2006, 3, 327-333.	0.8	38
1128	Measuring therapy adherence in Parkinson's disease: a comparison of methods. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 249-251.	0.9	55
1129	Practice Parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based) Tj ETQq1 1 0.784314 rgBT /Overlock 1.5 256	1.5	256
1130	Life goals of patients with Parkinson's disease: a pilot study on correlations with mood and cognitive functions. Clinical Rehabilitation, 2006, 20, 818-826.	1.0	29
1131	Immediate Placebo Effect in Parkinson's Disease " Is the Subjective Relief Accompanied by Objective Improvement?. European Neurology, 2006, 56, 222-229.	0.6	42

#	ARTICLE	IF	CITATIONS
1132	Levodopa, motor fluctuations and dyskinesia in Parkinson's disease. Expert Opinion on Pharmacotherapy, 2006, 7, 1715-1730.	0.9	70
1133	Multiregional Gene Expression Profiling Identifies MRPS6 as a Possible Candidate Gene for Parkinson's Disease. Gene Expression, 2006, 13, 205-215.	0.5	67
1134	Can mid-sagittal MRI be used to diagnose progressive supranuclear palsy?. Nature Clinical Practice Neurology, 2006, 2, 12-13.	2.7	2
1135	Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology, 2006, 67, 1786-1791.	1.5	180
1136	Measuring brain stem and cerebellar damage in parkinsonian syndromes using diffusion tensor MRI. Neurology, 2006, 67, 2199-2205.	1.5	137
1137	C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. Human Molecular Genetics, 2006, 15, 3251-3262.	1.4	130
1138	123I-FP-CIT SPECT Imaging of Dopamine Transporters in Patients with Recurrent Sudden Falls: Are Such Falls a Distinct Entity?. Journal of Nuclear Medicine Technology, 2007, 35, 232-236.	0.4	3
1139	Molecular markers of early Parkinson's disease based on gene expression in blood. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 955-960.	3.3	462
1141	Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. Occupational and Environmental Medicine, 2007, 64, 666-672.	1.3	228
1142	NICE guideline for Parkinson's disease. Age and Ageing, 2007, 36, 240-242.	0.7	36
1144	Metabolic Alterations in Patients With Parkinson Disease and Visual Hallucinations. Archives of Neurology, 2007, 64, 984.	4.9	110
1145	Mechanisms of body weight gain in patients with Parkinson's disease after subthalamic stimulation. Brain, 2007, 130, 1808-1818.	3.7	133
1146	G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 626-628.	0.9	90
1147	Diet with LPP for renal patients increases daily energy expenditure and improves motor function in Parkinsonian patients with motor fluctuations. Nutritional Neuroscience, 2007, 10, 129-135.	1.5	17
1148	Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders. Brain, 2007, 130, 1799-1807.	3.7	156
1149	Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia. Brain, 2007, 130, 1847-1860.	3.7	232
1150	A Prospective Study of Familial versus Sporadic Parkinson's Disease. Neurodegenerative Diseases, 2007, 4, 424-427.	0.8	42
1151	Serum Heart-Type Fatty Acid-Binding Protein and Cerebrospinal Fluid Tau: Marker Candidates for Dementia with Lewy Bodies. Neurodegenerative Diseases, 2007, 4, 366-375.	0.8	65

#	ARTICLE	IF	CITATIONS
1152	Comprehensive Screening of a North American Parkinson's Disease Cohort for LRRK2 Mutation. <i>Neurodegenerative Diseases</i> , 2007, 4, 386-391.	0.8	25
1153	Restoration of normal motor control in Parkinson's disease during REM sleep. <i>Brain</i> , 2007, 130, 450-456.	3.7	287
1154	Transcranial Brain Sonography Findings in Discriminating Between Parkinsonism and Idiopathic Parkinson Disease. <i>Archives of Neurology</i> , 2007, 64, 1635.	4.9	164
1155	Detection of the subthalamic nucleus in microelectrographic recordings in Parkinson disease using the high-frequency (> 500 Hz) neuronal background. <i>Journal of Neurosurgery</i> , 2007, 106, 175-179.	0.9	53
1156	Validation of a Standardized Normalization Template for Statistical Parametric Mapping Analysis of 123I-FP-CIT Images. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1459-1467.	2.8	57
1157	Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. <i>Neurology</i> , 2007, 69, 1270-1277.	1.5	226
1158	Cognitive slowing in Parkinson disease is accompanied by hypofunctioning of the striatum. <i>Neurology</i> , 2007, 68, 1062-1068.	1.5	67
1159	Consumption of Dairy Products and Risk of Parkinson's Disease. <i>American Journal of Epidemiology</i> , 2007, 165, 998-1006.	1.6	156
1160	The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease. <i>Neurology</i> , 2007, 69, 1595-1602.	1.5	159
1161	Randomized, Double-blind, Placebo-Controlled Trial on Symptomatic Effects of Coenzyme Q10 in Parkinson Disease. <i>Archives of Neurology</i> , 2007, 64, 938.	4.9	183
1162	New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset. <i>Journal of Psychopharmacology</i> , 2007, 21, 501-506.	2.0	159
1163	Motor and Nonmotor Symptom Follow-Up in Parkinsonian Patients after Deep Brain Stimulation of the Subthalamic Nucleus. <i>European Neurology</i> , 2007, 58, 218-223.	0.6	109
1164	Evaluation of LRRK2 G2019S penetrance: Relevance for genetic counseling in Parkinson disease. <i>Neurology</i> , 2007, 68, 1141-1143.	1.5	141
1165	Ablation of D1 dopamine receptor-expressing cells generates mice with seizures, dystonia, hyperactivity, and impaired oral behavior. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 4182-4187.	3.3	58
1166	Prevalence and pattern of perceived intelligibility changes in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1188-1190.	0.9	135
1167	Delayed blink reflex in dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1137-1139.	0.9	26
1168	Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced parkinsonism. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1250-1252.	0.9	57
1169	Effects of Tango on Functional Mobility in Parkinson's Disease: A Preliminary Study. <i>Journal of Neurologic Physical Therapy</i> , 2007, 31, 173-179.	0.7	236

#	ARTICLE	IF	CITATIONS
1170	Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1064-1068.	0.9	81
1171	The Role of Levodopa in the Chronic Neurodegenerative Disorder " Parkinson's Disease. , 2007, , 237-246.		0
1172	A novel computer-based technique for the assessment of tremor in Parkinson's disease. <i>Age and Ageing</i> , 2007, 36, 395-399.	0.7	45
1173	Circadian Variation of Core Body Temperature in Parkinson Disease Patients with Depression: A Potential Biological Marker for Depression in Parkinson Disease. <i>Neuropsychobiology</i> , 2007, 56, 172-179.	0.9	30
1174	Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 977-979.	0.9	89
1175	Analysis of ferritin genes in Parkinson disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 1450-6.	1.4	23
1176	Presynaptic α -Synuclein Aggregates, Not Lewy Bodies, Cause Neurodegeneration in Dementia with Lewy Bodies. <i>Journal of Neuroscience</i> , 2007, 27, 1405-1410.	1.7	480
1177	Influence of Motor Symptoms upon the Quality of Life of Patients with Parkinson's Disease. <i>European Neurology</i> , 2007, 57, 161-165.	0.6	104
1178	Functional Ability Correlates with Cognitive Impairment in Parkinson's Disease and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 327-334.	0.7	38
1179	Transcranial Sonography in the Evaluation of Parkinson Disease. <i>Journal of Ultrasound in Medicine</i> , 2007, 26, 509-512.	0.8	21
1180	Chapter 6 Progressive Supranuclear Palsy and Corticobasal Degeneration. <i>Blue Books of Neurology</i> , 2007, 30, 141-164.	0.1	0
1181	Screen for Excess FMR1 Premutation Alleles Among Males With Parkinsonism. <i>Archives of Neurology</i> , 2007, 64, 1002.	4.9	33
1182	Thalamic Hyperperfusion in Verbal Hallucination of Parkinsonian Patients. <i>Internal Medicine</i> , 2007, 46, 1765-1769.	0.3	10
1183	"Idiopathic" Rapid-Eye-Movement (REM) Sleep Behavior Disorder Is Associated With Future Development of Neurodegenerative Diseases. <i>Neurologist</i> , 2007, 13, 98-101.	0.4	27
1184	Educational Level as a Modulator of Cognitive Performance and Neuropsychiatric Features in Parkinson Disease. <i>Cognitive and Behavioral Neurology</i> , 2007, 20, 68-72.	0.5	30
1185	Hormonal Replacement Therapy in Women With Parkinson Disease and Levodopa-Induced Dyskinesia. <i>Clinical Neuropharmacology</i> , 2007, 30, 276-280.	0.2	41
1186	Leucine-Rich Repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. <i>NeuroReport</i> , 2007, 18, 273-275.	0.6	141
1187	[123 I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset. <i>NeuroReport</i> , 2007, 18, 1499-1502.	0.6	59

#	ARTICLE	IF	CITATIONS
1188	Progressive Supranuclear Palsy (Steele-Richardson-Olszewski Syndrome): A Short Historical Review. <i>Neurologist</i> , 2007, 13, 302-304.	0.4	4
1189	Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 1001-1005.	0.7	46
1190	Relation between subtype of Parkinson's disease and REM sleep behavior disorder. <i>Sleep Medicine</i> , 2007, 8, 779-783.	0.8	118
1191	Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. <i>Molecular Genetics and Metabolism</i> , 2007, 91, 195-200.	0.5	111
1192	LRRK2 mutations and Parkinson's disease in Sardinia: A Mediterranean genetic isolate. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 17-21.	1.1	21
1193	Effectiveness of physiotherapy in Parkinson's disease: The feasibility of a randomised controlled trial. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 115-121.	1.1	39
1194	Recognition memory for unfamiliar faces in Parkinson's disease: Behavioral and electrophysiologic measures. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 157-164.	1.1	18
1195	Heterogeneous factors in dementia with Parkinson's disease: IMP-SPECT study. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 174-181.	1.1	13
1196	The effect of cigarette smoking, tea, and coffee consumption on the progression of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 243-245.	1.1	39
1197	Association of α -synuclein gene haplotypes with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 343-347.	1.1	22
1198	Differentiation of Parkinson's disease and progressive supranuclear palsy with magnetic resonance imaging: The first Brazilian experience. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 389-393.	1.1	20
1199	Auditory event-related potentials in Parkinson's disease: Prominent correlation with attention. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 394-398.	1.1	22
1200	Botulinum toxin A for drooling in Parkinson's disease: A pilot study to compare submandibular to parotid gland injections. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 532-534.	1.1	32
1201	CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. <i>Neurobiology of Aging</i> , 2007, 28, 742-747.	1.5	121
1202	La Maladie de Parkinson. , 2007, , 11-88.		1
1203	Introduction to Parkinson's Disease. <i>Disease-a-Month</i> , 2007, 53, 195-199.	0.4	16
1204	Entacapone improves complex movement performance in patients with Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2007, 14, 424-428.	0.8	11
1205	Prevalence of Parkinson's disease in Korea. <i>Journal of Clinical Neuroscience</i> , 2007, 14, 1155-1157.	0.8	49

#	ARTICLE	IF	CITATIONS
1207	Phenotypic associations of tau and ApoE in Parkinson's disease. <i>Neuroscience Letters</i> , 2007, 414, 141-144.	1.0	51
1208	BDNF tagging polymorphisms and haplotype analysis in sporadic Parkinson's disease in diverse ethnic groups. <i>Neuroscience Letters</i> , 2007, 415, 59-63.	1.0	22
1209	Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson's disease. <i>Neuroscience Letters</i> , 2007, 424, 185-189.	1.0	53
1210	Substantia nigra echomorphology in the healthy very old: Correlation with motor slowing. <i>NeuroImage</i> , 2007, 34, 1054-1059.	2.1	66
1211	3,4-Dihydroxy-6-[18F]-Fluoro-L-Phenylalanine Positron Emission Tomography in Patients With Central Motor Disorders and in Evaluation of Brain and Other Tumors. <i>Seminars in Nuclear Medicine</i> , 2007, 37, 440-450.	2.5	32
1212	3.414 Guidelines for speech language therapy in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S183-S184.	1.1	8
1214	The effects of incremental speed-dependent treadmill training on postural instability and fear of falling in Parkinson's disease. <i>Clinical Rehabilitation</i> , 2007, 21, 698-705.	1.0	181
1216	Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study. , 2007, , 91-104.		66
1218	Early detection of Parkinson's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2007, 83, 457-477.	1.0	1
1219	Autosomal dominant Parkinson's disease and the route to new therapies. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 649-656.	1.4	2
1220	Cueing training in the home improves gait-related mobility in Parkinson's disease: the RESCUE trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 134-140.	0.9	677
1221	Neurophysiologic study of central pain in patients with Parkinson disease. <i>Neurology</i> , 2007, 69, 2162-2169.	1.5	211
1222	Changes in network activity with the progression of Parkinson's disease. <i>Brain</i> , 2007, 130, 1834-1846.	3.7	360
1223	Motor symptoms in Parkinson's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2007, 83, 329-342.	1.0	29
1224	Old age and Parkinson's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2007, 84, 427-444.	1.0	12
1226	New approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 1731-1750.	1.4	35
1228	A Multi-Center Blinded Prospective Study of Urine Neural Thread Protein Measurements in Patients With Suspected Alzheimer's Disease. <i>Journal of the American Medical Directors Association</i> , 2007, 8, 21-30.	1.2	23
1229	Is cerebral autoregulation impaired in Parkinson's disease? A transcranial Doppler study. <i>Journal of the Neurological Sciences</i> , 2007, 254, 49-53.	0.3	48

#	ARTICLE	IF	CITATIONS
1230	MRI confirms mild cognitive impairments prodromal for Alzheimer's, vascular and Parkinson-Lewy body dementias. Journal of the Neurological Sciences, 2007, 257, 97-104.	0.3	68
1232	Diagnostic accuracy of FP-CIT SPECT in patients with Parkinsonism. Revista Española De Medicina Nuclear, 2007, 26, 277-285.	0.3	8
1233	Parkinson's disease. BMJ: British Medical Journal, 2007, 335, 441-445.	2.4	74
1234	Lewy Body Disorders. , 2007, , 267-343.		4
1235	Cognitive function assessment in idiopathic Parkinson's disease. Archivos De Neuro-Psiquiatria, 2007, 65, 942-946.	0.3	20
1236	Use of the Putamen/Caudate Volume Ratio for Early Differentiation between Parkinsonian Variant of		

#	ARTICLE	IF	CITATIONS
1250	Midbrain sonography in patients with essential tremor. <i>Movement Disorders</i> , 2007, 22, 414-417.	2.2	117
1251	Caregiver burden in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 924-931.	2.2	208
1252	Simple clinical tests may predict severe oropharyngeal dysphagia in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 640-644.	2.2	72
1253	Determinants of quality of life in Brazilian patients with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1408-1415.	2.2	80
1254	Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1543-1549.	2.2	122
1255	Mild Parkinsonian signs: An overview of an emerging concept. <i>Movement Disorders</i> , 2007, 22, 1681-1688.	2.2	137
1256	Controlled study of decision-making and cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1430-1435.	2.2	116
1257	[123I] FP-CIT spect study in vascular parkinsonism and Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1278-1285.	2.2	100
1258	Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1004-1008.	2.2	91
1259	Deep brain stimulation and medication for parkinsonian tremor during secondary tasks. <i>Movement Disorders</i> , 2007, 22, 1157-1163.	2.2	13
1260	The Unified Parkinson's Disease Rating Scale: Validation study of the mentation, behavior, and mood section. <i>Movement Disorders</i> , 2007, 22, 2156-2161.	2.2	49
1261	High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal. <i>Movement Disorders</i> , 2007, 22, 1194-1201.	2.2	76
1262	Prognostic factors for the progression of Parkinson's disease: A systematic review. <i>Movement Disorders</i> , 2007, 22, 1839-1851.	2.2	187
1263	A nationwide survey of excessive daytime sleepiness in Parkinson's disease in France. <i>Movement Disorders</i> , 2007, 22, 1567-1572.	2.2	106
1264	Functional abnormalities in the primary orofacial sensorimotor cortex during speech in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 2043-2051.	2.2	89
1265	Video analysis of motor events in REM sleep behavior disorder. <i>Movement Disorders</i> , 2007, 22, 1464-1470.	2.2	121
1266	A novel LRRK2 mutation in an Austrian cohort of patients with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1640-1643.	2.2	20
1267	Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients. <i>Movement Disorders</i> , 2007, 22, 1623-1629.	2.2	461

#	ARTICLE	IF	CITATIONS
1268	The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. <i>Movement Disorders</i> , 2007, 22, 1901-1911.	2.2	838
1269	Restless legs syndrome in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1912-1916.	2.2	116
1270	Midbrain transcranial sonography in Korean patients with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1922-1926.	2.2	65
1271	Deep brain stimulation for the treatment of atypical parkinsonism. <i>Movement Disorders</i> , 2007, 22, 2149-2155.	2.2	80
1272	Myoclonus or tremor in orthostatism: An under-recognized cause of unsteadiness in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 2063-2069.	2.2	112
1273	Analysis of <i>LRRK2</i> Gly2385Arg genetic variant in non-Chinese Asians. <i>Movement Disorders</i> , 2007, 22, 1816-1818.	2.2	33
1274	Comparison of brain MRI and ¹⁸ F-FDG PET in the differential diagnosis of multiple system atrophy from Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 2352-2358.	2.2	38
1275	Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 2268-2273.	2.2	65
1276	Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole. <i>Movement Disorders</i> , 2007, 22, 2398-2404.	2.2	214
1277	The prevalence of <i>LRRK2</i> Gly2385Arg variant in Chinese Han population with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 2439-2443.	2.2	62
1278	Effective quantitative real-time polymerase chain reaction analysis of the parkin gene (PARK2) exon 1-12 dosage. <i>BMC Medical Genetics</i> , 2007, 8, 6.	2.1	26
1279	Association of A313G polymorphism (GSTP1*B) in the glutathione-S-transferase P1 gene with sporadic Parkinson's disease. <i>European Journal of Neurology</i> , 2007, 14, 156-161.	1.7	35
1280	Striatal dopamine transporter binding in patients with Parkinson's disease and severe occupational hydrocarbon exposure. <i>European Journal of Neurology</i> , 2007, 14, 070206022829003-???	1.7	11
1281	Immune reactivity towards insulin, its amyloid and protein S100B in blood sera of Parkinson's disease patients. <i>European Journal of Neurology</i> , 2007, 14, 070206022829002-???	1.7	68
1282	A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia. <i>European Journal of Neurology</i> , 2007, 14, 413-417.	1.7	25
1283	Molecular imaging in hereditary forms of parkinsonism. <i>European Journal of Neurology</i> , 2007, 14, 359-368.	1.7	7
1284	The G2019S LRRK2 mutation is uncommon amongst Greek patients with sporadic Parkinson's disease. <i>European Journal of Neurology</i> , 2007, 14, 1088-1090.	1.7	17
1285	A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. <i>European Journal of Neurology</i> , 2007, 14, 1357-1362.	1.7	122

#	ARTICLE	IF	CITATIONS
1286	Hyperechogenicity of the Substantia Nigra in Parkinson's Disease. <i>Journal of Neuroimaging</i> , 2007, 17, 164-167.	1.0	50
1287	Wisconsin Card Sorting Test in Parkinson's disease: diffusion tensor imaging. <i>Acta Neurologica Scandinavica</i> , 2007, 116, 108-112.	1.0	45
1288	Dementia in Parkinson's disease: diffusion tensor imaging. <i>Acta Neurologica Scandinavica</i> , 2007, 116, 177-181.	1.0	85
1289	Clinical evaluation of Parkinson's disease dementia: association with aging and visual hallucination. <i>Acta Neurologica Scandinavica</i> , 2007, 116, 190-195.	1.0	17
1290	Bone mass in elderly patients with Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2007, 116, 248-254.	1.0	42
1291	Assessment of hallucinations in Parkinson's disease using a novel scale. <i>Acta Neurologica Scandinavica</i> , 2008, 117, 35-40.	1.0	10
1292	Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. <i>BMC Neurology</i> , 2007, 7, 27.	0.8	112
1293	Protocol of a prospective study on the diagnostic value of transcranial duplex scanning of the substantia nigra in patients with parkinsonian symptoms. <i>BMC Neurology</i> , 2007, 7, 28.	0.8	7
1294	The striatum and probabilistic implicit sequence learning. <i>Brain Research</i> , 2007, 1137, 117-130.	1.1	59
1295	Feedback-based versus observational classification learning in healthy aging and Parkinson's disease. <i>Brain Research</i> , 2007, 1142, 178-188.	1.1	34
1296	The application of network mapping in differential diagnosis of parkinsonian disorders. <i>Clinical Neuroscience Research</i> , 2007, 6, 359-366.	0.8	13
1297	Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. <i>Neurobiology of Disease</i> , 2007, 25, 473-482.	2.1	111
1298	Impaired recognition of facial expressions of anger in Parkinson's disease patients acutely withdrawn from dopamine replacement therapy. <i>Neuropsychologia</i> , 2007, 45, 65-74.	0.7	143
1299	Dopamine asymmetry interacts with medication to affect cognition in Parkinson's disease. <i>Neuropsychologia</i> , 2007, 45, 357-367.	0.7	41
1300	Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. <i>Journal of Neuroimmunology</i> , 2007, 188, 117-127.	1.1	221
1301	Effects of STN DBS on Memory Guided Force Control in Parkinson's Disease (June 2007). <i>IEEE Transactions on Neural Systems and Rehabilitation Engineering</i> , 2007, 15, 155-165.	2.7	5
1302	Effects of STN DBS on Rigidity in Parkinson's Disease. <i>IEEE Transactions on Neural Systems and Rehabilitation Engineering</i> , 2007, 15, 173-181.	2.7	69
1303	Deep Brain Stimulation of the Subthalamic Nucleus Improves Set Shifting But Does Not Affect Dual Task Performance in Parkinson's Disease. <i>IEEE Transactions on Neural Systems and Rehabilitation Engineering</i> , 2007, 15, 198-206.	2.7	27

#	ARTICLE	IF	CITATIONS
1304	Gender differences in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 819-824.	0.9	554
1305	Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [¹²³ I]IBZM and [¹²³ I]FP-CIT SPECT study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 502-507.	3.3	42
1306	Quantification of Parkinson's disease-related network expression with ECD SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 496-501.	3.3	72
1307	Imaging Non-Dopaminergic Function in Parkinson's Disease. <i>Molecular Imaging and Biology</i> , 2007, 9, 217-222.	1.3	36
1308	Autonomic and Cognitive dysfunction in Parkinson's disease. <i>Clinical Autonomic Research</i> , 2007, 17, 93-98.	1.4	55
1309	A Study on the Effects of Argentine Tango as a Form of Partnered Dance for those with Parkinson Disease and the Healthy Elderly. <i>American Journal of Dance Therapy</i> , 2007, 29, 109-127.	0.7	107
1310	Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease. <i>Journal of Neural Transmission</i> , 2007, 114, 331-335.	1.4	143
1311	Motor fluctuations and dyskinesias in advanced/end stage Parkinson's disease: a study from a population of brain donors. <i>Journal of Neural Transmission</i> , 2007, 114, 341-345.	1.4	16
1312	Growth hormone response in low-dose apomorphine test correlates with nigrostriatal dopamine transporter binding in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2007, 114, 589-594.	1.4	3
1313	Orthostatic hypotension and attention in Parkinson's disease with and without dementia. <i>Journal of Neural Transmission</i> , 2007, 114, 585-588.	1.4	65
1314	Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson's disease from essential tremor. <i>Journal of Neural Transmission</i> , 2007, 114, 935-938.	1.4	34
1315	Tauopathies and synucleinopathies: Do cerebrospinal fluid β -amyloid peptides reflect disease-specific pathogenesis?. <i>Journal of Neural Transmission</i> , 2007, 114, 919-927.	1.4	33
1316	The attentional cost of external rhythmical cues and their impact on gait in Parkinson's disease: effect of cue modality and task complexity. <i>Journal of Neural Transmission</i> , 2007, 114, 1243-1248.	1.4	123
1317	Subacute hemispherical parkinsonism in 5 patients with infarcts of the basal ganglia. <i>Journal of Neural Transmission</i> , 2007, 114, 1463-1467.	1.4	12
1318	Detecting asymmetries in balance control with system identification: first experimental results from Parkinson patients. <i>Journal of Neural Transmission</i> , 2007, 114, 1333-1337.	1.4	35
1319	The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. <i>Human Genetics</i> , 2007, 120, 857-863.	1.8	157
1320	The effect of age of onset of PD on risk of dementia. <i>Journal of Neurology</i> , 2007, 254, 38-45.	1.8	141
1321	Depression in Parkinson's disease. <i>Journal of Neurology</i> , 2007, 254, 1170-1173.	1.8	81

#	ARTICLE	IF	CITATIONS
1322	Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease. <i>Journal of Neurology</i> , 2007, 254, 84-90.	1.8	114
1323	¹⁸ F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages. <i>Journal of Neurology</i> , 2007, 254, 185-190.	1.8	82
1324	Progression of brain atrophy in multiple system atrophy. <i>Journal of Neurology</i> , 2007, 254, 191-196.	1.8	108
1325	Relationship between age and subtypes of psychotic symptoms in Parkinson's disease. <i>Journal of Neurology</i> , 2007, 254, 448-452.	1.8	49
1326	Transcranial color-coded sonography helps differentiation between idiopathic Parkinson's disease and vascular parkinsonism. <i>Journal of Neurology</i> , 2007, 254, 501-507.	1.8	68
1327	Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson's disease. <i>Journal of Neurology</i> , 2007, 254, 1037-1043.	1.8	78
1328	T2*-weighted MRI in diagnosis of multiple system atrophy. <i>Journal of Neurology</i> , 2007, 254, 1184-1188.	1.8	62
1329	Olfactory dysfunction in Parkinson's disease. <i>Journal of Neurology</i> , 2007, 254, IV2-IV7.	1.8	6
1331	Ambulatory monitoring of freezing of gait in Parkinson's disease. <i>Journal of Neuroscience Methods</i> , 2008, 167, 340-348.	1.3	424
1332	Twenty-first century brain banking: practical prerequisites and lessons from the past: the experience of New York Brain Bank, Taub Institute, Columbia University. <i>Cell and Tissue Banking</i> , 2008, 9, 247-258.	0.5	52
1333	Rasch analysis of the short form 8-item Parkinson's Disease Questionnaire (PDQ-8). <i>Quality of Life Research</i> , 2008, 17, 541-548.	1.5	32
1334	Neuropsychological Characteristics of Dementia with Lewy Bodies and Parkinson's Disease with Dementia: Differentiation, Early Detection, and Implications for "Mild Cognitive Impairment" and Biomarkers. <i>Neuropsychology Review</i> , 2008, 18, 103-119.	2.5	161
1335	Metabolomic analysis of urine and serum in Parkinson's disease. <i>Metabolomics</i> , 2008, 4, 191-201.	1.4	86
1336	Sudden turn during walking is impaired in people with Parkinson's disease. <i>Experimental Brain Research</i> , 2008, 190, 43-51.	0.7	54
1337	The cost effectiveness of ¹²³ I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1367-1376.	3.3	45
1339	Nocturnal restlessness and distressing dreams in patients with early Parkinson's disease: Role of the Parkinson's disease sleep scale (PDSS). <i>Somnologie</i> , 2008, 12, 50-55.	0.9	1
1340	Nonsynonymous Polymorphisms of Histamine-Metabolising Enzymes in Patients with Parkinson's Disease. <i>NeuroMolecular Medicine</i> , 2008, 10, 10-16.	1.8	31
1341	The LRRK2 Arg1628Pro variant is a risk factor for Parkinson's disease in the Chinese population. <i>Neurogenetics</i> , 2008, 9, 271-276.	0.7	61

#	ARTICLE	IF	CITATIONS
1342	The PRIAMO study: background, methods and recruitment. <i>Neurological Sciences</i> , 2008, 29, 61-65.	0.9	28
1343	Dopaminergic modulation of emotional memory in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2008, 115, 1159-1163.	1.4	6
1344	Clinical characteristics of Parkinson's disease among Jewish Ethnic groups in Israel. <i>Journal of Neural Transmission</i> , 2008, 115, 1279-1284.	1.4	16
1345	Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. <i>Acta Neuropathologica</i> , 2008, 115, 437-444.	3.9	329
1346	MR imaging of brainstem atrophy in progressive supranuclear palsy. <i>Journal of Neurology</i> , 2008, 255, 37-44.	1.8	46
1347	Polymorphisms in the proteasomal subunit alpha4 are not associated with Parkinson's disease. <i>Journal of Neurology</i> , 2008, 255, 441-442.	1.8	0
1348	Is REM sleep Behaviour Disorder (RBD) a risk factor of dementia in idiopathic Parkinson's disease?. <i>Journal of Neurology</i> , 2008, 255, 192-196.	1.8	121
1349	Subthalamic nucleus stimulation and levodopa-resistant postural instability in Parkinson's disease. <i>Journal of Neurology</i> , 2008, 255, 205-210.	1.8	56
1350	The impact of subthalamic deep brain stimulation on bradykinesia of proximal and distal upper limb muscles in Parkinson's disease. <i>Journal of Neurology</i> , 2008, 255, 429-437.	1.8	23
1351	Cognitive impairment in 873 patients with idiopathic Parkinson's disease. <i>Journal of Neurology</i> , 2008, 255, 255-264.	1.8	242
1352	Movement disorders at a university hospital emergency room. <i>Journal of Neurology</i> , 2008, 255, 745-749.	1.8	10
1353	Parkinsonian patients show impaired predictive smooth pursuit. <i>Journal of Neurology</i> , 2008, 255, 1071-1078.	1.8	13
1354	Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson's disease. <i>Journal of Neurology</i> , 2008, 255, 1957-1962.	1.8	53
1355	Genetic variability of histamine receptors in patients with Parkinson's disease. <i>BMC Medical Genetics</i> , 2008, 9, 15.	2.1	26
1356	Test-retest repeatability of assessing environmental and lifestyle factors in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1032-1036.	2.2	5
1357	The arginine growth hormone stimulation test in bradykinetic-rigid parkinsonisms. <i>Movement Disorders</i> , 2008, 23, 190-194.	2.2	11
1358	Anger in Parkinson's disease: A case-control study. <i>Movement Disorders</i> , 2008, 23, 195-199.	2.2	17
1359	Psychometric attributes of the SCOPA-COG Brazilian version. <i>Movement Disorders</i> , 2008, 23, 81-87.	2.2	30

#	ARTICLE	IF	CITATIONS
1360	Tremor dominant parkinsonism: Clinical description and <i>LRRK2</i> mutation screening. Movement Disorders, 2008, 23, 518-523.	2.2	46
1361	Transcranial sonography findings in welding-related Parkinsonism in comparison to Parkinson's disease. Movement Disorders, 2008, 23, 141-145.	2.2	24
1362	Mirror movements in patients with Parkinson's disease. Movement Disorders, 2008, 23, 253-258.	2.2	40
1363	Benign tremulous parkinsonism: A clinicopathological study. Movement Disorders, 2008, 23, 311-312.	2.2	11
1364	Pathogenicity of LRRK2 P755L variant in Parkinson's disease. Movement Disorders, 2008, 23, 734-736.	2.2	12
1365	A prospective study of delusional misidentification syndromes in Parkinson's disease with dementia. Movement Disorders, 2008, 23, 443-448.	2.2	41
1366	A validation study of depressive syndromes in Parkinson's disease. Movement Disorders, 2008, 23, 538-546.	2.2	81
1367	Validity of spiral analysis in early Parkinson's disease. Movement Disorders, 2008, 23, 531-537.	2.2	115
1368	For better or worse: The effect of levodopa on speech in Parkinson's disease. Movement Disorders, 2008, 23, 574-580.	2.2	112
1369	Footstep adjustments used to turn during walking in Parkinson's disease. Movement Disorders, 2008, 23, 817-823.	2.2	59
1370	Abnormal metabolic networks in atypical parkinsonism. Movement Disorders, 2008, 23, 727-733.	2.2	168
1371	Head and trunk rotation during walking turns in Parkinson's disease. Movement Disorders, 2008, 23, 1391-1397.	2.2	70
1372	Ultrasound-guided injection of the iliopsoas muscle with botulinum toxin in camptocormia. Movement Disorders, 2008, 23, 889-892.	2.2	70
1373	Effect of short and long term STN stimulation periods on parkinsonian signs. Movement Disorders, 2008, 23, 866-874.	2.2	8
1374	Parkinson's disease-cognitive rating scale: A new cognitive scale specific for Parkinson's disease. Movement Disorders, 2008, 23, 998-1005.	2.2	264
1375	The montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease. Movement Disorders, 2008, 23, 1043-1046.	2.2	299
1376	On the structure of motor symptoms of Parkinson's disease. Movement Disorders, 2008, 23, 1307-1312.	2.2	38
1377	The frequency of cardiac valvular regurgitation in Parkinson's disease. Movement Disorders, 2008, 23, 935-941.	2.2	33

#	ARTICLE	IF	CITATIONS
1378	Circadian rest-activity rhythm is altered in Parkinson's disease patients with hallucinations. <i>Movement Disorders</i> , 2008, 23, 1137-1145.	2.2	87
1379	Cognitive dysfunction in Nigerians with Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1378-1383.	2.2	26
1380	Manifestations of Parkinson disease differ in association with REM sleep behavior disorder. <i>Movement Disorders</i> , 2008, 23, 1665-1672.	2.2	159
1381	REM behavior disorder, hallucinations and cognitive impairment in Parkinson's disease: A two-year follow up. <i>Movement Disorders</i> , 2008, 23, 1441-1445.	2.2	85
1382	Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1580-1587.	2.2	71
1383	High-frequency rTMS over the supplementary motor area for treatment of Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1524-1531.	2.2	133
1384	Cutoff score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1546-1550.	2.2	117
1385	Comparison of a timed motor test battery to the Unified Parkinson's Disease Rating Scale-III in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1707-1717.	2.2	60
1386	Longitudinal psychometric attributes, responsiveness, and importance of change: An approach using the SCOPA-Psychosocial questionnaire. <i>Movement Disorders</i> , 2008, 23, 1516-1523.	2.2	17
1387	Walking speed during single and dual tasks in Parkinson's disease: Which characteristics are important?. <i>Movement Disorders</i> , 2008, 23, 2312-2318.	2.2	84
1388	Frequency of social phobia and psychometric properties of the Liebowitz social anxiety scale in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1739-1743.	2.2	50
1389	Balance self-efficacy determines walking capacity in people with Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1936-1939.	2.2	26
1390	Prevalence of movement disorders in an elderly nursing home population. <i>Archives of Gerontology and Geriatrics</i> , 2008, 46, 359-366.	1.4	20
1391	The prevalence of Parkinson's disease among Vilnius inhabitants. <i>Open Medicine (Poland)</i> , 2008, 3, 195-198.	0.6	2
1392	Advances in the genetics of Parkinson's disease. <i>Acta Pharmacologica Sinica</i> , 2008, 29, 21-34.	2.8	27
1393	Executive dysfunction in non-demented Parkinson's disease patients with hallucinations. <i>Acta Neurologica Scandinavica</i> , 2008, 117, 255-259.	1.0	55
1394	Depressive illness in Parkinson's disease – indication of a more advanced and widespread neurodegenerative process?. <i>Acta Neurologica Scandinavica</i> , 2008, 117, 295-304.	1.0	44
1395	Diagnosis and management of Parkinson's disease dementia. <i>International Journal of Clinical Practice</i> , 2008, 62, 1581-1587.	0.8	77

#	ARTICLE	IF	CITATIONS
1396	Cerebral Mitochondrial Metabolism in Early Parkinson's Disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008, 28, 1754-1760.	2.4	32
1397	Conformationally altered p53: a novel Alzheimer's disease marker?. <i>Molecular Psychiatry</i> , 2008, 13, 641-647.	4.1	73
1398	Is quality of life in non-demented Parkinson's disease patients related to cognitive performance? A clinic-based cross-sectional study. <i>European Journal of Neurology</i> , 2008, 15, 128-133.	1.7	120
1399	LRRK2 Gly2385Arg variant is a risk factor of Parkinson's disease among Han-Chinese from mainland China. <i>European Journal of Neurology</i> , 2008, 15, 301-305.	1.7	79
1400	Impact of fatigue on quality of life in patients with Parkinson's disease. <i>European Journal of Neurology</i> , 2008, 15, 475-480.	1.7	76
1401	Diagnostic performance of clinical motor and non-motor tests of Parkinson disease: a matched case-control study. <i>European Journal of Neurology</i> , 2008, 15, 685-691.	1.7	48
1402	Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort. <i>European Journal of Neurology</i> , 2008, 15, 643-648.	1.7	5
1403	No association of the Val158Met COMT polymorphism with Parkinson's disease in the Greek population. <i>European Journal of Neurology</i> , 2008, 15, e83.	1.7	8
1404	Diagnostic value of brain MRI and ¹⁸ F-FDG PET in the differentiation of parkinsonian type multiple system atrophy from Parkinson's disease. <i>European Journal of Neurology</i> , 2008, 15, 1043-1049.	1.7	28
1405	Assessment of sexual dysfunction in patients with Parkinson's disease: a case-control study. <i>European Journal of Neurology</i> , 2008, 15, 1168-1172.	1.7	48
1406	Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2. <i>BMC Neurology</i> , 2008, 8, 1.	0.8	52
1407	A questionnaire-based (UM-PDHD) study of hallucinations in Parkinson's disease. <i>BMC Neurology</i> , 2008, 8, 21.	0.8	80
1408	The predictive value of transcranial duplex sonography for the clinical diagnosis in undiagnosed parkinsonian syndromes: comparison with SPECT scans. <i>BMC Neurology</i> , 2008, 8, 42.	0.8	37
1409	Trace elements in serum from patients with Parkinson's disease - a prospective case-control study. <i>Brain Research</i> , 2008, 1219, 111-115.	1.1	36
1410	The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. <i>Lancet Neurology</i> , The, 2008, 7, 417-424.	4.9	234
1411	Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. <i>Lancet Neurology</i> , The, 2008, 7, 605-614.	4.9	582
1412	Transcranial sonography in movement disorders. <i>Lancet Neurology</i> , The, 2008, 7, 1044-1055.	4.9	337
1413	Patients with Parkinson's disease learn to control complex systems via procedural as well as non-procedural learning. <i>Neuropsychologia</i> , 2008, 46, 2355-2363.	0.7	19

#	ARTICLE	IF	CITATIONS
1414	The effect of feedback on non-motor probabilistic classification learning in Parkinson's disease. <i>Neuropsychologia</i> , 2008, 46, 2683-2695.	0.7	39
1415	Chapter 5 Neuropsychology of aging and dementia. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 88, 113-135.	1.0	5
1416	Association of visual hallucinations with reduction of MIBG cardiac uptake in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2008, 264, 22-26.	0.3	30
1417	Serum heart-fatty acid binding protein levels in patients with Lewy body disease. <i>Journal of the Neurological Sciences</i> , 2008, 266, 20-24.	0.3	38
1418	Evaluation of ActiTrac [®] (ambulatory activity monitor) in Parkinson's Disease. <i>Journal of the Neurological Sciences</i> , 2008, 270, 67-69.	0.3	12
1419	Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. <i>Journal of the Neurological Sciences</i> , 2008, 270, 94-98.	0.3	35
1420	Excessive daytime sleepiness and sleep episodes in Japanese patients with Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2008, 271, 47-52.	0.3	53
1421	Decreased activities of lysosomal acid alpha-D-galactosidase A in the leukocytes of sporadic Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2008, 271, 168-173.	0.3	38
1422	Depression in patients with Parkinson's disease: Impact on functioning. <i>Journal of the Neurological Sciences</i> , 2008, 272, 158-163.	0.3	19
1423	Levodopa/carbidopa/entacapone-induced acute Pisa syndrome in a Parkinson's disease patient. <i>Journal of the Neurological Sciences</i> , 2008, 275, 154-156.	0.3	30
1424	Mutations in the GIGYF2 (TNRC15) Gene at the PARK11 Locus in Familial Parkinson Disease. <i>American Journal of Human Genetics</i> , 2008, 82, 822-833.	2.6	164
1425	Differentiating phase shift and delay in narrow band coherent signals. <i>Clinical Neurophysiology</i> , 2008, 119, 1062-1070.	0.7	17
1426	RNA biomarkers of Parkinson's disease: developing tools for novel therapies. <i>Biomarkers in Medicine</i> , 2008, 2, 41-53.	0.6	17
1427	Genetic variability in the <i>SNCA</i> gene influences α -synuclein levels in the blood and brain. <i>FASEB Journal</i> , 2008, 22, 1327-1334.	0.2	235
1428	Vascular parkinsonism. <i>Therapy: Open Access in Clinical Medicine</i> , 2008, 5, 237-255.	0.2	29
1429	Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. <i>Brain</i> , 2008, 131, 1294-1302.	3.7	247
1430	Is the G2019S LRRK2 mutation common in all southern European populations?. <i>Journal of Clinical Neuroscience</i> , 2008, 15, 1027-1030.	0.8	21
1431	Association between AKT1 gene and Parkinson's disease: A protective haplotype. <i>Neuroscience Letters</i> , 2008, 436, 232-234.	1.0	58

#	ARTICLE	IF	CITATIONS
1432	Lack of evidence for association of a UCH-L1 S18Y polymorphism with Parkinson's disease in a Han-Chinese population. <i>Neuroscience Letters</i> , 2008, 442, 200-202.	1.0	25
1433	Selective hyposmia in Parkinson disease: Association with hippocampal dopamine activity. <i>Neuroscience Letters</i> , 2008, 447, 12-16.	1.0	90
1434	Lack of association of APOE and tau polymorphisms with dementia in Parkinson's disease. <i>Neuroscience Letters</i> , 2008, 448, 20-23.	1.0	54
1435	An ambulatory persistence power curve: Motor planning affects ambulatory persistence in Parkinson's disease. <i>Neuroscience Letters</i> , 2008, 448, 105-109.	1.0	8
1436	Measuring Free-Living Physical Activity in Adults With and Without Neurologic Dysfunction With a Triaxial Accelerometer. <i>Archives of Physical Medicine and Rehabilitation</i> , 2008, 89, 1765-1771.	0.5	98
1437	Effect of subthalamic nucleus deep brain stimulation on axial motor control and protective arm responses in Parkinson's disease. <i>Neuroscience</i> , 2008, 157, 798-812.	1.1	24
1438	Social support plays a role in depression in Parkinson's disease: A cross-section study in a Chinese cohort. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 43-45.	1.1	55
1439	Screening for cognitive deficits in Parkinson's disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 93-101.	1.1	191
1440	Plasma lipid peroxidation and antioxidant status of Parkinson's disease patients in the Indian population. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 52-57.	1.1	42
1441	Association between Parkinson's disease and glucocerebrosidase mutations in Brazil. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 58-62.	1.1	62
1442	Anxiety and depression: Main determinants of health-related quality of life in Brazilian patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 102-108.	1.1	96
1443	Long-term outcome of 50 consecutive Parkinson's disease patients treated with subthalamic deep brain stimulation. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 114-119.	1.1	117
1444	Young onset Parkinson's disease. Practical management of medical issues. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 133-142.	1.1	31
1445	Clinical and psychosocial factors associated with fatigue in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 187-192.	1.1	45
1446	Parkin analysis in early onset Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 326-333.	1.1	42
1447	HFE gene mutations in a population of Italian Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 426-430.	1.1	24
1448	Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 465-470.	1.1	57
1449	Validation of the sleep related items of the Non-motor Symptoms Questionnaire for Parkinson's disease (NMSQuest). <i>Parkinsonism and Related Disorders</i> , 2008, 14, 641-645.	1.1	14

#	ARTICLE	IF	CITATIONS
1450	Early neuropsychological detection and the characteristics of Parkinson's disease associated with mild dementia. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 558-562.	1.1	24
1451	Handedness as a predictor of side of onset of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 633-635.	1.1	58
1452	Progress in Parkinson's disease—Where do we stand?. <i>Progress in Neurobiology</i> , 2008, 85, 376-392.	2.8	164
1453	Long-term Parkinson's disease — Time for optimism. <i>Biomedicine and Pharmacotherapy</i> , 2008, 62, 233-235.	2.5	9
1454	Unilateral subthalamic nucleus stimulation has a measurable ipsilateral effect on rigidity and bradykinesia in parkinson disease. <i>Experimental Neurology</i> , 2008, 211, 234-242.	2.0	75
1455	Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: An in vivo 11C-raclopride PET study. <i>Experimental Neurology</i> , 2008, 214, 112-116.	2.0	101
1456	Basal ganglia, dopamine and temporal processing: Performance on three timing tasks on and off medication in Parkinson's disease. <i>Brain and Cognition</i> , 2008, 68, 30-41.	0.8	103
1457	Tai Chi improves balance and mobility in people with Parkinson disease. <i>Gait and Posture</i> , 2008, 28, 456-460.	0.6	240
1458	The recognition of facial emotion expressions in Parkinson's disease. <i>European Neuropsychopharmacology</i> , 2008, 18, 835-848.	0.3	97
1459	Single-Photon Emission Computed Tomography and Positron Emission Tomography Evaluations of Patients With Central Motor Disorders. <i>Seminars in Nuclear Medicine</i> , 2008, 38, 274-286.	2.5	21
1460	Fatigue in Parkinson's disease is not related to excessive sleepiness or quality of sleep. <i>Journal of the Neurological Sciences</i> , 2008, 270, 107-113.	0.3	46
1461	Utilidad de la sonografía del parénquima cerebral en la enfermedad de Parkinson: Estudio comparativo con 123I-FP-CIT SPECT. <i>Medicina Clínica</i> , 2008, 131, 285-289.	0.3	4
1462	The Effects of Withdrawal of Dopaminergic Medication in Nursing Home Patients With Advanced Parkinsonism. <i>Journal of the American Medical Directors Association</i> , 2008, 9, 670-675.	1.2	15
1463	Diagnostic Value of ¹²³ I-Hoflupane and ¹²³ I-Hodobenzamide SPECT Scans in 248 Patients with Parkinsonian Syndromes. <i>European Neurology</i> , 2008, 59, 258-266.	0.6	114
1464	Sensory deficit in Parkinson's disease: evidence of a cutaneous denervation. <i>Brain</i> , 2008, 131, 1903-1911.	3.7	326
1465	The relationship between nosology, etiology and pathogenesis in neurodegenerative diseases. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 189-192.	1.0	2
1466	±-Synuclein gene duplication is present in sporadic Parkinson disease. <i>Neurology</i> , 2008, 70, 43-49.	1.5	230
1467	A review of Parkinson's disease. <i>British Medical Bulletin</i> , 2008, 86, 109-127.	2.7	639

#	ARTICLE	IF	CITATIONS
1468	STN-DBS activates the target area in Parkinson disease. <i>Neurology</i> , 2008, 71, 708-713.	1.5	63
1469	Subthalamic nucleus stimulation affects orbitofrontal cortex in facial emotion recognition: a pet study. <i>Brain</i> , 2008, 131, 1599-1608.	3.7	111
1470	Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease. <i>Brain</i> , 2008, 131, 2690-2700.	3.7	131
1471	Identification of Responders to Rivastigmine: A Prospective Cohort Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 60-66.	0.7	7
1472	Cognitive Dysfunctions in Mild Parkinson's Disease Dementia: Comparison with Patients Having Mild Alzheimer's Disease and Normal Controls. <i>European Neurology</i> , 2008, 59, 49-54.	0.6	17
1473	Cerebral Metabolic Dysfunction in Patients with Dementia with Lewy Bodies and Visual Hallucinations. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 531-538.	0.7	88
1474	Activities of Daily Living, Cerebral Glucose Metabolism, and Cognitive Reserve in Lewy Body and Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 475-481.	0.7	34
1475	Validity, sensitivity and specificity of the mentation, behavior and mood subscale of the UPDRS. <i>Neurological Research</i> , 2008, 30, 493-496.	0.6	11
1476	Comparison of cerebral glucose metabolism between multiple system atrophy Parkinsonian type and Parkinson's disease. <i>Neurological Research</i> , 2008, 30, 377-382.	0.6	13
1477	Dissociation of Metabolic and Neurovascular Responses to Levodopa in the Treatment of Parkinson's Disease. <i>Journal of Neuroscience</i> , 2008, 28, 4201-4209.	1.7	135
1478	Changes in Cerebral Glucose Metabolism in Patients with Parkinson Disease with Dementia After Cholinesterase Inhibitor Therapy. <i>Journal of Nuclear Medicine</i> , 2008, 49, 2006-2011.	2.8	21
1479	Neuropathology of dementia with Lewy bodies. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 321-330.	1.0	20
1480	Animal Models of Parkinson's Disease to Aid Drug Discovery and Development. , 2008, , 159-205.		3
1481	Objective monitoring of tremor and bradykinesia during DBS surgery for Parkinson disease. <i>Neurology</i> , 2008, 70, 1244-1249.	1.5	30
1482	Genotype-phenotype correlations between <i>GBA</i> mutations and Parkinson disease risk and onset. <i>Neurology</i> , 2008, 70, 2277-2283.	1.5	334
1483	How do I sound to me? Perceived changes in communication in Parkinson's disease. <i>Clinical Rehabilitation</i> , 2008, 22, 14-22.	1.0	103
1484	Parkinson's disease: emerging pharmacotherapy. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 573-591.	1.0	18
1485	Changes in diagnosis with follow-up in an incident cohort of patients with parkinsonism. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 1202-1207.	0.9	56

#	ARTICLE	IF	CITATIONS
1486	Evidence that common variation in NEDD9 is associated with susceptibility to late-onset Alzheimer's and Parkinson's disease. <i>Human Molecular Genetics</i> , 2008, 17, 759-767.	1.4	39
1487	Metabolomic profiling to develop blood biomarkers for Parkinson's disease. <i>Brain</i> , 2008, 131, 389-396.	3.7	362
1488	Technology Insight: imaging neurodegeneration in Parkinson's disease. <i>Nature Clinical Practice Neurology</i> , 2008, 4, 267-277.	2.7	34
1489	Subthalamic nucleus stimulation-induced regional blood flow responses correlate with improvement of motor signs in Parkinson disease. <i>Brain</i> , 2008, 131, 2710-2719.	3.7	88
1490	Single photon-emission computed tomography imaging in early Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1853-1864.	1.4	4
1491	Subthalamic deep brain stimulation after anesthetic inhalation in Parkinson disease: a preliminary study. <i>Journal of Neurosurgery</i> , 2008, 109, 238-244.	0.9	77
1492	REM sleep behaviour disorder in Parkinson's disease is associated with specific motor features. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 1117-1121.	0.9	218
1493	Comparative Genome Hybridization Array Analysis for Sporadic Parkinson's Disease. <i>International Journal of Neuroscience</i> , 2008, 118, 1331-1345.	0.8	7
1494	Efficacy and Safety of Acupuncture for Idiopathic Parkinson's Disease: A Systematic Review. <i>Journal of Alternative and Complementary Medicine</i> , 2008, 14, 663-671.	2.1	62
1495	Progress in the pathogenesis and genetics of Parkinson's disease. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2008, 363, 2215-2227.	1.8	63
1496	Levodopa improves time-based prospective memory in Parkinson's disease. <i>Journal of the International Neuropsychological Society</i> , 2008, 14, 601-610.	1.2	35
1497	Spinocerebellar Ataxia Type 12 was not Found in Korean Parkinsonian Patients. <i>Canadian Journal of Neurological Sciences</i> , 2008, 35, 488-490.	0.3	7
1499	Mutation Analysis of the PINK1 Gene in 391 Patients With Parkinson Disease. <i>Archives of Neurology</i> , 2008, 65, 802-8.	4.9	75
1500	Levodopa and executive performance in Parkinson's disease: A randomized study. <i>Journal of the International Neuropsychological Society</i> , 2008, 14, 832-841.	1.2	41
1501	Immunological Markers in Plasma and CSF distinguish Vascular Parkinsonism from Idiopathic Parkinson's Disease. <i>Pteridines</i> , 2008, 19, 7-11.	0.5	1
1503	Effects of Ropinirole on Nonmotor Symptoms of Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2008, 31, 261-266.	0.2	70
1504	Quantification of Electromyographic Activity During REM Sleep in Multiple Muscles in REM Sleep Behavior Disorder. <i>Sleep</i> , 2008, 31, 724-731.	0.6	160
1505	Local field potential recordings from the pedunculopontine nucleus in a Parkinsonian patient. <i>NeuroReport</i> , 2008, 19, 59-62.	0.6	28

#	ARTICLE	IF	CITATIONS
1506	OUTCOME OF BILATERAL DEEP BRAIN SUBTHALAMIC STIMULATION IN PATIENTS CARRYING THE R1441G MUTATION IN THE LRRK2 DARDARIN GENE. <i>Neurosurgery</i> , 2008, 62, 857-863.	0.6	19
1507	Nondemented Parkinson Disease Patients. <i>Cognitive and Behavioral Neurology</i> , 2008, 21, 87-91.	0.5	14
1508	Catechol-O-methyltransferase Inhibition Improves Levodopa-Associated Strength Increase in Patients With Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2008, 31, 134-140.	0.2	12
1509	A Dopamine-Sensitive Inherited Motor Syndrome Linked to the frissonnant Mutation. , 2008, , 81-96.		1
1511	Dementia and functional decline in patients with Parkinson's disease. <i>Dementia E Neuropsychologia</i> , 2008, 2, 96-101.	0.3	4
1512	Working memory in Parkinson's disease patients: clinical features and response to levodopa. <i>Arquivos De Neuro-Psiquiatria</i> , 2008, 66, 147-151.	0.3	47
1513	123I-MIBG Cardiac Scintigraphy Provides Clues to the Underlying Neurodegenerative Disorder in Idiopathic REM Sleep Behavior Disorder. <i>Sleep</i> , 2008, 31, 717-723.	0.6	119
1514	Lack of Effects of Pramipexole on REM Sleep Behavior Disorder in Parkinson Disease. <i>Sleep</i> , 2008, , .	0.6	29
1515	Dorsolateral Prefrontal Cortex: A Possible Target for Modulating Dyskinesias in Parkinson's Disease by Repetitive Transcranial Magnetic Stimulation. <i>International Journal of Biomedical Imaging</i> , 2008, 1-6.	3.0	26
1516	Dopaminergic Modulation of Prospective Memory in Parkinson's Disease. <i>Behavioural Neurology</i> , 2008, 19, 45-48.	1.1	22
1517	Features associated with the development of non-motor manifestations in Parkinson's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2008, 66, 22-25.	0.3	11
1518	Pain in Parkinson's disease: analysis of 50 cases in a clinic of movement disorders. <i>Arquivos De Neuro-Psiquiatria</i> , 2008, 66, 26-29.	0.3	27
1519	Association Between Parkinsonism and Participation in Agriculture in Korea. <i>Journal of Clinical</i>		

#	ARTICLE	IF	CITATIONS
1525	Evaluation of body image and self-concept and their correlation with depressive symptoms in Parkinson's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2009, 67, 585-590.	0.3	13
1526	Pain in Parkinson's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2009, 67, 591-594.	0.3	21
1527	Muscle strength is significantly associated with hip bone mineral density in women with Parkinson's disease: A cross-sectional study. <i>Journal of Rehabilitation Medicine</i> , 2009, 41, 223-230.	0.8	22
1528	A Cross-Study Transcriptional Analysis of Parkinson's Disease. <i>PLoS ONE</i> , 2009, 4, e4955.	1.1	81
1529	Regional Brain Stem Atrophy in Idiopathic Parkinson's Disease Detected by Anatomical MRI. <i>PLoS ONE</i> , 2009, 4, e8247.	1.1	60
1530	Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease. <i>Core Evidence</i> , 2009, , 1.	4.7	5
1531	Physiological MR in neurodegenerative diseases. , 0, , 630-641.		0
1532	Treatment Strategies and Quality-of-Care Indicators for Patients With Parkinson's Disease. <i>Journal of Managed Care Pharmacy</i> , 2009, 15, 1-22.	2.2	1
1533	The Short-Term Effects of Different Cueing Modalities on Turn Speed in People with Parkinson's Disease. <i>Neurorehabilitation and Neural Repair</i> , 2009, 23, 831-836.	1.4	99
1534	Deep brain stimulation activation volumes and their association with neurophysiological mapping and therapeutic outcomes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 659-666.	0.9	196
1535	The scientific and clinical basis for the treatment of Parkinson disease (2009). <i>Neurology</i> , 2009, 72, S1-136.	1.5	685
1536	Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. <i>Brain</i> , 2009, 132, 3285-3297.	3.7	191
1537	Is There an Association between the Level of High-Sensitivity C-Reactive Protein and Idiopathic Parkinson's Disease? A Comparison of Parkinson's Disease Patients, Disease Controls and Healthy Individuals. <i>European Neurology</i> , 2009, 62, 99-104.	0.6	47
1538	The Effect of a Vibratory Lumber Orthosis on Walking Velocity in Patients with Parkinson's Disease. <i>Prosthetics and Orthotics International</i> , 2009, 33, 82-88.	0.5	7
1540	Vascular Parkinsonism: A Clinical Review. <i>European Neurology</i> , 2009, 61, 11-15.	0.6	40
1541	Effect of Cabergoline on Parkinsonian Tremor Assessed by Long-Term Actigraphy. <i>European Neurology</i> , 2009, 61, 149-153.	0.6	14
1542	Simple Ratio Analysis of ¹⁸ F-Fluorodopa Uptake in Striatal Subregions Separates Patients with Early Parkinson Disease from Healthy Controls. <i>Journal of Nuclear Medicine</i> , 2009, 50, 893-899.	2.8	68
1543	A Population-Based Study of Parkinsonism in an Amish Community. <i>Neuroepidemiology</i> , 2009, 33, 225-230.	1.1	24

#	ARTICLE	IF	CITATIONS
1544	Central and peripheral dopamine transporter reduction in Parkinson's disease. <i>Neurological Research</i> , 2009, 31, 687-691.	0.6	19
1545	Variation in <i>GIGYF2</i> is not associated with Parkinson disease. <i>Neurology</i> , 2009, 72, 1886-1892.	1.5	42
1546	Cerebellar magnetic stimulation decreases levodopa-induced dyskinesias in Parkinson disease. <i>Neurology</i> , 2009, 73, 113-119.	1.5	178
1547	Changes in Prevalence and Incidence of Parkinson's Disease in Japan during a Quarter of a Century. <i>Neuroepidemiology</i> , 2009, 32, 263-269.	1.1	83
1548	Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. <i>Brain</i> , 2009, 132, 1783-1794.	3.7	612
1549	Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. <i>Neurology</i> , 2009, 73, 273-278.	1.5	318
1550	Association of Preoperative Symptom Profile With Psychiatric Symptoms Following Subthalamic Nucleus Stimulation in Patients With Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2009, 21, 398-405.	0.9	27
1551	DOES CLINICAL INTOLERANCE TO A DIAGNOSTIC ACUTE LEVODOPA CHALLENGE DIFFERENTIATE MULTIPLE SYSTEM ATROPHY FROM PD?. <i>International Journal of Neuroscience</i> , 2009, 119, 2257-2261.	0.8	4
1552	Subthalamic nucleus stimulation in Parkinson disease induces apathy. <i>Neurology</i> , 2009, 73, 1746-1751.	1.5	168
1553	Eye Tracking During a Visual Paired Comparison Task as a Predictor of Early Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2009, 24, 258-266.	0.9	113
1554	Course in Parkinson disease subtypes. <i>Neurology</i> , 2009, 73, 206-212.	1.5	228
1555	Clinical Features in Early Parkinson Disease and Survival. <i>Archives of Neurology</i> , 2009, 66, 1353-8.	4.9	98
1556	Association Between the Ubiquitin Carboxyl-Terminal Esterase L1 Gene (UCHL1) S18Y Variant and Parkinson's Disease: A HuGE Review and Meta-Analysis. <i>American Journal of Epidemiology</i> , 2009, 170, 1344-1357.	1.6	67
1557	Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia. <i>Brain</i> , 2009, 132, 3308-3317.	3.7	133
1558	History of falls in Parkinson disease is associated with reduced cholinergic activity. <i>Neurology</i> , 2009, 73, 1670-1676.	1.5	357
1559	Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease. <i>Brain</i> , 2009, 132, 3298-3307.	3.7	238
1560	Frontal FDG-PET activity correlates with cognitive outcome after STN-DBS in Parkinson disease. <i>Neurology</i> , 2009, 72, 42-49.	1.5	103
1561	Levodopa-related wearing-off in Parkinson's disease: identification and management. <i>Current Medical Research and Opinion</i> , 2009, 25, 841-849.	0.9	76

#	ARTICLE	IF	CITATIONS
1562	Network biomarkers for the diagnosis and treatment of movement disorders. <i>Neurobiology of Disease</i> , 2009, 35, 141-147.	2.1	32
1563	Are dopaminergic pathways involved in theory of mind? A study in Parkinson's disease. <i>Neuropsychologia</i> , 2009, 47, 406-414.	0.7	144
1564	Decision making under risk and under ambiguity in Parkinson's disease. <i>Neuropsychologia</i> , 2009, 47, 1901-1908.	0.7	65
1565	Startle reflex hyporeactivity in Parkinson's disease: An emotion-specific or arousal-modulated deficit?. <i>Neuropsychologia</i> , 2009, 47, 1917-1927.	0.7	45
1566	The role of the basal ganglia and its cortical connections in sequence learning: Evidence from implicit and explicit sequence learning in Parkinson's disease. <i>Neuropsychologia</i> , 2009, 47, 2564-2573.	0.7	74
1567	Dissociation of decision-making under ambiguity and decision-making under risk in patients with Parkinson's disease: A neuropsychological and psychophysiological study. <i>Neuropsychologia</i> , 2009, 47, 2882-2890.	0.7	151
1568	Detecting new neurodegenerative disease genes: does phenotype accuracy limit the horizon?. <i>Trends in Genetics</i> , 2009, 25, 486-488.	2.9	17
1569	Clinical diagnosis of Parkinson's disease. Proposal of diagnostic subgroups classified at different levels of confidence. <i>Acta Neurologica Scandinavica</i> , 1994, 89, 242-251.	1.0	137
1570	Prevalence of Parkinson's disease in the elderly: a population study in Gironde, France. <i>Acta Neurologica Scandinavica</i> , 1994, 90, 111-115.	1.0	83
1571	Proton magnetic resonance spectroscopy in suspected vascular ischemic parkinsonism. <i>Acta Neurologica Scandinavica</i> , 1994, 90, 405-411.	1.0	14
1572	Loss of Libido in Parkinson's Disease. <i>Journal of Sexual Medicine</i> , 2009, 6, 1024-1031.	0.3	48
1573	LRRK2 R1628P contributes to Parkinson's disease susceptibility in Chinese Han populations from mainland China. <i>Brain Research</i> , 2009, 1296, 113-116.	1.1	35
1574	In vivo imaging markers of neurodegeneration of the substantia nigra. <i>Experimental Gerontology</i> , 2009, 44, 4-9.	1.2	9
1575	Occupational factors and risk of Parkinson's disease: A population-based case-control study. <i>American Journal of Industrial Medicine</i> , 2010, 53, 217-223.	1.0	80
1576	Premotor Parkinson's disease: Clinical features, detection, and prospects for treatment. <i>Annals of Neurology</i> , 2008, 64, S139-S147.	2.8	54
1577	Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: The COMPARE Trial. <i>Annals of Neurology</i> , 2009, 65, 586-595.	2.8	489
1578	A novel haplotype-sharing approach for genome-wide case-control association studies implicates the calpastatin gene in Parkinson's disease. <i>Genetic Epidemiology</i> , 2009, 33, 657-667.	0.6	29
1579	Psychopathological features in patients with Parkinson's disease and related caregivers' burden. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 1158-1165.	1.3	41

#	ARTICLE	IF	CITATIONS
1580	Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: A 3-year European multicenter study with repeat [¹²³ I]FP-CIT SPECT. <i>Movement Disorders</i> , 2009, 24, 500-508.	2.2	195
1581	Adherence to antiparkinson medication in a multicenter European study. <i>Movement Disorders</i> , 2009, 24, 826-832.	2.2	146
1582	<i>Parkin</i> -related disease clinically diagnosed as a pallido-pyramidal syndrome. <i>Movement Disorders</i> , 2009, 24, 138-140.	2.2	9
1583	Expression of Lewy body protein septin 4 in postmortem brain of Parkinson's disease and control subjects. <i>Movement Disorders</i> , 2009, 24, 204-210.	2.2	33
1584	Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open-label study. <i>Movement Disorders</i> , 2009, 24, 277-282.	2.2	124
1585	No association between common <i>POLG1</i> variants and sporadic idiopathic Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1092-1094.	2.2	32
1586	Backward walking in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 218-223.	2.2	83
1587	Functional brain imaging in pure akinesia with gait freezing: [¹⁸ F] FDG PET and [¹⁸ F] FP-CIT PET analyses. <i>Movement Disorders</i> , 2009, 24, 237-245.	2.2	59
1588	Odor identification test as an indicator of idiopathic REM sleep behavior disorder. <i>Movement Disorders</i> , 2009, 24, 268-273.	2.2	57
1589	<i>LRRK2</i> R1628P variant is a risk factor of Parkinson's disease among Han-Chinese from mainland China. <i>Movement Disorders</i> , 2009, 24, 1902-1905.	2.2	47
1590	Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: Long-term observation. <i>Movement Disorders</i> , 2009, 24, 555-561.	2.2	71
1591	Premotor Parkinson's disease: Clinical features and detection strategies. <i>Movement Disorders</i> , 2009, 24, S665-70.	2.2	40
1592	Mortality in Parkinson's disease: A 20-year follow-up study. <i>Movement Disorders</i> , 2009, 24, 819-825.	2.2	108
1593	Validity of the Cornell scale for depression in dementia in Parkinson's disease with and without cognitive impairment. <i>Movement Disorders</i> , 2009, 24, 433-437.	2.2	17
1594	Effects of inhibitory rTMS on bladder function in Parkinson's disease patients. <i>Movement Disorders</i> , 2009, 24, 445-447.	2.2	49
1595	How cautious should we be when assessing apathy with the Unified Parkinson's Disease Rating Scale?. <i>Movement Disorders</i> , 2009, 24, 684-688.	2.2	33
1596	Examination of the Lille Apathy Rating Scale in Parkinson disease. <i>Movement Disorders</i> , 2009, 24, 677-683.	2.2	55
1597	Motor-related circuit dysfunction in MSA: Usefulness of combined whole-brain imaging analysis. <i>Movement Disorders</i> , 2009, 24, 863-870.	2.2	38

#	ARTICLE	IF	CITATIONS
1598	Weight loss, body fat mass, and leptin in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 885-890.	2.2	87
1599	Gene expression changes in blood as a putative biomarker for Huntington's disease. <i>Movement Disorders</i> , 2009, 24, 2277-2281.	2.2	28
1600	Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. <i>Movement Disorders</i> , 2009, 24, 1906-1909.	2.2	91
1601	Homocysteine and cognitive impairment in Parkinson's disease: A biochemical, neuroimaging, and genetic study. <i>Movement Disorders</i> , 2009, 24, 1437-1444.	2.2	82
1602	Trunk muscle strength, but not trunk rigidity, is independently associated with bone mineral density of the lumbar spine in patients with Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1176-1182.	2.2	20
1603	Are current recommendations to diagnose orthostatic hypotension in Parkinson's disease satisfactory?. <i>Movement Disorders</i> , 2009, 24, 1747-1751.	2.2	53
1604	Transcranial ultrasound as a risk marker for Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, S677-83.	2.2	33
1605	Perverted head-shaking and positional downbeat nystagmus in patients with multiple system atrophy. <i>Movement Disorders</i> , 2009, 24, 1290-1295.	2.2	33
1606	The syndromal validity and nosological position of apathy in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1211-1216.	2.2	134
1607	Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 2203-2210.	2.2	163
1608	Homocysteine levels after acute levodopa intake in patients with Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1339-1343.	2.2	36
1609	Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1333-1338.	2.2	246
1610	The relationship between quality of life and swallowing in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1352-1358.	2.2	169
1611	Micro lesion effect of the globus pallidus internus and outcome with deep brain stimulation in patients with Parkinson disease and dystonia. <i>Movement Disorders</i> , 2009, 24, 1488-1493.	2.2	54
1612	Potential of advanced MR imaging techniques in the differential diagnosis of parkinsonism. <i>Movement Disorders</i> , 2009, 24, S711-20.	2.2	49
1613	Handedness does not predict side of onset of motor symptoms in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1836-1839.	2.2	21
1614	Is impact of fatigue an independent factor associated with physical activity in patients with idiopathic Parkinson's disease?. <i>Movement Disorders</i> , 2009, 24, 1512-1518.	2.2	67
1615	Expanding the clinical phenotype of <i>SNCA</i> duplication carriers. <i>Movement Disorders</i> , 2009, 24, 1811-1819.	2.2	124

#	ARTICLE	IF	CITATIONS
1616	Restless legs syndrome in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 2076-2080.	2.2	111
1617	Fatigue in Japanese patients with Parkinson's disease: A study using Parkinson fatigue scale. <i>Movement Disorders</i> , 2009, 24, 1977-1983.	2.2	32
1618	Idiopathic REM sleep behavior disorder in the transition to degenerative disease. <i>Movement Disorders</i> , 2009, 24, 2225-2232.	2.2	100
1619	Levodopa response in early Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 2328-2336.	2.2	50
1620	Levosulpiride-induced movement disorders. <i>Movement Disorders</i> , 2009, 24, 2249-2253.	2.2	64
1621	Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland. <i>Movement Disorders</i> , 2009, 24, 2379-2385.	2.2	47
1622	The core body temperature rhythm is altered in progressive supranuclear palsy. <i>Clinical Autonomic Research</i> , 2009, 19, 65-68.	1.4	8
1623	Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease. <i>Neurological Sciences</i> , 2009, 30, 301-305.	0.9	16
1624	Effects of treadmill training on walking economy in Parkinson's disease: a pilot study. <i>Neurological Sciences</i> , 2009, 30, 499-504.	0.9	35
1625	Dopamine transporter immunoreactivity in peripheral blood lymphocytes in multiple system atrophy. <i>Journal of Neural Transmission</i> , 2009, 116, 161-165.	1.4	13
1626	A single-nucleotide polymorphism of the osteopontin gene may contribute to a susceptibility to Lewy body disease. <i>Journal of Neural Transmission</i> , 2009, 116, 599-605.	1.4	16
1627	Olfactory bulb α -synucleinopathy has high specificity and sensitivity for Lewy body disorders. <i>Acta Neuropathologica</i> , 2009, 117, 169-74.	3.9	193
1628	A decision tool to support appropriate referral for deep brain stimulation in Parkinson's disease. <i>Journal of Neurology</i> , 2009, 256, 83-88.	1.8	44
1629	The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. <i>Journal of Neurology</i> , 2009, 256, 483-487.	1.8	52
1630	Chocolate consumption is increased in Parkinson's disease. <i>Journal of Neurology</i> , 2009, 256, 488-492.	1.8	33
1631	Transcranial duplex in the differential diagnosis of parkinsonian syndromes. <i>Journal of Neurology</i> , 2009, 256, 530-538.	1.8	57
1632	Balance confidence and functional mobility are independently associated with falls in people with Parkinson's disease. <i>Journal of Neurology</i> , 2009, 256, 742-749.	1.8	125
1633	Greater improvement in quality of life following unilateral deep brain stimulation surgery in the globus pallidus as compared to the subthalamic nucleus. <i>Journal of Neurology</i> , 2009, 256, 1321-1329.	1.8	129

#	ARTICLE	IF	CITATIONS
1634	Parkinson's disease sleep scale, sleep logs, and actigraphy in the evaluation of sleep in parkinsonian patients. <i>Journal of Neurology</i> , 2009, 256, 1480-1484.	1.8	36
1635	HMPAO SPECT in Parkinson's disease (PD) with major depression (MD) before and after antidepressant treatment. <i>Journal of Neurology</i> , 2009, 256, 1510-1518.	1.8	21
1636	Fear of falling is independently associated with recurrent falls in patients with Parkinson's disease: a 1-year prospective study. <i>Journal of Neurology</i> , 2009, 256, 1689-1695.	1.8	154
1637	Is there a difference in gastric emptying between Parkinson's disease patients under long-term l-dopa therapy with and without motor fluctuations? An analysis using the ¹³ C-acetate breath test. <i>Journal of Neurology</i> , 2009, 256, 1972-1976.	1.8	31
1638	Interleukin-6 Serum Levels in Patients with Parkinson's Disease. <i>Neurochemical Research</i> , 2009, 34, 1401-1404.	1.6	75
1639	Neuroticism and extraversion in association with quality of life in patients with Parkinson's disease. <i>Quality of Life Research</i> , 2009, 18, 33-42.	1.5	41
1640	Quality of life in Serbian patients with Parkinson's disease. <i>Quality of Life Research</i> , 2009, 18, 833-839.	1.5	18
1641	Adaptive windowing for gait phase discrimination in Parkinsonian gait using 3-axis acceleration signals. <i>Medical and Biological Engineering and Computing</i> , 2009, 47, 1155-1164.	1.6	19
1644	Monoamine transporter availability in Parkinson's disease patients with or without depression. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 428-435.	3.3	72
1645	Î±-Synuclein and neuronal cell death. <i>Molecular Neurodegeneration</i> , 2009, 4, 9.	4.4	314
1646	Decrease of Nicotinic Receptors in the Nigrostriatal System in Parkinson's Disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 1601-1608.	2.4	52
1647	Genome-wide association study reveals genetic risk underlying Parkinson's disease. <i>Nature Genetics</i> , 2009, 41, 1308-1312.	9.4	1,745
1648	Autonomic dysfunction in Parkinson's disease and vascular parkinsonism. <i>Acta Neurologica Scandinavica</i> , 1997, 96, 359-365.	1.0	15
1649	Review article Progressive supranuclear palsy revisited. <i>Acta Neurologica Scandinavica</i> , 1998, 98, 73-84.	1.0	12
1650	Delayed motor response correlates with striatal degeneration in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 1999, 100, 227-230.	1.0	9
1651	Distinguishing Parkinson's disease and essential tremor with transcranial sonography. <i>Acta Neurologica Scandinavica</i> , 2009, 119, 17-21.	1.0	60
1652	The relationship of pain and health-related quality of life in Korean patients with Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2009, 119, 397-403.	1.0	43
1653	Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2010, 122, 46-51.	1.0	13

#	ARTICLE	IF	CITATIONS
1654	Dermal sheet preparations in the evaluation of dermal innervation in Parkinson's disease and multiple system atrophy. <i>Journal of Cutaneous Pathology</i> , 2009, 36, 296-301.	0.7	11
1655	Biomarkers in Huntington's and Parkinson's Disease. <i>Annals of the New York Academy of Sciences</i> , 2009, 1180, 97-110.	1.8	23
1656	Cross-Cultural Validation of the Scales for Outcomes in Parkinson's Disease-Psychosocial Questionnaire (SCOPA-PS) in Four Latin American Countries. <i>Value in Health</i> , 2009, 12, 385-391.	0.1	10
1657	Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice. <i>Journal of Neurochemistry</i> , 2009, 111, 696-702.	2.1	221
1658	Addenbrooke's Cognitive Examination validation in Parkinson's disease. <i>European Journal of Neurology</i> , 2009, 16, 142-147.	1.7	78
1659	Subthalamic deep brain stimulation and impulse control in Parkinson's disease. <i>European Journal of Neurology</i> , 2009, 16, 493-497.	1.7	179
1660	Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias. <i>European Journal of Neurology</i> , 2009, 16, 895-901.	1.7	67
1661	Trends in Parkinson's disease related mortality in England and Wales, 1993-2006. <i>European Journal of Neurology</i> , 2009, 16, 1010-1016.	1.7	27
1662	The severity of leukoaraiosis correlates with the clinical phenotype of Parkinson's disease. <i>Archives of Gerontology and Geriatrics</i> , 2009, 49, 255-259.	1.4	62
1663	Relationship between clinical phenotypes and cognitive impairment in Parkinson's disease (PD). <i>Archives of Gerontology and Geriatrics</i> , 2009, 49, 351-354.	1.4	32
1664	Dementias. , 2009, , 215-257.		0
1666	Parkinson's disease: the most common diagnostic mistakes in Lithuania. <i>Open Medicine (Poland)</i> , 2009, 4, 304-309.	0.6	2
1667	Systemic neurophysiological analysis of Parkinson's disease. <i>Human Physiology</i> , 2009, 35, 43-50.	0.1	2
1668	Perceptual characteristics of Parkinsonian speech: A comparison of the pharmacological effects of levodopa across speech and non-speech motor systems. <i>NeuroRehabilitation</i> , 2009, 24, 131-144.	0.5	83
1669	Awareness of Expressivity Deficits in Non-Demented Parkinson Disease. <i>Clinical Neuropsychologist</i> , 2009, 23, 805-817.	1.5	18
1670	The association of type D personality with quality of life in patients with Parkinson's disease. <i>Aging and Mental Health</i> , 2009, 13, 905-912.	1.5	23
1671	Therapeutic efficacy of unilateral subthalamotomy in Parkinson's disease: results in 89 patients followed for up to 36 months. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 979-985.	0.9	129
1672	Short duration, intensive tango dancing for Parkinson disease: An uncontrolled pilot study. <i>Complementary Therapies in Medicine</i> , 2009, 17, 203-207.	1.3	101

#	ARTICLE	IF	CITATIONS
1673	Reduced performance in balance, walking and turning tasks is associated with increased neck tone in Parkinson's disease. <i>Experimental Neurology</i> , 2009, 219, 430-438.	2.0	84
1674	Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2009, 111, 341-344.	0.6	52
1675	Application of depression criteria (DSM-IV) in patients with Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2009, 111, 665-669.	0.6	17
1676	Serum uric acid levels in patients with Parkinson's disease: Their relationship to treatment and disease duration. <i>Clinical Neurology and Neurosurgery</i> , 2009, 111, 724-728.	0.6	115
1677	Female gender but not cigarette smoking delays the onset of Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2009, 111, 738-741.	0.6	11
1678	A multicentre retrospective study of the clinical use of ropinirole in the treatment of Parkinson's disease: The ROPI-PARK Study. <i>Clinical Neurology and Neurosurgery</i> , 2009, 111, 742-747.	0.6	6
1679	Peripheral cytokines profile in Parkinson's disease. <i>Brain, Behavior, and Immunity</i> , 2009, 23, 55-63.	2.0	452
1680	Reliability of the new freezing of gait questionnaire: Agreement between patients with Parkinson's disease and their carers. <i>Gait and Posture</i> , 2009, 30, 459-463.	0.6	478
1681	Right prefrontal hypometabolism predicts delusions in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2009, 30, 1420-1429.	1.5	25
1682	Further delineation of the association signal on chromosome 5 from the first whole genome association study in Parkinson's disease. <i>Neurobiology of Aging</i> , 2009, 30, 1706-1709.	1.5	1
1683	Correlation between depressive symptoms and nocturnal disturbances in Japanese patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 15-19.	1.1	43
1684	Vascular pathology in patients with idiopathic Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 24-29.	1.1	55
1685	Smoking and tea consumption delay onset of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 41-46.	1.1	80
1686	Frequency of psychiatric disorders in young-onset Parkinson's disease does not differ from typical-onset Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 153-155.	1.1	19
1687	Neuro-psychiatric therapy during chronic subthalamic stimulation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 128-133.	1.1	11
1688	Cardiac denervation occurs independent of orthostatic hypotension and impaired heart rate variability in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 134-137.	1.1	92
1689	Brain magnetic resonance imaging (MRI) in parkinsonian disorders. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 165-174.	1.1	52
1690	The neuropathological basis for depression in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 144-148.	1.1	123

#	ARTICLE	IF	CITATIONS
1691	LRRK2 gene G2019S mutation and SNPs [haplotypes] in subtypes of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 175-180.	1.1	15
1692	Genetic screening for LRRK2 gene G2019S mutation in Parkinson's disease patients from Southern Italy. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 242-244.	1.1	16
1693	Transcranial sonography of the substantia nigra and MIBG myocardial scintigraphy: Complementary role in the diagnosis of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 270-272.	1.1	15
1694	Does laterality of motor impairment tell us something about cognition in Parkinson disease?. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 315-317.	1.1	39
1695	Acute stepwise challenge test with levodopa in treated patients with parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 354-358.	1.1	9
1696	Anxiety, depression and swallowing disorders in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 453-456.	1.1	50
1697	Psychometric properties of the Parkinson's Disease Sleep Scale – Brazilian version. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 495-499.	1.1	29
1698	PARK11 gene (GIGYF2) variants Asn56Ser and Asn457Thr are not pathogenic for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 532-534.	1.1	28
1699	128-Channel somatosensory evoked potentials in the differential diagnosis of parkinsonian disorders. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 564-571.	1.1	3
1700	Levodopa-induced striatal activation in Parkinson's disease: A functional MRI study. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 558-563.	1.1	47
1701	Performance on an Alzheimer-selective odor identification test in patients with Parkinson's disease and its relationship with cerebral dopamine transporter activity. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 640-643.	1.1	21
1702	Plantar cutaneous sensory stimulation improves single-limb support time, and EMG activation patterns among individuals with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 697-702.	1.1	70
1703	Enhanced cued recall and clock drawing test performances differ in Parkinson's and Alzheimer's disease-related cognitive dysfunction. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 688-691.	1.1	32
1704	Histopathological analysis of skeletal muscle in patients with Parkinson's disease and –dropped head–/–bent spine– syndrome. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 633-639.	1.1	63
1705	Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: An open preliminary trial in Japan. <i>Journal of Clinical Neuroscience</i> , 2009, 16, 790-792.	0.8	1
1706	Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2009, 16, 1034-1037.	0.8	15
1707	Electromyographic activity of sternocleidomastoid muscle in patients with Parkinson's disease. <i>Journal of Electromyography and Kinesiology</i> , 2009, 19, 591-597.	0.7	8
1708	EMG and MMG activities of agonist and antagonist muscles in Parkinson's disease patients during absolute submaximal load holding. <i>Journal of Electromyography and Kinesiology</i> , 2009, 19, 903-914.	0.7	42

#	ARTICLE	IF	CITATIONS
1709	Cerebrospinal fluid α -synuclein in neurodegenerative disorders—A marker of synapse loss?. <i>Neuroscience Letters</i> , 2009, 450, 332-335.	1.0	194
1710	Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. <i>Neuroscience Letters</i> , 2009, 452, 87-89.	1.0	94
1711	Quantitative plasma DNA analysis in Parkinson's disease. <i>Neuroscience Letters</i> , 2009, 452, 5-7.	1.0	6
1712	Impulse control disorders in Parkinson's disease in a Chinese population. <i>Neuroscience Letters</i> , 2009, 465, 6-9.	1.0	75
1713	Effect of deep brain stimulation of the subthalamic nucleus upon the contralateral subthalamic nucleus in Parkinson disease. <i>Neuroscience Letters</i> , 2009, 463, 12-16.	1.0	31
1714	GIGYF2 Asn56Ser mutation is rare in Chinese Parkinson's disease patients. <i>Neuroscience Letters</i> , 2009, 463, 172-175.	1.0	7
1715	Pharmacological Management of Psychosis in Elderly Patients with Parkinsonism. <i>American Journal of Medicine</i> , 2009, 122, 614-622.	0.6	19
1716	High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. <i>Neurology</i> , 2009, 72, 1378-1384.	1.5	409
1717	Variability of EMG patterns: A potential neurophysiological marker of Parkinson's disease?. <i>Clinical Neurophysiology</i> , 2009, 120, 390-397.	0.7	60
1718	High resolution positron emission tomography demonstrates basal ganglia dysfunction in early Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2009, 276, 27-30.	0.3	38
1719	Cardiac parasympathetic dysfunction concurrent with cardiac sympathetic denervation in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2009, 276, 79-83.	0.3	68
1720	Diabetes mellitus and drug-induced parkinsonism: A case-control study. <i>Journal of the Neurological Sciences</i> , 2009, 284, 140-143.	0.3	16
1721	High-frequency rTMS over the supplementary motor area improves bradykinesia in Parkinson's disease: Subanalysis of double-blind sham-controlled study. <i>Journal of the Neurological Sciences</i> , 2009, 287, 143-146.	0.3	59
1722	Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients. <i>Journal of the Neurological Sciences</i> , 2009, 287, 64-68.	0.3	37
1724	Biological fluid biomarkers in neurodegenerative parkinsonism. <i>Nature Reviews Neurology</i> , 2009, 5, 561-570.	4.9	66
1725	Is the N-Back Task a Valid Neuropsychological Measure for Assessing Working Memory?. <i>Archives of Clinical Neuropsychology</i> , 2009, 24, 711-717.	0.3	160
1726	Reduced circulating angiogenic cells in Alzheimer disease. <i>Neurology</i> , 2009, 72, 1858-1863.	1.5	66
1727	Impaired verbal memory in Parkinson disease: relationship to prefrontal dysfunction and somatosensory discrimination. <i>Behavioral and Brain Functions</i> , 2009, 5, 49.	1.4	7

#	ARTICLE	IF	CITATIONS
1728	Cognitive declines one year after unilateral deep brain stimulation surgery in parkinson's disease: A controlled study using reliable change. <i>Clinical Neuropsychologist</i> , 2009, 23, 385-405.	1.5	62
1730	Transcranial brain sonography findings in Parkinson's disease: implications for pathogenesis, early diagnosis and therapy. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 835-846.	1.4	13
1731	Swallowing problems in Parkinson disease: frequency and clinical correlates. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 1047-1049.	0.9	129
1732	Inappropriate crying and laughing in Parkinson disease and movement disorders. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 234-240.	1.3	36
1733	Recognition and management of Parkinson's disease during the premotor (prodromal) phase. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 847-857.	1.4	13
1734	MRI characteristics of the substantia nigra in Parkinson's disease: A combined quantitative T1 and DTI study. <i>NeuroImage</i> , 2009, 47, 435-441.	2.1	163
1735	Management of antiparkinsonian therapy during chronic subthalamic stimulation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S76-S80.	1.1	7
1736	Parkinson disease and comorbid cerebrovascular disease. <i>Nature Reviews Neurology</i> , 2009, 5, 533-541.	4.9	57
1738	Fluoro-Deoxy-Glucose Positron Emission Tomography Correlates of Impaired Activities of Daily Living in Dementia With Lewy Bodies: Implications for Cognitive Reserve. <i>American Journal of Geriatric Psychiatry</i> , 2009, 17, 188-195.	0.6	28
1739	The Pattern of Cognitive-Functional Decline in Elderly Essential Tremor Patients: An Exploratory-Comparative Study With Parkinson's and Alzheimer's Disease Patients. <i>Journal of the American Medical Directors Association</i> , 2009, 10, 238-242.	1.2	30
1740	Positron Emission Tomography for Neurologists. <i>Neurologic Clinics</i> , 2009, 27, 61-88.	0.8	13
1741	Botulinum Toxin A for Overactive Bladder and Detrusor Muscle Overactivity in Patients With Parkinson's Disease and Multiple System Atrophy. <i>Journal of Urology</i> , 2009, 182, 1453-1457.	0.2	124
1743	Education Effect on Depression and Quality of Life in Nondemented Parkinson's Disease Patients. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2009, 21, 314-322.	0.9	7
1744	Depression Impairs Executive Functioning in Parkinson Disease Patients With Low Educational Level. <i>Cognitive and Behavioral Neurology</i> , 2009, 22, 167-172.	0.5	28
1745	The G2019S LRRK2 Mutation is Rare in Korean Patients with Parkinson's Disease and Multiple System		

#	ARTICLE	IF	CITATIONS
1749	Peripheral Chemo-Cytokine Profiles in Alzheimers and Parkinsons Diseases. Mini-Reviews in Medicinal Chemistry, 2009, 9, 1229-1241.	1.1	76
1750	Anxiety, Depression, and Quality of Life in Parkinson's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2009, 21, 413-419.	0.9	69
1751	Interobserver reproducibility of the interpretation of I-123 FP-CIT single-photon emission computed tomography. Nuclear Medicine Communications, 2010, 31, 717-725.	0.5	19
1753	Dietary intake of folate, vitamin B ₆ , vitamin B ₁₂ and riboflavin and risk of Parkinson's disease: a case-control study in Japan. British Journal of Nutrition, 2010, 104, 757-764.	1.2	81
1754	Outcomes of Patients with Parkinson Disease and Pathological Gambling. Canadian Journal of Neurological Sciences, 2010, 37, 473-477.	0.3	19
1755	Corpus Callosum and Cingulum Tractography in Parkinson's Disease. Canadian Journal of Neurological Sciences, 2010, 37, 595-600.	0.3	47
1756	Social Anxiety in Patients With Parkinson's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2010, 22, 390-394.	0.9	24
1757	Cortical and Subcortical Patterns of I-123 Iodobenzamide SPECT in Striatal D2 Receptor Parkinsonisms. Clinical Nuclear Medicine, 2010, 35, 228-233.	0.7	5
1758	OVERVIEW OF COMMON MOVEMENT DISORDERS. CONTINUUM Lifelong Learning in Neurology, 2010, 16, 13-48.	0.4	12
1759	Downhill Walking Training in Individuals with Parkinson's Disease. American Journal of Physical Medicine and Rehabilitation, 2010, 89, 706-714.	0.7	37
1760	Whole Body and Cardiac Metaiodobenzylguanidine Kinetics in Parkinson Disease and Multiple System Atrophy. Clinical Nuclear Medicine, 2010, 35, 311-316.	0.7	7
1761	Generalized anxiety disorder and the Hamilton Anxiety Rating Scale in Parkinson's disease. Arquivos De Neuro-Psiquiatria, 2010, 68, 495-501.	0.3	55
1762	Neurovascular Coupling in Parkinson's Disease Patients: Effects of Dementia and Acetylcholinesterase Inhibitor Treatment. Journal of Alzheimer's Disease, 2010, 22, 415-421.	1.2	24
1763	Correlation Between Substantia Nigra Features Detected by Sonography and Parkinson Disease Symptoms. Journal of Ultrasound in Medicine, 2010, 29, 37-42.	0.8	24
1764	Role of polymorphisms in dopamine synthesis and metabolism genes and association of DBH haplotypes with Parkinson's disease among North Indians. Pharmacogenetics and Genomics, 2010, 20, 435-441.	0.7	20
1765	Subthalamic nucleus stimulation affects fear and sadness recognition in Parkinson's disease.. Neuropsychology, 2010, 24, 1-8.	1.0	64
1766	Recognition by familiarity is preserved in Parkinson's without dementia and Lewy-Body disease.. Neuropsychology, 2010, 24, 599-607.	1.0	18
1767	Significance of MRI in Diagnosis and Differential Diagnosis of Parkinson's Disease. Neurodegenerative Diseases, 2010, 7, 300-318.	0.8	116

#	ARTICLE	IF	CITATIONS
1768	Feeling of knowing in episodic memory in patients with Parkinson's disease with various motor symptoms. <i>Movement Disorders</i> , 2010, 25, 1034-1039.	2.2	18
1769	Predictive potential of pre-operative functional neuroimaging in patients treated with subthalamic stimulation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 12-22.	3.3	2
1770	Validation of cardiac 123I-MIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 3-11.	3.3	50
1771	Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 537-544.	3.3	35
1772	Subthalamic nucleus stimulation affects limbic and associative circuits: a PET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1512-1520.	3.3	58
1774	Effects of five years of chronic STN stimulation on muscle strength and movement speed. <i>Experimental Brain Research</i> , 2010, 205, 435-443.	0.7	8
1775	Hyperhomocysteinemia Due to Levodopa Treatment as a Risk Factor for Osteoporosis in Patients with Parkinson's Disease. <i>Calcified Tissue International</i> , 2010, 86, 132-141.	1.5	30
1776	Usefulness of 3D-PRESTO imaging in evaluating putaminal abnormality in parkinsonian variant of multiple system atrophy. <i>Neuroradiology</i> , 2010, 52, 809-814.	1.1	22
1777	Dynamical correlation of non-stationary signals in time domain—A comparative study. <i>Biomedical Signal Processing and Control</i> , 2010, 5, 205-213.	3.5	28
1778	Glucocerebrosidase is present in α -synuclein inclusions in Lewy body disorders. <i>Acta Neuropathologica</i> , 2010, 120, 641-649.	3.9	169
1779	Modulation of metabolic brain function by bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease. <i>Journal of Neurology</i> , 2010, 257, 72-78.	1.8	32
1780	Cognitive status of patients with Parkinson's disease and pathological gambling. <i>Journal of Neurology</i> , 2010, 257, 247-252.	1.8	49
1781	Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression. <i>Journal of Neurology</i> , 2010, 257, 524-532.	1.8	70
1782	Transient gender-related effects in Parkinson's disease patients with subthalamic stimulation. <i>Journal of Neurology</i> , 2010, 257, 603-608.	1.8	24
1783	Olfactory dysfunction and cardiovascular dysautonomia in Parkinson's disease. <i>Journal of Neurology</i> , 2010, 257, 969-976.	1.8	49
1784	Fluctuating cognition and different cognitive and behavioural profiles in Parkinson's disease with dementia: comparison of dementia with Lewy bodies and Alzheimer's disease. <i>Journal of Neurology</i> , 2010, 257, 1004-1011.	1.8	36
1785	Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. <i>Journal of Neurology</i> , 2010, 257, 1073-1082.	1.8	216
1786	The comparison of clonidine, arginine and both combined: a growth hormone stimulation test to differentiate multiple system atrophy from idiopathic Parkinson's disease. <i>Journal of Neurology</i> , 2010, 257, 1486-1491.	1.8	9

#	ARTICLE	IF	CITATIONS
1787	Late-stage Parkinsonâ€™s disease: the Barcelona and Lisbon cohort. <i>Journal of Neurology</i> , 2010, 257, 1524-1532.	1.8	106
1788	Parkinsonian single fallers versus recurrent fallers: different fall characteristics and clinical features. <i>Journal of Neurology</i> , 2010, 257, 1543-1551.	1.8	92
1789	The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism. <i>Journal of Neurology</i> , 2010, 257, 1882-1889.	1.8	39
1790	Putaminal abnormality on 3-T magnetic resonance imaging in early parkinsonism-predominant multiple system atrophy. <i>Journal of Neurology</i> , 2010, 257, 2065-2070.	1.8	33
1791	Dopaminergic therapy and subthalamic stimulation in Parkinsonâ€™s disease: a review of 5-year reports. <i>Journal of Neurology</i> , 2010, 257, 298-304.	1.8	32
1792	The effect of l-Dopa administration on pursuit ocular movements in suspected Parkinsonâ€™s disease. <i>Neurological Sciences</i> , 2010, 31, 381-385.	0.9	20
1793	Myocardial MIBG scintigraphy: a useful clinical tool?. <i>Neurological Sciences</i> , 2010, 31, 403-406.	0.9	17
1794	Protracted benefit from paradoxical kinesia in typical and atypical parkinsonisms. <i>Neurological Sciences</i> , 2010, 31, 751-756.	0.9	24
1795	Comprehensive autonomic assessment does not differentiate between Parkinsonâ€™s disease, multiple system atrophy and progressive supranuclear palsy. <i>Journal of Neural Transmission</i> , 2010, 117, 69-76.	1.4	43
1796	Cognition in multiple system atrophy: neuropsychological profile and interaction with mood. <i>Journal of Neural Transmission</i> , 2010, 117, 369-375.	1.4	49
1797	The cold hand sign in multiple system atrophy: skin perfusion revisited. <i>Journal of Neural Transmission</i> , 2010, 117, 475-479.	1.4	10
1798	CSF markers of neurodegeneration in Parkinsonâ€™s disease. <i>Journal of Neural Transmission</i> , 2010, 117, 1177-1181.	1.4	57
1799	Levetiracetam for levodopa-induced dyskinesia in Parkinsonâ€™s disease: a randomized, double-blind, placebo-controlled trial. <i>Journal of Neural Transmission</i> , 2010, 117, 1279-1286.	1.4	50
1801	Altered Regulation of CD200 Receptor in Monocyte-Derived Macrophages from Individuals with Parkinsonâ€™s Disease. <i>Neurochemical Research</i> , 2010, 35, 540-547.	1.6	40
1802	Efficacy of community-based physiotherapy networks for patients with Parkinson's disease: a cluster-randomised trial. <i>Lancet Neurology</i> , The, 2010, 9, 46-54.	4.9	143
1803	Imaging for early differential diagnosis of parkinsonism. <i>Lancet Neurology</i> , The, 2010, 9, 130-131.	4.9	10
1804	Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. <i>Lancet Neurology</i> , The, 2010, 9, 1070-1077.	4.9	349
1805	Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: A pathogenetically based approach. <i>Neurobiology of Disease</i> , 2010, 39, 229-241.	2.1	67

#	ARTICLE	IF	CITATIONS
1806	Staging of serotonergic dysfunction in Parkinson's Disease: An in vivo 11C-DASB PET study. <i>Neurobiology of Disease</i> , 2010, 40, 216-221.	2.1	213
1807	Recognition of emotional prosody is altered after subthalamic nucleus deep brain stimulation in Parkinson's disease. <i>Neuropsychologia</i> , 2010, 48, 1053-1062.	0.7	81
1808	Medication impairs probabilistic classification learning in Parkinson's disease. <i>Neuropsychologia</i> , 2010, 48, 1096-1103.	0.7	106
1809	Dietary glycemic index is inversely associated with the risk of Parkinson's disease: A case-control study in Japan. <i>Nutrition</i> , 2010, 26, 515-521.	1.1	53
1810	Charting the progression of disability in parkinson disease: study protocol for a prospective longitudinal cohort study. <i>BMC Neurology</i> , 2010, 10, 110.	0.8	42
1811	Alcohol drinking and risk of Parkinson's disease: a case-control study in Japan. <i>BMC Neurology</i> , 2010, 10, 111.	0.8	21
1812	A cross-sectional study of the nutritional status of community-dwelling people with idiopathic Parkinson's disease. <i>BMC Neurology</i> , 2010, 10, 124.	0.8	49
1813	Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: An in vivo MR study. <i>Brain Research</i> , 2010, 1330, 124-130.	1.1	154
1814	Oxidative damage in Parkinson disease: Measurement using accurate biomarkers. <i>Free Radical Biology and Medicine</i> , 2010, 48, 560-566.	1.3	226
1815	Basal ganglia hypoactivity during grip force in drug naïve Parkinson's disease. <i>Human Brain Mapping</i> , 2010, 31, 1928-1941.	1.9	61
1816	<i>LINGO1</i> is not associated with Parkinson's disease in German patients. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 1173-1178.	1.1	11
1817	Pathological gambling in Parkinson disease is reduced by amantadine. <i>Annals of Neurology</i> , 2010, 68, 400-404.	2.8	201
1818	Campyocormia in idiopathic Parkinson's disease: A focal myopathy of the paravertebral muscles. <i>Movement Disorders</i> , 2010, 25, 542-551.	2.2	108
1819	Anxiety disorders in Parkinson's disease: Prevalence and risk factors. <i>Movement Disorders</i> , 2010, 25, 838-845.	2.2	317
1820	Neurochemical biomarkers in the differential diagnosis of movement disorders. <i>Movement Disorders</i> , 2010, 25, 500-500.	2.2	4
1821	A comparison of gray and white matter density in patients with Parkinson's disease dementia and dementia with Lewy bodies using voxel-based morphometry. <i>Movement Disorders</i> , 2010, 25, 28-34.	2.2	57
1822	Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 332-340.	2.2	27
1823	The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: An international study using the nonmotor symptoms questionnaire. <i>Movement Disorders</i> , 2010, 25, 704-709.	2.2	342

#	ARTICLE	IF	CITATIONS
1824	Imaging essential tremor. <i>Movement Disorders</i> , 2010, 25, 679-686.	2.2	80
1825	PDDâ€‘Short Screen: A brief cognitive test for screening dementia in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 440-446.	2.2	31
1826	Psychometric properties of the SCOPAâ€‘AUT Brazilian Portuguese version. <i>Movement Disorders</i> , 2010, 25, 205-212.	2.2	23
1827	Obstacle avoidance to elicit freezing of gait during treadmill walking. <i>Movement Disorders</i> , 2010, 25, 57-63.	2.2	45
1828	Differential pattern of brainâ€‘specific CSF proteins tau and amyloidâ€‘beta in Parkinsonian syndromes. <i>Movement Disorders</i> , 2010, 25, 1284-1288.	2.2	44
1829	Motor laterality asymmetry and nonmotor symptoms in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 70-75.	2.2	79
1830	Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti-reward. <i>Movement Disorders</i> , 2010, 25, 867-876.	2.2	48
1831	Myopathy causing camptocormia in idiopathic Parkinson's disease: A multidisciplinary approach. <i>Movement Disorders</i> , 2010, 25, 552-559.	2.2	67
1832	Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies. <i>Movement Disorders</i> , 2010, 25, 167-171.	2.2	53
1833	Differentiating vascular parkinsonism from idiopathic Parkinson's disease: A systematic review. <i>Movement Disorders</i> , 2010, 25, 149-156.	2.2	96
1834	Kinematic study of whole body center of mass position during gait in Parkinson's disease patients with and without festination. <i>Movement Disorders</i> , 2010, 25, 747-754.	2.2	25
1835	What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsyâ€‘parkinsonism (PSPâ€‘P)? <i>Movement Disorders</i> , 2010, 25, 357-362.	2.2	106
1836	A case-control study of Parkinson's disease and tobacco use: Gene-tobacco interactions. <i>Movement Disorders</i> , 2010, 25, 912-919.	2.2	28
1837	Utility of the WHOâ€‘five wellâ€‘being index as a screening tool for depression in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 777-783.	2.2	48
1838	Fourâ€‘week trunkâ€‘specific rehabilitation treatment improves lateral trunk flexion in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 325-331.	2.2	62
1839	Glucocerebrosidase Gene L444P mutation is a risk factor for Parkinson's disease in Chinese population. <i>Movement Disorders</i> , 2010, 25, 1005-1011.	2.2	50
1840	Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: A clinical and electrophysiological study. <i>Movement Disorders</i> , 2010, 25, 560-569.	2.2	223
1841	Endoscopic characteristics and levodopa responsiveness of swallowing function in progressive supranuclear palsy. <i>Movement Disorders</i> , 2010, 25, 1239-1245.	2.2	84

#	ARTICLE	IF	CITATIONS
1842	Transcranial brain sonography in Parkinson's disease with restless legs syndrome. <i>Movement Disorders</i> , 2010, 25, 1373-1378.	2.2	35
1843	Risk factors for executive dysfunction after subthalamic nucleus stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1583-1589.	2.2	68
1844	Cross-cultural evaluation of the modified Parkinson Psychosis Rating Scale across disease stages. <i>Movement Disorders</i> , 2010, 25, 1391-1398.	2.2	8
1845	Decision making in de novo Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1432-1436.	2.2	56
1846	Timed motor tests can detect subtle motor dysfunction in early Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1150-1156.	2.2	48
1847	Rapid screening of <i>ATP13A2</i> variant with high-resolution melting analysis. <i>Movement Disorders</i> , 2010, 25, 2434-2437.	2.2	9
1848	Parkinson's disease symptoms: The patient's perspective. <i>Movement Disorders</i> , 2010, 25, 1646-1651.	2.2	464
1849	Standard guidelines for publication of deep brain stimulation studies in Parkinson's disease (Guide4DBS&PD). <i>Movement Disorders</i> , 2010, 25, 1530-1537.	2.2	20
1850	An magnetic resonance imaging T2-weighted sequence at short echo time to detect putaminal hypointensity in Parkinsonisms. <i>Movement Disorders</i> , 2010, 25, 2728-2734.	2.2	29
1851	Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1881-1887.	2.2	21
1852	Prevalence and risk factors of Parkinson's disease in retired Thai traditional boxers. <i>Movement Disorders</i> , 2010, 25, 1895-1901.	2.2	33
1853	Comorbid cancer in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1809-1817.	2.2	46
1854	Impaired sense of smell and color discrimination in monogenic and idiopathic Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2665-2669.	2.2	53
1855	Comprehensive sequencing of the <i>LRRK2</i> gene in patients with familial Parkinson's disease from North Africa. <i>Movement Disorders</i> , 2010, 25, 2052-2058.	2.2	23
1856	Cerebellar dysfunction in progressive supranuclear palsy: A transcranial magnetic stimulation study. <i>Movement Disorders</i> , 2010, 25, 2413-2419.	2.2	53
1857	Magnetic resonance imaging findings of shoulders in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2524-2530.	2.2	16
1858	Carbidopa/levodopa pharmacy errors in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2867-2871.	2.2	6
1859	Clinical expression of <i>LRRK2</i> G2019S mutations in the elderly. <i>Movement Disorders</i> , 2010, 25, 2571-2576.	2.2	21

#	ARTICLE	IF	CITATIONS
1860	Nonlinear dynamic analysis of oscillatory repetitive movements in Parkinson's disease and essential tremor. <i>Movement Disorders</i> , 2010, 25, 2577-2586.	2.2	26
1861	Cardiac autonomic dysfunction in idiopathic REM sleep behavior disorder. <i>Movement Disorders</i> , 2010, 25, 2304-2310.	2.2	135
1862	Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrainâ€”pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy. <i>Movement Disorders</i> , 2010, 25, 2444-2449.	2.2	74
1863	Blood oxygenation levelâ€”dependent activation in basal ganglia nuclei relates to specific symptoms in de novo Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2035-2043.	2.2	57
1864	Nonmotor symptoms are independently associated with impaired healthâ€”related quality of life in Chinese patients with Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2740-2746.	2.2	101
1865	What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them?. <i>Movement Disorders</i> , 2010, 25, 2493-2500.	2.2	405
1866	Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2785-2791.	2.2	70
1867	Sporadic Parkinsonism. <i>BMC Geriatrics</i> , 2010, 10, .	1.1	0
1868	Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease. <i>BMC Medical Genetics</i> , 2010, 11, 53.	2.1	26
1869	Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2010, 5, 43.	4.4	106
1870	Decisionâ€”making in Parkinsonâ€™s disease patients with and without pathological gambling. <i>European Journal of Neurology</i> , 2010, 17, 97-102.	1.7	97
1871	Apraxia in Parkinsonâ€™s disease and multiple system atrophy. <i>European Journal of Neurology</i> , 2010, 17, 413-418.	1.7	21
1872	Quantitative magnetic resonance spectroscopic imaging in Parkinsonâ€™s disease, progressive supranuclear palsy and multiple system atrophy. <i>European Journal of Neurology</i> , 2010, 17, 1193-1202.	1.7	37
1873	Differential diagnosis of dystonia. <i>European Journal of Neurology</i> , 2010, 17, 1-8.	1.7	21
1874	Diffuse occipital hypometabolism on [18F]-FDG PET scans in patients with idiopathic REM sleep behavior disorder: Prodromal dementia with Lewy bodies?. <i>Psychogeriatrics</i> , 2010, 10, 144-152.	0.6	48
1875	Active and passive smoking and risk of Parkinsonâ€™s disease. <i>Acta Neurologica Scandinavica</i> , 2010, 122, 377-382.	1.0	34
1876	Genetic variability at the PARK16 locus. <i>European Journal of Human Genetics</i> , 2010, 18, 1356-1359.	1.4	85
1877	Implementing deep brain stimulation into practice: Models of patient care. , 0, , 131-140.		0

#	ARTICLE	IF	CITATIONS
1878	Daytime sleepiness in elderly Parkinson's disease patients and treatment with the psychostimulant modafinil: A preliminary study. <i>Neuropsychiatric Disease and Treatment</i> , 2010, 6, 93.	1.0	12
1879	Brief practical clinical diagnostic criteria for the neurodegenerative diseases in the elderly. <i>Drugs and Therapy Studies</i> , 2010, 1, 6.	0.6	2
1880	A Tangled Web – Tau and Sporadic Parkinson's Disease. <i>Frontiers in Psychiatry</i> , 2010, 1, 150.	1.3	27
1881	Effects of dopamine medication on sequence learning with stochastic feedback in Parkinson's disease. <i>Frontiers in Systems Neuroscience</i> , 2010, 4, .	1.2	22
1882	Walking with Music Is a Safe and Viable Tool for Gait Training in Parkinson's Disease: The Effect of a 13-Week Feasibility Study on Single and Dual Task Walking. <i>Parkinson's Disease</i> , 2010, 2010, 1-9.	0.6	94
1883	Neuroimaging, Parkinson's Disease. , 2010, , 272-278.		0
1884	IBZM SPECT and FDG PET in the differential diagnosis of Parkinsonian syndromes. <i>Nuklearmedizin - Nuclear Medicine</i> , 2010, 49, 139-147.	0.3	6
1885	WHOQOL-OLD assessment of quality of life in elderly patients with Parkinson's disease: influence of sleep and depressive symptoms. <i>Revista Brasileira De Psiquiatria</i> , 2010, 32, 125-131.	0.9	26
1886	Objective Quantification of Neuromotor Symptoms in Parkinson's Disease: Implementation of a Portable, Computerized Measurement Tool. <i>Parkinson's Disease</i> , 2010, 2010, 1-6.	0.6	32
1887	Diagnostic and Pathophysiological Impact of Myocardial MIBG Scintigraphy in Parkinson's Disease. <i>Parkinson's Disease</i> , 2010, 2010, 1-6.	0.6	15
1888	Facial Emotion Recognition Impairment in Patients with Parkinson's Disease and Isolated Apathy. <i>Parkinson's Disease</i> , 2010, 2010, 1-5.	0.6	32
1889	Lewy Body and Parkinsonian Dementia. <i>Deutsches A&#x0308;rzteblatt International</i> , 2010, 107, 684-91.	0.6	40
1890	Mild cognitive impairment in Parkinson disease. <i>Neurology</i> , 2010, 75, 1062-1069.	1.5	643
1891	Dopamine Agonist Withdrawal Syndrome in Parkinson Disease. <i>Archives of Neurology</i> , 2010, 67, 58-63.	4.9	299
1892	Frequency of Known Mutations in Early-Onset Parkinson Disease. <i>Archives of Neurology</i> , 2010, 67, 1116-22.	4.9	121
1893	Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson's Patients with Neural Transplants. <i>Science Translational Medicine</i> , 2010, 2, 38ra46.	5.8	272
1894	Effects of acute tryptophan depletion on neuropsychological and motor function in Parkinson's disease. <i>Journal of Psychopharmacology</i> , 2010, 24, 1465-1472.	2.0	12
1895	Glycopyrrolate for sialorrhea in Parkinson disease. <i>Neurology</i> , 2010, 74, 1203-1207.	1.5	125

#	ARTICLE	IF	CITATIONS
1896	Safety and efficacy of sildenafil citrate in the treatment of Parkinson-emergent erectile dysfunction: a double-blind, placebo-controlled, randomized study. <i>International Journal of Impotence Research</i> , 2010, 22, 325-335.	1.0	24
1897	Autosomal recessive mutations in the development of Parkinson's disease. <i>Biomarkers in Medicine</i> , 2010, 4, 713-721.	0.6	12
1898	Influence of White Matter Hyperintensities on the Cognition of Patients With Parkinson Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 227-233.	0.6	84
1899	The effects of acute tryptophan depletion on mood in patients with Parkinson's disease and the healthy elderly. <i>Journal of Psychopharmacology</i> , 2010, 24, 615-619.	2.0	13
1900	Performance of Greek Demented and Nondemented Subjects on the Greek Version of the Mattis Dementia Rating Scale. A Validation Study. <i>International Journal of Neuroscience</i> , 2010, 120, 724-730.	0.8	7
1901	Dissociation of Cardinal Motor Signs in Parkinson's Disease Patients. <i>European Neurology</i> , 2010, 63, 307-310.	0.6	10
1902	Evaluation of Dementia Rating Scales in Parkinson's Disease Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2010, 25, 142-148.	0.9	16
1903	Care requirements of a prevalent population of people with idiopathic Parkinson's disease. <i>Age and Ageing</i> , 2010, 39, 57-61.	0.7	19
1904	Multi-Modal Hallucinations and Cognitive Function in Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 30, 51-56.	0.7	22
1905	Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. <i>Neurology</i> , 2010, 74, 885-892.	1.5	299
1906	Progression from Unilateral to Bilateral Parkinsonism in Early Parkinson Disease: Implication of Mesocortical Dopamine Dysfunction by PET. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1250-1257.	2.8	37
1907	Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease. <i>Archives of Neurology</i> , 2010, 67, 416-21.	4.9	220
1908	Clinical Criteria for the Diagnosis of Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2010, 7, 284-290.	0.8	104
1909	Sequence Variations in Mitochondrial Ferritin: Distribution in Healthy Controls and Different Types of Patients. <i>Genetic Testing and Molecular Biomarkers</i> , 2010, 14, 793-796.	0.3	9
1910	Volume quantification of 123I-DaTSCAN imaging by MatLab for the differentiation and grading of parkinsonism and essential tremor. , 2010, , .		3
1911	Functioning and disability in Parkinson's disease. <i>Disability and Rehabilitation</i> , 2010, 32, S33-S41.	0.9	20
1912	Impact of STN-DBS on life and health satisfaction in patients with Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 315-319.	0.9	40
1913	Abnormalities in Metabolic Network Activity Precede the Onset of Motor Symptoms in Parkinson's Disease. <i>Journal of Neuroscience</i> , 2010, 30, 1049-1056.	1.7	175

#	ARTICLE	IF	CITATIONS
1914	Incidental Encoding Strategies Did Not Improve Contextual Memory in Parkinson's Disease Patients. <i>Neurorehabilitation and Neural Repair</i> , 2010, 24, 450-456.	1.4	14
1915	Accuracy of clinical diagnosis in tremulous parkinsonian patients: a blinded video study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1223-1228.	0.9	91
1916	Pharmacotherapy in Parkinson's disease: case studies. <i>Therapeutic Advances in Neurological Disorders</i> , 2010, 3, 117-126.	1.5	5
1917	Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. <i>Brain</i> , 2010, 133, 2664-2676.	3.7	367
1918	Exploiting the potential of molecular profiling in Parkinson's disease: current practice and future probabilities. <i>Expert Review of Molecular Diagnostics</i> , 2010, 10, 1035-1050.	1.5	14
1919	The role of DAT-SPECT in movement disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 5-12.	0.9	248
1920	Subthalamic nucleus stimulation and somatosensory temporal discrimination in Parkinson's disease. <i>Brain</i> , 2010, 133, 2656-2663.	3.7	80
1921	Cohort study on somatoform disorders in Parkinson disease and dementia with Lewy bodies. <i>Neurology</i> , 2010, 74, 1598-1606.	1.5	88
1922	Episodic Memory in Dementia: Characteristics of New Learning that Differentiate Alzheimer's, Huntington's, and Parkinson's Diseases. <i>Archives of Clinical Neuropsychology</i> , 2010, 25, 396-409.	0.3	33
1923	Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease. <i>Brain</i> , 2010, 133, 727-745.	3.7	171
1924	A 15-year population-based cohort study of the incidence of Parkinson's disease and dementia with Lewy bodies in an elderly French cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 742-746.	0.9	51
1925	PINK1-linked parkinsonism is associated with Lewy body pathology. <i>Brain</i> , 2010, 133, 1128-1142.	3.7	223
1926	Regional patterns of brain tissue loss associated with depression in Parkinson disease. <i>Neurology</i> , 2010, 75, 857-863.	1.5	143
1927	Association of Cumulative Lead Exposure with Parkinson's Disease. <i>Environmental Health Perspectives</i> , 2010, 118, 1609-1613.	2.8	137
1928	REDUCED CIRCULATING ANGIOGENIC CELLS IN ALZHEIMER DISEASE. <i>Neurology</i> , 2010, 74, 346-347.	1.5	25
1929	Serotonergic neurotransmission in early Parkinson's disease: A pilot study to assess implications for depression in this disorder. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 781-787.	1.3	24
1930	Severity of REM atonia loss in idiopathic REM sleep behavior disorder predicts Parkinson disease. <i>Neurology</i> , 2010, 74, 239-244.	1.5	195
1931	Parkinsonism and Other Movement Disorders. , 2010, , 511-519.		1

#	ARTICLE	IF	CITATIONS
1932	TDP43-Positive Intraneuronal Inclusions in a Patient with Motor Neuron Disease and Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2010, 7, 260-264.	0.8	32
1933	Asymptomatic Deep Venous Thrombosis after Deep Brain Stimulation for Parkinson Disease. <i>Stereotactic and Functional Neurosurgery</i> , 2010, 88, 94-97.	0.8	9
1934	Occurrence of <i>PARK2</i> Mutations in a Never-Smoker Population with Parkinson's Disease in North India. <i>Neuroepidemiology</i> , 2010, 35, 152-159.	1.1	9
1935	Mapping Go-No-Go performance within the subthalamic nucleus region. <i>Brain</i> , 2010, 133, 3625-3634.	3.7	110
1936	Study of the prevalence of Parkinson's disease using dopamine transporter imaging. <i>Neurological Research</i> , 2010, 32, 845-851.	0.6	6
1937	Effects of a Dopamine Agonist on the Pharmacodynamics of Levodopa in Parkinson Disease. <i>Archives of Neurology</i> , 2010, 67, 27-32.	4.9	29
1938	Olfaction as a biomarker in Parkinson's disease. <i>Biomarkers in Medicine</i> , 2010, 4, 661-670.	0.6	42
1939	Positron Emission Tomography in Diagnosis and Differential Diagnosis of Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2010, 7, 330-340.	0.8	10
1940	SPINAL CORD STIMULATION FAILED TO RELIEVE AKINESIA OR RESTORE LOCOMOTION IN PARKINSON DISEASE. <i>Neurology</i> , 2010, 74, 1325-1327.	1.5	73
1941	Abnormal metabolic brain networks in Parkinson's disease. <i>Progress in Brain Research</i> , 2010, 184, 160-176.	0.9	26
1942	White Matter Microstructure Changes in the Thalamus in Parkinson Disease with Depression: A Diffusion Tensor MR Imaging Study. <i>American Journal of Neuroradiology</i> , 2010, 31, 1861-1866.	1.2	94
1943	Cognitive Declines After Unilateral Deep Brain Stimulation Surgery in Parkinson's Disease: A Controlled Study Using Reliable Change, Part II. <i>Clinical Neuropsychologist</i> , 2010, 24, 235-245.	1.5	38
1944	Transcranial Sonography for the Discrimination of Idiopathic Parkinson's Disease from the Atypical Parkinsonian Syndromes. <i>International Review of Neurobiology</i> , 2010, 90, 121-146.	0.9	31
1945	Using Evidence-Based Medicine in Neurology. <i>Neurologic Clinics</i> , 2010, 28, 489-503.	0.8	7
1946	18F-Fluorodeoxyglucose PET in the Evaluation of Parkinson Disease. <i>PET Clinics</i> , 2010, 5, 55-64.	1.5	36
1947	Role of Transcranial Ultrasound in the Diagnosis of Movement Disorders. <i>Neuroimaging Clinics of North America</i> , 2010, 20, 87-101.	0.5	18
1948	Extrapyramidal Syndromes: PET and SPECT. <i>Neuroimaging Clinics of North America</i> , 2010, 20, 57-68.	0.5	9
1949	Morbo di Parkinson idiopatico: aspetti clinici, diagnostici e terapeutici. <i>EMC - Neurologia</i> , 2010, 10, 1-29.	0.0	0

#	ARTICLE	IF	CITATIONS
1950	Transcranial Sonography in Relation to SPECT and MIBG. <i>International Review of Neurobiology</i> , 2010, 90, 48-62.	0.9	2
1951	Brain Magnetic Resonance Imaging Techniques in the Diagnosis of Parkinsonian Syndromes. <i>Neuroimaging Clinics of North America</i> , 2010, 20, 29-55.	0.5	91
1952	The Role of Imaging in the Diagnosis of Vascular Parkinsonism. <i>Neuroimaging Clinics of North America</i> , 2010, 20, 69-76.	0.5	22
1953	Problems associated with fluid biomarkers for Parkinson's disease. <i>Biomarkers in Medicine</i> , 2010, 4, 671-681.	0.6	14
1955	Suicide and suicidal ideation in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2010, 289, 40-43.	0.3	67
1956	The epidemiology of dementia associated with Parkinson disease. <i>Journal of the Neurological Sciences</i> , 2010, 289, 18-22.	0.3	384
1957	Restless Legs Syndrome (RLS) and Parkinson's disease (PD) – Related disorders or different entities?. <i>Journal of the Neurological Sciences</i> , 2010, 289, 135-137.	0.3	61
1958	Functional imaging studies of hyposmia in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2010, 289, 36-39.	0.3	23
1959	Dietary fat intake and risk of Parkinson's disease: A case-control study in Japan. <i>Journal of the Neurological Sciences</i> , 2010, 288, 117-122.	0.3	83
1960	Evaluation of patients with Clinically Unclear Parkinsonian Syndromes submitted to brain SPECT imaging using the technetium-99m labeled tracer TRODAT-1. <i>Journal of the Neurological Sciences</i> , 2010, 291, 64-68.	0.3	28
1961	Case-control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. <i>Journal of the Neurological Sciences</i> , 2010, 293, 82-86.	0.3	128
1962	Lower prevalence of sleep disturbances in familial versus sporadic Parkinson's disease: A questionnaire based study. <i>Journal of the Neurological Sciences</i> , 2010, 295, 27-30.	0.3	49
1963	LRRK2 Gly2385Arg polymorphism, cigarette smoking, and risk of sporadic Parkinson's disease: A case-control study in Japan. <i>Journal of the Neurological Sciences</i> , 2010, 297, 15-18.	0.3	26
1964	Substantia nigra echomorphology and motor cortex excitability. <i>NeuroImage</i> , 2010, 50, 1351-1356.	2.1	11
1965	Quantitative mapping of T1 and T2* discloses nigral and brainstem pathology in early Parkinson's disease. <i>NeuroImage</i> , 2010, 51, 512-520.	2.1	143
1967	Transcranial sonography for diagnosis of Parkinson's disease. <i>BMC Neurology</i> , 2010, 10, 9.	0.8	46
1968	Analysis of GWAS-linked loci in Parkinson disease reaffirms PARK16 as a susceptibility locus. <i>Neurology</i> , 2010, 75, 508-512.	1.5	68
1969	Early Diagnosis of Parkinson's Disease. <i>International Review of Neurobiology</i> , 2010, 90, 81-92.	0.9	26

#	ARTICLE	IF	CITATIONS
1970	Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. <i>Brain</i> , 2010, 133, 3423-3433.	3.7	374
1971	Actigraphic Evaluation of Motor Fluctuations in Patients with Parkinson's Disease. <i>International Journal of Neuroscience</i> , 2010, 120, 137-143.	0.8	14
1972	Diffusion tensor MRI changes in cerebellar structures of patients with familial essential tremor. <i>Neurology</i> , 2010, 74, 988-994.	1.5	134
1973	Quantification of α -synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. <i>Biomarkers in Medicine</i> , 2010, 4, 683-699.	0.6	113
1974	Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. <i>Brain</i> , 2010, 133, 1747-1754.	3.7	263
1975	A novel LRRK2 mutation in a mainland Chinese patient with familial Parkinson's disease. <i>Neuroscience Letters</i> , 2010, 468, 198-201.	1.0	22
1976	Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa. <i>Neuroscience Letters</i> , 2010, 468, 287-291.	1.0	20
1977	Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2'-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. <i>Neuroscience Letters</i> , 2010, 469, 159-163.	1.0	105
1978	Association between GBA L444P mutation and sporadic Parkinson's disease from Mainland China. <i>Neuroscience Letters</i> , 2010, 469, 256-259.	1.0	56
1979	Clinical availability of skin biopsy in the diagnosis of Parkinson's disease. <i>Neuroscience Letters</i> , 2010, 469, 357-359.	1.0	105
1980	Novel GIGYF2 gene variants in patients with Parkinson's disease in Chinese population. <i>Neuroscience Letters</i> , 2010, 473, 131-135.	1.0	12
1981	Expression analysis of suppression of tumorigenicity 13 gene in patients with Parkinson's disease. <i>Neuroscience Letters</i> , 2010, 473, 257-259.	1.0	7
1982	Lack of association between ATP13A2 Ala746Thr variant and Parkinson's disease in Han population of mainland China. <i>Neuroscience Letters</i> , 2010, 475, 61-63.	1.0	14
1983	Lack of replication of a previously reported association between polymorphism in the 3'UTR of the alpha-synuclein gene and Parkinson's disease in Chinese subjects. <i>Neuroscience Letters</i> , 2010, 479, 31-33.	1.0	20
1984	Proteome analysis of the sera from Chinese Parkinson's disease patients. <i>Neuroscience Letters</i> , 2010, 479, 175-179.	1.0	26
1985	Screening for two SNPs of LINGO1 gene in patients with essential tremor or sporadic Parkinson's disease in Chinese population. <i>Neuroscience Letters</i> , 2010, 481, 69-72.	1.0	35
1986	L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2010, 17, 717-721.	0.8	26
1987	Assessment of depression in Parkinson's disease: The contribution of somatic symptoms to the clinimetric performance of the Hamilton and Montgomery-Åsberg rating scales. <i>Journal of Psychosomatic Research</i> , 2010, 68, 561-565.	1.2	30

#	ARTICLE	IF	CITATIONS
1989	Impaired awareness of movement disorders in Parkinson's disease. <i>Brain and Cognition</i> , 2010, 72, 337-346.	0.8	53
1990	Ubiquitin specific proteases USP24 and USP40 and ubiquitin thiolesterase UCHL1 polymorphisms have synergic effect on the risk of Parkinson's disease among Taiwanese. <i>Clinica Chimica Acta</i> , 2010, 411, 955-958.	0.5	24
1991	Effects of subthalamic nucleus deep brain stimulation on sweating function in Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 213-217.	0.6	38
1992	Degenerative parkinsonism in patients with psychogenic parkinsonism: A dopamine transporter imaging study. <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 282-285.	0.6	34
1993	Factors influencing the symmetry of Parkinson's disease symptoms. <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 302-305.	0.6	20
1994	The differential diagnoses of parkinsonism: Findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics. <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 431-435.	0.6	43
1995	Risk of stroke in patients with idiopathic Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 31-35.	1.1	66
1996	Genetic screening for mutations in the Nrdp1 gene in Parkinson disease patients in a Chinese population. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 222-224.	1.1	8
1997	The effect of levodopa treatment on cerebral hemodynamics in patients with Parkinson's disease: Serial transcranial Doppler studies. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 225-227.	1.1	8
1998	The LRRK2 G2385R variant is a risk factor for sporadic Parkinson's disease in the Korean population. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 85-88.	1.1	56
1999	Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: A systematic review. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 237-242.	1.1	150
2000	Sensitivity and specificity of the finger tapping task for the detection of psychogenic movement disorders. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 197-201.	1.1	20
2001	Planned stopping in people with Parkinson. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 191-196.	1.1	8
2002	The GIGYF2 variants are not associated with Parkinson's disease in the mainland Chinese population. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 294-297.	1.1	8
2003	Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 202-207.	1.1	161
2004	Probable REM sleep behaviour disorder and STN-DBS outcome in Parkinson's Disease. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 265-269.	1.1	16
2005	Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 307-315.	1.1	31
2006	Predictive validity of the UPDRS postural stability score and the Functional Reach Test, when compared with ecologically valid reaching tasks. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 409-411.	1.1	25

#	ARTICLE	IF	CITATIONS
2007	Timed tests of motor function in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 442-446.	1.1	16
2008	The cause of death in idiopathic Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 434-437.	1.1	109
2009	Diffusion tensor imaging of the corpus callosum differentiates corticobasal syndrome from Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 498-502.	1.1	43
2010	Levodopa response in dementia with lewy bodies: A 1-year follow-up study. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 522-526.	1.1	45
2011	Proteomic profiling of cerebrospinal fluid in parkinsonian disorders. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 545-549.	1.1	38
2012	The prevalence of Parkinson's disease in a rural area of North-East England. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 572-575.	1.1	25
2013	A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death. <i>Neurobiology of Aging</i> , 2010, 31, 99-103.	1.5	107
2014	Is obstructive sleep apnea a problem in Parkinson's disease?. <i>Sleep Medicine</i> , 2010, 11, 247-252.	0.8	200
2015	Olfactory dysfunction in idiopathic REM sleep behavior disorder. <i>Sleep Medicine</i> , 2010, 11, 458-461.	0.8	58
2016	Relevance of substantia nigra hyperechogenicity and reduced odor identification in idiopathic REM sleep behavior disorder. <i>Sleep Medicine</i> , 2010, 11, 361-365.	0.8	65
2017	Aspiration and swallowing in Parkinson disease and rehabilitation with EMST. <i>Neurology</i> , 2010, 75, 1912-1919.	1.5	313
2018	Parkinson's Disease: Definition, Diagnosis, and Management. , 2010, , 405-412.		4
2019	A Double-blind, Randomized, Placebo and Active-controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 337-347.	1.9	21
2020	Short- and long-term dopaminergic effects on dysarthria in early Parkinson's disease. <i>Journal of Neural Transmission</i> , 2010, 117, 197-205.	1.4	107
2021	fMRI correlates of apraxia in Parkinson's disease patients OFF medication. <i>Experimental Neurology</i> , 2010, 225, 416-422.	2.0	24
2022	Emotion and object processing in Parkinson's disease. <i>Brain and Cognition</i> , 2010, 72, 457-463.	0.8	26
2023	Action Observation Improves Freezing of Gait in Patients With Parkinson's Disease. <i>Neurorehabilitation and Neural Repair</i> , 2010, 24, 746-752.	1.4	155
2024	No Evidence for Shorter Leukocyte Telomere Length in Parkinson's Disease Patients. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2010, 65A, 1181-1184.	1.7	45

#	ARTICLE	IF	CITATIONS
2025	The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future. <i>Progress in Brain Research</i> , 2010, 184, 133-157.	0.9	121
2027	Emerging parkinsonian phenotypes. <i>Revue Neurologique</i> , 2010, 166, 834-840.	0.6	3
2028	Activity-Rest Rhythm Abnormalities in Parkinson's Disease Patients are Related to Dopaminergic Therapy. <i>International Journal of Neuroscience</i> , 2010, 120, 11-16.	0.8	16
2029	Apathy and Depression in Parkinson Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2010, 23, 35-41.	1.2	126
2030	REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. <i>Neurology</i> , 2010, 75, 494-499.	1.5	347
2031	The Effects of a Secondary Task on Forward and Backward Walking in Parkinson's Disease. <i>Neurorehabilitation and Neural Repair</i> , 2010, 24, 97-106.	1.4	60
2032	The impact of comorbidity and other clinical and sociodemographic factors on health-related quality of life in Greek patients with Parkinson's disease. <i>Aging and Mental Health</i> , 2011, 15, 913-921.	1.5	25
2033	The Case for Testing Memory With Both Stories and Word Lists Prior to DBS Surgery for Parkinson's Disease. <i>Clinical Neuropsychologist</i> , 2011, 25, 348-358.	1.5	34
2034	Modelling the Cost Effectiveness of Treatments for Parkinson's Disease. <i>Pharmacoeconomics</i> , 2011, 29, 1025-1049.	1.7	26
2035	Depression and anxiety related subtypes in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 803-809.	0.9	150
2037	Pupil Light Reflex in Parkinson's Disease: Evaluation With Pupillometry. <i>International Journal of Neuroscience</i> , 2011, 121, 37-43.	0.8	63
2038	Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease. <i>Brain</i> , 2011, 134, 36-49.	3.7	187
2039	Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. <i>Brain</i> , 2011, 134, 969-978.	3.7	283
2040	Deep brain stimulation and general anesthesia. <i>Basal Ganglia</i> , 2011, 1, 79-82.	0.3	5
2041	Validity of the DESPAR questionnaire as a new screening tool for depression in Parkinson's disease. <i>Basal Ganglia</i> , 2011, 1, 97-103.	0.3	3
2043	White matter lesions in Parkinson disease. <i>Nature Reviews Neurology</i> , 2011, 7, 229-236.	4.9	180
2044	Diseases. , 2011, , 189-348.		0
2045	Regional Volume Analysis of the Parkinson Disease Brain in Early Disease Stage: Gray Matter, White Matter, Striatum, and Thalamus. <i>American Journal of Neuroradiology</i> , 2011, 32, 682-687.	1.2	67

#	ARTICLE	IF	CITATIONS
2046	Evaluation of doctor/patient satisfaction with the use of the Parkinson's Disease Dementia-Short-Screen (PDD-SS): a screening test for dementia in Parkinson's disease (DIFFUSION) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		
2047	Patterns of levels of biological metals in CSF differ among neurodegenerative diseases. <i>Journal of the Neurological Sciences</i> , 2011, 303, 95-99.	0.3	213
2048	Prevalence of parkinsonism and Parkinson's disease in the Arosa Island (Spain): A community-based door-to-door survey. <i>Journal of the Neurological Sciences</i> , 2011, 304, 49-54.	0.3	18
2049	Dietary intake of metals and risk of Parkinson's disease: A case-control study in Japan. <i>Journal of the Neurological Sciences</i> , 2011, 306, 98-102.	0.3	82
2050	Converging environmental and genetic pathways in the pathogenesis of Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2011, 306, 1-8.	0.3	52
2051	View point: Etiology in Parkinson's disease. Dual hit or spreading intoxication. <i>Journal of the Neurological Sciences</i> , 2011, 310, 9-11.	0.3	56
2052	Emotion recognition impairment in Parkinson's disease patients without dementia. <i>Journal of the Neurological Sciences</i> , 2011, 310, 237-240.	0.3	43
2053	Is there a need to redefine Parkinson's disease?. <i>Journal of the Neurological Sciences</i> , 2011, 310, 2-3.	0.3	3
2054	Cardiovascular autonomic dysfunction in MSA and Parkinson's disease: Similarities and differences. <i>Journal of the Neurological Sciences</i> , 2011, 310, 133-138.	0.3	68
2055	Localization of the subthalamic nucleus in Parkinson disease using multiunit activity. <i>Journal of the Neurological Sciences</i> , 2011, 310, 44-49.	0.3	53
2056	Initial neuropsychological impairments in patients with the E46K mutation of the α -synuclein gene (PARK 1). <i>Journal of the Neurological Sciences</i> , 2011, 310, 86-89.	0.3	46
2057	Trajectory Classes of Decline in Health-Related Quality of Life in Parkinson's Disease: A Pilot Study. <i>Value in Health</i> , 2011, 14, 329-338.	0.1	9
2058	Patterns of cortical thickness and surface area in early Parkinson's disease. <i>NeuroImage</i> , 2011, 55, 462-467.	2.1	162
2059	SNPs in axon guidance pathway genes and susceptibility for Parkinson's disease in the Korean population. <i>Journal of Human Genetics</i> , 2011, 56, 125-129.	1.1	14
2060	Resting Tremor in Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 1037.	4.9	31
2061	Idiopathic Parkinson Disease. <i>Academic Radiology</i> , 2011, 18, 70-73.	1.3	25
2062	Reproducibility and Validity of Patient-Rated Assessment of Speech, Swallowing, and Saliva Control in Parkinson's Disease. <i>Archives of Physical Medicine and Rehabilitation</i> , 2011, 92, 1152-1158.	0.5	62
2063	Pain is common in Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2011, 113, 11-13.	0.6	78

#	ARTICLE	IF	CITATIONS
2064	RBD in Parkinson's disease: A clinical case control study from North India. <i>Clinical Neurology and Neurosurgery</i> , 2011, 113, 472-476.	0.6	67
2065	Short questionnaire for Parkinson's disease as a screening instrument. <i>Clinical Neurology and Neurosurgery</i> , 2011, 113, 885-888.	0.6	3
2066	Levodopa effect on electromyographic activation patterns of tibialis anterior muscle during walking in Parkinson's disease. <i>Gait and Posture</i> , 2011, 33, 436-441.	0.6	28
2067	Motor sequence learning performance in Parkinson's disease patients depends on the stage of disease. <i>Brain and Cognition</i> , 2011, 75, 135-140.	0.8	50
2068	Gait-related cerebral alterations in patients with Parkinson's disease with freezing of gait. <i>Brain</i> , 2011, 134, 59-72.	3.7	316
2069	High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal β -amyloid in Parkinson disease. <i>Neuroscience Letters</i> , 2011, 487, 169-173.	1.0	18
2070	LRRK2 Pro755Leu variant in ethnic Chinese population with Parkinson's disease. <i>Neuroscience Letters</i> , 2011, 495, 35-38.	1.0	7
2071	Genetic variants of the PITX3 gene are not associated with late-onset sporadic Parkinson's disease in a Chinese population. <i>Neuroscience Letters</i> , 2011, 498, 124-126.	1.0	8
2072	PITX3 polymorphism is not associated with Parkinson's disease in a Chinese population. <i>Neuroscience Letters</i> , 2011, 505, 260-262.	1.0	7
2073	Acoustical Analysis of Speech in Progressive Supranuclear Palsy. <i>Journal of Voice</i> , 2011, 25, 725-731.	0.6	54
2074	Case-control study of the UCH-L1 S18Y variant in sporadic Parkinson's disease in the Chinese population. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 541-544.	0.8	10
2075	Tremor is attenuated during walking in essential tremor with resting tremor but not parkinsonian tremor. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 1224-1228.	0.8	19
2076	Association between apolipoprotein E genotypes and Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 1333-1335.	0.8	23
2077	Follow-up study of variants of the GIGYF2 gene in Chinese patients with Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 1699-1701.	0.8	8
2078	Prevalence of mental health disorders among patients with Parkinson's disease in the United Kingdom. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 1746-1747.	0.8	2
2079	Lessons learned from a large single center cohort of patients referred for DBS management. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 236-239.	1.1	20
2080	Assessing executive function in Parkinson disease: The Alternating Names Test. Part I. Reliability, validity, and normative data. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 100-105.	1.1	9
2081	The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 27-29.	1.1	16

#	ARTICLE	IF	CITATIONS
2082	Clinical predictors of frequent patient telephone calls in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 95-99.	1.1	19
2083	LRRK2 R1398H polymorphism is associated with decreased risk of Parkinson's disease in a Han Chinese population. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 291-292.	1.1	33
2084	Lack of association of dairy food, calcium, and vitamin D intake with the risk of Parkinson's disease: A case-control study in Japan. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 112-116.	1.1	41
2085	Testing balance and fall risk in persons with Parkinson disease, an argument for ecologically valid testing. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 166-171.	1.1	81
2086	The trajectory of apathy after deep brain stimulation: From pre-surgery to 6 months post-surgery in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 182-188.	1.1	66
2087	How common and what are the determinants of sub-optimal care for Parkinson's disease patients: The Milton Keynes community study. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 177-181.	1.1	8
2088	Relative contribution of SCA2, SCA3 and SCA17 in Korean patients with parkinsonism and ataxia. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 338-342.	1.1	20
2089	Intake of Japanese and Chinese teas reduces risk of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 446-450.	1.1	61
2090	Myocardial MIBG scintigraphy may predict the course of motor symptoms in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 372-375.	1.1	11
2091	Retinal thickness in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 431-436.	1.1	107
2092	Mild cognitive impairment and cognitive reserve in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 579-586.	1.1	86
2093	Estimation of further disease progression of Parkinson's disease by dopamin transporter scan vs clinical rating. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 459-463.	1.1	19
2094	A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 533-536.	1.1	10
2095	Subclinical signs in LRRK2 mutation carriers. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 528-532.	1.1	33
2096	Levodopa ameliorated anorectal constipation in de novo Parkinson's disease: The QL-GAT study. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 662-666.	1.1	46
2097	Correlation between the Movement Disorders Society Unified Parkinson's Disease rating scale (MDS-UPDRS) and the Unified Parkinson's Disease rating scale (UPDRS) during l-dopa acute challenge. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 705-707.	1.1	37
2098	The relation between depression and parkin genotype: The CORE-PD study. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 740-744.	1.1	38
2099	An association between the PARK16 locus and Parkinson's disease in a cohort from eastern China. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 737-739.	1.1	16

#	ARTICLE	IF	CITATIONS
2100	Imaging biomarkers in Parkinson's disease. <i>Progress in Neurobiology</i> , 2011, 95, 614-628.	2.8	151
2101	Biomarkers of Parkinson's disease and Dementia with Lewy bodies. <i>Progress in Neurobiology</i> , 2011, 95, 601-613.	2.8	32
2102	Behavioral, neuropsychiatric and cognitive disorders in Parkinson's disease patients with and without motor complications. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1009-1013.	2.5	46
2103	Association of transcription factor polymorphisms PITX3 and EN1 with Parkinson's disease. <i>Neurobiology of Aging</i> , 2011, 32, 302-307.	1.5	81
2104	Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors. <i>Neurobiology of Aging</i> , 2011, 32, 631-645.	1.5	32
2105	GSK3 β polymorphisms, MAPT H1 haplotype and Parkinson's disease in a Greek cohort. <i>Neurobiology of Aging</i> , 2011, 32, 546.e1-546.e5.	1.5	23
2106	Different MAPT haplotypes are associated with Parkinson's disease and progressive supranuclear palsy. <i>Neurobiology of Aging</i> , 2011, 32, 547.e11-547.e16.	1.5	32
2107	Mutational analysis of TARDBP in neurodegenerative diseases. <i>Neurobiology of Aging</i> , 2011, 32, 2096-2099.	1.5	43
2108	Mutational screening and zebrafish functional analysis of GIGYF2 as a Parkinson-disease gene. <i>Neurobiology of Aging</i> , 2011, 32, 1994-2005.	1.5	16
2109	Walking patterns in Parkinson's disease with and without freezing of gait. <i>Neuroscience</i> , 2011, 182, 217-224.	1.1	84
2110	Hallucinations in narcolepsy with and without cataplexy: Contrasts with Parkinson's disease. <i>Sleep Medicine</i> , 2011, 12, 497-504.	0.8	58
2111	Resting state fMRI reveals increased subthalamic nucleus-motor cortex connectivity in Parkinson's disease. <i>NeuroImage</i> , 2011, 55, 1728-1738.	2.1	220
2112	Functional parkin promoter polymorphism in Parkinson's disease: New data and meta-analysis. <i>Journal of the Neurological Sciences</i> , 2011, 302, 68-71.	0.3	8
2113	Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson's disease. <i>Journal of Neurology</i> , 2011, 258, 1254-1260.	1.8	133
2114	Brain energization in response to deep brain stimulation of subthalamic nuclei in Parkinson's disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 1612-1622.	2.4	11
2115	MRI-Guided Subthalamic Nucleus Deep Brain Stimulation without Microelectrode Recording: Can We Dispense with Surgery under Local Anaesthesia?. <i>Stereotactic and Functional Neurosurgery</i> , 2011, 89, 318-325.	0.8	82
2116	Botulinum Toxin Type A in Patients With Parkinson's Disease and Refractory Overactive Bladder. <i>Journal of Urology</i> , 2011, 186, 960-964.	0.2	98
2117	Interobserver agreement in the visual and semi-quantitative analysis of the 123I-FP-CIT SPECT images in the diagnosis of Parkinsonian syndrome. <i>Revista Española De Medicina Nuclear</i> , 2011, 30, 229-235.	0.3	2

#	ARTICLE	IF	CITATIONS
2118	Botulinum A Toxin Intravesical Injections in the Treatment of Refractory Overactive Bladder in Patients with Parkinson's Disease. , 0, , .		0
2119	Excessive daytime sleepiness in a prevalent population of people with Parkinson's disease. British Journal of Neuroscience Nursing, 2011, 7, 629-633.	0.1	2
2120	Analysis of Nucleotide Variations in Genes of Iron Management in Patients of Parkinson's Disease and Other Movement Disorders. Parkinson's Disease, 2011, 2011, 1-6.	0.6	4
2121	The Piet� study: epidemiological investigation on successful brain aging in Caet� (MG), Brazil. Methods and baseline cohort characteristics. Arquivos De Neuro-Psiquiatria, 2011, 69, 579-584.	0.3	34
2122	Idiopathic REM Sleep Behavior Disorder: Implications for the Pathogenesis of Lewy Body Diseases. Parkinson's Disease, 2011, 2011, 1-8.	0.6	8
2123	Mensura�o da qualidade de vida de indiv�duos com a doen�a de Parkinson por meio do question�rio PDQ-39. Fisioterapia Em Movimento, 2011, 24, 141-146.	0.4	14
2124	Transcranial sonography as a diagnostic tool for Parkinson's disease: a pilot study in the city of Rio de Janeiro, Brazil. Arquivos De Neuro-Psiquiatria, 2011, 69, 892-895.	0.3	16
2125	Impact of Dopamine Transporter Scan in Parkinson's Disease. , 2011, , .		0
2126	Verbal fluency in Alzheimer's disease, Parkinson's disease, and major depression. Clinics, 2011, 66, 623-627.	0.6	17
2127	Dementia in Parkinson's disease: a Brazilian sample. Arquivos De Neuro-Psiquiatria, 2011, 69, 733-738.	0.3	9
2128	Do neurologists in Germany adhere to the national Parkinson's disease guideline?. Neuropsychiatric Disease and Treatment, 2011, 7, 103.	1.0	10
2129	The Possible Clinical Predictors of Fatigue in Parkinson's Disease: A Study of 135 Patients as Part of International Nonmotor Scale Validation Project. Parkinson's Disease, 2011, 2011, 1-7.	0.6	13
2130	Modeling Accuracy and Variability of Motor Timing in Treated and Untreated Parkinson's Disease and Healthy Controls. Frontiers in Integrative Neuroscience, 2011, 5, 81.	1.0	25
2131	The On-Freezing Phenomenon: Cognitive and Behavioral Aspects. Parkinson's Disease, 2011, 2011, 1-7.	0.6	13
2132	Traditional Chinese Medicine Improves Activities of Daily Living in Parkinson's Disease. Parkinson's Disease, 2011, 2011, 1-7.	0.6	26
2133	Nonmotor Symptoms Groups in Parkinson's Disease Patients: Results of a Pilot, Exploratory Study. Parkinson's Disease, 2011, 2011, 1-5.	0.6	9
2134	Knowing Me, Knowing You: Can a Knowledge of Risk Factors for Alzheimer's Disease Prove Useful in Understanding the Pathogenesis of Parkinson's Disease?. Journal of Alzheimer's Disease, 2011, 25, 395-415.	1.2	24
2135	Diagnosis and Differential Diagnosis of Parkinson's Disease. , 0, , .		2

#	ARTICLE	IF	CITATIONS
2136	Genetic basis of Parkinson's disease: inheritance, penetrance, and expression. <i>The Application of Clinical Genetics</i> , 2011, 4, 67.	1.4	96
2137	Reliability and validity of a scale for measurement of trunk mobility in Parkinson's disease: Trunk Mobility Scale. <i>Arquivos De Neuro-Psiquiatria</i> , 2011, 69, 636-641.	0.3	14
2138	Familial Aggregation of Panic Disturbances in Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, 417-424.	0.9	6
2139	Diagnostic markers for Parkinson's disease. <i>Current Opinion in Neurology</i> , 2011, 24, 309-317.	1.8	38
2140	Leads from xenobiotic metabolism genes for Parkinson's disease among north Indians. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 790-797.	0.7	7
2141	A polymorphism located at an ATG transcription start site of the heme oxygenase-2 gene is associated with classical Parkinson's disease. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 565-571.	0.7	18
2142	Choice-option evaluation is preserved in early Huntington and Parkinson's disease. <i>NeuroReport</i> , 2011, 22, 753-757.	0.6	13
2143	The Dopaminergic System in Peripheral Blood Lymphocytes: From Physiology to Pharmacology and Potential Applications to Neuropsychiatric Disorders. <i>Current Neuropharmacology</i> , 2011, 9, 278-288.	1.4	76
2144	Excessive Daytime Sleepiness in Multiple System Atrophy (SLEEMSA Study). <i>Archives of Neurology</i> , 2011, 68, 223-30.	4.9	83
2145	Apathy and Depression: Separate Factors in Parkinson's Disease. <i>Journal of the International Neuropsychological Society</i> , 2011, 17, 1058-1066.	1.2	109
2146	Gastrointestinal Symptoms in Parkinson Disease: Clinical Aspects and Management. <i>Canadian Journal of Neurological Sciences</i> , 2011, 38, 557-564.	0.3	11
2147	Deep brain stimulation of the subthalamic nucleus selectively improves learning of weakly associated cue combinations during probabilistic classification learning in Parkinson's disease.. <i>Neuropsychology</i> , 2011, 25, 286-294.	1.0	12
2148	Access to care services for rural dwellers with idiopathic Parkinson's disease. <i>British Journal of Neuroscience Nursing</i> , 2011, 7, 494-496.	0.1	2
2149	Dry Mouth: An Overlooked Autonomic Symptom of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2011, 1, 169-173.	1.5	27
2150	SNCA Triplication Parkinson's Patient's iPSC-derived DA Neurons Accumulate α -Synuclein and Are Susceptible to Oxidative Stress. <i>PLoS ONE</i> , 2011, 6, e26159.	1.1	257
2151	Large Proportion of Amyotrophic Lateral Sclerosis Cases in Sardinia Due to a Single Founder Mutation of the TARDBP Gene. <i>Archives of Neurology</i> , 2011, 68, 594.	4.9	104
2153	Pramipexole Reduces the Prevalence of Fatigue in Patients with Parkinson's Disease. <i>Internal Medicine</i> , 2011, 50, 2163-2168.	0.3	17
2154	Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson's disease at the early stages: Molecular imaging with ¹²³ I-FP-CIT SPECT. <i>International Journal of Molecular Medicine</i> , 2011, 28, 881-6.	1.8	21

#	ARTICLE	IF	CITATIONS
2155	Exome sequencing in Parkinson's disease. <i>Clinical Genetics</i> , 2011, 80, 104-109.	1.0	17
2156	Dietary intake of antioxidant vitamins and risk of Parkinson's disease: a case-control study in Japan. <i>European Journal of Neurology</i> , 2011, 18, 106-113.	1.7	80
2157	Rapid assessment of postural instability in Parkinson's disease (RAPID): a pilot study. <i>European Journal of Neurology</i> , 2011, 18, 260-265.	1.7	25
2158	Cardiovascular dysautonomia in de novo Parkinson's disease without orthostatic hypotension. <i>European Journal of Neurology</i> , 2011, 18, 286-292.	1.7	46
2159	Confirmation of LRRK2 S1647T variant as a risk factor for Parkinson's disease in Southern China. <i>European Journal of Neurology</i> , 2011, 18, 538-540.	1.7	24
2160	Sequential imaging analysis using MIBG scintigraphy revealed progressive degeneration of cardiac sympathetic nerve in Parkinson's disease. <i>European Journal of Neurology</i> , 2011, 18, 1010-1013.	1.7	15
2161	Effect of controlled-release levodopa on the microstructure of sleep in Parkinson's disease. <i>European Journal of Neurology</i> , 2011, 18, 590-596.	1.7	54
2162	Behavioral and personality features in patients with lateralized Parkinson's disease. <i>European Journal of Neurology</i> , 2011, 18, 772-777.	1.7	11
2163	Contribution of glucocerebrosidase mutation in a large cohort of sporadic Parkinson's disease in Taiwan. <i>European Journal of Neurology</i> , 2011, 18, 1227-1232.	1.7	42
2164	LRRK2 mutations are uncommon in Turkey. <i>European Journal of Neurology</i> , 2011, 18, e137.	1.7	6
2165	Serum homocysteine and physical exercise in patients with Parkinson's disease. <i>Psychogeriatrics</i> , 2011, 11, 105-112.	0.6	19
2166	Incidence of Emergency Intestinal Pseudo-Obstruction in Parkinson's Disease. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 2373-2375.	1.3	15
2167	The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia. <i>Acta Neurologica Scandinavica</i> , 2011, 123, 117-121.	1.0	16
2168	Evaluation of fatigue in Parkinson's disease using the Brazilian version of Parkinson's Fatigue Scale. <i>Acta Neurologica Scandinavica</i> , 2011, 123, 130-136.	1.0	35
2169	Light subunit of neurofilament triplet protein in the cerebrospinal fluid after subthalamic nucleus stimulation for Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2011, 124, 206-210.	1.0	16
2170	The Creutzfeldt-Jakob disease (CJD) neurological status scale: a new tool for evaluation of disease severity and progression. <i>Acta Neurologica Scandinavica</i> , 2011, 124, 368-374.	1.0	14
2171	Orofacial function and oral health in patients with Parkinson's disease. <i>European Journal of Oral Sciences</i> , 2011, 119, 27-32.	0.7	103
2172	Expression of GSK3B in peripheral blood of patients with Parkinson's disease. <i>Molecular Biology</i> , 2011, 45, 417-420.	0.4	2

#	ARTICLE	IF	CITATIONS
2173	PET/CT in diagnosis of movement disorders. <i>Annals of the New York Academy of Sciences</i> , 2011, 1228, 93-108.	1.8	42
2174	Emotion and ocular responses in Parkinson's disease. <i>Neuropsychologia</i> , 2011, 49, 3247-3253.	0.7	29
2175	Understanding facial emotion perception in Parkinson's disease: The role of configural processing. <i>Neuropsychologia</i> , 2011, 49, 3295-3302.	0.7	44
2176	Evaluaci3n de la satisfacci3n m3dico/paciente con el uso del "Parkinson's Disease Dementia-Short-Screen"(PDD-SS): un test de cribado para la demencia en la enfermedad de Parkinson (estudio DIFUSION). <i>Neurolog3a</i> , 2011, 26, 461-467.	0.3	1
2178	A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. <i>Lancet Neurology</i> , The, 2011, 10, 415-423.	4.9	192
2179	Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. <i>Lancet Neurology</i> , The, 2011, 10, 797-805.	4.9	293
2180	Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. <i>Lancet Neurology</i> , The, 2011, 10, 898-908.	4.9	294
2181	The organization of narrative discourse in Lewy body spectrum disorder. <i>Brain and Language</i> , 2011, 119, 30-41.	0.8	74
2182	PITX3 gene polymorphism is associated with Parkinson's disease in Chinese population. <i>Brain Research</i> , 2011, 1392, 116-120.	1.1	19
2183	CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease. <i>Brain Research</i> , 2011, 1408, 88-97.	1.1	63
2184	The regulation of mitochondrial morphology: Intricate mechanisms and dynamic machinery. <i>Cellular Signalling</i> , 2011, 23, 1534-1545.	1.7	236
2185	Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson's disease. <i>European Radiology</i> , 2011, 21, 1962-1969.	2.3	24
2186	Analysis of single nucleotide polymorphism rs415430 in the WNT3 gene in Parkinson's disease in Russian population. <i>Molecular Genetics, Microbiology and Virology</i> , 2011, 26, 47-49.	0.0	0
2187	A Mutation in VPS35, Encoding a Subunit of the Retromer Complex, Causes Late-Onset Parkinson Disease. <i>American Journal of Human Genetics</i> , 2011, 89, 168-175.	2.6	757
2188	Absence of an Orphan Mitochondrial Protein, C19orf12, Causes a Distinct Clinical Subtype of Neurodegeneration with Brain Iron Accumulation. <i>American Journal of Human Genetics</i> , 2011, 89, 543-550.	2.6	224
2189	Epidemiology and etiology of Parkinson's disease: a review of the evidence. <i>European Journal of Epidemiology</i> , 2011, 26, 1-58.	2.5	897
2190	The national DBS brain tissue network pilot study: need for more tissue and more standardization. <i>Cell and Tissue Banking</i> , 2011, 12, 219-231.	0.5	18
2191	Drug-related problems in Parkinson's disease: the role of community pharmacists in primary care. <i>International Journal of Clinical Pharmacy</i> , 2011, 33, 674-682.	1.0	16

#	ARTICLE	IF	CITATIONS
2192	Axial rigidity and quality of life in patients with Parkinson's disease: a preliminary study. <i>Quality of Life Research</i> , 2011, 20, 817-823.	1.5	40
2193	Plasma Ceruloplasmin Ferroxidase Activity Correlates with the Nigral Sonographic Area in Parkinson's Disease Patients: A Pilot Study. <i>Neurochemical Research</i> , 2011, 36, 2111-2115.	1.6	31
2194	Risk of sleep-disordered breathing in Parkinson's disease. <i>Sleep and Breathing</i> , 2011, 15, 471-478.	0.9	41
2195	Respiratory-Swallowing Coordination and Swallowing Safety in Patients with Parkinson's Disease. <i>Dysphagia</i> , 2011, 26, 218-224.	1.0	86
2196	Lingo2 variants associated with essential tremor and Parkinson's disease. <i>Human Genetics</i> , 2011, 129, 611-615.	1.8	50
2197	Changes in the solubility and phosphorylation of α -synuclein over the course of Parkinson's disease. <i>Acta Neuropathologica</i> , 2011, 121, 695-704.	3.9	108
2198	Increased dopaminergic cells and protein aggregates in the olfactory bulb of patients with neurodegenerative disorders. <i>Acta Neuropathologica</i> , 2011, 122, 61-74.	3.9	151
2199	Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter. <i>Journal of Neurology</i> , 2011, 258, 19-26.	1.8	65
2200	Is there a delayed gastric emptying of patients with early-stage, untreated Parkinson's disease? An analysis using the ^{13}C -acetate breath test. <i>Journal of Neurology</i> , 2011, 258, 421-426.	1.8	69
2201	Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson's disease. <i>Journal of Neurology</i> , 2011, 258, 494-499.	1.8	118
2202	The effect of real and virtual visual cues on walking in Parkinson's disease. <i>Journal of Neurology</i> , 2011, 258, 991-1000.	1.8	72
2203	The association between motor subtypes and alexithymia in de novo Parkinson's disease. <i>Journal of Neurology</i> , 2011, 258, 1042-1045.	1.8	30
2204	Taste function in patients with Parkinson disease. <i>Journal of Neurology</i> , 2011, 258, 1076-1079.	1.8	37
2205	^{123}I -MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutations. <i>Journal of Neurology</i> , 2011, 258, 1126-1132.	1.8	31
2206	How well do we recognise non-motor symptoms in a British Parkinson's disease population?. <i>Journal of Neurology</i> , 2011, 258, 1513-1517.	1.8	44
2207	Cerebral cortical areas in which thickness correlates with severity of motor deficits of Parkinson's disease. <i>Journal of Neurology</i> , 2011, 258, 1871-1876.	1.8	23
2208	Pisa syndrome as presenting symptom of amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2011, 258, 2087-2089.	1.8	5
2209	Gender effect on time to levodopa-induced dyskinesias. <i>Journal of Neurology</i> , 2011, 258, 2048-2053.	1.8	50

#	ARTICLE	IF	CITATIONS
2210	The impact of sleep and mood disorders on quality of life in Parkinson's disease patients. <i>Journal of Neurology</i> , 2011, 258, 2222-2229.	1.8	46
2211	Phenotype analysis in patients with early onset Parkinson's disease with and without parkin mutations. <i>Journal of Neurology</i> , 2011, 258, 2260-2267.	1.8	29
2212	New clinical findings in the fragile X-associated tremor ataxia syndrome (FXTAS). <i>Neurogenetics</i> , 2011, 12, 123-135.	0.7	67
2213	Broadening the phenotype of TARDBP mutations: the TARDBP Ala382Thr mutation and Parkinson's disease in Sardinia. <i>Neurogenetics</i> , 2011, 12, 203-209.	0.7	78
2214	Association between high-sensitivity C-reactive protein and risk of early idiopathic Parkinson's disease. <i>Neurological Sciences</i> , 2011, 32, 31-34.	0.9	41
2215	Is C-reactive protein level a marker of advanced motor and neuropsychiatric complications in Parkinson's disease?. <i>Journal of Neural Transmission</i> , 2011, 118, 539-543.	1.4	21
2216	Reduced cardiac 123I-MIBG uptake reflects cardiac sympathetic dysfunction in de novo Parkinson's disease. <i>Journal of Neural Transmission</i> , 2011, 118, 1323-1327.	1.4	23
2217	Altered functional organization of the motor system related to ankle movements in Parkinson's disease: insights from functional MRI. <i>Journal of Neural Transmission</i> , 2011, 118, 783-793.	1.4	16
2218	Deep brain stimulation for movement disorders. Considerations on 276 consecutive patients. <i>Journal of Neural Transmission</i> , 2011, 118, 1497-1510.	1.4	39
2220	A novel computer-assisted image analysis of [123I] ^β -CIT SPECT images improves the diagnostic accuracy of parkinsonian disorders. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 702-710.	3.3	27
2221	Diagnostic cutoff points for 123I-MIBG myocardial scintigraphy in a Caucasian population with Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1139-1146.	3.3	17
2222	Deficits in inhibitory control and conflict resolution on cognitive and motor tasks in Parkinson's disease. <i>Experimental Brain Research</i> , 2011, 212, 371-384.	0.7	180
2223	Levodopa medication does not influence motor inhibition or conflict resolution in a conditional stop-signal task in Parkinson's disease. <i>Experimental Brain Research</i> , 2011, 213, 435-445.	0.7	68
2224	Variation in the Uric Acid Transporter Gene SLC2A9 and Its Association with AAO of Parkinson's Disease. <i>Journal of Molecular Neuroscience</i> , 2011, 43, 246-250.	1.1	44
2225	Comparison of parameters of 123I-metaiodobenzylguanidine scintigraphy for differential diagnosis in patients with parkinsonism: correlation with clinical features. <i>Annals of Nuclear Medicine</i> , 2011, 25, 478-485.	1.2	8
2226	Occupational risk factors for Parkinson's disease: a case-control study in Japan. <i>BMC Neurology</i> , 2011, 11, 83.	0.8	9
2227	Combined STN/SNr-DBS for the treatment of refractory gait disturbances in Parkinson's disease: study protocol for a randomized controlled trial. <i>Trials</i> , 2011, 12, 222.	0.7	18
2228	Posterior hypoperfusion in parkinson's disease With and without dementia measured with arterial spin labeling MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2011, 33, 803-807.	1.9	61

#	ARTICLE	IF	CITATIONS
2229	Tremorâ€”some controversial aspects. <i>Movement Disorders</i> , 2011, 26, 18-23.	2.2	169
2230	Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome. <i>Movement Disorders</i> , 2011, 26, 169-173.	2.2	38
2231	Alphaâ€”synuclein immunoreactivity in minor salivary gland biopsies of Parkinson's disease patients. <i>Movement Disorders</i> , 2011, 26, 188-190.	2.2	72
2232	Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases. <i>Movement Disorders</i> , 2011, 26, 176-181.	2.2	43
2233	Rhinorrhea: A common nondopaminergic feature of Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 320-323.	2.2	15
2234	Residual striatal dopaminergic nerve terminals in very long-standing Parkinson's disease: A single photon emission computed tomography imaging study. <i>Movement Disorders</i> , 2011, 26, 327-330.	2.2	30
2235	Cysteinyllâ€”glycine reduction as marker for levodopaâ€”induced oxidative stress in Parkinson's disease patients. <i>Movement Disorders</i> , 2011, 26, 543-546.	2.2	27
2236	Differential genetic susceptibility in diphasic and peakâ€”dose dyskinesias in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 73-79.	2.2	79
2237	The most cited works in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 380-390.	2.2	54
2238	Targeting dopaâ€”sensitive and dopaâ€”resistant gait dysfunction in Parkinson's disease: Selective responses to internal and external cues. <i>Movement Disorders</i> , 2011, 26, 430-435.	2.2	72
2239	<i>LINGO1</i> gene analysis in Parkinson's disease phenotypes. <i>Movement Disorders</i> , 2011, 26, 722-727.	2.2	17
2240	Facilitated temporal summation of pain at spinal level in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 442-448.	2.2	51
2241	Direct visualization of Parkinson's disease by in vivo human brain imaging using 7.0T magnetic resonance imaging. <i>Movement Disorders</i> , 2011, 26, 713-718.	2.2	77
2242	Akineticâ€”rigid and tremorâ€”dominant Parkinson's disease patients show different patterns of FPâ€”CIT Single photon emission computed tomography. <i>Movement Disorders</i> , 2011, 26, 416-423.	2.2	140
2243	The pattern of cortical atrophy in patients with Parkinson's disease according to cognitive status. <i>Movement Disorders</i> , 2011, 26, 289-296.	2.2	131
2244	Reduced sympathetically driven heart rate variability during sleep in Parkinson's disease: A case-control polysomnography-based study. <i>Movement Disorders</i> , 2011, 26, 234-240.	2.2	33
2245	Characterizing mild cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 629-636.	2.2	116
2246	Association of olfactory dysfunction and brain. Metabolism in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 621-628.	2.2	72

#	ARTICLE	IF	CITATIONS
2247	Increased prefrontal volume in PD with levodopa-induced dyskinesias: A voxel-based morphometry study. <i>Movement Disorders</i> , 2011, 26, 807-812.	2.2	67
2248	Small saccades restrict visual scanning area in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1619-1626.	2.2	49
2249	A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1552-1555.	2.2	26
2250	Blind randomized controlled study of the efficacy of cognitive training in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1251-1258.	2.2	133
2251	Subthreshold depression in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1740-1743.	2.2	18
2252	T1-Weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1633-1638.	2.2	158
2253	Differential role of dopamine in emotional attention and memory: Evidence from Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1677-1683.	2.2	14
2254	The <i>LRRK2</i> R1441C mutation is more frequent than G2019S in Parkinson's disease patients from Southern Italy. <i>Movement Disorders</i> , 2011, 26, 1732-1736.	2.2	24
2255	The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study. <i>Movement Disorders</i> , 2011, 26, 1851-1858.	2.2	97
2256	<i>fMRI</i> gray zone alleles: Association with Parkinson's disease in women?. <i>Movement Disorders</i> , 2011, 26, 1900-1906.	2.2	44
2257	Odor identification deficits identify Parkinson's disease patients with poor cognitive performance. <i>Movement Disorders</i> , 2011, 26, 2045-2050.	2.2	38
2258	Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 2190-2195.	2.2	61
2259	Do nonmotor symptoms in Parkinson's disease differ from normal aging?. <i>Movement Disorders</i> , 2011, 26, 2110-2113.	2.2	75
2260	Diagnostic criteria for depression in Parkinson's disease: A study of symptom patterns using latent class analysis. <i>Movement Disorders</i> , 2011, 26, 2239-2245.	2.2	42
2261	The <i>PLA2G6</i> gene in early-onset Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 2415-2417.	2.2	30
2262	Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 2246-2252.	2.2	90
2263	Subthalamic nucleus stimulation affects incentive salience attribution in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 2260-2266.	2.2	42
2264	Visual symptoms in Parkinson's disease and Parkinson's disease dementia. <i>Movement Disorders</i> , 2011, 26, 2387-2395.	2.2	164

#	ARTICLE	IF	CITATIONS
2265	Beyond nine years of continuous subthalamic nucleus deep brain stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 2327-2334.	2.2	166
2266	Genetic analysis of leucine-rich repeat (LRR) and immunoglobulin (Ig) domain-containing, Nogo receptor-interacting protein (LINGO1) in two independent Chinese parkinson's disease populations. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2011, 156, 99-103.	1.1	9
2267	Association of GWAS loci with PD in China. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2011, 156, 334-339.	1.1	58
2268	White matter changes in basis pontis in small expansion FMR1 allele carriers with parkinsonism. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2011, 156, 502-506.	1.1	20
2269	Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. <i>Annals of Neurology</i> , 2011, 69, 655-663.	2.8	126
2270	Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder. <i>Annals of Neurology</i> , 2011, 69, 811-818.	2.8	213
2271	Religious and spiritual beliefs in outpatients suffering from Parkinson Disease. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 916-922.	1.3	48
2272	Individual voxel-based subtype prediction can differentiate progressive supranuclear palsy from idiopathic parkinson syndrome and healthy controls. <i>Human Brain Mapping</i> , 2011, 32, 1905-1915.	1.9	122
2273	Quantitative analysis of the SN in Parkinson's disease implementing 3D modeling at 7.0T MRI. <i>International Journal of Imaging Systems and Technology</i> , 2011, 21, 253-259.	2.7	0
2274	Cognitive dysfunction in drug induced parkinsonism (DIP). <i>Archives of Gerontology and Geriatrics</i> , 2011, 53, e222-e226.	1.4	18
2275	Proteomics of human cerebrospinal fluid: Discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. <i>Journal of Proteomics</i> , 2011, 74, 371-388.	1.2	129
2276	Identification of blood microRNAs associated to Parkinson's disease. <i>Journal of Biotechnology</i> , 2011, 152, 96-101.	1.9	244
2277	Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease. <i>Brain</i> , 2011, 134, 2358-2365.	3.7	108
2278	Altered Microstructure in Corticospinal Tract in Idiopathic Normal Pressure Hydrocephalus: Comparison with Alzheimer Disease and Parkinson Disease with Dementia. <i>American Journal of Neuroradiology</i> , 2011, 32, 1681-1687.	1.2	76
2279	Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson's disease. <i>Brain</i> , 2011, 134, 845-855.	3.7	173
2280	Neurodegeneration Across Stages of Cognitive Decline in Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 1562.	4.9	180
2281	Chronic Subcutaneous Infusion Therapy with Apomorphine in Advanced Parkinson's Disease Compared to Conventional Therapy: A Real Life Study of Non Motor Effect. <i>Journal of Parkinson's Disease</i> , 2011, 1, 197-203.	1.5	107
2282	Effects of deep brain stimulation of dorsal versus ventral subthalamic nucleus regions on gait and balance in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1250-1255.	0.9	43

#	ARTICLE	IF	CITATIONS
2283	The 9-Hole Peg Test of Upper Extremity Function. <i>Journal of Neurologic Physical Therapy</i> , 2011, 35, 157-163.	0.7	135
2284	Impact of nonmotor symptoms on disability in patients with Parkinson's disease. <i>International Journal of Rehabilitation Research</i> , 2011, 34, 316-320.	0.7	15
2285	Differentiation of Typical and Atypical Parkinson Syndromes by Quantitative MR Imaging. <i>American Journal of Neuroradiology</i> , 2011, 32, 2087-2092.	1.2	78
2286	Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Combined with Magnetic Beads for Detecting Serum Protein Biomarkers in Parkinson's Disease. <i>European Neurology</i> , 2011, 65, 105-111.	0.6	22
2287	Dementia Risk in Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 359-64.	4.9	125
2288	Genetic Variants in the RAB7L1 and SLC41A1 Genes of the PARK16 Locus in Chinese Parkinson's Disease Patients. <i>International Journal of Neuroscience</i> , 2011, 121, 632-636.	0.8	27
2289	Diagnostic Accuracy of Combined FP-CIT, IBZM, and MIBG Scintigraphy in the Differential Diagnosis of Degenerative Parkinsonism: A Multidimensional Statistical Approach. <i>Journal of Nuclear Medicine</i> , 2011, 52, 733-740.	2.8	79
2290	Ten-Year Outcome of Subthalamic Stimulation in Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 1550.	4.9	397
2291	Rotenone, Paraquat, and Parkinson's Disease. <i>Environmental Health Perspectives</i> , 2011, 119, 866-872.	2.8	1,050
2292	Serological Profiles of Urate, Paraoxonase-1, Ferritin and Lipid in Parkinson's Disease: Changes Linked to Disease Progression. <i>Neurodegenerative Diseases</i> , 2011, 8, 252-258.	0.8	51
2293	Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 564-568.	0.9	90
2294	Alexithymia Is Associated with Depression in de novo Parkinson's Disease. <i>Psychotherapy and Psychosomatics</i> , 2011, 80, 251-253.	4.0	28
2295	FP-CIT SPECT Does Not Predict the Progression of Motor Symptoms in Parkinson's Disease. <i>European Neurology</i> , 2011, 65, 187-192.	0.6	14
2296	Effects of a Flexibility and Relaxation Programme, Walking, and Nordic Walking on Parkinson's Disease. <i>Journal of Aging Research</i> , 2011, 2011, 1-18.	0.4	129
2297	Î±-Synuclein in Parkinson disease and other neurodegenerative disorders. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 403-408.	1.4	63
2298	Behavioural disorders, disability and quality of life in Parkinson's disease. <i>Age and Ageing</i> , 2011, 40, 614-621.	0.7	90
2299	Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. <i>Human Molecular Genetics</i> , 2011, 20, 345-353.	1.4	202
2300	Initial Motor Symptoms of Parkinson Disease. <i>Neurologist</i> , 2011, 17, S18-S20.	0.4	18

#	ARTICLE	IF	CITATIONS
2301	Limb Collapse, Rather Than Instability, Causes Failure in Sit-to-Stand Performance Among Patients With Parkinson Disease. <i>Physical Therapy</i> , 2011, 91, 381-391.	1.1	21
2302	Referring Patients for Deep Brain Stimulation. <i>Archives of Neurology</i> , 2011, 68, 1027.	4.9	39
2303	Current concepts on the etiology and pathogenesis of Parkinson disease. , 2011, , 93-118.		2
2305	Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study. <i>Journal of the International Neuropsychological Society</i> , 2011, 17, 91-100.	1.2	21
2306	Utility of the Fluid-Attenuated Inversion Recovery Sequence in Detecting a Hyperintense Putaminal Rim in Multiple System Atrophy-Parkinsonism: A Preliminary Study. <i>European Neurology</i> , 2011, 66, 42-46.	0.6	3
2307	Enlarged Substantia Nigra Hyperechogenicity and Risk for Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 932.	4.9	146
2308	Parkinsonâ€™s Disease and Dementia: A Longitudinal Study (DEMPARK). <i>Neuroepidemiology</i> , 2011, 37, 168-176.	1.1	47
2309	Using the WHOQOL-DIS to Measure Quality of Life in Persons with Physical Disabilities Caused by Neurodegenerative Disorders. <i>Neurodegenerative Diseases</i> , 2011, 8, 178-186.	0.8	21
2310	Methods and Design of the Baseline Survey of the Neurological Disorders in Salamanca (NEDISA) Cohort: A Population-Based Study in Central-Western Spain. <i>Neuroepidemiology</i> , 2011, 36, 62-68.	1.1	2
2311	Unilateral subdural motor cortex stimulation improves essential tremor but not Parkinson's disease. <i>Brain</i> , 2011, 134, 2096-2105.	3.7	83
2312	The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinsonâ€™s disease: support from functional MRI. <i>Brain</i> , 2011, 134, 1447-1463.	3.7	112
2313	Phosphorylated Î±-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. <i>FASEB Journal</i> , 2011, 25, 4127-4137.	0.2	186
2314	Utility and Limitations of Addenbrookeâ€™s Cognitive Examination-Revised for Detecting Mild Cognitive Impairment in Parkinsonâ€™s Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 349-357.	0.7	27
2315	The risky business of dopamine agonists in Parkinson disease and impulse control disorders.. <i>Behavioral Neuroscience</i> , 2011, 125, 492-500.	0.6	92
2316	Treatment of Idiopathic Parkinson's Disease with Traditional Chinese Herbal Medicine: A Randomized Placebo-Controlled Pilot Clinical Study. <i>Evidence-based Complementary and Alternative Medicine</i> , 2011, 2011, 1-8.	0.5	36
2317	Serum Levels of Chemokines in Parkinsonâ€™s Disease. <i>NeuroImmunoModulation</i> , 2011, 18, 240-244.	0.9	28
2318	Lewy Bodies and Olfactory Dysfunction in Old Age. <i>Chemical Senses</i> , 2011, 36, 367-373.	1.1	73
2319	The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. <i>Brain</i> , 2011, 134, 3146-3166.	3.7	174

#	ARTICLE	IF	CITATIONS
2320	Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. <i>Neurology</i> , 2011, 77, 1357-1362.	1.5	79
2321	Diagnosis and Initiation of Treatment in Parkinson's Disease. <i>International Journal of Neuroscience</i> , 2011, 121, 27-36.	0.8	14
2322	Multimodal MRI in Neurodegenerative Disorders. <i>Neurology Research International</i> , 2012, 2012, 1-2.	0.5	8
2323	Chinese Herbal Medicine Paratherapy for Parkinson's Disease: A Meta-Analysis of 19 Randomized Controlled Trials. <i>Evidence-based Complementary and Alternative Medicine</i> , 2012, 2012, 1-15.	0.5	18
2324	Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort. <i>Neurology</i> , 2012, 79, 1615-1621.	1.5	40
2325	Pupillometry and 123I-DaTSCAN imaging in Parkinson's Disease: A Comparison Study. <i>International Journal of Neuroscience</i> , 2012, 122, 26-34.	0.8	15
2326	An Exploration of Apathy and Impulsivity in Parkinson Disease. <i>Current Gerontology and Geriatrics Research</i> , 2012, 2012, 1-10.	1.6	28
2327	Analysis of the genotype of diacylglycerol kinase delta single-nucleotide polymorphisms in Parkinson disease in the Han Chinese population. <i>Neurology India</i> , 2012, 60, 82.	0.2	1
2328	Psychiatric, nonmotor aspects of Parkinson's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 106, 477-490.	1.0	5
2329	Identification of VPS35 mutations replicated in French families with Parkinson disease. <i>Neurology</i> , 2012, 78, 1449-1450.	1.5	58
2330	A comparison of nine scales to detect depression in Parkinson disease. <i>Neurology</i> , 2012, 78, 998-1006.	1.5	118
2331	SPECT Molecular Imaging in Parkinson's Disease. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-11.	3.0	37
2332	Environmental risk factors for REM sleep behavior disorder. <i>Neurology</i> , 2012, 79, 428-434.	1.5	113
2333	The Effect of Dopamine Agonists on Adaptive and Aberrant Salience in Parkinson's Disease. <i>Neuropsychopharmacology</i> , 2012, 37, 950-958.	2.8	40
2334	Serotonin Neuron Loss and Nonmotor Symptoms Continue in Parkinson's Patients Treated with Dopamine Grafts. <i>Science Translational Medicine</i> , 2012, 4, 128ra41.	5.8	107
2335	Grey matter atrophy in cognitively impaired Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 188-194.	0.9	211
2336	Drug-induced movement disorders. <i>Adverse Drug Reaction Bulletin</i> , 2012, 275, 1059-1062.	0.6	1
2337	Clinical Characteristics of Exacerbations in Parkinson Disease. <i>Neurologist</i> , 2012, 18, 120-124.	0.4	43

#	ARTICLE	IF	CITATIONS
2338	Prevalence and Pharmacological Factors Associated With Impulse-Control Disorder Symptoms in Patients With Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2012, 35, 261-265.	0.2	85
2339	Perampanel in Parkinson Disease Fluctuations. <i>Clinical Neuropharmacology</i> , 2012, 35, 15-20.	0.2	50
2340	Ziprasidone Versus Clozapine in the Treatment of Psychotic Symptoms in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2012, 35, 61-66.	0.2	44
2341	Comparison of Personality Characteristics in Parkinson Disease Patients With and Without Impulse Control Disorders and in Healthy Volunteers. <i>Cognitive and Behavioral Neurology</i> , 2012, 25, 25-33.	0.5	16
2342	Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 58 Associated Disorders, 2012, 26, 213-216.	0.6	105
2343	Components of Depression in Parkinson Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2012, 25, 131-137.	1.2	34
2344	Pattern of brain tissue loss associated with freezing of gait in Parkinson disease. <i>Neurology</i> , 2012, 78, 409-416.	1.5	119
2345	Investigational agents in the treatment of Parkinson's disease: focus on safinamide. <i>Journal of Experimental Pharmacology</i> , 2012, 4, 85.	1.5	9
2346	Randomized Controlled Trial of Community-Based Dancing to Modify Disease Progression in Parkinson Disease. <i>Neurorehabilitation and Neural Repair</i> , 2012, 26, 132-143.	1.4	258
2347	Lower cognitive performance in healthy G2019S <i>LRRK2</i> mutation carriers. <i>Neurology</i> , 2012, 79, 1027-1032.	1.5	75
2348	Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). <i>Neurology</i> , 2012, 79, 163-169.	1.5	86
2349	L-745,870 Reduces L-DOPA-Induced Dyskinesia in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 342, 576-585.	1.3	39
2350	Apathy in patients with Parkinson disease without dementia or depression. <i>Neurology</i> , 2012, 79, 1155-1160.	1.5	88
2351	Ten year survival and outcomes in a prospective cohort of new onset Chinese Parkinson's disease patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 607-611.	0.9	151
2352	Analysis and validation of a Parkinson's disease register as a recruitment tool for clinical studies. <i>Clinical Medicine</i> , 2012, 12, 210-215.	0.8	3
2353	Clinical Approach to Parkinson's Disease: Features, Diagnosis, and Principles of Management. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a008870-a008870.	2.9	288
2354	The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. <i>Brain</i> , 2012, 135, 2440-2448.	3.7	81
2355	Network correlates of disease severity in multiple system atrophy. <i>Neurology</i> , 2012, 78, 1237-1244.	1.5	53

#	ARTICLE	IF	CITATIONS
2356	Different Iron-Deposition Patterns of Multiple System Atrophy with Predominant Parkinsonism and Idiopathic Parkinson Diseases Demonstrated by Phase-Corrected Susceptibility-Weighted Imaging. <i>American Journal of Neuroradiology</i> , 2012, 33, 266-273.	1.2	145
2357	The Effect of Encoding Condition on Free Recall in Parkinson's Disease: Incidental and Intentional Memory are Equally Affected. <i>Clinical Neuropsychologist</i> , 2012, 26, 909-925.	1.5	6
2358	Micrographia and related deficits in Parkinson's disease: a cross-sectional study. <i>BMJ Open</i> , 2012, 2, e000628.	0.8	78
2359	Evaluation of a Prototype Point-of-care Instrument Based on Monochromatic X-Ray Fluorescence Spectrometry: Potential for Monitoring Trace Element Status of Subjects with Neurodegenerative Disease. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2012, 75, 1253-1268.	1.1	11
2360	Apathy. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2012, 27, 196-201.	0.9	18
2361	Functional reorganization of sensorimotor cortex in early Parkinson disease. <i>Neurology</i> , 2012, 78, 1441-1448.	1.5	107
2362	Action Reprogramming in Parkinson's Disease: Response to Prediction Error Is Modulated by Levels of Dopamine. <i>Journal of Neuroscience</i> , 2012, 32, 542-550.	1.7	42
2363	Light and Heavy Touch Reduces Postural Sway and Modifies Axial Tone in Parkinson's Disease. <i>Neurorehabilitation and Neural Repair</i> , 2012, 26, 1007-1014.	1.4	23
2364	Everyday Action Impairment in Parkinson's Disease Dementia. <i>Journal of the International Neuropsychological Society</i> , 2012, 18, 787-798.	1.2	53
2365	Robotic Gait Training Is not Superior to Conventional Treadmill Training in Parkinson Disease. <i>Neurorehabilitation and Neural Repair</i> , 2012, 26, 1027-1034.	1.4	56
2366	White Matter Alteration of the Cingulum in Parkinson Disease with and without Dementia: Evaluation by Diffusion Tensor Tract-Specific Analysis. <i>American Journal of Neuroradiology</i> , 2012, 33, 890-895.	1.2	86
2367	Role of DaTSCAN and clinical diagnosis in Parkinson disease. <i>Neurology</i> , 2012, 78, 696-701.	1.5	125
2368	What is impact?: Figure 1. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 1-2.	0.9	20
2369	The Frontal Assessment Battery as a Tool for Evaluation of Frontal Lobe Dysfunction in Patients With Parkinson Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2012, 25, 71-77.	1.2	38
2370	Radioligand Binding to Brain Dopamine and Serotonin Receptors and Transporters in Parkinson's Disease: Relation to Gene Polymorphisms. <i>International Journal of Neuroscience</i> , 2012, 122, 124-132.	0.8	10
2371	GLIS1rs797906: An Increased Risk Factor for Late-Onset Parkinson's Disease in the Han Chinese Population. <i>European Neurology</i> , 2012, 68, 89-92.	0.6	13
2372	Lack of Genetic Association of the UCHL1 Gene with Alzheimer's Disease and Parkinson's Disease with Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 33, 250-254.	0.7	9
2373	Association Analysis of Single-Nucleotide Polymorphisms of USP24 and USP40 with Parkinson's Disease in the Han Chinese Population. <i>European Neurology</i> , 2012, 68, 181-184.	0.6	8

#	ARTICLE	IF	CITATIONS
2374	Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 601-606.	0.9	130
2375	[123I]FP-CIT SPECT in atypical degenerative parkinsonism. <i>Imaging in Medicine</i> , 2012, 4, 411-421.	0.0	3
2376	A Pilot Study of Quantitative MRI Measurements of Ventricular Volume and Cortical Atrophy for the Differential Diagnosis of Normal Pressure Hydrocephalus. <i>Neurology Research International</i> , 2012, 2012, 1-6.	0.5	36
2377	Efficacy of a Multimodal Cognitive Rehabilitation Including Psychomotor and Endurance Training in Parkinson's Disease. <i>Journal of Aging Research</i> , 2012, 2012, 1-15.	0.4	57
2378	Spectroscopic Changes Associated with Mild Cognitive Impairment and Dementia in Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 34, 312-318.	0.7	24
2379	Subcortical white matter hyperintensities within the cholinergic pathways of Parkinson's disease patients according to cognitive status. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 315-321.	0.9	51
2380	Prospective Memory Deficits are Associated with Poorer Everyday Functioning in Parkinson's Disease. <i>Journal of the International Neuropsychological Society</i> , 2012, 18, 986-995.	1.2	66
2381	Association of Common Variants in the Glucocerebrosidase Gene with High Susceptibility to Parkinson's Disease among Chinese. <i>Chinese Journal of Physiology</i> , 2012, 55, 398-404.	0.4	11
2382	Olfactory Deficits and Cognitive Dysfunction in Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2012, 10, 179-182.	0.8	32
2383	Gender differences in 1-year survival rates after weight loss in people with idiopathic Parkinson's disease. <i>International Journal of Palliative Nursing</i> , 2012, 18, 35-39.	0.2	14
2384	Correlation between LRRK2 gene G2385R polymorphisms and Parkinson's disease. <i>Molecular Medicine Reports</i> , 2012, 6, 879-883.	1.1	23
2385	Pathologic Accumulation of α -Synuclein and A β in Parkinson Disease Patients With Dementia. <i>Archives of Neurology</i> , 2012, 69, 1326.	4.9	173
2386	Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects. <i>Neurological Research</i> , 2012, 34, 669-676.	0.6	57
2387	Association analysis of LRP8 SNP rs3820198 and rs5174 with Parkinson's disease in Han Chinese population. <i>Neurological Research</i> , 2012, 34, 725-729.	0.6	5
2388	Subthalamic deep brain stimulation can improve gastric emptying in Parkinson's disease. <i>Brain</i> , 2012, 135, 1478-1485.	3.7	89
2389	Imaging studies as biomarkers of Parkinson's disease. <i>Imaging in Medicine</i> , 2012, 4, 263-266.	0.0	0
2390	Normative EMG Values during REM Sleep for the Diagnosis of REM Sleep Behavior Disorder. <i>Sleep</i> , 2012, 35, 835-847.	0.6	332
2391	Vibration Therapy for Parkinson's Disease: Charcot's Studies Revisited. <i>Journal of Parkinson's Disease</i> , 2012, 2, 23-27.	1.5	15

#	ARTICLE	IF	CITATIONS
2392	Impact of Ethnicity on Non-Motor Symptoms of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2012, 2, 281-285.	1.5	13
2393	Motor Imagery of Gait Tasks in Individuals with Parkinson Disease. <i>Journal of Parkinson's Disease</i> , 2012, 2, 19-22.	1.5	16
2394	The Effects of Visual and Auditory Cues on Freezing of Gait in Patients with Parkinson Disease. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2012, 91, 2-11.	0.7	87
2395	Increased brain temperature in Parkinson's disease. <i>NeuroReport</i> , 2012, 23, 129-133.	0.6	25
2396	Automated Assessment of Bradykinesia and Dyskinesia in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2012, 2, 47-55.	1.5	204
2397	Preoperative Regional Cerebral Blood Flow and Postoperative Clinical Improvement in Patients With Parkinson's Disease Undergoing Subthalamic Nucleus Deep Brain Stimulation. <i>Neurologia Medico-Chirurgica</i> , 2012, 52, 865-872.	1.0	4
2398	Different patterns of cardiac sympathetic denervation in tremor-type compared to akinetic-rigid-type Parkinson's disease: Molecular imaging with 123I-MIBG. <i>Molecular Medicine Reports</i> , 2012, 6, 1337-1342.	1.1	24
2399	Cognition, coping, and outcome in Parkinson's disease. <i>International Psychogeriatrics</i> , 2012, 24, 1656-1663.	0.6	41
2400	Increased Intestinal Permeability and Parkinson Disease Patients: Chicken or Egg?. <i>Canadian Journal of Neurological Sciences</i> , 2012, 39, 185-188.	0.3	63
2401	N-Methyl-D-Aspartate Antagonists in Levodopa Induced Dyskinesia: A Meta-Analysis. <i>Canadian Journal of Neurological Sciences</i> , 2012, 39, 465-472.	0.3	31
2402	The organization and anatomy of narrative comprehension and expression in Lewy body spectrum disorders. <i>Neuropsychology</i> , 2012, 26, 368-384.	1.0	30
2403	Mood and motor trajectories in Parkinson's disease: Multivariate latent growth curve modeling. <i>Neuropsychology</i> , 2012, 26, 71-80.	1.0	20
2404	VPS35 gene variants are not associated with Parkinson's disease in the mainland Chinese population. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 983-985.	1.1	15
2405	Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. <i>Journal of Neurochemistry</i> , 2012, 123, 396-405.	2.1	64
2406	Toys and Gadgets: Construct Validity of Apathy in Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2012, 24, 463-471.	0.9	4
2407	Color discrimination deficits in Parkinson's disease are related to cognitive impairment and white-matter alterations. <i>Movement Disorders</i> , 2012, 27, 1781-1788.	2.2	66
2408	Three-Dimensional Sonographic Examination of the Midbrain for Computer-Aided Diagnosis of Movement Disorders. <i>Ultrasound in Medicine and Biology</i> , 2012, 38, 2041-2050.	0.7	26
2409	Health comorbidities and cognition in 1948 patients with idiopathic Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 1073-1078.	1.1	29

#	ARTICLE	IF	CITATIONS
2410	Sleep disorders in Parkinson's disease: Many causes, few therapeutic options. <i>Journal of the Neurological Sciences</i> , 2012, 314, 12-19.	0.3	78
2411	Resting state functional connectivity of the striatum in Parkinson's disease. <i>Brain</i> , 2012, 135, 3699-3711.	3.7	368
2412	Dynamic modelling of protein and oxidative metabolisms simulates the pathogenesis of Parkinson's disease. <i>IET Systems Biology</i> , 2012, 6, 65.	0.8	30
2413	Mild cognitive impairment in De Novo Parkinson's disease according to movement disorder guidelines. <i>Movement Disorders</i> , 2012, 27, 1706-1706.	2.2	9
2414	Dopamine agonists and delusional jealousy in Parkinson's disease: A cross-sectional prevalence study. <i>Movement Disorders</i> , 2012, 27, 1679-1682.	2.2	48
2415	A study of subtle motor signs in early Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1563-1566.	2.2	20
2416	Association of Tef polymorphism with depression in Parkinson disease. <i>Movement Disorders</i> , 2012, 27, 1694-1697.	2.2	37
2417	REM sleep behavior disorder in Japanese patients with Parkinson's disease: a multicenter study using the REM sleep behavior disorder screening questionnaire. <i>Journal of Neurology</i> , 2012, 259, 1606-1612.	1.8	40
2418	Neurocognitive and atrophic patterns in Parkinson's disease based on subjective memory complaints. <i>Journal of Neurology</i> , 2012, 259, 1706-1712.	1.8	35
2419	Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients. <i>Journal of Neurology</i> , 2012, 259, 1808-1813.	1.8	60
2420	Comparison of chocolate to cacao-free white chocolate in Parkinson's disease: a single-dose, investigator-blinded, placebo-controlled, crossover trial. <i>Journal of Neurology</i> , 2012, 259, 2447-2451.	1.8	14
2421	Targeting the brain: considerations in 332 consecutive patients treated by deep brain stimulation (DBS) for severe neurological diseases. <i>Neurological Sciences</i> , 2012, 33, 1285-1303.	0.9	28
2422	Impact of community pharmaceutical care on patient health and quality of drug treatment in Parkinson's disease. <i>International Journal of Clinical Pharmacy</i> , 2012, 34, 746-756.	1.0	19
2423	Ubiquitin proteasome system in Parkinson's disease: A keeper or a witness?. <i>Experimental Neurology</i> , 2012, 238, 89-99.	2.0	37
2424	G1/S checkpoint proteins in peripheral blood lymphocytes are potentially diagnostic biomarkers for Alzheimer's disease. <i>Neuroscience Letters</i> , 2012, 526, 144-149.	1.0	14
2425	No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias. <i>Neuroscience Letters</i> , 2012, 531, 1-4.	1.0	7
2426	Genetic analysis of LRRK2 A419V variant in ethnic Chinese. <i>Neurobiology of Aging</i> , 2012, 33, 1849.e1-1849.e3.	1.5	16
2427	Prevalence of Psychotic Symptoms in a Community-Based Parkinson Disease Sample. <i>American Journal of Geriatric Psychiatry</i> , 2012, 20, 123-132.	0.6	100

#	ARTICLE	IF	CITATIONS
2428	Combined assessment of midbrain hyperechogenicity, hyposmia and motor asymmetry improves diagnostic accuracy in early Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 911-914.	1.4	7
2429	A Simple Question About Falls to Distinguish Balance and Gait Difficulties in Parkinson's Disease. <i>International Journal of Neuroscience</i> , 2012, 122, 710-715.	0.8	7
2430	Rates of diagnosis and treatment of neurological disorders within a prevalent population of community-dwelling elderly people in sub-Saharan Africa. <i>Journal of Epidemiology and Global Health</i> , 2012, 2, 207.	1.1	9
2431	Differential effects of dopaminergic medication on basic motor performance and executive functions in Parkinson's disease. <i>Neuropsychologia</i> , 2012, 50, 2506-2514.	0.7	26
2432	Neuropsychological assessment of driving safety risk in older adults with and without neurologic disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012, 34, 895-905.	0.8	57
2433	Central pain in patients with Parkinson disease evaluated by pain-related evoked potentials. , 2012, , .		0
2434	Is DaTSCAN really needed for accurate Parkinson's disease diagnosis?. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 1375-1377.	1.4	4
2435	Support Vector Machine Classification of Parkinson's Disease, Essential Tremor and Healthy Control Subjects Based on Upper Extremity Motion. , 2012, , .		8
2436	Value of combined midbrain sonography, olfactory and motor function assessment in the differential diagnosis of early Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 441-447.	0.9	81
2437	Medication Management and Neuropsychological Performance in Parkinson's Disease. <i>Clinical Neuropsychologist</i> , 2012, 26, 45-58.	1.5	31
2438	Tef polymorphism is associated with sleep disturbances in patients with Parkinson's disease. <i>Sleep Medicine</i> , 2012, 13, 297-300.	0.8	22
2439	A preliminary quantitative analysis of REM sleep chin EMG in Parkinson's disease with or without REM sleep behavior disorder. <i>Sleep Medicine</i> , 2012, 13, 707-713.	0.8	43
2440	Volumetric analysis of the substantia innominata in patients with Parkinson's disease according to cognitive status. <i>Neurobiology of Aging</i> , 2012, 33, 1265-1272.	1.5	74
2441	Histamine N-methyltransferase Thr105Ile polymorphism is associated with Parkinson's disease. <i>Neurobiology of Aging</i> , 2012, 33, 836.e1-836.e3.	1.5	29
2442	The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients. <i>Neurobiology of Aging</i> , 2012, 33, 2160-2171.	1.5	68
2443	Tau acts as an independent genetic risk factor in pathologically proven PD. <i>Neurobiology of Aging</i> , 2012, 33, 838.e7-838.e11.	1.5	23
2444	EIF4G1 in familial Parkinson's disease: pathogenic mutations or rare benign variants?. <i>Neurobiology of Aging</i> , 2012, 33, 2233.e1-2233.e5.	1.5	32
2445	First trial reactions and habituation rates over successive balance perturbations in Parkinson's disease. <i>Neuroscience</i> , 2012, 217, 123-129.	1.1	50

#	ARTICLE	IF	CITATIONS
2446	Doctor, is it Parkinson's disease?. Parkinsonism and Related Disorders, 2012, 18, 113-114.	1.1	1
2447	Advanced Theory of Mind in patients at early stage of Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, 21-24.	1.1	42
2448	Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications. Parkinsonism and Related Disorders, 2012, 18, 40-44.	1.1	49
2449	Relationships between disability, quality of life and prevalence of nonmotor symptoms in Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, 35-39.	1.1	38
2450	SCOPA-AUT scale in different parkinsonisms and its correlation with (123) I-MIBG cardiac scintigraphy. Parkinsonism and Related Disorders, 2012, 18, 45-48.	1.1	28
2451	Metabolic changes induced by theta burst stimulation of the cerebellum in dyskinetic Parkinson's disease patients. Parkinsonism and Related Disorders, 2012, 18, 59-62.	1.1	51
2452	Unilateral subthalamic nucleus deep brain stimulation improves sleep quality in Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, 63-68.	1.1	59
2453	Screening questionnaires for parkinsonism: A systematic review. Parkinsonism and Related Disorders, 2012, 18, 216-224.	1.1	17
2454	Appreciation of humor is decreased among patients with Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, 144-148.	1.1	18
2455	Freezer or non-freezer: Clinical assessment of freezing of gait. Parkinsonism and Related Disorders, 2012, 18, 149-154.	1.1	184
2456	Istradefylline for Parkinson's disease patients experiencing motor fluctuations: Results of the KW-6002-US-018 study. Parkinsonism and Related Disorders, 2012, 18, 178-184.	1.1	99
2457	Apathy and depression in Parkinson's disease: The Belgrade PD study report. Parkinsonism and Related Disorders, 2012, 18, 339-342.	1.1	43
2458	Acceleration of syllable repetition in Parkinson's disease is more prominent in the left-side dominant patients. Parkinsonism and Related Disorders, 2012, 18, 343-347.	1.1	14
2459	Assessment of appropriate medication administration for hospitalized patients with Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, 377-381.	1.1	49
2460	Genetic analysis of HLA-DRA region variation in Taiwanese Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, 391-393.	1.1	16
2461	Movement orientation switching with the eyes and lower limb in Parkinson disease. Parkinsonism and Related Disorders, 2012, 18, 462-468.	1.1	5
2462	Fibroblast growth factor 20 (FGF20) polymorphism is a risk factor for Parkinson's disease in Chinese population. Parkinsonism and Related Disorders, 2012, 18, 629-631.	1.1	18
2463	Reliability and structural validity of the Multidimensional Fatigue Inventory (MFI) in patients with idiopathic Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, 532-536.	1.1	58

#	ARTICLE	IF	CITATIONS
2464	SNCA polymorphisms, smoking, and sporadic Parkinson's disease in Japanese. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 557-561.	1.1	35
2465	Differentiating symptomatic Parkin mutations carriers from patients with idiopathic Parkinson's disease: Contribution of automated segmentation neuroimaging method. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 562-566.	1.1	12
2466	Intact limbic-prefrontal connections and reduced amygdala volumes in Parkinson's disease with mild depressive symptoms. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 809-813.	1.1	74
2467	Construction and validation of the Dynamic Parkinson Gait Scale (DYPAGS). <i>Parkinsonism and Related Disorders</i> , 2012, 18, 759-764.	1.1	13
2468	The relationship between cerebral vascular disease and parkinsonism: The VADO study. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 775-780.	1.1	58
2469	Associated movement disorders in orthostatic tremor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 725-729.	0.9	46
2470	A β -amyloid deposition in patients with Parkinson disease at risk for development of dementia. <i>Neurology</i> , 2012, 79, 1161-1167.	1.5	94
2471	Neuroanatomical substrates of visual hallucinations in patients with non-demented Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 1155-1161.	0.9	81
2472	Movement disorders: what lies beneath?: Figure 1. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 949-949.	0.9	1
2473	Cholinergic dysfunction contributes to gait disturbance in early Parkinson's disease. <i>Brain</i> , 2012, 135, 2779-2788.	3.7	187
2474	Fibroblast growth factor 2 regulates dopaminergic neuron development <i>in vivo</i> . <i>Journal of Neurochemistry</i> , 2012, 122, 94-105.	2.1	37
2475	Are Selective Serotonin Reuptake Inhibitors Associated With Greater Apathy in Parkinson's Disease?. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2012, 24, 326-330.	0.9	54
2476	Sympathetic skin response in Parkinson's disease before and after mental stress. <i>Neurophysiologie Clinique</i> , 2012, 42, 125-131.	1.0	12
2477	Gender differences in the IL6 γ 174G>C and ESR2 1730G>A polymorphisms and the risk of Parkinson's disease. <i>Neuroscience Letters</i> , 2012, 506, 312-316.	1.0	19
2478	Promoter methylation analysis of seven clock genes in Parkinson's disease. <i>Neuroscience Letters</i> , 2012, 507, 147-150.	1.0	67
2479	Selective attention deficits in early and moderate stage Parkinson's disease. <i>Neuroscience Letters</i> , 2012, 509, 50-55.	1.0	40
2480	Association of mutations in the glucocerebrosidase gene with Parkinson disease in a Korean population. <i>Neuroscience Letters</i> , 2012, 514, 12-15.	1.0	49
2481	Mutation analysis of LRRK2, SCNA, UCHL1, HtrA2 and GICYF2 genes in Chinese patients with autosomal dominant Parkinson's disease. <i>Neuroscience Letters</i> , 2012, 516, 207-211.	1.0	14

#	ARTICLE	IF	CITATIONS
2482	Combination of p53(ser15) and p21/p21(thr145) in peripheral blood lymphocytes as potential Alzheimer's disease biomarkers. <i>Neuroscience Letters</i> , 2012, 516, 226-231.	1.0	35
2483	Association study between two novel single nucleotide polymorphisms and sporadic Parkinson's disease in Chinese Han population. <i>Neuroscience Letters</i> , 2012, 517, 56-59.	1.0	10
2484	Genetic variation in LINGO-1 (rs9652490) and risk of Parkinson's disease: Twelve studies and a meta-analysis. <i>Neuroscience Letters</i> , 2012, 522, 67-72.	1.0	8
2485	A study of voice profiles and acoustic signs in patients with Parkinson's disease in North India. <i>Journal of Clinical Neuroscience</i> , 2012, 19, 1125-1129.	0.8	15
2486	Proteomic profiling of the substantia nigra demonstrates CNDP2 overexpression in Parkinson's disease. <i>Journal of Proteomics</i> , 2012, 75, 4656-4667.	1.2	53
2487	Sentence processing in Lewy body spectrum disorder: The role of working memory. <i>Brain and Cognition</i> , 2012, 78, 85-93.	0.8	18
2488	Early, severe and bilateral loss of LTP and LTD-like plasticity in motor cortex (M1) in de novo Parkinson's disease. <i>Clinical Neurophysiology</i> , 2012, 123, 822-828.	0.7	100
2489	Occupational exposure to pesticides and Parkinson's disease: A systematic review and meta-analysis of cohort studies. <i>Environment International</i> , 2012, 46, 30-43.	4.8	143
2490	Arm swing asymmetry in Parkinson's disease measured with ultrasound based motion analysis during treadmill gait. <i>Gait and Posture</i> , 2012, 35, 116-120.	0.6	54
2491	Left hemispheric predominance of nigrostriatal dysfunction in Parkinson's disease. <i>Brain</i> , 2012, 135, 3348-3354.	3.7	95
2492	Contribution of genetic variants to pain susceptibility in Parkinson disease. <i>European Journal of Pain</i> , 2012, 16, 1243-1250.	1.4	57
2493	Donepezil in Parkinson's disease dementia: A randomized, double-blind efficacy and safety study. <i>Movement Disorders</i> , 2012, 27, 1230-1238.	2.2	158
2494	Small vessel disease in patients with Parkinson's disease: A clinicopathological study. <i>Movement Disorders</i> , 2012, 27, 1506-1512.	2.2	49
2495	Brain activation pattern related to gait disturbances in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1498-1505.	2.2	40
2496	VPS35 mutation in Japanese patients with typical Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1413-1417.	2.2	70
2497	Imaging nigral pathology and clinical progression in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1636-1643.	2.2	107
2498	Microarray-based prediction of Parkinson's disease using clinical data as additional response variables. <i>Statistics in Medicine</i> , 2012, 31, 4369-4381.	0.8	3
2499	Analysis of the rs12720208 single-nucleotide polymorphism of the FGF20 gene in Russian patients with sporadic Parkinson's disease. <i>Russian Journal of Genetics</i> , 2012, 48, 1257-1259.	0.2	3

#	ARTICLE	IF	CITATIONS
2500	A novel conceptual framework for balance training in Parkinson's disease-study protocol for a randomised controlled trial. <i>BMC Neurology</i> , 2012, 12, 111.	0.8	48
2501	Signal alterations of the basal ganglia in the differential diagnosis of Parkinson's disease: a retrospective case-controlled MRI data bank analysis. <i>BMC Neurology</i> , 2012, 12, 163.	0.8	9
2502	UCHL1 S18Y variant is a risk factor for Parkinson's disease in Japan. <i>BMC Neurology</i> , 2012, 12, 62.	0.8	23
2503	Reduced striatal volumes in Parkinson's disease: a magnetic resonance imaging study. <i>Translational Neurodegeneration</i> , 2012, 1, 17.	3.6	81
2504	Motor Profile and Drug Treatment of Nursing Home Residents with Parkinson's Disease. <i>Journal of the American Geriatrics Society</i> , 2012, 60, 2277-2282.	1.3	32
2505	High Prevalence of Major Neurological Disorders in Two Albanian Communities: Results of a Door-to-Door Survey. <i>Neuroepidemiology</i> , 2012, 38, 138-147.	1.1	21
2506	Feasibility of [18F]-2-Fluoro-A85380-PET Imaging of Human Vascular Nicotinic Acetylcholine Receptors In Vivo. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, 528-536.	2.3	28
2507	Influence of Contraction Type, Speed, and Joint Angle on Ankle Muscle Weakness in Parkinson's Disease: Implications for Rehabilitation. <i>Archives of Physical Medicine and Rehabilitation</i> , 2012, 93, 2352-2359.	0.5	13
2508	Basal ganglia dysfunction reduces saccade amplitude during visual scanning in Parkinson's disease. <i>Basal Ganglia</i> , 2012, 2, 73-78.	0.3	14
2510	Depressive symptoms in Parkinson's disease. <i>Comprehensive Psychiatry</i> , 2012, 53, 727-731.	1.5	9
2511	Cortical hypoperfusion in Parkinson's disease assessed using arterial spin labeled perfusion MRI. <i>NeuroImage</i> , 2012, 59, 2743-2750.	2.1	82
2512	Oscillating central motor networks in pathological tremors and voluntary movements. What makes the difference?. <i>NeuroImage</i> , 2012, 60, 1331-1339.	2.1	115
2513	White matter pathology in Parkinson's disease: The effect of imaging protocol differences and relevance to executive function. <i>NeuroImage</i> , 2012, 62, 1675-1684.	2.1	102
2514	Effect of subthalamic deep brain stimulation on pain in Parkinson's disease. <i>Pain</i> , 2012, 153, 2267-2273.	2.0	65
2515	Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 941-947.	1.1	53
2516	Thermal and mechanical pain thresholds in patients with fluctuating Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 953-957.	1.1	21
2517	Penetrance of LRRK2 G2385R and R1628P is modified by common PD-associated genetic variants. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 958-963.	1.1	73
2518	Dyskinesias in patients with Parkinson's disease: Effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 1039-1041.	1.1	31

#	ARTICLE	IF	CITATIONS
2519	Asymmetrical diffusion tensor imaging indices of the rostral substantia nigra in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 1029-1033.	1.1	54
2520	Neuropsychological profile in patients with early stage of Parkinson's disease in Taiwan. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 1067-1072.	1.1	40
2521	Comparing three screening tools for drug-induced parkinsonism in patients with advanced schizophrenia: A pilot study. <i>Schizophrenia Research</i> , 2012, 137, 230-233.	1.1	8
2522	Cerebral oxygen metabolism in patients with early Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2012, 313, 123-128.	0.3	26
2523	Visuo-spatial interference affects the identification of emotional facial expressions in unmedicated Parkinson's patients. <i>Journal of the Neurological Sciences</i> , 2012, 313, 13-16.	0.3	9
2524	Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2012, 314, 41-47.	0.3	46
2525	The role of autonomic testing in the differentiation of Parkinson's disease from multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2012, 317, 92-96.	0.3	46
2526	Meta-analysis of association between PITX3 gene polymorphism and Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2012, 317, 80-86.	0.3	12
2527	Nocturnal disturbances and restlessness in Parkinson's disease: Using the Japanese version of the Parkinson's disease sleep scale-2. <i>Journal of the Neurological Sciences</i> , 2012, 318, 76-81.	0.3	67
2528	Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2012, 319, 86-88.	0.3	91
2529	White matter lesions and depression in patients with Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2012, 322, 132-136.	0.3	20
2530	Challenges in diagnosis of young onset Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2012, 323, 113-116.	0.3	38
2531	Relationship of dementia and visual hallucinations in tremor and non-tremor dominant Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2012, 323, 158-161.	0.3	12
2532	Lack of association between BST1 polymorphisms and sporadic Parkinson's disease in a Japanese population. <i>Journal of the Neurological Sciences</i> , 2012, 323, 162-166.	0.3	17
2533	<i>DRD2</i> haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients. <i>Pharmacogenomics</i> , 2012, 13, 1701-1710.	0.6	80
2534	Alexithymia Is a Non-Motor Symptom of Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2012, 20, 133-141.	0.6	38
2535	The influence of motor and cognitive impairment upon visually-guided saccades in Parkinson's disease. <i>Neuropsychologia</i> , 2012, 50, 3338-3347.	0.7	60
2536	Dimensions of Apathy in Parkinson's Disease: Exploratory Factor Analysis of the Apathy Scale. <i>Journal of Parkinson's Disease</i> , 2012, 2, 161-166.	1.5	13

#	ARTICLE	IF	CITATIONS
2537	Systems Biology of Parkinson's Disease. , 2012, , .		8
2538	Dyskinesia and motor state detection in Parkinson's Disease patients with a single movement sensor. , 2012, 2012, 1194-7.		42
2539	Plasma-Based Circulating MicroRNA Biomarkers for Parkinson's Disease. Journal of Parkinson's Disease, 2012, 2, 321-331.	1.5	161
2540	Combination of olfactory test and substantia nigra transcranial sonography in the differential diagnosis of Parkinsonâ€™s disease: a pilot study from China. Translational Neurodegeneration, 2012, 1, 25.	3.6	17
2541	Effects of Divided Attention on Swallowing in Persons with Idiopathic Parkinsonâ€™s Disease. Dysphagia, 2012, 27, 390-400.	1.0	28
2542	Quadriceps Muscle Weakness, Activation Deficits, and Fatigue With Parkinson Disease. Neurorehabilitation and Neural Repair, 2012, 26, 533-541.	1.4	75
2543	When does Parkinson's disease begin? From prodromal disease to motor signs. Revue Neurologique, 2012, 168, 809-814.	0.6	37
2544	Impact of Progression of Parkinsonâ€™s Disease on Drooling in Various Ethnic Groups. European Neurology, 2012, 67, 312-314.	0.6	24
2545	The combined effect of subthalamic nuclei deep brain stimulation and l-dopa increases emotion recognition in Parkinsonâ€™s disease. Neuropsychologia, 2012, 50, 2869-2879.	0.7	22
2546	Addiction-Like Manifestations and Parkinson's Disease: A Large Single Center 9-Year Experience. International Journal of Neuroscience, 2012, 122, 145-153.	0.8	37
2547	Heterogeneity of Cholinergic Denervation in Parkinson's Disease without Dementia. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 1609-1617.	2.4	154
2548	Virtual Reality as a Tool for Evaluation of Repetitive Rhythmic Movements in the Elderly and Parkinson's Disease Patients. PLoS ONE, 2012, 7, e30021.	1.1	34
2549	Optical Coherence Tomography in Parkinsonian Syndromes. PLoS ONE, 2012, 7, e34891.	1.1	145
2550	Accounting for Movement Increases Sensitivity in Detecting Brain Activity in Parkinson's Disease. PLoS ONE, 2012, 7, e36271.	1.1	9
2551	Biosignatures for Parkinsonâ€™s Disease and Atypical Parkinsonian Disorders Patients. PLoS ONE, 2012, 7, e43595.	1.1	52
2552	HLA-DRB1 Alleles Are Associated with the Susceptibility to Sporadic Parkinsonâ€™s Disease in Chinese Han Population. PLoS ONE, 2012, 7, e48594.	1.1	30
2553	123I-FP-CIT SPECT imaging of the dopaminergic state. Nuklearmedizin - NuclearMedicine, 2012, 51, 244-251.	0.3	9
2554	Repetitive step training with preparatory signals improves stability limits in patients with Parkinson's disease. Journal of Rehabilitation Medicine, 2012, 44, 944-949.	0.8	36

#	ARTICLE	IF	CITATIONS
2555	Effects of Levodopa on Vividness of Motor Imagery in Parkinson Disease. <i>Journal of Parkinson's Disease</i> , 2012, 2, 127-133.	1.5	17
2556	Efeito de uma intervenção cognitivo-motora sobre os sintomas depressivos de pacientes com doença de Parkinson. <i>Jornal Brasileiro De Psiquiatria</i> , 2012, 61, 78-83.	0.2	9
2557	Non-Gaussianity of Low Frequency Heart Rate Variability and Sympathetic Activation: Lack of Increases in Multiple System Atrophy and Parkinson Disease. <i>Frontiers in Physiology</i> , 2012, 3, 34.	1.3	32
2558	Interocular Asymmetry of Foveal Thickness in Parkinson Disease. <i>Journal of Ophthalmology</i> , 2012, 2012, 1-6.	0.6	59
2559	Neurocognitive Correlates of Apathy and Anxiety in Parkinson's Disease. <i>Parkinson's Disease</i> , 2012, 2012, 1-9.	0.6	32
2560	Gait Difficulty, Postural Instability, and Muscle Weakness Are Associated with Fear of Falling in People with Parkinson's Disease. <i>Parkinson's Disease</i> , 2012, 2012, 1-5.	0.6	40
2561	The PIT: SToPP Trial—A Feasibility Randomised Controlled Trial of Home-Based Physiotherapy for People with Parkinson's Disease Using Video-Based Measures to Preserve Assessor Blinding. <i>Parkinson's Disease</i> , 2012, 2012, 1-8.	0.6	12
2562	Neuropsychiatric Symptoms in Parkinson's Disease with Mild Cognitive Impairment and Dementia. <i>Parkinson's Disease</i> , 2012, 2012, 1-10.	0.6	43
2563	Adenosine A2A receptor antagonist istradefylline for levodopa-induced complications in Parkinson's disease. <i>The Cochrane Library</i> , 2012, , .	1.5	0
2567	Management of Parkinson's disease in the acute hospital environment. <i>Journal of the Royal College of Physicians of Edinburgh</i> , The, 2012, 42, 157-162.	0.2	9
2568	Behavioral and Psychological Symptoms in Patients with Parkinson's Disease According to Cognitive Function. <i>Dementia and Neurocognitive Disorders</i> , 2012, 11, 104.	0.4	1
2569	A Comparison of the Prospective Memory among College Students, Normal Elderly, and Parkinson's Disease Patients. <i>Dementia and Neurocognitive Disorders</i> , 2012, 11, 95.	0.4	1
2570	Is There the Preventive Effect of COMT-inhibitor on Parkinson's Disease Associated with Dementia?. <i>Dementia and Neurocognitive Disorders</i> , 2012, 11, 136.	0.4	2
2571			

#	ARTICLE	IF	CITATIONS
2576	Respiratory changes in Parkinson's disease may be unrelated to dopaminergic dysfunction. Arquivos De Neuro-Psiquiatria, 2012, 70, 847-851.	0.3	33
2577	Predictors of caregivers's burden of Parkinson's disease in India: experience of a tertiary care center in India. Journal of Parkinsonism and Restless Legs Syndrome, 2012, , 59.	0.8	9
2578	Idiopathic Parkinson's Disease, Vascular Risk Factors and Cognition: A Critical Review. , 2012, , .		2
2579	Adjunctive therapy in Parkinson's disease: the role of rasagiline. Neuropsychiatric Disease and Treatment, 2012, 8, 285.	1.0	5
2580	Levodopa versus non-levodopa brain language fMRI in Parkinson's disease. Einstein (Sao Paulo, Brazil), 2012, 10, 171-179.	0.3	0
2581	The management of gastrointestinal symptoms in Parkinson's disease. Expert Review of Neurotherapeutics, 2012, 12, 239-248.	1.4	28
2582	How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain, 2012, 135, 1860-1870.	3.7	270
2583	Impairment of brain vessels may contribute to mortality in patients with Parkinson's disease. Movement Disorders, 2012, 27, 1169-1172.	2.2	22
2584	The default mode network integrity in patients with Parkinson's disease is levodopa equivalent dose-dependent. Journal of Neural Transmission, 2012, 119, 443-454.	1.4	107
2585	Premotor Parkinson's disease: Concepts and definitions. Movement Disorders, 2012, 27, 608-616.	2.2	140
2586	Biochemical premotor biomarkers for Parkinson's disease. Movement Disorders, 2012, 27, 644-650.	2.2	37
2587	The neuropathology of genetic Parkinson's disease. Movement Disorders, 2012, 27, 831-842.	2.2	229
2588	Defining at-risk populations for Parkinson's disease: Lessons from ongoing studies. Movement Disorders, 2012, 27, 656-665.	2.2	113
2589	Cerebrospinal fluid proteomic patterns discriminate Parkinson's disease and multiple system atrophy. Movement Disorders, 2012, 27, 851-857.	2.2	27
2590	Can we define a premotor Parkinson's disease?. Movement Disorders, 2012, 27, 595-596.	2.2	5
2591	Depression and quality of life in monogenic compared to idiopathic, early-onset Parkinson's disease. Movement Disorders, 2012, 27, 754-759.	2.2	27
2592	Is alpha-synuclein in the colon a biomarker for premotor Parkinson's Disease? Evidence from 3 cases. Movement Disorders, 2012, 27, 716-719.	2.2	383
2593	A single-question screen for rapid eye movement sleep behavior disorder: A multicenter validation study. Movement Disorders, 2012, 27, 913-916.	2.2	311

#	ARTICLE	IF	CITATIONS
2594	Rapid eye movement sleep behavior disorder and subtypes of Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 996-1003.	2.2	164
2595	Glucose hypometabolism in primary visual cortex is commonly associated with clinical features of dementia with Lewy bodies regardless of cognitive conditions. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 1138-1146.	1.3	27
2596	Analysis of the regulatory and catalytic domains of PTEN-induced kinase-1 (PINK1). <i>Human Mutation</i> , 2012, 33, 1408-1422.	1.1	32
2597	Optogenetic investigation of neural circuits underlying brain disease in animal models. <i>Nature Reviews Neuroscience</i> , 2012, 13, 251-266.	4.9	655
2598	Distinguishing essential tremor from Parkinson's disease: bedside tests and laboratory evaluations. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 687-696.	1.4	118
2599	Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 673-686.	1.4	63
2600	GSK3 β reduces risk of sporadic Parkinson's disease in ethnic Chinese. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2012, 159B, 718-721.	1.1	6
2601	Solvent exposures and parkinson disease risk in twins. <i>Annals of Neurology</i> , 2012, 71, 776-784.	2.8	130
2602	Meta-analysis of Parkinson's Disease: Identification of a novel locus, <i>RIT2</i> . <i>Annals of Neurology</i> , 2012, 71, 370-384.	2.8	264
2603	Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. <i>Annals of Neurology</i> , 2012, 71, 560-568.	2.8	206
2604	A molecular signature in blood identifies early Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2012, 7, 26.	4.4	99
2605	Capturing Ambulatory Activity Decline in Parkinson's Disease. <i>Journal of Neurologic Physical Therapy</i> , 2012, 36, 51-57.	0.7	115
2606	Acute dopamine boost has a negative effect on plasticity of the primary motor cortex in advanced Parkinson's disease. <i>Brain</i> , 2012, 135, 2074-2088.	3.7	76
2607	Hallucinations in Parkinson's disease: cross-sectional study. <i>Acta Neurologica Belgica</i> , 2012, 112, 33-37.	0.5	11
2608	Modeling Parkinson's Disease Using Induced Pluripotent Stem Cells. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 237-242.	2.0	62
2609	Immunology, Autoimmunity, and Autoantibodies in Parkinson's Disease. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 42, 164-171.	2.9	35
2610	A Search for SNCA 3' UTR Variants Identified SNP rs356165 as a Determinant of Disease Risk and Onset Age in Parkinson's Disease. <i>Journal of Molecular Neuroscience</i> , 2012, 47, 425-430.	1.1	49
2611	Clinical and Pathological Characteristics of LRRK2 G2019S Patients with PD. <i>Journal of Molecular Neuroscience</i> , 2012, 47, 139-143.	1.1	40

#	ARTICLE	IF	CITATIONS
2612	Orthostatic Hypotension Is Differentially Associated with the Cerebellar Versus the Parkinsonian Variant of Multiple System Atrophy: a Comparative Study. <i>Cerebellum</i> , 2012, 11, 223-226.	1.4	22
2613	Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients. <i>Psychopharmacology</i> , 2012, 220, 519-528.	1.5	20
2614	Do Parkinsonâ€™s disease patients disclose their adverse events spontaneously?. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 857-865.	0.8	23
2615	Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]Î²-CIT SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1012-1020.	3.3	40
2616	Contribution of routine brain MRI to the differential diagnosis of parkinsonism: a 3-year prospective follow-up study. <i>Journal of Neurology</i> , 2012, 259, 929-935.	1.8	30
2617	GWAS-linked GAK locus in Parkinsonâ€™s disease in Han Chinese and meta-analysis. <i>Human Genetics</i> , 2012, 131, 1089-1093.	1.8	14
2618	CSF biomarkers in different phenotypes of Parkinson disease. <i>Journal of Neural Transmission</i> , 2012, 119, 455-456.	1.4	15
2619	Parkinsonâ€™s disease showing progressive conduction aphasia. <i>Neurological Sciences</i> , 2012, 33, 399-402.	0.9	3
2620	Concordance between severity of disease, prevalence of nonmotor symptoms, patient-reported quality of life and disability and use of medication in Parkinsonâ€™s disease. <i>Neurological Sciences</i> , 2012, 33, 847-853.	0.9	10
2621	Oroâ€œbuccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinsonâ€™s disease: preliminary analysis from the French COPARK cohort. <i>European Journal of Neurology</i> , 2012, 19, 28-37.	1.7	76
2622	Motor features and response to oral levodopa in patients with Parkinsonâ€™s disease under continuous dopaminergic infusion or deep brain stimulation. <i>European Journal of Neurology</i> , 2012, 19, 76-83.	1.7	31
2624	Levodopa influences striatal activity but does not affect cortical hyperâ€œactivity in Parkinsonâ€™s disease. <i>European Journal of Neuroscience</i> , 2012, 35, 572-583.	1.2	28
2625	Effects of subthalamic nucleus deep brain stimulation and l-dopa on blinking in Parkinson's disease. <i>Experimental Neurology</i> , 2012, 235, 265-272.	2.0	49
2626	Effect of subthalamic deep brain stimulation on turning kinematics and related saccadic eye movements in Parkinson disease. <i>Experimental Neurology</i> , 2012, 236, 389-394.	2.0	30
2627	Efectividad de los estÃmulos sensoriales sobre los trastornos de la marcha en pacientes con enfermedad de Parkinson. Estudio piloto. <i>Fisioterapia</i> , 2012, 34, 4-10.	0.2	4
2628	Impairments of speech fluency in Lewy body spectrum disorder. <i>Brain and Language</i> , 2012, 120, 290-302.	0.8	47
2629	Antagonist muscle co-activation during straight walking and its relation to kinematics: Insight from young, elderly and Parkinson's disease. <i>Brain Research</i> , 2012, 1455, 124-131.	1.1	35
2630	Diagnostic value of the rapid assessment of postural instability in parkinsonâ€™s disease (RAPID) questionnaire. <i>International Journal of Clinical Practice</i> , 2012, 66, 718-721.	0.8	7

#	ARTICLE	IF	CITATIONS
2631	[¹²³ I]FP-CIT (DaTscan) SPECT Brain Imaging in Patients with Suspected Parkinsonian Syndromes. <i>Journal of Neuroimaging</i> , 2012, 22, 225-230.	1.0	49
2632	Glucose metabolism in small subcortical structures in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2012, 125, 303-310.	1.0	36
2633	Clinical heterogeneity in Parkinson's disease revisited: a latent profile analysis. <i>Acta Neurologica Scandinavica</i> , 2012, 125, 311-318.	1.0	20
2634	[123I]FP-CIT-SPECT asymmetry index to differentiate Parkinson's disease from vascular parkinsonism. <i>Acta Neurologica Scandinavica</i> , 2012, 126, 12-16.	1.0	44
2635	Striatal dopamine loss and discriminative sensory dysfunction in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2012, 126, 344-349.	1.0	36
2636	Post mortem cerebrospinal fluid α -synuclein levels are raised in multiple system atrophy and distinguish this from the other α -synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2012, 45, 188-195.	2.1	84
2637	A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson's disease. <i>Neurobiology of Disease</i> , 2012, 45, 305-309.	2.1	128
2638	Impaired comprehension of temporal connectives in Parkinson's disease—A neuroimaging study. <i>Neuropsychologia</i> , 2012, 50, 1794-1800.	0.7	13
2639	Reproducibility of brain dopamine transporter binding with Tc-99m TRODAT-1 SPECT in healthy young men. <i>Psychiatry Research - Neuroimaging</i> , 2012, 201, 222-225.	0.9	8
2640	A comparison between colonic submucosa and mucosa to detect Lewy pathology in Parkinson's disease. <i>Neurogastroenterology and Motility</i> , 2012, 24, e202-5.	1.6	78
2641	Phase analysis identifies compound heterozygous deletions of the <i>PARK2</i> gene in patients with early-onset Parkinson disease. <i>Clinical Genetics</i> , 2012, 82, 77-82.	1.0	26
2642	Combination of transcranial sonography, olfactory testing, and MIBG myocardial scintigraphy as a diagnostic indicator for Parkinson's disease. <i>European Journal of Neurology</i> , 2012, 19, 411-416.	1.7	38
2643	Artistic productivity and creative thinking in Parkinson's disease. <i>European Journal of Neurology</i> , 2012, 19, 468-472.	1.7	53
2644	Are there ethnic differences in impulsive/compulsive behaviors in Parkinson's disease?. <i>European Journal of Neurology</i> , 2012, 19, 494-500.	1.7	29
2645	Dietary patterns and risk of Parkinson's disease: a case-control study in Japan. <i>European Journal of Neurology</i> , 2012, 19, 681-688.	1.7	48
2646	Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity. <i>European Journal of Neurology</i> , 2012, 19, 725-732.	1.7	29
2647	Mitochondrial fission proteins in peripheral blood lymphocytes are potential biomarkers for Alzheimer's disease. <i>European Journal of Neurology</i> , 2012, 19, 1015-1022.	1.7	58
2648	The impact of silent vascular brain burden in cognitive impairment in Parkinson's disease. <i>European Journal of Neurology</i> , 2012, 19, 1100-1107.	1.7	31

#	ARTICLE	IF	CITATIONS
2649	Incidence and prevalence of Parkinson's disease in Buenos Aires City, Argentina. <i>European Journal of Neurology</i> , 2012, 19, 1108-1113.	1.7	27
2650	Carer burden in apathy and impulse control disorders in Parkinson's disease. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 160-166.	1.3	134
2651	Cognitive status correlates with white matter alteration in Parkinson's disease. <i>Human Brain Mapping</i> , 2012, 33, 727-739.	1.9	180
2652	Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 709-715.	2.2	381
2653	Pisa syndrome in Parkinson's disease: Clinical, electromyographic, and radiological characterization. <i>Movement Disorders</i> , 2012, 27, 227-235.	2.2	75
2654	Weekly exercise does not improve fatigue levels in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 143-146.	2.2	42
2655	Fluorodeoxyglucose positron emission tomography in Richardson's syndrome and progressive supranuclear palsy-parkinsonism. <i>Movement Disorders</i> , 2012, 27, 151-155.	2.2	31
2656	Iowa gambling task in de novo Parkinson's disease: A comparison between good and poor performers. <i>Movement Disorders</i> , 2012, 27, 330-332.	2.2	6
2657	Prefrontal alterations in Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task. <i>Movement Disorders</i> , 2012, 27, 364-371.	2.2	66
2658	Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course. <i>Movement Disorders</i> , 2012, 27, 393-399.	2.2	144
2659	Taking sides: Is handedness involved in motor asymmetry of Parkinson's disease?. <i>Movement Disorders</i> , 2012, 27, 171-173.	2.2	18
2660	No correlation of substantia nigra echogenicity and nigrostriatal degradation in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 450-453.	2.2	20
2661	Evidence of an association between the scavenger receptor class B member 2 gene and Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 400-405.	2.2	56
2662	Diagnostic agreement in patients with psychogenic movement disorders. <i>Movement Disorders</i> , 2012, 27, 548-552.	2.2	60
2663	Intrathecal application of autologous bone marrow cell preparations in parkinsonian syndromes. <i>Movement Disorders</i> , 2012, 27, 1552-1555.	2.2	5
2664	Brain iron deposition fingerprints in Parkinson's disease and progressive supranuclear palsy. <i>Movement Disorders</i> , 2012, 27, 421-427.	2.2	69
2665	The possible price of auditory cueing: Influence on obstacle avoidance in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 574-578.	2.2	30
2666	Genetic influences on cognitive decline in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 512-518.	2.2	127

#	ARTICLE	IF	CITATIONS
2667	Movement disorders: role of imaging in diagnosis. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 239-256.	1.9	39
2668	<i>PLA2G6</i> mutations in PARK14-linked young-onset parkinsonism and sporadic Parkinson's disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2012, 159B, 183-191.	1.1	71
2669	The Age at Motor Symptoms Onset in LRRK2-Associated Parkinson's Disease is Affected by a Variation in the MAPT Locus: A Possible Interaction. <i>Journal of Molecular Neuroscience</i> , 2012, 46, 541-544.	1.1	25
2670	Predictive value of dopamine transporter SPECT imaging with [123I]PE2I in patients with subtle parkinsonian symptoms. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 242-250.	3.3	28
2671	Substantia nigra echogenicity in Parkinson's disease: relation to serum iron and C-reactive protein. <i>Journal of Neural Transmission</i> , 2012, 119, 53-57.	1.4	11
2672	Tau protein and beta-amyloid1-42 CSF levels in different phenotypes of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2012, 119, 353-362.	1.4	25
2673	Myofibrillar disorganization characterizes myopathy of camptocormia in Parkinson's disease. <i>Acta Neuropathologica</i> , 2012, 123, 419-432.	3.9	54
2674	Characterization of spontaneous Parkinsonism in drug-naive patients with nonaffective psychotic disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 131-138.	1.8	19
2675	Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's disease. <i>Journal of Neurology</i> , 2012, 259, 251-260.	1.8	38
2676	The pattern of cortical atrophy in Parkinson's disease with mild cognitive impairment according to the timing of cognitive dysfunction. <i>Journal of Neurology</i> , 2012, 259, 469-473.	1.8	11
2677	Variant in the 3' region of SNCA associated with Parkinson's disease and serum α -synuclein levels. <i>Journal of Neurology</i> , 2012, 259, 497-504.	1.8	37
2678	Screening for DSM-IV-TR cognitive disorder NOS in Parkinson's disease using the Mattis Dementia Rating Scale. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 364-371.	1.3	9
2679	The topography of brain damage at different stages of Parkinson's disease. <i>Human Brain Mapping</i> , 2013, 34, 2798-2807.	1.9	61
2680	<i>Glucocerebrosidase</i> mutations in a Serbian Parkinson's disease population. <i>European Journal of Neurology</i> , 2013, 20, 402-405.	1.7	53
2681	P268S in NOD2 associates with susceptibility to Parkinson's disease in Chinese population. <i>Behavioral and Brain Functions</i> , 2013, 9, 19.	1.4	28
2682	Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging. <i>Nuclear Medicine and Molecular Imaging</i> , 2013, 47, 44-51.	0.6	57
2683	Pathway analysis of genome-wide association studies for Parkinson's disease. <i>Molecular Biology Reports</i> , 2013, 40, 2599-2607.	1.0	21
2684	3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson's disease. <i>Neuroradiology</i> , 2013, 55, 719-724.	1.1	107

#	ARTICLE	IF	CITATIONS
2685	Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography. <i>Neuroradiology</i> , 2013, 55, 483-492.	1.1	70
2686	Type D, anxiety and depression in association with quality of life in patients with Parkinson's disease and patients with multiple sclerosis. <i>Quality of Life Research</i> , 2013, 22, 1353-1360.	1.5	48
2687	Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 747-754.	2.2	88
2688	Clinical and Biochemical Differences in Patients Having Parkinson Disease With vs Without GBA Mutations. <i>JAMA Neurology</i> , 2013, 70, 852.	4.5	115
2689	Neurotrophic factor expression in expandable cell populations from brain samples in living patients with Parkinson's disease. <i>FASEB Journal</i> , 2013, 27, 4157-4168.	0.2	17
2690	Dopaminergic modulation of memory and affective processing in Parkinson depression. <i>Psychiatry Research</i> , 2013, 210, 146-149.	1.7	11
2691	Parkinson's disease and pesticide exposure – a new assessment. <i>Critical Reviews in Toxicology</i> , 2013, 43, 515-534.	1.9	71
2692	Marginal association between SNP rs2046571 of the HAS2 gene and Parkinson's disease in the Chinese female population. <i>Neuroscience Letters</i> , 2013, 552, 58-61.	1.0	2
2693	Analysis of EIF4G1 in ethnic Chinese. <i>BMC Neurology</i> , 2013, 13, 38.	0.8	14
2694	A systematic review of biomarkers for disease progression in Parkinson's disease. <i>BMC Neurology</i> , 2013, 13, 35.	0.8	37
2695	Probable rapid eye movement sleep behavior disorder, nocturnal disturbances and quality of life in patients with Parkinson's disease: a case-controlled study using the rapid eye movement sleep behavior disorder screening questionnaire. <i>BMC Neurology</i> , 2013, 13, 18.	0.8	29
2696	Mutation in the SYN1 Gene Associated with Autosomal Recessive, Early-Onset Parkinsonism. <i>Human Mutation</i> , 2013, 34, 1208-1215.	1.1	276
2697	SNCA rs356219 variant increases risk of sporadic Parkinson's disease in ethnic Chinese. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2013, 162, 452-456.	1.1	20
2698	Parkinson Disease and Sleep: Sleep-Wake Changes in the Premotor Stage of Parkinson Disease; Impaired Olfaction and Other Prodromal Features. <i>Current Neurology and Neuroscience Reports</i> , 2013, 13, 373.	2.0	22
2699	Levodopa in the Treatment of Parkinson's Disease: Current Status and New Developments. <i>Journal of Parkinson's Disease</i> , 2013, 3, 255-269.	1.5	154
2700	Postural/Gait and Cognitive Function as Predictors of Driving Performance in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2013, 3, 153-160.	1.5	14
2701	The Movement Disorders Society criteria for the diagnosis of Parkinson's disease dementia: their usefulness and limitations in elderly patients. <i>Journal of Neurology</i> , 2013, 260, 2569-2579.	1.8	17
2702	Clinical, genetic, and brain sonographic features related to Parkinson's disease in Gaucher disease. <i>Journal of Neurology</i> , 2013, 260, 2523-2531.	1.8	16

#	ARTICLE	IF	CITATIONS
2703	Olfactory loss as a supporting feature in the diagnosis of Parkinson's disease: a pragmatic approach. <i>Journal of Neurology</i> , 2013, 260, 2951-2958.	1.8	34
2704	Validation and cross-cultural adaptation of the Self-Assessment Disability Scale in patients with Parkinson's disease in Serbia. <i>Journal of Neurology</i> , 2013, 260, 1970-1977.	1.8	11
2705	Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 1724-1730.	1.8	45
2706	Cohort study of prevalence and phenomenology of tremor in dementia with Lewy bodies. <i>Journal of Neurology</i> , 2013, 260, 1731-1742.	1.8	23
2707	ITIH4 and Gpx3 are potential biomarkers for amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2013, 260, 1782-1797.	1.8	17
2708	Profile of microRNAs in the plasma of Parkinson's disease patients and healthy controls. <i>Journal of Neurology</i> , 2013, 260, 1420-1422.	1.8	132
2709	Clinical characteristics of impulse control and repetitive behavior disorders in Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 429-437.	1.8	27
2710	Serum epidermal growth factor predicts cognitive functions in early, drug-naïve Parkinson's disease patients. <i>Journal of Neurology</i> , 2013, 260, 438-444.	1.8	46
2711	Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 521-527.	1.8	33
2712	Mutational Screening of PARKIN Identified a 3' UTR Variant (rs62637702) Associated with Parkinson's Disease. <i>Journal of Molecular Neuroscience</i> , 2013, 50, 264-269.	1.1	11
2713	Basal Ganglia Disorders. , 2013, , 1-39.		0
2714	Clozapine as a potential treatment for refractory impulsive, compulsive, and punning behaviors in Parkinson's disease. <i>Neurocase</i> , 2013, 19, 587-591.	0.2	16
2715	Iodine-123 metaiodobenzylguanidine imaging can predict future cardiac events in Japanese patients with Parkinson's disease. <i>Annals of Nuclear Medicine</i> , 2013, 27, 123-131.	1.2	8
2716	Prevalence of neurodegenerative parkinsonism in an isolated population in south-eastern Moravia, Czech Republic. <i>European Journal of Epidemiology</i> , 2013, 28, 833-836.	2.5	13
2717	Clinical significance of homocysteine (hcy) on dementia in Parkinson's disease (PD). <i>Archives of Gerontology and Geriatrics</i> , 2013, 57, 288-291.	1.4	28
2718	Long-term course of substantia nigra hyperechogenicity in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 455-459.	2.2	34
2719	Evaluation of transcranial sonographic findings and MIBG cardiac scintigraphy in the diagnosis of idiopathic Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 995-999.	1.1	8
2720	Association between dopaminergic medications and nocturnal sleep in early-stage Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 859-863.	1.1	40

#	ARTICLE	IF	CITATIONS
2721	Robot-assisted gait training versus equal intensity treadmill training in patients with mild to moderate Parkinson's disease: A randomized controlled trial. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 605-610.	1.1	67
2722	Relationship between cognitive impairment and white-matter alteration in Parkinson's disease with dementia: tract-based spatial statistics and tract-specific analysis. <i>European Radiology</i> , 2013, 23, 1946-1955.	2.3	80
2723	Parkinson's disease: diagnostic potential of high-resolution phase difference enhanced MR imaging at 3 T. <i>European Radiology</i> , 2013, 23, 1102-1111.	2.3	12
2724	Changes in Timing and kinematics of goal directed eye-hand movements in early-stage Parkinson's disease. <i>Translational Neurodegeneration</i> , 2013, 2, 1.	3.6	26
2725	Reduced cholinergic olfactory centrifugal inputs in patients with neurodegenerative disorders and MPTP-treated monkeys. <i>Acta Neuropathologica</i> , 2013, 126, 411-425.	3.9	26
2726	Loss of vesicular dopamine release precedes tauopathy in degenerative dopaminergic neurons in a <i>Drosophila</i> model expressing human tau. <i>Acta Neuropathologica</i> , 2013, 125, 711-725.	3.9	29
2727	A Prognostic View on the Application of Individualized Genomics in Parkinson's Disease. <i>Current Genetic Medicine Reports</i> , 2013, 1, 52-57.	1.9	13
2728	Clinical markers of early nigrostriatal neurodegeneration in idiopathic rapid eye movement sleep behavior disorder. <i>Sleep Medicine</i> , 2013, 14, 1064-1070.	0.8	33
2729	Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 883-888.	1.1	27
2730	Immediate effects of physical therapy on gait disturbance and frontal assessment battery in Parkinson's disease. <i>Geriatrics and Gerontology International</i> , 2013, 13, 630-637.	0.7	6
2731	Cerebrospinal fluid and plasma clusterin levels in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1079-1083.	1.1	26
2732	Retinal nerve changes in patients with tremor dominant and akinetic rigid Parkinson's disease. <i>Neurological Sciences</i> , 2013, 34, 689-693.	0.9	49
2733	Remodeling of the fovea in Parkinson disease. <i>Journal of Neural Transmission</i> , 2013, 120, 745-753.	1.4	64
2734	Interhemispheric inhibition in different phenotypes of progressive supranuclear palsy. <i>Journal of Neural Transmission</i> , 2013, 120, 453-461.	1.4	16
2735	Tear levels of tumor necrosis factor-alpha in patients with Parkinson's disease. <i>Neuroscience Letters</i> , 2013, 553, 63-67.	1.0	63
2736	VPS35 and EIF4G1 mutations are rare in Parkinson's disease among Indians. <i>Neurobiology of Aging</i> , 2013, 34, 2442.e1-2442.e3.	1.5	23
2737	Affective theory of mind in patients with Parkinson's disease. <i>Psychiatry and Clinical Neurosciences</i> , 2013, 67, 273-276.	1.0	30
2738	Enhanced temporal pain processing in multiple system atrophy. <i>Neuroscience Letters</i> , 2013, 555, 203-208.	1.0	12

#	ARTICLE	IF	CITATIONS
2739	Negative influence of L-dopa on subjectively assessed sleep but not on nocturnal polysomnography in Parkinson's disease. <i>Pharmacological Reports</i> , 2013, 65, 614-623.	1.5	16
2740	Association study of rs6812193 polymorphism with Parkinson's disease in a Greek population. <i>Neuroscience Letters</i> , 2013, 541, 190-192.	1.0	6
2741	“Effects of Tactile Touch on pain, sleep and health related quality of life in Parkinson's disease with chronic pain” A randomized, controlled and prospective study. <i>European Journal of Integrative Medicine</i> , 2013, 5, 141-152.	0.8	12
2742	Increased incidence of Parkinsonism among Chinese with β 2-glucosidase mutation in central Taiwan.		

#	ARTICLE	IF	CITATIONS
2757	Epidemiology and Clinical Diagnosis of Parkinson Disease. <i>PET Clinics</i> , 2013, 8, 447-458.	1.5	6
2758	Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. <i>Brain</i> , 2013, 136, 392-399.	3.7	266
2759	Apathy in Elderly Nondemented Patients With Parkinson's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2013, 26, 237-243.	1.2	30
2760	Non-homogeneous effect of levodopa on inhibitory circuits in Parkinson's disease and dyskinesia. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 165-170.	1.1	26
2761	Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson's disease: a review. <i>Therapeutic Advances in Psychopharmacology</i> , 2013, 3, 101-113.	1.2	79
2762	Integrated multidisciplinary care in Parkinson's disease: a non-randomised, controlled trial (IMPACT). <i>Lancet Neurology</i> , The, 2013, 12, 947-956.	4.9	105
2763	Gender differences in non-motor symptoms in early, drug naïve Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 2849-2855.	1.8	83
2764	Subthalamic stimulation modulates self-estimation of patients with Parkinson's disease and induces risk-seeking behaviour. <i>Brain</i> , 2013, 136, 3271-3281.	3.7	30
2765	Predicting treatment-seeking for visual hallucinations among Parkinson's disease patients. <i>Psychiatry and Clinical Neurosciences</i> , 2013, 67, 509-516.	1.0	4
2766	Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function. <i>Movement Disorders</i> , 2013, 28, 153-160.	2.2	49
2767	Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. <i>Movement Disorders</i> , 2013, 28, 1966-1971.	2.2	131
2768	Rest tremor suppression may separate essential from parkinsonian rest tremor. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 693-697.	1.1	61
2769	Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis. <i>Acta Neurologica Scandinavica</i> , 2013, 128, 73-82.	1.0	57
2770	LRRK2 G2385R variant carriers of female Parkinson's disease are more susceptible to motor fluctuation. <i>Journal of Neurology</i> , 2013, 260, 2884-2889.	1.8	27
2771	Diffusion tensor imaging and correlations to Parkinson rating scales. <i>Journal of Neurology</i> , 2013, 260, 2823-2830.	1.8	42
2772	Het cerebrale glucose-metabolisme bij neurodegeneratieve hersenaandoeningen. <i>Tijdschrift Voor Neuropsychiatrie En Gedragsneurologie</i> , 2013, 1, 51-59.	0.1	0
2773	Idiopathic Parkinson's disease phenotype related to C9ORF72 repeat expansions: contribution of the neuropsychological assessment. <i>BMC Research Notes</i> , 2013, 6, 343.	0.6	5
2774	Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?. <i>BMC Medicine</i> , 2013, 11, 76.	2.3	22

#	ARTICLE	IF	CITATIONS
2775	TLR9 $\hat{\sim}$ 1237 T/C and TLR2 $\hat{\sim}$ 194 to $\hat{\sim}$ 174 del polymorphisms and the risk of Parkinson's disease in the Greek population: a pilot study. <i>Neurological Sciences</i> , 2013, 34, 679-682.	0.9	17
2776	Autonomic function in a prevalent Tanzanian population with Parkinson's disease and its relationship to disease duration and 5-year mortality. <i>BMC Research Notes</i> , 2013, 6, 535.	0.6	4
2777	Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls. <i>Journal of Neurology</i> , 2013, 260, 3129-3133.	1.8	10
2778	Intravenous amantadine on freezing of gait in Parkinson's disease: a randomized controlled trial. <i>Journal of Neurology</i> , 2013, 260, 3030-3038.	1.8	20
2779	Neuropathological findings in benign tremulous Parkinsonism. <i>Movement Disorders</i> , 2013, 28, 145-152.	2.2	68
2780	Effect of cued training on motor evoked potential and cortical silent period in people with Parkinson's disease. <i>Clinical Neurophysiology</i> , 2013, 124, 545-550.	0.7	10
2781	Mesencephalic area measured by transcranial sonography in the differential diagnosis of parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 732-736.	1.1	11
2782	Gait initiation impairments in both Essential Tremor and Parkinson's disease. <i>Gait and Posture</i> , 2013, 38, 956-961.	0.6	29
2783	Occupational pesticide exposure and screening tests for neurodegenerative disease among an elderly population in Costa Rica. <i>Environmental Research</i> , 2013, 120, 96-101.	3.7	31
2784	Gastrointestinal manifestations in Parkinson's disease: prevalence and occurrence before motor symptoms. <i>Journal of Neurology</i> , 2013, 260, 1332-1338.	1.8	247
2785	Dopamine transporter levels drive striatal responses to apomorphine in Parkinson's disease. <i>Brain and Behavior</i> , 2013, 3, 249-262.	1.0	16
2786	Perceptions of a Videogame-Based Dance Exercise Program Among Individuals with Parkinson's Disease. <i>Games for Health Journal</i> , 2013, 2, 235-239.	1.1	18
2787	Vitamins K interact with N-terminus $\hat{\pm}$ -synuclein and modulate the protein fibrillization in vitro. Exploring the interaction between quinones and $\hat{\pm}$ -synuclein. <i>Neurochemistry International</i> , 2013, 62, 103-112.	1.9	45
2788	Cognitive decline in Parkinson's disease is associated with slowing of resting-state brain activity: a longitudinal study. <i>Neurobiology of Aging</i> , 2013, 34, 408-418.	1.5	130
2789	Prevalence of non-motor symptoms in young-onset versus late-onset Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 131-137.	1.8	72
2790	Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2013, 325, 29-35.	0.3	72
2791	Long-duration Parkinson's disease: Role of lateralization of motor features. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 77-80.	1.1	34
2792	EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 16-34.	1.7	460

#	ARTICLE	IF	CITATIONS
2793	The applause sign and neuropsychological profile in progressive supranuclear palsy and Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1230-1233.	0.6	20
2794	The spectrum of nonmotor symptoms in early Parkinson disease. <i>Neurology</i> , 2013, 80, 276-281.	1.5	349
2795	Clinical features and ¹²³ I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 122-129.	0.9	71
2796	The relationship between motor symptom lateralization and cognitive performance in newly diagnosed drug-naïve patients with Parkinson's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2013, 35, 124-131.	0.8	26
2797	Serum and cerebrospinal fluid urate levels in synucleinopathies versus tauopathies. <i>Acta Neurologica Scandinavica</i> , 2013, 127, e8-e12.	1.0	14
2798	Phenotypic variability in three families with <i>α</i> -synuclein-containing protein mutation. <i>European Journal of Neurology</i> , 2013, 20, 251-258.	1.7	66
2799	Sleep matters in Parkinson's disease: use of a priority list to assess the presence of sleep disturbances. <i>European Journal of Neurology</i> , 2013, 20, 259-265.	1.7	16
2800	Levodopa changes brain motor network function during ankle movements in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2013, 120, 423-433.	1.4	15
2801	Side of onset does not influence cognition in newly diagnosed untreated Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 256-259.	1.1	28
2802	Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study. <i>Journal of Neurology</i> , 2013, 260, 105-114.	1.8	63
2803	Cognitive and MRI correlates of orthostatic hypotension in Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 253-259.	1.8	62
2804	Evaluation of speech impairment in early stages of Parkinson's disease: a prospective study with the role of pharmacotherapy. <i>Journal of Neural Transmission</i> , 2013, 120, 319-329.	1.4	65
2805	C9orf72 repeat expansions are a rare genetic cause of parkinsonism. <i>Brain</i> , 2013, 136, 385-391.	3.7	143
2806	HEDONIC TONE AND ITS MOOD AND COGNITIVE CORRELATES IN PARKINSON'S DISEASE. <i>Depression and Anxiety</i> , 2013, 30, 85-91.	2.0	11
2807	DJ1 analysis in a large cohort of Italian early onset Parkinson Disease patients. <i>Neuroscience Letters</i> , 2013, 557, 165-170.	1.0	11
2808	Clinical correlates of anhedonia in patients with Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 2524-2527.	0.6	19
2809	Longitudinal assessment of olfactory function in idiopathic REM sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 600-604.	1.1	64
2810	Cerebral blood flow responses to dorsal and ventral STN DBS correlate with gait and balance responses in Parkinson's disease. <i>Experimental Neurology</i> , 2013, 241, 105-112.	2.0	41

#	ARTICLE	IF	CITATIONS
2812	The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia. <i>Neuroscience Letters</i> , 2013, 556, 109-112.	1.0	28
2813	RIT2 variant is not associated with Parkinson's disease in a Taiwanese population. <i>Neurobiology of Aging</i> , 2013, 34, 2236.e1-2236.e3.	1.5	11
2814	GAK rs1564282 and DGKQ rs11248060 increase the risk for Parkinson's disease in a Chinese population. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 880-883.	0.8	29
2815	Reduced step length, not step length variability is central to gait hypokinesia in people with Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 587-590.	0.6	21
2816	Prevalence of non motor features in a cohort of Parkinson's disease patients. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 673-677.	0.6	65
2817	Impairment of script comprehension in Lewy body spectrum disorders. <i>Brain and Language</i> , 2013, 125, 330-343.	0.8	5
2818	The effect of moderate Parkinson's disease on compensatory backwards stepping. <i>Gait and Posture</i> , 2013, 38, 800-805.	0.6	21
2820	The ELISA-Measured Increase in Cerebrospinal Fluid Tau that Discriminates Alzheimer's Disease from other Neurodegenerative Disorders is not Attributable to Differential Recognition of Tau Assembly Forms. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 923-928.	1.2	10
2821	The applause sign in Parkinson's disease patients is related to dysexecutive syndrome. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 1734-1736.	0.8	6
2822	Neuropsychologic assessment in collaborative Parkinson's disease research: A proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania and the University of Washington. <i>Alzheimer's and Dementia</i> , 2013, 9, 609-614.	0.4	24
2823	Past smoking and current dopamine agonist use show an independent and dose-dependent association with impulse control disorders in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 698-700.	1.1	44
2824	Video-assisted swallowing therapy for patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 207-211.	1.1	104
2825	Modulation of local field potential power of the subthalamic nucleus during isometric force generation in patients with Parkinson's disease. <i>Neuroscience</i> , 2013, 240, 106-116.	1.1	28
2826	Association between PARK16 and Parkinson's disease in the Han Chinese population: a meta-analysis. <i>Neurobiology of Aging</i> , 2013, 34, 2442.e5-2442.e9.	1.5	11
2827	Mutational analysis of FBXO7 gene in Parkinson's disease in a Taiwanese population. <i>Neurobiology of Aging</i> , 2013, 34, 1713.e1-1713.e4.	1.5	18
2828	Split-belt locomotion in Parkinson's disease with and without freezing of gait. <i>Neuroscience</i> , 2013, 236, 110-116.	1.1	48
2829	Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 869-877.	1.1	119
2830	Joint principles of motor and cognitive dysfunction in Parkinson's disease. <i>Neuropsychologia</i> , 2013, 51, 1417-1425.	0.7	10

#	ARTICLE	IF	CITATIONS
2831	Study in Parkinson Disease of Exercise (SPARX): Translating high-intensity exercise from animals to humans. <i>Contemporary Clinical Trials</i> , 2013, 36, 90-98.	0.8	30
2832	Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging. <i>Neuroscience Letters</i> , 2013, 541, 93-98.	1.0	144
2833	Parkinson's disease patients in institutionalized care. <i>European Geriatric Medicine</i> , 2013, 4, 376-379.	1.2	4
2834	The late positive potential, emotion and apathy in Parkinson's disease. <i>Neuropsychologia</i> , 2013, 51, 960-966.	0.7	32
2835	Parkinson's disease cognitive network correlates with caudate dopamine. <i>NeuroImage</i> , 2013, 78, 204-209.	2.1	83
2836	Thalamic volume and related visual recognition are associated with freezing of gait in non-demented patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1106-1109.	1.1	30
2837	Stimulation Region Within the Globus Pallidus Does Not Affect Verbal Fluency Performance. <i>Brain Stimulation</i> , 2013, 6, 248-253.	0.7	19
2838	Parkinson's disease redefined. <i>Lancet Neurology</i> , The, 2013, 12, 422-423.	4.9	6
2839	Striatal shape in Parkinson's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2510-2516.	1.5	60
2840	Mutational analysis of TARDBP in Parkinson's disease. <i>Neurobiology of Aging</i> , 2013, 34, 1517.e1-1517.e3.	1.5	3
2841	Different diagnostic criteria for Parkinson disease: what are the pitfalls?. <i>Journal of Neural Transmission</i> , 2013, 120, 619-625.	1.4	16
2842	Etiologies of Parkinsonism in a Century-Long Autopsy-Based Cohort. <i>Brain Pathology</i> , 2013, 23, 28-33.	2.1	39
2843	Parkinson disease is not associated with C9ORF72 repeat expansions. <i>Neurobiology of Aging</i> , 2013, 34, 1519.e1-1519.e2.	1.5	44
2844	Diabetes is associated with postural instability and gait difficulty in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 522-526.	1.1	90
2845	Nonmotor fluctuations in Parkinson disease. <i>Neurology</i> , 2013, 80, 800-809.	1.5	284
2846	Parkinson's Disease: Increased Motor Network Activity in the Absence of Movement. <i>Journal of Neuroscience</i> , 2013, 33, 4540-4549.	1.7	34
2847	Î²-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia. <i>Movement Disorders</i> , 2013, 28, 296-301.	2.2	77
2848	Hip fractures in people with idiopathic Parkinson's disease: Incidence and outcomes. <i>Movement Disorders</i> , 2013, 28, 334-340.	2.2	61

#	ARTICLE	IF	CITATIONS
2849	Prospective cohort study of impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 327-333.	2.2	136
2850	Diffusion-weighted imaging and its relationship to microglial activation in parkinsonian syndromes. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 527-532.	1.1	18
2851	Effect of deep brain stimulation of the subthalamic nucleus on non-motor fluctuations in Parkinson's disease: Two-year' follow-up. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 543-547.	1.1	21
2852	Questionnaire-based diagnosis of REM sleep behavior disorder in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1146-1149.	2.2	52
2853	The subthalamic nucleus is involved in successful inhibition in the stop-signal task: A local field potential study in Parkinson's disease. <i>Experimental Neurology</i> , 2013, 239, 1-12.	2.0	143
2854	Clinical determinants of primary and secondary fatigue in patients with Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 1554-1561.	1.8	29
2855	Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 443-453.	4.9	602
2856	Adaptive gene expression changes on the healthy side of parkinsonian rats. <i>Neuroscience</i> , 2013, 233, 157-165.	1.1	12
2857	Age-, gender-, and socioeconomic status-specific incidence of Parkinson's disease and parkinsonism in North East Scotland: The PINE study. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 515-521.	1.1	81
2858	Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. <i>Lancet Neurology</i> , The, 2013, 12, 514-524.	4.9	126
2859	Bilateral stimulation of the subthalamic nucleus has differential effects on reactive and proactive inhibition and conflict-induced slowing in Parkinson's disease. <i>Experimental Brain Research</i> , 2013, 226, 451-462.	0.7	67
2860	Gender differences in cholinergic and dopaminergic deficits in Parkinson disease. <i>Journal of Neural Transmission</i> , 2013, 120, 1421-1424.	1.4	16
2861	Impact of subcortical white matter lesions on dopamine transporter SPECT. <i>Journal of Neural Transmission</i> , 2013, 120, 1053-1060.	1.4	5
2862	Movement disorders in cerebrovascular disease. <i>Lancet Neurology</i> , The, 2013, 12, 597-608.	4.9	195
2863	Validation of the Brazilian version of the Apathy Inventory. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 979-986.	1.3	11
2864	Differences in Brain Activation Between Tremor- and Nontremor-Dominant Parkinson Disease. <i>JAMA Neurology</i> , 2013, 70, 100.	4.5	72
2865	Combined dementia-risk biomarkers in Parkinson's disease: A prospective longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 717-724.	1.1	133
2866	Motor and non-motor symptoms of 1453 patients with Parkinson's disease: Prevalence and risks. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 725-731.	1.1	79

#	ARTICLE	IF	CITATIONS
2867	Levodopa challenge test and ¹²³ I-metaiodobenzylguanidine scintigraphy for diagnosing Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2013, 128, 160-165.	1.0	8
2868	Pilot study of H ₂ therapy in Parkinson's disease: A randomized double-blind placebo-controlled trial. <i>Movement Disorders</i> , 2013, 28, 836-839.	2.2	137
2869	Plants traditionally used in age-related brain disorders (dementia): an ethanopharmacological survey. <i>Pharmaceutical Biology</i> , 2013, 51, 492-523.	1.3	36
2870	Prodromal autonomic symptoms and signs in Parkinson's disease and dementia with Lewy bodies. <i>Movement Disorders</i> , 2013, 28, 597-604.	2.2	182
2871	Motor-language coupling: Direct evidence from early Parkinson's disease and intracranial cortical recordings. <i>Cortex</i> , 2013, 49, 968-984.	1.1	129
2872	An accelerometry-based study of lower and upper limb tremor in Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 827-830.	0.8	32
2873	Striatal Dopamine Transporter Binding Does Not Correlate with Clinical Severity in Dementia with Lewy Bodies. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1072-1076.	2.8	39
2874	Quantitative assessment of subcortical atrophy and iron content in progressive supranuclear palsy and parkinsonian variant of multiple system atrophy. <i>Journal of Neurology</i> , 2013, 260, 2094-2101.	1.8	65
2875	Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson's disease. <i>Annals of Nuclear Medicine</i> , 2013, 27, 444-451.	1.2	27
2876	Effectiveness of multidisciplinary care for Parkinson's disease: A randomized, controlled trial. <i>Movement Disorders</i> , 2013, 28, 605-611.	2.2	111
2877	Deciphering the impact of cerebellar and basal ganglia dysfunction in accuracy and variability of motor timing. <i>Neuropsychologia</i> , 2013, 51, 267-274.	0.7	27
2878	G51D α -synuclein mutation causes a novel Parkinsonian "pyramidal syndrome. <i>Annals of Neurology</i> , 2013, 73, 459-471.	2.8	580
2879	Structural MRI in Idiopathic Parkinson Disease and Parkinsonism. , 2013, , 105-128.		2
2880	Elicitation of neurological knowledge with argument-based machine learning. <i>Artificial Intelligence in Medicine</i> , 2013, 57, 133-144.	3.8	18
2881	Colonic inflammation in Parkinson's disease. <i>Neurobiology of Disease</i> , 2013, 50, 42-48.	2.1	482
2882	Specific frequency band of amplitude low-frequency γ -rhythm predicts Parkinson's disease. <i>Behavioural Brain Research</i> , 2013, 252, 18-23.	1.2	56
2883	Nonmotor symptoms more closely related to Parkinson's disease: Comparison with normal elderly. <i>Journal of the Neurological Sciences</i> , 2013, 324, 70-73.	0.3	41
2884	Prefrontal thickening in PD with levodopa-induced dyskinesias: New evidence from cortical thickness measurement. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 123-125.	1.1	58

#	ARTICLE	IF	CITATIONS
2885	Impaired pain processing in Parkinson's disease and its relative association with the sense of smell. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 43-46.	1.1	9
2886	Independent validation of the Non motor Symptoms Scale for Parkinson's disease in Brazilian patients. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 115-119.	1.1	12
2887	Combination of rTMS and Treadmill Training Modulates Corticomotor Inhibition and Improves Walking in Parkinson Disease. <i>Neurorehabilitation and Neural Repair</i> , 2013, 27, 79-86.	1.4	68
2888	The Discriminating Properties of an Optoelectronic Movement Analysis Method in Patients With Parkinsonism. <i>Journal of Motor Behavior</i> , 2013, 45, 415-422.	0.5	1
2889	Differentiation between idiopathic and atypical parkinsonian syndromes using three-dimensional magnetic resonance spectroscopic imaging. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 644-649.	0.9	25
2890	Validation of the Bulgarian version of scales for outcomes in Parkinson's disease "autonomic (SCOPA-AUT-BG). <i>Folia Medica</i> , 2013, 55, 56-62.	0.2	6
2891	Sleep and impulsivity in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 991-994.	1.1	37
2892	Sex, Food and Threat: Startling Changes after Subthalamic Stimulation in Parkinson's Disease. <i>Brain Stimulation</i> , 2013, 6, 740-745.	0.7	18
2893	Burden and health-related quality of life among caregivers of Brazilian Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 943-948.	1.1	64
2894	A follow up study of non-demented patients with primary visual cortical hypometabolism: Prodromal dementia with Lewy bodies. <i>Journal of the Neurological Sciences</i> , 2013, 334, 48-54.	0.3	48
2895	Segmental progression of cardinal motor symptoms in Parkinson's disease: A pilot study suggesting a practical approach to rate disease course in the early stages. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1143-1148.	1.1	3
2896	Validation of parkinsonian disease-related metabolic brain patterns. <i>Movement Disorders</i> , 2013, 28, 547-551.	2.2	94
2897	Clinical and posturographic correlates of falling in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1250-1256.	2.2	60
2898	Standard strategies for diagnosis and treatment of patients with newly diagnosed Parkinson disease. <i>Neurology: Clinical Practice</i> , 2013, 3, 477-478.	0.8	0
2899	Relation of lead trajectory and electrode position to neuropsychological outcomes of subthalamic neurostimulation in Parkinson's disease: results from a randomized trial. <i>Brain</i> , 2013, 136, 2109-2119.	3.7	171
2900	Frequency, prevalence, incidence and risk factors associated with visual hallucinations in a sample of patients with Parkinson's disease: a longitudinal 4-year study. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 626-631.	1.3	97
2901	Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 130-135.	0.9	103
2902	Non-motor symptoms in early Parkinson's disease: a 2-year follow-up study on previously untreated patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 14-17.	0.9	158

#	ARTICLE	IF	CITATIONS
2903	Clinical and cognitive profiles of patients with both Parkinson's disease and essential tremor. <i>Acta Neurologica Belgica</i> , 2013, 113, 117-125.	0.5	8
2904	Rotigotine transdermal patch for the treatment of Parkinson's Disease. <i>Fundamental and Clinical Pharmacology</i> , 2013, 27, 81-95.	1.0	20
2905	Visual exploration in Parkinson's disease and Parkinson's disease dementia. <i>Brain</i> , 2013, 136, 739-750.	3.7	72
2906	Delay Discounting of Reward and Caudate Nucleus Volume in Individuals with a-Synuclein Gene Duplication before and after the Development of Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2013, 11, 72-78.	0.8	21
2907	The Role of Self-Awareness and Cognitive Dysfunction in Parkinson's Disease With and Without Impulse-Control Disorder. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2013, 25, 141-149.	0.9	29
2908	The mini-BESTest can predict Parkinsonian recurrent fallers: A 6-month prospective study. <i>Journal of Rehabilitation Medicine</i> , 2013, 45, 565-571.	0.8	54
2909	Evidence for adaptive cortical changes in swallowing in Parkinson's disease. <i>Brain</i> , 2013, 136, 726-738.	3.7	84
2910	Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases. <i>Neurology</i> , 2013, 81, 520-527.	1.5	36
2911	Polymorphisms in the dopamine transporter gene are associated with visual hallucinations and levodopa equivalent dose in Brazilians with Parkinson's disease. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1251-1258.	1.0	23
2912	Benign tremulous Parkinson's disease: A misnomer?. <i>Movement Disorders</i> , 2013, 28, 117-119.	2.2	13
2913	Thalamic Projection Fiber Integrity in de novo Parkinson Disease. <i>American Journal of Neuroradiology</i> , 2013, 34, 74-79.	1.2	48
2914	MDR1 C3435T Polymorphism and Interaction with Environmental Factors in Risk of Parkinson's Disease: A Case-control Study in Japan. <i>Drug Metabolism and Pharmacokinetics</i> , 2013, 28, 138-143.	1.1	16
2915	The p.L302P mutation in the lysosomal enzyme gene <i>SMPD1</i> is a risk factor for Parkinson disease. <i>Neurology</i> , 2013, 80, 1606-1610.	1.5	149
2916	RESEARCH OF UPPER LIMB BIOMECHANICS OF SUBJECTS WITH PARKINSON'S DISEASE AND ESSENTIAL TREMMOR / SERGANĖIŲ PARKINSONO IR ESENCIALINIO TREMORO LIGA VIRĀLUTINĀ-S GALĀNĀ-S BIOMECHANIKOS O TYRIMAS. <i>Science: Future of Lithuania</i> , 2013, 5, 587-590.		0
2917	Frontal and posterior subtypes of neuropsychological deficit in Parkinson's disease.. <i>Behavioral Neuroscience</i> , 2013, 127, 175-183.	0.6	33
2918	Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease. <i>Neurology</i> , 2013, 80, 1754-1761.	1.5	23
2919	Serum Uric Acid in Patients with Parkinson's Disease and Vascular Parkinsonism: A Cross-Sectional Study. <i>NeuroImmunoModulation</i> , 2013, 20, 19-28.	0.9	41
2920	Pre- and Postsynaptic Dopamine SPECT in Idiopathic Parkinsonian Diseases: A Follow-Up Study. <i>BioMed Research International</i> , 2013, 2013, 1-14.	0.9	14

#	ARTICLE	IF	CITATIONS
2921	The association of apathy with central fatigue perception in patients with Parkinson's disease.. Behavioral Neuroscience, 2013, 127, 237-244.	0.6	46
2922	Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (¹²³I) ioflupane in diagnosis of parkinsonian syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1288-1295.	0.9	161
2923	Emergence of nonmotor symptoms as the focus of research and treatment of Parkinson's disease: Introduction to the special section on nonmotor dysfunctions in Parkinson's disease.. Behavioral Neuroscience, 2013, 127, 135-138.	0.6	19
2924	White matter microstructure deteriorates across cognitive stages in Parkinson disease. Neurology, 2013, 80, 1841-1849.	1.5	129
2925	Identification of Three Novel LRRK2 Mutations associated with Parkinson's Disease in a Calabrian Population. Journal of Alzheimer's Disease, 2013, 38, 351-357.	1.2	5
2926	Nigrostriatal Dopamine Terminal Imaging with Dopamine Transporter SPECT: An Update. Journal of Nuclear Medicine, 2013, 54, 1331-1338.	2.8	97
2927	A Single-Center, Cross-Sectional Prevalence Study of Impulse Control Disorders in Parkinson Disease. Journal of Clinical Psychopharmacology, 2013, 33, 691-694.	0.7	79
2928	An FP-CIT PET Comparison of the Differences in Dopaminergic Neuronal Loss Between Idiopathic Parkinson Disease With Dementia and Without Dementia. Alzheimer Disease and Associated Disorders, 2013, 27, 51-55.	0.6	21
2929	Lies, damned lies– and citation metrics. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1-1.	0.9	5
2930	Association Between Early-Onset Parkinson Disease and 22q11.2 Deletion Syndrome. JAMA Neurology, 2013, 70, 1359.	4.5	132
2931	Genetic Variations of GAK in Two Chinese Parkinson–s Disease Populations: A Case-Control Study. PLoS ONE, 2013, 8, e67506.	1.1	18
2932	Specificity and sensitivity of transcranial sonography of the substantia nigra in the diagnosis of Parkinson's disease: prospective cohort study in 196 patients. BMJ Open, 2013, 3, e002613.	0.8	55
2933	Neuroimaging Markers of Motor and Nonmotor Features of Parkinson's Disease: An [¹⁸ F]Fluorodeoxyglucose Positron Emission Computed Tomography Study. Dementia and Geriatric Cognitive Disorders, 2013, 35, 183-196.	0.7	87
2934	Neuromelanin Magnetic Resonance Imaging in Parkinson's Disease and Multiple System Atrophy. European Neurology, 2013, 70, 70-77.	0.6	106
2935	Validation and internal consistency of Patient Health Questionnaire-9 for major depression in Parkinson's disease. Age and Ageing, 2013, 42, 645-649.	0.7	46
2936	Visualization of nigrosome 1 and its loss in PD. Neurology, 2013, 81, 534-540.	1.5	208
2937	Effect of Externally Cued Training on Dynamic Stability Control During the Sit-to-Stand Task in People With Parkinson Disease. Physical Therapy, 2013, 93, 492-503.	1.1	17
2938	Apathy Is Associated with Activities of Daily Living Ability in Parkinson's Disease. Dementia and Geriatric Cognitive Disorders, 2013, 35, 249-255.	0.7	30

#	ARTICLE	IF	CITATIONS
2939	Very Long-Standing Parkinson's Disease. <i>European Neurology</i> , 2013, 70, 172-174.	0.6	1
2940	Effect of dual-task interference on the hand flexibility of patients with Parkinson's disease carrying the leucine-rich repeat kinase 2 gene mutation. <i>Experimental and Therapeutic Medicine</i> , 2013, 6, 1469-1474.	0.8	2
2941	Quantitative Appraisal of Ventricular Cerebrospinal Fluid Biomarkers in Neuropathologically Diagnosed Parkinson's Disease Cases Lacking Alzheimer's Disease Pathology. <i>Biomarker Insights</i> , 2013, 8, BMI.S11422.	1.0	13
2942	Organochlorine Pesticide Levels and Risk of Parkinson's Disease in North Indian Population. <i>ISRN Neurology</i> , 2013, 2013, 1-6.	1.5	30
2943	Assessment of Platelet Indices in Patients with Neurodegenerative Diseases: Mean Platelet Volume Was Increased in Patients with Parkinson's Disease. <i>Current Gerontology and Geriatrics Research</i> , 2013, 2013, 1-5.	1.6	44
2944	Change in Plasma Levels of Amino Acid Neurotransmitters and its Correlation with Clinical Heterogeneity in Early Parkinson's Disease Patients. <i>CNS Neuroscience and Therapeutics</i> , 2013, 19, 889-896.	1.9	24
2945	How attentional boost interacts with reward: the effect of dopaminergic medications in Parkinson's disease. <i>European Journal of Neuroscience</i> , 2013, 38, 3650-3658.	1.2	5
2946	Reaffirmation of GAK, but not HLA-DRA, as a Parkinson's disease susceptibility gene in a Taiwanese population. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2013, 162, 841-846.	1.1	14
2947	The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 666-673.	0.9	43
2948	Nonmotor Symptoms in Nursing Home Residents with Parkinson's Disease: Prevalence and Effect on Quality of Life. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 1714-1721.	1.3	62
2949	White matter abnormalities in Parkinson's disease patients with glucocerebrosidase gene mutations. <i>Movement Disorders</i> , 2013, 28, 772-778.	2.2	34
2950	Decreased event-based prospective memory functioning in individuals with Parkinson's disease. <i>Journal of Neuropsychology</i> , 2013, 7, 153-163.	0.6	10
2951	Phase II a randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing "off" periods in patients with established Parkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 1445-1450.	1.7	35
2952	MCCC1/LAMP3 reduces risk of sporadic Parkinson's disease in Han Chinese. <i>Acta Neurologica Scandinavica</i> , 2013, 128, 136-139.	1.0	3
2953	Somatosensory temporal discrimination threshold may help to differentiate patients with multiple system atrophy from patients with Parkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 714-719.	1.7	35
2954	Use of catechol-O-methyltransferase inhibition to minimize 3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque. <i>European Journal of Neuroscience</i> , 2013, 37, 831-838.	1.2	5
2955	Validation and cross-cultural adaptation of the Falls Efficacy Scale in patients with Parkinson's disease in Serbia. <i>Geriatrics and Gerontology International</i> , 2013, 13, 936-941.	0.7	19
2956	Imprecise vowel articulation as a potential early marker of Parkinson's disease: Effect of speaking task. <i>Journal of the Acoustical Society of America</i> , 2013, 134, 2171-2181.	0.5	175

#	ARTICLE	IF	CITATIONS
2957	New evidence for, and challenges in, linking small <scp>CGG</scp> repeat expansion <scp>FMR1</scp> alleles with Parkinson's disease. <i>Clinical Genetics</i> , 2013, 84, 382-385.	1.0	19
2958	Mild affective symptoms in de novo <scp>P</scp>arkinson's disease patients: relationship with dopaminergic dysfunction. <i>European Journal of Neurology</i> , 2013, 20, 480-485.	1.7	52
2959	Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. <i>American Journal of Clinical Nutrition</i> , 2013, 97, 1004-1013.	2.2	185
2960	The LRRK2 Gene Is Mutated in a Chinese Autosomal-Dominant Parkinson's Disease Family. <i>Genetic Testing and Molecular Biomarkers</i> , 2013, 17, 131-134.	0.3	2
2961	Not all sounds sound the same: Parkinson's disease affects differently emotion processing in music and in speech prosody. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2013, 35, 373-392.	0.8	47
2962	A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1230-1240.	2.2	235
2963	Diurnal Variation of Hypothalamic Function and Chronic Subthalamic Nucleus Stimulation in Parkinson's Disease. <i>Neuroendocrinology</i> , 2013, 97, 283-290.	1.2	37
2964	Gait speed in Parkinson disease correlates with cholinergic degeneration. <i>Neurology</i> , 2013, 81, 1611-1616.	1.5	185
2965	Predictors of performance-based measures of instrumental activities of daily living in nondemented patients with Parkinson's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2013, 35, 926-933.	0.8	28
2966	Apathy in Patients With Parkinson Disease as a Function of Side of Onset. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2013, 26, 95-104.	1.2	17
2967	Primary Health Care Providers' Knowledge Gaps on Parkinson's Disease. <i>Educational Gerontology</i> , 2013, 39, 856-862.	0.7	7
2969	Screening for Anxiety Symptoms in Parkinson Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2013, 26, 34-40.	1.2	29
2970	Locomotor Velocity and Striatal Adaptive Gene Expression Changes of the Direct and Indirect Pathways in Parkinsonian Rats. <i>Journal of Parkinson's Disease</i> , 2013, 3, 341-349.	1.5	7
2971	Snoring is Associated with an Impaired Motor Function, Disease Severity and the Quality of Life but not with Excessive Daytime Sleepiness in Patients with Parkinson's Disease. <i>Internal Medicine</i> , 2013, 52, 863-869.	0.3	6
2972	Pluripotent stem cell-derived dopaminergic neurons as models of neurodegeneration. <i>Future Neurology</i> , 2013, 8, 649-661.	0.9	1
2973	Predictors of Mild Cognitive Impairment in Early-Stage Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2013, 3, 168-178.	0.6	23
2974	Adenosine A _{2A} receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1138-1141.	2.2	189
2975	Inhaled Apomorphine in Patients with "on-off" Fluctuations: A Randomized, Double-blind, Placebo-controlled, Clinic and Home Based, Parallel-group Study. <i>Journal of Parkinson's Disease</i> , 2013, 3, 31-37.	1.5	38

#	ARTICLE	IF	CITATIONS
2976	Improving Detection of Psychiatric Disturbances in Parkinson's Disease: The Role of Informants. <i>Journal of Parkinson's Disease</i> , 2013, 3, 55-60.	1.5	7
2977	Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 130-136.	0.9	106
2978	Rate of cognitive decline in premotor Parkinson's disease: A prospective study (NEDICES). <i>Movement Disorders</i> , 2013, 28, 161-168.	2.2	14
2979	Transdermal rotigotine in early stage Parkinson's disease: A randomized, double-blind, placebo-controlled trial. <i>Movement Disorders</i> , 2013, 28, 1447-1450.	2.2	27
2980	Nonmotor Symptoms in Drug-Induced Parkinsonism and Drug-Naïve Parkinson Disease. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, 36-41.	0.3	35
2981	The Value of GRE, ADC and Routine MRI in Distinguishing Parkinsonian Disorders. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, 389-402.	0.3	27
2982	Visual Hallucinations and Cognitive Impairment in Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, 657-662.	0.3	29
2983	Rapid eye movement sleep behavior disorder in Parkinson's disease: Magnetic resonance imaging study. <i>Movement Disorders</i> , 2013, 28, 832-836.	2.2	52
2984	The G2019S LRRK2 mutation: Another morbid burden for Ashkenazi Jews may provide new insights on sporadic Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1912-1914.	2.2	0
2985	Cumulative exposure to lead and cognition in persons with Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 176-182.	2.2	31
2986	Regions of Interest-Based Discriminant Analysis of DaTSCAN SPECT and FDG-PET for the Classification of Dementia. <i>Clinical Nuclear Medicine</i> , 2013, 38, e112-e117.	0.7	33
2987	The challenges of administering cell-based therapies to patients with Parkinson's disease. <i>NeuroReport</i> , 2013, 24, 1000-1004.	0.6	3
2988	Reduced Body Mass Index in Parkinson's Disease. <i>Journal of Nervous and Mental Disease</i> , 2013, 201, 76-79.	0.5	16
2989	Personality Affects Aspects of Health-Related Quality of Life in Parkinson's Disease via Psychological Coping Strategies. <i>Journal of Parkinson's Disease</i> , 2013, 3, 45-53.	1.5	31
2990	Found in transcription: Accurate Parkinson's disease classification in peripheral blood. <i>Journal of Parkinson's Disease</i> , 2013, 3, 19-29.	1.5	27
2991	Parkinson's and Alzheimer's diseases in Costa Rica: a feasibility study toward a national screening program. <i>Global Health Action</i> , 2013, 6, 23061.	0.7	6
2992	Is Neuroinflammation Involved in the Development of Dementia in Patients with Parkinson's Disease?. <i>Internal Medicine</i> , 2013, 52, 1787-1792.	0.3	30
2993	Anxiety and Depression in Patients with Parkinson's Disease. <i>Internal Medicine</i> , 2013, 52, 539-545.	0.3	93

#	ARTICLE	IF	CITATIONS
2994	Prosody and levodopa in Parkinsons disease. Arquivos De Neuro-Psiquiatria, 2013, 71, 835-840.	0.3	8
2995	Muscle strength and executive function as complementary parameters for the assessment of impairment in Parkinson's disease. Arquivos De Neuro-Psiquiatria, 2013, 71, 948-954.	0.3	2
2996	Validation of the Brazilian version of the Clinical Gait and Balance Scale and comparison with the Berg Balance Scale. Arquivos De Neuro-Psiquiatria, 2013, 71, 621-626.	0.3	6
2997	Effect of different exercise programs on the psychological and cognitive functions of people with Parkinson's disease. Motriz Revista De Educacao Fisica, 2013, 19, 597-604.	0.3	6
2998	Frequency of non-motor symptoms in Peruvian patients with Parkinson's disease. Arquivos De Neuro-Psiquiatria, 2013, 71, 216-219.	0.3	20
2999	Can Silent Ischemic Cerebral Lesions Affect Cognition of Parkinson's Disease Dementia?. Dementia and Neurocognitive Disorders, 2013, 12, 72.	0.4	0
3000	Ventricular orexin-A (hypocretin-1) levels correlate with rapid-eye-movement sleep without atonia in Parkinson's disease. Nature and Science of Sleep, 2013, 5, 87.	1.4	23
3001	Clinical utility of DaTscan™ (123I-Ioflupane Injection) in the diagnosis of Parkinsonian Syndromes. Degenerative Neurological and Neuromuscular Disease, 2013, 3, 33.	0.7	9
3002	Differentiating Non-Motor Symptoms in Parkinson's Disease from Controls and Hemifacial Spasm. PLoS ONE, 2013, 8, e49596.	1.1	9
3003	Association between GRN rs5848 Polymorphism and Parkinsons Disease in Taiwanese Population. PLoS ONE, 2013, 8, e54448.	1.1	19
3004	Motor Matters: Tackling Heterogeneity of Parkinsons Disease in Functional MRI Studies. PLoS ONE, 2013, 8, e56133.	1.1	10
3005	Automated, High Accuracy Classification of Parkinsonian Disorders: A Pattern Recognition Approach. PLoS ONE, 2013, 8, e69237.	1.1	39
3006	Calpastatin Gene (CAST) Is Not Associated with Late Onset Sporadic Parkinsons Disease in the Han Chinese Population. PLoS ONE, 2013, 8, e70935.	1.1	2
3007	Differential Effects of Parkinson's Disease and Dopamine Replacement on Memory Encoding and Retrieval. PLoS ONE, 2013, 8, e74044.	1.1	36
3008	Sleep Disorders in Parkinsons Disease: Clinical Features, Iron Metabolism and Related Mechanism. PLoS ONE, 2013, 8, e82924.	1.1	28
3009	Integrative Network Analysis Unveils Convergent Molecular Pathways in Parkinson's Disease and Diabetes. PLoS ONE, 2013, 8, e83940.	1.1	73
3010	Pattern of Regional Cortical Thinning Associated with Cognitive Deterioration in Parkinsons Disease. PLoS ONE, 2013, 8, e54980.	1.1	112
3011	Anatomical Correlates of Cognitive Functions in Early Parkinson's Disease Patients. PLoS ONE, 2013, 8, e64222.	1.1	47

#	ARTICLE	IF	CITATIONS
3012	White Matter Hyperintensities in Parkinson's Disease: Do They Explain the Disparity between the Postural Instability Gait Difficulty and Tremor Dominant Subtypes?. PLoS ONE, 2013, 8, e55193.	1.1	60
3013	C9orf72 mutation is rare in Alzheimer's disease, Parkinson's disease, and essential tremor in China. Frontiers in Cellular Neuroscience, 2013, 7, 164.	1.8	35
3014	The Management of Orthostatic Hypotension in Parkinson's Disease. Frontiers in Neurology, 2013, 4, 64.	1.1	47
3015	High Prevalence of Gastroesophageal Reflux Disease in Parkinson's Disease: A Questionnaire-Based Study. Parkinson's Disease, 2013, 2013, 1-6.	0.6	14
3016	Finger Tapping Clinimetric Score Prediction in Parkinson's Disease Using Low-Cost Accelerometers. Computational Intelligence and Neuroscience, 2013, 2013, 1-13.	1.1	72
3017	Reliability and Validity of the Persian Version of the Fatigue Severity Scale in Idiopathic Parkinson's Disease Patients. Parkinson's Disease, 2013, 2013, 1-7.	0.6	26
3018	Fundamentals of single-photon emission computed tomography (SPECT) and SPECT/CT imaging. , 0, , 41-56.		1
3019	Automated Volumes-of-Interest Identification for Classical and Atypical Parkinsonian Syndrome Differentiation Using T2-weighted MR Imaging. Methods of Information in Medicine, 2013, 52, 128-136.	0.7	3
3021	Parkinson's disease: making the diagnosis and monitoring progression. British Journal of Neuroscience Nursing, 2013, 9, 167-171.	0.1	2
3022	Insomnia and Sleepiness in Parkinson Disease: Associations with Symptoms and Comorbidities. Journal of Clinical Sleep Medicine, 2013, 09, 1131-1137.	1.4	74
3023	Profile of levodopa/carbidopa intestinal gel and its potential in the treatment of advanced Parkinson's disease. Journal of Parkinsonism and Restless Legs Syndrome, 2014, , 53.	0.8	0
3024	Movement disorders in stroke. , 0, , 247-267.		0
3025	Principles of management in movement disorders. , 0, , 31-38.		0
3026	Free and Cued Recall Memory in Parkinson's Disease Associated with Amnesic Mild Cognitive Impairment. PLoS ONE, 2014, 9, e86233.	1.1	40
3027	The Extracellular Domain of Neurotrophin Receptor p75 as a Candidate Biomarker for Amyotrophic Lateral Sclerosis. PLoS ONE, 2014, 9, e87398.	1.1	57
3028	No Association of Four Candidate Genetic Variants in MnSOD and SYNIII with Parkinson's Disease in Two Chinese Populations. PLoS ONE, 2014, 9, e88050.	1.1	3
3029	Comparable Autoantibody Serum Levels against Amyloid- and Inflammation-Associated Proteins in Parkinson's Disease Patients and Controls. PLoS ONE, 2014, 9, e88604.	1.1	36
3030	Trait Impulsivity Is Associated with the Risk of Falls in Parkinson's Disease. PLoS ONE, 2014, 9, e91190.	1.1	24

#	ARTICLE	IF	CITATIONS
3031	Coordinate-Based Lead Location Does Not Predict Parkinson's Disease Deep Brain Stimulation Outcome. PLoS ONE, 2014, 9, e93524.	1.1	48
3032	Risk for Femoral Fractures in Parkinson's Disease Patients with and without Severe Functional Impairment. PLoS ONE, 2014, 9, e97073.	1.1	33
3033	Factors Influencing the Measurement of Lysosomal Enzymes Activity in Human Cerebrospinal Fluid. PLoS ONE, 2014, 9, e101453.	1.1	23
3034	Eye Movements in Ephedrone-Induced Parkinsonism. PLoS ONE, 2014, 9, e104784.	1.1	15
3035	Reduced Topological Efficiency in Cortical-Basal Ganglia Motor Network of Parkinson's Disease: A Resting State fMRI Study. PLoS ONE, 2014, 9, e108124.	1.1	40
3036	Nonmotor Symptoms in LRRK2 G2019S Associated Parkinson's Disease. PLoS ONE, 2014, 9, e108982.	1.1	79
3037	Upregulation of GPR109A in Parkinson's Disease. PLoS ONE, 2014, 9, e109818.	1.1	68
3038	Asymmetrical Effect of Levodopa on the Neural Activity of Motor Regions in PD. PLoS ONE, 2014, 9, e111600.	1.1	17
3039	Mutational Analysis of Angiogenin Gene in Parkinson's Disease. PLoS ONE, 2014, 9, e112661.	1.1	6
3040	Dopamine Replacement Therapy and Deep Brain Stimulation of the Subthalamic Nuclei Induce Modulation of Emotional Processes at Different Spatial Frequencies in Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 97-110.	1.5	9
3041	Comparison of the Psychological Symptoms and Disease-Specific Quality of Life between Early- and Typical-Onset Parkinson's Disease Patients. Parkinson's Disease, 2014, 2014, 1-7.	0.6	14
3042	Quantitative Electromyographic Analysis of Reaction Time to External Auditory Stimuli in Drug-Naive Parkinson's Disease. Parkinson's Disease, 2014, 2014, 1-8.	0.6	4
3043	Influence of Hypertension on Neurocognitive Domains in Nondemented Parkinson's Disease Patients. Parkinson's Disease, 2014, 2014, 1-10.	0.6	14
3044	Using the Satisfaction with Life Scale in People with Parkinson's Disease: A Validation Study in Different European Countries. Scientific World Journal, The, 2014, 2014, 1-7.	0.8	27
3045	Measuring Hemoglobin Levels in the Optic Disc of Parkinson's Disease Patients Using New Colorimetric Analysis Software. Parkinson's Disease, 2014, 2014, 1-8.	0.6	7
3046	Recurrent Falls in People with Parkinson's Disease without Cognitive Impairment: Focusing on Modifiable Risk Factors. Parkinson's Disease, 2014, 2014, 1-8.	0.6	9
3047	Rasch validation of the Activities-specific Balance Confidence Scale and its short versions in patients with Parkinson's disease. Journal of Rehabilitation Medicine, 2014, 46, 532-539.	0.8	33
3048	Delayed latencies of auditory evoked potential P300 are associated with the severity of Parkinson's disease in older patients. Arquivos De Neuro-Psiquiatria, 2014, 72, 296-300.	0.3	24

#	ARTICLE	IF	CITATIONS
3049	Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1093.	1.0	20
3050	Decision and dopaminergic system: an ERPs study of Iowa gambling task in Parkinson's disease. <i>Frontiers in Psychology</i> , 2014, 5, 684.	1.1	36
3051	Serum Uric Acid Concentration is Linked to Wearing-off Fluctuation in Japanese Parkinson's Disease Patients. <i>Journal of Parkinson's Disease</i> , 2014, 4, 499-505.	1.5	14
3052	Dopaminergic modulation of emotional conflict in Parkinson's disease. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 164.	1.7	12
3053	Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and Multiple System Atrophy. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 156.	1.8	150
3054	An association study between Heme oxygenase-1 genetic variants and Parkinson's disease. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 298.	1.8	39
3055	Voxelwise meta-analysis of gray matter anomalies in progressive supranuclear palsy and Parkinson's disease using anatomic likelihood estimation. <i>Frontiers in Human Neuroscience</i> , 2014, 8, 63.	1.0	32
3056	Beyond the "urge to move" objective measures for the study of agency in the post-Libet era. <i>Frontiers in Human Neuroscience</i> , 2014, 8, 450.	1.0	47
3057	Dopaminergic medication impairs feedback-based stimulus-response learning but not response selection in Parkinson's disease. <i>Frontiers in Human Neuroscience</i> , 2014, 8, 784.	1.0	22
3058	Procedural-based category learning in patients with Parkinson's disease: impact of category number and category continuity. <i>Frontiers in Systems Neuroscience</i> , 2014, 8, 14.	1.2	6
3059	Electrophysiologic characteristics of tremor in Parkinson's disease and essential tremor. <i>Arquivos De Neuro-Psiquiatria</i> , 2014, 72, 301-306.	0.3	6
3060	Pull test performance and correlation with falls risk in Parkinson's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2014, 72, 587-591.	0.3	17
3061	Realidade virtual na reabilita�o f�sica de pacientes com doen�a de Parkinson. <i>Journal of Human Growth and Development</i> , 2014, 24, 31.	0.2	20
3062	Oxidized DJ-1 as a possible biomarker of Parkinson's disease. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2014, 54, 138-144.	0.6	58
3063	Dupla-tarefa na doen�a de Parkinson: uma revis�o sistem�tica de ensaios cl�nicos aleatorizados. <i>Revista Brasileira De Geriatria E Gerontologia</i> , 2014, 17, 191-199.	0.1	10
3064	Specificity and sensibility of 9-Items Wearing-off Questionnaire in Brazilian Parkinson disease patient sample. <i>Arquivos De Neuro-Psiquiatria</i> , 2014, 72, 867-873.	0.3	1
3065	An 85-Year Old Male with Levodopa-Responsive Parkinsonism Followed by Dementia and Supranuclear Ophthalmoplegia Caused by Alzheimer-Type Pathology without Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 471-476.	1.2	2
3066	Frequency of the LRRK2 G2019S mutation in late-onset sporadic patients with Parkinson's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2014, 72, 356-359.	0.3	14

#	ARTICLE	IF	CITATIONS
3067	Clinical Usefulness of ^{99m} Tc-Hexamethyl Propylene Amine Oxime Perfusion Single Photon Emission Computed Tomography for Early Phase Multiple System Atrophy. <i>Dementia and Neurocognitive Disorders</i> , 2014, 13, 37.	0.4	0
3068	Initial circulatory response to active standing in Parkinson's disease without typical orthostatic hypotension. <i>Arquivos De Neuro-Psiquiatria</i> , 2014, 72, 208-213.	0.3	0
3069	Addenbrooke's Cognitive Examination-Revised is accurate for detecting dementia in Parkinson's disease patients with low educational level. <i>Dementia E Neuropsychologia</i> , 2014, 8, 20-25.	0.3	10
3070	Emotional and Cognitive Processing Deficits in People with Parkinson's Disease and Apathy. , 2014, 04, .		5
3071	Dissociation between source and item memory in Parkinson's disease. <i>Chinese Medical Journal</i> , 2014, 127, 3224-3228.	0.9	1
3075	Application of LSVT BIG Intervention to Address Gait, Balance, Bed Mobility, and Dexterity in People With Parkinson Disease: A Case Series. <i>Physical Therapy</i> , 2014, 94, 1014-1023.	1.1	51
3076	The Subthalamic Nucleus Influences Visuospatial Attention in Humans. <i>Journal of Cognitive Neuroscience</i> , 2014, 26, 543-550.	1.1	18
3077	Clinical Biospecimens: Reference Materials, Certified for Nominal Properties?. <i>Biopreservation and Biobanking</i> , 2014, 12, 113-120.	0.5	4
3078	Non-Motor Symptoms Profile and Burden in Drug Naïve Versus Long-Term Parkinson's Disease Patients. <i>Journal of Parkinson's Disease</i> , 2014, 4, 541-547.	1.5	41
3079	Postural control in Parkinson's disease. <i>Brazilian Journal of Otorhinolaryngology</i> , 2014, 80, 508-514.	0.4	25
3080	Tolcapone addition improves Parkinson's disease associated nonmotor symptoms. <i>Therapeutic Advances in Neurological Disorders</i> , 2014, 7, 77-82.	1.5	24
3081	Apathy in untreated, de novo patients with Parkinson's disease: validation study of Apathy Evaluation Scale. <i>Journal of Neurology</i> , 2014, 261, 2319-2328.	1.8	74
3082	Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 7-16.	0.9	119
3083	Characterizing mild cognitive impairment in incident Parkinson disease. <i>Neurology</i> , 2014, 82, 308-316.	1.5	359
3084	Evolving Classifiers to Recognize the Movement Characteristics of Parkinson's Disease Patients. <i>IEEE Transactions on Evolutionary Computation</i> , 2014, 18, 559-576.	7.5	45
3085	Quality of life in advanced Parkinson's disease after bilateral subthalamic stimulation: 2 years follow-up study. <i>Clinical Neurology and Neurosurgery</i> , 2014, 124, 161-165.	0.6	19
3086	New treatments for the motor symptoms of Parkinson's disease. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 761-777.	1.3	28
3087	Analysis of cerebral blood flow in Parkinson's disease with dementia versus subcortical ischemic vascular dementia using single photon emission computed tomography. <i>International Journal of Imaging Systems and Technology</i> , 2014, 24, 306-312.	2.7	2

#	ARTICLE	IF	CITATIONS
3088	The role of social support in anxiety and depression among Parkinson's disease patients. <i>Disability and Rehabilitation</i> , 2014, 36, 2044-2049.	0.9	24
3089	Depression and Cognitive Impairment in Parkinson's Disease: A Role for Inflammation and Immunomodulation?. <i>NeuroImmunoModulation</i> , 2014, 21, 88-94.	0.9	45
3090	Serotonin Transporter Availability in Early Stage Parkinson's Disease and Multiple System Atrophy. <i>ISRN Neurology</i> , 2014, 2014, 1-4.	1.5	4
3091	Association of NQO1 and TNF polymorphisms with Parkinson's disease: A meta-analysis of 15 genetic association studies. <i>Biomedical Reports</i> , 2014, 2, 713-718.	0.9	13
3092	Influence of Deep Breathing on Heart Rate Variability in Parkinson's Disease: Co-relation with Severity of Disease and Non-Motor Symptom Scale Score. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2014, 8, BC01-3.	0.8	5
3093	Imaging of Dopamine and Serotonin Receptors and Transporters. , 2014, , 241-264.		0
3094	Comparison of IPX066 with carbidopa/levodopa plus entacapone in advanced PD patients. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1335-1340.	1.1	62
3095	Abnormal metabolic network activity in REM sleep behavior disorder. <i>Neurology</i> , 2014, 82, 620-627.	1.5	151
3096	Predicting Cognitive Decline in Parkinson's Disease: Can We Ask the Genes?. <i>Frontiers in Neurology</i> , 2014, 5, 224.	1.1	11
3097	Involvement of Endocytosis and Alternative Splicing in the Formation of the Pathological Process in the Early Stages of Parkinson's Disease. <i>BioMed Research International</i> , 2014, 2014, 1-6.	0.9	33
3098	Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1065-1075.	0.9	83
3099	Does a specialist unit improve outcomes for hospitalized patients with Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1242-1247.	1.1	31
3100	Dopamine Treatment and Cognitive Functioning in Individuals with Parkinson's Disease: The "Cognitive Flexibility" Hypothesis Seems to Work. <i>Behavioural Neurology</i> , 2014, 2014, 1-11.	1.1	33
3101	Cross-Cultural Validity, Reliability, and Psychometric Properties of the Persian Version of the Scales for Outcomes in Parkinson's Disease-Psychosocial Questionnaire. <i>Neurology Research International</i> , 2014, 2014, 1-7.	0.5	5
3102	Rationale and Clinical Pearls for Primary Care Doctors Referring Patients for Deep Brain Stimulation. <i>Gerontology</i> , 2014, 60, 38-48.	1.4	12
3103	Prevalence of nocturia in Parkinson's disease patients from various ethnicities. <i>Neurological Research</i> , 2014, 36, 234-238.	0.6	12
3104	Is action tremor in Parkinson's disease related to resting tremor?. <i>Neurological Research</i> , 2014, 36, 107-111.	0.6	8
3105	Detraining outcomes with expiratory muscle strength training in Parkinson disease. <i>Journal of Rehabilitation Research and Development</i> , 2014, 51, 305-310.	1.6	45

#	ARTICLE	IF	CITATIONS
3106	Parkinson's Disease and the Claustrum. , 2014, , 277-297.		4
3107	Testosterone level and the effect of levodopa and agonists in early Parkinson disease: results from the INSPECT cohort. Journal of Clinical Movement Disorders, 2014, 1, 8.	2.2	17
3108	Trunk muscle exercises as a means of improving postural stability in people with Parkinson's disease: a protocol for a randomised controlled trial. BMJ Open, 2014, 4, e006095.	0.8	25
3109	Invited Commentary on "Structural and Functional Imaging in Parkinsonian Syndromes": Radiographics, 2014, 34, 1292-1294.	1.4	0
3110	Multipinhole collimator with 20 apertures for a brain SPECT application. Medical Physics, 2014, 41, 112501.	1.6	15
3111	<i>In vitro</i> dopaminergic neurotoxicity of pesticides: a link with neurodegeneration?. Veterinary Quarterly, 2014, 34, 120-131.	3.0	12
3112	Parkinson disease and smoking revisited. Neurology, 2014, 83, 1396-1402.	1.5	118
3113	The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain, 2014, 137, 2731-2742.	3.7	251
3114	Primary sleep disorder prevalence in patients with newly diagnosed Parkinson's disease. Movement Disorders, 2014, 29, 259-262.	2.2	37
3115	Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: Flow-mediated dilation study. Movement Disorders, 2014, 29, 1551-1555.	2.2	19
3116	Mitochondrial serine protease HTRA2 p.G399S in a kindred with essential tremor and Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 18285-18290.	3.3	147
3117	Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing. Movement Disorders, 2014, 29, 1252-1257.	2.2	7
3118	The burden of white matter hyperintensities is a predictor of progressive mild cognitive impairment in patients with Parkinson's disease. European Journal of Neurology, 2014, 21, 922.	1.7	55
3119	Recurrent and fatal akinetic crisis in genetic mitochondrial parkinsonisms. European Journal of Neurology, 2014, 21, 1242-1246.	1.7	14
3120	Freezing of gait subtypes have different cognitive correlates in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 1359-1364.	1.1	51
3121	Viewpoint: Challenges in our understanding of neuroleptic induced parkinsonism. Parkinsonism and Related Disorders, 2014, 20, 1325-1328.	1.1	12
3122	Swallowing disturbances in Parkinson's disease: A multivariate analysis of contributing factors. Parkinsonism and Related Disorders, 2014, 20, 1382-1387.	1.1	93
3123	MTHFR C677T variant reduces risk of sporadic Parkinson's disease in ethnic Chinese. Acta Neurologica Scandinavica, 2014, 130, e30-e34.	1.0	8

#	ARTICLE	IF	CITATIONS
3124	Alimentary, my dear Watson? The challenges of enteric Î±-synuclein as a Parkinson's disease biomarker. <i>Movement Disorders</i> , 2014, 29, 444-450.	2.2	74
3125	Health-related quality of life in early Parkinson's disease: The impact of nonmotor symptoms. <i>Movement Disorders</i> , 2014, 29, 195-202.	2.2	292
3126	Cognitive correlates of hallucinations and delusions in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2014, 347, 316-321.	0.3	55
3127	SNCA variants rs2736990 and rs356220 as risk factors for Parkinson's disease but not for amyotrophic lateral sclerosis and multiple system atrophy in a Chinese population. <i>Neurobiology of Aging</i> , 2014, 35, 2882.e1-2882.e6.	1.5	30
3128	Analysis among cognitive profiles and gray matter volume in newly diagnosed Parkinson's disease with mild cognitive impairment. <i>Journal of the Neurological Sciences</i> , 2014, 347, 210-213.	0.3	27
3129	Impaired Executive Function Can Predict Recurrent Falls in Parkinson's Disease. <i>Archives of Physical Medicine and Rehabilitation</i> , 2014, 95, 2390-2395.	0.5	48
3130	Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1394-1398.	1.1	71
3131	People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance. <i>Movement Disorders</i> , 2014, 29, 1258-1264.	2.2	76
3132	The value of putaminal diffusion imaging versus 18F-fluorodeoxyglucose positron emission tomography for the differential diagnosis of the Parkinson variant of multiple system atrophy. <i>Movement Disorders</i> , 2014, 29, 380-387.	2.2	54
3133	Famotidine, a Histamine H ₂ Receptor Antagonist, Does Not Reduce Levodopa-Induced Dyskinesia in Parkinson's Disease: A Proof-of-Concept Study. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 219-224.	0.8	16
3134	Sonography for Diagnosis of Parkinson Disease—From Theory to Practice. <i>Journal of Ultrasound in Medicine</i> , 2014, 33, 2069-2074.	0.8	18
3135	Cardiac stress test is normal in pre-motor Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1158-1162.	2.2	1
3136	Reduced Î±-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity. <i>European Journal of Neurology</i> , 2014, 21, 388-394.	1.7	67
3137	Motor impulsivity in Parkinson disease: Associations with COMT and DRD2 polymorphisms. <i>Scandinavian Journal of Psychology</i> , 2014, 55, 278-286.	0.8	17
3138	Î±-Synuclein inclusions in the skin of Parkinson's disease and parkinsonism. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 471-478.	1.7	40
3139	Examining dorsal striatum in cognitive effort using Parkinson's disease and fMRI. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 390-400.	1.7	21
3140	Effects of Tyrosine on Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 348-353.	0.8	15
3141	Predictors of cognitive impairment in an early stage Parkinson's disease cohort. <i>Movement Disorders</i> , 2014, 29, 351-359.	2.2	124

#	ARTICLE	IF	CITATIONS
3142	Self-rated health mediates the association between functional status and health-related quality of life in <sc>Parkinson's disease. Journal of Clinical Nursing, 2014, 23, 1970-1977.	1.4	5
3143	Dopaminergic agents and nutritional status in Parkinson's disease. Movement Disorders, 2014, 29, 1543-1547.	2.2	22
3144	Transcranial direct current stimulation for treatment of freezing of gait: A cross-over study. Movement Disorders, 2014, 29, 1064-1069.	2.2	103
3145	Olfactory identification in <i><sc>LRRK2</sc> G2019S mutation carriers: a relevant marker?. Annals of Clinical and Translational Neurology, 2014, 1, 670-678.	1.7	43
3147	Parkinson's disease patients compensate for balance control asymmetry. Journal of Neurophysiology, 2014, 112, 3227-3239.	0.9	36
3148	Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: Evidence from a meta-analysis. Movement Disorders, 2014, 29, 1599-1605.	2.2	53
3149	Circadian Melatonin Rhythm and Excessive Daytime Sleepiness in Parkinson Disease. JAMA Neurology, 2014, 71, 463.	4.5	283
3150	Severity of mild cognitive impairment in early Parkinson's disease contributes to poorer quality of life. Parkinsonism and Related Disorders, 2014, 20, 1071-1075.	1.1	110
3151	Greater Loss of White Matter Integrity in Postural Instability and Gait Difficulty Subtype of Parkinson's Disease. Canadian Journal of Neurological Sciences, 2014, 41, 763-768.	0.3	28
3152	The Melanocortin 1 Receptor (Mc1r) Variants Do Not Account for the Co-occurrence of Parkinson's Disease and Malignant Melanoma. Journal of Molecular Neuroscience, 2014, 54, 820-825.	1.1	11
3153	Ultrasonographic (TCS) and clinical findings in overlapping phenotype of essential tremor and Parkinson's disease (ET-PD). BMC Neurology, 2014, 14, 54.	0.8	12
3154	Tremor and clinical fluctuation are related to sleep disorders in Chinese patients with Parkinson's disease. Translational Neurodegeneration, 2014, 3, 21.	3.6	2
3155	The sense-of-coherence predicts health-related quality of life and emotional distress but not disability in Parkinson's disease. BMC Neurology, 2014, 14, 193.	0.8	25
3156	The Mini-BESTest - a clinically reproducible tool for balance evaluations in mild to moderate Parkinson's disease?. BMC Neurology, 2014, 14, 235.	0.8	62
3157	Pharmacokinetics of Levodopa in Patients With Parkinson Disease and Motor Fluctuations Depending on the Presence of Helicobacter pylori Infection. Clinical Neuropharmacology, 2014, 37, 96-99.	0.2	36
3158	The incidence of Parkinson's disease in the North-East of England. Age and Ageing, 2014, 43, 257-263.	0.7	22
3159	Understanding Parkinson disease. Nurse Practitioner, 2014, 39, 1-10.	0.2	3
3160	Immunostaining of Oxidized DJ-1 in Human and Mouse Brains. Journal of Neuropathology and Experimental Neurology, 2014, 73, 714-728.	0.9	38

#	ARTICLE	IF	CITATIONS
3161	Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease. <i>Brain</i> , 2014, 137, 3025-3035.	3.7	28
3162	Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 840-844.	0.9	200
3163	Grooved Pegboard Predicts More of Cognitive Than Motor Involvement in Parkinson's Disease. <i>Assessment</i> , 2014, 21, 723-730.	1.9	35
3164	Evaluation of peripheral matrix metalloproteinase-1 in Parkinson's disease: a case-control study. <i>International Journal of Neuroscience</i> , 2014, 124, 88-92.	0.8	10
3165	Combining physical training with transcranial direct current stimulation to improve gait in Parkinson's disease: a pilot randomized controlled study. <i>Clinical Rehabilitation</i> , 2014, 28, 1115-1124.	1.0	113
3166	Withdrawing amantadine in dyskinetic patients with Parkinson disease. <i>Neurology</i> , 2014, 82, 300-307.	1.5	122
3167	Skin discolouration with acute onset parkinsonism secondary to systemic zirconium intoxication. <i>Annals of Clinical Biochemistry</i> , 2014, 51, 97-100.	0.8	5
3168	Lack of C9orf72 Repeat Expansion in Taiwanese Patients with Mixed Neurodegenerative Disorders. <i>Frontiers in Neurology</i> , 2014, 5, 59.	1.1	15
3169	Adult Hippocampal Neurogenesis in Parkinson's Disease: Impact on Neuronal Survival and Plasticity. <i>Neural Plasticity</i> , 2014, 2014, 1-12.	1.0	62
3170	The Utility of Neuroimaging in the Differential Diagnosis of Parkinsonian Syndromes. <i>Seminars in Neurology</i> , 2014, 34, 202-209.	0.5	26
3171	Nonmotor Symptoms and Cognitive Decline in <i>de novo</i> Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2014, 41, 597-602.	0.3	32
3172	Role of Trichloroethylene in Parkinson's Disease. <i>Molecular and Integrative Toxicology</i> , 2014, , 91-129.	0.5	0
3173	Cognition and dual-task performance in older adults with Parkinson's and Alzheimer's disease. <i>International Journal of General Medicine</i> , 2014, 7, 383.	0.8	26
3174	Attentional Set-Shifting in Parkinson's Disease Patients with Freezing of Gait-Acquisition and Discrimination Set Learning Deficits at the Background?. <i>Journal of the International Neuropsychological Society</i> , 2014, 20, 929-936.	1.2	15
3175	Blood and cerebrospinal fluid markers in Parkinson's disease: current biomarker findings. <i>Current Biomarker Findings</i> , 0, , 1.	0.4	7
3176	Prevalence, Determinants, and Effect on Quality of Life of Freezing of Gait in Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 884.	4.5	241
3177	Visualization of nigrosome 1 and its loss in PD: Pathoanatomical correlation and in vivo 7T MRI. <i>Neurology</i> , 2014, 82, 1752-1752.	1.5	32
3178	Serum hs-CRP Levels are Increased in de Novo Parkinson's Disease Independently from Age of Onset. <i>European Neurology</i> , 2014, 72, 285-289.	0.6	20

#	ARTICLE	IF	CITATIONS
3179	Influence of Depressive Symptoms on Dopaminergic Treatment of Parkinson's Disease. <i>Frontiers in Neurology</i> , 2014, 5, 188.	1.1	6
3180	Another perspective on fasciculations: when is it not caused by the classic form of amyotrophic lateral sclerosis or progressive spinal atrophy?. <i>Neurology International</i> , 2014, 6, 5208.	1.3	12
3181	Sleep disturbances in drug-naïve Parkinson's disease (PD) patients and effect of levodopa on sleep. <i>Annals of Indian Academy of Neurology</i> , 2014, 17, 416.	0.2	31
3182	The Relationships Between Poor Sleep Efficiency and Mild Cognitive Impairment in Parkinson Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2014, 27, 77-84.	1.2	11
3183	CCDC62 Variant rs12817488 Is Associated with the Risk of Parkinson's Disease in a Han Chinese Population. <i>European Neurology</i> , 2014, 71, 77-83.	0.6	9
3184	Accurate Detection of Parkinson's Disease in Tremor Syndromes Using Olfactory Testing. <i>European Neurology</i> , 2014, 72, 1-6.	0.6	7
3186	Relationship and factor structure in multisystem neurodegeneration in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2014, 130, 347-353.	1.0	12
3187	Prospective Memory Performance of Patients with Parkinson's Disease Depends on Shifting Aptitude: Evidence from Cognitive Rehabilitation. <i>Journal of the International Neuropsychological Society</i> , 2014, 20, 717-726.	1.2	23
3188	Cognitive Impairment in Parkinson's Disease: More than a Frontostriatal Dysfunction. <i>Spanish Journal of Psychology</i> , 2014, 17, E68.	1.1	11
3189	Risky driving and pedunculopontine nucleus-thalamic cholinergic denervation in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 13-16.	1.1	7
3190	High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia. <i>Alzheimer's and Dementia</i> , 2014, 10, 530.	0.4	18
3191	Immunohistochemical localization of apoptosome-related proteins in Lewy bodies in Parkinson's disease and dementia with Lewy bodies. <i>Brain Research</i> , 2014, 1571, 39-48.	1.1	11
3192	Assessing speech dysfunction using BOLD and acoustic analysis in parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 855-861.	1.1	25
3193	The difference in putamen volume between MSA and PD: Evidence from a meta-analysis. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 873-877.	1.1	30
3194	Microstructural changes in the substantia nigra of asymptomatic agricultural workers. <i>Neurotoxicology and Teratology</i> , 2014, 41, 60-64.	1.2	15
3195	Diagnostic accuracy of parkinsonism syndromes by general neurologists. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 840-844.	1.1	146
3196	Subjective visual vertical in Pisa syndrome. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 878-883.	1.1	37
3197	Safety and efficacy of recombinant human erythropoietin treatment of non-motor symptoms in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2014, 337, 47-54.	0.3	54

#	ARTICLE	IF	CITATIONS
3198	Parkin mutation and deep brain stimulation outcome. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 107-110.	0.8	18
3199	Circulating levels of adipokines in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2014, 339, 64-68.	0.3	17
3200	Olfactory performance acts as a cognitive reserve in non-demented patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 186-191.	1.1	26
3201	La définition de la maladie de Parkinson est-elle clinique? <i>Pratique Neurologique - FMC</i> , 2014, 5, 152-158.	0.1	1
3202	Time structure of leg movement activity during sleep in untreated Parkinson disease and effects of dopaminergic treatment. <i>Sleep Medicine</i> , 2014, 15, 816-824.	0.8	25
3203	Elevated blood harmaline (1-methyl-9H-pyrido[3,4-b]indole) concentrations in Parkinson's disease. <i>NeuroToxicology</i> , 2014, 40, 52-56.	1.4	37
3204	Event-related mu-rhythm desynchronization during movement observation is impaired in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2014, 125, 1819-1825.	0.7	30
3205	The value of novel MRI techniques in Parkinson-plus syndromes: Diffusion tensor imaging and anatomical connectivity studies. <i>Revue Neurologique</i> , 2014, 170, 266-276.	0.6	8
3206	Is acupuncture efficacious therapy in Parkinson's disease?. <i>Journal of the Neurological Sciences</i> , 2014, 341, 1-7.	0.3	26
3207	Is reduced arm and leg swing in Parkinson's disease associated with rigidity or bradykinesia?. <i>Journal of the Neurological Sciences</i> , 2014, 341, 32-35.	0.3	25
3208	Association analysis of PARK16-18 variants and Parkinson's disease in a Chinese population. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1029-1032.	0.8	14
3209	Association analysis of STK39, MCCC1/LAMP3 and sporadic PD in the Chinese Han population. <i>Neuroscience Letters</i> , 2014, 566, 206-209.	1.0	9
3210	Serotonin transporter polymorphic region 5-HTTLPR modulates risk for Parkinson's disease. <i>Neurobiology of Aging</i> , 2014, 35, 1957.e9-1957.e14.	1.5	10
3211	Nigrostriatal damage after systemic rotenone and/or lipopolysaccharide and the effect of cannabis. <i>Comparative Clinical Pathology</i> , 2014, 23, 1343-1358.	0.3	10
3212	Comprehensive morphometry of subcortical grey matter structures in early-stage Parkinson's disease. <i>Human Brain Mapping</i> , 2014, 35, 1681-1690.	1.9	84
3213	Effect of mild cognitive impairment on the patterns of neural activity in early Parkinson's disease. <i>Neurobiology of Aging</i> , 2014, 35, 223-231.	1.5	82
3214	Is reduced myocardial sympathetic innervation associated with clinical symptoms of autonomic impairment in idiopathic Parkinson's disease?. <i>Journal of Neurology</i> , 2014, 261, 45-51.	1.8	11
3215	Leakage of decision uncertainty into movement execution in Parkinson's disease?. <i>Experimental Brain Research</i> , 2014, 232, 21-30.	0.7	4

#	ARTICLE	IF	CITATIONS
3216	Differential Diagnosis of Patients with Inconclusive Parkinsonian Features Using [18F]FP-CIT PET/CT. Nuclear Medicine and Molecular Imaging, 2014, 48, 106-113.	0.6	16
3217	Identification of blood serum microRNAs associated with idiopathic and <i>LRRK2</i> Parkinson's disease. Journal of Neuroscience Research, 2014, 92, 1071-1077.	1.3	122
3218	Dietary Herb Extract Rikkunshi-To Ameliorates Gastroparesis in Parkinson's Disease: A Pilot Study. European Neurology, 2014, 71, 193-195.	0.6	28
3219	REM sleep behavior disorder: Association with motor complications and impulse control disorders in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 1081-1084.	1.1	42
3220	Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet, The, 2014, 383, 533-540.	6.3	756
3221	Differential diagnosis of parkinsonism with visual inspection of posture and gait in the early stage. Gait and Posture, 2014, 39, 1138-1141.	0.6	5
3222	Postural inflexibility in PD: Does it affect compensatory stepping?. Gait and Posture, 2014, 39, 700-706.	0.6	34
3223	Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease. Journal of Neurology, 2014, 261, 561-569.	1.8	53
3224	The effects of dual tasking on handwriting in patients with Parkinson's disease. Neuroscience, 2014, 263, 193-202.	1.1	57
3225	Pathomechanisms and compensatory efforts related to Parkinsonian speech. NeuroImage: Clinical, 2014, 4, 82-97.	1.4	72
3226	Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism and Related Disorders, 2014, 20, 525-529.	1.1	107
3227	Diagnostic procedures during the course of Parkinson's Disease. Basal Ganglia, 2014, 4, 15-18.	0.3	17
3228	Neuropeptide S counteracts 6-OHDA-induced motor deficits in mice. Behavioural Brain Research, 2014, 266, 29-36.	1.2	19
3229	Spinopelvic balance: new biomechanical insights with clinical implications for Parkinson's disease. European Spine Journal, 2014, 23, 576-583.	1.0	29
3230	Neurofunctional correlates of attention rehabilitation in Parkinson's disease: an explorative study. Neurological Sciences, 2014, 35, 1173-1180.	0.9	80
3231	Gait and upper limb variability in Parkinson's disease patients with and without freezing of gait. Journal of Neurology, 2014, 261, 330-342.	1.8	67
3232	Lack of association of morphologic and functional retinal changes with motor and non-motor symptoms severity in Parkinson's disease. Journal of Neural Transmission, 2014, 121, 139-145.	1.4	19
3233	The timing between REM sleep behavior disorder and Parkinson's disease. Sleep and Breathing, 2014, 18, 319-323.	0.9	24

#	ARTICLE	IF	CITATIONS
3234	Clinical, cognitive, and behavioural correlates of white matter damage in progressive supranuclear palsy. <i>Journal of Neurology</i> , 2014, 261, 913-924.	1.8	50
3235	Neuropathology of prodromal Lewy body disease. <i>Movement Disorders</i> , 2014, 29, 410-415.	2.2	71
3236	REM sleep behavior disorder in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2014, 121, 41-47.	1.4	42
3237	How embodied is action language? Neurological evidence from motor diseases. <i>Cognition</i> , 2014, 131, 311-322.	1.1	83
3238	Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson's disease longitudinally. <i>Brain</i> , 2014, 137, 1120-1129.	3.7	172
3239	Advances in the Genetics of Parkinson's Disease: A Guide for the Clinician. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 3-13.	0.8	17
3240	Ropinirole treatment in Parkinson's disease associated with higher serum level of inflammatory biomarker NT-proCNP. <i>Neuroscience Letters</i> , 2014, 566, 147-150.	1.0	8
3241	Clinical REM sleep behavior disorder and motor subtypes in Parkinson's disease: A questionnaire-based study. <i>Clinical Neurology and Neurosurgery</i> , 2014, 119, 54-58.	0.6	10
3242	Clinicogenetic study of GBA mutations in patients with familial Parkinson's disease. <i>Neurobiology of Aging</i> , 2014, 35, 935.e3-935.e8.	1.5	69
3243	The evaluation of polyglutamine repeats in autosomal dominant Parkinson's disease. <i>Neurobiology of Aging</i> , 2014, 35, 1779.e17-1779.e21.	1.5	17
3244	Early Diagnosis of Alzheimer's Disease and Parkinson's Disease Associated with Dementia Using Cerebral Perfusion SPECT. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 37, 276-285.	0.7	16
3245	Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 527-531.	2.2	53
3246	Asymmetric dopamine loss differentially affects effort to maximize gain or minimize loss. <i>Cortex</i> , 2014, 51, 82-91.	1.1	38
3247	Movement disorders in childhood. <i>Parkinsonism and Related Disorders</i> , 2014, 20, S13-S16.	1.1	11
3248	Effect of a multimodal exercise program on sleep disturbances and instrumental activities of daily living performance on Parkinson's and Alzheimer's disease patients. <i>Geriatrics and Gerontology International</i> , 2014, 14, 259-266.	0.7	71
3249	Cognitive, Neuropsychiatric, and Motor Features Associated With Apolipoprotein E ε4 Allele in a Sample of Bulgarian Patients With Late-Onset Parkinson's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2014, 29, 614-619.	0.9	9
3250	Surface EMG activity during REM sleep in Parkinson's disease correlates with disease severity. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 766-771.	1.1	36
3251	Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2014, 29, 899-905.	1.3	25

#	ARTICLE	IF	CITATIONS
3252	History of smoking and olfaction in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1069-1074.	2.2	17
3253	PRKAR1B mutation associated with a new neurodegenerative disorder with unique pathology. <i>Brain</i> , 2014, 137, 1361-1373.	3.7	54
3254	The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease. <i>Journal of Neurology</i> , 2014, 261, 1126-1132.	1.8	14
3255	Balance and Gait Training With Augmented Feedback Improves Balance Confidence in People With Parkinson's Disease. <i>Neurorehabilitation and Neural Repair</i> , 2014, 28, 524-535.	1.4	86
3256	Impact of fatigue on health-related quality of life in patients with Parkinson's disease: a prospective study. <i>Clinical Rehabilitation</i> , 2014, 28, 300-311.	1.0	22
3257	Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naïve Parkinson's disease. <i>European Journal of Neurology</i> , 2014, 21, 802-807.	1.7	41
3258	Advanced Age, Cardiovascular Risk Burden, and Timed Up and Go Test Performance in Parkinson Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2014, 69, 1569-1575.	1.7	12
3259	Anxiety Has Specific Syndromal Profiles in Parkinson Disease: A Data-Driven Approach. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 1410-1417.	0.6	32
3260	Neural correlates of minor hallucinations in non-demented patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 290-296.	1.1	87
3261	Heart rate circadian profile in the differential diagnosis between Parkinson disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 217-221.	1.1	25
3262	REM sleep behavior disorder in Parkinson disease: Association with abnormal ocular motor findings. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 444-446.	1.1	14
3263	Autonomic dysfunction according to disease progression in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 303-307.	1.1	54
3264	Triad-conditioning Transcranial Magnetic Stimulation in Parkinson's Disease. <i>Brain Stimulation</i> , 2014, 7, 74-79.	0.7	8
3265	REM sleep behaviour disorder is associated with worse quality of life and other non-motor features in early Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 560-566.	0.9	150
3266	The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. <i>Neurobiology of Aging</i> , 2014, 35, 266.e5-266.e14.	1.5	36
3267	Do non-motor symptoms in Parkinson's disease differ from essential tremor before initial diagnosis? A clinical and scintigraphic study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 17-21.	1.1	21
3268	Clinical profiles of Parkinson's disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals. <i>Neurobiology of Aging</i> , 2014, 35, 725.e1-725.e6.	1.5	72
3269	Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 27-31.	1.1	73

#	ARTICLE	IF	CITATIONS
3270	Gait freezing and speech disturbance in Parkinson's disease. <i>Neurological Sciences</i> , 2014, 35, 357-363.	0.9	35
3271	A quantitative study of α -synuclein pathology in fifteen cases of dementia associated with Parkinson disease. <i>Journal of Neural Transmission</i> , 2014, 121, 171-181.	1.4	37
3272	Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience. <i>European Journal of Neurology</i> , 2014, 21, 312-318.	1.7	98
3273	Triple stimulation technique findings in vascular Parkinsonism and Parkinson's disease. <i>Clinical Neurophysiology</i> , 2014, 125, 1834-1839.	0.7	8
3274	Association between PITX3 promoter polymorphism and risk of Parkinson's disease: The impact of ethnicity and onset age. <i>Neuroscience Letters</i> , 2014, 561, 128-133.	1.0	6
3275	Substantia nigra in Parkinson's disease: a multimodal MRI comparison between early and advanced stages of the disease. <i>Neurological Sciences</i> , 2014, 35, 753-758.	0.9	50
3276	Clinical Features in Association with Neurodegenerative Diseases and Malignancies. <i>European Neurology</i> , 2014, 71, 99-105.	0.6	4
3277	Acoustic Investigation of Stress Patterns in Parkinson's Disease. <i>Journal of Voice</i> , 2014, 28, 129.e1-129.e8.	0.6	25
3278	White Matter Changes in Patients with Parkinson's Disease Carrying Small CGG Expansion FMR1 Alleles: A Pilot Study. <i>Neurodegenerative Diseases</i> , 2014, 14, 67-76.	0.8	9
3279	Novel, high-intensity exercise prescription improves muscle mass, mitochondrial function, and physical capacity in individuals with Parkinson's disease. <i>Journal of Applied Physiology</i> , 2014, 116, 582-592.	1.2	96
3280	Accumulation of α -synuclein in the bowel of patients in the pre-clinical phase of Parkinson's disease. <i>Acta Neuropathologica</i> , 2014, 127, 235-241.	3.9	272
3281	Depression and voice handicap in Parkinson disease. <i>Journal of the Neurological Sciences</i> , 2014, 346, 112-115.	0.3	22
3282	Correlation of impaired subjective visual vertical and postural instability in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2014, 346, 60-65.	0.3	24
3283	A historical review of classic articles in surgery field. <i>American Journal of Surgery</i> , 2014, 208, 841-849.	0.9	55
3284	Can dopamine agonists trigger tactile hallucinations in patients with Parkinson's disease?. <i>Journal of the Neurological Sciences</i> , 2014, 347, 361-363.	0.3	15
3285	Unbiased Approaches to Biomarker Discovery in Neurodegenerative Diseases. <i>Neuron</i> , 2014, 84, 594-607.	3.8	51
3286	Whole-Brain Proton MR Spectroscopic Imaging in Parkinson's Disease. <i>Journal of Neuroimaging</i> , 2014, 24, 39-44.	1.0	34
3287	Cerebellar Sensory Processing Alterations Impact Motor Cortical Plasticity in Parkinson's Disease: Clues from Dyskinetic Patients. <i>Cerebral Cortex</i> , 2014, 24, 2055-2067.	1.6	66

#	ARTICLE	IF	CITATIONS
3288	Parkinson's disease with a predominant right-sided putaminal FP-CIT SPECT deficiency shows stronger decline of asymmetry over time. <i>Basal Ganglia</i> , 2014, 4, 101-108.	0.3	1
3289	Do CSF levels of t-Tau, p-Tau and β -amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A 123I-FP-CIT study in the early stages of the disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2137-2143.	3.3	13
3290	Chemical exchange saturation transfer MR imaging of Parkinson's disease at 3 Tesla. <i>European Radiology</i> , 2014, 24, 2631-2639.	2.3	81
3291	Automatic Evaluation of Articulatory Disorders in Parkinson's Disease. <i>IEEE/ACM Transactions on Audio Speech and Language Processing</i> , 2014, 22, 1366-1378.	4.0	115
3292	Apathy in Parkinson disease. <i>Frontiers in Biology</i> , 2014, 9, 324-331.	0.7	7
3293	Glucocerebrosidase mutations in primary parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1215-1220.	1.1	63
3294	Later age at onset in Parkinson's disease over twenty years in an Italian tertiary clinic. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1181-1185.	1.1	3
3295	The Cognition and Emotional Well-being indices of the Parkinson's disease questionnaire-39: What do they really measure?. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1236-1241.	1.1	33
3296	Cortical volume and folding abnormalities in Parkinson's disease patients with pathological gambling. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1209-1214.	1.1	36
3297	Comparison of voluntary and reflex cough effectiveness in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1226-1230.	1.1	41
3298	Topographic pattern of cortical thinning with consideration of motor laterality in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1186-1190.	1.1	27
3299	Effects of cognitive training in Parkinson's disease: A randomized controlled trial. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1196-1202.	1.1	84
3300	Lifetime exposure to estrogens and Parkinson's disease in California teachers. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1149-1156.	1.1	52
3301	Exploring recollection and familiarity impairments in Parkinson's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2014, 36, 494-506.	0.8	7
3302	Rotigotine vs ropinirole in advanced stage Parkinson's disease: A double-blind study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1388-1393.	1.1	51
3303	Extra-nigral pathological conditions are common in Parkinson's disease with freezing of gait: An <i>in vivo</i> positron emission tomography study. <i>Movement Disorders</i> , 2014, 29, 1118-1124.	2.2	101
3304	Performance of Repetitive Alternating Elbow Movements in Parkinson's Disease. <i>European Neurology</i> , 2014, 71, 84-88.	0.6	2
3305	Diagnostic accuracy of Parkinson's disease and atypical parkinsonism in nursing homes. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1157-1160.	1.1	7

#	ARTICLE	IF	CITATIONS
3306	Comparison of two accelerometer filter settings in individuals with Parkinson's disease. <i>Physiological Measurement</i> , 2014, 35, 2287-2296.	1.2	32
3307	Nicotinic $\alpha 4 \beta 2$ acetylcholine receptors and cognitive function in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2014, 130, 164-171.	1.0	21
3308	Correlates of quality of sexual life in male and female patients with Parkinson disease and their partners. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1085-1088.	1.1	38
3309	Acute Changes in Mood Induced by Subthalamic Deep Brain Stimulation in Parkinson Disease Are Modulated by Psychiatric Diagnosis. <i>Brain Stimulation</i> , 2014, 7, 701-708.	0.7	21
3310	Dopamine-dependent functional connectivity in Parkinson disease. <i>Neurology</i> , 2014, 83, 202-203.	1.5	6
3311	In Vivo Detection of Monoaminergic Degeneration in Early Parkinson Disease by ¹⁸ F-Fluoropropyl-(+)-Dihydrotetrabenzazine PET. <i>Journal of Nuclear Medicine</i> , 2014, 55, 73-79.	2.8	48
3312	Glucocerebrosidase mutations in Thai patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 986-991.	1.1	35
3313	Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process. <i>Brain</i> , 2014, 137, 2356-2367.	3.7	119
3314	Neurodegenerative Disorders Increase Decline in Respiratory Muscle Strength in Older Adults. <i>Respiratory Care</i> , 2014, 59, 1838-1845.	0.8	21
3315	Automated gait and balance parameters diagnose and correlate with severity in Parkinson disease. <i>Journal of the Neurological Sciences</i> , 2014, 345, 131-138.	0.3	68
3316	Skin nerve α -synuclein deposits. <i>Neurology</i> , 2014, 82, 1362-1369.	1.5	247
3317	Focusing Brain Therapeutic Interventions in Space and Time for Parkinson's Disease. <i>Current Biology</i> , 2014, 24, R898-R909.	1.8	18
3318	The prevalence of Parkinson's disease: A systematic review and meta-analysis. <i>Movement Disorders</i> , 2014, 29, 1583-1590.	2.2	1,532
3319	Submandibular gland needle biopsy for the diagnosis of Parkinson disease. <i>Neurology</i> , 2014, 82, 858-864.	1.5	120
3320	Confirmation of the association between LRRK2 R1628P variant and susceptibility to Parkinson's disease in the Thai population. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1018-1021.	1.1	26
3321	Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: A placebo controlled study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1140-1144.	1.1	51
3322	Detection of Common Synaptic Inputs Shared by Populations of Motor Neurons Innervating Different Muscles: Methodology and Considerations for Neuroprosthetic Treatment of Tremor. <i>Biosystems and Biorobotics</i> , 2014, , 373-382.	0.2	0
3323	Neurovegetative Regulation of the Vascular System. , 2014, , 1-25.		0

#	ARTICLE	IF	CITATIONS
3324	Screening for dopa-responsive dystonia in patients with scans without evidence of dopaminergic deficiency (SWEDD). <i>Journal of Neurology</i> , 2014, 261, 2204-2208.	1.8	12
3325	Time up and go task performance improves after transcranial direct current stimulation in patient affected by Parkinson's disease. <i>Neuroscience Letters</i> , 2014, 580, 74-77.	1.0	55
3326	Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson's disease. <i>Journal of Neurology</i> , 2014, 261, 2112-2118.	1.8	37
3327	Flt3 ligand does not differentiate between Parkinsonian disorders. <i>Movement Disorders</i> , 2014, 29, 1319-1322.	2.2	9
3328	Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. <i>Brain</i> , 2014, 137, 2480-2492.	3.7	169
3329	Self-unawareness of levodopa induced dyskinesias in patients with Parkinson's disease. <i>Brain and Cognition</i> , 2014, 90, 135-141.	0.8	34
3330	A Test for Creutzfeldt-Jakob Disease Using Nasal Brushings. <i>New England Journal of Medicine</i> , 2014, 371, 519-529.	13.9	291
3331	Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: Cognitive and neurochemical correlates. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1076-1080.	1.1	60
3332	Structural and Functional Imaging in Parkinsonian Syndromes. <i>Radiographics</i> , 2014, 34, 1273-1292.	1.4	74
3333	Psychometric properties of the self-report version of the Quick Inventory of Depressive Symptoms (QIDS-SR16) questionnaire in patients with schizophrenia. <i>BMC Psychiatry</i> , 2014, 14, 247.	1.1	15
3334	Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease. <i>Neurology</i> , 2014, 82, 1514-1520.	1.5	67
3335	Reduced thalamic volume in Parkinson disease with REM sleep behavior disorder: Volumetric study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1004-1008.	1.1	54
3336	Low clinical diagnostic accuracy of early vs advanced Parkinson disease. <i>Neurology</i> , 2014, 83, 406-412.	1.5	395
3337	The relationship of leukoaraiosis and the clinical severity of vascular Parkinsonism. <i>Journal of the Neurological Sciences</i> , 2014, 346, 255-259.	0.3	17
3338	Retinal thinning and correlation with functional disability in patients with Parkinson's disease. <i>British Journal of Ophthalmology</i> , 2014, 98, 350-355.	2.1	103
3339	Accuracy of Parkinson disease diagnosis unchanged in 2 decades. <i>Neurology</i> , 2014, 83, 386-387.	1.5	32
3340	Short rapid steps to provoke freezing of gait in Parkinson's disease. <i>Journal of Neurology</i> , 2014, 261, 1763-1767.	1.8	26
3341	Sequential Voluntary Cough and Aspiration or Aspiration Risk in Parkinson's Disease. <i>Lung</i> , 2014, 192, 601-608.	1.4	70

#	ARTICLE	IF	CITATIONS
3342	Motivational modulation of bradykinesia in Parkinson's disease off and on dopaminergic medication. <i>Journal of Neurology</i> , 2014, 261, 1080-1089.	1.8	32
3343	Autonomic symptoms in idiopathic REM behavior disorder: a multicentre case-control study. <i>Journal of Neurology</i> , 2014, 261, 1112-1118.	1.8	90
3344	Variable phenotypic expression in families with early-onset Parkinsonism due to PRKN mutations. <i>Journal of Neurology</i> , 2014, 261, 1223-1226.	1.8	3
3345	Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study. <i>Journal of Neurology</i> , 2014, 261, 1575-1583.	1.8	37
3346	Effect of a single intrastriatal rotenone injection on oxidative stress and neurodegeneration in the rat brain. <i>Comparative Clinical Pathology</i> , 2014, 23, 1457-1467.	0.3	4
3347	Quantitative evaluation of electroconvulsive therapy for Parkinson's disease with refractory psychiatric symptoms. <i>Journal of Neural Transmission</i> , 2014, 121, 1405-1410.	1.4	25
3348	A Review of Lower Urinary Tract Symptoms in Patients with Parkinson's Disease. <i>Current Urology Reports</i> , 2014, 15, 435.	1.0	25
3349	Nizatidine ameliorates gastroparesis in Parkinson's disease: A pilot study. <i>Movement Disorders</i> , 2014, 29, 562-566.	2.2	17
3350	Attentional resource allocation and swallowing safety in Parkinson's disease: A dual task study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 439-443.	1.1	37
3351	Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 518-526.	2.2	112
3352	CSF α -synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 382-387.	1.1	68
3353	Potential of a new MRI for visualizing cerebellar involvement in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 157-161.	1.1	9
3354	Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 212-216.	1.1	37
3355	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 454-462.	2.2	379
3356	Factors associated with fall-related fractures in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 88-92.	1.1	40
3357	Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation. <i>Movement Disorders</i> , 2014, 29, 1057-1060.	2.2	27
3358	Dopaminergic modulation of resting-state functional connectivity in de novo patients with Parkinson's disease. <i>Human Brain Mapping</i> , 2014, 35, 5431-5441.	1.9	30
3359	Can dopamine transporter imaging define early PD?. <i>Nature Reviews Neurology</i> , 2014, 10, 432-433.	4.9	10

#	ARTICLE	IF	CITATIONS
3360	Sequence Variants in SLC6A3, DRD2, and BDNF Genes and Time to Levodopa-Induced Dyskinesias in Parkinson's Disease. <i>Journal of Molecular Neuroscience</i> , 2014, 53, 183-188.	1.1	67
3361	Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study. <i>BMC Neurology</i> , 2014, 14, 113.	0.8	68
3362	Protocol for a randomized comparison of integrated versus consecutive dual task practice in Parkinson's disease: the DUALITY trial. <i>BMC Neurology</i> , 2014, 14, 61.	0.8	29
3363	Psychometric study of the Persian short-form eight-item Parkinson's disease questionnaire (PDQ-8) to evaluate health related quality of life (HRQoL). <i>Health and Quality of Life Outcomes</i> , 2014, 12, 78.	1.0	20
3364	Robot-assisted arm training in patients with Parkinson's disease: a pilot study. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2014, 11, 28.	2.4	37
3365	123I-MIBG cardiac uptake, smell identification and 123I-FP-CIT SPECT in the differential diagnosis between vascular parkinsonism and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 192-197.	1.1	30
3366	Clinical features and neuropsychological profile in vascular parkinsonism. <i>Journal of the Neurological Sciences</i> , 2014, 345, 193-197.	0.3	15
3367	Cortico-striatal-thalamic network functional connectivity in hemiparkinsonism. <i>Neurobiology of Aging</i> , 2014, 35, 2592-2602.	1.5	77
3368	An association analysis of the rs1572931 polymorphism of the <i>RAB7L1</i> gene in Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy in China. <i>European Journal of Neurology</i> , 2014, 21, 1337-1343.	1.7	21
3369	Randomized cross-over trial to investigate the efficacy of a two-week physiotherapy programme with repetitive exercises of cueing to reduce the severity of freezing of gait in patients with Parkinson's disease. <i>Clinical Rehabilitation</i> , 2014, 28, 902-911.	1.0	49
3370	Freezing of gait in Chinese patients with Parkinson Disease. <i>Journal of the Neurological Sciences</i> , 2014, 345, 56-60.	0.3	25
3371	Prevalence of fatigue in Parkinson disease and its clinical correlates. <i>Neurology</i> , 2014, 83, 215-220.	1.5	98
3372	A New Assessment Tool for Parkinson Disease. <i>Journal of Ultrasound in Medicine</i> , 2014, 33, 1635-1640.	0.8	9
3373	Transcranial Sonography and 123I-FP-CIT Single Photon Emission Computed Tomography in Movement Disorders. <i>Ultrasound in Medicine and Biology</i> , 2014, 40, 2365-2371.	0.7	18
3374	The impact of age and disease duration on the long term outcome of neurostimulation of the subthalamic nucleus. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 47-52.	1.1	33
3375	CHRN3 c.-57A>G functional promoter change affects Parkinson's disease and smoking. <i>Neurobiology of Aging</i> , 2014, 35, 2179.e1-2179.e6.	1.5	10
3376	[¹²³ I]-FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson's disease and vascular or drug-induced parkinsonisms: a meta-analysis. <i>European Journal of Neurology</i> , 2014, 21, 1369.	1.7	63
3377	High beta activity in the subthalamic nucleus and freezing of gait in Parkinson's disease. <i>Neurobiology of Disease</i> , 2014, 64, 60-65.	2.1	113

#	ARTICLE	IF	CITATIONS
3378	Low-frequency repetitive transcranial magnetic stimulation for dyskinesia and motor performance in Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1373-1376.	0.8	30
3379	Gender differences in non-motor symptoms in early Parkinson's disease: A 2-years follow-up study on previously untreated patients. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 850-854.	1.1	60
3380	Quantification of α -synuclein in cerebrospinal fluid: How ideal is this biomarker for Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , 2014, 20, S76-S79.	1.1	36
3381	Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 755-760.	1.1	121
3382	Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 142-148.	1.1	76
3383	Evaluation of a screening questionnaire for Parkinson's disease in a Chinese population. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 278-281.	0.8	6
3384	Determining the Association of the 5HTTLPR Polymorphism with Delusions and Hallucinations in Lewy Body Dementias. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 580-586.	0.6	19
3385	Hypomethylation of SNCA in blood of patients with sporadic Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2014, 337, 123-128.	0.3	90
3386	A Neurodegenerative Disease Sleep Questionnaire: Principal component analysis in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2014, 336, 243-246.	0.3	12
3387	Efficacy of occupational therapy for patients with Parkinson's disease: a randomised controlled trial. <i>Lancet Neurology</i> , The, 2014, 13, 557-566.	4.9	177
3388	Clinical characteristics of Parkinson's disease patients in Greece: A multicenter, nation-wide, cross-sectional study. <i>Journal of the Neurological Sciences</i> , 2014, 343, 36-40.	0.3	12
3389	Comparison of 99mTc-TRODAT-1 SPECT and 18 F-AV-133 PET imaging in healthy controls and Parkinson's disease patients. <i>Nuclear Medicine and Biology</i> , 2014, 41, 322-329.	0.3	20
3390	Reduced functional connectivity in early-stage drug-naive Parkinson's disease: a resting-state fMRI study. <i>Neurobiology of Aging</i> , 2014, 35, 431-441.	1.5	145
3391	Microsubthalamotomy improves sleep in patients affected by advanced Parkinson's disease. <i>Sleep Medicine</i> , 2014, 15, 637-641.	0.8	18
3392	Vitamin D receptor genetic variants and Parkinson's disease in a Taiwanese population. <i>Neurobiology of Aging</i> , 2014, 35, 1212.e11-1212.e13.	1.5	31
3393	Forehead sympathetic skin responses in determining autonomic involvement in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2014, 125, 2436-2440.	0.7	11
3394	Brain activity during complex imagined gait tasks in Parkinson disease. <i>Clinical Neurophysiology</i> , 2014, 125, 995-1005.	0.7	57
3395	Decision-making under risk is improved by both dopaminergic medication and subthalamic stimulation in Parkinson's disease. <i>Experimental Neurology</i> , 2014, 254, 70-77.	2.0	37

#	ARTICLE	IF	CITATIONS
3396	Imaging of olfactory bulb and gray matter volumes in brain areas associated with olfactory function in patients with Parkinson's disease and multiple system atrophy. <i>European Journal of Radiology</i> , 2014, 83, 564-570.	1.2	55
3397	Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients?. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 772-775.	1.1	32
3398	Rapid eye movement sleep behaviour disorder in young- and older-onset Parkinson disease: a questionnaire-based study. <i>Sleep Medicine</i> , 2014, 15, 642-646.	0.8	25
3400	Primary vision and facial emotion recognition in early Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2014, 338, 178-182.	0.3	48
3401	Structural brain plasticity in Parkinson's disease induced by balance training. <i>Neurobiology of Aging</i> , 2014, 35, 232-239.	1.5	135
3402	Effect of Partial Weight-Supported Treadmill Gait Training on Balance in Patients With Parkinson Disease. <i>PM and R</i> , 2014, 6, 22-33.	0.9	58
3403	Psychiatric diseases predated the occurrence of Parkinson disease: a retrospective cohort study. <i>Annals of Epidemiology</i> , 2014, 24, 206-213.	0.9	30
3404	C9orf72 repeat expansions are restricted to the ALS-FTD spectrum. <i>Neurobiology of Aging</i> , 2014, 35, 936.e13-936.e17.	1.5	28
3405	Pyrosequencing analysis of SNCA methylation levels in leukocytes from Parkinson's disease patients. <i>Neuroscience Letters</i> , 2014, 569, 85-88.	1.0	44
3406	Absence of <i>C9ORF72</i> expanded or intermediate repeats in autopsy-confirmed Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 827-830.	2.2	24
3407	Photoreceptor layer thinning in idiopathic Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1163-1170.	2.2	84
3408	Cutaneous neuropathy in Parkinson's disease: a window into brain pathology. <i>Acta Neuropathologica</i> , 2014, 128, 99-109.	3.9	203
3409	Extrastriatal dopaminergic changes in Parkinson's disease patients with impulse control disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 23-30.	0.9	42
3410	Problematic Internet use in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 482-487.	1.1	13
3411	Additional weight load increases freezing of gait episodes in Parkinson's disease; an experimental study. <i>Journal of Neurology</i> , 2014, 261, 999-1008.	1.8	13
3412	Enhanced creative thinking under dopaminergic therapy in Parkinson disease. <i>Annals of Neurology</i> , 2014, 75, 935-942.	2.8	57
3413	Characteristics of non-motor symptoms in patients with Parkinson's disease exhibiting camptocormia. <i>Gait and Posture</i> , 2014, 40, 447-450.	0.6	14
3414	Postprandial hypotension in de novo Parkinson's disease: A comparison with orthostatic hypotension. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 573-577.	1.1	18

#	ARTICLE	IF	CITATIONS
3415	Sudden death in Parkinson's disease: A retrospective autopsy study. <i>Journal of the Neurological Sciences</i> , 2014, 343, 149-152.	0.3	39
3416	Tau protein, beta-amyloid1 β 42 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia. <i>Journal of the Neurological Sciences</i> , 2014, 343, 120-124.	0.3	58
3417	A retrospective study of the clinical and electrophysiological characteristics of 32 patients with orthostatic myoclonus. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 889-893.	1.1	33
3418	Circumstances of falls and fall-related injuries among patients with Parkinson's disease in an outpatient setting. <i>Geriatric Nursing</i> , 2014, 35, 364-369.	0.9	42
3419	Cerebral microbleeds in patients with Parkinson's disease. <i>Journal of Neurology</i> , 2014, 261, 1628-1635.	1.8	51
3420	Determinants of Objectively Measured Physical Functional Performance in Early to Mid-stage Parkinson Disease. <i>PM and R</i> , 2014, 6, 992-998.	0.9	21
3421	Variant R244H in Na ⁺ /Mg ²⁺ exchanger SLC41A1 in Taiwanese Parkinson's disease is associated with loss of Mg ²⁺ efflux function. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 600-603.	1.1	14
3422	The nuclear accumulation of alpha-synuclein is mediated by importin alpha and promotes neurotoxicity by accelerating the cell cycle. <i>Neuropharmacology</i> , 2014, 82, 132-142.	2.0	54
3423	Swallowing impairment and pulmonary dysfunction in Parkinson's disease: The silent threats. <i>Journal of the Neurological Sciences</i> , 2014, 339, 149-152.	0.3	58
3424	Clinical manifestations of Parkinson disease and the onset of rapid eye movement sleep behavior disorder. <i>Sleep Medicine</i> , 2014, 15, 647-653.	0.8	62
3425	Biased binomial assessment of cross-validated estimation of classification accuracies illustrated in diagnosis predictions. <i>NeuroImage: Clinical</i> , 2014, 4, 687-694.	1.4	112
3426	Transcallosal diffusion tensor abnormalities in predominant gait disorder parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 53-59.	1.1	46
3427	Brain Iron Homeostasis: From Molecular Mechanisms To Clinical Significance and Therapeutic Opportunities. <i>Antioxidants and Redox Signaling</i> , 2014, 20, 1324-1363.	2.5	165
3428	Parkinson's Disease and the Cardio-ankle Vascular Stiffness Index. <i>Internal Medicine</i> , 2014, 53, 421-426.	0.3	5
3429	Neuropathology of Parkinsonism in Patients with Pure Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 115-120.	1.2	38
3430	MRI Can Detect Nigral Volume Loss in Patients with Parkinson's Disease: Evidence from a Meta-Analysis. <i>Journal of Parkinson's Disease</i> , 2014, 4, 405-411.	1.5	11
3431	Prevalence of Malnutrition in Patients with Parkinson's Disease: A Comparative Study with Healthy Controls using Mini Nutritional Assessment (MNA) Questionnaire. <i>Journal of Parkinson's Disease</i> , 2014, 4, 473-481.	1.5	21
3432	The "Swallow Tail" Appearance of the Healthy Nigrosome - A New Accurate Test of Parkinson's Disease: A Case-Control and Retrospective Cross-Sectional MRI Study at 3T. <i>PLoS ONE</i> , 2014, 9, e93814.	1.1	252

#	ARTICLE	IF	CITATIONS
3433	Cognitive Status Correlates with CXCL10/IP-10 Levels in Parkinson's Disease. <i>Parkinson's Disease</i> , 2014, 2014, 1-7.	0.6	28
3434	Idiopathic Parkinsonism: The Role of Flunarizine and Cinnarizine. <i>Journal of Parkinson's Disease</i> , 2014, 4, 645-649.	1.5	10
3435	Cardiac 123I-MIBG uptake in de novo Brazilian patients with Parkinson's disease without clinically defined dysautonomia. <i>Arquivos De Neuro-Psiquiatria</i> , 2014, 72, 430-434.	0.3	5
3436	Prevalence of wearing-off and dyskinesia among the patients with Parkinson's disease on levodopa therapy: a multi-center registry survey in mainland China. <i>Translational Neurodegeneration</i> , 2014, 3, 26.	3.6	37
3437	T313M polymorphism of the PINK1 gene in Parkinson's disease. <i>Experimental and Therapeutic Medicine</i> , 2014, 8, 286-290.	0.8	2
3438	Visuomotor adaptation in Parkinson's disease: effects of perturbation type and medication state. <i>Journal of Neurophysiology</i> , 2014, 111, 2675-2687.	0.9	14
3440	Longitudinal Assessment of the Pattern of Cognitive Decline in Non-Demented Patients with Advanced Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2014, 4, 677-686.	1.5	32
3441	Instrumental activities of daily living are impaired in Parkinson's disease patients with mild cognitive impairment. <i>Neuropsychology</i> , 2014, 28, 229-237.	1.0	75
3442	A Novel 6-Item Screening Questionnaire for Parkinsonism: Validation and Comparison Between Different Instruments. <i>Neuroepidemiology</i> , 2014, 43, 178-193.	1.1	14
3443	Dopaminergic therapy affects learning and impulsivity in Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 833-843.	1.7	19
3444	Power spectra for screening parkinsonian patients for mild cognitive impairment. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 884-890.	1.7	28
3445	Newer Dopaminergic Agents Cause Minimal Endocrine Effects in Idiopathic Parkinson's Disease. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2014, 7, CMED.S14902.	1.0	4
3446	Diagnostic Thresholds for Quantitative REM Sleep Phasic Burst Duration, Phasic and Tonic Muscle Activity, and REM Atonia Index in REM Sleep Behavior Disorder with and without Comorbid Obstructive Sleep Apnea. <i>Sleep</i> , 2014, 37, 1649-1662.	0.6	105
3447	A Smart Tool for the Diagnosis of Parkinsonian Syndromes using Wireless Watches. <i>Smart Science</i> , 2014, 2, 178-184.	1.9	0
3448	Cortical gyrification reductions and subcortical atrophy in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 122-126.	2.2	44
3449	Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S Parkinsonism. <i>Movement Disorders</i> , 2014, 29, 1684-1687.	2.2	20
3450	Frequency-dependent neural activity in Parkinson's disease. <i>Human Brain Mapping</i> , 2014, 35, 5815-5833.	1.9	68
3451	Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder. <i>Movement Disorders</i> , 2014, 29, 1774-1780.	2.2	74

#	ARTICLE	IF	CITATIONS
3452	Sagittal Spinopelvic Malalignment in Parkinson Disease. <i>Spine</i> , 2014, 39, E833-E841.	1.0	37
3453	Combined DaT imaging and olfactory testing for differentiating parkinsonian disorders. <i>International Journal of Clinical Practice</i> , 2014, 68, 1345-1351.	0.8	12
3454	Therapies under investigation for treating Parkinson's disease psychosis. <i>Clinical Investigation</i> , 2014, 4, 889-901.	0.0	2
3455	Postural adaptation to a slow sensorimotor set-changing task in Parkinson's disease1. <i>Comprehensive Psychology</i> , 2014, 3, Article 9.	0.3	4
3456	Retinal nerve fiber layer thickness and visual hallucinations in Parkinson's Disease. <i>Movement Disorders</i> , 2014, 29, 61-67.	2.2	103
3457	Clinical experience in the Hospital Central Militar with bilateral deep brain stimulation of ventro-medial globus pallidus in patients with Parkinson's disease. <i>Revista Médica Del Hospital General De México</i> , 2014, 77, 190-194.	0.0	0
3458	Decreased Cough Sensitivity and Aspiration in Parkinson Disease. <i>Chest</i> , 2014, 146, 1294-1299.	0.4	102
3459	Non-motor symptoms: the core of multi-morbid Parkinson's disease. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2014, 75, 18-24.	0.2	38
3460	Levels of functional disability in elderly people in Tanzania with dementia, stroke and Parkinson's disease. <i>Acta Neuropsychiatrica</i> , 2015, 27, 206-212.	1.0	17
3461	Dilated Virchow-Robin Space and Dopamine Transporter Imaging in the Striatum of Patients with Parkinsonism. <i>Canadian Journal of Neurological Sciences</i> , 2015, 42, 248-254.	0.3	12
3462	Increased Risk of Parkinson Disease in Patients With Carbon Monoxide Intoxication. <i>Medicine (United States)</i> , 2015, 94, 100-104.	0.4	21
3463	Intertemporal choice in Parkinson's disease and restless legs syndrome. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1330-1335.	1.1	26
3464	Platelet mitochondrial membrane potential in Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 67-73.	1.7	12
3465	Intraventricular cerebrospinal fluid temperature analysis using MR diffusion-weighted imaging thermometry in Parkinson's disease patients, multiple system atrophy patients, and healthy subjects. <i>Brain and Behavior</i> , 2015, 5, e00340.	1.0	21
3466	Delineating nonmotor symptoms in early Parkinson's disease and first-degree relatives. <i>Movement Disorders</i> , 2015, 30, 1759-1766.	2.2	54
3467	Exercise improves cognition in Parkinson's disease: The PRET-PD randomized, clinical trial. <i>Movement Disorders</i> , 2015, 30, 1657-1663.	2.2	143
3468	Non-motor symptoms burden in treated and untreated early Parkinson's disease patients: argument for non-motor subtypes. <i>European Journal of Neurology</i> , 2015, 22, 1145-1150.	1.7	64
3469	Parkinson's is complex: considering earlier use of advanced, non-oral therapies. <i>British Journal of Neuroscience Nursing</i> , 2015, 11, 92-97.	0.1	2

#	ARTICLE	IF	CITATIONS
3470	Kinematic analysis of arm and trunk movements in the gait of Parkinson's disease patients based on external signals. <i>Journal of Physical Therapy Science</i> , 2015, 27, 3783-3786.	0.2	6
3471	Cognitive training interventions for dementia and mild cognitive impairment in Parkinson's Disease. <i>The Cochrane Library</i> , 0, , .	1.5	7
3472	Why do patients with Parkinson's disease fall? A cross-sectional analysis of possible causes of falls. <i>Npj Parkinson's Disease</i> , 2015, 1, 15011.	2.5	44
3473	Perceived changes to swallowing in people with Parkinson's disease. <i>International Journal of Therapy and Rehabilitation</i> , 2015, 22, 573-581.	0.1	5
3474	Latent growth-curve analysis reveals that worsening Parkinson's disease quality of life is driven by depression.. <i>Neuropsychology</i> , 2015, 29, 603-609.	1.0	17
3475	Betting on DBS: Effects of subthalamic nucleus deep brain stimulation on risk taking and decision making in patients with Parkinson's disease.. <i>Neuropsychology</i> , 2015, 29, 622-631.	1.0	24
3476	Procedural Learning of Semantic Categorization in Parkinson's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 205-216.	1.2	6
3477	Dopaminergic Modulation of Arm Swing During Gait Among Parkinson's Disease Patients. <i>Journal of Parkinson's Disease</i> , 2015, 5, 141-150.	1.5	41
3478	Immediate effects of adding mental practice to physical practice on the gait of individuals with Parkinson's disease: Randomized clinical trial. <i>NeuroRehabilitation</i> , 2015, 37, 263-271.	0.5	17
3479	Aripiprazole Can Improve Apraxia of Eyelid Opening in Parkinson's Disease. <i>Internal Medicine</i> , 2015, 54, 3061-3064.	0.3	10
3480	Neuroleptic parkinsonism. , 0, , 53-60.		0
3481	Speech Prosody Across Stimulus Types for Individuals with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 291-299.	1.5	15
3482	Elevated Plasma Angiogenesis Factors in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 245-252.	1.2	22
3483	MAPT H1 Haplotype is Associated with Late-Onset Alzheimer's Disease Risk in APOE ε4 Noncarriers: Results from the Dementia Genetics Spanish Consortium. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 343-352.	1.2	32
3484	Association of ARNTL and PER1 genes with Parkinson's disease: a case-control study of Han Chinese. <i>Scientific Reports</i> , 2015, 5, 15891.	1.6	76
3485	Disability is an Independent Predictor of Falls and Recurrent Falls in People with Parkinson's Disease Without a History of Falls: A One-Year Prospective Study. <i>Journal of Parkinson's Disease</i> , 2015, 5, 855-864.	1.5	30
3486	Intensive cycle ergometer training improves gait speed and endurance in patients with Parkinson's disease: A comparison with treadmill training. <i>Restorative Neurology and Neuroscience</i> , 2015, 34, 125-138.	0.4	21
3487	Non-Motor Correlates of Smoking Habits in Novo Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 913-924.	1.5	10

#	ARTICLE	IF	CITATIONS
3488	Narrative Discourse Cohesion in Early Stage Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 403-411.	1.5	15
3489	Memory for gist and detail information in patients with Parkinson's disease. <i>BMJ Open</i> , 2015, 5, e009795.	0.8	19
3490	Audiovisual Processing is Abnormal in Parkinson's Disease and Correlates with Freezing of Gait and Disease Duration. <i>Journal of Parkinson's Disease</i> , 2015, 5, 925-936.	1.5	15
3491	Common genetic variant association with altered HLA expression, synergy with pyrethroid exposure, and risk for Parkinson's disease: an observational and case-control study. <i>Npj Parkinson's Disease</i> , 2015, 1, .	2.5	108
3492	The value of brain perfusion SPECT for differentiation between mildly symptomatic idiopathic Parkinson's disease and the Parkinson variant of multiple system atrophy. <i>Nuclear Medicine Communications</i> , 2015, 36, 1049-1054.	0.5	11
3493	The Unique and Combined Effects of Apathy and Depression on Cognition in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 351-359.	1.5	16
3494	Physical Activity in Advanced Parkinson's Disease: Impact of Subthalamic Deep Brain Stimulation. <i>Journal of Parkinson's Disease</i> , 2015, 5, 85-93.	1.5	3
3495	Quantitative Analysis Versus Visual Assessment of Neuromelanin MR Imaging for the Diagnosis of Parkinson's disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 561-567.	1.5	13
3496	The Utility of Segmental Analysis in Cardiac I-123 MIBG SPECT in Parkinson's Disease. <i>Nuclear Medicine and Molecular Imaging</i> , 2015, 49, 298-302.	0.6	5
3497	Interaction between SNCA, LRRK2 and GAK increases susceptibility to Parkinson's disease in a Chinese population. <i>ENeurologicalSci</i> , 2015, 1, 3-6.	0.5	9
3498	Festination in Chinese patients with Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2015, 139, 172-176.	0.6	3
3499	High rates of parkinsonism in adults with autism. <i>Journal of Neurodevelopmental Disorders</i> , 2015, 7, 29.	1.5	63
3500	Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping. <i>Human Brain Mapping</i> , 2015, 36, 4407-4420.	1.9	181
3501	Impact of Parkinson's disease risk loci on age at onset. <i>Movement Disorders</i> , 2015, 30, 847-850.	2.2	38
3502	Default mode network links to visual hallucinations: A comparison between Parkinson's disease and multiple system atrophy. <i>Movement Disorders</i> , 2015, 30, 1237-1247.	2.2	70
3503	Distinctive distribution of phospho-alpha-synuclein in dermal nerves in multiple system atrophy. <i>Movement Disorders</i> , 2015, 30, 1688-1692.	2.2	91
3504	Appendectomy may delay Parkinson's disease Onset. <i>Movement Disorders</i> , 2015, 30, 1404-1407.	2.2	46
3505	Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1825-1830.	2.2	34

#	ARTICLE	IF	CITATIONS
3506	Spike shape analysis of electromyography for parkinsonian tremor evaluation. <i>Muscle and Nerve</i> , 2015, 52, 1096-1098.	1.0	5
3507	Different Patterns of Spontaneous Brain Activity between Tremorâ€Dominant and Postural Instability/Gait Difficulty Subtypes of Parkinson's Disease: A Restingâ€State <sc>fMRI</sc> Study. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 855-866.	1.9	52
3508	Relationship between apathy and cognitive dysfunctions in <i>de novo</i> untreated <sc>P</sc>arkinson's disease: a prospective longitudinal study. <i>European Journal of Neurology</i> , 2015, 22, 253-260.	1.7	58
3509	Association between vestibulo-ocular reflex suppression, balance, gait, and fall risk in ageing and neurodegenerative disease: protocol of a one-year prospective follow-up study. <i>BMC Neurology</i> , 2015, 15, 192.	0.8	15
3510	Do cognitive measures and brain circuitry predict outcomes of exercise in Parkinson Disease: a randomized clinical trial. <i>BMC Neurology</i> , 2015, 15, 218.	0.8	25
3511	Temporal fluctuations of tremor signals from inertial sensor: a preliminary study in differentiating Parkinsonâ€™s disease from essential tremor. <i>BioMedical Engineering OnLine</i> , 2015, 14, 101.	1.3	29
3512	BEWARE: Body awareness training in the treatment of wearing-off related anxiety in patients with Parkinsonâ€™s disease: study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 283.	0.7	7
3513	Individual time course of pre- and postsynaptic PET imaging may improve differential diagnosis of Parkinsonâ€™s disease and multiple system atrophy: a case report. <i>BMC Research Notes</i> , 2015, 8, 496.	0.6	2
3514	Brain structural and functional connectivity in <sc>P</sc>arkinson's disease with freezing of gait. <i>Human Brain Mapping</i> , 2015, 36, 5064-5078.	1.9	154
3515	Serum Ferritin Levels in Parkinson's Disease Patients with and without Restless Legs Syndrome. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 249-252.	0.8	8
3516	Ultrasoundâ€based motion analysis demonstrates bilateral arm hypokinesia during gait in heterozygous PINK1 mutation carriers. <i>Movement Disorders</i> , 2015, 30, 386-392.	2.2	16
3517	King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation. <i>Movement Disorders</i> , 2015, 30, 1623-1631.	2.2	189
3518	Longitudinal study of the substantia nigra in Parkinson disease: A highâ€field ¹Hâ€MR spectroscopy imaging study. <i>Movement Disorders</i> , 2015, 30, 1400-1404.	2.2	24
3519	Levodopa Does Not Worsen Gastric Emptying in Parkinson's Disease. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 2185-2186.	1.3	10
3520	Transdermal Dopamine Agonist Ameliorates Gastric Emptying in Parkinson's Disease. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 2416-2418.	1.3	6
3521	Sleepiness in Idiopathic REM Sleep Behavior Disorder and Parkinson Disease. <i>Sleep</i> , 2015, 38, 1529-1535.	0.6	76
3522	Antidepressants Increase REM Sleep Muscle Tone in Patients with and without REM Sleep Behavior Disorder. <i>Sleep</i> , 2015, 38, 907-17.	0.6	86
3523	The Rationale for Exercise in the Management of Pain in Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 229-239.	1.5	47

#	ARTICLE	IF	CITATIONS
3542	Olfactory identification deficits and increased mortality in the community. <i>Annals of Neurology</i> , 2015, 78, 401-411.	2.8	107
3543	Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early-stage Parkinson's disease. <i>Annals of Neurology</i> , 2015, 78, 1000-1004.	2.8	106
3544	Dopaminergic correlates of metabolic network activity in Parkinson's disease. <i>Human Brain Mapping</i> , 2015, 36, 3575-3585.	1.9	71
3545	Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 945-952.	2.2	138
3546	Economic evaluation of occupational therapy in Parkinson's disease: A randomized controlled trial. <i>Movement Disorders</i> , 2015, 30, 1059-1067.	2.2	30
3547	Educational attainment and motor burden in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1143-1147.	2.2	32
3548	Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients. <i>Movement Disorders</i> , 2015, 30, 1648-1656.	2.2	66
3549	Colonic bacterial composition in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1351-1360.	2.2	932
3550	Progressive retinal structure abnormalities in multiple system atrophy. <i>Movement Disorders</i> , 2015, 30, 1944-1953.	2.2	34
3551	DNAJC13 p.Asn855Ser mutation screening in Parkinson's disease and pathologically confirmed Lewy body disease patients. <i>European Journal of Neurology</i> , 2015, 22, 1323-1325.	1.7	21
3552	Markers of Parkinson's Disease Progression Using Cerebrovascular, Autonomic and Small Fiber Polyneuropathy Features. <i>Journal of Neurological Disorders</i> , 2015, 03, .	0.1	0
3553	Load-Dependent Interference of Deep Brain Stimulation of the Subthalamic Nucleus with Switching from Automatic to Controlled Processing During Random Number Generation in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 321-331.	1.5	9
3554	Movement Smoothness Differentiates Voluntary from Parkinsonian Bradykinesia. <i>Journal of Addiction Research & Therapy</i> , 2015, 07, .	0.2	2
3555	Utility of the Midbrain Tegmentum Diameter in the Differential Diagnosis of Progressive Supranuclear		

#	ARTICLE	IF	CITATIONS
3560	Wearing-off in Parkinson's disease: neuropsychological differences between on and off periods. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 1175.	1.0	15
3561	Diagnosis of Parkinson's disease: progress and future prospects. <i>Journal of Parkinsonism and Restless Legs Syndrome</i> , 0, , 19.	0.8	3
3562	Restless legs syndrome: associated non-motor symptoms and medical comorbidities: a controlled study. <i>Journal of Parkinsonism and Restless Legs Syndrome</i> , 2015, , 33.	0.8	1
3563	The resurgence of neurotransmitter modulation in Parkinson's disease with safinamide. <i>Journal of Parkinsonism and Restless Legs Syndrome</i> , 2015, , 11.	0.8	2
3564	Clinical Implication of High Sensitivity C-Reactive Protein for the Development of Dementia in Parkinson's Disease. <i>Dementia and Neurocognitive Disorders</i> , 2015, 14, 123.	0.4	0
3565	The behavior of migraine in patients with Parkinson's disease. <i>Neurology International</i> , 2015, 7, 6133.	1.3	4
3566	Change in Motor and Nonmotor Symptoms Severity in a "Real-Life" Cohort of Subjects with Parkinson's Disease. <i>Neuroscience Journal</i> , 2015, 2015, 1-5.	2.3	0
3567	Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials. <i>Journal of Parkinson's Disease</i> , 2015, 5, 837-845.	1.5	22
3568	Dopamine Agonists Exert Nurr1-inducing Effect in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease. <i>Chinese Medical Journal</i> , 2015, 128, 1755-1760.	0.9	14
3569	The Natural Progression of Parkinson's Disease in a Small Cohort with 15 Drug-naïve Patients. <i>Chinese Medical Journal</i> , 2015, 128, 1761-1764.	0.9	5
3570	Lower Bone Mineral Density in Patients with Parkinson's Disease: A Cross-Sectional Study from Chinese Mainland. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 203.	1.7	24
3571	Automatic Evaluation of Speech Rhythm Instability and Acceleration in Dysarthrias Associated with Basal Ganglia Dysfunction. <i>Frontiers in Bioengineering and Biotechnology</i> , 2015, 3, 104.	2.0	31
3572	Chemical Exchange Saturation Transfer MR Imaging is Superior to Diffusion-Tensor Imaging in the Diagnosis and Severity Evaluation of Parkinson's Disease: A Study on Substantia Nigra and Striatum. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 198.	1.7	21
3573	Differential Effects of Tango Versus Dance for PD in Parkinson Disease. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 239.	1.7	43
3574	Alterations in neuronal activity in basal ganglia-thalamocortical circuits in the parkinsonian state. <i>Frontiers in Neuroanatomy</i> , 2015, 9, 5.	0.9	153
3575	Brain-derived neurotrophic factor serum levels correlate with cognitive performance in Parkinson's disease patients with mild cognitive impairment. <i>Frontiers in Behavioral Neuroscience</i> , 2015, 9, 253.	1.0	55
3576	Contra-Directional Expression of Serum Homocysteine and Uric Acid as Important Biomarkers of Multiple System Atrophy Severity: A Cross-Sectional Study. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 247.	1.8	38
3577	End of OSLE Test Sessions in Parkinson's Disease do not Correspond to True Sleep Onset: Results from an Exploratory Study. <i>Frontiers in Neurology</i> , 2015, 6, 200.	1.1	2

#	ARTICLE	IF	CITATIONS
3578	Retrospective Evaluation of Deep Transcranial Magnetic Stimulation as Add-On Treatment for Parkinson's Disease. <i>Frontiers in Neurology</i> , 2015, 6, 210.	1.1	23
3579	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2015, 6, 216.	1.1	36
3580	Gestures make memories, but what kind? Patients with impaired procedural memory display disruptions in gesture production and comprehension. <i>Frontiers in Human Neuroscience</i> , 2014, 8, 1054.	1.0	18
3581	A pilot study on the effect of cognitive training on BDNF serum levels in individuals with Parkinson's disease. <i>Frontiers in Human Neuroscience</i> , 2015, 9, 130.	1.0	72
3582	Time-based prospective memory functioning in mild cognitive impairment associated with Parkinson's disease: relationship with autonomous management of daily living commitments. <i>Frontiers in Human Neuroscience</i> , 2015, 9, 333.	1.0	12
3583	Alteration of Basal Ganglia and Right Frontoparietal Network in Early Drug-Naïve Parkinson's Disease during Heat Pain Stimuli and Resting State. <i>Frontiers in Human Neuroscience</i> , 2015, 9, 467.	1.0	24
3584	Abnormal lipopolysaccharide binding protein as marker of gastrointestinal inflammation in Parkinson disease. <i>Frontiers in Neuroscience</i> , 2015, 9, 306.	1.4	52
3585	Mortality in Iranian Patients with Parkinson's Disease: Cumulative Impact of Cardiovascular Comorbidities as One Major Risk Factor. <i>Parkinson's Disease</i> , 2015, 2015, 1-6.	0.6	2
3586	Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. <i>Oncotarget</i> , 2015, 6, 37043-37053.	0.8	449
3587	Do physical exercise and reading reduce the risk of Parkinson's disease? a cross-sectional study on factors associated with Parkinson's disease in elderly Chinese veterans. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 695.	1.0	8
3588	The impact of nocturnal disturbances on daily quality of life in patients with Parkinson's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 2005.	1.0	15
3589	The Effects of Two Polymorphisms on p21cip1 Function and Their Association with Alzheimer's Disease in a Population of European Descent. <i>PLoS ONE</i> , 2015, 10, e0114050.	1.1	16
3590	Heterogeneous Determinants of Quality of Life in Different Phenotypes of Parkinson's Disease. <i>PLoS ONE</i> , 2015, 10, e0137081.	1.1	27
3591	Emotion Processing in Parkinson's Disease: A Three-Level Study on Recognition, Representation, and Regulation. <i>PLoS ONE</i> , 2015, 10, e0131470.	1.1	67
3592	Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinson's Disease. <i>PLoS ONE</i> , 2015, 10, e0132227.	1.1	55
3593	Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0132368.	1.1	67
3594	Patterns of Neuropsychological Profile and Cortical Thinning in Parkinson's Disease with Punding. <i>PLoS ONE</i> , 2015, 10, e0134468.	1.1	20
3595	The Pathogenic Role of Low Range Repeats in SCA17. <i>PLoS ONE</i> , 2015, 10, e0135275.	1.1	23

#	ARTICLE	IF	CITATIONS
3596	Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease. PLoS ONE, 2015, 10, e0138462.	1.1	7
3597	Investigation on Abnormal Iron Metabolism and Related Inflammation in Parkinson Disease Patients with Probable RBD. PLoS ONE, 2015, 10, e0138997.	1.1	31
3598	Reduced Verbal Fluency following Subthalamic Deep Brain Stimulation: A Frontal-Related Cognitive Deficit?. PLoS ONE, 2015, 10, e0140083.	1.1	20
3599	Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis. PLoS ONE, 2015, 10, e0145310.	1.1	35
3600	Challenging Postural Tasks Increase Asymmetry in Patients with Parkinson's Disease. PLoS ONE, 2015, 10, e0137722.	1.1	33
3601	Dopaminergic modulation of positive expectations for goal-directed action: evidence from Parkinson's disease. Frontiers in Psychology, 2015, 6, 1514.	1.1	14
3602	Clinical predictors of cognitive impairment and psychiatric complications in Parkinson's disease. Arquivos De Neuro-Psiquiatria, 2015, 73, 390-395.	0.3	10
3603	Balance Dysfunction in Parkinson's Disease: The Role of Posturography in Developing a Rehabilitation Program. Parkinson's Disease, 2015, 2015, 1-10.	0.6	27
3604	Freezing of Gait and its Associations in the Early and Advanced Clinical Motor Stages of Parkinson's Disease: A Cross-Sectional Study. Journal of Parkinson's Disease, 2015, 5, 881-891.	1.5	24
3605	Dopaminergic Modulation of Medial Prefrontal Cortex Deactivation in Parkinson Depression. Parkinson's Disease, 2015, 2015, 1-11.	0.6	9
3606	Salivary Acetylcholinesterase Activity Is Increased in Parkinson's Disease: A Potential Marker of Parasympathetic Dysfunction. Parkinson's Disease, 2015, 2015, 1-7.	0.6	28
3607	Relationship between Cognitive Performance and Motor Dysfunction in Patients with Parkinson's Disease: A Pilot Cross-Sectional Study. BioMed Research International, 2015, 2015, 1-6.	0.9	52
3608	A Polysomnographic Study of Parkinson's Disease Sleep Architecture. Parkinson's Disease, 2015, 2015, 1-7.	0.6	19
3609	Validation of the Official Slovak Version of the Unified Dyskinesia Rating Scale (UDysRS). Parkinson's Disease, 2015, 2015, 1-7.	0.6	4
3610	Medical Record Review to Differentiate between Idiopathic Parkinson's Disease and Parkinsonism: A Danish Record Linkage Study with 10 Years of Follow-Up. Parkinson's Disease, 2015, 2015, 1-9.	0.6	10
3611	Transdermal Rotigotine Improves Sleep Fragmentation in Parkinson's Disease: Results of the Multicenter, Prospective SLEEP-FRAM Study. Parkinson's Disease, 2015, 2015, 1-7.	0.6	20
3612	Iron Accumulation Is Not Homogenous among Patients with Parkinson's Disease. Parkinson's Disease, 2015, 2015, 1-8.	0.6	30
3613	Rapid Screening for Cognitive Impairment in Parkinson's Disease: A Pilot Study. Parkinson's Disease, 2015, 2015, 1-6.	0.6	6

#	ARTICLE	IF	CITATIONS
3614	Personality Changes after Deep Brain Stimulation in Parkinson's Disease. <i>Parkinson's Disease</i> , 2015, 2015, 1-7.	0.6	40
3615	Assessment of Nonverbal and Verbal Apraxia in Patients with Parkinson's Disease. <i>Parkinson's Disease</i> , 2015, 2015, 1-8.	0.6	3
3616	Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies. <i>BioMed Research International</i> , 2015, 2015, 1-12.	0.9	160
3617	German Translation and Validation of the "Freezing of Gait Questionnaire" in Patients with Parkinson's Disease. <i>Parkinson's Disease</i> , 2015, 2015, 1-5.	0.6	20
3618	Clinical Utility of Skin Biopsy in Differentiating between Parkinson's Disease and Multiple System Atrophy. <i>Parkinson's Disease</i> , 2015, 2015, 1-7.	0.6	33
3619	Diagnosis of Obstructive Sleep Apnea in Parkinson's Disease Patients: Is Unattended Portable Monitoring a Suitable Tool?. <i>Parkinson's Disease</i> , 2015, 2015, 1-11.	0.6	9
3620	Postural and Balance Disorders in Patients with Parkinson's Disease: A Prospective Open-Label Feasibility Study with Two Months of Action Observation Treatment. <i>Parkinson's Disease</i> , 2015, 2015, 1-7.	0.6	11
3621	L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson's Disease: A Randomised Study. <i>Parkinson's Disease</i> , 2015, 2015, 1-7.	0.6	11
3622	Fully Automated Quantification of the Striatal Uptake Ratio of [^{99m} Tc]-TRODAT with SPECT Imaging: Evaluation of the Diagnostic Performance in Parkinson's Disease and the Temporal Regression of Striatal Tracer Uptake. <i>BioMed Research International</i> , 2015, 2015, 1-11.	0.9	5
3623	Effects of Night-Time Use of Rotigotine on Nocturnal Symptoms in Parkinson's Disease. <i>Parkinson's Disease</i> , 2015, 2015, 1-6.	0.6	8
3624	Effect of GBA Mutations on Phenotype of Parkinson's Disease: A Study on Chinese Population and a Meta-Analysis. <i>Parkinson's Disease</i> , 2015, 2015, 1-10.	0.6	38
3625	Clinical and Epidemiological Factors Associated with Mortality in Parkinson's Disease in a Brazilian Cohort. <i>Parkinson's Disease</i> , 2015, 2015, 1-6.	0.6	10
3626	Potential Biomarkers of the Earliest Clinical Stages of Parkinson's Disease. <i>Parkinson's Disease</i> , 2015, 2015, 1-6.	0.6	11
3627	Clinical Features Associated with Frozen Shoulder Syndrome in Parkinson's Disease. <i>Parkinson's Disease</i> , 2015, 2015, 1-7.	0.6	3
3628	The Natural History of Depression in Parkinson's Disease within 30-Month Follow-Up. <i>Parkinson's Disease</i> , 2015, 2015, 1-7.	0.6	5
3629	Parkinsonism and Sjögren's Syndrome: A Fortuitous Association or a Shared Immunopathogenesis?. <i>Case Reports in Medicine</i> , 2015, 2015, 1-4.	0.3	7
3630	The Effects of Uric Acid, Serum Vitamin D3, and Their Interaction on Parkinson's Disease Severity. <i>Parkinson's Disease</i> , 2015, 2015, 1-7.	0.6	9
3631	Qualitative Characteristics of Depression in Parkinson's Patients and Controls. <i>Behavioural Neurology</i> , 2015, 2015, 1-5.	1.1	15

#	ARTICLE	IF	CITATIONS
3632	Mitochondrial DNA Haplogroups and the Risk of Sporadic Parkinson's Disease in Han Chinese. Chinese Medical Journal, 2015, 128, 1748-1754.	0.9	16
3633	Impaired Switching from Self-Prepared Actions in Mild Parkinson Disease. Journal of Parkinson's Disease, 2015, 5, 961-970.	1.5	3
3634	Cognitive processes affect the gait of subjects with Parkinson's and Alzheimer's disease in dual tasks. Jornal Brasileiro De Psiquiatria, 2015, 64, 154-159.	0.2	2
3635	Dysphagia in Parkinson's Disease. , 2015, , .		0
3636	Analysis of the LRRK2 p.G2019S mutation in Colombian Parkinson's Disease Patients. Colombia Medica, 2015, , 117-121.	0.7	15
3637	Sleep Disturbances in Essential Tremor and Parkinson Disease: A Polysomnographic Study. Journal of Clinical Sleep Medicine, 2015, 11, 655-662.	1.4	26
3638	Phosphorylated α -synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy. Brain, 2015, 138, 2310-2321.	3.7	116
3639	Specific brainstem and cortico-spinal reflex abnormalities in coexisting essential tremor and Parkinson's disease (ET-PD). Neurophysiologie Clinique, 2015, 45, 143-149.	1.0	6
3640	A longitudinal study of non-motor symptom burden in Parkinson's disease after a transition to expert care. Parkinsonism and Related Disorders, 2015, 21, 843-847.	1.1	11
3641	Olfactory function combined with morphology distinguishes Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 771-777.	1.1	24
3642	The association between infectious burden and Parkinson's disease: A case-control study. Parkinsonism and Related Disorders, 2015, 21, 877-881.	1.1	116
3643	Syntax, action verbs, action semantics, and object semantics in Parkinson's disease: Dissociability, progression, and executive influences. Cortex, 2015, 69, 237-254.	1.1	147
3644	Robot-assisted gait training is not superior to balance training for improving postural instability in patients with mild to moderate Parkinson's disease: a single-blind randomized controlled trial. Clinical Rehabilitation, 2015, 29, 339-347.	1.0	40
3645	Dynamics of postural control in Parkinson patients with and without symptoms of freezing of gait. Gait and Posture, 2015, 42, 246-250.	0.6	38
3646	Beneficial effect of levodopa therapy on stooped posture in Parkinson's disease. Gait and Posture, 2015, 42, 263-268.	0.6	15
3647	Relationship between the non-motor items of the MDS-UPDRS and Quality of Life in patients with Parkinson's disease. Journal of the Neurological Sciences, 2015, 353, 87-91.	0.3	58
3648	Polygenic determinants of Parkinson's disease in a Chinese population. Neurobiology of Aging, 2015, 36, 1765.e1-1765.e6.	1.5	73
3649	Longitudinal midbrain changes in early Parkinson's disease: Iron content estimated from R2*/MRI. Parkinsonism and Related Disorders, 2015, 21, 179-183.	1.1	56

#	ARTICLE	IF	CITATIONS
3650	Quitting smoking: An early non-motor feature of Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 216-220.	1.1	19
3651	Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 494-499.	1.1	45
3652	Transcranial sonography of the substantia nigra and its correlation with DAT-SPECT in the diagnosis of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 923-928.	1.1	19
3653	Impaired smooth-pursuit in Parkinson's disease: normal cue-information memory, but dysfunction of extra-retinal mechanisms for pursuit preparation and execution. <i>Physiological Reports</i> , 2015, 3, e12361.	0.7	18
3654	Use of Jebsen Taylor Hand Function Test in evaluating the hand dexterity in people with Parkinson's disease. <i>Journal of Hand Therapy</i> , 2015, 28, 389-395.	0.7	46
3655	Mitochondrial DNA mutations in neurodegeneration. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2015, 1847, 1401-1411.	0.5	120
3656	Colonic mucosal α -synuclein lacks specificity as a biomarker for Parkinson disease. <i>Neurology</i> , 2015, 84, 609-616.	1.5	130
3657	Frequency of Cholinergic and Caudate Nucleus Dopaminergic Deficits Across the Predemented Cognitive Spectrum of Parkinson Disease and Evidence of Interaction Effects. <i>JAMA Neurology</i> , 2015, 72, 194.	4.5	121
3658	Differences in early speech patterns between Parkinson variant of multiple system atrophy and Parkinson's disease. <i>Brain and Language</i> , 2015, 147, 14-20.	0.8	25
3659	Partial Body Weight-Supported Treadmill Training in Patients With Parkinson Disease: Impact on Gait and Clinical Manifestation. <i>Archives of Physical Medicine and Rehabilitation</i> , 2015, 96, 1557-1565.	0.5	35
3660	Detection of α -synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease. <i>Neuroscience Letters</i> , 2015, 599, 115-119.	1.0	121
3661	Plasma antioxidant status and motor features in <i>de novo</i> Chinese Parkinson's disease patients. <i>International Journal of Neuroscience</i> , 2016, 126, 1-6.	0.8	11
3662	A data mining methodology for predicting early stage Parkinson's disease using non-invasive, high-dimensional gait sensor data. <i>IIE Transactions on Healthcare Systems Engineering</i> , 2015, 5, 238-254.	0.8	17
3663	Tremor Reduction by Deep Brain Stimulation Is Associated With Gamma Power Suppression in Parkinson's Disease. <i>Neuromodulation</i> , 2015, 18, 349-354.	0.4	60
3664	Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 949-959.	1.7	144
3665	Pain in multiple system atrophy and progressive supranuclear palsy compared to Parkinson's disease. <i>Brain and Behavior</i> , 2015, 5, e00320.	1.0	32
3666	Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study). <i>Movement Disorders</i> , 2015, 30, 788-795.	2.2	123
3667	MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1591-1601.	2.2	4,389

#	ARTICLE	IF	CITATIONS
3668	Dopamine Transporter Single-Photon Emission Computerized Tomography Supports Diagnosis of Akinetic Crisis of Parkinsonism and of Neuroleptic Malignant Syndrome. <i>Medicine (United States)</i> , 2015, 94, e649.	0.4	13
3669	Trust behavior in Parkinson's disease: results of a trust game experiment. <i>BMC Neurology</i> , 2015, 15, 126.	0.8	12
3670	Mitochondrial targeting sequence variants of the <i>CHCHD2</i> gene are a risk for Lewy body disorders. <i>Neurology</i> , 2015, 85, 2016-2025.	1.5	51
3671	Aldehyde dehydrogenase 2 genetic variations may increase susceptibility to Parkinson's disease in Han Chinese population. <i>Neurobiology of Aging</i> , 2015, 36, 2660.e9-2660.e13.	1.5	26
3672	Autonomic dysfunction in subjects at high risk for Parkinson's disease. <i>Journal of Neurology</i> , 2015, 262, 2643-2652.	1.8	17
3673	Computational approaches for understanding the diagnosis and treatment of Parkinson's disease. <i>IET Systems Biology</i> , 2015, 9, 226-233.	0.8	15
3674	Artistic occupations are associated with a reduced risk of Parkinson's disease. <i>Journal of Neurology</i> , 2015, 262, 2171-2176.	1.8	6
3675	Short-latency afferent inhibition in patients with Parkinson's disease and freezing of gait. <i>Journal of Neural Transmission</i> , 2015, 122, 1533-1540.	1.4	22
3676	Parkinson's disease research in a prospective cohort in China. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1200-1204.	1.1	27
3677	STK39, But Not BST1, HLA-DQB1, and SPPL2B Polymorphism, Is Associated With Han-Chinese Parkinson's Disease in Taiwan. <i>Medicine (United States)</i> , 2015, 94, e1690.	0.4	17
3678	Atlas-based segmentation of brainstem regions in neuromelanin-sensitive magnetic resonance images. , 2015, , .		1
3679	Accelerometer recorder and display system for ambulatory patients. , 2015, , .		0
3680	Evidence that non-dreamers do dream: a REM sleep behaviour disorder model. <i>Journal of Sleep Research</i> , 2015, 24, 602-609.	1.7	42
3681	MRI Correlates of Parkinson's Disease Progression: A Voxel Based Morphometry Study. <i>Parkinson's Disease</i> , 2015, 2015, 1-8.	0.6	34
3682	The olfactory bulb volume in patients with idiopathic Parkinson's disease. <i>European Journal of Neurology</i> , 2015, 22, 1068-1073.	1.7	37
3683	Spinopelvic balance and body image perception in Parkinson's disease: analysis of correlation. <i>European Spine Journal</i> , 2015, 24, 898-905.	1.0	16
3684	Discriminating features of gait performance in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 888-893.	1.1	21
3685	Quality of sleep in young onset Parkinson's disease: Any difference from older onset Parkinson's disease?. <i>Sleep Medicine</i> , 2015, 16, S56.	0.8	0

#	ARTICLE	IF	CITATIONS
3686	Gait in drug naïve patients with <i>de novo</i> Parkinson's disease "altered but symmetric. Neurological Research, 2015, 37, 712-716.	0.6	25
3687	Brain mediators of systemic oxidative stress on perceptual impairments in Parkinson's disease. Journal of Translational Medicine, 2015, 13, 386.	1.8	18
3688	Association between nocturia and anxiety in Parkinson's disease. Neurological Research, 2015, 37, 563-567.	0.6	10
3689	Is There a Role for DAT-SPECT Imaging in a Specialty Movement Disorders Practice?. Neurodegenerative Diseases, 2015, 15, 81-86.	0.8	17
3690	Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice. Parkinsonism and Related Disorders, 2015, 21, 87-94.	1.1	134
3691	Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurology, The, 2015, 14, 57-64.	4.9	487
3692	Structural covariance networks of striatum subdivision in patients with Parkinson's disease. Human Brain Mapping, 2015, 36, 1567-1584.	1.9	33
3693	Validation of Secondary Data Sources to Identify Parkinson Disease Against Clinical Diagnostic Criteria. American Journal of Epidemiology, 2015, 181, 185-190.	1.6	16
3694	Cutaneous autonomic denervation in Parkinson's disease. Journal of Neural Transmission, 2015, 122, 1149-1155.	1.4	29
3695	The Face Behind the Mask: Can Imaging Help Early Parkinson Diagnosis?. Movement Disorders Clinical Practice, 2015, 2, 1-2.	0.8	0
3696	A comparison between rate of nonmotor symptom development in essential tremor and Parkinson's disease. Acta Neurologica Belgica, 2015, 115, 289-294.	0.5	13
3697	Dysfunctional action control as a specific feature of Parkinson's disease. Journal of Neural Transmission, 2015, 122, 1125-1133.	1.4	3
3698	Validation of the nonmotor symptoms questionnaire for Parkinson's disease: results from a Chinese pilot study. International Journal of Neuroscience, 2015, 125, 929-935.	0.8	12
3699	Systematic review and meta-analysis of hydrocarbon exposure and the risk of Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 243-248.	1.1	11
3700	Nonmotor symptoms in essential tremor: Comparison with Parkinson's disease and normal control. Journal of the Neurological Sciences, 2015, 349, 168-173.	0.3	41
3701	CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study. Lancet Neurology, The, 2015, 14, 274-282.	4.9	285
3702	Prevalence of Mild Cognitive Impairment and Dementia among the Elderly Population of Qena Governorate, Upper Egypt: A Community-Based Study. Journal of Alzheimer's Disease, 2015, 45, 117-126.	1.2	31
3703	<i>PARK10</i> is a major locus for sporadic neuropathologically confirmed Parkinson disease. Neurology, 2015, 84, 972-980.	1.5	48

#	ARTICLE	IF	CITATIONS
3704	Prevalence and clinical correlates of drooling in Parkinson disease: A study on 518 Chinese patients. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 211-215.	1.1	26
3705	NREM sleep alpha and sigma activity in Parkinson's disease: Evidence for conflicting electrophysiological activity?. <i>Clinical Neurophysiology</i> , 2015, 126, 951-958.	0.7	17
3706	Neurovegetative Regulation of the Vascular System. , 2015, , 681-701.		0
3707	Severity of orthostatic hypotension in the course of Parkinson's disease: No correlation with the duration of the disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 314-316.	1.1	22
3708	Freezing of gait in Parkinson's disease is related to impaired motor switching during stepping. <i>Movement Disorders</i> , 2015, 30, 1090-1097.	2.2	30
3709	The increase of carcinoembryonic antigen (CEA), high-sensitivity C-reactive protein, and neutrophil/lymphocyte ratio in Parkinson's disease. <i>Neurological Sciences</i> , 2015, 36, 423-428.	0.9	105
3710	Abnormal functional connectivity density in Parkinson's disease. <i>Behavioural Brain Research</i> , 2015, 280, 113-118.	1.2	31
3711	Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 106-110.	1.1	58
3712	Sex differences in cognition among Chinese people with Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 488-492.	0.8	20
3713	Validation of a Psycho-Sensory Hallucinations Scale (PSAS) in schizophrenia and Parkinson's disease. <i>Schizophrenia Research</i> , 2015, 161, 269-276.	1.1	23
3714	The <i>MC1R</i> melanoma risk variant p.R160W is associated with Parkinson disease. <i>Annals of Neurology</i> , 2015, 77, 889-894.	2.8	52
3715	Speech disorders reflect differing pathophysiology in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. <i>Journal of Neurology</i> , 2015, 262, 992-1001.	1.8	115
3716	Placebo effect of medication cost in Parkinson disease. <i>Neurology</i> , 2015, 84, 794-802.	1.5	112
3717	Putaminal hypointensity on T2*-weighted MR imaging is the most practically useful sign in diagnosing multiple system atrophy: A preliminary study. <i>Journal of the Neurological Sciences</i> , 2015, 349, 174-178.	0.3	21
3718	Mendelian genes for Parkinson's disease contribute to the sporadic forms of the disease. <i>Human Molecular Genetics</i> , 2015, 24, 2023-2034.	1.4	45
3719	Dopaminergic modulation of motor network dynamics in Parkinson's disease. <i>Brain</i> , 2015, 138, 664-678.	3.7	105
3720	Fall frequency and risk factors in patients with Parkinson's disease in Belgrade, Serbia: A cross-sectional study. <i>Geriatrics and Gerontology International</i> , 2015, 15, 472-480.	0.7	18
3721	Exploring determinants of progression in Parkinson's disease. Is there a difference among Jewish ethnic groups?. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 184-188.	1.1	2

#	ARTICLE	IF	CITATIONS
3722	Depressive symptoms in Parkinson's disease are related to decreased hippocampus and amygdala volume. <i>Movement Disorders</i> , 2015, 30, 245-252.	2.2	118
3723	Technology-Assisted Balance and Gait Training Reduces Falls in Patients With Parkinson's Disease. <i>Neurorehabilitation and Neural Repair</i> , 2015, 29, 103-111.	1.4	92
3724	Changes in oxygenated hemoglobin link freezing of gait to frontal activation in patients with Parkinson disease: an fNIRS study of transient motor-cognitive failures. <i>Journal of Neurology</i> , 2015, 262, 899-908.	1.8	107
3725	Clinical routine use of dopamine transporter imaging in 516 consecutive patients. <i>Journal of Neurology</i> , 2015, 262, 909-915.	1.8	9
3726	Effect of dopaminergic medication on speech dysfluency in Parkinson's disease: a longitudinal study. <i>Journal of Neural Transmission</i> , 2015, 122, 1135-1142.	1.4	42
3727	A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 1240-1247.	0.9	196
3728	Distinct phenotypes of speech and voice disorders in Parkinson's disease after subthalamic nucleus deep brain stimulation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 856-864.	0.9	85
3729	Ancillary investigations to diagnose parkinsonism: a prospective clinical study. <i>Journal of Neurology</i> , 2015, 262, 346-356.	1.8	34
3730	Assessment of the efficacy of early phase parameters by 123I-MIBG dynamic imaging for distinguishing Lewy body-related diseases from Parkinson's syndrome. <i>Annals of Nuclear Medicine</i> , 2015, 29, 149-156.	1.2	3
3731	Transcranial midbrain sonography and depressive symptoms in patients with Parkinson's disease. <i>Journal of Neurology</i> , 2015, 262, 689-695.	1.8	13
3732	A comparison of Montreal Cognitive Assessment between patients with visual hallucinations and without visual hallucinations in Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2015, 130, 98-100.	0.6	5
3733	Attention to Automatic Movements in Parkinson's Disease: Modified Automatic Mode in the Striatum. <i>Cerebral Cortex</i> , 2015, 25, 3330-3342.	1.6	86
3734	Action tremor in Parkinson's disease: frequency and relationship to motor and non-motor signs. <i>European Journal of Neurology</i> , 2015, 22, 223-228.	1.7	43
3735	Effects of Stochastic Vestibular Galvanic Stimulation and LDOPA on Balance and Motor Symptoms in Patients With Parkinson's Disease. <i>Brain Stimulation</i> , 2015, 8, 474-480.	0.7	61
3736	Catechol-O-Methyltransferase Inhibitors in Parkinson's Disease. <i>Drugs</i> , 2015, 75, 157-174.	4.9	135
3737	Detecting and Predicting Balance Decline in Parkinson Disease: A Prospective Cohort Study. <i>Journal of Parkinson's Disease</i> , 2015, 5, 131-139.	1.5	21
3738	Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 688-695.	2.2	83
3739	Evolution of Prodromal Clinical Markers of Parkinson Disease in a GBA Mutation-Positive Cohort. <i>JAMA Neurology</i> , 2015, 72, 201.	4.5	180

#	ARTICLE	IF	CITATIONS
3740	A network centred on the inferior frontal cortex is critically involved in levodopa-induced dyskinesias. <i>Brain</i> , 2015, 138, 414-427.	3.7	83
3741	Machine learning models for the differential diagnosis of vascular parkinsonism and Parkinson's disease using [123I]FP-CIT SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 112-119.	3.3	46
3742	Current Concepts in the Treatment of Multiple System Atrophy. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 6-16.	0.8	24
3743	Parkinson's disease patients showed delayed awareness of motor intention. <i>Neuroscience Research</i> , 2015, 95, 74-77.	1.0	15
3744	Nizatidine Ameliorates Slow Transit Constipation in Parkinson's Disease. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 399-401.	1.3	16
3745	Prodromal dementia with Lewy bodies. <i>Geriatrics and Gerontology International</i> , 2015, 15, 817-826.	0.7	55
3746	Analysis of several loci from genome-wide association studies in Parkinson's disease in mainland China. <i>Neuroscience Letters</i> , 2015, 587, 68-71.	1.0	15
3747	Assessment of RIT2 rs12456492 association with Parkinson's disease in Mainland China. <i>Neurobiology of Aging</i> , 2015, 36, 1600.e9-1600.e11.	1.5	13
3748	Non-motor symptoms in Chinese Parkinson's disease patients with and without LRRK2 G2385R and R1628P variants. <i>Journal of Neural Transmission</i> , 2015, 122, 661-667.	1.4	18
3749	Substantia nigra neuromelanin MR imaging differentiates essential tremor from Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 953-959.	2.2	69
3750	Correlates of cerebrospinal fluid levels of oligomeric- and total- α -synuclein in premotor, motor and dementia stages of Parkinson's disease. <i>Journal of Neurology</i> , 2015, 262, 294-306.	1.8	85
3751	Interest in Genetic Testing in Ashkenazi Jewish Parkinson's Disease Patients and Their Unaffected Relatives. <i>Journal of Genetic Counseling</i> , 2015, 24, 238-246.	0.9	23
3752	Effect of neurostimulation on camptocormia in Parkinson's disease depends on symptom duration. <i>Movement Disorders</i> , 2015, 30, 368-372.	2.2	52
3753	Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 373-378.	2.2	41
3754	Impulse control disorders in Parkinson's disease: don't set your mind at rest by self-assessments. <i>European Journal of Neurology</i> , 2015, 22, 603-609.	1.7	42
3755	Cardiocirculatory manifestations in Parkinson's disease patients without orthostatic hypotension. <i>Journal of Human Hypertension</i> , 2015, 29, 604-609.	1.0	13
3756	Adapted step length estimators for patients with Parkinson's disease using a lateral belt worn accelerometer. <i>Technology and Health Care</i> , 2015, 23, 179-194.	0.5	9
3757	One central oscillatory drive is compatible with experimental motor unit behaviour in essential and Parkinsonian tremor. <i>Journal of Neural Engineering</i> , 2015, 12, 046019.	1.8	15

#	ARTICLE	IF	CITATIONS
3758	The highly-selective 5-HT1A agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque. <i>Neuropharmacology</i> , 2015, 97, 306-311.	2.0	39
3759	White matter differences between multiple system atrophy (parkinsonian type) and Parkinson's disease: A diffusion tensor image study. <i>Neuroscience</i> , 2015, 305, 109-116.	1.1	30
3760	Clinical correlates of rapid eye movement sleep without atonia in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2015, 126, 1198-1203.	0.7	12
3761	Identification of novel variants in LRRK2 gene in patients with Parkinson's disease in Serbian population. <i>Journal of the Neurological Sciences</i> , 2015, 353, 59-62.	0.3	7
3762	The single nucleotide polymorphism Rs12817488 is associated with Parkinson's disease in the Chinese population. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1002-1004.	0.8	11
3763	A neurophysiological profile in Parkinson's disease with mild cognitive impairment and dementia in China. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 981-985.	0.8	23
3764	Mild Cognitive Impairment in Early Parkinson's Disease Using the Movement Disorder Society Task Force Criteria: Cross-Sectional Study in Hoehn and Yahr Stage 1. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 40, 199-209.	0.7	30
3765	Subtalomomía bilateral diferida en enfermedad de Parkinson: evaluación motora, cognitiva y conductual. <i>Neurología Argentina</i> , 2015, 7, 67-75.	0.1	3
3766	Inter-limb coupling during diadochokinesis in Parkinson's and Huntington's disease. <i>Neuroscience Research</i> , 2015, 97, 60-68.	1.0	10
3767	Parkinson disease: α -synuclein mutational screening and new clinical insight into the p.E46K mutation. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 586-589.	1.1	18
3768	Diurnal drooling in Chinese patients with Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2015, 353, 74-78.	0.3	19
3769	Assessment of planning performance in clinical samples: Reliability and validity of the Tower of London task (TOL-F). <i>Neuropsychologia</i> , 2015, 75, 646-655.	0.7	28
3770	Lack of association between the ATP13A2A746T variant and Parkinson's disease susceptibility in Han Chinese: a meta-analysis. <i>International Journal of Neuroscience</i> , 2015, 126, 1-7.	0.8	2
3771	Inverse association between yerba mate consumption and idiopathic Parkinson's disease. A case-control study. <i>Journal of the Neurological Sciences</i> , 2015, 356, 163-167.	0.3	17
3772	When DLB, PD, and PSP masquerade as MSA. <i>Neurology</i> , 2015, 85, 404-412.	1.5	272
3773	The Impact of Emotional Distress on Motor Blocks and Festination in Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2015, 27, 121-126.	0.9	15
3774	Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. <i>Brain</i> , 2015, 138, 2687-2700.	3.7	168
3775	Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson's disease patients with chronic pain. <i>Journal of Neurology</i> , 2015, 262, 2164-2170.	1.8	35

#	ARTICLE	IF	CITATIONS
3776	Dopamine transporter imaging in essential tremor with and without parkinsonian features. <i>Journal of Neural Transmission</i> , 2015, 122, 1515-1521.	1.4	27
3777	Excessive Daytime Sleepiness and Unintended Sleep Episodes Associated with Parkinson's Disease. <i>Oman Medical Journal</i> , 2015, 30, 3-10.	0.3	21
3778	Using 'dead or dependent' as an outcome measure in clinical trials in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 180-185.	0.9	8
3779	Induced Pluripotent Stem Cells and Their Use in Cardiac and Neural Regenerative Medicine. <i>International Journal of Molecular Sciences</i> , 2015, 16, 4043-4067.	1.8	20
3780	CSF proteins and resting-state functional connectivity in Parkinson disease. <i>Neurology</i> , 2015, 84, 2413-2421.	1.5	51
3781	Mutational analysis of SYNJ1 gene (PARK20) in Parkinson's disease in a Taiwanese population. <i>Neurobiology of Aging</i> , 2015, 36, 2905.e7-2905.e8.	1.5	13
3782	Cortical dynamics and subcortical signatures of motor-language coupling in Parkinson's disease. <i>Scientific Reports</i> , 2015, 5, 11899.	1.6	63
3783	Postural instability in Parkinson Disease: To step or not to step. <i>Journal of the Neurological Sciences</i> , 2015, 357, 146-151.	0.3	12
3784	Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. <i>Brain</i> , 2015, 138, 2648-2658.	3.7	326
3785	The prevalence and risk factors of cerebral microbleeds in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1076-1081.	1.1	30
3786	Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. <i>Lancet Neurology</i> , The, 2015, 14, 795-803.	4.9	219
3787	Association of the mt-ND2 5178A/C polymorphism with Parkinson's disease. <i>Neuroscience Letters</i> , 2015, 587, 98-101.	1.0	11
3788	Recent Advances and Applications of Metabolomics to Investigate Neurodegenerative Diseases. <i>International Review of Neurobiology</i> , 2015, 122, 95-132.	0.9	18
3789	Characterization of retinal architecture in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2015, 355, 44-48.	0.3	56
3790	Factors associated with the quality of life of subjects with Parkinson's disease and burden on their caregivers. <i>Neurologia (English Edition)</i> , 2015, 30, 257-263.	0.2	13
3791	Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 514-520.	1.1	60
3792	Utility of the Japanese version of the 9-item Wearing-off Questionnaire. <i>Clinical Neurology and Neurosurgery</i> , 2015, 134, 110-115.	0.6	11
3793	Structural and functional imaging study in dementia with Lewy bodies and Parkinson's disease dementia. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1049-1055.	1.1	70

#	ARTICLE	IF	CITATIONS
3794	Environmental Exposures and Risks for Parkinson's Disease. , 2015, , 253-265.		1
3795	Is there a role for <i>ADORA2A</i> polymorphisms in levodopa-induced dyskinesia in Parkinson's disease patients?. <i>Pharmacogenomics</i> , 2015, 16, 573-582.	0.6	32
3796	Parkinson's disease and intensive exercise therapy – a systematic review and meta-analysis of randomized controlled trials. <i>Journal of the Neurological Sciences</i> , 2015, 353, 9-19.	0.3	151
3797	Hyposmia correlates with SNCA variant and non-motor symptoms in Chinese patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 610-614.	1.1	38
3798	Preliminary study of zonisamide monotherapy in <i>de novo</i> patients with early Parkinson's disease. <i>Neurology and Clinical Neuroscience</i> , 2015, 3, 163-166.	0.2	7
3799	Antisaccades and executive dysfunction in early drug-naïve Parkinson's disease: The discovery study. <i>Movement Disorders</i> , 2015, 30, 843-847.	2.2	79
3800	Use of ¹¹ C-PE2I PET in Differential Diagnosis of Parkinsonian Disorders. <i>Journal of Nuclear Medicine</i> , 2015, 56, 234-242.	2.8	41
3801	Dopaminergic denervation is not necessary to induce gait disorders in atypical parkinsonian syndrome. <i>Journal of the Neurological Sciences</i> , 2015, 351, 127-132.	0.3	6
3802	Topography of cortical thinning associated with white matter hyperintensities in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 372-377.	1.1	10
3803	Interventions for preventing falls in Parkinson's disease. <i>The Cochrane Library</i> , 0, , .	1.5	11
3804	Defining neurodegeneration on <i>G</i> by targeted genomic sequencing. <i>Annals of Neurology</i> , 2015, 77, 458-468.	2.8	63
3805	Dementia and severity of parkinsonism determines the handicap of patients in late-stage Parkinson's disease: the Barcelona~Lisbon cohort. <i>European Journal of Neurology</i> , 2015, 22, 305-312.	1.7	38
3806	The relationship between real world ambulatory activity and falls in incident Parkinson's disease: Influence of classification scheme. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 236-242.	1.1	59
3807	The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study. <i>Neurobiology of Aging</i> , 2015, 36, 1736-1742.	1.5	42
3808	Heterogeneity among patients with Parkinson's disease: Cluster analysis and genetic association. <i>Journal of the Neurological Sciences</i> , 2015, 351, 41-45.	0.3	29
3809	Motivation~cognition interaction: how feedback processing changes in healthy ageing and in Parkinson's disease. <i>Aging Clinical and Experimental Research</i> , 2015, 27, 911-920.	1.4	19
3810	Side of motor onset is associated with hemisphere-specific memory decline and lateralized gray matter loss in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 465-470.	1.1	26
3811	Potential diagnostic value of regional myocardial adrenergic imaging using ¹²³ I-MIBG SPECT to identify patients with Lewy body diseases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1043-1051.	3.3	9

#	ARTICLE	IF	CITATIONS
3812	Investigation of Apparent Diffusion Coefficient from Ultra-high b-Values in Parkinson's Disease. <i>European Radiology</i> , 2015, 25, 2593-2600.	2.3	29
3813	Resting-state functional connectivity associated with mild cognitive impairment in Parkinson's disease. <i>Journal of Neurology</i> , 2015, 262, 425-434.	1.8	175
3814	Preoperative brain metabolism and quality of life after subthalamic nucleus stimulation in Parkinson's disease. <i>Journal of Neurology</i> , 2015, 262, 881-889.	1.8	5
3815	Correlations between plasma levels of amino acids and nonmotor symptoms in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2015, 122, 411-417.	1.4	16
3816	Quantitative motor assessment of dyskinesias in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2015, 122, 1271-1278.	1.4	5
3817	The heterogeneity of non-motor symptoms of Parkinson's disease. <i>Neurological Sciences</i> , 2015, 36, 577-584.	0.9	11
3818	The validation of an Italian version of the Freezing of Gait Questionnaire. <i>Neurological Sciences</i> , 2015, 36, 759-764.	0.9	19
3819	Association of MTHFR C677T with total homocysteine plasma levels and susceptibility to Parkinson's disease: a meta-analysis. <i>Neurological Sciences</i> , 2015, 36, 945-951.	0.9	26
3820	Reliability of administrative data for the identification of Parkinson's disease cohorts. <i>Neurological Sciences</i> , 2015, 36, 783-786.	0.9	23
3821	Risk factors and safe dosage of levodopa for wearing-off phenomenon in Chinese patients with Parkinson's disease. <i>Neurological Sciences</i> , 2015, 36, 1217-1223.	0.9	13
3822	The diagnostic value of minor salivary gland biopsy in clinically diagnosed patients with Parkinson's disease: comparison with DAT PET scans. <i>Neurological Sciences</i> , 2015, 36, 1575-1580.	0.9	18
3823	Underactive and overactive bladders are related to motor function and quality of life in Parkinson's disease. <i>International Urology and Nephrology</i> , 2015, 47, 751-757.	0.6	31
3824	Increased bilirubin levels in <i>de novo</i> Parkinson's disease. <i>European Journal of Neurology</i> , 2015, 22, 954-959.	1.7	29
3825	Toward Understanding Ambulatory Activity Decline in Parkinson Disease. <i>Physical Therapy</i> , 2015, 95, 1142-1150.	1.1	57
3826	Clinical markers for identifying cholinergic deficits in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 269-273.	2.2	54
3827	The relation of sexual dysfunction to depression and anxiety in patients with Parkinson's disease. <i>Acta Neuropsychiatrica</i> , 2015, 27, 33-37.	1.0	20
3828	Understanding and managing parkinsonism in patients with glucocerebrosidase mutations. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 549-562.	0.5	1
3829	Characteristics of language impairment in Parkinson's disease and its influencing factors. <i>Translational Neurodegeneration</i> , 2015, 4, 2.	3.6	32

#	ARTICLE	IF	CITATIONS
3830	Comparing interventions and exploring neural mechanisms of exercise in Parkinson disease: a study protocol for a randomized controlled trial. <i>BMC Neurology</i> , 2015, 15, 9.	0.8	31
3831	The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review. <i>EJNMMI Research</i> , 2015, 5, 12.	1.1	91
3832	Quality of sleep in young onset Parkinson's disease: Any difference from older onset Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 461-464.	1.1	15
3833	Emergence of restless legs syndrome after subthalamic stimulation in Parkinson's disease: a dopaminergic overstimulation?. <i>Sleep Medicine</i> , 2015, 16, 583-588.	0.8	33
3834	Remote control of apomorphine infusion rate in Parkinson's disease: Real-time dose variations according to the patients' motor state. A proof of concept. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 996-998.	1.1	12
3835	Thyroid hormone level is associated with motor symptoms in de novo Parkinson's disease. <i>Journal of Neurology</i> , 2015, 262, 1762-1768.	1.8	16
3836	Prevalence and timeline of nonmotor symptoms in idiopathic rapid eye movement sleep behavior disorder. <i>Journal of Neurology</i> , 2015, 262, 1568-1578.	1.8	59
3837	Single versus multiple impulse control disorders in Parkinson's disease: an 11C-raclopride positron emission tomography study of reward cue-evoked striatal dopamine release. <i>Journal of Neurology</i> , 2015, 262, 1504-1514.	1.8	41
3838	In Parkinson's disease pallidal deep brain stimulation speeds up response initiation but has no effect on reactive inhibition. <i>Journal of Neurology</i> , 2015, 262, 1741-1750.	1.8	11
3839	Toll-Like Receptor Expression in the Blood and Brain of Patients and a Mouse Model of Parkinson's Disease. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu103-pyu103.	1.0	97
3840	Mitochondrial serine protease HTRA2 gene mutation in Asians with coexistent essential tremor and Parkinson disease. <i>Neurogenetics</i> , 2015, 16, 241-242.	0.7	14
3841	To rise and to fall: functional connectivity in cognitively normal and cognitively impaired patients with Parkinson's disease. <i>Neurobiology of Aging</i> , 2015, 36, 1727-1735.	1.5	119
3842	Incidence and prediction of falls in Parkinson's disease: a prospective cohort study. <i>European Journal of Epidemiology</i> , 2015, 30, 349-352.	2.5	12
3843	Decreased interhemispheric functional connectivity in subtypes of Parkinson's disease. <i>Journal of Neurology</i> , 2015, 262, 760-767.	1.8	39
3844	Lateralization of brain activity pattern during unilateral movement in Parkinson's disease. <i>Human Brain Mapping</i> , 2015, 36, 1878-1891.	1.9	35
3845	Saskatchewan Movement Disorders Program. <i>Canadian Journal of Neurological Sciences</i> , 2015, 42, 74-87.	0.3	11
3846	Lifestyle, Family History, and Risk of Idiopathic Parkinson Disease: A Large Danish Case-Control Study. <i>American Journal of Epidemiology</i> , 2015, 181, 808-816.	1.6	26
3847	Aberrant functional connectivity within the basal ganglia of patients with Parkinson's disease. <i>NeuroImage: Clinical</i> , 2015, 8, 126-132.	1.4	45

#	ARTICLE	IF	CITATIONS
3848	Clinical Validity of the Mattis Dementia Rating Scale in Differentiating Mild Cognitive Impairment in Parkinson's Disease and Normative Data. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 39, 303-311.	0.7	23
3849	The role of <i>TREM2</i> R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1407-1416.	0.4	152
3850	Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson's Disease: A Prospective, Cross-Sectional Study in Non-demented Patients. <i>Drugs and Aging</i> , 2015, 32, 401-407.	1.3	18
3851	Gait velocity and step length at baseline predict outcome of Nordic walking training in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 413-416.	1.1	17
3852	Non-dipping nocturnal blood pressure and psychosis parameters in Parkinson disease. <i>Clinical Autonomic Research</i> , 2015, 25, 109-116.	1.4	13
3853	Correlation Between Structural and Functional Retinal Changes in Parkinson Disease. <i>Journal of Neuro-Ophthalmology</i> , 2015, 35, 254-258.	0.4	58
3854	Bio-Interface of Conducting Polymer-Based Materials for Neuroregeneration. <i>Advanced Materials Interfaces</i> , 2015, 2, 1500059.	1.9	33
3855	Differentiation among parkinsonisms using quantitative diffusion kurtosis imaging. <i>NeuroReport</i> , 2015, 26, 267-272.	0.6	15
3856	Comparison of the diagnostic performance of H/M ratio between early and delayed phases for Lewy body disease. <i>Nuclear Medicine Communications</i> , 2015, 36, 477-480.	0.5	6
3857	Deep brain stimulation for treating Parkinson's disease. , 2015, , 341-359.		2
3858	Parkinsonian Syndromes. , 2015, , 769-785.		3
3859	Low-variance RNAs identify Parkinson's disease molecular signature in blood. <i>Movement Disorders</i> , 2015, 30, 813-821.	2.2	18
3860	Exercise and Medication Effects on Persons With Parkinson Disease Across the Domains of Disability. <i>Journal of Neurologic Physical Therapy</i> , 2015, 39, 85-92.	0.7	42
3861	Characterization of gastrointestinal disorders in patients with parkinsonian syndromes. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 455-460.	1.1	46
3862	Heart rate variability shows different cardiovascular modulation in Parkinson's disease patients with tremor dominant subtype compared to those with akinetic rigid dominant subtype. <i>Journal of Neural Transmission</i> , 2015, 122, 1441-1446.	1.4	17
3863	Cognitive impairment in Parkinson's disease. <i>Postgraduate Medical Journal</i> , 2015, 91, 212-220.	0.9	50
3864	Health-related quality of life in patients with Parkinson's disease: Implications for falling. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 573-576.	1.1	11
3865	The medical treatment of patients with Parkinson's disease receiving subthalamic neurostimulation. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 555-560.	1.1	12

#	ARTICLE	IF	CITATIONS
3866	Parkinson disease with REM sleep behavior disorder. <i>Neurology</i> , 2015, 84, 888-894.	1.5	77
3867	Micro<scp>RNA</scp> association with synucleinopathy conversion in rapid eye movement behavior disorder. <i>Annals of Neurology</i> , 2015, 77, 895-901.	2.8	50
3868	The Effects of Highly Challenging Balance Training in Elderly With Parkinsonâ€™s Disease. <i>Neurorehabilitation and Neural Repair</i> , 2015, 29, 827-836.	1.4	158
3869	Detecting and monitoring the symptoms of Parkinson's disease using smartphones: A pilot study. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 650-653.	1.1	285
3870	Variation in complement protein C1q is not a major contributor to cognitive impairment in Parkinsonâ€™s disease. <i>Neuroscience Letters</i> , 2015, 594, 66-69.	1.0	11
3871	The utility of cerebral perfusion SPECT analysis using SPM8, eZIS and vbSEE for the diagnosis of multiple system atrophy-parkinsonism. <i>Annals of Nuclear Medicine</i> , 2015, 29, 206-213.	1.2	4
3872	Randomized controlled trial protocol: balance training with rhythmical cues to improve and maintain balance control in Parkinsonâ€™s disease. <i>BMC Neurology</i> , 2015, 15, 162.	0.8	19
3873	Clinical efficacy of istradefylline versus rTMS on Parkinsonâ€™s disease in a randomized clinical trial. <i>Current Medical Research and Opinion</i> , 2015, 31, 2055-2058.	0.9	11
3874	Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 911-916.	1.1	70
3875	No parkinsonism in SCA2 and SCA3 despite severe neurodegeneration of the dopaminergic substantia nigra. <i>Brain</i> , 2015, 138, 3316-3326.	3.7	54
3876	Deep Brain Stimulation in a Dopaminergic Non-responsive Patient With Parkinson's Disease: Case Report and Systematic Review. <i>Brain Stimulation</i> , 2015, 8, 983-985.	0.7	0
3877	Nigrosome 1 Detection at 3T MRI for the Diagnosis of Early-Stage Idiopathic Parkinson Disease: Assessment of Diagnostic Accuracy and Agreement on Imaging Asymmetry and Clinical Laterality. <i>American Journal of Neuroradiology</i> , 2015, 36, 2010-2016.	1.2	81
3878	Exon dosage analysis of parkin gene in Chinese sporadic Parkinsonâ€™s disease. <i>Neuroscience Letters</i> , 2015, 604, 47-51.	1.0	17
3879	Contribution of a Trunk Accelerometer System to the Characterization of Gait in Patients With Mild-to-Moderate Parkinson's Disease. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2015, 19, 1803-1808.	3.9	32
3880	A System for Real-Time Feedback to Improve Gait and Posture in Parkinson's Disease. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2015, 19, 1809-1819.	3.9	17
3881	Cardiovascular responses during cold pressor test are different in Parkinson disease and multiple system atrophy with parkinsonism. <i>Clinical Autonomic Research</i> , 2015, 25, 219-224.	1.4	6
3882	Identification of a new target muscle for treatment in patients with Parkinson's disease who have lateral trunk flexion?. <i>Journal of the Neurological Sciences</i> , 2015, 358, 435-439.	0.3	9
3883	The effect of tremor onset on middle cerebellar peduncle of Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2015, 358, 172-177.	0.3	7

#	ARTICLE	IF	CITATIONS
3884	Resting-state functional connectivity of dentate nucleus is associated with tremor in Parkinson's disease. <i>Journal of Neurology</i> , 2015, 262, 2247-2256.	1.8	22
3885	Pathogenesis of Parkinson disease—the gut-brain axis and environmental factors. <i>Nature Reviews Neurology</i> , 2015, 11, 625-636.	4.9	465
3886	The Prague Stroop Test: Normative standards in older Czech adults and discriminative validity for mild cognitive impairment in Parkinson's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2015, 37, 794-807.	0.8	33
3887	Accuracy and cutoff values of delayed heart to mediastinum ratio with ¹²³ I-metaiodobenzylguanidine cardiac scintigraphy for Lewy body disease diagnoses. <i>BMC Neurology</i> , 2015, 15, 83.	0.8	9
3888	Characteristic laryngoscopic findings in Parkinson's disease patients after subthalamic nucleus deep brain stimulation and its correlation with voice disorder. <i>Journal of Neural Transmission</i> , 2015, 122, 1663-1672.	1.4	21
3889	What is a clinically important change in the Unified Dyskinesia Rating Scale in Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1349-1354.	1.1	24
3890	Anxiety and Depression Are Better Correlates of Parkinson's Disease Quality of Life Than Apathy. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2015, 27, 213-218.	0.9	40
3891	Putaminal serotonergic innervation. <i>Neurology</i> , 2015, 85, 853-860.	1.5	51
3892	Subthalamic deep brain stimulation effects on odor identification in Parkinson's disease. <i>European Journal of Neurology</i> , 2015, 22, 207-210.	1.7	16
3893	Identifying freezing of gait in Parkinson's disease during freezing provoking tasks using waist-mounted accelerometry. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1362-1366.	1.1	70
3894	Normal substantia nigra patients treated with levodopa – Clinical, therapeutic and pathological observations. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1232-1237.	1.1	4
3895	Is dominant-side onset associated with a better motor compensation in Parkinson's disease?. <i>Movement Disorders</i> , 2015, 30, 1921-1925.	2.2	47
3896	Enteric nervous system α -synuclein immunoreactivity in idiopathic REM sleep behavior disorder. <i>Neurology</i> , 2015, 85, 1761-1768.	1.5	121
3897	Generalized motor inhibitory deficit in Parkinson's disease patients who freeze. <i>Journal of Neural Transmission</i> , 2015, 122, 1693-1701.	1.4	20
3898	Motion discrimination in dementia with Lewy bodies and Alzheimer disease. <i>Neurology</i> , 2015, 85, 1376-1382.	1.5	13
3899	Cerebral small vessel disease and incident parkinsonism. <i>Neurology</i> , 2015, 85, 1569-1577.	1.5	85
3900	Differentiating progressive supranuclear palsy from Parkinson's disease by MRI-based dynamic cerebrospinal fluid flow. <i>Journal of the Neurological Sciences</i> , 2015, 357, 178-182.	0.3	5
3901	Caffeine and Neuroprotection in Parkinson's Disease. <i>Current Topics in Neurotoxicity</i> , 2015, , 233-272.	0.4	1

#	ARTICLE	IF	CITATIONS
3902	Head injury and risk for Parkinson disease. <i>Neurology</i> , 2015, 84, 1098-1103.	1.5	37
3903	Antisaccade errors reveal cognitive control deficits in Parkinson's disease with freezing of gait. <i>Journal of Neurology</i> , 2015, 262, 2745-2754.	1.8	34
3904	Progression of subcortical atrophy and iron deposition in multiple system atrophy: a comparison between clinical subtypes. <i>Journal of Neurology</i> , 2015, 262, 1876-1882.	1.8	33
3905	Metabolic Topology of Neurodegenerative Disorders: Influence of Cognitive and Motor Deficits. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1916-1921.	2.8	22
3906	Combined therapy of Di-Huang-Yi-Zhi with Donepezil in patients with Parkinson's disease dementia. <i>Neuroscience Letters</i> , 2015, 606, 13-17.	1.0	15
3907	Nigrostriatal dopamine-independent resting-state functional networks in Parkinson's disease. <i>NeuroImage</i> , 2015, 119, 296-304.	2.1	29
3908	Reduced plasma taurine level in Parkinson's disease: association with motor severity and levodopa treatment. <i>International Journal of Neuroscience</i> , 2016, 126, 1-7.	0.8	21
3909	Reduced facial expressiveness in Parkinson's disease: A pure motor disorder?. <i>Journal of the Neurological Sciences</i> , 2015, 358, 125-130.	0.3	52
3910	LRRK2 A419V variant is a risk factor for Parkinson's disease in Asian population. <i>Neurobiology of Aging</i> , 2015, 36, 2908.e11-2908.e15.	1.5	35
3911	Quantitative assessment of non-motor fluctuations in Parkinson's disease using the Non-Motor Symptoms Scale (NMSS). <i>Journal of Neural Transmission</i> , 2015, 122, 1673-1684.	1.4	52
3912	Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2015-311387.	0.9	207
3913	Dysrhythmia of timed movements in Parkinson's disease and freezing of gait. <i>Brain Research</i> , 2015, 1624, 222-231.	1.1	20
3914	Association between α -synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. <i>Brain</i> , 2015, 138, 2659-2671.	3.7	69
3915	The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 1. <i>American Journal of Neuroradiology</i> , 2015, 36, 229-235.	1.2	68
3916	Analysis and meta-analysis of five polymorphisms of the LINGO1 and LINGO2 genes in Parkinson's disease and multiple system atrophy in a Chinese population. <i>Journal of Neurology</i> , 2015, 262, 2478-2483.	1.8	18
3917	Automatic detection of voice onset time in dysarthric speech. , 2015, , .		2
3918	Impact of Rivastigmine on Cognitive Dysfunction and Falling in Parkinson's Disease Patients. <i>European Neurology</i> , 2015, 74, 86-91.	0.6	40
3919	The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1067-1071.	1.1	55

#	ARTICLE	IF	CITATIONS
3920	Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1170-1176.	1.1	43
3921	Differentiation of Parkinsonism-Predominant Multiple System Atrophy from Idiopathic Parkinson Disease Using 3T Susceptibility-Weighted MR Imaging, Focusing on Putaminal Change and Lesion Asymmetry. <i>American Journal of Neuroradiology</i> , 2015, 36, 2227-2234.	1.2	29
3922	Mutation analysis of CHCHD2 gene in Chinese familial Parkinson's disease. <i>Neurobiology of Aging</i> , 2015, 36, 3117.e7-3117.e8.	1.5	22
3923	Parkinson's Disease-Related Impairments in Body Movement, Coordination and Postural Control Mechanisms When Performing 80° Lateral Gaze Shifts. <i>IEEE Transactions on Neural Systems and Rehabilitation Engineering</i> , 2015, 23, 849-856.	2.7	7
3924	Association of depressive symptoms with circadian blood pressure alterations in Parkinson's disease. <i>Journal of Neurology</i> , 2015, 262, 2564-2571.	1.8	17
3925	Neuropsychological and imaging profile of patients with Parkinson's disease and freezing of gait. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1184-1190.	1.1	53
3926	Low FAB score as a predictor of future falling in patients with Parkinson's disease: a 2.5-year prospective study. <i>Journal of Neurology</i> , 2015, 262, 2049-2055.	1.8	11
3927	Effect of 24-h continuous rotigotine treatment on stationary and non-stationary locomotion in de novo patients with Parkinson disease in an open-label uncontrolled study. <i>Journal of Neurology</i> , 2015, 262, 2539-2547.	1.8	19
3928	Role for the microtubule-associated protein tau variant p.A152T in risk of α -synucleinopathies. <i>Neurology</i> , 2015, 85, 1680-1686.	1.5	31
3929	Machine learning classification of medication adherence in patients with movement disorders using non-wearable sensors. <i>Computers in Biology and Medicine</i> , 2015, 66, 120-134.	3.9	68
3930	The association between clinically relevant anxiety and other non-motor symptoms in Parkinson's disease. <i>Neurological Sciences</i> , 2015, 36, 2105-2109.	0.9	9
3931	No association of FAM47E rs6812193, SCARB2 rs6825004 and STX1B rs4889603 polymorphisms with Parkinson's disease in a Chinese Han population. <i>Journal of Neural Transmission</i> , 2015, 122, 1547-1552.	1.4	5
3932	Longitudinal study of normal cognition in Parkinson disease. <i>Neurology</i> , 2015, 85, 1276-1282.	1.5	197
3933	Task- and Context-Specific Balance Training Program Enhances Dynamic Balance and Functional Performance in Parkinsonian Nonfallers: A Randomized Controlled Trial With Six-Month Follow-Up. <i>Archives of Physical Medicine and Rehabilitation</i> , 2015, 96, 2103-2111.	0.5	29
3934	Motor loop dysfunction causes impaired cognitive sequencing in patients suffering from Parkinson's disease. <i>Neuropsychologia</i> , 2015, 77, 409-420.	0.7	14
3935	Balance differences in people with Parkinson disease with and without freezing of gait. <i>Gait and Posture</i> , 2015, 42, 306-309.	0.6	23
3936	Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. <i>Neurology</i> , 2015, 85, 1283-1292.	1.5	25
3937	Levels and Patterns of Physical Activity and Sedentary Behavior in Elderly People With Mild to Moderate Parkinson Disease. <i>Physical Therapy</i> , 2015, 95, 1135-1141.	1.1	102

#	ARTICLE	IF	CITATIONS
3938	Overnight S100B in Parkinson's Disease: A glimpse into sleep-related neuroinflammation. <i>Neuroscience Letters</i> , 2015, 608, 57-63.	1.0	13
3939	Different effects of dopaminergic medication on perceptual decision-making in Parkinson's disease as a function of task difficulty and speed-accuracy instructions. <i>Neuropsychologia</i> , 2015, 75, 577-587.	0.7	39
3940	D620N mutation in the VPS35 gene and R1205H mutation in the EIF4G1 gene are uncommon in the Greek population. <i>Neuroscience Letters</i> , 2015, 606, 113-116.	1.0	7
3941	Putamen-midbrain functional connectivity is related to striatal dopamine transporter availability in patients with Lewy body diseases. <i>NeuroImage: Clinical</i> , 2015, 8, 554-559.	1.4	22
3942	Diagnostic value of combined assessment of olfaction and substantia nigra hyperechogenicity for Parkinson's disease. <i>Neurologia (English Edition)</i> , 2015, 30, 496-501.	0.2	3
3943	Voxelwise meta-analysis of gray matter anomalies in Parkinson variant of multiple system atrophy and Parkinson's disease using anatomic likelihood estimation. <i>Neuroscience Letters</i> , 2015, 587, 79-86.	1.0	45
3944	Substantia nigra neuromelanin magnetic resonance imaging in <i>de novo</i> Parkinson's disease patients. <i>European Journal of Neurology</i> , 2015, 22, 540-546.	1.7	90
3945	Parkinson's disease beyond 20...years. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 849-855.	0.9	55
3946	Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis. <i>International Journal of Neuroscience</i> , 2015, 125, 645-654.	0.8	145
3947	miRNA expression is highly sensitive to a drug therapy in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 72-74.	1.1	58
3948	Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. <i>Movement Disorders</i> , 2015, 30, 19-36.	2.2	76
3949	Genotype-Phenotype Correlations in Parkinson Disease. , 2015, , 259-285.		1
3950	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. <i>Nature Reviews Neurology</i> , 2015, 11, 41-55.	4.9	144
3951	ON-OFF Effects of Dopaminergic Therapy on Psychiatric Symptoms in Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2015, 27, e134-e139.	0.9	7
3952	Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 49, 157-170.	2.9	31
3953	The Phenotypic Spectrum of Parkinson Disease. , 2015, , 229-241.		0
3954	Presence and progression of non-motor symptoms in relation to uric acid in <i>de novo</i> Parkinson's disease. <i>European Journal of Neurology</i> , 2015, 22, 93-98.	1.7	49
3955	Coronal plane spinal malalignment and Parkinson's disease: prevalence and associations with disease severity. <i>Spine Journal</i> , 2015, 15, 115-121.	0.6	32

#	ARTICLE	IF	CITATIONS
3956	Akinetic-rigid and tremor-dominant Parkinson's disease patients show different patterns of intrinsic brain activity. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 23-30.	1.1	82
3957	Cognitive functioning differentially predicts different dimensions of older drivers' on-road safety. <i>Accident Analysis and Prevention</i> , 2015, 75, 236-244.	3.0	76
3958	Fall frequency, predicting falls and participating in falls research: Similarities among people with Parkinson's disease with and without cognitive impairment. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 55-60.	1.1	20
3959	COQ2 p.V393A variant, rs148156462, is not associated with Parkinson's disease in a Taiwanese population. <i>Neurobiology of Aging</i> , 2015, 36, 546.e17-546.e18.	1.5	4
3960	Proficient motor impulse control in Parkinson disease patients with impulsive and compulsive behaviors. <i>Pharmacology Biochemistry and Behavior</i> , 2015, 129, 19-25.	1.3	43
3961	The onset of nonmotor symptoms in Parkinson's disease (The ONSET PD Study). <i>Movement Disorders</i> , 2015, 30, 229-237.	2.2	402
3962	Uric acid relates to dopamine transporter availability in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2015, 131, 127-131.	1.0	29
3963	The role of executive control in bilingual language production: A study with Parkinson's disease individuals. <i>Neuropsychologia</i> , 2015, 66, 99-110.	0.7	42
3964	Motor Switching and Motor Adaptation Deficits Contribute to Freezing of Gait in Parkinson's Disease. <i>Neurorehabilitation and Neural Repair</i> , 2015, 29, 132-142.	1.4	38
3965	Pure psychiatric presentation of the Lewy body disease is depression: an analysis of 60 cases verified with myocardial metaiodobenzylguanidine study. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 663-668.	1.3	13
3966	In vivo gastric detection of α -synuclein inclusions in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 517-524.	2.2	111
3967	Improving Response Inhibition in Parkinson's Disease with Atomoxetine. <i>Biological Psychiatry</i> , 2015, 77, 740-748.	0.7	93
3968	The effect of cannabis on oxidative stress and neurodegeneration induced by intrastriatal rotenone injection in rats. <i>Comparative Clinical Pathology</i> , 2015, 24, 359-378.	0.3	15
3969	Factores asociados a la calidad de vida de sujetos con enfermedad de Parkinson y a la carga en el cuidador. <i>Neurología</i> , 2015, 30, 257-263.	0.3	30
3970	Valor de la evaluación combinada de olfacción e hipercogenidad de sustancia negra en el diagnóstico de la enfermedad de Parkinson. <i>Neurología</i> , 2015, 30, 496-501.	0.3	10
3971	Quality of Life and Mild Cognitive Impairment in Early Parkinson's Disease: Does Subtype Matter?. <i>Journal of Parkinson's Disease</i> , 2015, 4, 331-336.	1.5	22
3972	Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 135-143.	0.9	217
3973	Accelerometer-based quantitative analysis of axial nocturnal movements differentiates patients with Parkinson's disease, but not high-risk individuals, from controls. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 32-37.	0.9	34

#	ARTICLE	IF	CITATIONS
3974	Steadiness of syllable repetition in early motor stages of Parkinson's disease. <i>Biomedical Signal Processing and Control</i> , 2015, 17, 55-59.	3.5	12
3975	No evidence of association between common European mitochondrial DNA variants in Alzheimer, Parkinson, and migraine in the Spanish population. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2015, 168, 54-65.	1.1	37
3976	The major impact of freezing of gait on quality of life in Parkinson's disease. <i>Journal of Neurology</i> , 2015, 262, 108-115.	1.8	105
3977	An exome study of Parkinson's disease in Sardinia, a Mediterranean genetic isolate. <i>Neurogenetics</i> , 2015, 16, 55-64.	0.7	20
3978	The Impact of Mitochondrial Fusion and Fission Modulation in Sporadic Parkinson's Disease. <i>Molecular Neurobiology</i> , 2015, 52, 573-586.	1.9	79
3979	Prevalence of Parkinson's disease in Baskale, Turkey: a population based study. <i>Neurological Sciences</i> , 2015, 36, 411-413.	0.9	13
3980	Association between ubiquitin carboxy-terminal hydrolase-L1 S18Y variant and risk of Parkinson's disease: the impact of ethnicity and onset age. <i>Neurological Sciences</i> , 2015, 36, 179-188.	0.9	14
3981	The Upshot of LRRK2 Inhibition to Parkinson's Disease Paradigm. <i>Molecular Neurobiology</i> , 2015, 52, 1804-1820.	1.9	25
3982	What matters to people with Parkinson's disease living in Australia?. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 338-341.	0.8	9
3983	Parkinson's disease: chameleons and mimics. <i>Practical Neurology</i> , 2015, 15, 14-25.	0.5	61
3984	Vitamin D receptor gene polymorphisms and the risk of Parkinson's disease. <i>Neurological Sciences</i> , 2015, 36, 247-255.	0.9	21
3985	Impaired cognitive control in Parkinson's disease patients with freezing of gait in response to cognitive load. <i>Journal of Neural Transmission</i> , 2015, 122, 653-660.	1.4	29
3986	Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 767-773.	0.9	93
3987	The associations between fatigue, apathy, and depression in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2015, 131, 80-87.	1.0	93
3988	Restless legs syndrome in patients with Parkinson's disease: a comparative study on prevalence, clinical characteristics, quality of life and nutritional status. <i>Acta Neurologica Scandinavica</i> , 2015, 131, 211-218.	1.0	60
3989	Parkinson's disease patients with pain suffer from more severe non-motor symptoms. <i>Neurological Sciences</i> , 2015, 36, 263-268.	0.9	19
3990	Clinicoradiological comparison between vascular parkinsonism and Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 547-553.	0.9	36
3991	Increased risk of impulse control symptoms in Parkinson's disease with REM sleep behaviour disorder. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 174-179.	0.9	58

#	ARTICLE	IF	CITATIONS
3992	Correlation between decreased CSF α -synuclein and A β 42 in Parkinson disease. <i>Neurobiology of Aging</i> , 2015, 36, 476-484.	1.5	59
3993	Sleep spindles in Parkinson's disease may predict the development of dementia. <i>Neurobiology of Aging</i> , 2015, 36, 1083-1090.	1.5	130
3994	The correlation between <i>Toxoplasma gondii</i> infection and Parkinson's disease: a case-control study. <i>Journal of Parasitic Diseases</i> , 2016, 40, 872-876.	0.4	22
3995	Informe de la Fundaci3n del Cerebro sobre el impacto social de la enfermedad de Parkinson en EspaAa. <i>NeurologAa</i> , 2016, 31, 401-413.	0.3	29
3996	Rapid Eye Movement Sleep Homeostatic Response: A Potential Marker for Early Detection of Parkinson's Disease. , 2016, 6, .		0
3997	Cluster analysis of cognitive performance in a sample of patients with Parkinson's disease. <i>Dementia E Neuropsychologia</i> , 2016, 10, 315-319.	0.3	6
3998	The impact of cognitive performance on quality of life in individuals with Parkinson's disease. <i>Dementia E Neuropsychologia</i> , 2016, 10, 303-309.	0.3	11
4000	Cognitive Impairment in Parkinson's Disease: Historical Review, Past, and Present. , 2016, , .		0
4001	Pesticide-induced Immunotoxicity May Underlie Synergistic Gene-environment Interactions that Increase Parkinson's Disease Risk for High-risk Genotype Individuals at rs3129882 in the HLA-DRA Gene. <i>Journal of Clinical & Cellular Immunology</i> , 2016, 07, .	1.5	0
4002	Traffic-Related Air Pollution and Parkinson's Disease in Denmark: A Case-Control Study. <i>Environmental Health Perspectives</i> , 2016, 124, 351-356.	2.8	144
4003	Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid. <i>Journal of Parkinson's Disease</i> , 2016, 6, 307-315.	1.5	24
4004	TraduAe o e adaptaAe o cultural do swallowing disturbance questionnaire para o portuguAs-brasileiro. <i>Revista CEFAC: AtualizaAe o CientAfica Em Fonoaudiologia</i> , 2016, 18, 828-834.	0.2	7
4005	Main determinants of physical activity levels in individuals with Parkinson's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2016, 74, 112-116.	0.3	13
4006	Parkinson's Disease with Fatigue: Clinical Characteristics and Potential Mechanisms Relevant to		

#	ARTICLE	IF	CITATIONS
4011	Enabling breakthroughs in Parkinson's disease with wearable technologies and big data analytics. <i>MHealth</i> , 2016, 2, 20-20.	0.9	28
4012	Speech disorders did not correlate with age at onset of Parkinson's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2016, 74, 117-121.	0.3	16
4013	Comparison of the use of screening tools for evaluating cognitive impairment in patients with Parkinson's disease. <i>Dementia E Neuropsychologia</i> , 2016, 10, 344-350.	0.3	8
4014	Insula Volume and Saliency Network Are Associated with Memory Decline in Parkinson Disease: Complementary Analyses of Voxel-Based Morphometry versus Volume of Interest. <i>Parkinson's Disease</i> , 2016, 2016, 1-8.	0.6	9
4015	Relationships among Depression, Anxiety, Sleep, and Quality of Life in Patients with Parkinson's Disease in Taiwan. <i>Parkinson's Disease</i> , 2016, 2016, 1-8.	0.6	25
4016	Median and Ulnar Neuropathy Assessment in Parkinson's Disease regarding Symptom Severity and Asymmetry. <i>Parkinson's Disease</i> , 2016, 2016, 1-7.	0.6	6
4017	An Expert Diagnosis System for Parkinson Disease Based on Genetic Algorithm-Wavelet Kernel-Extreme Learning Machine. <i>Parkinson's Disease</i> , 2016, 2016, 1-9.	0.6	44
4018	Abnormal Echogenicity of the Substantia Nigra, Raphe Nuclei, and Third-Ventricle Width as Markers of Cognitive Impairment in Parkinsonian Disorders: A Cross-Sectional Study. <i>Parkinson's Disease</i> , 2016, 2016, 1-9.	0.6	3
4019	Altered Spontaneous Brain Activity in Cortical and Subcortical Regions in Parkinson's Disease. <i>Parkinson's Disease</i> , 2016, 2016, 1-6.	0.6	14
4020	Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective?. <i>BioMed Research International</i> , 2016, 2016, 1-6.	0.9	25
4021	Mindfulness for Motor and Nonmotor Dysfunctions in Parkinson's Disease. <i>Parkinson's Disease</i> , 2016, 2016, 1-13.	0.6	53
4022	The Effect of Hyperhomocysteinemia on Motor Symptoms, Cognitive Status, and Vascular Risk in Patients with Parkinson's Disease. <i>Parkinson's Disease</i> , 2016, 2016, 1-7.	0.6	9
4023	Cognitive Function in Parkinson's Disease Patients with and without Anxiety. <i>Neurology Research International</i> , 2016, 2016, 1-7.	0.5	9
4024	Clinical Pain and Neuropsychological Functioning in Parkinson's Disease: Are They Related?. <i>Parkinson's Disease</i> , 2016, 2016, 1-9.	0.6	3
4025	Parkinson's Disease and Homocysteine: A Community-Based Study in a Folate and Vitamin B12 Deficient Population. <i>Parkinson's Disease</i> , 2016, 2016, 1-6.	0.6	7
4026	Deep Brain Stimulation Frequency of the Subthalamic Nucleus Affects Phonemic and Action Fluency in Parkinson's Disease. <i>Parkinson's Disease</i> , 2016, 2016, 1-9.	0.6	14
4027	Degraded Impairment of Emotion Recognition in Parkinson's Disease Extends from Negative to Positive Emotions. <i>Behavioural Neurology</i> , 2016, 2016, 1-8.	1.1	18
4028	Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and Rehabilitation. <i>Parkinson's Disease</i> , 2016, 2016, 1-18.	0.6	161

#	ARTICLE	IF	CITATIONS
4029	Diagnosing Parkinson's Diseases Using Fuzzy Neural System. Computational and Mathematical Methods in Medicine, 2016, 2016, 1-9.	0.7	37
4030	Postural Stability in Parkinson's Disease Patients Is Improved after Stochastic Resonance Therapy. Parkinson's Disease, 2016, 2016, 1-7.	0.6	12
4031	Anticholinergic agents in the management of Parkinson's disease. , 0, , 5-12.		0

4032 Cardiovascular Baroreflex Sensitivity in Parkinson's Disease and Multiple-System Atrophy. Journal of

#	ARTICLE	IF	CITATIONS
4047	GLP-2 Attenuates LPS-Induced Inflammation in BV-2 Cells by Inhibiting ERK1/2, JNK1/2 and NF- κ B Signaling Pathways. <i>International Journal of Molecular Sciences</i> , 2016, 17, 190.	1.8	42
4048	Analysis and Visualization of 3D Motion Data for UPDRS Rating of Patients with Parkinson's Disease. <i>Sensors</i> , 2016, 16, 930.	2.1	24
4049	Assessing Motor Fluctuations in Parkinson's Disease Patients Based on a Single Inertial Sensor. <i>Sensors</i> , 2016, 16, 2132.	2.1	34
4050	Interdisciplinary Parkinson's Disease Deep Brain Stimulation Screening and the Relationship to Unintended Hospitalizations and Quality of Life. <i>PLoS ONE</i> , 2016, 11, e0153785.	1.1	15
4051	Alterations in Lipid and Inositol Metabolisms in Two Dopaminergic Disorders. <i>PLoS ONE</i> , 2016, 11, e0147129.	1.1	31
4052	Motor Subtype as a Predictor of Future Working Memory Performance in Idiopathic Parkinson's Disease. <i>PLoS ONE</i> , 2016, 11, e0152534.	1.1	12
4053	Bilateral Deep Brain Stimulation of the Subthalamic Nucleus under Sedation with Propofol and Fentanyl. <i>PLoS ONE</i> , 2016, 11, e0152619.	1.1	12
4054	Cerebral Metabolic Differences Associated with Cognitive Impairment in Parkinson's Disease. <i>PLoS ONE</i> , 2016, 11, e0152716.	1.1	32
4055	Exploring the Effects of Genetic Variants on Clinical Profiles of Parkinson's Disease Assessed by the Unified Parkinson's Disease Rating Scale and the Hoehn-Yahr Stage. <i>PLoS ONE</i> , 2016, 11, e0155758.	1.1	12
4056	Gene Expression Differences in Peripheral Blood of Parkinson's Disease Patients with Distinct Progression Profiles. <i>PLoS ONE</i> , 2016, 11, e0157852.	1.1	36
4057	Bee Venom for the Treatment of Parkinson Disease – A Randomized Controlled Clinical Trial. <i>PLoS ONE</i> , 2016, 11, e0158235.	1.1	39
4058	A Validation Study of a Smartphone-Based Finger Tapping Application for Quantitative Assessment of Bradykinesia in Parkinson's Disease. <i>PLoS ONE</i> , 2016, 11, e0158852.	1.1	91
4059	Odor Identification Test in Idiopathic REM-Behavior Disorder and Parkinson's Disease in China. <i>PLoS ONE</i> , 2016, 11, e0160199.	1.1	13
4060	Evaluation of Retinal Vessel Morphology in Patients with Parkinson's Disease Using Optical Coherence Tomography. <i>PLoS ONE</i> , 2016, 11, e0161136.	1.1	35
4061	Postural instability and falls are more frequent in Parkinson's disease patients with worse trunk mobility. <i>Arquivos De Neuro-Psiquiatria</i> , 2016, 74, 519-523.	0.3	13
4062	A Comparison of Substantia Nigra T1 Hyperintensity in Parkinson's Disease Dementia, Alzheimer's Disease and Age-Matched Controls: Volumetric Analysis of Neuromelanin Imaging. <i>Korean Journal of Radiology</i> , 2016, 17, 633.	1.5	16
4063	Biomarkers of Parkinson's disease: recent insights, current challenges, and future prospects. <i>Journal of Parkinsonism and Restless Legs Syndrome</i> , 2016, , 1.	0.8	2
4064	Comparing postural balance among older adults and Parkinson's disease patients. <i>Motriz Revista De Educacao Fisica</i> , 2016, 22, 261-265.	0.3	6

#	ARTICLE	IF	CITATIONS
4065	Single-photon emission tomography. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 135, 241-250.	1.0	12
4066	Relationship between resting and action tremors in Parkinson's disease. Journal of Neurosciences in Rural Practice, 2016, 07, 232-237.	0.3	3
4067	Serum Leptin Levels and Cognition in Parkinson's Disease Patients. Noropsikiyatri Arsivi, 2016, 53, 241-244.	0.7	5
4068	Dopaminergic Therapy Modulates Cortical Perfusion in Parkinson Disease With and Without Dementia According to Arterial Spin Labeled Perfusion Magnetic Resonance Imaging. Medicine (United States), 2016, 95, e2206.	0.4	28
4069	Association Between Sagittal Balance and Scoliosis in Patients with Parkinson Disease. American Journal of Physical Medicine and Rehabilitation, 2016, 95, 39-46.	0.7	15
4070	How neuropathology can contribute to the understanding of dementia. Neurodegenerative Disease Management, 2016, 6, 183-186.	1.2	1
4071	Predictors of postprandial hypotension in elderly patients with de novo Parkinson's disease. Journal of Neural Transmission, 2016, 123, 1331-1339.	1.4	21
4072	Comparative Gait Analysis in Progressive Supranuclear Palsy and Parkinson's Disease. European Neurology, 2016, 75, 282-289.	0.6	35
4073	Dopaminergic system and dream recall: An MRI study in Parkinson's disease patients. Human Brain Mapping, 2016, 37, 1136-1147.	1.9	36
4074	Quantitative susceptibility mapping of the midbrain in Parkinson's disease. Movement Disorders, 2016, 31, 317-324.	2.2	133
4075	Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease. Movement Disorders, 2016, 31, 325-334.	2.2	87
4076	Treatment of Mild Camptocormia with Selegiline in Patients with Parkinson's Disease. European Neurology, 2016, 76, 35-39.	0.6	6
4077	Resistance Training with Instability for Patients with Parkinson's Disease. Medicine and Science in Sports and Exercise, 2016, 48, 1678-1687.	0.2	67
4078	Psychological Predictors of Anxiety and Depression in Parkinson's Disease: A Systematic Review. Journal of Clinical Psychology, 2016, 72, 979-998.	1.0	29
4079	Î±-Synuclein genetic variability: A biomarker for dementia in Parkinson disease. Annals of Neurology, 2016, 79, 991-999.	2.8	85
4080	DRUM-EPD: The Use of a Drum Circle to Improve the Symptoms and Signs of Parkinson's Disease (PD). Movement Disorders Clinical Practice, 2016, 3, 243-249.	0.8	30
4081	Altered inhibitory interaction among inferior frontal and motor cortex in dopamine-induced dyskinesias. Movement Disorders, 2016, 31, 755-759.	2.2	20
4082	Relearning of Writing Skills in Parkinson's Disease After Intensive Amplitude Training. Movement Disorders, 2016, 31, 1209-1216.	2.2	36

#	ARTICLE	IF	CITATIONS
4083	Loss of Nigral Hyperintensity on 3 Tesla MRI of Parkinsonism: Comparison With ¹²³ I-β-CIT SPECT. <i>Movement Disorders</i> , 2016, 31, 684-692.	2.2	96
4084	Impact of sleep quality on the quality of life of patients with Parkinson's disease: a questionnaire based study. <i>Clinical Neurology and Neurosurgery</i> , 2016, 148, 29-34.	0.6	32
4085	The potential benefits of Zumba Gold® in people with mild-to-moderate Parkinson's disease: Feasibility and effects of dance styles and number of sessions. <i>Complementary Therapies in Medicine</i> , 2016, 27, 68-73.	1.3	16
4086	Imaging-based differential diagnosis between multiple system atrophy and Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2016, 368, 104-108.	0.3	23
4087	Associations of pain and depression with marital status in patients diagnosed with Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2016, 133, 276-280.	1.0	11
4088	The Neural Basis of Postural Instability Gait Disorder Subtype of Parkinson's Disease: A PET and fMRI Study. <i>CNS Neuroscience and Therapeutics</i> , 2016, 22, 360-367.	1.9	29
4089	The impact of non-motor symptoms on the quality of life of Parkinson's disease patients: a longitudinal study. <i>European Journal of Neurology</i> , 2016, 23, 854-860.	1.7	167
4090	Lung Function Testing <i>On</i> and <i>Off</i> Dopaminergic Medication in Parkinson's Disease Patients With and Without Dysphagia. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 146-150.	0.8	7
4091	DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 ^{R1441G} Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 335-343.	2.2	33
4092	Functional Connectivity of Vim Nucleus in Tremor and Akinetic/Rigid Dominant Parkinson's Disease. <i>CNS Neuroscience and Therapeutics</i> , 2016, 22, 378-386.	1.9	27
4093	Hypersialylation is a common feature of neurofibrillary tangles and granulovacuolar degenerations in Alzheimer's disease and tauopathy brains. <i>Neuropathology</i> , 2016, 36, 333-345.	0.7	19
4094	Health-related quality of life as a predictor of recurrent falling in Parkinson's disease: 1-year follow-up study. <i>Psychogeriatrics</i> , 2016, 16, 362-367.	0.6	7
4095	Neuropsychological correlates of Pisa syndrome in patients with Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2016, 134, 101-107.	1.0	23
4096	Skin nerve misfolded α-synuclein in pure autonomic failure and Parkinson disease. <i>Annals of Neurology</i> , 2016, 79, 306-316.	2.8	118
4097	Substantia nigra hyperechogenicity and Parkinson's disease risk in patients with essential tremor. <i>Movement Disorders</i> , 2016, 31, 579-583.	2.2	17
4098	Facilitating effects of deep brain stimulation on feedback learning in Parkinson's disease. <i>Behavioural Brain Research</i> , 2016, 313, 88-96.	1.2	3
4099	Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson's disease patients with mild cognitive impairment. <i>Human Brain Mapping</i> , 2016, 37, 968-977.	1.9	40
4100	Functional Connectivity Differences of the Subthalamic Nucleus Related to Parkinson's Disease. <i>Human Brain Mapping</i> , 2016, 37, 1235-1253.	1.9	25

#	ARTICLE	IF	CITATIONS
4101	Clinical assessment and prevalence of parkinsonism in Japanese elderly people. <i>Acta Neurologica Scandinavica</i> , 2016, 133, 373-379.	1.0	17
4102	Position Emission Tomography/Single-Photon Emission Tomography Neuroimaging for Detection of Premotor Parkinson's Disease. <i>CNS Neuroscience and Therapeutics</i> , 2016, 22, 167-177.	1.9	18
4103	Dysautonomia in prodromal α -synucleinopathy: peripheral versus central autonomic degeneration. <i>European Journal of Neurology</i> , 2016, 23, 878-890.	1.7	13
4104	Night-time sleep in Parkinson's disease – the potential use of Parkinson's KinetiGraph: a prospective comparative study. <i>European Journal of Neurology</i> , 2016, 23, 1275-1288.	1.7	38
4105	Different PD-MCI criteria and risk of dementia in Parkinson's disease: 4-year longitudinal study. <i>Npj Parkinson's Disease</i> , 2016, 2, 15027.	2.5	55
4106	Prediction of orthostatic hypotension in multiple system atrophy and Parkinson disease. <i>Scientific Reports</i> , 2016, 6, 21649.	1.6	13
4107	Paired Studies Comparing Clinical Profiles of Lewy Body Dementia with Alzheimer's and Parkinson's Diseases. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 995-1004.	1.2	23
4108	Prodromal Clinical Markers of Parkinson disease in Gaucher Disease Individuals. <i>European Neurology</i> , 2016, 76, 19-21.	0.6	13
4109	Serum Lymphocyte-Associated Cytokine Concentrations Change More Rapidly over Time in Multiple System Atrophy Compared to Parkinson Disease. <i>NeuroImmunoModulation</i> , 2016, 23, 301-308.	0.9	23
4110	Hallucinations in schizophrenia and Parkinson's disease: an analysis of sensory modalities involved and the repercussion on patients. <i>Scientific Reports</i> , 2016, 6, 38152.	1.6	64
4111	Salivary total α -synuclein, oligomeric α -synuclein and SNCA variants in Parkinson's disease patients. <i>Scientific Reports</i> , 2016, 6, 28143.	1.6	55
4112	Apathy in Mild Parkinson's Disease: Neuropsychological and Neuroimaging Evidence. <i>Journal of Parkinson's Disease</i> , 2016, 6, 821-832.	1.5	28
4113	Objectively Assessed Physical Activity and its Association with Balance, Physical Function and Dyskinesia in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2016, 6, 833-840.	1.5	12
4114	Evaluating the Efficacy of Nocturnal Continuous Subcutaneous Apomorphine Infusion in Sleep Disorders in Advanced Parkinson's Disease: The APO-NIGHT Study. <i>Journal of Parkinson's Disease</i> , 2016, 6, 787-792.	1.5	18
4115	Cognitive and Neuroanatomical Correlates in Early Versus Late Onset Parkinson's Disease Dementia. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 485-495.	1.2	6
4116	Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists. <i>Internal Medicine</i> , 2016, 55, 2765-2769.	0.3	10
4117	Subjective Perceived Motor Improvement after Acute Levodopa Challenge in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2016, 6, 779-785.	1.5	9
4118	Impaired Pain Processing Correlates with Cognitive Impairment in Parkinson's Disease. <i>Internal Medicine</i> , 2016, 55, 3113-3118.	0.3	6

#	ARTICLE	IF	CITATIONS
4119	Importance of ¹²³ I-ioflupane SPECT and Myocardial MIBG Scintigraphy to Determine the Candidate of Deep Brain Stimulation for Parkinson's Disease. <i>Neurologia Medico-Chirurgica</i> , 2016, 56, 125-131.	1.0	5
4120	Global cognitive function and processing speed are associated with gait and balance dysfunction in Parkinson's disease. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2016, 13, 94.	2.4	32
4121	Assessment of Nonmotor Fluctuations Using a Diary in Advanced Parkinson's disease. <i>Journal of Parkinson's Disease</i> , 2016, 6, 597-607.	1.5	19
4122	Diagnostic utility of CSF α -synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2016, 6, e011113.	0.8	10
4123	Development and Validation of the Parkinson's Disease Medication Beliefs Scale (PD-Rx). <i>Journal of Parkinson's Disease</i> , 2016, 6, 383-392.	1.5	7
4124	Use of Gray-Level Histograms to Assess Substantia Nigra Echogenicity in Transcranial Sonography Images of Parkinson Disease Patients. <i>Journal of Diagnostic Medical Sonography</i> , 2016, 32, 326-333.	0.1	0
4125	Lack of association between IL-10 and IL-18 gene promoter polymorphisms and Parkinson's disease with cognitive impairment in a Chinese population. <i>Scientific Reports</i> , 2016, 6, 19021.	1.6	35
4126	Validation of a Smartphone Application Measuring Motor Function in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2016, 6, 371-382.	1.5	44
4127	Increased Cognitive Control During Execution of Finger Tap Movement in People with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2016, 6, 639-650.	1.5	9
4128	Motor and non-motor symptoms of Parkinson's disease and their impact on quality of life and on different clinical subgroups. <i>Neurologia (English Edition)</i> , 2016, 31, 585-591.	0.2	36
4129	Parkinsonism Differentiates Idiopathic Normal Pressure Hydrocephalus from Its Mimics. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 123-127.	1.2	10
4130	Prevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body Disorders. <i>Journal of Parkinson's Disease</i> , 2016, 6, 153-163.	1.5	58
4131	Mild Cognitive Impairment in Parkinson's Disease: Impact on Caregiver Outcomes. <i>Journal of Parkinson's Disease</i> , 2016, 6, 589-596.	1.5	20
4132	Cortical Implications of Advancing Age and Disease Duration in Parkinson's Disease Patients with Postural Instability and Gait Dysfunction. <i>Journal of Parkinson's Disease</i> , 2016, 6, 441-451.	1.5	18
4133	Botulinum Toxin Use in Refractory Pain and Other Symptoms in Parkinsonism. <i>Canadian Journal of Neurological Sciences</i> , 2016, 43, 697-702.	0.3	33
4134	RAB39B gene mutations are not linked to familial Parkinson's disease in China. <i>Scientific Reports</i> , 2016, 6, 34502.	1.6	9
4135	Aldehyde dehydrogenase 2 is associated with cognitive functions in patients with Parkinson's disease. <i>Scientific Reports</i> , 2016, 6, 30424.	1.6	27
4136	Clinical subtypes and genetic heterogeneity: of lumping and splitting in Parkinson disease. <i>Current Opinion in Neurology</i> , 2016, 29, 727-734.	1.8	55

#	ARTICLE	IF	CITATIONS
4137	Modified serpinA1 as risk marker for Parkinson's disease dementia: Analysis of baseline data. <i>Scientific Reports</i> , 2016, 6, 26145.	1.6	24
4138	Suitability of the Depression, Anxiety, and Stress Scale in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2016, 6, 609-616.	1.5	12
4139	Reduction of Small Fibers of Thoracic Ventral Roots and Neurons of Intermediolateral Nucleus in Parkinson Disease and Dementia with Lewy Bodies. <i>Journal of Parkinson's Disease</i> , 2016, 6, 325-334.	1.5	7
4140	The Clinical Phenotype of Idiopathic Rapid Eye Movement Sleep Behavior Disorder at Presentation: A Study in 203 Consecutive Patients. <i>Sleep</i> , 2016, 39, 121-132.	0.6	177
4141	Mortality and Its Risk Factors in Patients with Rapid Eye Movement Sleep Behavior Disorder. <i>Sleep</i> , 2016, 39, 1543-1550.	0.6	20
4142	A prospective study of freezing of gait with early Parkinson disease in Chinese patients. <i>Medicine (United States)</i> , 2016, 95, e4056.	0.4	53
4143	Non-Motor symptoms in Portuguese Parkinson's Disease patients: correlation and impact on Quality of Life and Activities of Daily Living. <i>Scientific Reports</i> , 2016, 6, 32267.	1.6	38
4144	24-Hour Ambulatory Blood Pressure Monitoring in SWEDDs Patients With Parkinsonism. <i>Canadian Journal of Neurological Sciences</i> , 2016, 43, 390-397.	0.3	9
4145	Intérêts de la réalité virtuelle pour l'évaluation et la prise en charge des perturbations cognitives et comportementales associées au vieillissement pathologique. <i>NPG Neurologie - Psychiatrie - Gériatrie</i> , 2016, 16, 313-319.	0.1	2
4146	Biomarkers in Prodromal Parkinson Disease: a Qualitative Review. <i>Journal of the International Neuropsychological Society</i> , 2016, 22, 956-967.	1.2	19
4147	Serotonergic dysfunctions and abnormal iron metabolism: Relevant to mental fatigue of Parkinson disease. <i>Scientific Reports</i> , 2016, 6, 19.	1.6	72
4148	Vascular Risk Factors and Cognition in Parkinson's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 563-570.	1.2	49
4149	Verbal memory declines more in female patients with Parkinson's disease: the importance of gender-corrected normative data. <i>Psychological Medicine</i> , 2016, 46, 2275-2286.	2.7	14
4150	Prevalence and type of cervical deformities among adults with Parkinson's disease: a cross-sectional study. <i>Journal of Neurosurgery: Spine</i> , 2016, 24, 527-534.	0.9	18
4151	Assessment of α -synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. <i>Lancet Neurology</i> , The, 2016, 15, 708-718.	4.9	145
4152	Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease. <i>Pharmacogenomics</i> , 2016, 17, 481-488.	0.6	35
4153	Prevalence of impaired odor identification in Parkinson disease with imaging evidence of nigrostriatal denervation. <i>Journal of Neural Transmission</i> , 2016, 123, 421-424.	1.4	26
4154	Comparison of Self-report and Performance-Based Balance Measures for Predicting Recurrent Falls in People With Parkinson Disease: Cohort Study. <i>Physical Therapy</i> , 2016, 96, 1074-1084.	1.1	31

#	ARTICLE	IF	CITATIONS
4155	Cardiac sympathetic index identifies patients with Parkinson's disease and REM behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2016, 26, 62-66.	1.1	20
4156	A Japanese multicenter survey characterizing pain in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2016, 365, 162-166.	0.3	8
4157	Clinical and psychopathological factors associated with impulse control disorders in Parkinson's disease. <i>Neurología (English Edition)</i> , 2016, 31, 231-238.	0.2	15
4158	Alterations of functional and structural connectivity of freezing of gait in Parkinson's disease. <i>Journal of Neurology</i> , 2016, 263, 1583-1592.	1.8	122
4159	Effects of leg muscle fatigue on gait in patients with Parkinson's disease and controls with high and low levels of daily physical activity. <i>Gait and Posture</i> , 2016, 47, 86-91.	0.6	34
4160	Early Onset Parkinson's disease due to DJ1 mutations: An Indian study. <i>Parkinsonism and Related Disorders</i> , 2016, 32, 20-24.	1.1	18
4161	Predictors of the placebo response in clinical trials on Parkinson's disease: A meta-analysis. <i>Parkinsonism and Related Disorders</i> , 2016, 29, 83-89.	1.1	19
4162	SLC1A2 rs3794087 are associated with susceptibility to Parkinson's disease, but not essential tremor, amyotrophic lateral sclerosis or multiple system atrophy in a Chinese population. <i>Journal of the Neurological Sciences</i> , 2016, 365, 96-100.	0.3	17
4163	The difference of apparent diffusion coefficient in the middle cerebellar peduncle among parkinsonian syndromes: Evidence from a meta-analysis. <i>Journal of the Neurological Sciences</i> , 2016, 363, 90-94.	0.3	9
4164	A homozygous parkin p.G284R mutation in a Chinese family with autosomal recessive juvenile parkinsonism. <i>Neuroscience Letters</i> , 2016, 624, 100-104.	1.0	13
4165	Early-onset vs. Late-onset Parkinson's disease: A Clinical-pathological Study. <i>Canadian Journal of Neurological Sciences</i> , 2016, 43, 113-119.	0.3	66
4166	Effect of high-frequency repetitive transcranial magnetic stimulation on major depressive disorder in patients with Parkinson's disease. <i>Journal of Neurology</i> , 2016, 263, 1442-1448.	1.8	41
4167	Evidence for small fiber neuropathy in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 94-99.	1.1	60
4168	Acute and Long-Term Effects of Multidirectional Treadmill Training on Gait and Balance in Parkinson Disease. <i>PM and R</i> , 2016, 8, 1151-1158.	0.9	17
4169	The social impact of Parkinson's disease in Spain: Report by the Spanish Foundation for the Brain. <i>Neurología (English Edition)</i> , 2016, 31, 401-413.	0.2	16
4170	Disease-specific longevity of impulse generators in deep brain stimulation and review of the literature. <i>Journal of Neural Transmission</i> , 2016, 123, 621-630.	1.4	27
4171	No association of GPNMB rs156429 polymorphism with Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy in Chinese population. <i>Neuroscience Letters</i> , 2016, 622, 113-117.	1.0	15
4172	Mild cerebello-thalamo-cortical impairment in patients with normal dopaminergic scans (SWEDD). <i>Parkinsonism and Related Disorders</i> , 2016, 28, 23-28.	1.1	20

#	ARTICLE	IF	CITATIONS
4173	The relationship between specific cognitive defects and burden of care in Parkinson's disease. <i>International Psychogeriatrics</i> , 2016, 28, 275-281.	0.6	27
4174	Perception of Communicative and Non-communicative Motion-Defined Gestures in Parkinson's Disease. <i>Journal of the International Neuropsychological Society</i> , 2016, 22, 540-550.	1.2	14
4175	Parkinson disease patients' perspectives on palliative care needs. <i>Neurology: Clinical Practice</i> , 2016, 6, 209-219.	0.8	75
4176	Physicians' experience with RYTARY (carbidopa and levodopa) extended-release capsules in patients who have Parkinson disease. <i>Neurology</i> , 2016, 86, S25-35.	1.5	5
4177	Impact of limiting visual input on gait: Individuals with Parkinson disease, age-matched controls, and healthy young participants. <i>Somatosensory & Motor Research</i> , 2016, 33, 29-34.	0.4	5
4178	Strategies in probabilistic feedback learning in Parkinson patients OFF medication. <i>Neuroscience</i> , 2016, 320, 8-18.	1.1	9
4179	A new MEMS neural probe system integrated with push-pull microfluidic channels and biosensors for real-time monitoring of neurochemicals. , 2016, , .		1
4180	Secondary task performance during challenging walking tasks and freezing episodes in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2016, 123, 495-501.	1.4	10
4181	FP-CIT- and IBZM-SPECT in Corticobasal Syndrome: Results from a Clinical Follow-Up Study. <i>Neurodegenerative Diseases</i> , 2016, 16, 342-347.	0.8	19
4182	Restless leg syndrome: a risk factor of higher prevalence of anxiety and depression in Parkinson's disease patients. <i>Neurological Research</i> , 2016, 38, 309-312.	0.6	15
4183	Age-dependent cognitive and affective differences in Alzheimer's and Parkinson's diseases in relation to MRI findings. <i>Journal of the Neurological Sciences</i> , 2016, 365, 3-8.	0.3	24
4184	Cognitive decline and quality of life in incident Parkinson's disease: The role of attention. <i>Parkinsonism and Related Disorders</i> , 2016, 27, 47-53.	1.1	133
4185	Drugs with potential cardiac adverse effects: Retrospective study in a large cohort of parkinsonian patients. <i>Revue Neurologique</i> , 2016, 172, 318-323.	0.6	20
4186	Quetiapine for Psychosis in Parkinson Disease and Neurodegenerative Parkinsonian Disorders. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2016, 29, 227-236.	1.2	31
4187	The GBA, DYRK1A and MS4A6A polymorphisms influence the age at onset of Chinese Parkinson patients. <i>Neuroscience Letters</i> , 2016, 621, 133-136.	1.0	16
4188	Monte Carlo cross-validation analysis screens pathway cross-talk associated with Parkinson's disease. <i>Neurological Sciences</i> , 2016, 37, 1327-1333.	0.9	11
4189	Urinary dysfunction and motor symptoms in untreated Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2016, 365, 147-150.	0.3	8
4190	The single intake of levodopa modulates implicit learning in drug naïve, de novo patients with idiopathic Parkinson's disease. <i>Journal of Neural Transmission</i> , 2016, 123, 601-610.	1.4	9

#	ARTICLE	IF	CITATIONS
4191	Vitamin D receptor gene rs4334089 polymorphism and Parkinsonâ€™s disease in Iranian population. <i>Basal Ganglia</i> , 2016, 6, 157-160.	0.3	2
4192	Reliability of the Handgrip Strength Test in Elderly Subjects With Parkinson Disease. <i>Hand</i> , 2016, 11, 54-58.	0.7	39
4193	Handwriting Impairments in People With Parkinsonâ€™s Disease and Freezing of Gait. <i>Neurorehabilitation and Neural Repair</i> , 2016, 30, 911-919.	1.4	27
4194	Peripheral arterial endothelial dysfunction of neurodegenerative diseases. <i>Journal of the Neurological Sciences</i> , 2016, 366, 94-99.	0.3	9
4195	Clinical course and prognosis in patients with Gaucher disease and parkinsonism. <i>Neurology: Genetics</i> , 2016, 2, e57.	0.9	29
4196	Levodopaâ€™s Carbidopa Intestinal Gel in Patients with Parkinsonâ€™s Disease: A Systematic Review. <i>CNS Drugs</i> , 2016, 30, 381-404.	2.7	81
4197	Gender and non motor fluctuations in Parkinson's disease: A prospective study. <i>Parkinsonism and Related Disorders</i> , 2016, 27, 89-92.	1.1	42
4198	Clinical, Genetic, and Radiological Features of Extrapyrimalidal Movement Disorders in Mitochondrial Disease. <i>JAMA Neurology</i> , 2016, 73, 668.	4.5	69
4199	Correlative factors of cognitive dysfunction in PD patients: a cross-sectional study from Southwest China. <i>Neurological Research</i> , 2016, 38, 434-440.	0.6	13
4200	DCTN1 p.K56R in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 56-61.	1.1	27
4201	Mental slowness in patients with Parkinsonâ€™s disease: Associations with cognitive functions?. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2016, 38, 844-852.	0.8	26
4202	Associations of Matrix Metalloproteinase-9 and Tissue Inhibitory Factor-1 Polymorphisms With Parkinson Disease in Taiwan. <i>Medicine (United States)</i> , 2016, 95, e2672.	0.4	9
4203	High patient satisfaction with telehealth in Parkinson disease. <i>Neurology: Clinical Practice</i> , 2016, 6, 241-251.	0.8	83
4204	Effects of a balance-based exergaming intervention using the Kinect sensor on posture stability in individuals with Parkinsonâ€™s disease: a single-blinded randomized controlled trial. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2016, 13, 78.	2.4	89
4205	Neuropsychiatric characteristics of GBA-associated Parkinson disease. <i>Journal of the Neurological Sciences</i> , 2016, 370, 63-69.	0.3	50
4206	Analyses of Rule Breaks and Errors During Planning in Computerized Tower Tasks: Insights From Neurological Patients. <i>Archives of Clinical Neuropsychology</i> , 2016, 31, 738-753.	0.3	7
4207	Variant U1 snRNAs are implicated in human pluripotent stem cell maintenance and neuromuscular disease. <i>Nucleic Acids Research</i> , 2016, 44, 10960-10973.	6.5	26
4208	Patterns and predictors of freezing of gait improvement following rasagiline therapy: A pilot study. <i>Clinical Neurology and Neurosurgery</i> , 2016, 150, 117-124.	0.6	7

#	ARTICLE	IF	CITATIONS
4209	CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease. <i>Proteomics - Clinical Applications</i> , 2016, 10, 1242-1253.	0.8	64
4210	Clinical markers of neurodegeneration in Chinese patients with idiopathic rapid eye movement sleep behavior disorder. <i>Clinical Neurology and Neurosurgery</i> , 2016, 150, 105-109.	0.6	9
4211	SNP rs1805874 of the Calbindin1 Gene Is Associated with Parkinson's Disease in Han Chinese. <i>Genetic Testing and Molecular Biomarkers</i> , 2016, 20, 753-757.	0.3	4
4212	Evidence of mutations in <i>RIC3</i> acetylcholine receptor chaperone as a novel cause of autosomal-dominant Parkinson's disease with non-motor phenotypes. <i>Journal of Medical Genetics</i> , 2016, 53, 559-566.	1.5	40
4213	A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. <i>Molecular Neurodegeneration</i> , 2016, 11, 61.	4.4	39
4214	Cognitive impairment in patients with Parkinson's disease: A 30-month follow-up study. <i>Clinical Neurology and Neurosurgery</i> , 2016, 151, 65-69.	0.6	21
4215	Walking Turns in Parkinson's Disease Patients with Freezing of Gait: The Short-term Effects of Different Cueing Strategies. <i>International Journal of Gerontology</i> , 2016, 10, 71-75.	0.7	13
4216	Associations between plasma ceramides and cognitive and neuropsychiatric manifestations in Parkinson's disease dementia. <i>Journal of the Neurological Sciences</i> , 2016, 370, 82-87.	0.3	48
4217	Cognitive impairment in Parkinson's disease: Association between patient-reported and clinically measured outcomes. <i>Parkinsonism and Related Disorders</i> , 2016, 33, 107-114.	1.1	21
4218	Akinetic crisis in dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1123-1126.	0.9	9
4219	Levodopa medication improves incidental sequence learning in Parkinson's disease. <i>Neuropsychologia</i> , 2016, 93, 53-60.	0.7	21
4220	Conjugal parkinsonism – Clinical, pathology and genetic study. No evidence of person-to-person transmission. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 87-90.	1.1	17
4221	Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 3126-3138.	2.5	92
4222	Characterisation of foot clearance during gait in people with early Parkinson's disease: Deficits associated with a dual task. <i>Journal of Biomechanics</i> , 2016, 49, 2763-2769.	0.9	29
4223	The Implications of Parkinson's Disease for Women's Health. <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 2016, 45, 723-736.	0.2	2
4225	Heart rate variability in patients with essential tremor: A cross sectional study. <i>Parkinsonism and Related Disorders</i> , 2016, 33, 134-137.	1.1	10
4226	Increased likelihood of anxiety and poor sleep quality in Parkinson's disease patients with pain. <i>Journal of the Neurological Sciences</i> , 2016, 369, 212-215.	0.3	16
4227	Genetic analysis of <i>CHCHD2</i> gene in Chinese Parkinson's disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2016, 171, 1148-1152.	1.1	10

#	ARTICLE	IF	CITATIONS
4228	White matter hyperintensities, cerebrospinal amyloid- β^2 and dementia in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2016, 367, 284-290.	0.3	26
4229	Content and Temporal Order Memory for Performed Activities in Parkinson's Disease. <i>Archives of Clinical Neuropsychology</i> , 2016, 31, 700-709.	0.3	10
4230	Transcranial direct current stimulation (tDCS) for idiopathic Parkinson's disease. <i>The Cochrane Library</i> , 2016, 2016, CD010916.	1.5	34
4231	LRRK2, GBA and SMPD1 Mutations and Parkinson's Disease in Ashkenazi Jews. <i>Dementia and Geriatric Cognitive Disorders</i> , 2016, 42, 1-6.	0.7	17
4232	Correlation of 3D FLAIR and Dopamine Transporter Imaging in Patients With Parkinsonism. <i>American Journal of Roentgenology</i> , 2016, 207, 1089-1094.	1.0	20
4233	How language flows when movements don't: An automated analysis of spontaneous discourse in Parkinson's disease. <i>Brain and Language</i> , 2016, 162, 19-28.	0.8	89
4234	Finger tapping analysis in patients with Parkinson's disease and atypical parkinsonism. <i>Journal of Clinical Neuroscience</i> , 2016, 30, 49-55.	0.8	37
4235	Sexual dysfunction in women with Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1685-1693.	2.2	30
4236	Impacts of religious semantic priming on an intertemporal discounting task: Response time effects and neural correlates. <i>Neuropsychologia</i> , 2016, 89, 403-413.	0.7	8
4237	Epidemiology of Parkinson's Disease: A Population-Based Study in Primary Care in Italy. <i>Neuroepidemiology</i> , 2016, 47, 38-45.	1.1	21
4238	Distribution and Load of Amyloid- β^2 Pathology in Parkinson Disease and Dementia with Lewy Bodies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 936-945.	0.9	109
4239	No Difference on Adherence Between Immediate-Release Versus Extended-Release Dopamine Agonists in Uninsured Subjects with Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 68-72.	0.8	4
4240	The Verbal Fluency Decline After Deep Brain Stimulation in Parkinson's Disease: Is There an Influence of Age?. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 48-52.	0.8	2
4241	Gray and white matter imaging: A biomarker for cognitive impairment in early Parkinson's disease?. <i>Movement Disorders</i> , 2016, 31, 103-110.	2.2	129
4242	Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire. <i>Movement Disorders</i> , 2016, 31, 126-134.	2.2	20
4243	Striatal and Cortical Amyloidopathy and Cognition in Parkinson's Disease. <i>Movement Disorders</i> , 2016, 31, 111-117.	2.2	52
4244	Minor hallucinations occur in drug-naïve Parkinson's disease patients, even from the premotor phase. <i>Movement Disorders</i> , 2016, 31, 45-52.	2.2	167
4245	Gut Feelings About Synuclein in Gastrointestinal Biopsies: A Biomarker in the Making?. <i>Movement Disorders</i> , 2016, 31, 193-202.	2.2	56

#	ARTICLE	IF	CITATIONS
4246	Dopaminergic treatment modulates sensory attenuation at the onset of the movement in Parkinson's disease: A test of a new framework for bradykinesia. <i>Movement Disorders</i> , 2016, 31, 143-146.	2.2	26
4247	Time on timing: Dissociating premature responding from interval sensitivity in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1163-1172.	2.2	20
4248	The combined effect of REM sleep behavior disorder and hyposmia on cognition and motor phenotype in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2016, 368, 374-378.	0.3	30
4249	Quantifying rigidity of Parkinson's disease in relation to laxative treatment: a service evaluation. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 441-450.	1.1	9
4250	Review: The spectrum of clinical features seen with alpha synuclein pathology. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 6-19.	1.8	67
4251	Randomized, Blinded Pilot Testing of Nonconventional Stimulation Patterns and Shapes in Parkinson's Disease and Essential Tremor: Evidence for Further Evaluating Narrow and Biphasic Pulses. <i>Neuromodulation</i> , 2016, 19, 343-356.	0.4	60
4252	Peculiarities of Neurological Disorders and Study Designs. <i>Frontiers of Neurology and Neuroscience</i> , 2016, 39, 8-23.	3.0	1
4253	The effects of cognitive reserve and lifestyle on cognition and dementia in Parkinson's disease—a longitudinal cohort study. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 13-23.	1.3	63
4254	Long-term double-blind unilateral pedunculopontine area stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1570-1574.	2.2	47
4255	Delayed saccade to perceptually demanding locations in Parkinson's disease: analysis from the perspective of the speed-accuracy trade-off. <i>Neurological Sciences</i> , 2016, 37, 1841-1848.	0.9	2
4256	The clinical symptoms of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2016, 139, 318-324.	2.1	830
4257	Review: Sporadic Parkinson's disease: development and distribution of α -synuclein pathology. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 33-50.	1.8	309
4258	Medium-term prognosis of an incident cohort of parkinsonian patients compared to controls. <i>Parkinsonism and Related Disorders</i> , 2016, 32, 36-41.	1.1	21
4259	Alpha-synuclein $^{RT-QuIC}$ in the CSF of patients with alpha-synucleinopathies. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 812-818.	1.7	388
4260	Cancer in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 28-33.	1.1	41
4261	Chemical profiling of cerebrospinal fluid by multiple reaction monitoring mass spectrometry. <i>Analyst</i> , 2016, 141, 5252-5255.	1.7	29
4262	Cerebrospinal τ -synuclein in τ -synuclein aggregation disorders: tau/ τ -synuclein ratio as potential biomarker for dementia with Lewy bodies. <i>Journal of Neurology</i> , 2016, 263, 2271-2277.	1.8	37
4263	SIPA1L2, MIR4697, GCH1 and VPS13C loci and risk of Parkinson's diseases in Iranian population: A case-control study. <i>Journal of the Neurological Sciences</i> , 2016, 369, 1-4.	0.3	15

#	ARTICLE	IF	CITATIONS
4264	Speech and gait in Parkinson's disease: When rhythm matters. <i>Parkinsonism and Related Disorders</i> , 2016, 32, 42-47.	1.1	27
4265	Predictors of functional dependency in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1482-1488.	2.2	30
4266	A randomized double-blind multi-center trial of hydrogen water for Parkinson's disease: protocol and baseline characteristics. <i>BMC Neurology</i> , 2016, 16, 66.	0.8	23
4267	Effect of subthalamic stimulation on distal and proximal upper limb movements in Parkinson's disease. <i>Brain Research</i> , 2016, 1648, 438-444.	1.1	11
4268	SNCA rs356182 variant increases risk of sporadic Parkinson's disease in ethnic Chinese. <i>Journal of the Neurological Sciences</i> , 2016, 368, 231-234.	0.3	17
4269	Acupuncture for Symptomatic Treatment of Fatigue in Parkinson's Disease: Trial Design and Implementation. <i>Medical Acupuncture</i> , 2016, 28, 194-205.	0.3	5
4270	Evaluation of parkinsonism and striatal dopamine transporter loss in patients with spinocerebellar ataxia type 6. <i>Journal of Neurology</i> , 2016, 263, 2302-2307.	1.8	8
4271	Different clinical features in siblings with identical mutations of the Parkin gene (PARK2). <i>Journal of the Neurological Sciences</i> , 2016, 368, 147-149.	0.3	2
4272	Is <scp>PIGD</scp> a legitimate motor subtype in Parkinson disease?. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 473-477.	1.7	38
4273	Genetic analysis of the CHCHD2 gene in a cohort of Chinese patients with Parkinson disease. <i>Neuroscience Letters</i> , 2016, 629, 116-118.	1.0	5
4274	Levodopa modulates small-world architecture of functional brain networks in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1676-1684.	2.2	81
4275	Pathogenic mechanisms of prion protein, amyloid β and α -synuclein misfolding: the prion concept and neurotoxicity of protein oligomers. <i>Journal of Neurochemistry</i> , 2016, 139, 162-180.	2.1	77
4276	Motor performance differentiates individuals with Lewy body dementia, Parkinson's and Alzheimer's disease. <i>Gait and Posture</i> , 2016, 50, 1-7.	0.6	69
4277	Current Issues in Randomized Clinical Trials of Neurodegenerative Disorders at Enrolment and Reporting: Diagnosis, Recruitment, Representativeness of Patients, Ethnicity, and Quality of Reporting. <i>Frontiers of Neurology and Neuroscience</i> , 2016, 39, 24-36.	3.0	4
4278	Peripheral levels of angiotensins are associated with depressive symptoms in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2016, 368, 235-239.	0.3	26
4279	Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 287-295.	1.2	77
4280	Statistical Models of Parkinson's Disease Progression: Predictive Validity in a 3-Year Follow-up. <i>Journal of Parkinson's Disease</i> , 2016, 6, 793-804.	1.5	5
4281	Progressive resistance exercise restores some properties of the triphasic EMG pattern and improves bradykinesia: the PRET-PD randomized clinical trial. <i>Journal of Neurophysiology</i> , 2016, 116, 2298-2311.	0.9	39

#	ARTICLE	IF	CITATIONS
4282	Combined accelerometer and EMG analysis to differentiate essential tremor from Parkinson's disease. , 2016, 2016, 672-675.		18
4283	Prevalence and Prescribed Treatments of Orthostatic Hypotension in Institutionalized Patients with Parkinson's Disease. Journal of Parkinson's Disease, 2016, 6, 805-810.	1.5	9
4284	Botulinum toxin for drooling in Parkinson's disease. The Cochrane Library, 0, , .	1.5	5
4285	Resting-state functional connectivity of subthalamic nucleus in different Parkinson's disease phenotypes. Journal of the Neurological Sciences, 2016, 371, 137-147.	0.3	31
4286	Survival and dementia in GBA-associated Parkinson's disease: The mutation matters. Annals of Neurology, 2016, 80, 662-673.	2.8	312
4287	Predicting first fall in newly diagnosed Parkinson's disease: Insights from a fall-naïve cohort. Movement Disorders, 2016, 31, 1829-1836.	2.2	87
4288	Clinical heterogeneity of LRRK2 p.I2012T mutation. Parkinsonism and Related Disorders, 2016, 33, 36-43.	1.1	17
4289	Cardiovascular dysfunction in untreated Parkinson's disease: A multi-modality assessment. Journal of the Neurological Sciences, 2016, 370, 251-255.	0.3	43
4290	Gene-environment interactions linking air pollution and inflammation in Parkinson's disease. Environmental Research, 2016, 151, 713-720.	3.7	55
4291	A longitudinal study of neuromelanin-sensitive magnetic resonance imaging in Parkinson's disease. Neuroscience Letters, 2016, 633, 112-117.	1.0	57
4292	Parkinson's disease and cerebrovascular disease: is there a link? A neurosonological case-control study. Neurological Sciences, 2016, 37, 1707-1711.	0.9	6
4293	The diagnostic discrimination of cutaneous α -synuclein deposition in Parkinson disease. Neurology, 2016, 87, 505-512.	1.5	83
4294	Using epigenetic networks for the analysis of movement associated with levodopa therapy for Parkinson's disease. BioSystems, 2016, 146, 35-42.	0.9	5
4295	Patterns of striatal functional connectivity differ in early and late onset Parkinson's disease. Journal of Neurology, 2016, 263, 1993-2003.	1.8	27
4296	Unmasking levodopa resistance in Parkinson's disease. Movement Disorders, 2016, 31, 1602-1609.	2.2	80
4297	New methods for the assessment of Parkinson's disease (2005 to 2015): A systematic review. Movement Disorders, 2016, 31, 1283-1292.	2.2	119
4298	Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease. Neurodegenerative Disease Management, 2016, 6, 289-298.	1.2	25
4299	Scan without evidence of dopaminergic deficit: A 10-year retrospective study. Parkinsonism and Related Disorders, 2016, 31, 53-58.	1.1	38

#	ARTICLE	IF	CITATIONS
4300	The heterozygous A53T mutation in the alpha-synuclein gene in a Chinese Han patient with Parkinson disease: case report and literature review. <i>Journal of Neurology</i> , 2016, 263, 1984-1992.	1.8	19
4301	Image-guided preoperative prediction of pyramidal tract side effect in deep brain stimulation: proof of concept and application to the pyramidal tract side effect induced by pallidal stimulation. <i>Journal of Medical Imaging</i> , 2016, 3, 025001.	0.8	9
4302	Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis. <i>Neurology</i> , 2016, 87, 237-238.	1.5	36
4303	Motor symptoms in Parkinson's disease: A unified framework. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 68, 727-740.	2.9	231
4304	The rs3756063 polymorphism is associated with SNCA methylation in the Chinese Han population. <i>Journal of the Neurological Sciences</i> , 2016, 367, 11-14.	0.3	24
4305	The high prevalence of impulse control behaviors in patients with early-onset Parkinson's disease: A cross-sectional multicenter study. <i>Journal of the Neurological Sciences</i> , 2016, 368, 150-154.	0.3	115
4306	Case Studies in Tremor. <i>Neurologic Clinics</i> , 2016, 34, 651-665.	0.8	4
4307	Neuropsychological impairment in prodromal Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2016, 371, 117-120.	0.3	13
4308	Progresi3n cl3nica de la enfermedad de Parkinson: an3lisis retrospectivo en un consultorio especializado en trastornos del movimiento. <i>Neurologia Argentina</i> , 2016, 8, 258-262.	0.1	1
4309	Oxidation and interaction of DJ-1 with 20S proteasome in the erythrocytes of early stage Parkinson's disease patients. <i>Scientific Reports</i> , 2016, 6, 30793.	1.6	30
4310	Biomarkers in Randomized Clinical Trials: Magnetic Resonance Imaging. <i>Frontiers of Neurology and Neuroscience</i> , 2016, 39, 101-108.	3.0	4
4311	Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management. <i>Drugs and Aging</i> , 2016, 33, 855-863.	1.3	31
4312	Medulla oblongata damage and cardiac autonomic dysfunction in Parkinson disease. <i>Neurology</i> , 2016, 87, 2540-2545.	1.5	32
4313	Enteric neurons from Parkinson's disease patients display ex vivo aberrations in mitochondrial structure. <i>Scientific Reports</i> , 2016, 6, 33117.	1.6	22
4315	Functional volumetric analysis of striatum using F-18 FP-CIT PET in patients with idiopathic Parkinson's disease and normal subjects. <i>Annals of Nuclear Medicine</i> , 2016, 30, 572-578.	1.2	3
4316	Genetics of Parkinson's disease. <i>Molecular and Cellular Probes</i> , 2016, 30, 386-396.	0.9	282
4317	Blood biomarker for Parkinson disease: peptoids. <i>Npj Parkinson's Disease</i> , 2016, 2, .	2.5	14
4318	Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson's disease. <i>Journal of Clinical Movement Disorders</i> , 2016, 3, 8.	2.2	35

#	ARTICLE	IF	CITATIONS
4319	Central nervous system uptake of intranasal glutathione in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2016, 2, 16002.	2.5	43
4320	Deep brain stimulation of the subthalamic nucleus modulates sensitivity to decision outcome value in Parkinson's disease. <i>Scientific Reports</i> , 2016, 6, 32509.	1.6	17
4321	Sleep problems and hypothalamic dopamine D3 receptor availability in Parkinson disease. <i>Neurology</i> , 2016, 87, 2451-2456.	1.5	32
4322	A Four-Year Longitudinal Study on Restless Legs Syndrome in Parkinson Disease. <i>Sleep</i> , 2016, 39, 405-412.	0.6	73
4323	Spontaneous Swallowing during All-Night Sleep in Patients with Parkinson Disease in Comparison with Healthy Control Subjects. <i>Sleep</i> , 2016, 39, 847-854.	0.6	10
4324	SCARB2 variants and glucocerebrosidase activity in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2016, 2, .	2.5	36
4325	The experience of being diagnosed with Parkinson's disease. <i>British Journal of Neuroscience Nursing</i> , 2016, 12, 288-296.	0.1	7
4326	Impact of Cognitive Loading on Postural Control in Parkinson's Disease With Freezing of Gait. <i>Gerontology and Geriatric Medicine</i> , 2016, 2, 233372141667375.	0.8	4
4327	Altered directional connectivity between emotion network and motor network in Parkinson's disease with depression. <i>Medicine (United States)</i> , 2016, 95, e4222.	0.4	33
4328	Cortical cerebral atrophy in patients with Parkinson's disease: New opportunities for in vivo diagnostics. <i>Human Physiology</i> , 2016, 42, 905-909.	0.1	0
4329	Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 42.	3.0	14
4331	Advances in Neurotrophic Factor and Cell-Based Therapies for Parkinson's Disease: A Mini-Review. <i>Gerontology</i> , 2016, 62, 371-380.	1.4	19
4332	Nonmotor symptoms in patients with Parkinson disease. <i>Medicine (United States)</i> , 2016, 95, e5400.	0.4	48
4333	The Relationship between the Experience of Hypomimia and Social Wellbeing in People with Parkinson's Disease and their Care Partners. <i>Journal of Parkinson's Disease</i> , 2016, 6, 625-630.	1.5	32
4334	NAJC Mutations Associated With Early-Onset Parkinson's Disease. <i>Annals of Neurology</i> , 2016, 79, 244-256.	2.8	148
4335	The longitudinal impact of depression on disability in Parkinson disease. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 458-465.	1.3	43
4336	Occurrence of Writing Tremor in Patients With Scans Without Evidence of Dopaminergic Deficit. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 421-424.	0.8	2
4337	Randomized, Controlled Trial of Acupuncture for Fatigue in Parkinson's Disease. <i>Movement Disorders</i> , 2016, 31, 1027-1032.	2.2	58

#	ARTICLE	IF	CITATIONS
4338	Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseasesâ€”From pathophysiology to clinical practice. <i>Movement Disorders</i> , 2016, 31, 836-847.	2.2	54
4339	High-resolution Anorectal Manometry in Parkinson Disease With Defecation Disorder. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 566-571.	1.1	12
4340	Smoking in Patients with Parkinson's Disease: preliminary striatal DaT-SPECT findings. <i>Acta Neurologica Scandinavica</i> , 2016, 134, 265-270.	1.0	7
4341	No relevant midbrain atrophy in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2016, 134, 378-381.	1.0	5
4342	Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of earlyâ€”stage Parkinson's disease. <i>European Journal of Neurology</i> , 2016, 23, 368-374.	1.7	62
4343	CADAâ€”computer-aided DaTSCAN analysis. <i>EJNMMI Physics</i> , 2016, 3, 4.	1.3	28
4344	White matter changes and the development of motor phenotypes in de novo Parkinson's Disease. <i>Journal of the Neurological Sciences</i> , 2016, 367, 215-219.	0.3	23
4345	The association between symptoms of sexual dysfunction and age at onset in Parkinsonâ€™s disease. <i>Clinical Autonomic Research</i> , 2016, 26, 205-209.	1.4	22
4346	Altered regional homogeneity of prefrontal cortex in Parkinsonâ€™s disease with mild cognitive impairment. <i>Chinese Neurosurgical Journal</i> , 2016, 2, .	0.3	2
4347	Analysis of DNAJC13 mutations in French-Canadian/French cohort of Parkinson's disease. <i>Neurobiology of Aging</i> , 2016, 45, 212.e13-212.e17.	1.5	38
4348	Basal ganglia dysfunction in idiopathic REM sleep behaviour disorder parallels that in early Parkinsonâ€™s disease. <i>Brain</i> , 2016, 139, 2224-2234.	3.7	119
4349	Neuropsychiatric symptoms in Serbian patients with Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2016, 367, 342-346.	0.3	11
4350	Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinsonâ€™s disease patients. <i>Parkinsonism and Related Disorders</i> , 2016, 30, 13-17.	1.1	53
4351	Use of the World Health Organization Quality of Life Assessment Short Version in Mild to Moderate Parkinson Disease. <i>Archives of Physical Medicine and Rehabilitation</i> , 2016, 97, 2123-2129.e1.	0.5	8
4352	Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting. <i>Parkinsonism and Related Disorders</i> , 2016, 22, 54-61.	1.1	20
4353	Indoor and outdoor falls in persons with Parkinsonâ€™s disease after 1Â”year follow-up study: differences and consequences. <i>Neurological Sciences</i> , 2016, 37, 597-602.	0.9	22
4354	Multi-parametric analysis assists in STN localization in Parkinson's patients. <i>Journal of the Neurological Sciences</i> , 2016, 366, 37-43.	0.3	9
4355	Structural Validity of the Mini-Balance Evaluation Systems Test (Mini-BESTest) in People With Mild to Moderate Parkinson Disease. <i>Physical Therapy</i> , 2016, 96, 1799-1806.	1.1	26

#	ARTICLE	IF	CITATIONS
4356	Fatigue is associated with the onset of hallucinations in patients with Parkinson's disease: A 3-year prospective study. <i>ENeurologicalSci</i> , 2016, 4, 25-29.	0.5	3
4357	Co-morbidity burden in Parkinson's disease: Comparison with controls and its influence on prognosis. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 124-129.	1.1	20
4358	Association of rapid eye movement sleep behavior disorder with sleep-disordered breathing in Parkinson's disease. <i>Sleep Medicine</i> , 2016, 20, 110-115.	0.8	30
4359	Levodopa responsiveness of dysphagia in advanced Parkinson's disease and reliability testing of the FEES-Levodopa-test. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 100-106.	1.1	90
4360	Combined MEG and pT-TMS study in Parkinson's disease. <i>Journal of Integrative Neuroscience</i> , 2016, 15, 145-162.	0.8	8
4361	Subcortical matter in the α -synucleinopathies spectrum: an MRI pilot study. <i>Journal of Neurology</i> , 2016, 263, 1575-1582.	1.8	12
4362	From sweet to sweat: Hedonic olfactory range is impaired in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 22, 9-14.	1.1	22
4363	Comparison of transcranial sonography-magnetic resonance fusion imaging in Wilson's and early-onset Parkinson's diseases. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 87-93.	1.1	16
4364	Trinucleotide repeat expansion of TATA-binding protein gene associated with Parkinson's disease: A Thai multicenter study. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 146-149.	1.1	14
4365	Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2016, 11, 7.	4.4	198
4366	Clinical characteristics of fatigued Parkinson's patients and the response to dopaminergic treatment. <i>Translational Neurodegeneration</i> , 2016, 5, 9.	3.6	16
4367	Explant Analysis from a Patient Exhibiting Rapid Acceleration of Parkinson Disease Symptoms and Hypercobaltemia Following Metal-on-Metal Total Hip Arthroplasty. <i>JBJS Case Connector</i> , 2016, 6, e45.	0.1	11
4368	Clinical Epidemiology, Evaluation, and Management of Dementia in Parkinson Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2016, 31, 585-594.	0.9	14
4369	Genetic Mutation Analysis of Parkinson's Disease Patients Using Multigene Next-Generation Sequencing Panels. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 481-491.	1.6	18
4370	Impulse control disorder in PD: A lateralized monoaminergic frontostriatal disconnection syndrome?. <i>Parkinsonism and Related Disorders</i> , 2016, 30, 62-66.	1.1	29
4371	Validation of an automated morphological MRI-based 123I-FP-CIT SPECT evaluation method. <i>Parkinsonism and Related Disorders</i> , 2016, 29, 24-29.	1.1	6
4372	Factors influencing psychosocial adjustment and quality of life in Parkinson patients and informal caregivers. <i>Quality of Life Research</i> , 2016, 25, 1959-1968.	1.5	49
4373	Learning More from Finger Tapping in Parkinson's Disease: Up and Down from Dyskinesia to Bradykinesia. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 184-187.	0.8	10

#	ARTICLE	IF	CITATIONS
4374	Amyloid β Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 367-375.	0.8	28
4375	Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. <i>CNS Drugs</i> , 2016, 30, 703-717.	2.7	40
4376	Copy number variation analysis of the 17q21.31 region and its role in neurodegenerative diseases. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2016, 171, 175-180.	1.1	13
4377	Association of four new candidate genetic variants with Parkinson's disease in a Han Chinese population. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2016, 171, 342-347.	1.1	18
4378	Association Between Autonomic Impairment and Structural Deficit in Parkinson Disease. <i>Medicine (United States)</i> , 2016, 95, e3086.	0.4	18
4379	Olfaction in single and compound heterozygotes in a cohort of young onset Parkinson's disease patients. <i>Acta Neurologica Scandinavica</i> , 2016, 134, 271-276.	1.0	21
4380	Motor complications in an incident Parkinson's disease cohort. <i>European Journal of Neurology</i> , 2016, 23, 304-312.	1.7	58
4381	Association of restless legs syndrome, pain, and mood disorders in parkinson's disease. <i>International Journal of Neuroscience</i> , 2016, 126, 116-120.	0.8	20
4382	Síntomas no motores y motores en la enfermedad de Parkinson y su relación con la calidad de vida y los distintos subgrupos clínicos. <i>Neurología</i> , 2016, 31, 585-591.	0.3	60
4383	Cognitive profile of Parkinson's disease patients: a comparative study between early-onset and late-onset Parkinson's disease. <i>International Journal of Neuroscience</i> , 2016, 126, 227-234.	0.8	26
4384	What do patients with scans without evidence of dopaminergic deficit (SWEDD) have? New evidence and continuing controversies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 319-323.	0.9	186
4385	Multimodal imaging evaluation of excessive daytime sleepiness in Parkinson's disease. <i>International Journal of Neuroscience</i> , 2016, 126, 422-428.	0.8	19
4386	Randomized Controlled Trial of a Home-Based Action Observation Intervention to Improve Walking in Parkinson Disease. <i>Archives of Physical Medicine and Rehabilitation</i> , 2016, 97, 665-673.	0.5	32
4387	Expression changes of genes associated with apoptosis and survival processes in Parkinson's disease. <i>Neuroscience Letters</i> , 2016, 615, 72-77.	1.0	22
4388	Association of GCH1 and MIR4697, but not SIPA1L2 and VPS13C polymorphisms, with Parkinson's disease in Taiwan. <i>Neurobiology of Aging</i> , 2016, 39, 221.e1-221.e5.	1.5	15
4389	Blunted Maximal and Submaximal Responses to Cardiopulmonary Exercise Tests in Patients With Parkinson Disease. <i>Archives of Physical Medicine and Rehabilitation</i> , 2016, 97, 720-725.	0.5	36
4390	Are factors related to dual-task performance in people with Parkinson's disease dependent on the type of dual task?. <i>Parkinsonism and Related Disorders</i> , 2016, 23, 23-30.	1.1	30
4391	Increased CSF neurogranin concentration is specific to Alzheimer disease. <i>Neurology</i> , 2016, 86, 829-835.	1.5	170

#	ARTICLE	IF	CITATIONS
4392	Bilateral low frequency rTMS of the primary motor cortex may not be a suitable treatment for levodopa-induced dyskinesias in late stage Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 22, 62-67.	1.1	30
4393	Accuracy of clinical diagnosis of Parkinson disease. <i>Neurology</i> , 2016, 86, 566-576.	1.5	547
4394	Neural substrates of rapid eye movement sleep behavior disorder in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 23, 31-36.	1.1	56
4395	Detecting freezing of gait with a tri-axial accelerometer in Parkinson's disease patients. <i>Medical and Biological Engineering and Computing</i> , 2016, 54, 223-233.	1.6	94
4396	Visual short-term memory deficits in REM sleep behaviour disorder mirror those in Parkinson's disease. <i>Brain</i> , 2016, 139, 47-53.	3.7	36
4397	Abnormal fronto-striatal functional connectivity in Parkinson's disease. <i>Neuroscience Letters</i> , 2016, 613, 66-71.	1.0	23
4398	Epidemiology of Parkinson's disease. <i>Revue Neurologique</i> , 2016, 172, 14-26.	0.6	292
4399	Parkinson's Disease's Cognitive Functional Rating Scale across different conditions and degrees of cognitive impairment. <i>Journal of the Neurological Sciences</i> , 2016, 361, 66-71.	0.3	9
4400	Clusterin CSF levels in differential diagnosis of neurodegenerative disorders. <i>Journal of the Neurological Sciences</i> , 2016, 361, 117-121.	0.3	26
4401	Progression of non-motor symptoms in Parkinson's disease among different age populations: A two-year follow-up study. <i>Journal of the Neurological Sciences</i> , 2016, 360, 72-77.	0.3	28
4402	The role of prefrontal cortex during postural control in Parkinsonian syndromes a functional near-infrared spectroscopy study. <i>Brain Research</i> , 2016, 1633, 126-138.	1.1	52
4403	Somatic mtDNA variation is an important component of Parkinson's disease. <i>Neurobiology of Aging</i> , 2016, 38, 217.e1-217.e6.	1.5	61
4404	The characterization of a base-width neutral step as the first step for balance recovery in moderate Parkinson's disease. <i>International Journal of Neuroscience</i> , 2016, 126, 713-722.	0.8	0
4405	Clinical Implications of the National Institute of Neurological Disorders and Stroke Criteria for Diagnosing Psychosis in Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2016, 28, 26-31.	0.9	8
4406	Loss of fractal gait harmony in Parkinson's Disease. <i>Clinical Neurophysiology</i> , 2016, 127, 1540-1546.	0.7	27
4407	Reduced mitochondrial DNA copy number is a biomarker of Parkinson's disease. <i>Neurobiology of Aging</i> , 2016, 38, 216.e7-216.e10.	1.5	178
4408	Complementary and alternative medicine in Indian Parkinson's disease patients. <i>Journal of Traditional and Complementary Medicine</i> , 2016, 6, 377-382.	1.5	5
4409	Exploring the Association Between Rosacea and Parkinson Disease. <i>JAMA Neurology</i> , 2016, 73, 529.	4.5	95

#	ARTICLE	IF	CITATIONS
4410	Ultrasound strain elastography in assessment of resting biceps brachii muscle stiffness in patients with Parkinson's disease: a primary observation. <i>Clinical Imaging</i> , 2016, 40, 440-444.	0.8	17
4411	Challenges of modifying disease progression in prediagnostic Parkinson's disease. <i>Lancet Neurology</i> , The, 2016, 15, 637-648.	4.9	78
4412	Know thyself: Exploring interoceptive sensitivity in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2016, 364, 110-115.	0.3	28
4413	Advanced Parkinson disease patients have impairment in prosody processing. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2016, 38, 208-216.	0.8	17
4414	Excessive Iron and α -Synuclein Oligomer in Brain are Relevant to Pure Apathy in Parkinson Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2016, 29, 187-194.	1.2	18
4415	The Potential Mutation of GAK Gene in the Typical Sporadic Parkinson's Disease from the Han Population of Chinese Mainland. <i>Molecular Neurobiology</i> , 2016, 53, 7119-7136.	1.9	6
4416	Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. <i>Lancet Neurology</i> , The, 2016, 15, 585-596.	4.9	77
4417	DBSproc: An open source process for DBS electrode localization and tractographic analysis. <i>Human Brain Mapping</i> , 2016, 37, 422-433.	1.9	47
4418	Developing a Tool for Remote Digital Assessment of Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 59-64.	0.8	55
4419	Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. <i>Journal of Neurochemistry</i> , 2016, 139, 290-317.	2.1	58
4420	Extraction of Stride Events From Gait Accelerometry During Treadmill Walking. <i>IEEE Journal of Translational Engineering in Health and Medicine</i> , 2016, 4, 1-11.	2.2	58
4421	Image-guided preoperative prediction of pyramidal tract side effect in deep brain stimulation. , 2016, , .		0
4422	PARK16 polymorphisms, interaction with smoking, and sporadic Parkinson's disease in Japan. <i>Journal of the Neurological Sciences</i> , 2016, 362, 47-52.	0.3	9
4423	Val66Met BDNF polymorphism is associated with Parkinson's disease cognitive impairment. <i>Neuroscience Letters</i> , 2016, 615, 88-91.	1.0	36
4424	Test-Retest Reliability of Dual-Task Outcome Measures in People With Parkinson Disease. <i>Physical Therapy</i> , 2016, 96, 1276-1286.	1.1	29
4425	Compensatory striatal-cerebellar connectivity in mild-moderate Parkinson's disease. <i>NeuroImage: Clinical</i> , 2016, 10, 54-62.	1.4	83
4426	Continuous leg dyskinesia assessment in Parkinson's disease - clinical validity and ecological effect. <i>Parkinsonism and Related Disorders</i> , 2016, 26, 41-46.	1.1	36
4427	Rumination and behavioural factors in Parkinson's disease depression. <i>Journal of Psychosomatic Research</i> , 2016, 82, 48-53.	1.2	18

#	ARTICLE	IF	CITATIONS
4428	Diabetes, Gray Matter Loss, and Cognition in the Setting of Parkinson Disease. <i>Academic Radiology</i> , 2016, 23, 577-581.	1.3	30
4429	A review of current and novel levodopa formulations for the treatment of Parkinson's disease. <i>Therapeutic Delivery</i> , 2016, 7, 179-191.	1.2	19
4430	The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 245-258.	1.4	25
4431	Proton MR Spectroscopy for Monitoring Pathologic Changes in the Substantia Nigra and Globus Pallidus in Parkinson Disease. <i>American Journal of Roentgenology</i> , 2016, 206, 385-389.	1.0	12
4432	Stimulation sites in the subthalamic nucleus and clinical improvement in Parkinson's disease: a new approach for active contact localization. <i>Journal of Neurosurgery</i> , 2016, 125, 1068-1079.	0.9	41
4433	Effects of dopaminergic replacement therapy on motor speech disorders in Parkinson's disease: longitudinal follow-up study on previously untreated patients. <i>Journal of Neural Transmission</i> , 2016, 123, 379-387.	1.4	51
4434	Motivational engagement in Parkinson's disease: Preparation for motivated action. <i>International Journal of Psychophysiology</i> , 2016, 99, 24-32.	0.5	15
4435	Comparison of motor and non-motor features between essential tremor and tremor dominant Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2016, 361, 34-38.	0.3	25
4436	Visuomotor control in patients with Parkinson's disease. <i>Neuropsychologia</i> , 2016, 80, 102-114.	0.7	15
4437	Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2016, 23, 17-22.	1.1	63
4438	Atypical parkinsonism in C9orf72 expansions: a case report and systematic review of 45 cases from the literature. <i>Journal of Neurology</i> , 2016, 263, 558-574.	1.8	40
4439	Establishing On-Site Reference Values for 123I-FP-CIT SPECT (DaTSCAN®) Using a Cohort of Individuals with Non-Degenerative Conditions. <i>Molecular Imaging and Biology</i> , 2016, 18, 302-312.	1.3	33
4440	Dopaminergic-induced dyskinesia assessment based on a single belt-worn accelerometer. <i>Artificial Intelligence in Medicine</i> , 2016, 67, 47-56.	3.8	45
4441	The contribution of white matter lesions to Parkinson's disease motor and gait symptoms: a critical review of the literature. <i>Journal of Neural Transmission</i> , 2016, 123, 241-250.	1.4	40
4442	Discovery of a frameshift mutation in podocalyxin-like (PODXL) gene, coding for a neural adhesion molecule, as causal for autosomal-recessive juvenile Parkinsonism. <i>Journal of Medical Genetics</i> , 2016, 53, 450-456.	1.5	37
4443	Tremor pattern differentiates drug-induced resting tremor from Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2016, 25, 100-103.	1.1	17
4444	The coeruleus/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder. <i>Brain</i> , 2016, 139, 1180-1188.	3.7	148
4445	Maladie de Parkinson et facteurs de risque professionnels et environnementaux: enquête cas-témoins dans l'ouest algérien. <i>Archives Des Maladies Professionnelles Et De L'Environnement</i> , 2016, 77, 21-26.	0.1	3

#	ARTICLE	IF	CITATIONS
4446	123I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in α -synucleinopathies. <i>Ageing Research Reviews</i> , 2016, 30, 122-133.	5.0	65
4447	Age, Gender, Comorbidity, and the MDS-UPDRS: Results from a Population-Based Study. <i>Neuroepidemiology</i> , 2016, 46, 222-227.	1.1	35
4448	Serum uric acid is associated with apathy in early, drug-naïve Parkinson's disease. <i>Journal of Neural Transmission</i> , 2016, 123, 371-377.	1.4	9
4449	Do patients with late-stage Parkinson's disease still respond to levodopa?. <i>Parkinsonism and Related Disorders</i> , 2016, 26, 10-16.	1.1	60
4450	Tractography patterns of subthalamic nucleus deep brain stimulation. <i>Brain</i> , 2016, 139, 1200-1210.	3.7	115
4451	The effect of the rehabilitation program on balance, gait, physical performance and trunk rotation in Parkinson's disease. <i>Aging Clinical and Experimental Research</i> , 2016, 28, 1169-1177.	1.4	32
4452	Recurrent falls in Parkinson's disease after one year of follow-up: A nested case-control study. <i>Archives of Gerontology and Geriatrics</i> , 2016, 65, 17-24.	1.4	19
4453	Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. <i>American Journal of Human Genetics</i> , 2016, 98, 500-513.	2.6	333
4454	Synaptotagmin XI in Parkinson's disease: New evidence from an association study in Spain and Mexico. <i>Journal of the Neurological Sciences</i> , 2016, 362, 321-325.	0.3	17
4455	Association of three candidate genetic variants in RAB7L1/NUCKS1, MCCC1 and STK39 with sporadic Parkinson's disease in Han Chinese. <i>Journal of Neural Transmission</i> , 2016, 123, 425-430.	1.4	15
4456	In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin. <i>Neurobiology of Disease</i> , 2016, 91, 59-68.	2.1	78
4457	Effects of movement imitation training in Parkinson's disease: A virtual reality pilot study. <i>Parkinsonism and Related Disorders</i> , 2016, 26, 17-23.	1.1	24
4458	Dementia in Parkinson's disease: Is male gender a risk factor?. <i>Parkinsonism and Related Disorders</i> , 2016, 26, 67-72.	1.1	52
4459	Loss of substantia nigra hyperintensity on 7 Tesla MRI of Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2016, 26, 47-54.	1.1	62
4460	Psychiatric Symptoms in the Initial Motor Stage of Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2016, 28, 205-210.	0.9	7
4461	Putaminal dopamine turnover in de novo Parkinson disease predicts later motor complications. <i>Neurology</i> , 2016, 86, 231-240.	1.5	27
4462	Pathological α -synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology. <i>Acta Neuropathologica</i> , 2016, 131, 393-409.	3.9	123
4463	Drug-induced Parkinsonism versus Idiopathic Parkinson Disease: Utility of Nigrosome 1 with 3-T Imaging. <i>Radiology</i> , 2016, 279, 849-858.	3.6	54

#	ARTICLE	IF	CITATIONS
4464	Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. <i>Lancet Neurology</i> , The, 2016, 15, 154-165.	4.9	219
4465	Influence of urinary urgency and other urinary disturbances on falls in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2016, 360, 153-157.	0.3	31
4466	Gray matter atrophy associated with mild cognitive impairment in Parkinson's disease. <i>Neuroscience Letters</i> , 2016, 617, 160-165.	1.0	48
4467	Repetitive deep transcranial magnetic stimulation for motor symptoms in Parkinson's disease: A feasibility study. <i>Clinical Neurology and Neurosurgery</i> , 2016, 140, 73-78.	0.6	14
4468	Association between antidepressants and falls in Parkinson's disease. <i>Journal of Neurology</i> , 2016, 263, 76-82.	1.8	12
4469	Freezing of gait in early Parkinson's disease: Nigral iron content estimated from magnetic resonance imaging. <i>Journal of the Neurological Sciences</i> , 2016, 361, 87-91.	0.3	17
4470	Regional homogeneity alterations differentiate between tremor dominant and postural instability gait difficulty subtypes of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2016, 123, 219-229.	1.4	32
4471	Advances in Biomarker Research in Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 7.	2.0	37
4472	Abnormal regional homogeneity in Parkinson's disease: a resting state fMRI study. <i>Clinical Radiology</i> , 2016, 71, e28-e34.	0.5	48
4473	Head injury at early ages is associated with risk of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 23, 57-61.	1.1	50
4474	Different Functional and Microstructural Changes Depending on Duration of Mild Cognitive Impairment in Parkinson Disease. <i>American Journal of Neuroradiology</i> , 2016, 37, 897-903.	1.2	23
4475	Unravelling the nonmotor mysteries of Parkinson disease. <i>Nature Reviews Neurology</i> , 2016, 12, 10-11.	4.9	28
4476	Neuroimaging and clinical predictors of fatigue in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2016, 23, 45-49.	1.1	33
4477	Free-water imaging in Parkinson's disease and atypical parkinsonism. <i>Brain</i> , 2016, 139, 495-508.	3.7	165
4478	Effects of disease severity and medication state on postural control asymmetry during challenging postural tasks in individuals with Parkinson's disease. <i>Human Movement Science</i> , 2016, 46, 96-103.	0.6	24
4479	Magnetic resonance imaging as a potential biomarker for Parkinson's disease. <i>Translational Research</i> , 2016, 175, 4-16.	2.2	23
4480	Environmental exposure to manganese in air: Associations with tremor and motor function. <i>Science of the Total Environment</i> , 2016, 541, 646-654.	3.9	38
4481	Clinical characteristics of supine hypertension in de novo Parkinson disease. <i>Clinical Autonomic Research</i> , 2016, 26, 15-21.	1.4	41

#	ARTICLE	IF	CITATIONS
4482	Eukaryotic translation initiation factor 4 ^{Î³} , 1 ^{Î±} gene mutations are rare in Parkinson's disease among Taiwanese. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 728-733.	0.8	3
4483	Whole-Exome Sequencing in Familial Parkinson Disease. <i>JAMA Neurology</i> , 2016, 73, 68.	4.5	71
4484	Electroencephalogram slowing predicts neurodegeneration in rapid eye movement sleep behavior disorder. <i>Neurobiology of Aging</i> , 2016, 37, 74-81.	1.5	65
4485	Mild cognitive impairment in Parkinson's disease: Diagnosis and progression to dementia. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2016, 38, 40-50.	0.8	51
4486	Proton MR Spectroscopy for Diagnosis and Evaluation of Treatment Efficacy in Parkinson Disease. <i>Radiology</i> , 2016, 278, 505-513.	3.6	35
4487	Comparison of Olfactory Identification Patterns among Parkinson's Disease Patients from Different Countries. <i>Chemical Senses</i> , 2016, 41, 77-83.	1.1	11
4488	Neurite orientation dispersion and density imaging in the substantia nigra in idiopathic Parkinson disease. <i>European Radiology</i> , 2016, 26, 2567-2577.	2.3	100
4489	Neural correlates underlying micrographia in Parkinson's disease. <i>Brain</i> , 2016, 139, 144-160.	3.7	72
4491	Time trends in the prevalence and incidence of Parkinson's disease in Taiwan: A nationwide, population-based study. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 531-538.	0.8	56
4492	The cross-sectional and longitudinal relationships between white matter hyperintensities and dementia in patients with Parkinson's disease: A retrospective analysis of 132 patients in a single center. <i>Archives of Gerontology and Geriatrics</i> , 2016, 62, 133-137.	1.4	10
4493	Challenges in the reproducibility of clinical studies with resting state fMRI: An example in early Parkinson's disease. <i>NeuroImage</i> , 2016, 124, 704-713.	2.1	81
4494	The utility of Î±-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. <i>Biomarkers in Medicine</i> , 2016, 10, 19-34.	0.6	86
4495	Impact of ethnicity on mood disorders in Parkinson's disease. <i>International Journal of Neuroscience</i> , 2016, 126, 734-738.	0.8	3
4496	Speech discrimination is impaired in parkinsonian patients: Expanding the audiologic findings of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 22, S138-S143.	1.1	21
4497	Variants in GBA , SNCA , and MAPT influence Parkinson disease risk, age at onset, and progression. <i>Neurobiology of Aging</i> , 2016, 37, 209.e1-209.e7.	1.5	106
4498	The option of sonographic guidance in Botulinum toxin injection for drooling in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2016, 123, 51-55.	1.4	30
4499	Changes in postural control in patients with Parkinson's disease: a posturographic study. <i>Physiotherapy</i> , 2016, 102, 272-279.	0.2	60
4500	Association analysis of the GRN ^{rs5848} and MAPT ^{rs242557} polymorphisms in Parkinson's disease and multiple system atrophy: a large-scale population-based study and meta-analysis. <i>International Journal of Neuroscience</i> , 2016, 126, 947-954.	0.8	6

#	ARTICLE	IF	CITATIONS
4501	Impact of localisation of deep brain stimulation electrodes on motor and neurobehavioural outcomes in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 758-766.	0.9	17
4502	Opposite Effects of Visual Cueing During Writing-Like Movements of Different Amplitudes in Parkinson's Disease. <i>Neurorehabilitation and Neural Repair</i> , 2016, 30, 431-439.	1.4	25
4503	Use of a Short-Form Balance Confidence Scale to Predict Future Recurrent Falls in People With Parkinson Disease. <i>Archives of Physical Medicine and Rehabilitation</i> , 2016, 97, 152-156.	0.5	19
4504	Beneficial Effects of Bilateral Subthalamic Stimulation on Non-Motor Symptoms in Parkinson's Disease. <i>Brain Stimulation</i> , 2016, 9, 78-85.	0.7	86
4505	Obstructive sleep apnea in Parkinson's disease patients: effect of Sinemet CR taken at bedtime. <i>Sleep and Breathing</i> , 2016, 20, 205-212.	0.9	36
4506	Spinal cord stimulation for Parkinson's disease: a systematic review. <i>Neurosurgical Review</i> , 2016, 39, 27-35.	1.2	58
4507	A Pooling Genome-Wide Association Study Combining a Pathway Analysis for Typical Sporadic Parkinson's Disease in the Han Population of Chinese Mainland. <i>Molecular Neurobiology</i> , 2016, 53, 4302-4318.	1.9	27
4508	Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 633-641.	0.9	11
4509	MDS-UPDRS to assess non-motor symptoms after STN DBS for Parkinson's disease. <i>International Journal of Neuroscience</i> , 2016, 126, 25-29.	0.8	12
4510	Are studies of motor cortex plasticity relevant in human patients with Parkinson's disease?. <i>Clinical Neurophysiology</i> , 2016, 127, 50-59.	0.7	23
4511	Graphical Tasks to Measure Upper Limb Function in Patients With Parkinson's Disease: Validity and Response to Dopaminergic Medication. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2017, 21, 283-289.	3.9	21
4512	Association of metabolic syndrome with falls in patients with Parkinson's disease. <i>Clinical Nutrition</i> , 2017, 36, 559-563.	2.3	7
4513	Smoking history is associated to cognitive impairment in Parkinson's disease. <i>Aging and Mental Health</i> , 2017, 21, 322-326.	1.5	13
4514	"Locus of control", health-related quality of life, emotional distress and disability in Parkinson's disease. <i>Journal of Health Psychology</i> , 2017, 22, 844-852.	1.3	19
4515	Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the "cortical hypothesis" of NeuroAIDS. <i>Applied Neuropsychology Adult</i> , 2017, 24, 410-419.	0.7	11
4516	Rapid eye movement sleep without atonia may help diagnose Lewy body disease in middle-aged and older patients with somatic symptom disorder. <i>Psychogeriatrics</i> , 2017, 17, 61-69.	0.6	8
4517	Dentate nucleus iron deposition is a potential biomarker for tremor-dominant Parkinson's disease. <i>NMR in Biomedicine</i> , 2017, 30, e3554.	1.6	42
4518	Personality and reported quality of life in Parkinson's disease. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 324-330.	1.3	19

#	ARTICLE	IF	CITATIONS
4519	Influence of treadmill gait training with additional load on motor function, postural instability and history of falls for individuals with Parkinson's disease: A randomized clinical trial. <i>Journal of Bodywork and Movement Therapies</i> , 2017, 21, 93-100.	0.5	11
4520	Relación entre el trastorno de conducta del sueño REM y el trastorno de control de impulsos en pacientes con enfermedad de Parkinson. <i>Neurología</i> , 2017, 32, 494-499.	0.3	7
4521	Possible selves in patients with right- versus left-onset Parkinson's disease. <i>Aging, Neuropsychology, and Cognition</i> , 2017, 24, 198-215.	0.7	3
4522	REM sleep without atonia in middle-aged and older psychiatric patients and Lewy body disease: a case series. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 397-406.	1.3	7
4523	Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review. <i>Acta Neurologica Scandinavica</i> , 2017, 135, 34-56.	1.0	96
4524	Affective Correlates of Psychosis in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 225-230.	0.8	2
4525	Quantitative Measurement of Akinesia in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 316-322.	0.8	16
4526	Unilateral ultra-brief pulse electroconvulsive therapy for depression in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2017, 135, 407-411.	1.0	20
4527	Patients with Parkinson disease present high ambulatory blood pressure variability. <i>Clinical Physiology and Functional Imaging</i> , 2017, 37, 530-535.	0.5	19
4528	Pre-frontal-insular-cerebellar modifications correlate with disgust feeling blunting after subthalamic stimulation: A positron emission tomography study in Parkinson's disease. <i>Journal of Neuropsychology</i> , 2017, 11, 378-395.	0.6	10
4529	Working memory in healthy aging and in Parkinson's disease: evidence of interference effects. <i>Aging, Neuropsychology, and Cognition</i> , 2017, 24, 281-298.	0.7	8
4530	Natural history of pure autonomic failure: A United States prospective cohort. <i>Annals of Neurology</i> , 2017, 81, 287-297.	2.8	229
4531	Drugs Against Neurodegenerative Diseases: Design and Synthesis of 6-Amino-substituted Imidazo[1,2-b]pyridazines as Acetylcholinesterase Inhibitors. <i>ChemistrySelect</i> , 2017, 2, 842-847.	0.7	21
4532	Decreased intestinal acetylcholinesterase in early Parkinson disease. <i>Neurology</i> , 2017, 88, 775-781.	1.5	75
4533	Precision medicine for disease modification in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 119-126.	4.9	141
4534	Resistance training with instability is more effective than resistance training in improving spinal inhibitory mechanisms in Parkinson's disease. <i>Journal of Applied Physiology</i> , 2017, 122, 1-10.	1.2	23
4535	Using "swallow-tail" sign and putaminal hypointensity as biomarkers to distinguish multiple system atrophy from idiopathic Parkinson's disease: A susceptibility-weighted imaging study. <i>European Radiology</i> , 2017, 27, 3174-3180.	2.3	44
4536	Vocal emotion decoding in the subthalamic nucleus: An intracranial ERP study in Parkinson's disease. <i>Brain and Language</i> , 2017, 168, 1-11.	0.8	29

#	ARTICLE	IF	CITATIONS
4537	Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment. <i>Neurochemistry International</i> , 2017, 105, 58-63.	1.9	33
4538	Octogenarian parkinsonism – Clinicopathological observations. <i>Parkinsonism and Related Disorders</i> , 2017, 37, 50-57.	1.1	8
4539	The heterozygous R1441C mutation of leucine-rich repeat kinase 2 gene in a Chinese patient with Parkinson disease: A five-year follow-up and literatures review. <i>Journal of the Neurological Sciences</i> , 2017, 373, 23-26.	0.3	11
4540	Rest tremor in Parkinson's disease: Body distribution and time of appearance. <i>Journal of the Neurological Sciences</i> , 2017, 375, 215-219.	0.3	13
4541	Cross-sectional and longitudinal associations of motor fluctuations and non-motor predominance with cerebrospinal β , and $A\beta$ as well as dementia-risk in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2017, 373, 223-229.	0.3	14
4542	Longitudinal changes of cortical microstructure in Parkinson's disease assessed with T1 relaxometry. <i>NeuroImage: Clinical</i> , 2017, 13, 405-414.	1.4	33
4543	Esophageal dysfunction in different stages of Parkinson's disease. <i>Neurogastroenterology and Motility</i> , 2017, 29, e12915.	1.6	63
4544	Pathology of Neurodegenerative Diseases. <i>Cold Spring Harbor Perspectives in Biology</i> , 2017, 9, a028035.	2.3	865
4545	Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 610-614.	2.2	18
4546	The visual kinetic depth effect is altered with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 37, 97-100.	1.1	2
4547	Extended –Timed Up and Go–assessment as a clinical indicator of cognitive state in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2017, 375, 86-91.	0.3	17
4548	Monitoring training activity during gait-related balance exercise in individuals with Parkinson's disease: a proof-of-concept-study. <i>BMC Neurology</i> , 2017, 17, 19.	0.8	22
4549	Phase II randomised controlled trial of a 6-month self-managed community exercise programme for people with Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 204-211.	0.9	30
4550	Serum uric acid levels in Parkinson's disease and related disorders. <i>Brain and Behavior</i> , 2017, 7, e00598.	1.0	34
4551	Progression of postural changes in Parkinson's disease: quantitative assessment. <i>Journal of Neurology</i> , 2017, 264, 675-683.	1.8	18
4552	Parkinson's disease alters multisensory perception: Insights from the Rubber Hand Illusion. <i>Neuropsychologia</i> , 2017, 97, 38-45.	0.7	25
4553	Parkinson's disease as a multisystem disorder. <i>Journal of Neural Transmission</i> , 2017, 124, 709-713.	1.4	43
4554	Misperceptions and Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2017, 374, 42-46.	0.3	16

#	ARTICLE	IF	CITATIONS
4555	Ferroptosis and cell death mechanisms in Parkinson's disease. <i>Neurochemistry International</i> , 2017, 104, 34-48.	1.9	260
4556	<i>Neurodegeneration.</i> , 2017, , 345-354.		3
4557	Dementia in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2017, 374, 26-31.	0.3	115
4558	Blood RNA biomarkers in prodromal PARK4 and REM sleep behavior disorder show role of complexin-1 loss for risk of Parkinson's disease. <i>DMM Disease Models and Mechanisms</i> , 2017, 10, 619-631.	1.2	20
4559	Unspeakable motion: Selective action-verb impairments in Parkinsonâ€™s disease patients without mild cognitive impairment. <i>Brain and Language</i> , 2017, 168, 37-46.	0.8	87
4560	The impact of motor symptoms on self-reported anxiety in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 38, 26-30.	1.1	21
4561	Antisaccades in Parkinson disease. <i>Neurology</i> , 2017, 88, 853-861.	1.5	36
4562	Retrospective Neuropsychological Profile of Patients With Parkinson Disease Prior to Developing Visual Hallucinations. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2017, 30, 90-95.	1.2	8
4563	Are Parkinsonâ€™s Patients More Vulnerable to the Effects of Cardiovascular Risk: A Neuroimaging and Neuropsychological Study. <i>Journal of the International Neuropsychological Society</i> , 2017, 23, 322-331.	1.2	18
4564	Improving Prospective Memory in Persons With Parkinson Disease: A Randomized Controlled Trial. <i>Neurorehabilitation and Neural Repair</i> , 2017, 31, 451-461.	1.4	16
4565	Reduced cognitive function in patients with Parkinson disease and obstructive sleep apnea. <i>Neurology</i> , 2017, 88, 1120-1128.	1.5	61
4566	The Potential Role of Gut-Derived Inflammation in Multiple System Atrophy. <i>Journal of Parkinson's Disease</i> , 2017, 7, 331-346.	1.5	68
4567	Association of <i>IGF1</i> gene polymorphism with Parkinson's disease in a Han Chinese population. <i>Journal of Gene Medicine</i> , 2017, 19, e2949.	1.4	7
4568	<i>Parkinsonâ€™s Disease and Gait Asymmetry.</i> , 2017, , 161-175.		0
4569	The Motor Syndrome of Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 25-32.	0.9	23
4570	Treatment of Older Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 381-405.	0.9	15
4572	Predictors of Recurrent Falls in People with Parkinsonâ€™s Disease and Proposal for a Predictive Tool. <i>Journal of Parkinson's Disease</i> , 2017, 7, 313-324.	1.5	20
4573	Does Nordic Walking restore the temporal organization of gait variability in Parkinsonâ€™s disease?. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2017, 14, 17.	2.4	28

#	ARTICLE	IF	CITATIONS
4574	Differences in <scp>MDS</scp>â€<scp>UPDRS</scp> Scores Based on Hoehn and Yahr Stage and Disease Duration. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 536-544.	0.8	65
4575	Source-Based Morphometry Multivariate Approach to Analyze [123I]FP-CIT SPECT Imaging. <i>Molecular Imaging and Biology</i> , 2017, 19, 772-778.	1.3	19
4576	Language Deficits as a Preclinical Window into Parkinsonâ€™s Disease: Evidence from Asymptomatic Parkin and Dardarin Mutation Carriers. <i>Journal of the International Neuropsychological Society</i> , 2017, 23, 150-158.	1.2	62
4577	Dual Anchor Internal Pulse Generator Technique May Lower Risk of Twiddlerâ€™s Syndrome: A Case Series and Literature Review. <i>Neuromodulation</i> , 2017, 20, 606-612.	0.4	18
4578	Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. <i>Parkinsonism and Related Disorders</i> , 2017, 37, 65-71.	1.1	34
4579	Acupuncture as Adjuvant Therapy for Sleep Disorders in Parkinsonâ€™s Disease. <i>JAMS Journal of Acupuncture and Meridian Studies</i> , 2017, 10, 33-38.	0.3	29
4580	Fractional Anisotropy and Mean Diffusion as Measures of Dopaminergic Function in Parkinsonâ€™s Disease: Challenging Results. <i>Journal of Parkinson's Disease</i> , 2017, 7, 129-142.	1.5	11
4581	Automatic classification of patients with idiopathic Parkinson's disease and progressive supranuclear palsy using diffusion MRI datasets. , 2017, , .		1
4582	Dual time point method for the quantification of irreversible tracer kinetics: A reference tissue approach applied to [18F]-FDOPA brain PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 3124-3134.	2.4	3
4583	A clinical study of the coronal plane deformity in Parkinson disease. <i>European Spine Journal</i> , 2017, 26, 1862-1870.	1.0	18
4584	Mechanisms of Parkinsonâ€™s disease-related proteins in mediating secondary brain damage after cerebral ischemia. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 1910-1926.	2.4	51
4585	Impulsive and Compulsive Behaviors in Parkinsonâ€™s Disease: The Norwegian ParkWest Study. <i>Journal of Parkinson's Disease</i> , 2017, 7, 183-191.	1.5	48
4586	Weight loss in the early stage of progressive supranuclear palsy. <i>Brain and Behavior</i> , 2017, 7, e00616.	1.0	9
4587	Pain in Parkinson disease: a cross-sectional survey of its prevalence, specifics, and therapy. <i>Journal of Neurology</i> , 2017, 264, 758-769.	1.8	74
4588	Anticipatory Postural Adjustment During Self-Initiated, Cued, and Compensatory Stepping in Healthy Older Adults and Patients With Parkinson Disease. <i>Archives of Physical Medicine and Rehabilitation</i> , 2017, 98, 1316-1324.e1.	0.5	39
4589	Vitamin D receptor gene polymorphisms, smoking, and risk of sporadic Parkinsonâ€™s disease in Japan. <i>Neuroscience Letters</i> , 2017, 643, 97-102.	1.0	19
4590	MicroRNA biomarkers of Parkinsonâ€™s disease in serum exosome-like microvesicles. <i>Neuroscience Letters</i> , 2017, 644, 94-99.	1.0	164
4591	Ocular and visual disorders in Parkinson's disease: Common but frequently overlooked. <i>Parkinsonism and Related Disorders</i> , 2017, 40, 1-10.	1.1	110

#	ARTICLE	IF	CITATIONS
4592	Gait improvement via rhythmic stimulation in Parkinson's disease is linked to rhythmic skills. <i>Scientific Reports</i> , 2017, 7, 42005.	1.6	110
4593	Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of DOPA treatment and changes in levodopa-induced dyskinesia. <i>Journal of Neurochemistry</i> , 2017, 141, 614-625.	2.1	31
4594	A parsimonious scoring and normative calculator for the Parkinson's disease mild cognitive impairment battery. <i>Clinical Neuropsychologist</i> , 2017, 31, 1231-1247.	1.5	11
4595	What increases the risk of malnutrition in Parkinson's disease?. <i>Journal of the Neurological Sciences</i> , 2017, 375, 235-238.	0.3	24
4596	Meta-analysis on the prevalence of REM sleep behavior disorder symptoms in Parkinson's disease. <i>BMC Neurology</i> , 2017, 17, 23.	0.8	62
4597	Cerebral Amyloid Burden and Hoehn and Yahr Stage 3 Scoring in Parkinson Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 143-147.	1.5	7
4598	Combined use of dopamine transporter imaging (DAT-SPECT) and 123 I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy for diagnosing Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2017, 375, 80-85.	0.3	32
4599	Whole-exome sequencing of 228 patients with sporadic Parkinson's disease. <i>Scientific Reports</i> , 2017, 7, 41188.	1.6	27
4600	The effect of 18F-FDG-PET image reconstruction algorithms on the expression of characteristic metabolic brain network in Parkinson's disease. <i>Physica Medica</i> , 2017, 41, 129-135.	0.4	23
4601	Personality and addictive behaviours in early Parkinson's disease and REM sleep behaviour disorder. <i>Parkinsonism and Related Disorders</i> , 2017, 37, 72-78.	1.1	27
4602	Blood-based NfL. <i>Neurology</i> , 2017, 88, 930-937.	1.5	369
4603	The Prevalence of Constipation and Irritable Bowel Syndrome in Parkinson's Disease Patients According to Rome III Diagnostic Criteria. <i>Journal of Parkinson's Disease</i> , 2017, 7, 353-357.	1.5	31
4604	Plasma levels of miR-137 and miR-124 are associated with Parkinson's disease but not with Parkinson's disease with depression. <i>Neurological Sciences</i> , 2017, 38, 761-767.	0.9	88
4605	Striato-cortical connections in Parkinson's and Alzheimer's diseases: Relation to cognition. <i>Movement Disorders</i> , 2017, 32, 917-922.	2.2	45
4606	High-Field Neuroimaging in Parkinson's Disease. , 2017, , 239-253.		0
4607	Serum uric acid levels and freezing of gait in Parkinson's disease. <i>Neurological Sciences</i> , 2017, 38, 955-960.	0.9	14
4608	Clinical characteristics of sleep disorders in patients with Parkinson's disease. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2017, 37, 100-104.	1.0	15
4609	Clinical Features and Differential Diagnosis of Parkinson's Disease. , 2017, , 103-115.		5

#	ARTICLE	IF	CITATIONS
4610	Use of ACE-inhibitors and falls in patients with Parkinson's disease. <i>Gait and Posture</i> , 2017, 54, 39-44.	0.6	13
4611	Immunochemical Detection of α -Synuclein Autoantibodies in Parkinson's Disease: Correlation between Plasma and Cerebrospinal Fluid Levels. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1170-1176.	1.7	52
4612	Impaired intracortical transmission in G2019S leucine rich repeat kinase Parkinson patients. <i>Movement Disorders</i> , 2017, 32, 750-756.	2.2	16
4613	Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease. <i>Acta Neuropathologica</i> , 2017, 133, 535-545.	3.9	195
4614	Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. <i>Movement Disorders</i> , 2017, 32, 739-749.	2.2	649
4615	Coffee consumption is associated with DNA methylation levels of human blood. <i>European Journal of Human Genetics</i> , 2017, 25, 608-616.	1.4	31
4616	Excessive Daytime Sleepiness Predicts Neurodegeneration in Idiopathic REM Sleep Behavior Disorder. <i>Sleep</i> , 2017, 40, .	0.6	40
4617	Abnormal metabolic brain network associated with Parkinson's disease: replication on a new European sample. <i>Neuroradiology</i> , 2017, 59, 507-515.	1.1	55
4618	Sagittal balance is correlated with Parkinson's Disease clinical parameters: an overview of spinopelvic alignment on 175 consecutive cases. <i>European Spine Journal</i> , 2017, 26, 471-478.	1.0	12
4619	Combined visual and semi-quantitative assessment of 123I-FP-CIT SPECT for the diagnosis of dopaminergic neurodegenerative diseases. <i>Neurological Sciences</i> , 2017, 38, 1187-1191.	0.9	16
4620	Patterns of Eye Movement Impairment Correlate with Regional Brain Atrophy in Neurodegenerative Parkinsonism. <i>Neurodegenerative Diseases</i> , 2017, 17, 117-126.	0.8	22
4621	Appendectomy History is not Related to Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 347-352.	1.5	23
4622	Brain Functional Connectivity in Parkinson's disease – EEG resting analysis. <i>IFMBE Proceedings</i> , 2017, , 185-188.	0.2	5
4623	Can loss of the swallow tail sign help distinguish between Parkinson Disease and the Parkinson-Plus syndromes?. <i>Clinical Imaging</i> , 2017, 44, 66-69.	0.8	20
4624	Validation of the MDS research criteria for prodromal Parkinson's disease: Longitudinal assessment in a REM sleep behavior disorder (RBD) cohort. <i>Movement Disorders</i> , 2017, 32, 865-873.	2.2	102
4625	SNCA 3'UTR genetic variants in patients with Parkinson's disease and REM sleep behavior disorder. <i>Neurological Sciences</i> , 2017, 38, 1233-1240.	0.9	27
4626	Treadmill Walking Combined With Anodal Transcranial Direct Current Stimulation in Parkinson Disease. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2017, 96, 801-808.	0.7	22
4627	Coronal Transcranial Sonography and Mode Tremor Frequency Determination in Parkinson's Disease and Essential Tremor. <i>Journal of Neuroimaging</i> , 2017, 27, 524-530.	1.0	9

#	ARTICLE	IF	CITATIONS
4629	Dual tasking in Parkinson's disease: Cognitive consequences while walking.. <i>Neuropsychology</i> , 2017, 31, 613-623.	1.0	44
4630	The utility of the combination of a SPECT study with [123I]-FP-CIT of dopamine transporters and [123I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes. <i>Nuclear Medicine Communications</i> , 2017, 38, 487-492.	0.5	20
4631	Depressive Symptoms are Frequent in Atypical Parkinsonian Disorders. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 191-197.	0.8	24
4632	Can postural abnormality really respond to levodopa in Parkinson's disease?. <i>Journal of the Neurological Sciences</i> , 2017, 377, 179-184.	0.3	22
4633	Automated analysis of connected speech reveals early biomarkers of Parkinson's disease in patients with rapid eye movement sleep behaviour disorder. <i>Scientific Reports</i> , 2017, 7, 12.	1.6	245
4634	Genetic Identification in Early Onset Parkinsonism among Norwegian Patients. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 499-508.	0.8	25
4635	Psychometric properties of the apathy evaluation scale in patients with Parkinson's disease. <i>International Journal of Methods in Psychiatric Research</i> , 2017, 26, .	1.1	10
4636	Parkinson Symptoms in Dementia with Lewy Bodies. , 2017, , 93-109.		1
4637	Role of habenula and amygdala dysfunction in Parkinson disease patients with puning. <i>Neurology</i> , 2017, 88, 2207-2215.	1.5	32
4638	Management Impact of Imaging Brain Vesicular Monoamine Transporter Type 2 in Clinically Uncertain Parkinsonian Syndrome with ¹⁸ F-AV133 and PET. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1815-1820.	2.8	17
4639	On the Role of Mining Exposure in Epigenetic Effects in Parkinson's Disease. <i>Neurotoxicity Research</i> , 2017, 32, 172-174.	1.3	13
4640	Mild Cognitive Impairment in Parkinson's Disease: Clustering and Switching Analyses in Verbal Fluency Test. <i>Journal of the International Neuropsychological Society</i> , 2017, 23, 511-520.	1.2	17
4641	Donepezil for Constipation in Lewy Body Diseases: Four Case Studies. <i>Activitas Nervosa Superior</i> , 2017, 59, 19-27.	0.4	6
4642	Gut microbiota in Parkinson disease in a northern German cohort. <i>Brain Research</i> , 2017, 1667, 41-45.	1.1	264
4643	Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation's Refractory Symptoms in Advanced Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2017, 40, 103-107.	0.2	24
4644	The Phenomenology of Parkinson's Disease. <i>Seminars in Neurology</i> , 2017, 37, 109-117.	0.5	28
4645	Recognizing Atypical Parkinsonisms: "Red Flags" and Therapeutic Approaches. <i>Seminars in Neurology</i> , 2017, 37, 215-227.	0.5	30
4646	Accelerated Age-Dependent Hippocampal Volume Loss in Parkinson Disease With Mild Cognitive Impairment. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2017, 32, 313-319.	0.9	16

#	ARTICLE	IF	CITATIONS
4648	Motorâ€symptom laterality affects acquisition in Parkinson's disease: A cognitive and functional magnetic resonance imaging study. <i>Movement Disorders</i> , 2017, 32, 1047-1055.	2.2	26
4649	Identification and intensity of disgust: Distinguishing visual, linguistic and facial expressions processing in Parkinson disease. <i>Behavioural Brain Research</i> , 2017, 330, 30-36.	1.2	12
4650	Tremor stability index: a new tool for differential diagnosis in tremor syndromes. <i>Brain</i> , 2017, 140, 1977-1986.	3.7	103
4651	Gray Matter Abnormalities in Idiopathic Parkinson's Disease: Evaluation by Diffusional Kurtosis Imaging and Neurite Orientation Dispersion and Density Imaging. <i>Human Brain Mapping</i> , 2017, 38, 3704-3722.	1.9	78
4652	Cognitive Behavior Therapy for Anxiety in Parkinsonâ€™s Disease: Outcomes for Patients and Caregivers. <i>Clinical Gerontologist</i> , 2017, 40, 159-171.	1.2	36
4653	Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinsonâ€™s disease patients. <i>Genome Medicine</i> , 2017, 9, 39.	3.6	420
4654	Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to Î±-synuclein pathology. <i>Movement Disorders</i> , 2017, 32, 884-892.	2.2	55
4655	Training dual tasks together or apart in Parkinson's disease: Results from the DUALITY trial. <i>Movement Disorders</i> , 2017, 32, 1201-1210.	2.2	108
4656	The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity. <i>Molecular Neurodegeneration</i> , 2017, 12, 32.	4.4	62
4657	Resistance Training Improves Sleep Quality in Subjects With Moderate Parkinson's Disease. <i>Journal of Strength and Conditioning Research</i> , 2017, 31, 2270-2277.	1.0	42
4658	Differential Progression of Midbrain Atrophy in Parkinsonism: Longitudinal MRI Study. <i>Neurodegenerative Diseases</i> , 2017, 17, 31-37.	0.8	10
4659	Osteopathic manipulation as a complementary approach to Parkinsonâ€™s disease: A controlled pilot study. <i>NeuroRehabilitation</i> , 2017, 40, 145-151.	0.5	12
4660	Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinsonâ€™s disease. <i>Journal of Neural Transmission</i> , 2017, 124, 353-360.	1.4	37
4661	Serum glutathione peroxidase, xanthine oxidase, and superoxide dismutase activities and malondialdehyde levels in patients with Parkinsonâ€™s disease. <i>Neurological Sciences</i> , 2017, 38, 425-431.	0.9	43
4662	Computer-assisted cognitive rehabilitation on freezing of gait in Parkinsonâ€™s disease: A pilot study. <i>Neuroscience Letters</i> , 2017, 654, 38-41.	1.0	16
4663	Bougainvillea spectabilis flowers extract protects against the rotenone-induced toxicity. <i>Asian Pacific Journal of Tropical Medicine</i> , 2017, 10, 478-490.	0.4	17
4664	Association of polymorphisms and reduced expression levels of the NR4A2 gene with Parkinson's disease in a Mexican population. <i>Journal of the Neurological Sciences</i> , 2017, 379, 58-63.	0.3	9
4665	Premotor symptoms and the risk of Parkinsonâ€™s disease: A case-control study in Mexican population. <i>Clinical Neurology and Neurosurgery</i> , 2017, 160, 46-49.	0.6	14

#	ARTICLE	IF	CITATIONS
4666	The role of the prefrontal cortex in freezing of gait in Parkinson's disease: insights from a deep repetitive transcranial magnetic stimulation exploratory study. <i>Experimental Brain Research</i> , 2017, 235, 2463-2472.	0.7	57
4667	Cognitive Estimation in Non-demented Parkinson's Disease. <i>Archives of Clinical Neuropsychology</i> , 2017, 32, 381-390.	0.3	5
4668	Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease. <i>Neuroscience Bulletin</i> , 2017, 33, 561-567.	1.5	45
4669	Palliative Care and Parkinson's Disease: Caregiver Perspectives. <i>Journal of Palliative Medicine</i> , 2017, 20, 930-938.	0.6	70
4670	Longitudinal decline in speech production in Parkinson's disease spectrum disorders. <i>Brain and Language</i> , 2017, 171, 42-51.	0.8	43
4671	Somatization in Parkinson's Disease: A systematic review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 78, 18-26.	2.5	23
4672	Effects of 2 Years of Exercise on Gait Impairment in People With Parkinson Disease: The PRET-PD Randomized Trial. <i>Journal of Neurologic Physical Therapy</i> , 2017, 41, 21-30.	0.7	40
4673	Structural connectivity differences in motor network between tremor-dominant and nontremor Parkinson's disease. <i>Human Brain Mapping</i> , 2017, 38, 4716-4729.	1.9	57
4674	Serum Ceruloplasmin and Striatal Dopamine Transporter Density in Parkinson Disease. <i>Clinical Nuclear Medicine</i> , 2017, 42, 675-679.	0.7	4
4675	Serum Klotho, vitamin D, and homocysteine in combination predict the outcomes of Chinese patients with multiple system atrophy. <i>CNS Neuroscience and Therapeutics</i> , 2017, 23, 657-666.	1.9	24
4676	Freezing of gait is an early clinical feature of progressive supranuclear palsy. <i>Neurology and Clinical Neuroscience</i> , 2017, 5, 86-90.	0.2	9
4677	Frontal Tasks and Behavior in Rigid or Tremor-Dominant Parkinson Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2017, 32, 300-306.	0.9	7
4678	Parkinson's Disease Subtypes Show Distinct Tradeoffs Between Response Initiation and Inhibition Latencies. <i>Journal of the International Neuropsychological Society</i> , 2017, 23, 665-674.	1.2	5
4679	Baseline motor findings and Parkinson disease prognostic subtypes. <i>Neurology</i> , 2017, 89, 138-143.	1.5	33
4680	Structural changes of gut microbiota in Parkinson's disease and its correlation with clinical features. <i>Science China Life Sciences</i> , 2017, 60, 1223-1233.	2.3	316
4681	Altered Brain Wiring in Parkinson's Disease: A Structural Connectome-Based Analysis. <i>Brain Connectivity</i> , 2017, 7, 347-356.	0.8	29
4682	A New Hope for a Devastating Disease: Hydrogen Sulfide in Parkinson's Disease. <i>Molecular Neurobiology</i> , 2018, 55, 3789-3799.	1.9	58
4683	Clinimetric validity of the Trail Making Test Czech version in Parkinson's disease and normative data for older adults. <i>Clinical Neuropsychologist</i> , 2017, 31, 42-60.	1.5	12

#	ARTICLE	IF	CITATIONS
4684	Tau/Î±-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study. <i>Movement Disorders</i> , 2017, 32, 1066-1073.	2.2	44
4685	Instability Resistance Training Improves Neuromuscular Outcome in Parkinson's Disease. <i>Medicine and Science in Sports and Exercise</i> , 2017, 49, 652-660.	0.2	16
4686	Plasma Î±-synuclein predicts cognitive decline in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 818-824.	0.9	128
4687	Death certificate data and causes of death in patients with parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2017, 41, 99-103.	1.1	38
4688	Early-onset mild cognitive impairment in Parkinson's disease: Altered corticopetal cholinergic network. <i>Scientific Reports</i> , 2017, 7, 2381.	1.6	15
4689	Cystatin C as a potential therapeutic mediator against Parkinson's disease via VEGF-induced angiogenesis and enhanced neuronal autophagy in neurovascular units. <i>Cell Death and Disease</i> , 2017, 8, e2854-e2854.	2.7	99
4690	Disability from pain directly correlated with depression in Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2017, 160, 1-4.	0.6	27
4691	ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study). <i>JAMA Neurology</i> , 2017, 74, 941.	4.5	137
4692	Mild cognitive impairment as a risk factor for Parkinson's disease dementia. <i>Movement Disorders</i> , 2017, 32, 1056-1065.	2.2	117
4693	Effects of levodopa on corticostriatal circuits supporting working memory in Parkinson's disease. <i>Cortex</i> , 2017, 93, 193-205.	1.1	41
4694	Remotely Programmed Deep Brain Stimulation of the Bilateral Subthalamic Nucleus for the Treatment of Primary Parkinson Disease: A Randomized Controlled Trial Investigating the Safety and Efficacy of a Novel Deep Brain Stimulation System. <i>Stereotactic and Functional Neurosurgery</i> , 2017, 95, 174-182.	0.8	37
4695	Assessing Visuospatial Skills in Parkinson's: Comparison of Neuropsychological Assessment Battery Visual Discrimination to the Judgment of Line Orientation. <i>Archives of Clinical Neuropsychology</i> , 2017, 32, 123-127.	0.3	3
4696	Characterization of patients with longstanding idiopathic REM sleep behavior disorder. <i>Neurology</i> , 2017, 89, 242-248.	1.5	75
4697	Classification of advanced stages of Parkinson's disease: translation into stratified treatments. <i>Journal of Neural Transmission</i> , 2017, 124, 1015-1027.	1.4	64
4698	Combined Diffusion Tensor Imaging and Apparent Transverse Relaxation Rate Differentiate Parkinson Disease and Atypical Parkinsonism. <i>American Journal of Neuroradiology</i> , 2017, 38, 966-972.	1.2	32
4699	Validation of an informant-based cognitive screening tool for Parkinson disease. <i>Asia-Pacific Psychiatry</i> , 2017, 9, e12278.	1.2	1
4700	Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 310-316.	0.9	84
4701	Phenotype of postural instability/gait difficulty in Parkinson disease: relevance to cognitive impairment and mechanism relating pathological proteins and neurotransmitters. <i>Scientific Reports</i> , 2017, 7, 44872.	1.6	27

#	ARTICLE	IF	CITATIONS
4702	Predictive markers for early conversion of iRBD to neurodegenerative synucleinopathy diseases. <i>Neurology</i> , 2017, 88, 1493-1500.	1.5	86
4703	Differential diagnosis between patients with probable Alzheimer's disease, Parkinson's disease dementia, or dementia with Lewy bodies and frontotemporal dementia, behavioral variant, using quantitative electroencephalographic features. <i>Journal of Neural Transmission</i> , 2017, 124, 569-581.	1.4	57
4704	Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test. <i>Parkinsonism and Related Disorders</i> , 2017, 39, 37-43.	1.1	44
4705	The utility of FDG-PET in the differential diagnosis of Parkinsonism. <i>Neurological Research</i> , 2017, 39, 675-684.	0.6	38
4706	Diagnostic Value of Isolated Mentalis Versus Mentalis Plus Upper Limb Electromyography in Idiopathic REM Sleep Behavior Disorder Patients Eventually Developing a Neurodegenerative Syndrome. <i>Sleep</i> , 2017, 40, .	0.6	38
4707	Novel conformation-selective alpha-synuclein antibodies raised against different <i>in vitro</i> fibril forms show distinct patterns of Lewy pathology in Parkinson's disease. <i>Neuropathology and Applied Neurobiology</i> , 2017, 43, 604-620.	1.8	51
4708	The effects of omega-3 fatty acids and vitamin E co-supplementation on clinical and metabolic status in patients with Parkinson's disease: A randomized, double-blind, placebo-controlled trial. <i>Neurochemistry International</i> , 2017, 108, 183-189.	1.9	106
4709	Seeding and transgenic overexpression of alpha-synuclein triggers dendritic spine pathology in the neocortex. <i>EMBO Molecular Medicine</i> , 2017, 9, 716-731.	3.3	58
4710	The validity of the Gait Variability Index for individuals with mild to moderate Parkinson's disease. <i>Gait and Posture</i> , 2017, 54, 311-317.	0.6	21
4711	The cerebellum in dual-task performance in Parkinson's disease. <i>Scientific Reports</i> , 2017, 7, 45662.	1.6	29
4712	Axial rigidity is related to the risk of falls in patients with Parkinson's disease. <i>NeuroRehabilitation</i> , 2017, 40, 569-577.	0.5	13
4713	Modulating risky decision-making in Parkinson's disease by transcranial direct current stimulation. <i>European Journal of Neurology</i> , 2017, 24, 751-754.	1.7	13
4714	Parkinson's disease: diagnostic utility of volumetric imaging. <i>Neuroradiology</i> , 2017, 59, 367-377.	1.1	6
4715	Impact of disease duration and cardiovascular dysautonomia on hypertension in Parkinson's disease. <i>Journal of Clinical Hypertension</i> , 2017, 19, 418-423.	1.0	10
4716	TMEM230 in Parkinson's disease. <i>Neurobiology of Aging</i> , 2017, 56, 212.e1-212.e3.	1.5	9
4717	Development of a Biochemical Diagnosis of Parkinson Disease by Detection of \pm -Synuclein Misfolded Aggregates in Cerebrospinal Fluid. <i>JAMA Neurology</i> , 2017, 74, 163.	4.5	312
4718	Estimating personalized diagnostic rules depending on individualized characteristics. <i>Statistics in Medicine</i> , 2017, 36, 1099-1117.	0.8	5
4719	Current status of the development of PET radiotracers for imaging alpha synuclein aggregates in Lewy bodies and Lewy neurites. <i>Clinical and Translational Imaging</i> , 2017, 5, 3-14.	1.1	38

#	ARTICLE	IF	CITATIONS
4720	Depressive symptoms in Parkinson's disease correlate with cortical atrophy over time. <i>Brain and Cognition</i> , 2017, 111, 127-133.	0.8	28
4721	Cognitive impairment in Parkinson's disease: impact on quality of life of carers. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 1362-1370.	1.3	41
4722	The impact of early versus late levodopa administration. <i>Journal of Neural Transmission</i> , 2017, 124, 471-476.	1.4	5
4723	Volumetric analysis of the cerebellum in patients with progressive supranuclear palsy. <i>European Journal of Neurology</i> , 2017, 24, 212-218.	1.7	4
4724	Autonomic disturbances including impaired hand thermoregulation in multiple system atrophy and Parkinson's disease. <i>Journal of Neural Transmission</i> , 2017, 124, 965-972.	1.4	14
4725	Parkinson's disease-related increase of α -synuclein-weighted hypointensity in substantia nigra pars compacta. <i>Movement Disorders</i> , 2017, 32, 441-449.	2.2	61
4726	Enhanced neuroprotection with decellularized brain extracellular matrix containing bFGF after intracerebral transplantation in Parkinson's disease rat model. <i>International Journal of Pharmaceutics</i> , 2017, 517, 383-394.	2.6	25
4727	Analysis of Extrastriatal ^{123}I -FP-CIT Binding Contributes to the Differential Diagnosis of Parkinsonian Diseases. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1117-1123.	2.8	35
4728	Long-term risk of falls in an incident Parkinson's disease cohort: the Norwegian ParkWest study. <i>Journal of Neurology</i> , 2017, 264, 364-372.	1.8	21
4729	Impact of autonomic dysfunctions on the quality of life in Parkinson's disease patients. <i>Acta Neurologica Belgica</i> , 2017, 117, 207-211.	0.5	34
4730	Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations. <i>JAMA Neurology</i> , 2017, 74, 197.	4.5	146
4731	Imposed Faster and Slower Walking Speeds Influence Gait Stability Differently in Parkinson Fallers. <i>Archives of Physical Medicine and Rehabilitation</i> , 2017, 98, 639-648.	0.5	23
4732	Spatial learning deficits in Parkinson's disease with and without mild cognitive impairment. <i>Parkinsonism and Related Disorders</i> , 2017, 36, 83-88.	1.1	16
4733	A dose-effect of mutations in the GBA gene on Parkinson's disease phenotype. <i>Parkinsonism and Related Disorders</i> , 2017, 36, 47-51.	1.1	78
4734	Motor preparation rather than decision-making differentiates Parkinson's disease patients with and without freezing of gait. <i>Clinical Neurophysiology</i> , 2017, 128, 463-471.	0.7	19
4735	^{131}I -MIBG myocardial scintigraphy for differentiation of Parkinson's disease from multiple system atrophy or essential tremor in Chinese population. <i>Journal of the Neurological Sciences</i> , 2017, 373, 48-51.	0.3	12
4736	Nurr1 overexpression exerts neuroprotective and anti-inflammatory roles via down-regulating CCL2 expression in both in vivo and in vitro Parkinson's disease models. <i>Biochemical and Biophysical Research Communications</i> , 2017, 482, 1312-1319.	1.0	43
4737	Lack of association between LRRK2 G2385R and cognitive dysfunction in Korean patients with Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2017, 36, 108-113.	0.8	16

#	ARTICLE	IF	CITATIONS
4738	Downregulation of neuronal vasoactive intestinal polypeptide in Parkinson's disease and chronic constipation. <i>Neurogastroenterology and Motility</i> , 2017, 29, e12995.	1.6	45
4739	A Neurophysiological Study of Semantic Processing in Parkinson's Disease. <i>Journal of the International Neuropsychological Society</i> , 2017, 23, 78-89.	1.2	14
4740	MDS clinical diagnostic criteria for Parkinson's disease in China. <i>Journal of Neurology</i> , 2017, 264, 476-481.	1.8	32
4741	Distinct patterns of imprecise consonant articulation among Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. <i>Brain and Language</i> , 2017, 165, 1-9.	0.8	69
4742	Association between DNA methyltransferase gene polymorphism and Parkinson's disease. <i>Neuroscience Letters</i> , 2017, 639, 146-150.	1.0	19
4743	Anxiety is associated with cognitive impairment in newly-diagnosed Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 36, 63-68.	1.1	50
4744	Abnormal Resting-State Neural Activity and Connectivity of Fatigue in Parkinson's Disease. <i>CNS Neuroscience and Therapeutics</i> , 2017, 23, 241-247.	1.9	35
4745	Optimized temporal pattern of brain stimulation designed by computational evolution. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	113
4746	Effect of subthalamic nucleus deep brain stimulation on balance in Parkinson's disease: A static posturographic analysis. <i>Gait and Posture</i> , 2017, 52, 374-380.	0.6	16
4747	The risk factors and pattern of cerebral microbleeds in Parkinson's disease. <i>International Journal of Neuroscience</i> , 2017, 127, 909-914.	0.8	4
4749	Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: a cross-sectional study of iron-related magnetic resonance imaging susceptibility. <i>European Journal of Neurology</i> , 2017, 24, 357-365.	1.7	62
4750	Dopaminergic medication unrelated myoclonus is less related to tremor in idiopathic Parkinson's disease. <i>Neurological Sciences</i> , 2017, 38, 679-682.	0.9	5
4751	The value of the bulbocavernosus reflex and pudendal nerve somatosensory evoked potentials in distinguishing between multiple system atrophy and Parkinson's disease at an early stage. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 195-203.	1.0	8
4752	Improvement of Pyramidal Tract Side Effect Prediction Using a Data-Driven Method in Subthalamic Stimulation. <i>IEEE Transactions on Biomedical Engineering</i> , 2017, 64, 2134-2141.	2.5	7
4753	Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2017, 373, 116-123.	0.3	6
4754	Effects of postural exercises in patients with Parkinson's disease and Pisa syndrome: A pilot study. <i>NeuroRehabilitation</i> , 2017, 41, 423-428.	0.5	13
4755	Cognition and the course of prodromal Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1640-1645.	2.2	39
4756	Correlations between dopamine transporter density measured by 123I-FP-CIT SPECT and regional gray matter volume in Parkinson's disease. <i>Japanese Journal of Radiology</i> , 2017, 35, 755-759.	1.0	7

#	ARTICLE	IF	CITATIONS
4757	A mixed methods evaluation of a Mindfulness-Based Stress Reduction course for people with Parkinson's disease. <i>Complementary Therapies in Clinical Practice</i> , 2017, 29, 220-228.	0.7	26
4758	Early weight loss in parkinsonism predicts poor outcomes. <i>Neurology</i> , 2017, 89, 2254-2261.	1.5	40
4759	Walking behavior over multiple obstacles in people with Parkinson's disease. <i>Gait and Posture</i> , 2017, 58, 510-515.	0.6	11
4760	Bisphenol A glucuronidation in patients with Parkinson's disease. <i>NeuroToxicology</i> , 2017, 63, 90-96.	1.4	24
4761	Smoking and age-at-onset of both motor and non-motor symptoms in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 94-96.	1.1	14
4762	Disrupted Brain Network Hubs in Subtype-Specific Parkinson's Disease. <i>European Neurology</i> , 2017, 78, 200-209.	0.6	32
4763	Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2017, 16, 557-563.	1.4	47
4764	Reduced Empathy Scores in Patients with Parkinson's Disease: A Non-Motor Symptom Associated with Advanced Disease Stages. <i>Journal of Parkinson's Disease</i> , 2017, 7, 713-718.	1.5	7
4765	A New Evolutionary Algorithm-Based Home Monitoring Device for Parkinson's Dyskinesia. <i>Journal of Medical Systems</i> , 2017, 41, 176.	2.2	19
4767	The Relationship Between Fatigue and Other Non-Motor Symptoms in Parkinson's Disease in Chinese Population. <i>International Journal of Gerontology</i> , 2017, 11, 171-175.	0.7	2
4768	Symptomatic, non-infectious, non-hemorrhagic edema after subthalamic nucleus deep brain stimulation surgery for Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2017, 383, 42-46.	0.3	23
4769	CSF biomarkers β -amyloid, tau proteins and α -synuclein in the differential diagnosis of Parkinson-plus syndromes. <i>Journal of the Neurological Sciences</i> , 2017, 382, 91-95.	0.3	66
4770	Dementia-Predicting Cognitive Risk Score and Its Correlation with Cortical Thickness in Parkinson Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2017, 44, 203-212.	0.7	16
4771	Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 33-38.	1.1	34
4772	Association of <i>DNMT3b</i> gene variants with sporadic Parkinson's disease in a Chinese Han population. <i>Journal of Gene Medicine</i> , 2017, 19, 360-365.	1.4	13
4773	Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2017, 381, 160-164.	0.3	27
4774	Early clinical features of the parkinsonian-related dementias. , 0, , 245-277.		1
4775	Caffeine as symptomatic treatment for Parkinson disease (Caf $\text{\textcircled{C}}$ -PD). <i>Neurology</i> , 2017, 89, 1795-1803.	1.5	102

#	ARTICLE	IF	CITATIONS
4776	Depression and social phobia in essential tremor and Parkinson's disease. <i>Brain and Behavior</i> , 2017, 7, e00781.	1.0	37
4777	Dementia with Lewy bodies. <i>NeuroReport</i> , 2017, 28, 1061-1065.	0.6	6
4778	Development of a Thai Parkinson's Disease Screening Tool and the Prevalence of Parkinsonism and Parkinson's Disease, Based on a Community Survey in Bangkok. <i>Neuroepidemiology</i> , 2017, 49, 74-81.	1.1	6
4779	Dopaminergic and non-dopaminergic gait components assessed by instrumented timed up and go test in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2017, 124, 1539-1546.	1.4	7
4780	Fatigue correlates with LRRK2 G2385R variant in Chinese Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2017, 44, 101-105.	1.1	6
4781	Feasibility and safety of group exercises for individuals with Parkinson's disease: A case series. <i>International Journal of Therapy and Rehabilitation</i> , 2017, 24, 223-227.	0.1	0
4782	Current evidence on the effect of dietary polyphenols intake on chronic diseases. <i>Food and Chemical Toxicology</i> , 2017, 110, 286-299.	1.8	200
4783	Biomechanical Analysis of Dance for Parkinson's Disease: A Paradoxical Case Study of Balance and Gait Effects?. <i>Explore: the Journal of Science and Healing</i> , 2017, 13, 409-413.	0.4	4
4784	Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 491-501.	1.5	44
4785	Microstructural white matter alterations in patients with drug induced parkinsonism. <i>Human Brain Mapping</i> , 2017, 38, 6043-6052.	1.9	4
4786	Magnetic Resonance Imaging Biomarkers to Assess Substantia Nigra Damage in Idiopathic Rapid Eye Movement Sleep Behavior Disorder. <i>Sleep</i> , 2017, 40, .	0.6	55
4787	Olfactory Dysfunction as an Early Biomarker in Parkinson's Disease. <i>Neuroscience Bulletin</i> , 2017, 33, 515-525.	1.5	200
4788	Epigenetic approach to early-onset Parkinson's disease: low methylation status of <i>SNCA</i> and <i>PARK2</i> promoter regions. <i>Neurological Research</i> , 2017, 39, 965-972.	0.6	29
4789	Genetic analysis of SNCA gene polymorphisms in Parkinson's disease in an Iranian population. <i>Basal Ganglia</i> , 2017, 10, 4-7.	0.3	2
4790	Clinicopathologic discrepancies in a population-based incidence study of parkinsonism in olmsted county: 1991-2010. <i>Movement Disorders</i> , 2017, 32, 1439-1446.	2.2	19
4791	Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1401-1408.	2.2	91
4792	Changes of brain structure in Parkinson's disease patients with mild cognitive impairment analyzed via VBM technology. <i>Neuroscience Letters</i> , 2017, 658, 121-132.	1.0	51
4793	Preserving Self: Theorizing the Social and Psychological Processes of Living With Parkinson Disease. <i>Qualitative Health Research</i> , 2017, 27, 964-982.	1.0	44

#	ARTICLE	IF	CITATIONS
4794	Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. <i>Annals of Neurology</i> , 2017, 82, 419-428.	2.8	161
4795	Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). <i>Movement Disorders</i> , 2017, 32, 1701-1709.	2.2	134
4796	Tumor necrosis factor alpha polymorphisms are associated with Parkinson's disease age at onset. <i>Neuroscience Letters</i> , 2017, 658, 133-136.	1.0	18
4797	Association between REM sleep behaviour disorder and impulse control disorder in patients with Parkinson's disease. <i>Neurología (English Edition)</i> , 2017, 32, 494-499.	0.2	5
4798	Fall-Prone Older People's Attitudes towards the Use of Virtual Reality Technology for Fall Prevention. <i>Gerontology</i> , 2017, 63, 590-598.	1.4	28
4799	Gender Differences of Nonmotor Symptoms Affecting Quality of Life in Parkinson Disease. <i>Neurodegenerative Diseases</i> , 2017, 17, 276-280.	0.8	25
4800	Near-falls in people with Parkinson's disease: Circumstances, contributing factors and association with falling. <i>Clinical Neurology and Neurosurgery</i> , 2017, 161, 51-55.	0.6	29
4801	Analysis of blood-based gene expression in idiopathic Parkinson disease. <i>Neurology</i> , 2017, 89, 1676-1683.	1.5	112
4802	Essential tremor & Parkinson disease. <i>Nurse Practitioner</i> , 2017, 42, 35-40.	0.2	2
4803	Trunk muscle activation pattern in parkinsonian camptocormia as revealed with surface electromyography. <i>Parkinsonism and Related Disorders</i> , 2017, 44, 44-50.	1.1	11
4804	Impact of sleep-related symptoms on clinical motor subtypes and disability in Parkinson's disease: a multicentre cross-sectional study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 953-959.	0.9	48
4805	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017, 32, 1264-1310.	2.2	608
4806	Comparing abnormalities of amplitude of low-frequency fluctuations in multiple system atrophy and idiopathic Parkinson's disease measured with resting-state fMRI. <i>Psychiatry Research - Neuroimaging</i> , 2017, 269, 73-81.	0.9	30
4807	Induced Pluripotent Stem Cell Therapy and Safety Concerns in Age-Related Chronic Neurodegenerative Diseases. <i>Stem Cells in Clinical Applications</i> , 2017, , 23-65.	0.4	0
4808	Predictors of onset of psychosis in patients with Parkinson's disease: Who gets it early?. <i>Parkinsonism and Related Disorders</i> , 2017, 44, 91-94.	1.1	17
4809	Separate neural representations of depression, anxiety and apathy in Parkinson's disease. <i>Scientific Reports</i> , 2017, 7, 12164.	1.6	49
4810	Síndromes parkinsonianos. <i>EMC - Tratado De Medicina</i> , 2017, 21, 1-6.	0.0	0
4811	Dopaminergic Modulation of Biological Motion Perception in patients with Parkinson's disease. <i>Scientific Reports</i> , 2017, 7, 10159.	1.6	5

#	ARTICLE	IF	CITATIONS
4812	Evaluation of sexual dysfunction in Parkinson's disease between two different regions of Turkey. <i>Clinical Neurology and Neurosurgery</i> , 2017, 161, 117-120.	0.6	7
4813	Two polysomnographic features of REM sleep behavior disorder: Clinical variations insight for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 44, 66-72.	1.1	16
4814	On the integrity of functional brain networks in schizophrenia, Parkinson's disease, and advanced age: Evidence from connectivity-based single-subject classification. <i>Human Brain Mapping</i> , 2017, 38, 5845-5858.	1.9	35
4815	Diagnostic utility of cerebrospinal fluid α -synuclein in Parkinson's disease: A systematic review and meta-analysis. <i>Movement Disorders</i> , 2017, 32, 1389-1400.	2.2	157
4816	Istradefylline improves daytime sleepiness in patients with Parkinson's disease: An open-label, 3-month study. <i>Journal of the Neurological Sciences</i> , 2017, 380, 230-233.	0.3	45
4817	Restless legs syndrome in Parkinson disease: Clinical characteristics, abnormal iron metabolism and altered neurotransmitters. <i>Scientific Reports</i> , 2017, 7, 10547.	1.6	50
4818	Color discrimination errors associate with axial motor impairments in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 864-869.	0.8	5
4819	Altered N100-potential associates with working memory impairment in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2017, 124, 1197-1203.	1.4	6
4820	Characterization of motor events in REM sleep behavior disorder. <i>Journal of Neural Transmission</i> , 2017, 124, 1183-1186.	1.4	16
4821	The Role of Recollection and Familiarity in Nondemented Parkinson's Patients. <i>Journal of General Psychology</i> , 2017, 144, 230-243.	1.6	4
4824	Dynamics of change in self-reported disability among persons with Parkinson's disease after 2 years of follow-up. <i>Neurological Sciences</i> , 2017, 38, 1415-1421.	0.9	8
4825	FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder. <i>Movement Disorders</i> , 2017, 32, 1482-1486.	2.2	67
4826	A user's guide for α -synuclein biomarker studies in biological fluids: Perianalytical considerations. <i>Movement Disorders</i> , 2017, 32, 1117-1130.	2.2	54
4827	Frontal Assessment Battery in Parkinson's Disease: Validity and Morphological Correlates. <i>Journal of the International Neuropsychological Society</i> , 2017, 23, 675-684.	1.2	19
4828	Sleep Disturbance May Alter White Matter and Resting State Functional Connectivities in Parkinson's Disease. <i>Sleep</i> , 2017, 40, .	0.6	15
4829	123 I-Meta-iodobenzylguanidine (MIBG) myocardial scintigraphy in patients showing scans without evidence of dopaminergic deficits (SWEDDs). <i>Clinical Neurology and Neurosurgery</i> , 2017, 160, 73-77.	0.6	2
4830	Central and systemic C-type Natriuretic Peptide are both reduced in Parkinson's Disease. <i>Parkinsonism and Related Disorders</i> , 2017, 43, 15-19.	1.1	6
4831	Downregulation of blood serum microRNA 29 family in patients with Parkinson's disease. <i>Scientific Reports</i> , 2017, 7, 5411.	1.6	89

#	ARTICLE	IF	CITATIONS
4832	Derivation of Leptomeninges Explant Cultures from Postmortem Human Brain Donors. <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	1
4833	Occurrence of spleen qi deficiency as defined by Chinese medicine in Parkinson disease. <i>Journal of Traditional Chinese Medical Sciences</i> , 2017, 4, 24-30.	0.1	3
4834	Subthalamic deep brain stimulation sweet spots and hyperdirect cortical connectivity in Parkinson's disease. <i>NeuroImage</i> , 2017, 158, 332-345.	2.1	197
4835	Loss of cutaneous large and small fibers in naive and <scp>l</scp> -dopaâ€‘treated PD patients. <i>Neurology</i> , 2017, 89, 776-784.	1.5	66
4836	Depression and Catechol-O-methyltransferase (COMT) genetic variants are associated with pain in Parkinsonâ€™s disease. <i>Scientific Reports</i> , 2017, 7, 6306.	1.6	41
4837	The New Diagnostic Criteria for Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 55-78.	0.9	37
4838	Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2017, 390, 1664-1675.	6.3	527
4839	Pain processing in atypical Parkinsonisms and Parkinson disease: A comparative neurophysiological study. <i>Clinical Neurophysiology</i> , 2017, 128, 1978-1984.	0.7	10
4840	Metals and neurodegenerative diseases. A systematic review. <i>Environmental Research</i> , 2017, 159, 82-94.	3.7	178
4841	Longâ€™term safety and effectiveness of levodopaâ€™carbidopa intestinal gel infusion. <i>Brain and Behavior</i> , 2017, 7, e00758.	1.0	32
4842	Lack of <i>TMEM230</i> mutations in patients with familial and sporadic Parkinson's disease in a Taiwanese population. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2017, 174, 751-756.	1.1	9
4843	Acute Levodopa Challenge Test in Patients with de novo Parkinson's Disease: Data from the DeNoPa Cohort. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 755-762.	0.8	31
4844	Micro lesion effect of the globus pallidus internus with deep brain stimulation in Parkinsonâ€™s disease patients. <i>Acta Neurochirurgica</i> , 2017, 159, 1727-1731.	0.9	6
4845	Establishing the role of rare coding variants in known Parkinson's disease risk loci. <i>Neurobiology of Aging</i> , 2017, 59, 220.e11-220.e18.	1.5	15
4846	Serum Growth Differentiation Factor 15 in Parkinson Disease. <i>Neurodegenerative Diseases</i> , 2017, 17, 251-260.	0.8	14
4848	Whole-exome sequencing associates novel <i>CSMD1</i> gene mutations with familial Parkinson disease. <i>Neurology: Genetics</i> , 2017, 3, e177.	0.9	27
4849	Different iron deposition patterns in early- and middle-late-onset Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 44, 23-27.	1.1	53
4850	Apathy in drug-naïve patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 44, 28-32.	1.1	13

#	ARTICLE	IF	CITATIONS
4851	A Brief Nonmotor Screen Combined with Transcranial Ultrasound may Improve Diagnostic Accuracy of Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 397-402.	0.8	0
4852	Selection of gait parameters for differential diagnostics of patients with <i>de novo</i> Parkinson's disease. <i>Neurological Research</i> , 2017, 39, 853-861.	0.6	24
4853	Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson's disease: protocol for a systematic review and individual participant data meta-analysis. <i>BMJ Open</i> , 2017, 7, e018177.	0.8	4
4854	Effectiveness and Safety of Acupuncture Combined with Madopar for Parkinson's Disease: A Systematic Review with Meta-Analysis. <i>Acupuncture in Medicine</i> , 2017, 35, 404-412.	0.4	19
4855	The significance of uric acid in the diagnosis and treatment of Parkinson disease. <i>Medicine (United States)</i> , 2017, 96, 101-106.	0.4	36
4856	DJ-1 as a Biomarker of Parkinson's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1037, 149-171.	0.8	29
4857	Role of medicinal plants in neurodegenerative diseases. <i>Biomanufacturing Reviews</i> , 2017, 2, 1.	4.8	45
4858	Can there be learning potential in Parkinson's disease? A comparison with healthy older adults. <i>Developmental Neuropsychology</i> , 2017, 42, 460-469.	1.0	0
4859	Depression and associated factors in nondemented Chinese patients with Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2017, 163, 142-148.	0.6	12
4860	Statins and Cognition in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 661-667.	1.5	13
4861	SNPs in A β clearance proteins. <i>Neurology</i> , 2017, 89, 2335-2340.	1.5	13
4862	Body awareness training in the treatment of wearing-off related anxiety in patients with Parkinson's disease: Results from a pilot randomized controlled trial. <i>Journal of Psychosomatic Research</i> , 2017, 103, 1-8.	1.2	30
4864	Hypothesis of Ascension in Idiopathic Parkinson's Disease. <i>Neurology International Open</i> , 2017, 01, E28-E35.	0.4	0
4865	Early detection of speech and voice disorders in Parkinson's disease patients treated with subthalamic nucleus deep brain stimulation: a 1-year follow-up study. <i>Journal of Neural Transmission</i> , 2017, 124, 1547-1556.	1.4	24
4866	Iron deposition in substantia nigra: abnormal iron metabolism, neuroinflammatory mechanism and clinical relevance. <i>Scientific Reports</i> , 2017, 7, 14973.	1.6	40
4867	Associations between cognitive impairment and motor dysfunction in Parkinson's disease. <i>Brain and Behavior</i> , 2017, 7, e00719.	1.0	35
4868	Cognitive performance correlates with the degree of dopaminergic degeneration in the associative part of the striatum in non-demented Parkinson's patients. <i>Journal of Neural Transmission</i> , 2017, 124, 1073-1081.	1.4	20
4869	Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 15-25.	1.7	40

#	ARTICLE	IF	CITATIONS
4870	Frenchay dysarthria assessment (FDA-2) in Parkinson's disease: cross-cultural adaptation and psychometric properties of the European Portuguese version. <i>Journal of Neurology</i> , 2017, 264, 21-31.	1.8	15
4871	Differential diagnosis of parkinsonism by a combined use of diffusion kurtosis imaging and quantitative susceptibility mapping. <i>Neuroradiology</i> , 2017, 59, 759-769.	1.1	36
4872	Nordic Walking for the Management of People With Parkinson Disease: A Systematic Review. <i>PM and R</i> , 2017, 9, 1157-1166.	0.9	33
4873	Visual System Involvement in Patients with Newly Diagnosed Parkinson Disease. <i>Radiology</i> , 2017, 285, 885-895.	3.6	42
4874	Urinary Extracellular Domain of Neurotrophin Receptor p75 as a Biomarker for Amyotrophic Lateral Sclerosis in a Chinese cohort. <i>Scientific Reports</i> , 2017, 7, 5127.	1.6	17
4875	Altered brain metabolic connectivity at multiscale level in early Parkinson's disease. <i>Scientific Reports</i> , 2017, 7, 4256.	1.6	64
4876	<i>Mucuna pruriens</i> in Parkinson disease. <i>Neurology</i> , 2017, 89, 432-438.	1.5	79
4877	Quantitative positron emission tomography in brain research. <i>Brain Research</i> , 2017, 1670, 220-234.	1.1	38
4878	Unilateral subthalamotomy in Parkinson's disease: Cognitive, psychiatric and neuroimaging changes. <i>Cortex</i> , 2017, 94, 39-48.	1.1	16
4879	Resting-state brain networks in patients with Parkinson's disease and impulse control disorders. <i>Cortex</i> , 2017, 94, 63-72.	1.1	53
4880	Parkinsonism and other movement disorders in 23 cases of neurocysticercosis. <i>Parkinsonism and Related Disorders</i> , 2017, 42, 47-53.	1.1	13
4881	Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. <i>Lancet Neurology</i> , The, 2017, 16, 789-796.	4.9	155
4882	Comparison Between Automatic and Visual Scorings of REM Sleep Without Atonia for the Diagnosis of REM Sleep Behavior Disorder in Parkinson Disease. <i>Sleep</i> , 2017, 40, .	0.6	42
4883	Study protocol: Insight 46 – a neuroscience sub-study of the MRC National Survey of Health and Development. <i>BMC Neurology</i> , 2017, 17, 75.	0.8	64
4884	Factors predicting the instant effect of motor function after subthalamic nucleus deep brain stimulation in Parkinson's disease. <i>Translational Neurodegeneration</i> , 2017, 6, 14.	3.6	14
4885	Heterozygous PINK1 p.G411S increases risk of Parkinson's disease via a dominant-negative mechanism. <i>Brain</i> , 2017, 140, 98-117.	3.7	116
4886	The whole-brain pattern of magnetic susceptibility perturbations in Parkinson's disease. <i>Brain</i> , 2017, 140, 118-131.	3.7	154
4887	Comparison of neutrophil-lymphocyte ratio (NLR) in Parkinson's disease subtypes. <i>Neurological Sciences</i> , 2017, 38, 287-293.	0.9	35

#	ARTICLE	IF	CITATIONS
4888	Neuropsychiatric Predictors of Cognitive Decline in Parkinson Disease: A Longitudinal Study. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 279-289.	0.6	38
4889	Impaired contrast sensitivity is associated with more severe cognitive impairment in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2017, 34, 15-19.	1.1	29
4890	Effects of coordination and manipulation therapy for patients with Parkinson disease. <i>International Journal of Neuroscience</i> , 2017, 127, 762-769.	0.8	8
4891	A future perspective on neurodegenerative diseases: nasopharyngeal and gut microbiota. <i>Journal of Applied Microbiology</i> , 2017, 122, 306-320.	1.4	17
4892	Imaging of nigrosome 1 in substantia nigra at 3T using multiecho susceptibility map-weighted imaging (SMWI). <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 528-536.	1.9	60
4893	Default-mode network connectivity in cognitively unimpaired drug-naïve patients with rigidity-dominant Parkinson's disease. <i>Journal of Neurology</i> , 2017, 264, 152-160.	1.8	33
4894	The impact of Parkinson disease on patients' sexuality and relationship. <i>Journal of Neural Transmission</i> , 2017, 124, 983-996.	1.4	37
4895	MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson's Disease and Multiple System Atrophy. <i>Molecular Neurobiology</i> , 2017, 54, 7736-7745.	1.9	119
4896	Differential Pattern of Cerebellar Atrophy in Tremor-Predominant and Akinetic/Rigidity-Predominant Parkinson's Disease. <i>Cerebellum</i> , 2017, 16, 623-628.	1.4	34
4897	Polestriding Intervention Improves Gait and Axial Symptoms in Mild to Moderate Parkinson Disease. <i>Archives of Physical Medicine and Rehabilitation</i> , 2017, 98, 613-621.	0.5	4
4898	Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients. <i>Movement Disorders</i> , 2017, 32, 235-240.	2.2	18
4899	Action observation and motor imagery for rehabilitation in Parkinson's disease: A systematic review and an integrative hypothesis. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 72, 210-222.	2.9	143
4900	Clinical Impact of ¹²³ I-Ioflupane SPECT (DaTscan) in a Movement Disorder Center. <i>Neurodegenerative Diseases</i> , 2017, 17, 38-43.	0.8	13
4901	Efficacy of a novel drug, zonisamide, in the modulation of oxidative stress in Parkinson's disease. <i>Neurology and Clinical Neuroscience</i> , 2017, 5, 49-54.	0.2	2
4902	A Randomized Clinical Trial of Atomoxetine for Mild Cognitive Impairment in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 416-423.	0.8	30
4903	Reduced MIBG accumulation of the parotid and submandibular glands in idiopathic Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 34, 26-30.	1.1	9
4904	TMEM230 mutation analysis in Parkinson's disease in a Chinese population. <i>Neurobiology of Aging</i> , 2017, 49, 219.e1-219.e3.	1.5	34
4905	Visual Hallucination and Pattern of Brain Degeneration in Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2017, 17, 63-72.	0.8	22

#	ARTICLE	IF	CITATIONS
4906	Chinese medicine for idiopathic Parkinson's disease: A meta analysis of randomized controlled trials. Chinese Journal of Integrative Medicine, 2017, 23, 55-61.	0.7	8
4907	Prevalence and risk factors for visual hallucinations in Chinese patients with Parkinson's disease. Journal of the Neurological Sciences, 2017, 372, 471-476.	0.3	15
4908	Second mutation in PARK2 is absent in patients with sporadic Parkinson's disease and heterozygous exonic deletions/duplications in parkin gene. International Journal of Neuroscience, 2017, 127, 781-784.	0.8	9
4909	Contribution of Quantitative EEG to the Diagnosis of Early Cognitive Impairment in Patients With Idiopathic Parkinson's Disease. Clinical EEG and Neuroscience, 2017, 48, 348-354.	0.9	24
4910	Neuromuscular Impairments Are Associated With Impaired Head and Trunk Stability During Gait in Parkinson Fallers. Neurorehabilitation and Neural Repair, 2017, 31, 34-47.	1.4	35
4911	Association of the DRD2 CA n -STR and DRD3 Ser9Gly polymorphisms with Parkinson's disease and response to dopamine agonists. Journal of the Neurological Sciences, 2017, 372, 433-438.	0.3	19
4912	Machine learning-based classification of simple drawing movements in Parkinson's disease. Biomedical Signal Processing and Control, 2017, 31, 174-180.	3.5	127
4913	Influence of regional iron on the motor impairments of Parkinson's disease: A quantitative susceptibility mapping study. Journal of Magnetic Resonance Imaging, 2017, 45, 1335-1342.	1.9	68
4914	Contribution of four lifelong factors of cognitive reserve on late cognition in normal aging and Parkinson's disease. Journal of Clinical and Experimental Neuropsychology, 2017, 39, 142-162.	0.8	35
4915	Decrease of Delta Oscillatory Responses in Cognitively Normal Parkinson's Disease. Clinical EEG and Neuroscience, 2017, 48, 355-364.	0.9	17
4916	Levodopa Effect on Basal Ganglia Motor Circuit in Parkinson's Disease. CNS Neuroscience and Therapeutics, 2017, 23, 76-86.	1.9	33
4917	A single dose of l-DOPA changes perceptual experiences and decreases latent inhibition in Parkinson's disease. Journal of Neural Transmission, 2017, 124, 113-119.	1.4	4
4918	The Diagnostic Accuracy of Parkinson's Disease Mild Cognitive Impairment Battery Using the Movement Disorder Society Task Force Criteria. Movement Disorders Clinical Practice, 2017, 4, 237-244.	0.8	19
4919	The role of dopamine in positive and negative prediction error utilization during incidental learning: Insights from Positron Emission Tomography, Parkinson's disease and Huntington's disease. Cortex, 2017, 90, 149-162.	1.1	19
4920	An observational clinical and video-polysomnographic study of the effects of rotigotine in sleep disorder in Parkinson's disease. Sleep and Breathing, 2017, 21, 319-325.	0.9	15
4921	Body weight and dysautonomia in early Parkinson's disease. Acta Neurologica Scandinavica, 2017, 135, 560-567.	1.0	15
4922	Evidence of compensatory joint kinetics during stair ascent and descent in Parkinson's disease. Gait and Posture, 2017, 52, 33-39.	0.6	12
4923	Sniffing the diagnosis: Olfactory testing in neurodegenerative parkinsonism. Parkinsonism and Related Disorders, 2017, 35, 36-41.	1.1	67

#	ARTICLE	IF	CITATIONS
4924	Transcranial sonography in dopa-responsive dystonia. <i>European Journal of Neurology</i> , 2017, 24, 161-166.	1.7	5
4925	Genetic association study between RIT2 and Parkinson's disease in a Han Chinese population. <i>Neurological Sciences</i> , 2017, 38, 343-347.	0.9	5
4926	Abnormal baseline brain activity in Parkinson's disease with and without REM sleep behavior disorder: A resting-state functional MRI study. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 697-703.	1.9	45
4927	Are the average gait speeds during the 10 meter and 6 minute walk tests redundant in Parkinson disease?. <i>Gait and Posture</i> , 2017, 52, 178-182.	0.6	22
4928	The effects of unilateral versus bilateral subthalamic nucleus deep brain stimulation on prosaccades and antisaccades in Parkinson's disease. <i>Experimental Brain Research</i> , 2017, 235, 615-626.	0.7	25
4929	A novel approach to falls classification in Parkinson's disease: development of the Fall-Related Activity Classification (FRAC). <i>Physiotherapy</i> , 2017, 103, 459-464.	0.2	12
4930	Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer's Disease: Potential and Limitations. <i>Molecular Neurobiology</i> , 2017, 54, 5550-5562.	1.9	119
4931	Investigating the Mini-BESTest's construct validity in elderly with Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2017, 135, 614-621.	1.0	17
4932	Validation of the National Institute of Neurological Disorders and Stroke Criteria for Psychosis in Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 73-80.	0.6	4
4933	The Perceive, Recall, Plan and Perform (PRPP) system for persons with Parkinson's disease: a psychometric study. <i>Scandinavian Journal of Occupational Therapy</i> , 2017, 24, 65-73.	1.1	7
4934	Vocal markers of motor, cognitive, and depressive symptoms in Parkinson's disease. , 2017, , .		7
4935	Network Structure and Function in Parkinson's Disease. <i>Cerebral Cortex</i> , 2018, 28, 1-15.	1.6	39
4936	Non motor symptoms in progressive supranuclear palsy: prevalence and severity. <i>Npj Parkinson's Disease</i> , 2017, 3, 35.	2.5	29
4937	Ecografía transcraneal mesencefálica en el estudio de enfermedad de Parkinson y su diagnóstico diferencial con parkinsonismos en un hospital público de Tucumán. <i>Neurología Argentina</i> , 2017, 9, 210-218.	0.1	0
4938	Technologies Assessing Limb Bradykinesia in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 65-77.	1.5	50
4939	The Relationship between Visuospatial Impairments and Retinal and Cortical Thickness in Parkinson's Disease. <i>Human Physiology</i> , 2017, 43, 863-869.	0.1	1
4940	The Role of Vitamin D in Disease Progression in Early Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 669-675.	1.5	55
4941	Relationship between Gait Parameters and Postural Stability in Early and Late Parkinson's Disease and Visual Feedback-Based Balance Training Effects. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2017, 5, 207-214.	0.1	3

#	ARTICLE	IF	CITATIONS
4942	Aging and Neurological Diseases. , 2017, , .		13
4943	Clinical Profile of Cognitive Decline in Patients with Parkinson's Disease, Progressive Supranuclear Palsy, and Multiple System Atrophy. Journal of Neurosciences in Rural Practice, 2017, 08, 562-568.	0.3	7
4944	Tonic Electromyogram Density in Multiple System Atrophy with Predominant Parkinsonism and Parkinson's Disease. Chinese Medical Journal, 2017, 130, 684-690.	0.9	11
4945	Botulinum Toxin Is Effective in the Management of Neurogenic Dysphagia. Clinical-Electrophysiological Findings and Tips on Safety in Different Neurological Disorders. Frontiers in Pharmacology, 2017, 8, 80.	1.6	36
4946	Association of <i>Helicobacter pylori</i> with Parkinson's Disease. Journal of Clinical Neurology		

#	ARTICLE	IF	CITATIONS
4961	Slowed Prosaccades and Increased Antisaccade Errors As a Potential Behavioral Biomarker of Multiple System Atrophy. <i>Frontiers in Neurology</i> , 2017, 8, 261.	1.1	15
4962	Usability of Three-dimensional Augmented Visual Cues Delivered by Smart Glasses on (Freezing of) Gait in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2017, 8, 279.	1.1	61
4963	Correlation between Dopamine Transporter Degradation and Striatocortical Network Alteration in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2017, 8, 323.	1.1	12
4964	Analysis of Correlation between an Accelerometer-Based Algorithm for Detecting Parkinsonian Gait and UPDRS Subscales. <i>Frontiers in Neurology</i> , 2017, 8, 431.	1.1	47
4965	Speech and Voice Response to a Levodopa Challenge in Late-Stage Parkinson's Disease. <i>Frontiers in Neurology</i> , 2017, 8, 432.	1.1	50
4966	Therapeutic Interventions for Vascular Parkinsonism: A Systematic Review and Meta-analysis. <i>Frontiers in Neurology</i> , 2017, 8, 481.	1.1	20
4967	Gait and Cognition in Parkinson's Disease: Cognitive Impairment Is Inadequately Reflected by Gait Performance during Dual Task. <i>Frontiers in Neurology</i> , 2017, 8, 550.	1.1	36
4968	Mutation Analysis of Consanguineous Moroccan Patients with Parkinson's Disease Combining Microarray and Gene Panel. <i>Frontiers in Neurology</i> , 2017, 8, 567.	1.1	19
4969	Elevated Serum α -Synuclein Autoantibodies in Patients with Parkinson's Disease Relative to Alzheimer's Disease and Controls. <i>Frontiers in Neurology</i> , 2017, 8, 720.	1.1	44
4970	Decision-Making Deficits Associated with Amyloidosis in Lewy Body Disorders. <i>Frontiers in Human Neuroscience</i> , 2017, 10, 693.	1.0	1
4971	Effects of More-Affected vs. Less-Affected Motor Cortex tDCS in Parkinson's Disease. <i>Frontiers in Human Neuroscience</i> , 2017, 11, 309.	1.0	32
4972	Rapid Alleviation of Parkinson's Disease Symptoms via Electrostimulation of Intrinsic Auricular Muscle Zones. <i>Frontiers in Human Neuroscience</i> , 2017, 11, 338.	1.0	20
4973	Altered Functional Connectivity Density in Subtypes of Parkinson's Disease. <i>Frontiers in Human Neuroscience</i> , 2017, 11, 458.	1.0	22
4974	Narrative Organization Deficit in Lewy Body Disorders Is Related to Alzheimer Pathology. <i>Frontiers in Neuroscience</i> , 2017, 11, 53.	1.4	7
4975	Perception of Time in Music in Patients with Parkinson's Disease—The Processing of Musical Syntax Compensates for Rhythmic Deficits. <i>Frontiers in Neuroscience</i> , 2017, 11, 68.	1.4	4
4976	Chemical Exchange Saturation Transfer MRI Signal Loss of the Substantia Nigra as an Imaging Biomarker to Evaluate the Diagnosis and Severity of Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2017, 11, 489.	1.4	26
4977	Multi-modal Brain MRI in Subjects with PD and iRBD. <i>Frontiers in Neuroscience</i> , 2017, 11, 709.	1.4	18
4978	Apolipoprotein ϵ 4: A Biomarker for Executive Dysfunction among Parkinson's Disease Patients with Mild Cognitive Impairment. <i>Frontiers in Neuroscience</i> , 2017, 11, 712.	1.4	16

#	ARTICLE	IF	CITATIONS
4979	Cognitive Function Characteristics of Parkinson's Disease with Sleep Disorders. <i>Parkinson's Disease</i> , 2017, 2017, 1-6.	0.6	8
4980	The Single Nucleotide Polymorphism rs1014290 of the SLC2A9 Gene Is Associated with Uric Acid Metabolism in Parkinson's Disease. <i>Parkinson's Disease</i> , 2017, 2017, 1-6.	0.6	3
4981	Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease. <i>Parkinson's Disease</i> , 2017, 2017, 1-8.	0.6	3
4982	Technology-Assisted Rehabilitation of Writing Skills in Parkinson's Disease: Visual Cueing versus Intelligent Feedback. <i>Parkinson's Disease</i> , 2017, 2017, 1-7.	0.6	7
4983	A Randomized Controlled Trial of Chinese Medicine on Nonmotor Symptoms in Parkinson's Disease. <i>Parkinson's Disease</i> , 2017, 2017, 1-8.	0.6	13
4984	Benefit from the Chin-Down Maneuver in the Swallowing Performance and Self-Perception of Parkinson's Disease Patients. <i>Parkinson's Disease</i> , 2017, 2017, 1-8.	0.6	13
4985	Earlier Intervention with Deep Brain Stimulation for Parkinson's Disease. <i>Parkinson's Disease</i> , 2017, 2017, 1-9.	0.6	20
4986	Iron and Parkinson's disease: A systematic review and meta-analysis. <i>Molecular Medicine Reports</i> , 2017, 15, 3383-3389.	1.1	27
4987	<i>LRRK2</i> G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson's Disease. <i>Parkinson's Disease</i> , 2017, 2017, 1-7.	0.6	36
4988	Plasma DNA Mediate Autonomic Dysfunctions and White Matter Injuries in Patients with Parkinson's Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-10.	1.9	12
4989	Correlation of MRI Visual Scales with Neuropsychological Profile in Mild Cognitive Impairment of Parkinson's Disease. <i>Parkinson's Disease</i> , 2017, 2017, 1-6.	0.6	3
4998	A (Familial) PSP Look-Alike: Perry Syndrome. , 0, , 24-25.		1
5054	LSVT-BIG Improves UPDRS III Scores at 4 Weeks in Parkinson's Disease Patients with Wearing Off: A Prospective, Open-Label Study. <i>Parkinson's Disease</i> , 2017, 2017, 1-4.	0.6	7
5055	Sexual dimorphism in Parkinson's disease: differences in clinical manifestations, quality of life and psychosocial functioning between males and females. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 329-338.	1.0	16
5056	Comparison of three physical therapy interventions with an emphasis on the gait of individuals with Parkinson's disease. <i>Fisioterapia Em Movimento</i> , 2017, 30, 691-701.	0.4	0
5057	A Novel p.Glu298Lys Mutation in the ACMSD Gene in Sporadic Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 459-463.	1.5	15
5058	The role of deep brain stimulation in Parkinson's disease: an overview and update on new developments. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 723-732.	1.0	53
5059	The Utility of Post-Void Residual Volume versus Sphincter Electromyography to Distinguish between Multiple System Atrophy and Parkinson's Disease. <i>PLoS ONE</i> , 2017, 12, e0169405.	1.1	17

#	ARTICLE	IF	CITATIONS
5060	Tackling psychosocial maladjustment in Parkinsonâ€™s disease patients following subthalamic deep-brain stimulation: A randomised clinical trial. PLoS ONE, 2017, 12, e0174512.	1.1	32
5061	Lexical ambiguity resolution during sentence processing in Parkinsonâ€™s disease: An event-related potential study. PLoS ONE, 2017, 12, e0176281.	1.1	7
5062	No relevant association of kinematic gait parameters with Health-related Quality of Life in Parkinsonâ€™s disease. PLoS ONE, 2017, 12, e0176816.	1.1	19
5063	Comparison of peripapillary choroidal thickness between healthy subjects and patients with Parkinsonâ€™s disease. PLoS ONE, 2017, 12, e0177163.	1.1	22
5064	Regional brain amyloid-Î² accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. PLoS ONE, 2017, 12, e0177924.	1.1	33
5065	The composite autonomic symptom scale 31 is a useful screening tool for patients with Parkinsonism. PLoS ONE, 2017, 12, e0180744.	1.1	27
5066	Handwriting training in Parkinsonâ€™s disease: A trade-off between size, speed and fluency. PLoS ONE, 2017, 12, e0190223.	1.1	21
5067	Factors influencing psychological well-being in patients with Parkinsonâ€™s disease. PLoS ONE, 2017, 12, e0189682.	1.1	32
5068	Differential diagnosis between Parkinson's disease and essential tremor using the smartphone's accelerometer. PLoS ONE, 2017, 12, e0183843.	1.1	68
5069	Effectiveness of spinal cord stimulation for painful camptocormia with Pisa syndrome in Parkinsonâ€™s disease: a case report. BMC Neurology, 2017, 17, 148.	0.8	25
5070	Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels. BMC Neurology, 2017, 17, 198.	0.8	55
5071	Blink rate is associated with drug-induced parkinsonism in patients with severe mental illness, but does not meet requirements to serve as a clinical test: the Curacao extrapyramidal syndromes study XIII. Journal of Negative Results in BioMedicine, 2017, 16, 15.	1.4	1
5072	Evaluation of PDQ-8 and its relationship with PDQ-39 in China: a three-year longitudinal study. Health and Quality of Life Outcomes, 2017, 15, 170.	1.0	21
5073	Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinsonâ€™s disease. Journal of Neuroinflammation, 2017, 14, 164.	3.1	64
5074	Parkinsonâ€™s disease is associated with DNA methylation levels in human blood and saliva. Genome Medicine, 2017, 9, 76.	3.6	122
5075	Differential role of CSF fatty acid binding protein 3, Î±-synuclein, and Alzheimerâ€™s disease core biomarkers in Lewy body disorders and Alzheimerâ€™s dementia. Alzheimer's Research and Therapy, 2017, 9, 52.	3.0	101
5076	Effects of a sensory-motor orthotic on postural instability rehabilitation in Parkinsonâ€™s disease: a pilot study. Journal of Clinical Movement Disorders, 2017, 4, 11.	2.2	1
5078	Changes in the symptom frequency of rapid eye movement sleep behavior disorder according to disease duration. Sleep Science and Practice, 2017, 1, .	0.6	9

#	ARTICLE	IF	CITATIONS
5079	Volume of Interest Analysis of Spatially Normalized PRESTO Imaging to Differentiate between Parkinson Disease and Atypical Parkinsonian Syndrome. <i>Magnetic Resonance in Medical Sciences</i> , 2017, 16, 16-22.	1.1	15
5080	Machine Learning Based Approaches for SWEDD diagnosis in DaTSCAN SPECT imaging. , 2017, , .		2
5081	Development and Validation of the Way-Finding Ability Scale for Middle-Aged and Older Adults. <i>Dementia and Neurocognitive Disorders</i> , 2017, 16, 95.	0.4	0
5082	A Card-type Odor Identification Test for Japanese Patients with Parkinson's Disease and Related Disorders. <i>Internal Medicine</i> , 2017, 56, 2871-2878.	0.3	12
5083	Modelling in miniature: Using <i>Drosophila melanogaster</i> to study human neurodegeneration. <i>Drug Discovery Today: Disease Models</i> , 2017, 25-26, 3-10.	1.2	3
5084	Towards Mobile Gait Analysis: Concurrent Validity and Test-Retest Reliability of an Inertial Measurement System for the Assessment of Spatio-Temporal Gait Parameters. <i>Sensors</i> , 2017, 17, 1522.	2.1	113
5085	Role of magnetic resonance planimetry and magnetic resonance parkinsonism index in discriminating Parkinson's disease and progressive supranuclear palsy: a retrospective study based on 1.5 and 3 T MRI. <i>International Journal of General Medicine</i> , 2017, Volume 10, 375-384.	0.8	7
5086	Psychosocial therapy for Parkinson's-related dementia: intervention development. <i>Clinical Interventions in Aging</i> , 2017, Volume 12, 1779-1789.	1.3	8
5087	Resolvin D1 Attenuates Mpp+-Induced Parkinson Disease via Inhibiting Inflammation in PC12 Cells. <i>Medical Science Monitor</i> , 2017, 23, 2684-2691.	0.5	30
5088	Transcranial Brain Sonography in Parkinson's Disease and Other Parkinsonian Disorders: a Hospital Study from Tuzla, Bosnia and Herzegovina. <i>Medicinski Arhiv = Medical Archives = Archives De MÃ©decine</i> , 2017, 71, 261.	0.4	6
5089	Patients and Their Caregivers' Burdens for Parkinson's Disease in Korea. <i>Journal of Movement Disorders</i> , 2017, 10, 109-115.	0.7	13
5090	18F-FP-CIT Positron Emission Tomography for Correlating Motor and Cognitive Symptoms of Parkinson's Disease. <i>Dementia and Neurocognitive Disorders</i> , 2017, 16, 57.	0.4	7
5091	Meta-analysis of the association between variants in <i>MAPT</i> and neurodegenerative diseases. <i>Oncotarget</i> , 2017, 8, 44994-45007.	0.8	41
5092	Risk of unsuccessful noninvasive ventilation for acute respiratory failure in heterogeneous neuromuscular diseases: a retrospective study. <i>Neurology International</i> , 2017, 9, 6904.	1.3	2
5093	An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease. <i>Oncotarget</i> , 2017, 8, 57316-57326.	0.8	28
5094	Interleukin-1 ² , interleukin-1 receptor antagonist, interleukin-6, interleukin-10, and tumor necrosis factor- β levels in CSF and serum in relation to the clinical diversity of Parkinson's disease. <i>Cellular Immunology</i> , 2018, 327, 77-82.	1.4	100
5095	Persistence of Mania After Cessation of Stimulation Following Subthalamic Deep Brain Stimulation. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2018, 30, 246-249.	0.9	13
5096	Effectiveness of a Goal-Based Intensive Rehabilitation in Parkinsonian Patients in Advanced Stages of Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 113-119.	1.5	12

#	ARTICLE	IF	CITATIONS
5097	Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia. <i>Journal of Neural Transmission</i> , 2018, 125, 1237-1250.	1.4	61
5098	In vivo exploration of retinal nerve fiber layer morphology in Parkinson's disease patients. <i>Journal of Neural Transmission</i> , 2018, 125, 931-936.	1.4	11
5099	Alterations of regional homogeneity in freezing of gait in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2018, 387, 54-59.	0.3	20
5100	Expression of the gene coding for PGC-1 α in peripheral blood leukocytes and related gene variants in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 51, 30-35.	1.1	15
5101	Step Numbers and Hoehn-Yahr Stage after Six Years. <i>European Neurology</i> , 2018, 79, 118-124.	0.6	4
5102	α -synuclein (<i>SNCA</i>) but not dynamin 3 (<i>DNM3</i>) influences age at onset of leucine-rich repeat kinase 2 (<i>LRKK2</i>) Parkinson's disease in Spain. <i>Movement Disorders</i> , 2018, 33, 637-641.	2.2	25
5103	Flavor perception and the risk of malnutrition in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2018, 125, 925-930.	1.4	18
5104	MRI supervised and unsupervised classification of Parkinson's disease and multiple system atrophy. <i>Movement Disorders</i> , 2018, 33, 600-608.	2.2	77
5105	200 Years of Parkinson's disease: what have we learnt from James Parkinson?. <i>Age and Ageing</i> , 2018, 47, 209-214.	0.7	44
5106	Identification of aberrant circulating miRNAs in Parkinson's disease plasma samples. <i>Brain and Behavior</i> , 2018, 8, e00941.	1.0	70
5107	Stress-evoking emotional stimuli exaggerate deficits in motor function in Parkinson's disease. <i>Neuropsychologia</i> , 2018, 112, 66-76.	0.7	24
5108	Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 439-447.	1.9	20
5109	Head-to-head comparison of ¹⁸ F-FP-CIT and ¹²³ I-FP-CIT for dopamine transporter imaging in patients with Parkinson's disease: A preliminary study. <i>Synapse</i> , 2018, 72, e22032.	0.6	22
5110	Evaluation of salivary heme oxygenase-1 as a potential biomarker of early Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 583-591.	2.2	40
5111	Mitochondrial DNA variants modulate genetic susceptibility to Parkinson's disease in Han Chinese. <i>Neurobiology of Disease</i> , 2018, 114, 17-23.	2.1	15
5112	Glucocerebrosidase gene variants are accumulated in idiopathic REM sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2018, 50, 94-98.	1.1	23
5113	Measurements of autoantibodies to α -synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease. <i>Journal of Neurochemistry</i> , 2018, 145, 489-503.	2.1	47
5114	Quantifying changes in nigrosomes using quantitative susceptibility mapping and neuromelanin imaging for the diagnosis of early-stage Parkinson's disease. <i>British Journal of Radiology</i> , 2018, 91, 20180037.	1.0	41

#	ARTICLE	IF	CITATIONS
5115	Brain Morphometry: Parkinson's Disease. <i>NeuroMethods</i> , 2018, , 267-277.	0.2	0
5116	Deep Brain Stimulation of the Subthalamic Nucleus Does Not Affect the Decrease of Decision Threshold during the Choice Process When There Is No Conflict, Time Pressure, or Reward. <i>Journal of Cognitive Neuroscience</i> , 2018, 30, 876-884.	1.1	7
5117	The association between <i>HSD3B7</i> gene variant and Parkinson's disease in ethnic Chinese. <i>Brain and Behavior</i> , 2018, 8, e00913.	1.0	3
5118	Delivery systems for theranostics in neurodegenerative diseases. <i>Nano Research</i> , 2018, 11, 5535-5555.	5.8	29
5119	Caregiver burden and caregiver appraisal of psychiatric symptoms are not modulated by subthalamic deep brain stimulation for Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2018, 4, 12.	2.5	27
5120	Are functional mobility tests responsive to group physical therapy intervention in individuals with Parkinson's disease?. <i>NeuroRehabilitation</i> , 2018, 42, 465-472.	0.5	9
5121	Detecting neurodegenerative disorders from web search signals. <i>Npj Digital Medicine</i> , 2018, 1, 8.	5.7	36
5122	Association analysis of <i>NUCKS1</i> and <i>INPP5K</i> polymorphism with Parkinson's disease. <i>Genes and Genetic Systems</i> , 2018, 93, 59-64.	0.2	8
5123	Chalcones and Five-Membered Heterocyclic Isosteres Bind to Alpha Synuclein Fibrils in Vitro. <i>ACS Omega</i> , 2018, 3, 4486-4493.	1.6	28
5124	White matter degeneration profile in the cognitive cortico-subcortical tracts in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1139-1150.	2.2	11
5125	The reliability of gait variability measures for individuals with Parkinson's disease and healthy older adults – The effect of gait speed. <i>Gait and Posture</i> , 2018, 62, 505-509.	0.6	56
5126	Impulse control disorders in Parkinson's: Sleep disorders and nondopaminergic associations. <i>Brain and Behavior</i> , 2018, 8, e00904.	1.0	12
5127	Early fine motor impairment and behavioral dysfunction in (Thy1) ^{A30P} alpha-synuclein mice. <i>Brain and Behavior</i> , 2018, 8, e00915.	1.0	34
5128	Lateralisation in Parkinson disease. <i>Cell and Tissue Research</i> , 2018, 373, 297-312.	1.5	67
5129	Serotonin, β -amyloid, and cognition in Parkinson disease. <i>Annals of Neurology</i> , 2018, 83, 994-1002.	2.8	45
5130	Tremor severity in Parkinson's disease and cortical changes of areas controlling movement sequencing: A preliminary study. <i>Journal of Neuroscience Research</i> , 2018, 96, 1341-1352.	1.3	12
5131	Decreased sleep quality in Parkinson's patients is associated with higher anxiety and depression prevalence and severity, and correlates with pain intensity and quality. <i>Neurological Research</i> , 2018, 40, 1-6.	0.6	22
5132	Study of GCH1 and TH genes in Chinese patients with Parkinson's disease. <i>Neurobiology of Aging</i> , 2018, 68, 159.e3-159.e6.	1.5	8

#	ARTICLE	IF	CITATIONS
5133	Gender-specific effect of uric acid on resting-state functional networks in de novo Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 49-54.	1.1	20
5134	Initial experience with a sensorimotor rhythm-based brain-computer interface in a Parkinson's disease patient. <i>Brain-Computer Interfaces</i> , 2018, 5, 88-96.	0.9	4
5135	<i>MAO-B</i> and <i>COMT</i> Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 920-926.	1.0	51
5136	Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson's Disease Substantia Nigra. <i>Neurotoxicity Research</i> , 2018, 33, 560-568.	1.3	31
5137	New Imaging Markers for Movement Disorders. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 22.	2.0	7
5138	Peripheral neuropathy is associated with more frequent falls in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 54, 46-50.	1.1	17
5139	Demoralization in Parkinson disease. <i>Neurology</i> , 2018, 90, e1613-e1617.	1.5	28
5140	MRI Planimetry and Magnetic Resonance Parkinsonism Index in the Differential Diagnosis of Patients with Parkinsonism. <i>American Journal of Neuroradiology</i> , 2018, 39, 1047-1051.	1.2	23
5141	Substantia Nigra Echogenicity Associated with Clinical Subtypes of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 333-340.	1.5	7
5142	The prospective memory of patients with idiopathic REM sleep behavior disorder. <i>Sleep Medicine</i> , 2018, 47, 19-24.	0.8	15
5143	Descriptive epidemiology of parkinsonism in the Canton of Geneva, Switzerland. <i>Parkinsonism and Related Disorders</i> , 2018, 54, 30-39.	1.1	42
5145	COQ2 variants in Parkinson's disease and multiple system atrophy. <i>Journal of Neural Transmission</i> , 2018, 125, 937-944.	1.4	10
5146	Author response: A new potential biomarker for dementia with Lewy bodies: Skin nerve α -synuclein deposits. <i>Neurology</i> , 2018, 90, 531-531.	1.5	0
5147	Interleukin 6 and complement serum level study in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2018, 125, 875-881.	1.4	38
5148	The reorganization of functional architecture in the early-stages of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 50, 61-68.	1.1	64
5149	Single-subject SPM FDG-PET patterns predict risk of dementia progression in Parkinson disease. <i>Neurology</i> , 2018, 90, e1029-e1037.	1.5	51
5150	PINK1 Phosphorylates MIC60/Mitofilin to Control Structural Plasticity of Mitochondrial Crista Junctions. <i>Molecular Cell</i> , 2018, 69, 744-756.e6.	4.5	88
5151	Relation of overactive bladder with motor symptoms and dopamine transporter imaging in drug-naïve Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 50, 37-41.	1.1	13

#	ARTICLE	IF	CITATIONS
5152	The Effects of Functional Training, Bicycle Exercise, and Exergaming on Walking Capacity of Elderly Patients With Parkinson Disease: A Pilot Randomized Controlled Single-blinded Trial. Archives of Physical Medicine and Rehabilitation, 2018, 99, 826-833.	0.5	87
5153	High-resolution diffusion tensor-imaging indicates asymmetric microstructural disorganization within substantia nigra in early Parkinson's disease. Journal of Clinical Neuroscience, 2018, 50, 199-202.	0.8	17
5154	Alpha galactosidase A activity in Parkinson's disease. Neurobiology of Disease, 2018, 112, 85-90.	2.1	56
5155	Connectivity derived thalamic segmentation in deep brain stimulation for tremor. NeuroImage: Clinical, 2018, 18, 130-142.	1.4	154
5156	Perceived Treatment Status of Fluctuations in Parkinson Disease Impacts Suicidality. American Journal of Geriatric Psychiatry, 2018, 26, 700-710.	0.6	5
5157	Orthostatic heart rate changes in patients with autonomic failure caused by neurodegenerative synucleinopathies. Annals of Neurology, 2018, 83, 522-531.	2.8	150
5158	Postural control deficit during sit-to-walk in patients with Parkinson's disease and freezing of gait. Gait and Posture, 2018, 61, 325-330.	0.6	15
5159	Diagnostic potential of dentatorubrothalamic tract analysis in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2018, 49, 81-87.	1.1	27
5160	Real life evaluation of safinamide effectiveness in Parkinson's disease. Neurological Sciences, 2018, 39, 733-739.	0.9	22
5161	The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study. Lancet Neurology, The, 2018, 17, 309-316.	4.9	57
5162	Early Corneal Innervation and Trigeminal Alterations in Parkinson Disease: A Pilot Study. Cornea, 2018, 37, 448-454.	0.9	21
5163	Analysis of 3D spatial trajectories in Parkinsonian, essential and physiological tremors. Journal of Neural Transmission, 2018, 125, 681-687.	1.4	2
5164	Repetitive Deep TMS for Parkinson Disease: A 3-Month Double-Blind, Randomized Sham-Controlled Study. Journal of Clinical Neurophysiology, 2018, 35, 159-165.	0.9	32
5165	Association of grey matter changes with stability and flexibility of prediction in akinetic-rigid Parkinson's disease. Brain Structure and Function, 2018, 223, 2097-2111.	1.2	5
5166	Features of GBA-associated Parkinson's disease at presentation in the UK Tracking Parkinson's study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 702-709.	0.9	103
5167	Pisa Syndrome in Parkinson's Disease: Pathogenic Roles of Verticality Perception Deficits. Scientific Reports, 2018, 8, 1804.	1.6	20
5168	Association of Polygenic Risk Score With Cognitive Decline and Motor Progression in Parkinson Disease. JAMA Neurology, 2018, 75, 360.	4.5	79
5169	Postural instability differences between idiopathic normal pressure hydrocephalus and Parkinson's disease. Clinical Neurology and Neurosurgery, 2018, 165, 103-107.	0.6	26

#	ARTICLE	IF	CITATIONS
5170	Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping. <i>Journal of the Neurological Sciences</i> , 2018, 386, 46-52.	0.3	74
5171	Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease. <i>European Journal of Neurology</i> , 2018, 25, 680-686.	1.7	42
5172	The use of non-oral therapies in Parkinson's disease. <i>NursePrescribing</i> , 2018, 16, 26-30.	0.1	3
5173	Cognitive impairment in Parkinson's disease, Alzheimer's dementia, and vascular dementia: the role of the clock-drawing test. <i>Psychogeriatrics</i> , 2018, 18, 123-131.	0.6	26
5174	Optimizing olfactory testing for the diagnosis of Parkinson's disease: item analysis of the university of Pennsylvania smell identification test. <i>Npj Parkinson's Disease</i> , 2018, 4, 2.	2.5	47
5175	Feature-based information filtering in visual working memory is impaired in Parkinson's disease. <i>Neuropsychologia</i> , 2018, 111, 317-323.	0.7	9
5176	Catechol-O-methyltransferase (COMT) genetic variants are associated with cognitive decline in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 50, 48-53.	1.1	10
5177	Multitarget transcranial direct current stimulation for freezing of gait in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 642-646.	2.2	105
5178	Bilateral deep brain stimulation of the subthalamic nucleus increases pointing error during memory-guided sequential reaching. <i>Experimental Brain Research</i> , 2018, 236, 1053-1065.	0.7	6
5179	Effectiveness of Rotigotine plus intensive and goal-based rehabilitation versus Rotigotine alone in de-novo Parkinsonian subjects: a randomized controlled trial with 18-month follow-up. <i>Journal of Neurology</i> , 2018, 265, 906-916.	1.8	7
5180	Pyrosequencing analysis of methylation levels of clock genes in leukocytes from Parkinson's disease patients. <i>Neuroscience Letters</i> , 2018, 668, 115-119.	1.0	13
5181	Serum concentration and clinical significance of brain-derived neurotrophic factor in patients with Parkinson's disease or essential tremor. <i>Journal of International Medical Research</i> , 2018, 46, 1477-1485.	0.4	33
5182	Are Clinical Certainty Ratings Helpful in the Diagnosis of Parkinson's Disease?. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 165-170.	0.8	1
5183	Chronic coffee consumption and striatal DAT-SPECT findings in Parkinson's disease. <i>Neurological Sciences</i> , 2018, 39, 551-555.	0.9	11
5184	DNA methylation of TOMM40-APOE-APOC2 in Alzheimer's disease. <i>Journal of Human Genetics</i> , 2018, 63, 459-471.	1.1	57
5185	Obstacle circumvention and eye coordination during walking to least and most affected side in people with Parkinson's disease. <i>Behavioural Brain Research</i> , 2018, 346, 105-114.	1.2	8
5186	Role of LRRK2 and SNCA in autosomal dominant Parkinson's disease in Turkey. <i>Parkinsonism and Related Disorders</i> , 2018, 48, 34-39.	1.1	8
5187	Can Dual Task Walking Improve in Parkinson's Disease After External Focus of Attention Exercise? A Single Blind Randomized Controlled Trial. <i>Neurorehabilitation and Neural Repair</i> , 2018, 32, 18-33.	1.4	25

#	ARTICLE	IF	CITATIONS
5188	White matter hyperintensities on MRI in dementia with Lewy bodies, Parkinson's disease with dementia, and Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2018, 385, 99-104.	0.3	45
5189	Dopaminergic polymorphisms associated with medication responsiveness of gait in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 48, 54-60.	1.1	16
5190	A randomized, double-blind, placebo-controlled trial of camicalin in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 329-332.	2.2	14
5191	Cerebral microbleeds and blood pressure abnormalities in Parkinson's disease. <i>ENeurologicalSci</i> , 2018, 10, 5-11.	0.5	13
5192	Effects of intestinal Levodopa infusion on freezing of gait in Parkinson disease. <i>Journal of the Neurological Sciences</i> , 2018, 385, 105-108.	0.3	22
5193	Could istradefylline be a treatment option for postural abnormalities in mid-stage Parkinson's disease?. <i>Journal of the Neurological Sciences</i> , 2018, 385, 131-133.	0.3	18
5194	The relation between plasma α -synuclein level and clinical symptoms or signs of Parkinson's disease. <i>Neurologia I Neurochirurgia Polska</i> , 2018, 52, 243-251.	0.6	33
5195	Loss of Substantia Nigra Hyperintensity at 3.0-T MR Imaging in Idiopathic REM Sleep Behavior Disorder: Comparison with ¹²³ I-FP-CIT SPECT. <i>Radiology</i> , 2018, 287, 285-293.	3.6	37
5196	Alpha-synucleinopathies. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 145, 339-353.	1.0	50
5197	Altered functional connectivity of the subthalamic nucleus during self-initiated movement in Parkinson's disease. <i>Journal of Neuroradiology</i> , 2018, 45, 249-255.	0.6	23
5198	An updated diagnostic approach to subtype definition of vascular parkinsonism – Recommendations from an expert working group. <i>Parkinsonism and Related Disorders</i> , 2018, 49, 9-16.	1.1	55
5199	Bilateral Deep Brain Stimulation of the Nucleus Basalis of Meynert for Parkinson Disease Dementia. <i>JAMA Neurology</i> , 2018, 75, 169.	4.5	112
5201	Subthalamic Stimulation Improves Quality of Life of Patients Aged 61 Years or Older With Short Duration of Parkinson's Disease. <i>Neuromodulation</i> , 2018, 21, 532-540.	0.4	26
5202	MR findings in the substantia nigra on phase difference enhanced imaging in neurodegenerative parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2018, 48, 10-16.	1.1	14
5203	Rasagiline improves polysomnographic sleep parameters in patients with Parkinson's disease: a double-blind, baseline-controlled trial. <i>European Journal of Neurology</i> , 2018, 25, 672-679.	1.7	33
5204	Characteristic Motor and Nonmotor Symptoms Related to Quality of Life in Drug-Naïve Patients with Late-Onset Parkinson Disease. <i>Neurodegenerative Diseases</i> , 2018, 18, 19-25.	0.8	13
5205	Transcranial Ultrasonographic Image Analysis System for Decision Support in Parkinson Disease. <i>Journal of Ultrasound in Medicine</i> , 2018, 37, 1753-1761.	0.8	5
5206	Parkinson disease with constipation: clinical features and relevant factors. <i>Scientific Reports</i> , 2018, 8, 567.	1.6	80

#	ARTICLE	IF	CITATIONS
5207	Efficacy of intensive multidisciplinary rehabilitation in Parkinson's disease: a randomised controlled study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 828-835.	0.9	81
5208	Comparison of clinical features among Parkinson's disease subtypes: A large retrospective study in a single center. <i>Journal of the Neurological Sciences</i> , 2018, 386, 39-45.	0.3	42
5209	Depression and posture in patients with Parkinson's disease. <i>Gait and Posture</i> , 2018, 61, 81-85.	0.6	22
5210	Balance and fear of falling in subjects with Parkinson's disease is improved after exercises with motor complexity. <i>Gait and Posture</i> , 2018, 61, 90-97.	0.6	56
5211	Stridor combined with other sleep breathing disorders in multiple system atrophy: a tailored treatment?. <i>Sleep Medicine</i> , 2018, 42, 53-60.	0.8	22
5212	Effect of Pharmacist-Led Interventions on (Non)Motor Symptoms, Medication-Related Problems, and Quality of Life in Parkinson Disease Patients: A Pilot Study. <i>Clinical Neuropharmacology</i> , 2018, 41, 14-19.	0.2	11
5213	The LRRK2 signalling system. <i>Cell and Tissue Research</i> , 2018, 373, 39-50.	1.5	31
5214	Alterations of the amplitude of low-frequency fluctuations in anxiety in Parkinson's disease. <i>Neuroscience Letters</i> , 2018, 668, 19-23.	1.0	22
5215	Functional variants in the <i>LRRK2</i> gene confer shared effects on risk for Crohn's disease and Parkinson's disease. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	273
5216	Circadian dysfunction and fluctuations in gait initiation impairment in Parkinson's disease. <i>Experimental Brain Research</i> , 2018, 236, 655-664.	0.7	17
5217	Alternations of Metabolic Profile and Kynurenine Metabolism in the Plasma of Parkinson's Disease. <i>Molecular Neurobiology</i> , 2018, 55, 6319-6328.	1.9	95
5218	Being on Target: Visual Information during Writing Affects Effective Connectivity in Parkinson's Disease. <i>Neuroscience</i> , 2018, 371, 484-494.	1.1	9
5219	Motor asymmetry and neuromelanin imaging: Concordance in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 53, 28-32.	1.1	26
5220	Association analysis of EIF4G1 and Parkinson disease in Xinjiang Uygur and Han nationality. <i>Medicine (United States)</i> , 2018, 97, e0234.	0.4	3
5221	Increased foot strike variability in Parkinson's disease patients with freezing of gait. <i>Parkinsonism and Related Disorders</i> , 2018, 53, 58-63.	1.1	33
5222	Accuracy of Activity Trackers in Parkinson Disease: Should We Prescribe Them?. <i>Physical Therapy</i> , 2018, 98, 705-714.	1.1	32
5223	Predictors of freezing of gait in Chinese patients with Parkinson's disease. <i>Brain and Behavior</i> , 2018, 8, e00931.	1.0	31
5225	Lower 123I-FP-CIT binding to the striatal dopamine transporter, but not to the extrastriatal serotonin transporter, in Parkinson's disease compared with dementia with Lewy bodies. <i>NeuroImage: Clinical</i> , 2018, 19, 130-136.	1.4	17

#	ARTICLE	IF	CITATIONS
5226	Exploring cancer in <i>LRRK2</i> mutation carriers and idiopathic Parkinson's disease. <i>Brain and Behavior</i> , 2018, 8, e00858.	1.0	19
5227	Cerebello-cortical network fingerprints differ between essential, Parkinson's and mimicked tremors. <i>Brain</i> , 2018, 141, 1770-1781.	3.7	97
5228	Improving Dual-Task Control With a Posture-Second Strategy in Early-Stage Parkinson Disease. <i>Archives of Physical Medicine and Rehabilitation</i> , 2018, 99, 1540-1546.e2.	0.5	11
5229	Dynamic balance control during stair negotiation for older adults and people with Parkinson disease. <i>Human Movement Science</i> , 2018, 59, 30-36.	0.6	12
5230	Analysis of medications change in Parkinson's disease progression data. <i>Journal of Intelligent Information Systems</i> , 2018, 51, 301-337.	2.8	7
5231	Abnormal ventral tegmental area-anterior cingulate cortex connectivity in Parkinson's disease with depression. <i>Behavioural Brain Research</i> , 2018, 347, 132-139.	1.2	24
5232	Serum metabolomics study in a group of Parkinson's disease patients from northern India. <i>Clinica Chimica Acta</i> , 2018, 480, 214-219.	0.5	41
5233	Clinical characteristics and quality of life in Chinese patients with Parkinson's disease beyond 20 years. <i>Neurological Research</i> , 2018, 40, 312-317.	0.6	4
5234	A Randomized Trial of Oral and Transdermal Rivastigmine for Postural Instability in Parkinson Disease Dementia. <i>Clinical Neuropharmacology</i> , 2018, 41, 87-93.	0.2	7
5235	Early diagnosis of Lewy body disease in patients with late-onset psychiatric disorders using clinical history of rapid eye movement sleep behavior disorder and [¹²³ I]metaiodobenzylguanidine cardiac scintigraphy. <i>Psychiatry and Clinical Neurosciences</i> , 2018, 72, 423-434.	1.0	30
5236	Cerebrospinal fluid α -synuclein contributes to the differential diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1052-1062.	0.4	34
5237	Detecting Alpha Synuclein Seeding Activity in Formaldehyde-Fixed MSA Patient Tissue by PMCA. <i>Molecular Neurobiology</i> , 2018, 55, 8728-8737.	1.9	38
5238	Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease. <i>Journal of Neurology</i> , 2018, 265, 1279-1287.	1.8	19
5239	Cardiovascular Risk Factor Burden in Veterans and Non-Veterans with Parkinson Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 153-160.	1.5	7
5240	Association analyses of variants of SIPA1L2, MIR4697, GCH1, VPS13C, and DDRGK1 with Parkinson's disease in East Asians. <i>Neurobiology of Aging</i> , 2018, 68, 159.e7-159.e14.	1.5	17
5241	Exploring the relationship between motor impairment, vascular burden and cognition in Parkinson's disease. <i>Journal of Neurology</i> , 2018, 265, 1320-1327.	1.8	30
5242	Parkinson's disease in adults. <i>InnovAiT</i> , 2018, 11, 256-259.	0.0	0
5243	Brain oscillations reveal impaired novelty detection from early stages of Parkinson's disease. <i>NeuroImage: Clinical</i> , 2018, 18, 923-931.	1.4	28

#	ARTICLE	IF	CITATIONS
5244	Mild cognitive impairment disrupts attention network connectivity in Parkinson's disease: A combined multimodal MRI and meta-analytical study. <i>Neuropsychologia</i> , 2018, 112, 105-115.	0.7	31
5245	Parkinson's Disease: Contemporary Concepts and Clinical Management. , 2018, , 349-378.		0
5246	Do people with Parkinson's disease look at task relevant stimuli when walking? An exploration of eye movements. <i>Behavioural Brain Research</i> , 2018, 348, 82-89.	1.2	15
5247	The site of stimulation moderates neuropsychiatric symptoms after subthalamic deep brain stimulation for Parkinson's disease. <i>NeuroImage: Clinical</i> , 2018, 18, 996-1006.	1.4	55
5248	The Impact of Deep Brain Stimulation on the Quality of Life and Swallowing in Individuals with Parkinson's Disease. <i>International Archives of Otorhinolaryngology</i> , 2018, 22, 125-129.	0.3	12
5249	Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease. <i>CNS Drugs</i> , 2018, 32, 387-398.	2.7	44
5250	Prediction of Falls in Subjects Suffering From Parkinson Disease, Multiple Sclerosis, and Stroke. <i>Archives of Physical Medicine and Rehabilitation</i> , 2018, 99, 641-651.	0.5	51
5251	Neurite orientation dispersion and density imaging of the nigrostriatal pathway in Parkinson's disease: Retrograde degeneration observed by tract-profile analysis. <i>Parkinsonism and Related Disorders</i> , 2018, 51, 55-60.	1.1	47
5252	Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease. <i>Pharmacogenomics Journal</i> , 2018, 18, 196-200.	0.9	22
5253	Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs. <i>Journal of Neural Transmission</i> , 2018, 125, 35-43.	1.4	19
5254	Reduced Activated T Lymphocytes (CD4+CD25+) and Plasma Levels of Cytokines in Parkinson's Disease. <i>Molecular Neurobiology</i> , 2018, 55, 1488-1497.	1.9	39
5255	Challenges and opportunities for brainstem neuroimaging with ultrahigh field MRI. <i>NeuroImage</i> , 2018, 168, 412-426.	2.1	121
5256	Magnetic resonance-guided focused ultrasound thalamotomy for tremor: a report of 30 Parkinson's disease and essential tremor cases. <i>Journal of Neurosurgery</i> , 2018, 128, 202-210.	0.9	153
5257	Brain structural and functional signatures of impulsive-compulsive behaviours in Parkinson's disease. <i>Molecular Psychiatry</i> , 2018, 23, 459-466.	4.1	54
5258	Pain Correlates with Sleep Disturbances in Parkinson's Disease Patients. <i>Pain Practice</i> , 2018, 18, 29-37.	0.9	17
5259	Domain-specific cognitive impairment in non-demented Parkinson's disease psychosis. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, e131-e139.	1.3	9
5260	Word selection processing in Parkinson's disease: When nouns are more difficult than verbs. <i>Cortex</i> , 2018, 100, 8-20.	1.1	31
5261	Facial emotion recognition in Parkinson's disease: Association with age and olfaction. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2018, 40, 274-284.	0.8	11

#	ARTICLE	IF	CITATIONS
5262	Effects of Transcranial Direct Current Stimulation Plus Physical Therapy on Gait in Patients With Parkinson Disease. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2018, 97, 7-15.	0.7	31
5263	Reduction of white matter integrity correlates with apathy in Parkinson's disease. <i>International Journal of Neuroscience</i> , 2018, 128, 25-31.	0.8	21
5264	Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a033118.	2.3	616
5265	Diagnosis of Parkinson's disease and the level of oxidized DJ-1 protein. <i>Neuroscience Research</i> , 2018, 128, 58-62.	1.0	15
5266	The Role of Sex Therapy in the Management of Patients with Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 6-13.	0.8	20
5267	Extrapyramidal signs in neurosarcoidosis versus multiple sclerosis: Is TNF alpha the link?. <i>Immunobiology</i> , 2018, 223, 259-263.	0.8	8
5268	Encoding strategy training and self-reported everyday prospective memory in people with Parkinson disease: a randomized-controlled trial. <i>Clinical Neuropsychologist</i> , 2018, 32, 1282-1302.	1.5	10
5269	Deep learning for freezing of gait detection in Parkinson's disease patients in their homes using a waist-worn inertial measurement unit. <i>Knowledge-Based Systems</i> , 2018, 139, 119-131.	4.0	151
5270	Association between abnormal nocturnal blood pressure profile and dementia in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 46, 24-29.	1.1	19
5271	Disturbance of verticality perception and postural dysfunction in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2018, 137, 212-217.	1.0	18
5272	¹¹ C-PE2I and ¹⁸ F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study. <i>Movement Disorders</i> , 2018, 33, 117-127.	2.2	45
5273	Trunk Exercises Improve Gait Symmetry in Parkinson Disease. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2018, 97, 151-159.	0.7	22
5274	Sleep and REM sleep behaviour disorder in Parkinson's disease with impulse control disorder. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 305-310.	0.9	29
5275	Differential involvement of nigral subregions in idiopathic parkinson's disease. <i>Human Brain Mapping</i> , 2018, 39, 542-553.	1.9	28
5276	The prevalence, course and clinical correlates of migraine in Parkinson's disease: A multicentre case-controlled study. <i>Cephalalgia</i> , 2018, 38, 1535-1544.	1.8	10
5277	Inhibition of cathepsin L alleviates the microglia-mediated neuroinflammatory responses through caspase-8 and NF- κ B pathways. <i>Neurobiology of Aging</i> , 2018, 62, 159-167.	1.5	28
5278	A "HOLTER" for Parkinson's disease: Validation of the ability to detect on-off states using the REMPARK system. <i>Gait and Posture</i> , 2018, 59, 1-6.	0.6	46
5279	Spinal Lewy body pathology in older adults without an antemortem diagnosis of Parkinson's disease. <i>Brain Pathology</i> , 2018, 28, 560-568.	2.1	18

#	ARTICLE	IF	CITATIONS
5280	Identification of specific gait patterns in patients with cerebellar ataxia, spastic paraplegia, and Parkinson's disease: A non-hierarchical cluster analysis. <i>Human Movement Science</i> , 2018, 57, 267-279.	0.6	36
5281	Development and validation of prognostic survival models in newly diagnosed Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 108-116.	2.2	22
5282	Sex differences in Parkinson's disease: Features on clinical symptoms, treatment outcome, sexual hormones and genetics. <i>Frontiers in Neuroendocrinology</i> , 2018, 50, 18-30.	2.5	106
5283	Vascular Parkinsonism in a Tertiary Care Stroke Prevention Clinic and the Development of a New Screening Strategy. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 153-161.	0.7	3
5284	The effectiveness of istradefylline for the treatment of gait deficits and sleepiness in patients with Parkinson's disease. <i>Neuroscience Letters</i> , 2018, 662, 158-161.	1.0	31
5285	Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders. <i>Journal of Drug Delivery Science and Technology</i> , 2018, 43, 295-310.	1.4	86
5286	Brain metabolic correlates of fatigue in Parkinson's disease: a PET study. <i>International Journal of Neuroscience</i> , 2018, 128, 330-336.	0.8	11
5287	Noradrenergic Deficits in Parkinson Disease Imaged with ¹¹ C-MeNER. <i>Journal of Nuclear Medicine</i> , 2018, 59, 659-664.	2.8	40
5288	Critical Dysphagia is Common in Parkinson Disease and Occurs Even in Early Stages: A Prospective Cohort Study. <i>Dysphagia</i> , 2018, 33, 41-50.	1.0	114
5289	Serotonin transporter binding and anxiety symptoms in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 89-94.	0.9	34
5290	Evaluating psychiatric symptoms in Parkinson's Disease by a clinimetric analysis of the Hopkins Symptom Checklist (SCL-90-R). <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 131-137.	2.5	24
5291	<i>APOE</i> , thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 289-297.	2.2	35
5292	Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. <i>Parkinsonism and Related Disorders</i> , 2018, 47, 50-56.	1.1	14
5293	Three cases of isolated resting tremor of the lower limbs. <i>Basal Ganglia</i> , 2018, 11, 1-3.	0.3	1
5294	Drooling is no early sign of dysphagia in Parkinson's disease. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13259.	1.6	21
5295	Sleep quality is associated with the severity of clinical symptoms in Parkinson's disease. <i>Acta Neurologica Belgica</i> , 2018, 118, 85-91.	0.5	14
5296	Associations Between Tau, β -Amyloid, and Cognition in Parkinson Disease. <i>JAMA Neurology</i> , 2018, 75, 227.	4.5	57
5297	Autoimmune rheumatic diseases and the risk of Parkinson disease: a nationwide population-based cohort study in Taiwan. <i>Annals of Medicine</i> , 2018, 50, 83-90.	1.5	46

#	ARTICLE	IF	CITATIONS
5298	The different faces of the p. A53T alpha-synuclein mutation: A screening of Greek patients with parkinsonism and/or dementia. <i>Neuroscience Letters</i> , 2018, 672, 136-139.	1.0	10
5299	Altered effective connectivity contributes to micrographia in patients with Parkinson's disease and freezing of gait. <i>Journal of Neurology</i> , 2018, 265, 336-347.	1.8	12
5300	A low blood copper concentration is a co-morbidity burden factor in Parkinson's disease development. <i>Neuroscience Research</i> , 2018, 135, 54-62.	1.0	16
5301	Simple linear brainstem MRI measurements in the differential diagnosis of progressive supranuclear palsy from the parkinsonian variant of multiple system atrophy. <i>Neurological Sciences</i> , 2018, 39, 359-364.	0.9	8
5302	Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2018, 46, 16-23.	1.1	32
5303	Association analysis of SNP rs11868035 in SREBF1 with sporadic Parkinson's disease, sporadic amyotrophic lateral sclerosis and multiple system atrophy in a Chinese population. <i>Neuroscience Letters</i> , 2018, 664, 128-132.	1.0	9
5304	Exploring the association of the Comprehensive Trail Making Test with driving indexes in patients with Parkinson's disease. <i>Transportation Research Part F: Traffic Psychology and Behaviour</i> , 2018, 59, 535-544.	1.8	5
5305	Predicting the onset of freezing of gait: A longitudinal study. <i>Movement Disorders</i> , 2018, 33, 128-135.	2.2	73
5306	Prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson's disease. <i>International Journal of Neuroscience</i> , 2018, 128, 600-607.	0.8	16
5307	Efficacy and safety of perampanel in Parkinson's disease. A systematic review with meta-analysis. <i>Journal of Neurology</i> , 2018, 265, 733-740.	1.8	25
5308	Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils. <i>Biochemical Journal</i> , 2018, 475, 23-44.	1.7	136
5309	Gait bradykinesia in Parkinson's disease: a change in the motor program which controls the synergy of gait. <i>Experimental Brain Research</i> , 2018, 236, 43-57.	0.7	13
5310	Connectome analysis with diffusion MRI in idiopathic Parkinson's disease: Evaluation using multi-shell, multi-tissue, constrained spherical deconvolution. <i>NeuroImage: Clinical</i> , 2018, 17, 518-529.	1.4	51
5311	Olfactory dysfunctions in drug-naïve Parkinson's disease with mild cognitive impairment. <i>Parkinsonism and Related Disorders</i> , 2018, 46, 69-73.	1.1	28
5312	Apathy Profile in Parkinson's and Huntington's Disease: A Comparative Cross-Sectional Study. <i>European Neurology</i> , 2018, 79, 13-20.	0.6	26
5313	Utility of Autonomic Function Tests to Differentiate Dementia with Lewy Bodies and Parkinson Disease with Dementia from Alzheimer Disease. <i>European Neurology</i> , 2018, 79, 27-32.	0.6	14
5314	Onset and Remission of Psychosis in Parkinson's Disease: Pharmacologic and Motoric Markers. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 31-38.	0.8	9
5315	Clinical utility of visualisation of nigrosome-1 in patients with Parkinson's disease. <i>European Radiology</i> , 2018, 28, 718-726.	2.3	23

#	ARTICLE	IF	CITATIONS
5316	Facial emotion decoding in patients with Parkinson's disease. <i>International Journal of Neuroscience</i> , 2018, 128, 71-78.	0.8	12
5317	Somatosensory Focused Balance Training without cues can improve balance and gait in early Parkinson's disease – a randomised pilot study. <i>European Journal of Physiotherapy</i> , 2018, 20, 67-73.	0.7	4
5318	Parkinson's Disease in Sub-Saharan Africa: A Review of Epidemiology, Genetics and Access to Care. <i>Journal of Movement Disorders</i> , 2018, 11, 53-64.	0.7	45
5319	miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson's disease. <i>Oncotarget</i> , 2018, 9, 17455-17465.	0.8	94
5320	The UK Parkinson's Audit 2017: Transforming care. <i>British Journal of Neuroscience Nursing</i> , 2018, 14, 195-196.	0.1	1
5321	Re-standardization of the Korean-Instrumental Activities of Daily Living (K-IADL): Clinical Usefulness for Various Neurodegenerative Diseases. <i>Dementia and Neurocognitive Disorders</i> , 2018, 17, 11.	0.4	40
5322	Non-motor Symptoms in Patients with Parkinson's Disease: A Cross-sectional Survey. <i>Cureus</i> , 2018, 10, e3412.	0.2	6
5323	Asymmetric Dopaminergic Degeneration and Attentional Resources in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 972.	1.4	11
5324	Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis. <i>Experimental and Therapeutic Medicine</i> , 2019, 17, 1611-1624.	0.8	35
5325	Research on Wind & Thermal Power Joint Bidding Strategy Considering Penalties for Wind Power's Bidding Deviation. , 2018, , .		0
5326	Goal management training – home-based approach for mild cognitive impairment in Parkinson's disease: a multiple baseline case report. <i>Neurocase</i> , 2018, 24, 276-286.	0.2	3
5327	Rehabilitation Therapy Utilization in Patients with Parkinson's Disease in Korea. <i>Parkinson's Disease</i> , 2018, 2018, 1-7.	0.6	13
5328	Alteration in the Local and Global Functional Connectivity of Resting State Networks in Parkinson's Disease. <i>Journal of Movement Disorders</i> , 2018, 11, 13-23.	0.7	10
5329	Continuous glucose monitoring can disclose glucose fluctuation in advanced Parkinsonian syndromes. <i>Neurology International</i> , 2018, 10, 7921.	1.3	4
5330	Dietary Variations in a Multiethnic Parkinson's Disease Cohort and Possible Influences on Nonmotor Aspects: A Cross-Sectional Multicentre Study. <i>Parkinson's Disease</i> , 2018, 2018, 1-9.	0.6	4
5331	Manganese-Enhanced Magnetic Resonance Imaging: Overview and Central Nervous System Applications With a Focus on Neurodegeneration. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 403.	1.7	23
5332	Study protocol: Care of Late-Stage Parkinsonism (CLaSP): a longitudinal cohort study. <i>BMC Neurology</i> , 2018, 18, 185.	0.8	27
5333	Factor Structure of the Ways of Coping Questionnaire in Parkinson's Disease. <i>Parkinson's Disease</i> , 2018, 2018, 1-7.	0.6	5

#	ARTICLE	IF	CITATIONS
5334	Stress Management Training (SMT) Improves Coping of Tremor-Boosting Psychosocial Stressors and Depression in Patients with Parkinson's Disease: A Controlled Prospective Study. <i>Parkinson's Disease</i> , 2018, 2018, 1-12.	0.6	5
5335	Change in Cognition and Other Non-Motor Symptoms With Obstructive Sleep Apnea Treatment in Parkinson Disease. <i>Journal of Clinical Sleep Medicine</i> , 2018, 14, 819-828.	1.4	60
5336	Clinical Profile of Parkinson's Disease: Experience of Niger. <i>Journal of Neurosciences in Rural Practice</i> , 2018, 09, 214-218.	0.3	10
5337	Impact of Progression of Parkinson's Disease and Various Other Factors on Generalized Anxiety Disorder. <i>Journal of Neurosciences in Rural Practice</i> , 2018, 09, 287-290.	0.3	4
5338	Impact of DAT-SPECT on Management of Patients Suspected of Parkinsonism. <i>Clinical Nuclear Medicine</i> , 2018, 43, 710-714.	0.7	16
5339	An early diagnosis is not the same as a timely diagnosis of Parkinson's disease. <i>F1000Research</i> , 2018, 7, 1106.	0.8	30
5340	Herbal Medicine Formulas for Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Double-Blind Placebo-Controlled Clinical Trials. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 349.	1.7	23
5341	SPECT Molecular Imaging in Atypical Parkinsonism. <i>International Review of Neurobiology</i> , 2018, 142, 37-65.	0.9	7
5342	The Prevalence of Cerebral Microbleeds in Non-Demented Parkinson's Disease Patients. <i>Journal of Korean Medical Science</i> , 2018, 33, e289.	1.1	8
5343	Neural Correlates of Hypokinetic Dysarthria and Mechanisms of Effective Voice Treatment in Parkinson Disease. <i>Neurorehabilitation and Neural Repair</i> , 2018, 32, 1055-1066.	1.4	33
5344	Suggestive association between <i>OPRM1</i> and impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1878-1886.	2.2	37
5345	Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patients. <i>BMJ Open</i> , 2018, 8, e025533.	0.8	10
5346	Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson's Disease with Motor Fluctuations. <i>Parkinson's Disease</i> , 2018, 2018, 1-8.	0.6	4
5347	Parkinson-Associated SNCA Enhancer Variants Revealed by Open Chromatin in Mouse Dopamine Neurons. <i>American Journal of Human Genetics</i> , 2018, 103, 874-892.	2.6	30
5348	Parkinsonism is a Phenotypical Signature of Amyloidopathy in Patients with Gait Disorders. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1373-1381.	1.2	3
5349	Measuring executive dysfunction in Parkinson's disease: Reliability and validity of the Spanish version of Frontal Assessment Battery (FAB-E). <i>PLoS ONE</i> , 2018, 13, e0207698.	1.1	19
5350	Design and development of a gait training system for Parkinson's disease. <i>PLoS ONE</i> , 2018, 13, e0207136.	1.1	19
5351	A Comprehensive Analysis of the Association Between SNCA Polymorphisms and the Risk of Parkinson's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 391.	1.4	31

#	ARTICLE	IF	CITATIONS
5352	Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study. <i>Movement Disorders</i> , 2018, 33, 1809-1813.	2.2	7
5353	K-variant BCHE and pesticide exposure: Gene-environment interactions in a case-control study of Parkinson's disease in Egypt. <i>Scientific Reports</i> , 2018, 8, 16525.	1.6	21
5354	The Luxembourg Parkinson's Study: A Comprehensive Approach for Stratification and Early Diagnosis. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 326.	1.7	57
5355	Î±-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. <i>Movement Disorders</i> , 2018, 33, 1724-1733.	2.2	79
5356	Cerebrospinal fluid pro-inflammatory cytokines differentiate parkinsonian syndromes. <i>Journal of Neuroinflammation</i> , 2018, 15, 305.	3.1	45
5357	Enfermedad de Parkinson: fisiopatología, diagnóstico y tratamiento. <i>Revista De La Universidad Industrial De Santander Salud</i> , 2018, 50, 79-92.	0.0	7
5358	Dermal Phospho-Alpha-Synuclein Deposition in Patients With Parkinson's Disease and Mutation of the Glucocerebrosidase Gene. <i>Frontiers in Neurology</i> , 2018, 9, 1094.	1.1	16
5359	Distinct Incidence of Takotsubo Syndrome Between Amyotrophic Lateral Sclerosis and Synucleinopathies: A Cohort Study. <i>Frontiers in Neurology</i> , 2018, 9, 1099.	1.1	4
5360	COMPARISON OF SPATIO-TEMPORAL GAIT VARIABLES IN PATIENTS WITH PARKINSON'S DISEASE AND SWEDD. <i>Journal of Mechanics in Medicine and Biology</i> , 2018, 18, 1840023.	0.3	3
5361	Genetic Impact on Clinical Features in Parkinson's Disease: A Study on SNCA-rs11931074. <i>Parkinson's Disease</i> , 2018, 2018, 1-4.	0.6	2
5362	Gastrointestinal Dysfunctions Are Associated with IL-10 Variants in Parkinson's Disease. <i>Parkinson's Disease</i> , 2018, 2018, 1-6.	0.6	2
5363	Indirect Targeting of Subthalamic Deep Brain Stimulation Guided by Stereotactic Computed Tomography and Microelectrode Recordings in Patients With Parkinson's Disease. <i>Frontiers in Human Neuroscience</i> , 2018, 12, 470.	1.0	10
5364	Profile of caregivers of Parkinson's disease patients and burden measured by Zarit Scale Analysis of potential burden-generating factors and their correlation with disease severity. <i>Dementia E Neuropsychologia</i> , 2018, 12, 299-305.	0.3	14
5365	Need for high-resolution Genetic Analysis in iPSC: Results and Lessons from the ForIPS Consortium. <i>Scientific Reports</i> , 2018, 8, 17201.	1.6	70
5366	Evaluation of dysphagia in different phenotypes of early and idiopathic Parkinsonism. <i>Egyptian Journal of Neurology, Psychiatry and Neurosurgery</i> , 2018, 54, 28.	0.4	5
5367	Assessing Walking Adaptability in Parkinson's Disease: "The Interactive Walkway". <i>Frontiers in Neurology</i> , 2018, 9, 1096.	1.1	21
5368	Using Kinect to classify Parkinson's disease stages related to severity of gait impairment. <i>BMC Bioinformatics</i> , 2018, 19, 471.	1.2	41
5369	Efficacy and safety of rasagiline in Chinese patients with early Parkinson's disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study. <i>Translational Neurodegeneration</i> , 2018, 7, 32.	3.6	7

#	ARTICLE	IF	CITATIONS
5370	Diagnostic Validation for Participants in the Washington State Parkinson Disease Registry. <i>Parkinson's Disease</i> , 2018, 2018, 1-6.	0.6	17
5371	High-Order Visual Processing, Visual Symptoms, and Visual Hallucinations: A Possible Symptomatic Progression of Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 999.	1.1	15
5372	LRP10 in α -synucleinopathies. <i>Lancet Neurology</i> , The, 2018, 17, 1034-1035.	4.9	12
5373	Insula as the Interface Between Body Awareness and Movement: A Neurofeedback-Guided Kinesthetic Motor Imagery Study in Parkinson's Disease. <i>Frontiers in Human Neuroscience</i> , 2018, 12, 496.	1.0	26
5374	The E3 Ubiquitin Ligases TRIM17 and TRIM41 Modulate α -Synuclein Expression by Regulating ZSCAN21. <i>Cell Reports</i> , 2018, 25, 2484-2496.e9.	2.9	34
5375	Disruption of Multiple Distinctive Neural Networks Associated With Impulse Control Disorder in Parkinson's Disease. <i>Frontiers in Human Neuroscience</i> , 2018, 12, 462.	1.0	21
5376	Importance of low diagnostic Accuracy for early Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1551-1554.	2.2	70
5377	Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes. <i>Movement Disorders</i> , 2018, 33, 1656-1660.	2.2	14
5378	The frequency and diagnostic accuracy of hand deformities in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2018, 125, 1813-1817.	1.4	4
5379	Resting-state network connectivity in cognitively unimpaired drug-naïve patients with rigidity-dominant Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2018, 395, 147-152.	0.3	14
5380	Gait bradykinesia and hypometria decrease as arm swing frequency and amplitude increase. <i>Neuroscience Letters</i> , 2018, 687, 248-252.	1.0	10
5381	Tremor Types in Parkinson Disease: A Descriptive Study Using a New Classification. <i>Parkinson's Disease</i> , 2018, 2018, 1-5.	0.6	22
5382	Pharmacokinetics and safety/efficacy of levodopa pro-drug ONO-2160/carbidopa for Parkinson's disease. <i>ENeurologicalSci</i> , 2018, 13, 8-13.	0.5	13
5383	Clinical Heterogeneity Among LRRK2 Variants in Parkinson's Disease: A Meta-Analysis. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 283.	1.7	40
5384	Translation, linguistic and cultural adaptation, reliability and validity of the Radboud Oral Motor Inventory for Parkinson's Disease "ROMP" questionnaire. <i>Arquivos De Neuro-Psiquiatria</i> , 2018, 76, 316-323.	0.3	8
5385	Which cognitive dual-task walking causes most interference on the Timed Up and Go test in Parkinson's disease: a controlled study. <i>Neurological Sciences</i> , 2018, 39, 2151-2157.	0.9	29
5386	Patterns of striatal and cerebellar functional connectivity in early-stage drug-naïve patients with Parkinson's disease subtypes. <i>Neuroradiology</i> , 2018, 60, 1323-1333.	1.1	20
5387	Psychometric properties of the Berg balance scale in idiopathic Parkinson's disease in the drug off-phase. <i>Neurological Sciences</i> , 2018, 39, 2175-2181.	0.9	13

#	ARTICLE	IF	CITATIONS
5388	Influence of obstacle color on locomotor and gaze behaviors during obstacle avoidance in people with Parkinson's disease. <i>Experimental Brain Research</i> , 2018, 236, 3319-3325.	0.7	4
5389	Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology</i> , The, 2018, 17, 939-953.	4.9	1,573
5390	A new visual rating scale for loflupane imaging in Lewy body disease. <i>NeuroImage: Clinical</i> , 2018, 20, 823-829.	1.4	14
5391	A Meta-Analysis of <i>GBA</i>-Related Clinical Symptoms in Parkinson's Disease. <i>Parkinson's Disease</i> , 2018, 2018, 1-7.	0.6	29
5392	Prevalent cerebrovascular and cardiovascular disease in people with Parkinson's disease: a meta-analysis. <i>Clinical Epidemiology</i> , 2018, Volume 10, 1147-1154.	1.5	29
5393	Does nutritional status affect Parkinson's Disease features and quality of life?. <i>PLoS ONE</i> , 2018, 13, e0205100.	1.1	32
5394	Effects of tapentadol on pain, motor symptoms and cognitive functions in Parkinson's disease. <i>Journal of Pain Research</i> , 2018, Volume 11, 1849-1856.	0.8	16
5395	Cognitive Deficits and Associated ERP N400 Abnormalities in FXTAS With Parkinsonism. <i>Frontiers in Genetics</i> , 2018, 9, 327.	1.1	0
5396	Unraveling connectivity changes due to dopaminergic therapy in chronically treated Parkinson's disease patients. <i>Scientific Reports</i> , 2018, 8, 14328.	1.6	18
5397	Does the Geriatric Depression Scale measure depression in Parkinson's disease?. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1662-1670.	1.3	15
5398	Elevated microRNA-520d-5p in the serum of patients with Parkinson's disease, possibly through regulation of cereloplasmin expression. <i>Neuroscience Letters</i> , 2018, 687, 88-93.	1.0	14
5399	Automated Indices of Clustering and Switching of Semantic Verbal Fluency in Parkinson's Disease. <i>Journal of the International Neuropsychological Society</i> , 2018, 24, 1047-1056.	1.2	8
5400	Validation of a performance-based assessment of cognitive functional ability in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1760-1768.	2.2	17
5401	Phenoconversion from Idiopathic Rapid Eye Movement Sleep Behavior Disorder to Lewy Body Disease. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 506-511.	0.8	19
5402	Is there an order of loss of sounds in speakers with Parkinson's disease?. <i>Clinical Linguistics and Phonetics</i> , 2018, 32, 997-1011.	0.5	5
5403	SNCA variants and alpha-synuclein level in CD45+ blood cells in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2018, 395, 135-140.	0.3	18
5404	Testing the <sc>MDS</sc> clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1518-1520.	2.2	4
5405	Sensory attenuation in Parkinson's disease is related to disease severity and dopamine dose. <i>Scientific Reports</i> , 2018, 8, 15643.	1.6	30

#	ARTICLE	IF	CITATIONS
5406	Determinants of the use of physiotherapy services among individuals with Parkinson's disease living in Brazil. <i>Arquivos De Neuro-Psiquiatria</i> , 2018, 76, 592-598.	0.3	10
5407	Differential Progression of Regional Hippocampal Atrophy in Aging and Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 325.	1.7	26
5408	Early predictors of mortality in parkinsonism and Parkinson disease. <i>Neurology</i> , 2018, 91, e2045-e2056.	1.5	111
5409	Evaluation of cerebrospinal fluid proteins as potential biomarkers for early stage Parkinson's disease diagnosis. <i>PLoS ONE</i> , 2018, 13, e0206536.	1.1	29
5410	Region-Based Analysis of Prevalence and Incidence of Parkinson's Disease: Analysis of the National		

#	ARTICLE	IF	CITATIONS
5424	Functional monoamine oxidase B gene intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1496-1501.	2.2	10
5425	Postural Disorders and Antiparkinsonian Treatments in Parkinson Disease: An Exploratory Case-Control Study. <i>Clinical Neuropharmacology</i> , 2018, 41, 123-128.	0.2	8
5426	Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease. <i>Nature Neuroscience</i> , 2018, 21, 1482-1492.	7.1	79
5427	Comparative cognitive and neuropsychiatric profiles between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. <i>Journal of Neurology</i> , 2018, 265, 2602-2613.	1.8	80
5428	Negative impact of severity of pain on mood, social life and general activity in Parkinson's disease. <i>Neurological Research</i> , 2018, 40, 1054-1059.	0.6	10
5429	Hallucinations in Neurological Disorders. , 2018, , 99-130.		0
5430	Motor and non-motor wearing-off and its impact in the quality of life of patients with Parkinson's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2018, 76, 517-521.	0.3	28
5431	ESM-CT: a precise method for localization of DBS electrodes in CT images. <i>Journal of Neuroscience Methods</i> , 2018, 308, 366-376.	1.3	6
5432	Quality of life in a German cohort of Parkinson's patients assessed with three different measures. <i>Journal of Neurology</i> , 2018, 265, 2713-2722.	1.8	14
5433	Potential Metabolomic Linkage in Blood between Parkinson's Disease and Traumatic Brain Injury. <i>Metabolites</i> , 2018, 8, 50.	1.3	14
5434	Antibody biomarker for de novo Parkinson disease: attempted validation. <i>Npj Parkinson's Disease</i> , 2018, 4, 28.	2.5	8
5435	Remotely-supervised transcranial direct current stimulation paired with cognitive training in Parkinson's disease: An open-label study. <i>Journal of Clinical Neuroscience</i> , 2018, 57, 51-57.	0.8	41
5436	Sensor-based gait analysis of individualized improvement during apomorphine titration in Parkinson's disease. <i>Journal of Neurology</i> , 2018, 265, 2656-2665.	1.8	31
5437	Weight Loss in Parkinson's Disease: The Relationship with Motor Symptoms and Disease Progression. <i>BioMed Research International</i> , 2018, 2018, 1-6.	0.9	33
5438	The Hamburg Parkinson day-clinic: a new treatment concept at the border of in- and outpatient care. <i>Journal of Neural Transmission</i> , 2018, 125, 1461-1472.	1.4	9
5439	The Pattern of Striatal Dopamine Depletion as a Prognostic Marker in De Novo Parkinson Disease. <i>Clinical Nuclear Medicine</i> , 2018, 43, 787-792.	0.7	19
5440	Assessment of Atrial Conduction Times in Patients with Newly Diagnosed Parkinson's Disease. <i>Parkinson's Disease</i> , 2018, 2018, 1-5.	0.6	10
5441	Evidence for the role of <i>FMR1</i> gray zone alleles as a risk factor for parkinsonism in females. <i>Movement Disorders</i> , 2018, 33, 1178-1181.	2.2	20

#	ARTICLE	IF	CITATIONS
5442	Dopaminergic imaging separates normal pressure hydrocephalus from its mimics. <i>Journal of Neurology</i> , 2018, 265, 2434-2441.	1.8	14
5443	Health-Related Quality of Life Subdomains in Patients with Parkinson's Disease: The Role of Gender. <i>Parkinson's Disease</i> , 2018, 2018, 1-9.	0.6	18
5444	The Effects of LSVT [®] LOUD on Monopitch of Speech for Oral Reading and Monologue in Japanese-Speaking Patients with Parkinson's Disease. <i>Japan Journal of Logopedics and Phoniatics</i> , 2018, 59, 327-333.	0.1	2
5445	Candidate biomarkers for Parkinson's disease. <i>Biomedicine and Pharmacotherapy</i> , 2018, 104, 699-704.	2.5	20
5446	The impact of Apolipoprotein E alleles on cognitive performance in patients with Parkinson's disease. <i>Neurologia I Neurochirurgia Polska</i> , 2018, 52, 477-482.	0.6	5
5447	Parkinson's disease related signal change in the nigrosomes 1 ⁴⁵ and the substantia nigra using T2* weighted 7T MRI. <i>NeuroImage: Clinical</i> , 2018, 19, 683-689.	1.4	39
5448	Rotigotine Improves Abnormal Circadian Rhythm of Blood Pressure in Parkinson's Disease. <i>European Neurology</i> , 2018, 79, 281-286.	0.6	9
5449	âœt Is Hard Work, But It Is Worth Itâœt. <i>Advances in Nursing Science</i> , 2018, 41, 174-187.	0.6	7
5450	Cognitive training for freezing of gait in Parkinson's disease: a randomized controlled trial. <i>Npj Parkinson's Disease</i> , 2018, 4, 15.	2.5	66
5451	Short-term temporal memory in idiopathic and Parkin-associated Parkinson's disease. <i>Scientific Reports</i> , 2018, 8, 7637.	1.6	10
5452	Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 2146-2159.	0.7	25
5453	Frequency of non-motor symptoms in Parkinson's disease presenting to tertiary care centre in Pakistan: an observational, cross-sectional study. <i>BMJ Open</i> , 2018, 8, e019172.	0.8	18
5454	Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study. <i>Journal of the Neurological Sciences</i> , 2018, 391, 5-9.	0.3	16
5455	Parkinson's disease phenotype is influenced by the severity of the mutations in the GBA gene. <i>Parkinsonism and Related Disorders</i> , 2018, 55, 45-49.	1.1	90
5456	Quality of life and swallowing questionnaire for individuals with Parkinson's disease: development and validation. <i>International Journal of Language and Communication Disorders</i> , 2018, 53, 864-874.	0.7	4
5457	Apathy in individuals with Parkinson's disease associated with mild cognitive impairment. A neuropsychological investigation. <i>Neuropsychologia</i> , 2018, 118, 4-11.	0.7	27
5458	Drooling in Parkinson's Disease: Evidence of a Role for Divided Attention. <i>Dysphagia</i> , 2018, 33, 809-817.	1.0	26
5459	Metabolic syndrome contributes to cognitive impairment in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 55, 68-74.	1.1	15

#	ARTICLE	IF	CITATIONS
5460	Does dual-task training improve spatiotemporal gait parameters in Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , 2018, 55, 86-91.	1.1	51
5461	Alpha-synuclein Aggregates in Labial Salivary Glands of Idiopathic Rapid Eye Movement Sleep Behavior Disorder. <i>Sleep</i> , 2018, 41, .	0.6	18
5462	Symptoms and medications change patterns for Parkinson's disease patients stratification. <i>Artificial Intelligence in Medicine</i> , 2018, 91, 82-95.	3.8	15
5463	Complex networks reveal early MRI markers of Parkinson's disease. <i>Medical Image Analysis</i> , 2018, 48, 12-24.	7.0	112
5464	The cholinergic contribution to the resting-state functional network in non-demented Parkinson's disease. <i>Scientific Reports</i> , 2018, 8, 7683.	1.6	13
5465	Can Postural Control Asymmetry Predict Falls in People With Parkinson's Disease?. <i>Motor Control</i> , 2018, 22, 449-461.	0.3	11
5466	Other Major and Mild Neurocognitive Disorders: Parkinson Disease, Atypical Parkinsonism, and Traumatic Brain Injury Types. , 2018, , 243-268.		0
5467	Changes in Parkinson's disease sleep symptoms and daytime somnolence after bilateral subthalamic deep brain stimulation in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2018, 4, 16.	2.5	14
5468	Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives. <i>Brain Topography</i> , 2018, 31, 1029-1036.	0.8	23
5469	Acquired premature ejaculation in Parkinson's disease and possible mechanisms. <i>International Journal of Impotence Research</i> , 2018, 30, 153-157.	1.0	10
5470	Hippocampal subfield atrophy in patients with Parkinson's disease and psychosis. <i>Journal of Neural Transmission</i> , 2018, 125, 1361-1372.	1.4	34
5471	Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients. <i>Movement Disorders</i> , 2018, 33, 1423-1431.	2.2	75
5472	Effects of feedback delay on learning from positive and negative feedback in patients with Parkinson's disease off medication. <i>Neuropsychologia</i> , 2018, 117, 46-54.	0.7	14
5473	Cardiovascular Responses During Resistance Exercise in Patients With Parkinson Disease. <i>PM and R</i> , 2018, 10, 1145-1152.	0.9	16
5474	A Case of Parkinson's Disease with No Lewy Body Pathology due to a Homozygous Exon Deletion in <i>Parkin</i> . <i>Case Reports in Neurological Medicine</i> , 2018, 2018, 1-4.	0.3	33
5475	Glucocerebrosidase mRNA is Diminished in Brain of Lewy Body Diseases and Changes with Disease Progression in Blood. , 2018, 9, 208.		14
5476	Hyperhomocysteinemia influenced malnutrition in Parkinson's disease patients. <i>Neurological Sciences</i> , 2018, 39, 1691-1695.	0.9	11
5477	Psychometric Properties of an Abbreviated Version of the Apathy Evaluation Scale for Parkinson Disease (AES-12PD). <i>American Journal of Geriatric Psychiatry</i> , 2018, 26, 1079-1090.	0.6	5


#	ARTICLE	IF	CITATIONS
5478	CLOCK 3111T/C Variant Correlates with Motor Fluctuation and Sleep Disorders in Chinese Patients with Parkinson's Disease. <i>Parkinson's Disease</i> , 2018, 2018, 1-6.	0.6	11
5479	Dynamic Neuro-Cognitive Imagery Improves Mental Imagery Ability, Disease Severity, and Motor and Cognitive Functions in People with Parkinson's Disease. <i>Neural Plasticity</i> , 2018, 2018, 1-15.	1.0	29
5480	Validation of a novel Montreal Cognitive Assessment scoring algorithm in non-demented Parkinson's disease patients. <i>Journal of Neurology</i> , 2018, 265, 1976-1984.	1.8	7
5481	Combination of Multifocal Electroretinogram and Spectral-Domain OCT Can Increase Diagnostic Efficacy of Parkinson's Disease. <i>Parkinson's Disease</i> , 2018, 2018, 1-7.	0.6	8
5482	Distinctive Olfactory Pattern in Parkinson's Disease and Non-Neurodegenerative Causes of Hyposmia. <i>Neurodegenerative Diseases</i> , 2018, 18, 143-149.	0.8	8
5483	Disrupted amplitude of low-frequency fluctuations and causal connectivity in Parkinson's disease with apathy. <i>Neuroscience Letters</i> , 2018, 683, 75-81.	1.0	20
5484	A Basal Ganglia Model of Freezing of Gait in Parkinson's Disease. <i>Cognitive Science and Technology</i> , 2018, , 113-129.	0.2	0
5485	Sequencing of the GBA coactivator, Saposin C, in Parkinson disease. <i>Neurobiology of Aging</i> , 2018, 72, 187.e1-187.e3.	1.5	16
5486	Difference in severity of sleep apnea in patients with rapid eye movement sleep behavior disorder with or without parkinsonism. <i>Sleep Medicine</i> , 2018, 49, 99-104.	0.8	4
5487	The factors associated with impulse control behaviors in Parkinson's disease: A 2-year longitudinal retrospective cohort study. <i>Brain and Behavior</i> , 2018, 8, e01036.	1.0	21
5488	Evaluation of Linguistic Markers of Word-Finding Difficulty and Cognition in Parkinson's Disease. <i>Journal of Speech, Language, and Hearing Research</i> , 2018, 61, 1691-1699.	0.7	19
5489	Absent Audiovisual Integration Elicited by Peripheral Stimuli in Parkinson's Disease. <i>Parkinson's Disease</i> , 2018, 2018, 1-10.	0.6	8
5490	Prospective study of relevance of 123I-MIBG myocardial scintigraphy and clonidine GH test to distinguish Parkinson's disease and multiple system atrophy. <i>Journal of Neurology</i> , 2018, 265, 2033-2039.	1.8	3
5491	Coping with Cognitive Impairment in People with Parkinson's Disease and Their Carers: A Qualitative Study. <i>Parkinson's Disease</i> , 2018, 2018, 1-10.	0.6	19
5492	In Vivo Positron Emission Tomography of Extrastriatal Non-Dopaminergic Pathology in Parkinson Disease. <i>Contemporary Clinical Neuroscience</i> , 2018, , 143-170.	0.3	1
5493	Factors associated with deterioration of health-related quality of life in multiple system atrophy: 1-year follow-up study. <i>Acta Neurologica Belgica</i> , 2018, 118, 589-595.	0.5	6
5494	Identification of mutations in the PARK2 gene in Serbian patients with Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2018, 393, 27-30.	0.3	8
5495	WearUp. , 2018, , 173-192.		3

#	ARTICLE	IF	CITATIONS
5496	The role of substantia nigra sonography in the differentiation of Parkinson's disease and multiple system atrophy. <i>Translational Neurodegeneration</i> , 2018, 7, 15.	3.6	12
5497	Effectiveness of high-frequency repetitive transcranial magnetic stimulation in patients with depression and Parkinson's disease: a meta-analysis of randomized, controlled clinical trials. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 273-284.	1.0	3
5498	Quantitative analysis of finger and forearm movements in patients with off state early stage Parkinson's disease and scans without evidence of dopaminergic deficit (SWEDD). <i>Parkinsonism and Related Disorders</i> , 2018, 57, 33-38.	1.1	15
5499	Clinical Profile of Chinese Long-Term Parkinson's Disease Survivors With 10 Years of Disease Duration and Beyond. , 2018, 9, 8.		14
5500	Circulating levels of neurotrophic factors are unchanged in patients with Parkinson's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2018, 76, 310-315.	0.3	6
5501	Neuroscience learning from longitudinal cohort studies of Alzheimer's disease: Lessons for disease-modifying drug programs and an introduction to the Center for Neurodegeneration and Translational Neuroscience. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 350-356.	1.8	11
5502	Gait Complexity and Regularity Are Differently Modulated by Treadmill Walking in Parkinson's Disease and Healthy Population. <i>Frontiers in Physiology</i> , 2018, 9, 68.	1.3	46
5503	Brain-Area Specific White Matter Hyperintensities: Associations to Falls in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 455-462.	1.5	6
5504	Disruption of Inferior Longitudinal Fasciculus Microstructure in Parkinson's Disease: A Systematic Review of Diffusion Tensor Imaging Studies. <i>Frontiers in Neurology</i> , 2018, 9, 598.	1.1	23
5505	Parkinson's Disease Diagnostic Observations (PADD0): study rationale and design of a prospective cohort study for early differentiation of parkinsonism. <i>BMC Neurology</i> , 2018, 18, 69.	0.8	7
5506	Advances in the discovery of genetic risk factors for complex forms of neurodegenerative disorders: contemporary approaches, success, challenges and prospects. <i>Journal of Genetics</i> , 2018, 97, 625-648.	0.4	7
5507	Transcranial direct current stimulation combined with cognitive training for the treatment of Parkinson Disease: A randomized, placebo-controlled study. <i>Brain Stimulation</i> , 2018, 11, 1251-1262.	0.7	52
5508	Hemispheric specialization of the basal ganglia during vocal emotion decoding: Evidence from asymmetric Parkinson's disease and 18FDG PET. <i>Neuropsychologia</i> , 2018, 119, 1-11.	0.7	19
5509	Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxylase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 709-719.	0.9	5
5510	The Multiple Object Test as a performance-based tool to assess the decline of ADL function in Parkinson's disease. <i>PLoS ONE</i> , 2018, 13, e0200990.	1.1	9
5511	Adaptations to Postural Perturbations in Patients With Freezing of Gait. <i>Frontiers in Neurology</i> , 2018, 9, 540.	1.1	16
5512	Non-Motor Symptom Burdens Are Not Associated with Iron Accumulation in Early Parkinson's Disease: a Quantitative Susceptibility Mapping Study. <i>Journal of Korean Medical Science</i> , 2018, 33, e96.	1.1	16
5513	Promising Metabolite Profiles in the Plasma and CSF of Early Clinical Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 51.	1.7	74

#	ARTICLE	IF	CITATIONS
5514	Gray/White Matter Contrast in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 89.	1.7	7
5515	Pupillary Response to Cognitive Demand in Parkinson's Disease: A Pilot Study. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 90.	1.7	10
5516	Emotion Detection Deficits and Decreased Empathy in Patients with Alzheimer's Disease and Parkinson's Disease Affect Caregiver Mood and Burden. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 120.	1.7	64
5517	Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 123.	1.7	43
5518	Whole-Exome Sequencing in Searching for New Variants Associated With the Development of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 136.	1.7	17
5519	The Bulbocavernosus Reflex in the Differential Diagnosis of Multiple System Atrophy with Predominant Parkinsonism and Parkinson's Disease. <i>Frontiers in Neurology</i> , 2017, 8, 697.	1.1	6
5520	Action Observation Plus Sonification. A Novel Therapeutic Protocol for Parkinson's Patient with Freezing of Gait. <i>Frontiers in Neurology</i> , 2017, 8, 723.	1.1	41
5521	Diagnostic Criteria for Parkinson's Disease: From James Parkinson to the Concept of Prodromal Disease. <i>Frontiers in Neurology</i> , 2018, 9, 156.	1.1	136
5522	Non-Motor Symptoms of Parkinson's Disease and Their Impact on Quality of Life in a Cohort of Moroccan Patients. <i>Frontiers in Neurology</i> , 2018, 9, 170.	1.1	78
5523	Non-Motor Symptoms as Predictors of Quality of Life in Egyptian Patients With Parkinson's Disease: A Cross-Sectional Study Using a Culturally Adapted 39-Item Parkinson's Disease Questionnaire. <i>Frontiers in Neurology</i> , 2018, 9, 357.	1.1	35
5524	Analysis of Single Nucleotide Polymorphisms of STK32B, PPARGC1A and CTNNA3 Gene With Sporadic Parkinson's Disease Susceptibility in Chinese Han Population. <i>Frontiers in Neurology</i> , 2018, 9, 387.	1.1	5
5525	Osteoarthritis Increases Paresthetic and Akathic Pain, Anxiety Case-ness, and Depression Severity in Patients With Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 409.	1.1	9
5526	Dopaminergic Therapy Increases Go Timeouts in the Go/No-Go Task in Patients with Parkinson's Disease. <i>Frontiers in Human Neuroscience</i> , 2017, 11, 642.	1.0	9
5527	Brain Atrophy and Reorganization of Structural Network in Parkinson's Disease With Hemiparkinsonism. <i>Frontiers in Human Neuroscience</i> , 2018, 12, 117.	1.0	25
5528	Training for Micrographia Alters Neural Connectivity in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 3.	1.4	16
5529	Impairment in the Intention Formation and Execution Phases of Prospective Memory in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 98.	1.4	4
5530	Pleiotropic Effects of Variants in Dementia Genes in Parkinson Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 230.	1.4	21
5531	A Novel Posture for Better Differentiation Between Parkinson's Tremor and Essential Tremor. <i>Frontiers in Neuroscience</i> , 2018, 12, 317.	1.4	19

#	ARTICLE	IF	CITATIONS
5532	Î±-Synuclein Heterocomplexes with Î²-Amyloid Are Increased in Red Blood Cells of Parkinsonâ€™s Disease Patients and Correlate with Disease Severity. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 53.	1.4	51
5533	The LRRK2 Variant E193K Prevents Mitochondrial Fission Upon MPP+ Treatment by Altering LRRK2 Binding to DRP1. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 64.	1.4	32
5534	2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling. <i>Molecular Neurodegeneration</i> , 2018, 13, 27.	4.4	157
5535	Professional occupation and the risk of Parkinson's disease. <i>European Journal of Neurology</i> , 2018, 25, 1470-1476.	1.7	8
5536	Pallidal Stimulation Modulates Pedunclopontine Nuclei in Parkinsonâ€™s Disease. <i>Brain Sciences</i> , 2018, 8, 117.	1.1	1
5537	Dysfunctional inhibitory control in Parkinsonâ€™s disease patients with levodopa-induced dyskinesias. <i>Journal of Neurology</i> , 2018, 265, 2088-2096.	1.8	23
5538	Effect of Group-Based Rehabilitation Combining Action Observation with Physiotherapy on Freezing of Gait in Parkinsonâ€™s Disease. <i>Neural Plasticity</i> , 2018, 2018, 1-7.	1.0	44
5539	Preservation of explicit learning of visuomotor sequences during Parkinsonâ€™s disease progression. <i>Scientific Reports</i> , 2018, 8, 10337.	1.6	0
5540	Stimulation in Supplementary Motor Area Versus Motor Cortex for Freezing of Gait in Parkinson's		

#	ARTICLE	IF	CITATIONS
5550	Hand Tremor Questionnaire: A Useful Screening Tool for Differentiating Patients with Hand Tremor		



#	ARTICLE	IF	CITATIONS
5568	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1643-1646.	2.2	114
5569	Brainstem Raphe Alterations in TCS: A Biomarker for Depression and Apathy in Parkinson's Disease Patients. <i>Frontiers in Neurology</i> , 2018, 9, 645.	1.1	15
5570	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1601-1608.	2.2	171
5571	The presence of cerebral microbleeds is associated with cognitive impairment in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2018, 393, 39-44.	0.3	17
5572	Injection of Onabotulinum Toxin A into the Bilateral External Oblique Muscle Attenuated Camptocormia: A Prospective Open-Label Study in Six Patients with Parkinson's Disease. <i>Neurology and Therapy</i> , 2018, 7, 365-371.	1.4	10
5573	A High-Intensity Multicomponent Agility Intervention Improves Parkinson Patients' Clinical and Motor Symptoms. <i>Archives of Physical Medicine and Rehabilitation</i> , 2018, 99, 2478-2484.e1.	0.5	27
5574	Cytological and cytometric analysis of oral mucosa in patients with Alzheimer's and Parkinson's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 1901-1906.	1.0	7
5575	Mapping movement, mood, motivation and mentation in the subthalamic nucleus. <i>Royal Society Open Science</i> , 2018, 5, 171177.	1.1	29
5576	Effects of aging and Parkinson's disease on motor unit remodeling: influence of resistance exercise training. <i>Journal of Applied Physiology</i> , 2018, 124, 888-898.	1.2	30
5577	Retinal thinning associates with nigral dopaminergic loss in de novo Parkinson disease. <i>Neurology</i> , 2018, 91, e1003-e1012.	1.5	85
5578	Deep Brain Stimulation in Moroccan Patients With Parkinson's Disease: The Experience of Neurology Department of Rabat. <i>Frontiers in Neurology</i> , 2018, 9, 532.	1.1	10
5579	Galangin Reduces the Loss of Dopaminergic Neurons in an LPS-Evoked Model of Parkinson's Disease in Rats. <i>International Journal of Molecular Sciences</i> , 2018, 19, 12.	1.8	79
5580	Diagnosis of Early-Stage Idiopathic Parkinson's Disease Using High-Resolution Quantitative Susceptibility Mapping Combined with Histogram Analysis in the Substantia Nigra at 3 T. <i>Journal of</i>		

#	ARTICLE	IF	CITATIONS
5586	SNCA REP1 and Parkinson's disease. <i>Neuroscience Letters</i> , 2018, 682, 79-84.	1.0	5
5587	Age-related selection bias in Parkinson's disease research: are we recruiting the right participants?. <i>Parkinsonism and Related Disorders</i> , 2018, 55, 128-133.	1.1	28
5588	Mortality from Parkinson's disease in China: Findings from a ten-year follow up study in Shanghai. <i>Parkinsonism and Related Disorders</i> , 2018, 55, 75-80.	1.1	20
5589	Individualization of music-based rhythmic auditory cueing in Parkinson's disease. <i>Annals of the New York Academy of Sciences</i> , 2018, 1423, 308-317.	1.8	51
5590	PDE8B mutation is not associated with Parkinson's disease in a Taiwanese population. <i>Neurobiology of Aging</i> , 2018, 71, 265.e15-265.e16.	1.5	1
5591	Peripheral and central autonomic nervous system: does the sympathetic or parasympathetic nervous system bear the brunt of the pathology during the course of sporadic PD?. <i>Cell and Tissue Research</i> , 2018, 373, 267-286.	1.5	32
5592	LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study. <i>Lancet Neurology</i> , The, 2018, 17, 597-608.	4.9	101
5593	Association between White Matter Lesions and Non-Motor Symptoms in Parkinson Disease. <i>Neurodegenerative Diseases</i> , 2018, 18, 127-132.	0.8	14
5594	Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. <i>Journal of Neural Transmission</i> , 2018, 125, 1373-1379.	1.4	25
5595	Cross-cultural adaptation and psychometric evaluations of the Turkish version of Parkinson Fatigue Scale. <i>Quality of Life Research</i> , 2018, 27, 2719-2730.	1.5	5
5596	Cardinal Motor Features of Parkinson's Disease Coexist with Peak-Dose Choreic-Type Drug-Induced Dyskinesia. <i>Journal of Parkinson's Disease</i> , 2018, 8, 323-331.	1.5	12
5597	Sleep disturbances and depression severity in patients with Parkinson's disease. <i>Brain and Behavior</i> , 2018, 8, e00967.	1.0	44
5598	Beyond factor analysis: Multidimensionality and the Parkinson's Disease Sleep Scale-Revised. <i>PLoS ONE</i> , 2018, 13, e0192394.	1.1	5
5599	Pooled-DNA target sequencing of Parkinson genes reveals novel phenotypic associations in Spanish population. <i>Neurobiology of Aging</i> , 2018, 70, 325.e1-325.e5.	1.5	6
5600	High norepinephrine orthostatic hypotension in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 55, 97-102.	1.1	10
5601	Excess amounts of 3-iodo-L-tyrosine induce Parkinson-like features in experimental approaches of Parkinsonism. <i>NeuroToxicology</i> , 2018, 67, 178-189.	1.4	10
5602	Quality of life and Parkinson's disease: Philippine translation and validation of the Parkinson's disease questionnaire. <i>Journal of Clinical Neuroscience</i> , 2018, 54, 156-160.	0.8	8
5603	The <i>GBA</i> p.Trp378Gly mutation is a probable French-Canadian founder mutation causing Gaucher disease and synucleinopathies. <i>Clinical Genetics</i> , 2018, 94, 339-345.	1.0	9

#	ARTICLE	IF	CITATIONS
5604	Use of anti-Parkinson medication during pregnancy: a case series. <i>Journal of Neurology</i> , 2018, 265, 1922-1929.	1.8	9
5605	Dopamine Receptor D3 rs6280 is Associated with Aberrant Decision-Making in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 413-416.	0.8	10
5606	Consistent decreased activity in the putamen in Parkinson's disease: a meta-analysis and an independent validation of resting-state fMRI. <i>GigaScience</i> , 2018, 7, .	3.3	56
5607	Clinical and metabolic response to probiotic administration in people with Parkinson's disease: A randomized, double-blind, placebo-controlled trial. <i>Clinical Nutrition</i> , 2019, 38, 1031-1035.	2.3	230
5608	Sensitivity and specificity of cardiac metaiodobenzylguanidine scintigraphy in the early diagnosis of Parkinson's disease. <i>Clinical Autonomic Research</i> , 2019, 29, 567-574.	1.4	7
5609	Claustal structural connectivity and cognitive impairment in drug naïve Parkinson's disease. <i>Brain Imaging and Behavior</i> , 2019, 13, 933-944.	1.1	13
5610	Misfolded Protein Linked Strategies Toward Biomarker Development for Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2019, 56, 2559-2578.	1.9	2
5611	Submandibular gland is a suitable site for alpha synuclein pathology in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2019, 58, 35-39.	1.1	22
5612	Olfactory Function in SCA10. <i>Cerebellum</i> , 2019, 18, 85-90.	1.4	11
5613	Upgraded Methodology for the Development of Early Diagnosis of Parkinson's Disease Based on Searching Blood Markers in Patients and Experimental Models. <i>Molecular Neurobiology</i> , 2019, 56, 3437-3450.	1.9	24
5614	Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the Last Decade. <i>Chemical Reviews</i> , 2019, 119, 1221-1322.	23.0	360
5615	Cognitive disorders in normal pressure hydrocephalus with initial parkinsonism in comparison with de novo Parkinson's disease. <i>European Journal of Neurology</i> , 2019, 26, 74-79.	1.7	14
5616	Diagnostic Accuracy, Item Analysis and Age Effects of the UPSIT Spanish Version in Parkinson's Disease. <i>Archives of Clinical Neuropsychology</i> , 2019, 34, 435-444.	0.3	8
5617	The prevalence of psychological distress in Parkinson's disease patients: The brief symptom inventory (BSI-18) versus the Hopkins symptom checklist (SCL-90-R). <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 88, 96-101.	2.5	15
5618	Arterial spin labeling reveals relationships between resting cerebral perfusion and motor learning in Parkinson's disease. <i>Brain Imaging and Behavior</i> , 2019, 13, 577-587.	1.1	20
5619	Analysis of on-surface and in-air movement in handwriting of subjects with Parkinson's disease and atypical parkinsonism. <i>Biomedizinische Technik</i> , 2019, 64, 187-194.	0.9	7
5620	Deep Learning With EEG Spectrograms in Rapid Eye Movement Behavior Disorder. <i>Frontiers in Neurology</i> , 2019, 10, 806.	1.1	67
5621	Frontal and subcortical contribution to visual hallucinations in dementia with Lewy bodies and Parkinson's disease. <i>Postgraduate Medicine</i> , 2019, 131, 509-522.	0.9	24

#	ARTICLE	IF	CITATIONS
5622	Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 440-445.	0.8	15
5623	The diagnostic value of SNpc using NM-MRI in Parkinson's disease: meta-analysis. <i>Neurological Sciences</i> , 2019, 40, 2479-2489.	0.9	19
5624	Nutritional ketosis for mild cognitive impairment in Parkinson's disease: A controlled pilot trial. <i>Clinical Parkinsonism & Related Disorders</i> , 2019, 1, 41-47.	0.5	29
5625	Salivary alpha-synuclein as a biomarker for Parkinson's disease: a systematic review. <i>Journal of Neural Transmission</i> , 2019, 126, 1373-1382.	1.4	34
5626	Diagnostic validity of magnetic resonance parkinsonism index in differentiating patients with progressive supranuclear palsy from patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 176-181.	1.1	15
5627	Predicting motor, cognitive & functional impairment in Parkinson's. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1498-1509.	1.7	35
5628	Morphological MRI investigations of the hypothalamus in 232 individuals with Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1566-1570.	2.2	9
5629	Sleep as a Therapeutic Target in the Aging Brain. <i>Neurotherapeutics</i> , 2019, 16, 554-568.	2.1	35
5630	Quantitative analysis of nasal transcripts reveals potential biomarkers for Parkinson's disease. <i>Scientific Reports</i> , 2019, 9, 11111.	1.6	3
5631	The therapeutic effect of deep brain stimulation on olfactory functions and clinical scores in Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2019, 68, 55-61.	0.8	13
5632	The current status of blood epigenetic biomarkers for dementia. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2019, 56, 435-457.	2.7	21
5633	Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2019, 47, 187-197.	0.7	15
5634	Prediction of Responsiveness of Gait Variables to Rehabilitation Training in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 826.	1.1	29
5635	Targeting neurons in the gastrointestinal tract to treat Parkinson's disease. <i>Clinical Parkinsonism & Related Disorders</i> , 2019, 1, 2-7.	0.5	18
5636	Design and validation of a new instrument to assess fear of falling in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1496-1504.	2.2	10
5637	Neuroimaging in Parkinson's disease dementia: connecting the dots. <i>Brain Communications</i> , 2019, 1, fcz006.	1.5	62
5638	Home monitoring of motor fluctuations in Parkinson's disease patients. <i>Journal of Reliable Intelligent Environments</i> , 2019, 5, 145-162.	3.8	32
5639	Short-term resistance training with instability reduces impairment in V wave and H reflex in individuals with Parkinson's disease. <i>Journal of Applied Physiology</i> , 2019, 127, 89-97.	1.2	2

#	ARTICLE	IF	CITATIONS
5640	A tale of two patients: Levodopa and creative awakening in parkinsonâ€™s disease â€“ A qualitative report. Asian Journal of Psychiatry, 2019, 43, 179-181.	0.9	3
5641	Dual-task demands in various motor skills through Parkinsonâ€™s disease progression. Motriz Revista De Educacao Fisica, 2019, 25, .	0.3	2
5642	Oligomeric Î±-synuclein is increased in basal tears of Parkinsonâ€™s patients. Biomarkers in Medicine, 2019, 13, 941-952.	0.6	40
5643	Magnetic Resonance Imagingâ€™s Visible Perivascular Spaces in Basal Ganglia Predict Cognitive Decline in Parkinson's Disease. Movement Disorders, 2019, 34, 1672-1679.	2.2	60
5644	Impulse control disorders in Parkinson disease and RBD. Neurology, 2019, 93, e675-e687.	1.5	44
5645	Mild behavioral impairment is linked to worse cognition and brain atrophy in Parkinson disease. Neurology, 2019, 93, e766-e777.	1.5	45
5646	On the Role of Adenosine A2A Receptor Gene Transcriptional Regulation in Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2019, 13, 683.	1.4	6
5647	Motor adjustments during time-constrained sit-to-walk in people with Parkinson's disease. Experimental Gerontology, 2019, 124, 110654.	1.2	6
5648	Falls in Parkinsonâ€™s Disease Subtypes: Risk Factors, Locations and Circumstances. International Journal of Environmental Research and Public Health, 2019, 16, 2216.	1.2	104
5649	Development and clinical validation of inertial sensor-based gait-clustering methods in Parkinsonâ€™s disease. Journal of NeuroEngineering and Rehabilitation, 2019, 16, 77.	2.4	19
5650	<p>The efficacy of a â€œcocktail therapyâ€•on Parkinsonâ€™s disease with dementia</p>. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 1639-1647.	1.0	5
5651	Severe Constipation in Parkinson's Disease and in Parkinsonisms: Prevalence and Affecting Factors. Frontiers in Neurology, 2019, 10, 621.	1.1	25
5652	Cognitive associations with comprehensive gait and static balance measures in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 69, 104-110.	1.1	41
5653	Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study. Brain, 2019, 142, 2813-2827.	3.7	121
5654	Impaired Motor Skill Acquisition Using Mirror Visual Feedback Improved by Transcranial Direct Current Stimulation (tDCS) in Patients With Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2019, 13, 602.	1.4	18
5655	Predictors of motor complications in early Parkinson's disease: A prospective cohort study. Movement Disorders, 2019, 34, 1174-1183.	2.2	47
5656	Haptic perception of verticality correlates with postural and balance deficits in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2019, 66, 45-50.	1.1	4
5657	Midbrain atrophy in patients with presymptomatic progressive supranuclear palsy-Richardson's syndrome. Parkinsonism and Related Disorders, 2019, 66, 80-86.	1.1	11

#	ARTICLE	IF	CITATIONS
5658	Globus pallidus internus deep brain stimulation improves axial symptoms of Parkinson patients after long-term subthalamic nucleus stimulation: A case series study. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2019, 18, 100516.	0.2	2
5659	Isolated rapid eye movement sleep behavior disorder and cyclic alternating pattern: is sleep microstructure a predictive parameter of neurodegeneration?. <i>Sleep</i> , 2019, 42, .	0.6	27
5660	Non-cell autonomous mechanism of Parkinsonâ€™s disease pathology caused by G2019S LRRK2 mutation in Ashkenazi Jewish patient: Single cell analysis. <i>Brain Research</i> , 2019, 1722, 146342.	1.1	8
5661	The embodiment of language in tremor-dominant Parkinsonâ€™s disease patients. <i>Brain and Cognition</i> , 2019, 135, 103586.	0.8	5
5662	Protocol: Using N-of-1 tests to identify responders to melatonin for sleep disturbance in Parkinson's disease. <i>Contemporary Clinical Trials Communications</i> , 2019, 15, 100397.	0.5	7
5663	Dysregulation of Respiratory Center Drive (P0.1) and Muscle Strength in Patients With Early Stage Idiopathic Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 724.	1.1	22
5664	Increased facilitation of the primary motor cortex in de novo Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 125-129.	1.1	20
5665	L-3-n-butylphthalide soft capsules in the treatment of Parkinson disease dementia. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT /Ove</i>	0.4	8
5666	Posturographic abnormalities in ambulatory atypical parkinsonian disorders: Differentiating characteristics. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 94-99.	1.1	11
5667	Low Back Pain-Related Disability in Parkinson Disease: Impact on Functional Mobility, Physical Activity, and Quality of Life. <i>Physical Therapy</i> , 2019, 99, 1346-1353.	1.1	6
5668	Coupling Between Leg Muscle Activation and EEG During Normal Walking, Intentional Stops, and Freezing of Gait in Parkinson's Disease. <i>Frontiers in Physiology</i> , 2019, 10, 870.	1.3	23
5669	<p>Sleep disturbances in Parkinsonâ€™s disease are associated with central parkinsonian pain</p>. <i>Journal of Pain Research</i> , 2019, Volume 12, 2137-2144.	0.8	6
5670	Turning Analysis during Standardized Test Using On-Shoe Wearable Sensors in Parkinsonâ€™s Disease. <i>Sensors</i> , 2019, 19, 3103.	2.1	19
5671	How to Select Balance Measures Sensitive to Parkinsonâ€™s Disease from Body-Worn Inertial Sensorsâ€™Separating the Trees from the Forest. <i>Sensors</i> , 2019, 19, 3320.	2.1	44
5672	Parkinsonâ€™s patients delay fixations when circumventing an obstacle and performing a dual cognitive task. <i>Gait and Posture</i> , 2019, 73, 291-298.	0.6	4
5673	Radiomic Features of the Nigrosome-1 Region of the Substantia Nigra: Using Quantitative Susceptibility Mapping to Assist the Diagnosis of Idiopathic Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 167.	1.7	52
5674	â€ˆDraw your pelvisâ€™ test for assessing pelvic schema in people with Parkinsonâ€™s disease: a validity and reliability study. <i>Somatosensory & Motor Research</i> , 2019, 36, 156-161.	0.4	1
5675	Altered gut microbiota and inflammatory cytokine responses in patients with Parkinsonâ€™s disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 129.	3.1	283

#	ARTICLE	IF	CITATIONS
5676	Elevated Serum SIRT 2 May Differentiate Parkinson's Disease From Atypical Parkinsonian Syndromes. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 129.	1.4	17
5677	Potential usefulness of signal intensity of cerebral gyri on quantitative susceptibility mapping for discriminating corticobasal degeneration from progressive supranuclear palsy and Parkinson's disease. <i>Neuroradiology</i> , 2019, 61, 1251-1259.	1.1	6
5678	Deep learning to differentiate parkinsonian disorders separately using single midsagittal MR imaging: a proof of concept study. <i>European Radiology</i> , 2019, 29, 6891-6899.	2.3	51
5679	A computer-based cognitive training in Mild Cognitive Impairment in Parkinson's Disease. <i>NeuroRehabilitation</i> , 2019, 44, 555-567.	0.5	24
5680	Linking Individual Patient Data to Estimate Incidence and Prevalence of Parkinson's Disease by Comparing Reports of Neurological Services and Pharmacy Prescription Refills at a Nationwide Level. <i>Frontiers in Neurology</i> , 2019, 10, 640.	1.1	9
5681	Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from α -Synucleinopathies. <i>Radiology</i> , 2019, 293, 646-653.	3.6	20
5682	Plasma pS129- α -Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson's Disease. <i>Journal of Clinical Medicine</i> , 2019, 8, 1601.	1.0	24
5683	Impact of dopamine and cognitive impairment on neural reactivity to facial emotion in Parkinson's disease. <i>European Neuropsychopharmacology</i> , 2019, 29, 1258-1272.	0.3	20
5684	Rescue levodopa-carbidopa intestinal gel (LCIG) therapy in Parkinson's disease patients with suboptimal response to deep brain stimulation. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1989-1995.	1.7	10
5685	Evidence From Parkinson's Disease That the Superior Colliculus Couples Action and Perception. <i>Movement Disorders</i> , 2019, 34, 1680-1689.	2.2	8
5686	Subjective estimates of uncertainty during gambling and impulsivity after subthalamic deep brain stimulation for Parkinson's disease. <i>Scientific Reports</i> , 2019, 9, 14795.	1.6	15
5687	Proprioceptive Focal Stimulation (Equistasi [®]) May Improve the Quality of Gait in Middle-Moderate Parkinson's Disease Patients. Double-Blind, Double-Dummy, Randomized, Crossover, Italian Multicentric Study. <i>Frontiers in Neurology</i> , 2019, 10, 998.	1.1	25
5688	Association between CSF1 and CSF1R Polymorphisms and Parkinson's Disease in Taiwan. <i>Journal of Clinical Medicine</i> , 2019, 8, 1529.	1.0	5
5689	The effect of levodopa on saccades "Oxford Quantification in Parkinsonism study. <i>Parkinsonism and Related Disorders</i> , 2019, 68, 49-56.	1.1	27
5690	Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study. <i>Brain Sciences</i> , 2019, 9, 272.	1.1	13
5691	Midnolin is a confirmed genetic risk factor for Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2205-2211.	1.7	7
5692	Therapies for Restless Legs in Parkinson's Disease. <i>Current Treatment Options in Neurology</i> , 2019, 21, 56.	0.7	17
5693	Altered brain structural topological properties in Parkinson's disease with levodopa-induced dyskinesias. <i>Parkinsonism and Related Disorders</i> , 2019, 67, 36-41.	1.1	12

#	ARTICLE	IF	CITATIONS
5694	From action to abstraction: The sensorimotor grounding of metaphor in Parkinson's disease. <i>Cortex</i> , 2019, 121, 362-384.	1.1	12
5695	Acupuncture Effect and Mechanism for Treating Pain in Patients With Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 1114.	1.1	39
5696	REM sleep muscle activity in idiopathic REM sleep behavior disorder predicts phenoconversion. <i>Neurology</i> , 2019, 93, e1171-e1179.	1.5	45
5697	Helping People With Parkinson Disease Build Exercise Self-Efficacy. <i>Physical Therapy</i> , 2020, 100, 205-208.	1.1	12
5698	A machine learning algorithm successfully screens for Parkinson's in web users. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2503-2509.	1.7	15
5699	The structural connectivity of discrete networks underlies impulsivity and gambling in Parkinson's disease. <i>Brain</i> , 2019, 142, 3917-3935.	3.7	33
5700	Square Biphasic Pulse Deep Brain Stimulation for Parkinson's Disease: The BiP-PD Study. <i>Frontiers in Human Neuroscience</i> , 2019, 13, 368.	1.0	11
5701	Frequency and Dynamics of Non-motor Symptoms Presentation in Hispanic Patients With Parkinson Disease. <i>Frontiers in Neurology</i> , 2019, 10, 1197.	1.1	11
5702	Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimer's Disease, Parkinson's Disease, and Healthy Controls. <i>Frontiers in Neuroscience</i> , 2019, 13, 1259.	1.4	29
5703	Genetic analysis of PODXL gene in patients with familial and young-onset Parkinson's disease in a Taiwanese population. <i>Neurobiology of Aging</i> , 2019, 84, 235.e9-235.e10.	1.5	1
5704	Dopaminergic Modulation of Sensory Attenuation in Parkinson's Disease: Is There an Underlying Modulation of Beta Power?. <i>Frontiers in Neurology</i> , 2019, 10, 1001.	1.1	3
5705	Sex differences in Parkinson's disease: A transcranial magnetic stimulation study. <i>Movement Disorders</i> , 2019, 34, 1873-1881.	2.2	14
5706	Circulating amino acid signature in older people with Parkinson's disease: A metabolic complement to the EXosomes in Parkinson Disease (EXPAND) study. <i>Experimental Gerontology</i> , 2019, 128, 110766.	1.2	32
5707	Combining quantitative susceptibility mapping to the morphometric index in differentiating between progressive supranuclear palsy and Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2019, 406, 116443.	0.3	16
5708	Acoustic Tracking of Pitch, Modal, and Subharmonic Vibrations of Vocal Folds in Parkinson's Disease and Parkinsonism. <i>IEEE Access</i> , 2019, 7, 150339-150354.	2.6	23
5709	Neuroprotective Effects of Rasagiline in Parkinson's Disease: A Regional Cerebral Blood Flow Study. <i>Journal of Neuroimaging</i> , 2019, 29, 707-711.	1.0	4
5710	Effect of subthalamic deep brain stimulation on posture in Parkinson's disease: A blind computerized analysis. <i>Parkinsonism and Related Disorders</i> , 2019, 62, 122-127.	1.1	26
5711	Transcranial direct current stimulation enhances theory of mind in Parkinson's disease patients with mild cognitive impairment: a randomized, double-blind, sham-controlled study. <i>Translational Neurodegeneration</i> , 2019, 8, 1.	3.6	59

#	ARTICLE	IF	CITATIONS
5712	Similarities and differences in cerebellar grey matter volume and disrupted functional connectivity in idiopathic Parkinson's disease and multiple system atrophy. <i>Neuropsychologia</i> , 2019, 124, 125-132.	0.7	10
5713	Alterations in Blood Monocyte Functions in Parkinson's Disease. <i>Movement Disorders</i> , 2019, 34, 1711-1721.	2.2	67
5714	Probiotics for Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4121.	1.8	97
5715	Non-motor symptoms in newly diagnosed Parkinson's disease patients. <i>Egyptian Journal of Neurology, Psychiatry and Neurosurgery</i> , 2019, 55, .	0.4	8
5716	Pavement patterns can be designed to improve gait in Parkinson's disease patients. <i>Movement Disorders</i> , 2019, 34, 1831-1838.	2.2	8
5717	Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease. <i>Clinical Autonomic Research</i> , 2019, 29, 603-614.	1.4	10
5718	Deep brain stimulation in Parkinson's disease: A multicentric, long-term, observational pilot study. <i>Journal of the Neurological Sciences</i> , 2019, 405, 116411.	0.3	6
5719	<p></p>Affective theory of mind in Parkinson's disease: the effect of cognitive performance</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2521-2535.	1.0	27
5720	Bilateral subthalamic nucleus deep brain stimulation increases fixational saccades during movement preparation: evidence for impaired preparatory set. <i>Experimental Brain Research</i> , 2019, 237, 2841-2851.	0.7	6
5721	Paraquat and Parkinson's disease: a systematic review and meta-analysis of observational studies. <i>Journal of Toxicology and Environmental Health - Part B: Critical Reviews</i> , 2019, 22, 172-202.	2.9	49
5722	Changes in Resting-State Functional Connectivity Related to Freezing of Gait in Parkinson's Disease. <i>Neuroscience</i> , 2019, 418, 311-317.	1.1	21
5723	Parkinson's Disease in Central Asian and Transcaucasian Countries: A Review of Epidemiology, Genetics, Clinical Characteristics, and Access to Care. <i>Parkinson's Disease</i> , 2019, 2019, 1-7.	0.6	5
5724	A Narrative Review of Lifestyle Factors Associated with Parkinson's Disease Risk and Progression. <i>Neurodegenerative Diseases</i> , 2019, 19, 51-59.	0.8	21
5725	Recall and Recognition Discriminability in Parkinson's Disease and Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2019, 8, 459-465.	0.9	1
5726	Long-Term Effects of Balance Training on Habitual Physical Activity in Older Adults with Parkinson's Disease. <i>Parkinson's Disease</i> , 2019, 2019, 1-9.	0.6	8
5727	Blood NfL. <i>Neurology</i> , 2019, 93, e1104-e1111.	1.5	144
5728	Is Low Psychomotor Speed a Marker of Brain Vulnerability in Late Life? Digit Symbol Substitution Test in the Prediction of Alzheimer, Parkinson, Stroke, Disability, and Depression. <i>Dementia and Geriatric Cognitive Disorders</i> , 2019, 47, 297-305.	0.7	27
5729	Somatic symptoms disorders in Parkinson's disease are related to default mode and salience network dysfunction. <i>NeuroImage: Clinical</i> , 2019, 23, 101932.	1.4	14

#	ARTICLE	IF	CITATIONS
5730	Virtual Reality Rehabilitation Versus Conventional Physical Therapy for Improving Balance and Gait in Parkinson's Disease Patients: A Randomized Controlled Trial. <i>Medical Science Monitor</i> , 2019, 25, 4186-4192.	0.5	133
5731	Diagnostic Potential of Multimodal MRI Markers in Atypical Parkinsonian Disorders. <i>Journal of Parkinson's Disease</i> , 2019, 9, 681-691.	1.5	15
5732	Estimating dyskinesia severity in Parkinson's disease by using a waist-worn sensor: concurrent validity study. <i>Scientific Reports</i> , 2019, 9, 13434.	1.6	13
5733	Considerations before initiating therapy in Parkinsonism: basing on the quality of life. <i>Journal of Neurology</i> , 2019, 266, 3119-3125.	1.8	1
5734	Quantitative susceptibility mapping in atypical Parkinsonisms. <i>NeuroImage: Clinical</i> , 2019, 24, 101999.	1.4	49
5735	The Parkinson's Disease Composite Scale Is Adequately Responsive to Acute Levodopa Challenge. <i>Parkinson's Disease</i> , 2019, 2019, 1-8.	0.6	5
5736	Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study. <i>The Lancet Digital Health</i> , 2019, 1, e222-e231.	5.9	73
5737	Dynamic Alterations of Spontaneous Neural Activity in Parkinson's Disease: A Resting-State fMRI Study. <i>Frontiers in Neurology</i> , 2019, 10, 1052.	1.1	38
5738	Heightened orofacial, manual, and gait variability in Parkinson's disease results from a general rhythmic impairment. <i>Npj Parkinson's Disease</i> , 2019, 5, 19.	2.5	21
5739	Altered Body Composition of Psoas and Thigh Muscles in Relation to Frailty and Severity of Parkinson's Disease. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3667.	1.2	17
5740	Expression Profiling of Blood microRNAs 885, 361, and 17 in the Patients with the Parkinson's disease: Integrating Interaction Data to Uncover the Possible Triggering Age-Related Mechanisms. <i>Scientific Reports</i> , 2019, 9, 13759.	1.6	21
5741	Levels of oligomeric α -Synuclein in reflex tears distinguish Parkinson's disease patients from healthy controls. <i>Biomarkers in Medicine</i> , 2019, 13, 1447-1457.	0.6	18
5742	Large-Fiber Neuropathy in Parkinson's Disease: Clinical, Biological, and Electroneurographic Assessment of a Romanian Cohort. <i>Journal of Clinical Medicine</i> , 2019, 8, 1533.	1.0	7
5743	Food toxins and the Caribbean Parkinson plus types. <i>Revue Neurologique</i> , 2019, 175, 641-643.	0.6	2
5744	Apomorphine-induced reorganization of striato-frontal connectivity in patients with tremor-dominant Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 67, 14-20.	1.1	9
5745	Sensitivity and specificity of cardiac ^{123}I -MIBG scintigraphy for diagnosis of early-phase Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2019, 407, 116409.	0.3	10
5746	Orthostatic hypotension in Parkinson disease. <i>Neurology</i> , 2019, 93, e1526-e1534.	1.5	49
5747	Reliability, validity and responsiveness of the squares test for manual dexterity in people with Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2019, 186, 105542.	0.6	4

#	ARTICLE	IF	CITATIONS
5748	To scan or not to scan your Parkinson patient: that is the question!. Practical Neurology, 2019, 19, 462-464.	0.5	0
5749	Automated and objective measures of gait dynamics in camptocormia Parkinson's Disease subthalamic deep brain stimulation. Clinical Neurology and Neurosurgery, 2019, 186, 105537.	0.6	1
5750	Progressive Modular Rebalancing System and Visual Cueing for Gait Rehabilitation in Parkinson's Disease: A Pilot, Randomized, Controlled Trial With Crossover. Frontiers in Neurology, 2019, 10, 902.	1.1	15
5751	Assessing blink reflex circuits by three different afferent routes in Parkinson's disease. Clinical Neurophysiology, 2019, 130, 582-587.	0.7	6
5752	Modified Mindfulness-Based Cognitive Therapy for Depressive Symptoms in Parkinson's Disease: a Pilot Trial. Behavioural and Cognitive Psychotherapy, 2019, 47, 446-461.	0.9	27
5753	BST1 rs4698412 allelic variant increases the risk of gait or balance deficits in patients with Parkinson's disease. CNS Neuroscience and Therapeutics, 2019, 25, 422-429.	1.9	15
5754	Precuneus Dysfunction in Parkinson's Disease With Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2018, 10, 427.	1.7	40
5755	Ultrasensitive Detection of Aggregated α -Synuclein in Glial Cells, Human Cerebrospinal Fluid, and Brain Tissue Using the RT-QuIC Assay: New High-Throughput Neuroimmune Biomarker Assay for Parkinsonian Disorders. Journal of Neuroimmune Pharmacology, 2019, 14, 423-435.	2.1	66
5756	A Comprehensive Analysis of Population Differences in LRRK2 Variant Distribution in Parkinson's Disease. Frontiers in Aging Neuroscience, 2019, 11, 13.	1.7	53
5757	Dopaminergic denervation using [123 I]-FPCIT and pain in Parkinson's disease: a correlation study. Journal of Neural Transmission, 2019, 126, 279-287.	1.4	7
5758	Electromyography activity level in rapid eye movement sleep predicts neurodegenerative diseases in idiopathic rapid eye movement sleep behavior disorder: a 5-year longitudinal study. Sleep Medicine, 2019, 56, 128-134.	0.8	27
5759	Prevalence and duration of non-motor symptoms in prodromal Parkinson's disease. European Journal of Neurology, 2019, 26, 979-985.	1.7	73
5760	Impairment of Motor Function Correlates with Neurometabolite and Brain Iron Alterations in Parkinson's Disease. Cells, 2019, 8, 96.	1.8	28
5761	Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment. Journal of Alzheimer's Disease, 2019, 67, 481-488.	1.2	171
5762	Increased DJ-1 and α -Synuclein in Plasma Neural-Derived Exosomes as Potential Markers for Parkinson's Disease. Frontiers in Aging Neuroscience, 2018, 10, 438.	1.7	122
5763	Effects of Qigong Exercise on Non-Motor Symptoms and Inflammatory Status in Parkinson's Disease: A Protocol for a Randomized Controlled Trial. Medicines (Basel, Switzerland), 2019, 6, 13.	0.7	7
5764	External cueing facilitates auditory-motor integration for speech control in individuals with Parkinson's disease. Neurobiology of Aging, 2019, 76, 96-105.	1.5	12
5765	Executive Functions, Episodic Autobiographical Memory, Problem-Solving Capacity, and Depression Proposal for a Structural Equations Model. Journal of Geriatric Psychiatry and Neurology, 2019, 32, 81-89.	1.2	5

#	ARTICLE	IF	CITATIONS
5766	Identifying Parkinson's disease and parkinsonism cases using routinely collected healthcare data: A systematic review. <i>PLoS ONE</i> , 2019, 14, e0198736.	1.1	20
5767	The Diagnostic Scope of Sensor-Based Gait Analysis in Atypical Parkinsonism: Further Observations. <i>Frontiers in Neurology</i> , 2019, 10, 5.	1.1	25
5768	Plasma alpha-synuclein levels in patients with Parkinson's disease: a systematic review and meta-analysis. <i>Neurological Sciences</i> , 2019, 40, 929-938.	0.9	59
5769	Polymorphisms of <i>ACMSD</i> , <i>TMEM163</i> , <i>MCCC1</i> , and <i>BCKDK</i> - <i>STX1B</i> Are Not Associated with Parkinson's Disease in Taiwan. <i>Parkinson's Disease</i> , 2019, 2019, 1-6.	0.6	8
5770	Do Neurodegenerative Diseases Affect Creativity? Divergent Thinking in Frontotemporal Dementia and Parkinson's Disease. <i>Creativity Research Journal</i> , 2019, 31, 102-109.	1.7	7
5771	Emotional Processing Impairments in Apathetic Patients with Parkinson's Disease: An ERP Study in Early Time Windows. <i>Parkinson's Disease</i> , 2019, 2019, 1-9.	0.6	1
5772	Erythrocytic α -Synuclein as a potential biomarker for Parkinson's disease. <i>Translational Neurodegeneration</i> , 2019, 8, 15.	3.6	65
5773	Diagnosing Parkinson's Disease. <i>Current Clinical Neurology</i> , 2019, , 3-6.	0.1	1
5774	Substantia nigra locations of iron-content, free-water and mean diffusivity abnormalities in moderate stage Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 146-152.	1.1	27
5775	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	4.5	455
5776	Randomized phase I clinical trial of anti- α -synuclein antibody BIIB054. <i>Movement Disorders</i> , 2019, 34, 1154-1163.	2.2	128
5777	The renin-angiotensin aldosterone system and osteoporosis: findings from the Women's Health Initiative. <i>Osteoporosis International</i> , 2019, 30, 2039-2056.	1.3	24
5778	Variants in the SNCA Locus Are Associated With the Progression of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 110.	1.7	8
5779	Diplopia in Parkinson's disease: visual illusion or oculomotor impairment?. <i>Journal of Neurology</i> , 2019, 266, 2457-2464.	1.8	12
5780	Association of the Polygenic Risk Score with the Incidence Risk of Parkinson's Disease and Cerebrospinal Fluid α -Synuclein in a Chinese Cohort. <i>Neurotoxicity Research</i> , 2019, 36, 515-522.	1.3	8
5781	Parkinson Disease-Related Pattern of Glucose Metabolism Associated With the Potential for Motor Improvement After Deep Brain Stimulation. <i>Neurosurgery</i> , 2019, 86, 492-499.	0.6	5
5782	Asymptomatic Hearing Impairment Frequently Occurs in Early-Onset Parkinson's Disease. <i>Journal of Movement Disorders</i> , 2019, 12, 84-90.	0.7	15
5783	The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson's disease patients. <i>Scientific Reports</i> , 2019, 9, 8898.	1.6	31

#	ARTICLE	IF	CITATIONS
5784	Basal ganglia contributions during the learning of a visuomotor rotation: Effect of dopamine, deep brain stimulation and reinforcement. <i>European Journal of Neuroscience</i> , 2019, 50, 3349-3364.	1.2	10
5785	One line: A method for differential diagnosis of parkinsonian syndromes. <i>Acta Neurologica Scandinavica</i> , 2019, 140, 229-235.	1.0	9
5786	Retinal texture biomarkers may help to discriminate between Alzheimer's, Parkinson's, and healthy controls. <i>PLoS ONE</i> , 2019, 14, e0218826.	1.1	54
5787	Fatigue in Parkinson's Disease Associates with Lower Ambulatory Diastolic Blood Pressure. <i>Journal of Parkinson's Disease</i> , 2019, 9, 575-581.	1.5	8
5788	Clinical profiles of late-onset psychiatric patients exhibiting incidental REM sleep without atonia. <i>Journal of Neural Transmission</i> , 2019, 126, 1095-1104.	1.4	7
5789	Cancer risk in patients with Parkinson's disease in South Korea: A nationwide, population-based cohort study. <i>European Journal of Cancer</i> , 2019, 117, 5-13.	1.3	37
5790	Auditory entrainment of motor responses in older adults with and without Parkinson's disease: An MEG study. <i>Neuroscience Letters</i> , 2019, 708, 134331.	1.0	5
5791	Clinical Correlates of Cerebral Amyloid Deposition in Parkinson's Disease Dementia: Evidence from a PET Study. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 597-609.	1.2	13
5792	Proposal of a new conceptual gait model for patients with Parkinson's disease based on factor analysis. <i>BioMedical Engineering OnLine</i> , 2019, 18, 70.	1.3	17
5793	Pain Characteristics and Their Relationship With Motor Dysfunction in Individuals With Parkinson Disease—A Cross-Sectional Study. <i>Pain Practice</i> , 2019, 19, 732-739.	0.9	15
5794	CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1117-1123.	0.9	61
5795	A metabolomic signature of treated and drug-naïve patients with Parkinson's disease: a pilot study. <i>Metabolomics</i> , 2019, 15, 90.	1.4	14
5796	Midbrain area for differentiating Parkinson's disease from progressive supranuclear palsy. <i>Clinical Neurology and Neurosurgery</i> , 2019, 183, 105383.	0.6	6
5797	Application of Machine Learning in a Parkinson's Disease Digital Biomarker Dataset Using Neural Network Construction (NNC) Methodology Discriminates Patient Motor Status. <i>Frontiers in ICT</i> , 2019, 6, .	3.6	22
5798	Lower Limb Rigidity Is Associated with Frequent Falls in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 446-451.	0.8	8
5799	Excessive phase synchronization in cortical activation during locomotion in persons with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 210-216.	1.1	18
5800	Leucine rich repeat kinase 2: a paradigm for pleiotropy. <i>Journal of Physiology</i> , 2019, 597, 3511-3521.	1.3	12
5801	Deep Brain Stimulation for the Treatment of Juvenile Parkinsonism: Case Report. <i>Brazilian Neurosurgery</i> , 2019, 38, 124-127.	0.0	1

#	ARTICLE	IF	CITATIONS
5802	Dual vs. Single Tasking During Circular Walking: What Better Reflects Progression in Parkinson's Disease?. <i>Frontiers in Neurology</i> , 2019, 10, 372.	1.1	6
5803	The influence of one session of low frequency rTMS on pre-supplementary motor area metabolites in late stage Parkinson's disease. <i>Clinical Neurophysiology</i> , 2019, 130, 1292-1298.	0.7	7
5804	Neuronal spiking in the pedunculopontine nucleus in progressive supranuclear palsy and in idiopathic Parkinson's disease. <i>Journal of Neurology</i> , 2019, 266, 2244-2251.	1.8	5
5805	Biomechanical System Versus Observational Rating Scale for Parkinson's Disease Tremor Assessment. <i>Scientific Reports</i> , 2019, 9, 8117.	1.6	3
5806	Accuracy of nigrosome-1 detection to discriminate patients with Parkinson's disease and essential tremor. <i>Neuroradiology Journal</i> , 2019, 32, 395-400.	0.6	23
5807	Diffusion tensor and restriction spectrum imaging reflect different aspects of neurodegeneration in Parkinson's disease. <i>PLoS ONE</i> , 2019, 14, e0217922.	1.1	17
5808	Dysbiosis of gut microbiota in a selected population of Parkinson's patients. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 124-130.	1.1	144
5809	Meta-analysis of related factors of impulse control disorders in patients with Parkinson's disease. <i>Neuroscience Letters</i> , 2019, 707, 134313.	1.0	10
5810	Hierarchical Data-Driven Analysis of Clinical Symptoms Among Patients With Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 531.	1.1	13
5811	Systematic review of the pharmacoeconomics of Parkinson disease medications. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1659-1670.	0.9	6
5812	Acute kinematic and neurophysiological effects of treadmill and overground walking in Parkinson's disease. <i>NeuroRehabilitation</i> , 2019, 44, 433-443.	0.5	2
5813	How do Parkinson's disease patients manage Ramadan fasting? An observational study. <i>Revue Neurologique</i> , 2019, 175, 560-563.	0.6	2
5814	Volitional Suppression of Parkinsonian Resting Tremor. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 470-478.	0.8	5
5815	Elevated Serum Homocysteine Levels Have Differential Gender-Specific Associations with Motor and Cognitive States in Parkinson's Disease. <i>Parkinson's Disease</i> , 2019, 2019, 1-8.	0.6	25
5816	The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. <i>Expert Review of Proteomics</i> , 2019, 16, 593-600.	1.3	41
5817	The Gut and Parkinson's Disease—A Bidirectional Pathway. <i>Frontiers in Neurology</i> , 2019, 10, 574.	1.1	110
5818	Structural brain signature of cognitive decline in Parkinson's disease: DTI-based evidence from the LANDSCAPE study. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641984344.	1.5	17
5819	Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson's disease: A pilot study. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641984345.	1.5	16

#	ARTICLE	IF	CITATIONS
5820	Association of homocysteine, folate, and white matter hyperintensities in Parkinson's patients with different motor phenotypes. <i>Neurological Sciences</i> , 2019, 40, 1855-1863.	0.9	15
5821	Cerebrospinal fluid neurofilament light and tau protein as mortality biomarkers in parkinsonism. <i>Acta Neurologica Scandinavica</i> , 2019, 140, 147-156.	1.0	15
5822	Unveiling the relationship between central parkinsonian pain and motor symptoms in Parkinson's disease. <i>European Journal of Pain</i> , 2019, 23, 1475-1485.	1.4	6
5823	Source activity during emotion processing and its relationship to cognitive impairment in Parkinson's disease. <i>Journal of Affective Disorders</i> , 2019, 253, 327-335.	2.0	7
5824	Responses to anterior and posterior perturbations in Parkinson's disease with early postural instability: role of axial and limb rigidity. <i>Experimental Brain Research</i> , 2019, 237, 1853-1867.	0.7	10
5825	Framing advance care planning in Parkinson disease. <i>Neurology</i> , 2019, 92, e2571-e2579.	1.5	53
5826	Mild cognitive impairment in Parkinson's disease is associated with decreased P300 amplitude and reduced putamen volume. <i>Clinical Neurophysiology</i> , 2019, 130, 1208-1217.	0.7	42
5827	Use of Magnetic Resonance Imaging and Artificial Intelligence in Studies of Diagnosis of Parkinson's Disease. <i>ACS Chemical Neuroscience</i> , 2019, 10, 2658-2667.	1.7	25
5828	Gait Training in Virtual Reality: Short-Term Effects of Different Virtual Manipulation Techniques in Parkinson's Disease. <i>Cells</i> , 2019, 8, 419.	1.8	36
5829	Clinical correlations of striatal hand deformities in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2019, 140, 162-166.	1.0	1
5830	L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 55-61.	1.1	14
5831	Quantification of movement in normal and parkinsonian macaques using video analysis. <i>Journal of Neuroscience Methods</i> , 2019, 322, 96-102.	1.3	1
5832	The Effect of High-Frequency Repetitive Transcranial Magnetic Stimulation on Advancing Parkinson's Disease With Dysphagia: Double Blind Randomized Clinical Trial. <i>Neurorehabilitation and Neural Repair</i> , 2019, 33, 442-452.	1.4	46
5833	Dementias. , 2019, , 287-345.		2
5835	Widespread Tau-Specific CD4 T Cell Reactivity in the General Population. <i>Journal of Immunology</i> , 2019, 203, 84-92.	0.4	36
5836	Frontal atrophy as a marker for dementia conversion in Parkinson's disease with mild cognitive impairment. <i>Human Brain Mapping</i> , 2019, 40, 3784-3794.	1.9	41
5837	Phytosynthesized metal oxide nanoparticles for pharmaceutical applications. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2019, 392, 755-771.	1.4	67
5838	The Association between DRD3 Ser9Gly Polymorphism and Depression Severity in Parkinson's Disease. <i>Parkinson's Disease</i> , 2019, 2019, 1-8.	0.6	13

#	ARTICLE	IF	CITATIONS
5839	Quantitative MRI evaluation of gastric motility in patients with Parkinson's disease: Correlation of dyspeptic symptoms with volumetry and motility indices. <i>PLoS ONE</i> , 2019, 14, e0216396.	1.1	13
5840	Mitochondrial-Derived Vesicles as Candidate Biomarkers in Parkinson's Disease: Rationale, Design and Methods of the EXosomes in Parkinson Disease (EXPAND) Study. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2373.	1.8	72
5841	Attenuated NoGo-related beta desynchronisation and synchronisation in Parkinson's disease revealed by magnetoencephalographic recording. <i>Scientific Reports</i> , 2019, 9, 7235.	1.6	16
5842	Assessment of cognitive profile as a prodromal marker of the evolution of rapid eye movement sleep behavior disorder. <i>Sleep</i> , 2019, 42, .	0.6	22
5843	Cross-Sectional Area Analysis of the Head of the Caudate Nucleus in Huntington's Disease. <i>European Neurology</i> , 2019, 81, 13-18.	0.6	3
5844	DL-3-n-butylphthalide therapy for Parkinson's disease: A randomized controlled trial. <i>Experimental and Therapeutic Medicine</i> , 2019, 17, 3800-3806.	0.8	12
5845	Inflammation in mild cognitive impairment due to Parkinson's disease, Lewy body disease, and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1244-1250.	1.3	31
5846	Effect of STN DBS on vesicular monoamine transporter 2 and glucose metabolism in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 235-241.	1.1	12
5847	Optimizing the Diagnosis of Parkinsonian Syndromes With ¹²³ I-Hoflupane Brain SPECT. <i>American Journal of Roentgenology</i> , 2019, 213, 243-253.	1.0	9
5848	Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system. <i>Brain</i> , 2019, 142, 2023-2036.	3.7	48
5849	Test-retest reliability of stride length-cadence gait relationship in Parkinson's disease. <i>Gait and Posture</i> , 2019, 71, 177-180.	0.6	3
5850	Descriptive analysis of the French NS-Park registry: Towards a nation-wide Parkinson's disease cohort?. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 226-234.	1.1	4
5851	Driving Difficulties Among Patients with Alzheimer's Disease and Other Neurodegenerative Disorders. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 1019-1030.	1.2	15
5852	Anxiety and Levodopa Equivalent Daily Dose Are Potential Predictors of Sleep Quality in Patients With Parkinson Disease in Taiwan. <i>Frontiers in Neurology</i> , 2019, 10, 340.	1.1	11
5853	Evaluation of intracerebral ventricles volume of patients with Parkinson's disease using the atlas-based method: A methodological study. <i>Journal of Chemical Neuroanatomy</i> , 2019, 98, 124-130.	1.0	5
5854	The educational programs for extrapyramidal disease and spinocerebellar degeneration patients and their families. <i>Neurology and Clinical Neuroscience</i> , 2019, 7, 61-64.	0.2	1
5855	Scaled Subprofile Modeling and Convolutional Neural Networks for the Identification of Parkinson's Disease in 3D Nuclear Imaging Data. <i>International Journal of Neural Systems</i> , 2019, 29, 1950010.	3.2	48
5856	Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 391.	1.1	50

#	ARTICLE	IF	CITATIONS
5857	Is lowering stimulation frequency a feasible option for subthalamic deep brain stimulation in Parkinson's disease patients with dysarthria?. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 242-248.	1.1	9
5858	Time Perception of an Artwork's Manipulation Is Distorted by Patients With Parkinson's Disease. <i>Frontiers in Integrative Neuroscience</i> , 2019, 13, 6.	1.0	1
5859	"Woe Betides Anybody Who Tries to Turn me Down." A Qualitative Analysis of Neuropsychiatric Symptoms Following Subthalamic Deep Brain Stimulation for Parkinson's Disease. <i>Neuroethics</i> , 2021, 14, 47-63.	1.7	22
5860	Analysis of Contact Position for Subthalamic Nucleus Deep Brain Stimulation-Induced Hyperhidrosis. <i>Parkinson's Disease</i> , 2019, 2019, 1-6.	0.6	6
5861	Ultrasonication-based rapid amplification of α -synuclein aggregates in cerebrospinal fluid. <i>Scientific Reports</i> , 2019, 9, 6001.	1.6	28
5862	Comparing postural instability and gait disorder and akinetic-rigid subtyping of Parkinson disease and their stability over time. <i>European Journal of Neurology</i> , 2019, 26, 1212-1218.	1.7	17
5863	Evaluation of tremor interference with control of voluntary reaching movements in patients with Parkinson's disease. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2019, 16, 38.	2.4	8
5864	Clinical correlates of repetitive speech disorders in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2019, 401, 67-71.	0.3	10
5865	Clonazepam for probable REM sleep behavior disorder in Parkinson's disease: A randomized placebo-controlled trial. <i>Journal of the Neurological Sciences</i> , 2019, 401, 81-86.	0.3	49
5866	Levodopa imparts a normalizing effect on default-mode network connectivity in non-demented Parkinson's disease. <i>Neuroscience Letters</i> , 2019, 705, 159-166.	1.0	22
5867	Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2019, 140, 157-161.	1.0	11
5868	The usefulness of [123 I]-metaiodobenzylguanidine myocardial scintigraphy in patients with subacute myelo-optico-neuropathy. <i>Neurology and Clinical Neuroscience</i> , 2019, 7, 57-60.	0.2	0
5869	Hemorrhagic complications seen on immediate intraprocedural stereotactic computed tomography imaging during deep brain stimulation implantation. <i>Journal of the Neurological Sciences</i> , 2019, 400, 97-103.	0.3	7
5870	Assessment of response to medication in individuals with Parkinson's disease. <i>Medical Engineering and Physics</i> , 2019, 67, 33-43.	0.8	28
5871	Association of three candidate genetic variants in ACMSD/TMEM163, GPNMB and BCKDK /STX1B with sporadic Parkinson's disease in Han Chinese. <i>Neuroscience Letters</i> , 2019, 703, 45-48.	1.0	9
5872	Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An 123I-FP-CIT SPECT study. <i>NeuroImage: Clinical</i> , 2019, 22, 101755.	1.4	23
5873	Periventricular White Matter Abnormalities on Diffusion Tensor Imaging of Postural Instability Gait Disorder Parkinsonism. <i>American Journal of Neuroradiology</i> , 2019, 40, 609-613.	1.2	7
5874	An Overview of Systematic Reviews of Chinese Herbal Medicine for Parkinson's Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 155.	1.6	8

#	ARTICLE	IF	CITATIONS
5875	Slow-wave sleep and motor progression in Parkinson disease. <i>Annals of Neurology</i> , 2019, 85, 765-770.	2.8	55
5876	Neuropsychiatric Symptoms and Cognitive Impairment in Chinese Patients with Parkinson's Disease in Han and Hui Ethnicity. <i>Current Medical Science</i> , 2019, 39, 122-126.	0.7	4
5877	Activities of Daily Living and Their Relationship to Health-Related Quality of Life in Patients with Parkinson Disease After Subthalamic Nucleus Deep Brain Stimulation. <i>World Neurosurgery</i> , 2019, 125, e552-e562.	0.7	11
5878	Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 20.	3.0	67
5879	Quantitative Sensory Testing (QST) in Drug-Naïve Patients with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2019, 9, 369-378.	1.5	8
5880	An experience at a movement disorders center in Honduras. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 238-239.	1.1	0
5881	Proteomic analysis of tear fluid reveals disease-specific patterns in patients with Parkinson's disease – A pilot study. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 3-9.	1.1	57
5882	Translational methods to detect asymmetries in temporal and spatial walking metrics in parkinsonian mouse models and human subjects with Parkinson's disease. <i>Scientific Reports</i> , 2019, 9, 2437.	1.6	7
5883	Caught in the act: LRRK2 in exosomes. <i>Biochemical Society Transactions</i> , 2019, 47, 663-670.	1.6	12
5884	Serum NFL discriminates Parkinson disease from atypical parkinsonisms. <i>Neurology</i> , 2019, 92, e1479-e1486.	1.5	100
5885	Does outpatient palliative care improve patient-centered outcomes in Parkinson's disease: Rationale, design, and implementation of a pragmatic comparative effectiveness trial. <i>Contemporary Clinical Trials</i> , 2019, 79, 28-36.	0.8	26
5887	Excessive daytime sleepiness and its impact on quality of life in de novo Parkinson's disease. <i>Neurological Sciences</i> , 2019, 40, 1151-1156.	0.9	32
5888	The Effect of 20 Hz versus 1 Hz Repetitive Transcranial Magnetic Stimulation on Motor Dysfunction in Parkinson's Disease: Which Is More Beneficial?. <i>Journal of Parkinson's Disease</i> , 2019, 9, 379-387.	1.5	14
5889	SLC6A4 Repeat and Single-Nucleotide Polymorphisms Are Associated With Depression and Rest Tremor in Parkinson's Disease: An Exploratory Study. <i>Frontiers in Neurology</i> , 2019, 10, 333.	1.1	14
5890	The Parkinson's phenotype traits associated with Parkinson's disease in a broadly phenotyped cohort. <i>Npj Parkinson's Disease</i> , 2019, 5, 4.	2.5	34
5891	Impact of Cognitive Profile on Impulse Control Disorders Presence and Severity in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 266.	1.1	8
5892	Network basis of the dysexecutive and posterior cortical cognitive profiles in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 893-902.	2.2	24
5893	Identification of Shared Genes Between Ischemic Stroke and Parkinson's Disease Using Genome-Wide Association Studies. <i>Frontiers in Neurology</i> , 2019, 10, 297.	1.1	18

#	ARTICLE	IF	CITATIONS
5894	Potential Markers of Progression in Idiopathic Parkinson's Disease Derived From Assessment of Circular Gait With a Single Body-Fixed-Sensor: A 5 Year Longitudinal Study. <i>Frontiers in Human Neuroscience</i> , 2019, 13, 59.	1.0	27
5895	Distinctive speech signature in cerebellar and parkinsonian subtypes of multiple system atrophy. <i>Journal of Neurology</i> , 2019, 266, 1394-1404.	1.8	29
5896	Genetic analysis of DNA methylation and hydroxymethylation genes in Parkinson's disease. <i>Neurobiology of Aging</i> , 2019, 84, 242.e13-242.e16.	1.5	10
5897	The aggregation state of α -synuclein deposits in dermal nerve fibers of patients with Parkinson's disease resembles that in the brain. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 66-72.	1.1	24
5898	Classic animal models of Parkinson's disease: a historical perspective. <i>Behavioural Pharmacology</i> , 2019, 30, 291-310.	0.8	23
5899	Dysphagia predicts poor outcome in late-stage Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 73-81.	1.1	26
5900	Association of Pisa Syndrome With Mortality in Patients With Parkinson's Disease. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 1037-1041.e1.	1.2	4
5901	Effect of levodopa on handwriting tasks of different complexity in Parkinson's disease: a kinematic study. <i>Journal of Neurology</i> , 2019, 266, 1376-1382.	1.8	10
5902	Relationship between Lower Urinary Tract Dysfunction and Clinical Features in Chinese Parkinson's Disease Patients. <i>Parkinson's Disease</i> , 2019, 2019, 1-7.	0.6	6
5903	Revision of Diagnosis in Early Parkinsonism with Abnormal Dopamine Transporter Imaging. <i>Journal of Parkinson's Disease</i> , 2019, 9, 327-334.	1.5	6
5904	When motor control gets out of hand: Speeding up triggers freezing in the upper limb in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 163-168.	1.1	11
5905	Neurocognitive Predictors of Understanding of Intentions in Parkinson Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2019, 32, 178-185.	1.2	9
5906	Perturbation Treadmill Training Improves Clinical Characteristics of Gait and Balance in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2019, 9, 413-426.	1.5	23
5907	Remnants of Cardinal Symptoms of Parkinson's Disease, Not Dyskinesia, Are Problematic for Dyskinetic Patients Performing Activities of Daily Living. <i>Frontiers in Neurology</i> , 2019, 10, 256.	1.1	8
5908	A Kinematic Study of Progressive Micrographia in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 403.	1.1	11
5909	Factor Analysis of the Apathy Scale in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 379-386.	0.8	13
5910	<i>LRP10</i> in autosomal dominant Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 912-916.	2.2	22
5911	The impact of evoked cutaneous afferents on voluntary reaching movement in patients with Parkinson's disease. <i>Journal of Neural Engineering</i> , 2019, 16, 036029.	1.8	11

#	ARTICLE	IF	CITATIONS
5912	Longitudinal Epigenome-Wide Methylation Study of Cognitive Decline and Motor Progression in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2019, 9, 389-400.	1.5	37
5913	Tremor-Dominant in Parkinson Disease: The Relevance to Iron Metabolism and Inflammation. <i>Frontiers in Neuroscience</i> , 2019, 13, 255.	1.4	21
5914	Distinct FP-CIT PET patterns of Alzheimer's disease with parkinsonism and dementia with Lewy bodies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1652-1660.	3.3	11
5915	Presynaptic Striatal Dopaminergic Function in Atypical Parkinsonism: A Metaanalysis of Imaging Studies. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1757-1763.	2.8	29
5916	Analysis of characteristics affecting instrumental activities of daily living in Parkinson's disease patients without dementia. <i>Neurological Sciences</i> , 2019, 40, 1403-1408.	0.9	7
5917	Involvement of cortical dysfunction in frequent falls in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 169-174.	1.1	16
5918	Urate and Homocysteine: Predicting Motor and Cognitive Changes in Newly Diagnosed Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2019, 9, 351-359.	1.5	28
5919	The Ventral Intermediate Nucleus Differently Modulates Subtype-Related Networks in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 202.	1.4	8
5921	Catastrophizing mediates the relationship between non-motor symptoms and quality of life in Parkinson's disease. <i>Disability and Health Journal</i> , 2019, 12, 673-678.	1.6	11
5922	Cerebral glucose metabolism in idiopathic REM sleep behavior disorder is different from tau-related and β -synuclein-related neurodegenerative disorders: A brain [18F]FDG PET study. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 97-105.	1.1	22
5923	A divergent breakdown of neurocognitive networks in Parkinson's Disease mild cognitive impairment. <i>Human Brain Mapping</i> , 2019, 40, 3233-3242.	1.9	38
5924	Levodopa effect on spontaneous speech in Parkinson's disease. <i>Journal of Neurolinguistics</i> , 2019, 51, 194-198.	0.5	1
5925	Alpha-Synuclein in Skin Nerve Fibers as a Biomarker for Alpha-Synucleinopathies. <i>Journal of Clinical</i>		

#	ARTICLE	IF	CITATIONS
5931	Eye movement abnormalities in essential tremor versus tremor dominant Parkinson's disease. <i>Clinical Neurophysiology</i> , 2019, 130, 683-691.	0.7	14
5932	Genetic variants in nicotinic receptors and smoking cessation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 62, 57-61.	1.1	10
5933	Revisiting eligibility for deep brain stimulation: Do preoperative mood symptoms predict outcomes in Parkinson's disease patients?. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 131-136.	1.1	8
5934	Cholinergic system changes of falls and freezing of gait in Parkinson's disease. <i>Annals of Neurology</i> , 2019, 85, 538-549.	2.8	115
5935	Factors Associated With Responsiveness to Gait and Balance Training in People With Parkinson Disease. <i>Journal of Neurologic Physical Therapy</i> , 2019, 43, 42-49.	0.7	21
5936	An Investigation on the Clinical Features and Neurochemical Changes in Parkinson's Disease With Depression. <i>Frontiers in Psychiatry</i> , 2018, 9, 723.	1.3	23
5937	Does the Side Onset of Parkinson's Disease Influence the Time to Develop Levodopa-Induced Dyskinesia?. <i>Journal of Parkinson's Disease</i> , 2019, 9, 241-247.	1.5	9
5938	A Multi-Layer Gaussian Process for Motor Symptom Estimation in People With Parkinson's Disease. <i>IEEE Transactions on Biomedical Engineering</i> , 2019, 66, 3038-3049.	2.5	5
5939	Abnormal α -synuclein deposits in skin nerves: intra- and inter-laboratory reproducibility. <i>European Journal of Neurology</i> , 2019, 26, 1245-1251.	1.7	38
5940	Association between physical activity and dementia's risk factors in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2019, 126, 319-325.	1.4	26
5941	Movement Disorders Emergencies. <i>Seminars in Neurology</i> , 2019, 39, 125-136.	0.5	21
5942	Investigating the perceived timing of sensory events triggering actions in patients with Parkinson's disease and the effects of dopaminergic therapy. <i>Cortex</i> , 2019, 115, 309-323.	1.1	2
5943	Impulsivity across reactive, proactive and cognitive domains in Parkinson's disease on dopaminergic medication: Evidence for multiple domain impairment. <i>PLoS ONE</i> , 2019, 14, e0210880.	1.1	8
5944	High-Spatial-Resolution Diffusion MRI in Parkinson Disease: Lateral Asymmetry of the Substantia Nigra. <i>Radiology</i> , 2019, 291, 149-157.	3.6	35
5945	Preliminary Neurophysiological Evidence of Altered Cortical Activity and Connectivity With Neurologic Music Therapy in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 105.	1.4	24
5946	Assessment of Parkinson's Disease At-home Using a Natural Interface Based System. <i>Lecture Notes in Electrical Engineering</i> , 2019, , 417-427.	0.3	0
5947	The Effects of SNCA rs894278 on Resting-State Brain Activity in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 47.	1.4	12
5948	Gastrointestinal function in dementia with Lewy bodies: a comparison with Parkinson disease. <i>Clinical Autonomic Research</i> , 2019, 29, 633-638.	1.4	11

#	ARTICLE	IF	CITATIONS
5949	Fenotipos de linfocitos periféricos en las enfermedades de Alzheimer y Parkinson. <i>Neurología</i> , 2022, 37, 110-121.	0.3	8
5950	Topography of emotional valence and arousal within the motor part of the subthalamic nucleus in Parkinson's disease. <i>Scientific Reports</i> , 2019, 9, 19924.	1.6	5
5951	Clinical Features and Risk Factors of Parkinson's Disease in a Population of Khyber Pakhtunkhwa, Pakistan: A Case-Control Study. <i>Neurodegenerative Diseases</i> , 2019, 19, 211-217.	0.8	15
5952	The Therapeutic Effect of Nordic Walking on Freezing of Gait in Parkinson's Disease: A Pilot Study. <i>Parkinson's Disease</i> , 2019, 2019, 1-10.	0.6	12
5953	A Comparative Study of the Diagnostic Potential of Plasma and Erythrocytic α -Synuclein in Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2019, 19, 204-210.	0.8	13
5954	P2Y6 and P2X7 Receptor Antagonism Exerts Neuroprotective/ Neuroregenerative Effects in an Animal Model of Parkinson's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 476.	1.8	38
5955	Low Pulvinar Intensity in Susceptibility-Weighted Imaging May Suggest Cognitive Worsening After Deep Brain Stimulation Therapy in Patients With Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 1158.	1.1	7
5956	Parkinson's disease: Diagnosis and appreciation of comorbidities. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 167, 257-277.	1.0	7
5957	Oscillation-specific nodal alterations in early to middle stages Parkinson's disease. <i>Translational Neurodegeneration</i> , 2019, 8, 36.	3.6	11
5958	How Cognition and Motivation "Freeze" the Motor Behavior in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 1302.	1.4	9
5959	Slowed Movement Stopping in Parkinson's Disease and Focal Dystonia is Improved by Standard Treatment. <i>Scientific Reports</i> , 2019, 9, 19504.	1.6	8
5960	Experiences of health services and unmet care needs of people with late-stage Parkinson's in England: A qualitative study. <i>PLoS ONE</i> , 2019, 14, e0226916.	1.1	26
5961	Cell Ratio Differences in Peripheral Blood between Early- and Late-Onset Parkinson's Disease: A Case-Control Study. <i>BioMed Research International</i> , 2019, 2019, 1-6.	0.9	6
5962	Investigation of apomorphine during sleep in Parkinson's: Improvement in UPDRS Scores. <i>Neurology International</i> , 2019, 11, 8207.	1.3	5
5963	Early Postural Instability in Parkinson's Disease: A Biomechanical Analysis of the Pull Test. <i>Parkinson's Disease</i> , 2019, 2019, 1-11.	0.6	12
5964	Occupational Therapy for Parkinsonian Patients: A Retrospective Study. <i>Parkinson's Disease</i> , 2019, 2019, 1-7.	0.6	4
5965	How to approach a patient with parkinsonism "red flags for atypical parkinsonism. <i>International Review of Neurobiology</i> , 2019, 149, 1-34.	0.9	4
5966	"Atypical" Parkinson's disease "sporadic. <i>International Review of Neurobiology</i> , 2019, 149, 195-206.	0.9	0

#	ARTICLE	IF	CITATIONS
5967	Secondary parkinsonism due to drugs, vascular lesions, tumors, trauma, and other insults. <i>International Review of Neurobiology</i> , 2019, 149, 377-418.	0.9	17
5968	Multilingual Validation of the First French Version of Munich Dysphagia Test in Parkinson's Disease (MDT-PD) in the Luxembourg Parkinson's Study. <i>Frontiers in Neurology</i> , 2019, 10, 1180.	1.1	3
5969	Self-reported and experimentally induced self-disgust is heightened in Parkinson's disease: Contribution of behavioural symptoms. <i>PLoS ONE</i> , 2019, 14, e0223663.	1.1	7
5970	A longitudinal voxel-based analysis of white matter alterations in patients with Parkinson's disease. <i>NeuroImage: Clinical</i> , 2019, 24, 102098.	1.4	35
5971	Freezing of Gait can persist after an acute levodopa challenge in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2019, 5, 25.	2.5	40
5972	The Effect of Medication and Deep Brain Stimulation on Posture in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 1254.	1.1	18
5973	Corneal Evaluation in Patients With Parkinsonism on Long-Term Amantadine Therapy. <i>Cornea</i> , 2019, 38, 1131-1136.	0.9	13
5974	Correlation of 99mTc-TRODAT-1 SPECT Imaging Findings and Clinical Staging of Parkinson Disease. <i>Clinical Nuclear Medicine</i> , 2019, 44, 347-350.	0.7	5
5975	Ocular motor manifestations of movement disorders. <i>Current Opinion in Ophthalmology</i> , 2019, 30, 443-448.	1.3	5
5976	Differential proteomic analysis of serum exosomes reveals alterations in progression of Parkinson disease. <i>Medicine (United States)</i> , 2019, 98, e17478.	0.4	42
5977	Side-to-Side Variability in Muscle Function With Parkinson Disease. <i>Topics in Geriatric Rehabilitation</i> , 2019, 35, 231-236.	0.2	0
5978	Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations. <i>Clinical Neuropharmacology</i> , 2019, 42, 149-156.	0.2	11
5979	Treatment of Parkinson's Disease Psychosis. <i>Current Treatment Options in Psychiatry</i> , 2019, 6, 412-421.	0.7	0
5980	Amnesic mild cognitive impairment in Parkinson's disease: White matter structural changes and mechanisms. <i>PLoS ONE</i> , 2019, 14, e0226175.	1.1	11
5981	Role of Adenosine A _{2A} Receptors in the Central Fatigue of Neurodegenerative Diseases. <i>Journal of Caffeine and Adenosine Research</i> , 2019, 9, 145-156.	0.8	9
5982	Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules. <i>Clinical Neuropharmacology</i> , 2019, 42, 4-8.	0.2	10
5983	Luminescent conjugated oligothiophenes distinguish between α -synuclein assemblies of Parkinson's disease and multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2019, 7, 193.	2.4	35
5984	Facial Expression Processing Is Not Affected by Parkinson's Disease, but by Age-Related Factors. <i>Frontiers in Psychology</i> , 2019, 10, 2458.	1.1	5

#	ARTICLE	IF	CITATIONS
5985	Exergaming-Based Dexterity Training in Persons With Parkinson Disease: A Pilot Feasibility Study. <i>Journal of Neurologic Physical Therapy</i> , 2019, 43, 168-174.	0.7	35
5986	An investigation of asymmetric reduction in dopamine transporter density in patients with Parkinson's disease. <i>Nuclear Medicine Communications</i> , 2019, 40, 1187-1192.	0.5	1
5987	Trunk Exercises Improve Balance in Parkinson Disease: A Phase II Randomized Controlled Trial. <i>Journal of Neurologic Physical Therapy</i> , 2019, 43, 96-105.	0.7	22
5988	Effect of ALDH2 on Sleep Disturbances in Patients with Parkinson's Disease. <i>Scientific Reports</i> , 2019, 9, 18950.	1.6	17
5989	Analysis of the Gut Microflora in Patients With Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 1184.	1.4	60
5990	Processing of Local and Global Auditory Deviants in Parkinson Disease: Electrophysiological Evidence for Enhanced Attention Capture. <i>Cognitive and Behavioral Neurology</i> , 2019, 32, 31-38.	0.5	4
5991	Common and rare GCH1 variants are associated with Parkinson's disease. <i>Neurobiology of Aging</i> , 2019, 73, 231.e1-231.e6.	1.5	20
5992	Comparison of gait parameters between drug-naïve patients diagnosed with multiple system atrophy with predominant parkinsonism and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 87-91.	1.1	7
5993	The impact of cognitive interventions on cognitive symptoms in idiopathic Parkinson's disease: a systematic review. <i>Aging, Neuropsychology, and Cognition</i> , 2019, 26, 637-659.	0.7	9
5994	Lewy body pathology in Alzheimer's disease: A clinicopathological prospective study. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 76-81.	1.0	32
5995	Everyday functioning in Parkinson's disease: Evidence from the Revised-Observed Tasks of Daily Living (OTDL-R). <i>Parkinsonism and Related Disorders</i> , 2019, 60, 167-170.	1.1	5
5996	Anxiety Independently Contributes to Severity of Freezing of Gait in People With Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2019, 31, 80-85.	0.9	21
5997	What a neurologist should know about PET and SPECT functional imaging for parkinsonism: A practical perspective. <i>Parkinsonism and Related Disorders</i> , 2019, 59, 93-100.	1.1	29
5998	Prevalence and Associated Factors of Sarcopenia and Frailty in Parkinson's Disease: A Cross-Sectional Study. <i>Gerontology</i> , 2019, 65, 216-228.	1.4	63
5999	The importance of preclinical diagnostics in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 20-28.	1.1	37
6000	A baseline study for detection of Parkinson's disease with 3D-transcranial sonography and uni-lateral reconstruction. <i>Journal of the Neurological Sciences</i> , 2019, 397, 16-21.	0.3	2
6001	The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications. <i>Journal of the Neurological Sciences</i> , 2019, 396, 262-265.	0.3	4
6002	Wait and you shall see: sexual delay discounting in hypersexual Parkinson's disease. <i>Brain</i> , 2019, 142, 146-162.	3.7	28

#	ARTICLE	IF	CITATIONS
6003	The effect of a structured medication review on quality of life in Parkinson's disease: The study protocol. <i>Contemporary Clinical Trials Communications</i> , 2019, 13, 100308.	0.5	6
6004	Swallowing in Parkinson's disease: How is it affected?. <i>Clinical Neurology and Neurosurgery</i> , 2019, 177, 37-41.	0.6	18
6005	Î±-Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson's disease. <i>Neuroscience Letters</i> , 2019, 696, 114-120.	1.0	113
6006	Effect of Low versus High Frequency Subthalamic Deep Brain Stimulation on Speech Intelligibility and Verbal Fluency in Parkinson's Disease: A Double-Blind Study. <i>Journal of Parkinson's Disease</i> , 2019, 9, 141-151.	1.5	22
6007	Smartphone Sensing Technologies for Tailored Parkinson's Disease Diagnosis and Monitoring. <i>EAI/Springer Innovations in Communication and Computing</i> , 2019, , 251-273.	0.9	5
6008	Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations. <i>Parkinsonism and Related Disorders</i> , 2019, 62, 179-184.	1.1	58
6009	Polysomnographic data in Dementia with Lewy Bodies: correlation with clinical symptoms and comparison with other Î±-synucleinopathies. <i>Sleep Medicine</i> , 2019, 55, 62-68.	0.8	20
6010	Postural control, falls and Parkinson's disease: Are fallers more asymmetric than non-fallers?. <i>Human Movement Science</i> , 2019, 63, 129-137.	0.6	10
6011	Regional gray matter changes and age predict individual treatment response in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2019, 21, 101636.	1.4	18
6012	Cerebrospinal fluid biomarker for Parkinson's disease: An overview. <i>Molecular and Cellular Neurosciences</i> , 2019, 97, 60-66.	1.0	32
6013	The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes. <i>Movement Disorders</i> , 2019, 34, 246-254.	2.2	46
6014	The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression related to inflammation, insulin and lipid in patients with Parkinson's disease: A randomized, double-blind, placebo-controlled trial. <i>Clinical Neurology and Neurosurgery</i> , 2019, 176, 116-121.	0.6	30
6015	Effectiveness of acute transcranial direct current stimulation on non-motor and motor symptoms in Parkinson's disease. <i>Neuroscience Letters</i> , 2019, 696, 46-51.	1.0	32
6016	Reproducible detection of nigral iron deposition in 2 Parkinson's disease cohorts. <i>Movement Disorders</i> , 2019, 34, 416-419.	2.2	40
6017	Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinson's disease. <i>Journal of Neurology</i> , 2019, 266, 636-641.	1.8	28
6018	Depression symptomatology correlates with event-related potentials in Parkinson's disease: An affective priming study. <i>Journal of Affective Disorders</i> , 2019, 245, 897-904.	2.0	10
6019	Impairments in gait kinematics and postural control may not correlate with dopamine transporter depletion in individuals with mild to moderate Parkinson's disease. <i>European Journal of Neuroscience</i> , 2019, 49, 1640-1648.	1.2	11
6020	Will you draw me a pelvis? Dynamic neuro-cognitive imagery improves pelvic schema and graphic-metric representation in people with Parkinson's Disease: A randomized controlled trial. <i>Complementary Therapies in Medicine</i> , 2019, 43, 28-35.	1.3	10

#	ARTICLE	IF	CITATIONS
6021	3D texture analyses within the substantia nigra of Parkinson's disease patients on quantitative susceptibility maps and R2* maps. <i>NeuroImage</i> , 2019, 188, 465-472.	2.1	60
6022	Auditory Cueing for Gait Impairment in Persons With Parkinson Disease: A Pilot Study of Changes in Response With Disease Progression. <i>Journal of Neurologic Physical Therapy</i> , 2019, 43, 50-55.	0.7	13
6023	Acetylation as a major determinant to microtubule-dependent autophagy: Relevance to Alzheimer's and Parkinson disease pathology. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 2008-2023.	1.8	69
6024	Is the Munich dysphagia Test "Parkinson's disease (MDT-PD) a valid screening tool for patients at risk for aspiration?. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 138-143.	1.1	17
6025	Botulinum toxin for Pisa syndrome: An MRI-, ultrasound- and electromyography-guided pilot study. <i>Parkinsonism and Related Disorders</i> , 2019, 62, 231-235.	1.1	25
6026	Iron-related nigral degeneration influences functional topology mediated by striatal dysfunction in Parkinson's disease. <i>Neurobiology of Aging</i> , 2019, 75, 83-97.	1.5	35
6027	Auditory and visual hallucination prevalence in Parkinson's disease and dementia with Lewy bodies: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2019, 49, 2342-2353.	2.7	49
6028	Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases. <i>Journal of Neurochemistry</i> , 2019, 151, 397-416.	2.1	34
6029	Thalamic and ventricular volumes predict motor response to deep brain stimulation for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 64-69.	1.1	18
6030	Magnetic resonance T_1/T_2 ratio: A parsimonious marker for Parkinson disease. <i>Annals of Neurology</i> , 2019, 85, 96-104.	2.8	33
6031	Effects of auditory cues on gait initiation and turning in patients with Parkinson's disease. <i>Neurologia (English Edition)</i> , 2019, 34, 396-407.	0.2	1
6032	Calycosin attenuates MPTP-induced Parkinson's disease by suppressing the activation of TLR/NF- κ B and MAPK pathways. <i>Phytotherapy Research</i> , 2019, 33, 309-318.	2.8	59
6033	Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson's disease: a detailed PET analysis of 12 striatal subregions. <i>Neurological Sciences</i> , 2019, 40, 311-317.	0.9	33
6034	The relationship of anxious and depressive symptoms in Parkinson's disease with voxel-based neuroanatomical and functional connectivity measures. <i>Journal of Affective Disorders</i> , 2019, 245, 580-588.	2.0	25
6035	Quality of life in functional movement disorders is as altered as in organic movement disorders. <i>Journal of Psychosomatic Research</i> , 2019, 116, 10-16.	1.2	24
6036	Age-related diseases as vicious cycles. <i>Ageing Research Reviews</i> , 2019, 49, 11-26.	5.0	58
6037	The prodromes of Parkinson's disease. <i>European Journal of Neuroscience</i> , 2019, 49, 320-327.	1.2	30
6038	Excitability of the supplementary motor area in Parkinson's disease depends on subcortical damage. <i>Brain Stimulation</i> , 2019, 12, 152-160.	0.7	35

#	ARTICLE	IF	CITATIONS
6039	Impact of major earthquakes on Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2019, 61, 130-135.	0.8	6
6040	The role of exposure to pesticides in the etiology of Parkinson's disease: a 18F-DOPA positron emission tomography study. <i>Journal of Neural Transmission</i> , 2019, 126, 159-166.	1.4	2
6041	Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls. <i>Molecular Neurobiology</i> , 2019, 56, 5067-5074.	1.9	7
6042	Walking on a treadmill improves the stride length-cadence relationship in individuals with Parkinson's disease. <i>Gait and Posture</i> , 2019, 68, 136-140.	0.6	12
6043	A novel electrochemical nanosensor based on NH ₂ -functionalized multi walled carbon nanotubes for the determination of catechol-ortho-methyltransferase inhibitor entacapone. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 165, 73-81.	1.4	23
6044	Alpha-synuclein in salivary gland as biomarker for Parkinson's disease. <i>Reviews in the Neurosciences</i> , 2019, 30, 455-462.	1.4	19
6045	Systematically analyzing rare variants of autosomal-dominant genes for sporadic Parkinson's disease in a Chinese cohort. <i>Neurobiology of Aging</i> , 2019, 76, 215.e1-215.e7.	1.5	17
6046	Biomarkers of Parkinson's disease: Striatal sub-regional structural morphometry and diffusion MRI. <i>NeuroImage: Clinical</i> , 2019, 21, 101597.	1.4	29
6047	The role of dopamine in the brain - lessons learned from Parkinson's disease. <i>NeuroImage</i> , 2019, 190, 79-93.	2.1	123
6048	A Randomized Crossover Pilot Study of Telemedicine Delivered via iPads in Parkinson's Disease. <i>Parkinson's Disease</i> , 2019, 2019, 1-7.	0.6	26
6049	Reliability and Validity of Fall Efficacy Scale-International in People with Parkinson's Disease during On- and Off-Drug Phases. <i>Parkinson's Disease</i> , 2019, 2019, 1-7.	0.6	20
6050	Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation. <i>Journal of Parkinson's Disease</i> , 2019, 9, 173-182.	1.5	10
6051	The association between lifestyle factors and Parkinson's disease progression and mortality. <i>Movement Disorders</i> , 2019, 34, 58-66.	2.2	77
6052	Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Neurology</i> , The, 2019, 18, 145-154.	4.9	82
6053	Sardinian Folk Dance for Individuals with Parkinson's Disease: A Randomized Controlled Pilot Trial. <i>Journal of Alternative and Complementary Medicine</i> , 2019, 25, 305-316.	2.1	58
6054	The Parkinson fatigue scale: an evaluation of its validity and reliability in Greek Parkinson's disease patients. <i>Neurological Sciences</i> , 2019, 40, 683-690.	0.9	4
6055	Fall Risk in Relation to Individual Physical Activity Exposure in Patients with Different Neurodegenerative Diseases: a Pilot Study. <i>Cerebellum</i> , 2019, 18, 340-348.	1.4	16
6056	Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease. <i>JAMA Neurology</i> , 2019, 76, 420.	4.5	169

#	ARTICLE	IF	CITATIONS
6057	Subjective cognitive decline and progression to dementia in Parkinson's disease: a long-term follow-up study. <i>Journal of Neurology</i> , 2019, 266, 745-754.	1.8	42
6058	MicroRNA-26a/Death-Associated Protein Kinase-1 Signaling Induces Synucleinopathy and Dopaminergic Neuron Degeneration in Parkinson's Disease. <i>Biological Psychiatry</i> , 2019, 85, 769-781.	0.7	92
6059	Interaction between toll-like receptor 4 (TLR4) gene and alcohol drinking on Parkinson's disease risk in Chinese Han population. <i>Journal of Clinical Neuroscience</i> , 2019, 62, 128-132.	0.8	3
6060	Parkinson's pain is more aching and interfering with social life in Caucasians compared to Indians. <i>International Journal of Neuroscience</i> , 2019, 129, 746-753.	0.8	1
6061	Postural control after unexpected external perturbation: Effects of Parkinson's disease subtype. <i>Human Movement Science</i> , 2019, 64, 12-18.	0.6	14
6062	Differential Acute Effect of High-Intensity Interval or Continuous Moderate Exercise on Cognition in Individuals With Parkinson's Disease. <i>Journal of Physical Activity and Health</i> , 2019, 16, 157-164.	1.0	43
6063	Treatment of Parkinson's Disease through Personalized Medicine and Induced Pluripotent Stem Cells. <i>Cells</i> , 2019, 8, 26.	1.8	82
6064	Evaluation of sleep quality in individuals with Parkinson's disease using objective and subjective measures. <i>Sleep and Biological Rhythms</i> , 2019, 17, 103-112.	0.5	5
6065	Levodopa/carbidopa intestinal gel infusion and weight loss in Parkinson's disease. <i>European Journal of Neurology</i> , 2019, 26, 490-496.	1.7	25
6066	The hidden side of Parkinson's disease: Studying pain, anxiety and depression in animal models. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 96, 335-352.	2.9	42
6067	Machine Learning Based Classification Using Clinical and DaTSCAN SPECT Imaging Features: A Study on Parkinson's Disease and SWEDD. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2019, 3, 170-177.	2.7	21
6068	Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 30-37.	0.9	16
6069	High-sensitivity C-reactive protein and high mobility group box-1 levels in Parkinson's disease. <i>Neurological Sciences</i> , 2019, 40, 167-173.	0.9	21
6070	Factors associated with freezing of gait in patients with Parkinson's disease. <i>Neurological Sciences</i> , 2019, 40, 293-298.	0.9	18
6071	A forced gaussians based methodology for the differential evaluation of Parkinson's Disease by means of speech processing. <i>Biomedical Signal Processing and Control</i> , 2019, 48, 205-220.	3.5	44
6072	Dorsal striatum does not mediate feedback-based, stimulus-response learning: An event-related fMRI study in patients with Parkinson's disease tested on and off dopaminergic therapy. <i>NeuroImage</i> , 2019, 185, 455-470.	2.1	12
6073	MRI evaluation of progressive supranuclear palsy: differentiation from Parkinson's disease and multiple system atrophy. <i>Neurological Research</i> , 2019, 41, 110-117.	0.6	13
6074	Rhythmic auditory cues shape neural network recruitment in Parkinson's disease during repetitive motor behavior. <i>European Journal of Neuroscience</i> , 2019, 49, 849-858.	1.2	42

#	ARTICLE	IF	CITATIONS
6075	Cerebral Metabolic Changes Related to Freezing of Gait in Parkinson Disease. <i>Journal of Nuclear Medicine</i> , 2019, 60, 671-676.	2.8	20
6076	DAT gene polymorphisms (rs28363170, rs393795) and levodopa-induced dyskinesias in Parkinson's disease. <i>Neuroscience Letters</i> , 2019, 690, 83-88.	1.0	18
6077	Comparison of three scales to evaluate personality traits in Parkinson's disease: which one to use?. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2019, 55, 183-190.	1.1	0
6078	Predictive clinical factors for penetration and aspiration in Parkinson's disease. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13524.	1.6	34
6079	Multimodal magnetic resonance imaging investigation of basal forebrain damage and cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 516-525.	2.2	42
6080	Determinants of Dual-Task Training Effect Size in Parkinson Disease: Who Will Benefit Most?. <i>Journal of Neurologic Physical Therapy</i> , 2019, 43, 3-11.	0.7	33
6081	Defining Palliative Care Needs in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 125-131.	0.8	38
6082	High-intensity interval training in people with Parkinson's disease: a randomized, controlled feasibility trial. <i>Clinical Rehabilitation</i> , 2019, 33, 428-438.	1.0	29
6083	A randomized controlled study of whether setting specific goals improves the effectiveness of therapy in people with Parkinson's disease. <i>Clinical Rehabilitation</i> , 2019, 33, 465-472.	1.0	12
6084	Single-Cell Sequencing of iPSC-Dopamine Neurons Reconstructs Disease Progression and Identifies HDAC4 as a Regulator of Parkinson Cell Phenotypes. <i>Cell Stem Cell</i> , 2019, 24, 93-106.e6.	5.2	123
6085	White matter differences between essential tremor and Parkinson disease. <i>Neurology</i> , 2019, 92, e30-e39.	1.5	32
6086	Understanding the role of genetic variability in <i>LRRK2</i> in Indian population. <i>Movement Disorders</i> , 2019, 34, 496-505.	2.2	14
6087	Association between the missense alcohol dehydrogenase rs1229984T variant with the risk for Parkinson's disease in women. <i>Journal of Neurology</i> , 2019, 266, 346-352.	1.8	14
6089	The Role of Neuroinflammation in Neurodegenerative Disorders. , 2019, , 241-267.		7
6090	Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 51-56.	1.1	15
6091	Cognitive decline in Parkinson's disease: the impact of the motor phenotype on cognition. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 171-179.	0.9	54
6092	Promises and Challenges of MSC-Based Therapies: Parkinson Disease and Parkinsonism. , 2019, , 297-320.		0
6093	Laryngopharyngeal motor dysfunction and obstructive sleep apnea in Parkinson's disease. <i>Sleep and Breathing</i> , 2019, 23, 543-550.	0.9	20

#	ARTICLE	IF	CITATIONS
6094	Executive dysfunctions and behavioral changes in early drug-naïve patients with Parkinson's disease. <i>Journal of Affective Disorders</i> , 2019, 243, 525-530.	2.0	5
6095	Predictors of self-perceived stigma in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 76-80.	1.1	29
6096	Pathology and Cell-Based Therapy of Parkinson's Disease. , 2019, , 31-38.		0
6097	The polymorphism of <i>SREBF1</i> gene rs11868035 G/A is associated with susceptibility to Parkinson's disease in a Chinese population. <i>International Journal of Neuroscience</i> , 2019, 129, 660-665.	0.8	5
6098	¹⁸ F-FPEB PET/CT Shows mGluR5 Upregulation in Parkinson's Disease. <i>Journal of Neuroimaging</i> , 2019, 29, 97-103.	1.0	24
6099	Multisystem Balance Training Reduces Injurious Fall Risk in Parkinson Disease. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2019, 98, 239-244.	0.7	12
6100	Use of Herbal Products/Alternative Medicines in Neurodegenerative Diseases (Alzheimer's Disease and) Tj ETQq0 0 0 rgBT ₂ /Overlock		
6101	The Diagnosis of Parkinson's Disease: Current Clinical Practice and Future Trends. , 2019, , 103-116.		1
6102	Dynamic Atlas-Based Segmentation and Quantification of Neuromelanin-Rich Brainstem Structures in Parkinson Disease. <i>IEEE Transactions on Medical Imaging</i> , 2019, 38, 813-823.	5.4	36
6103	PET imaging of [¹¹ C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 367-375.	3.3	50
6104	Cognitive performance in mid-stage Parkinson's disease: functional connectivity under chronic antiparkinson treatment. <i>Brain Imaging and Behavior</i> , 2019, 13, 200-209.	1.1	11
6105	Parkinson's disease with mild cognitive impairment: severe cortical thinning antedates dementia. <i>Brain Imaging and Behavior</i> , 2019, 13, 180-188.	1.1	25
6106	Change in fear of falling in Parkinson's disease: a two-year prospective cohort study. <i>International Psychogeriatrics</i> , 2019, 31, 13-20.	0.6	7
6107	Quantitative susceptibility mapping as a biomarker for evaluating white matter alterations in Parkinson's disease. <i>Brain Imaging and Behavior</i> , 2019, 13, 220-231.	1.1	30
6108	Does transcranial direct current stimulation during writing alleviate upper limb freezing in people with Parkinson's disease? A pilot study. <i>Human Movement Science</i> , 2019, 65, 142-153.	0.6	26
6109	Does dual task walking affect gait symmetry in individuals with Parkinson's disease?. <i>European Journal of Physiotherapy</i> , 2019, 21, 8-14.	0.7	7
6110	Multifocal alterations of white matter accompany the transition from normal cognition to dementia in Parkinson's disease patients. <i>Brain Imaging and Behavior</i> , 2019, 13, 232-240.	1.1	24
6111	KM-34, a Novel Antioxidant Compound, Protects against 6-Hydroxydopamine-Induced Mitochondrial Damage and Neurotoxicity. <i>Neurotoxicity Research</i> , 2019, 36, 279-291.	1.3	8

#	ARTICLE	IF	CITATIONS
6112	The role and profile of the informal carer in meeting the needs of people with advancing Parkinson's disease. <i>Aging and Mental Health</i> , 2019, 23, 337-344.	1.5	29
6113	Efectos de los est�mulos auditivos en la fase de iniciaci3n de la marcha y de giro en pacientes con enfermedad de Parkinson. <i>Neurolog�a</i> , 2019, 34, 396-407.	0.3	5
6114	Rules of Meridians and Acupoints Selection in Treatment of Parkinson's Disease Based on Data Mining Techniques. <i>Chinese Journal of Integrative Medicine</i> , 2020, 26, 624-628.	0.7	13
6115	Dysphonia and Dysarthria in People With Parkinson's Disease After Subthalamic Nucleus Deep Brain Stimulation: Effect of Frequency Modulation. <i>Journal of Voice</i> , 2020, 34, 477-484.	0.6	12
6116	Balance and mobility in patients with newly diagnosed Parkinson�s disease �� a five-year follow-up of a cohort in northern Sweden. <i>Disability and Rehabilitation</i> , 2020, 42, 770-778.	0.9	11
6117	Assessment of cognitive�driven activity of daily living impairment in non�demented Parkinson's patients. <i>Journal of Neuropsychology</i> , 2020, 14, 69-84.	0.6	17
6118	Common and specific altered amplitude of low-frequency fluctuations in Parkinson�s disease patients with and without freezing of gait in different frequency bands. <i>Brain Imaging and Behavior</i> , 2020, 14, 857-868.	1.1	18
6119	Active information storage in Parkinson�s disease: a resting state fMRI study over the sensorimotor cortex. <i>Brain Imaging and Behavior</i> , 2020, 14, 1143-1153.	1.1	4
6120	Cognitive-Behavioral Therapy for Anxiety in Parkinson�s Disease. <i>Behavior Modification</i> , 2020, 44, 552-579.	1.1	39
6121	Assessment of Motor Impairments in Early Untreated Parkinson's Disease Patients: The Wearable Electronics Impact. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2020, 24, 120-130.	3.9	45
6122	Nocturnal blood pressure changes in Parkinson�s disease: correlation with autonomic dysfunction and vitamin D levels. <i>Acta Neurologica Belgica</i> , 2020, 120, 915-920.	0.5	11
6123	Cognitive profiles and optimal cut�offs for routine cognitive tests in elderly individuals with Parkinson's disease, Parkinson's disease dementia, Alzheimer's disease, and normal cognition. <i>Psychogeriatrics</i> , 2020, 20, 20-27.	0.6	4
6124	A Survey of Application of Complementary and Alternative Medicine in Chinese Patients with Parkinson�s Disease: A Pilot Study. <i>Chinese Journal of Integrative Medicine</i> , 2020, 26, 168-173.	0.7	11
6125	Determining a Short Form Montreal Cognitive Assessment (s-MoCA) Czech Version: Validity in Mild Cognitive Impairment Parkinson�s Disease and Cross-Cultural Comparison. <i>Assessment</i> , 2020, 27, 1960-1970.	1.9	16
6126	Speeding Up Gait in Parkinson�s Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 245-253.	1.5	21
6127	Risk for later rapid eye movement sleep behavior disorder in Parkinson�s disease: a 6-year prospective study. <i>International Journal of Neuroscience</i> , 2020, 130, 237-242.	0.8	2
6128	Sleep parameters associated with long-term outcome following subthalamic deep brain stimulation in Parkinson's disease. <i>Revue Neurologique</i> , 2020, 176, 277-284.	0.6	5
6129	Retention of touchscreen skills is compromised in Parkinson�s disease. <i>Behavioural Brain Research</i> , 2020, 378, 112265.	1.2	8

#	ARTICLE	IF	CITATIONS
6130	Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 483-498.	2.8	30
6131	Quantitative associations between objective sleep measures and early-morning mobility in Parkinson's disease: cross-sectional analysis of the PHASE study. <i>Sleep</i> , 2020, 43, .	0.6	10
6132	Evolution of impulsive-compulsive behaviors and cognition in Parkinson's disease. <i>Journal of Neurology</i> , 2020, 267, 259-266.	1.8	5
6133	The interactions of dopamine and oxidative damage in the striatum of patients with neurodegenerative diseases. <i>Journal of Neurochemistry</i> , 2020, 152, 235-251.	2.1	17
6134	Prevalence of Obsessive-Compulsive Symptoms in Elderly Parkinson Disease Patients: A Case-Control Study. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 167-175.	0.6	9
6135	Melatonin and Parkinson Disease: Current Status and Future Perspectives for Molecular Mechanisms. <i>Cellular and Molecular Neurobiology</i> , 2020, 40, 15-23.	1.7	44
6136	Difficulties in activities of daily living are associated with stigma in patients with Parkinson's disease who are candidates for deep brain stimulation. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 190-194.	0.9	13
6137	Neurofilament Light Chain as a Biomarker, and Correlation with Magnetic Resonance Imaging in Diagnosis of CNS-Related Disorders. <i>Molecular Neurobiology</i> , 2020, 57, 469-491.	1.9	50
6138	Minimal Detectable Change for Balance Using the Biodex Balance System in Patients with Parkinson Disease. <i>PM and R</i> , 2020, 12, 281-287.	0.9	4
6139	On the specificity of bilingual language control: A study with Parkinson's disease patients. <i>Bilingualism</i> , 2020, 23, 570-578.	1.0	9
6140	The Mini-BESTest is an independent predictor of falls in Parkinson Disease. <i>Brazilian Journal of Physical Therapy</i> , 2020, 24, 433-440.	1.1	14
6141	Utility of the D-KEFS Color Word Interference Test as an embedded measure of performance validity. <i>Clinical Neuropsychologist</i> , 2020, 34, 332-352.	1.5	22
6142	Functional Motor Symptoms in Parkinson's Disease and Functional Parkinsonism: A Systematic Review. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020, 32, 4-13.	0.9	37
6143	Occupational exposure to chronic ionizing radiation increases risk of Parkinson's disease incidence in Russian Mayak workers. <i>International Journal of Epidemiology</i> , 2020, 49, 435-447.	0.9	48
6144	Risk of Parkinson's disease after colectomy: longitudinal follow-up study using a national sample cohort. <i>Journal of Neurology</i> , 2020, 267, 513-521.	1.8	3
6145	Objective sleep measures between patients with Parkinson's disease and community-based older adults. <i>Sleep Medicine</i> , 2020, 68, 110-114.	0.8	6
6146	Inflammasome and α -synuclein in Parkinson's disease: A cross-sectional study. <i>Journal of Neuroimmunology</i> , 2020, 338, 577089.	1.1	76
6147	Asymmetry of Periodic Leg Movements in Sleep (PLMS) in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 255-266.	1.5	6

#	ARTICLE	IF	CITATIONS
6148	Parkinson's Disease: <i>Glucocerebrosidase 1</i> Mutation Severity Is Associated with CSF Alpha-Synuclein Profiles. <i>Movement Disorders</i> , 2020, 35, 495-499.	2.2	32
6149	Association of genetic variants within HLA-DR region with Parkinson's disease in Taiwan. <i>Neurobiology of Aging</i> , 2020, 87, 140.e13-140.e18.	1.5	7
6150	Asymmetric dynamic center-of-pressure in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2020, 408, 116559.	0.3	15
6151	Cholinergic denervation in patients with idiopathic rapid eye movement sleep behaviour disorder. <i>European Journal of Neurology</i> , 2020, 27, 644-652.	1.7	30
6152	Are genetic and idiopathic forms of Parkinson's disease the same disease?. <i>Journal of Neurochemistry</i> , 2020, 152, 515-522.	2.1	28
6153	Genetic, Structural, and Functional Evidence Link <i>TMEM175</i> to Synucleinopathies. <i>Annals of Neurology</i> , 2020, 87, 139-153.	2.8	65
6154	Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson's disease. <i>World Journal of Urology</i> , 2020, 38, 2013-2019.	1.2	16
6155	Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson's disease. <i>Rapid Communications in Mass Spectrometry</i> , 2020, 34, e8595.	0.7	19
6156	Impaired metabolism of kynurenine and its metabolites in CSF of parkinson's disease. <i>Neuroscience Letters</i> , 2020, 714, 134576.	1.0	32
6157	Safety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson's disease: A large single-center study. <i>Revue Neurologique</i> , 2020, 176, 268-276.	0.6	11
6158	The New Freezing of Gait Questionnaire: Unsuitable as an Outcome in Clinical Trials?. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 199-205.	0.8	57
6159	Reliability and validity of the timed 360° turn test in people with Parkinson's disease. <i>European Geriatric Medicine</i> , 2020, 11, 417-426.	1.2	8
6160	Whole-exome sequencing in early-onset Parkinson's disease among ethnic Chinese. <i>Neurobiology of Aging</i> , 2020, 90, 150.e5-150.e11.	1.5	29
6161	Dynamics of impulsive-compulsive behaviors in early Parkinson's disease: a prospective study. <i>Journal of Neurology</i> , 2020, 267, 1127-1136.	1.8	15
6162	High discriminatory ability of peripheral and CSF biomarkers in Lewy body diseases. <i>Journal of Neural Transmission</i> , 2020, 127, 311-322.	1.4	13
6163	Validation of the Freezing of Gait Questionnaire in patients with Parkinson's disease treated with deep brain stimulation. <i>Neurological Sciences</i> , 2020, 41, 1133-1138.	0.9	5
6164	Serum adiponectin levels between patients with Parkinson's disease and those with PSP. <i>Neurological Sciences</i> , 2020, 41, 1125-1131.	0.9	5
6165	Systemic activation of NLRP3 inflammasome and plasma α -synuclein levels are correlated with motor severity and progression in Parkinson's disease. <i>Journal of Neuroinflammation</i> , 2020, 17, 11.	3.1	127

#	ARTICLE	IF	CITATIONS
6166	Multimodal Balance Training Supported by Rhythmical Auditory Stimuli in Parkinson's Disease: A Randomized Clinical Trial. <i>Journal of Parkinson's Disease</i> , 2020, 10, 333-346.	1.5	19
6167	Olfactory dysfunction correlates with putaminal dopamine turnover in early de novo Parkinson's disease. <i>Journal of Neural Transmission</i> , 2020, 127, 9-16.	1.4	8
6168	Differences in cerebellar perfusion between Parkinson's disease and multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2020, 409, 116627.	0.3	6
6169	Differential leukocyte count is associated with clinical phenotype in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2020, 409, 116638.	0.3	28
6170	Functional connectivity markers of depression in advanced Parkinson's disease. <i>NeuroImage: Clinical</i> , 2020, 25, 102130.	1.4	25
6171	The Latent-Variable Structure of the Addenbrooke's Cognitive Examination-Revised. <i>Archives of Clinical Neuropsychology</i> , 2020, 35, 205-212.	0.3	4
6172	Proteinopathy and longitudinal changes in functional connectivity networks in Parkinson disease. <i>Neurology</i> , 2020, 94, e718-e728.	1.5	26
6173	Cognitive correlates of cerebellar resting-state functional connectivity in Parkinson disease. <i>Neurology</i> , 2020, 94, e384-e396.	1.5	30
6174	Apathy rating scores and β -amyloidopathy in patients with Parkinson disease at risk for cognitive decline. <i>Neurology</i> , 2020, 94, e376-e383.	1.5	20
6175	Association of RIT2 and RAB7L1 with Parkinson's disease: a case-control study in a Taiwanese cohort and a meta-analysis in Asian populations. <i>Neurobiology of Aging</i> , 2020, 87, 140.e5-140.e11.	1.5	4
6176	CSF or Serum Neurofilament Light Added to α -Synuclein Panel Discriminates Parkinson's From Controls. <i>Movement Disorders</i> , 2020, 35, 288-295.	2.2	69
6177	Disease severity and quality of life in homebound people with advanced Parkinson disease. <i>Neurology: Clinical Practice</i> , 2020, 10, 277-286.	0.8	18
6178	Longitudinal Change of DAT SPECT in Parkinson's Disease and Multiple System Atrophy. <i>Journal of Parkinson's Disease</i> , 2020, 10, 123-130.	1.5	14
6179	Mild cognitive impairment, psychiatric symptoms, and executive functioning in patients with Parkinson's disease. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 396-404.	1.3	27
6180	Intracranial hemorrhage risk factors of deep brain stimulation for Parkinson's disease: a 2-year follow-up study. <i>Journal of International Medical Research</i> , 2020, 48, 030006051985674.	0.4	14
6181	Determinants of Low Body Mass Index in Patients with Parkinson's Disease: A Multicenter Case-Control Study. <i>Journal of Parkinson's Disease</i> , 2020, 10, 213-221.	1.5	9
6182	LRRK2 and GBA Variants Exert Distinct Influences on Parkinson's Disease-Specific Metabolic Networks. <i>Cerebral Cortex</i> , 2020, 30, 2867-2878.	1.6	35
6183	The Neuropsychological Profile of Mild Cognitive Impairment in Lewy Body Dementias. <i>Journal of the International Neuropsychological Society</i> , 2020, 26, 210-225.	1.2	15

#	ARTICLE	IF	CITATIONS
6184	Quantitative Evaluation of Iron Content in Idiopathic Rapid Eye Movement Sleep Behavior Disorder. <i>Movement Disorders</i> , 2020, 35, 478-485.	2.2	43
6185	Little Change in Functional Brain Networks Following Acute Levodopa in Drug-Naïve Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 499-503.	2.2	12
6186	Whole-Transcriptome Analysis of Dermal Fibroblasts, Derived from Three Pairs of Monozygotic Twins, Discordant for Parkinson's Disease. <i>Journal of Molecular Neuroscience</i> , 2020, 70, 284-293.	1.1	6
6187	Obstructive sleep apnea in Parkinson's disease: a study in 239 Chinese patients. <i>Sleep Medicine</i> , 2020, 67, 237-243.	0.8	20
6188	Gait bradykinesia: difficulty in switching posture/gait measured by the anatomical y-axis vector of the sole in Parkinson's disease. <i>Experimental Brain Research</i> , 2020, 238, 139-151.	0.7	2
6189	Assessment of Cognitive-Driven Performance-Based Activities of Daily Living Dysfunction in Parkinson's Disease. <i>Journal of the International Neuropsychological Society</i> , 2020, 26, 430-440.	1.2	5
6190	Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Neurology</i> , The, 2020, 19, 135-144.	4.9	80
6191	The effect of repetitive transcranial magnetic stimulation on cognitive impairment in Parkinson's disease with dementia: Pilot study. <i>Restorative Neurology and Neuroscience</i> , 2020, 38, 55-66.	0.4	15
6192	Performance at the clock drawing test of individuals affected by Parkinson's disease and healthy subjects: a retrospective study. <i>Neurological Sciences</i> , 2020, 41, 843-849.	0.9	7
6193	Decline in drawing ability and cerebral perfusion in Parkinson's disease patients after subthalamic nucleus deep brain stimulation surgery. <i>Parkinsonism and Related Disorders</i> , 2020, 70, 60-66.	1.1	9
6194	Diagnostic accuracy of MRI parameters in pure akinesia with gait freezing. <i>Journal of Neurology</i> , 2020, 267, 752-759.	1.8	7
6195	Microstructural abnormalities of substantia nigra in Parkinson's disease: A neuromelanin sensitive MRI atlas based study. <i>Human Brain Mapping</i> , 2020, 41, 1323-1333.	1.9	25
6196	Treatment Responsiveness of Motor Features in Parkinson's Disease: A Matched Case-Control Analysis. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 45-51.	0.8	2
6197	Cerebellar continuous theta burst stimulation reduces levodopa-induced dyskinesias and decreases serum BDNF levels. <i>Neuroscience Letters</i> , 2020, 716, 134653.	1.0	20
6198	Clinical Evaluation of Sibling Pairs With Gaucher Disease Discordant for Parkinsonism. <i>Movement Disorders</i> , 2020, 35, 359-365.	2.2	10
6199	Parkinson's Disease Multimodal Complex Treatment improves motor symptoms, depression and quality of life. <i>Journal of Neurology</i> , 2020, 267, 954-965.	1.8	23
6200	Obstructive sleep apnea, CPAP therapy and Parkinson's disease motor function: A longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2020, 70, 45-50.	1.1	35
6201	Altered Granger causality connectivity within motor-related regions of patients with Parkinson's disease: a resting-state fMRI study. <i>Neuroradiology</i> , 2020, 62, 63-69.	1.1	14

#	ARTICLE	IF	CITATIONS
6202	The Effects of Music-Contingent Gait Training on Cognition and Mood in Parkinson Disease: A Feasibility Study. <i>Neurorehabilitation and Neural Repair</i> , 2020, 34, 82-92.	1.4	17
6203	Psychiatric Patients on Neuroleptics: Evaluation of Parkinsonism and Quantified Assessment of Gait. <i>Clinical Neuropharmacology</i> , 2020, 43, 1-6.	0.2	8
6204	Neural Correlates of Cognitive Performance in Alzheimer's Disease- and Lewy Bodies-Related Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 873-885.	1.2	4
6205	Senescence and Inflammatory Markers for Predicting Clinical Progression in Parkinson's Disease: The ICICLE-PD Study. <i>Journal of Parkinson's Disease</i> , 2020, 10, 193-206.	1.5	34
6206	Integrated Plasma and Neuroimaging Biomarkers Associated with Motor and Cognition Severity in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 77-88.	1.5	20
6207	Lentiform Nucleus Hyperechogenicity in Parkinsonian Syndromes: A Systematic Review and Meta-Analysis with Consideration of Molecular Pathology. <i>Cells</i> , 2020, 9, 2.	1.8	15
6208	Brain Mitochondrial Impairment in Early-Onset Parkinson's Disease With or Without <i>PINK1</i> Mutation. <i>Movement Disorders</i> , 2020, 35, 504-507.	2.2	21
6209	The neutrophil-to-lymphocyte ratio as a marker of peripheral inflammation in progressive supranuclear palsy: a retrospective study. <i>Neurological Sciences</i> , 2020, 41, 1233-1237.	0.9	14
6210	New markers in Parkinson's disease. <i>Advances in Clinical Chemistry</i> , 2020, 96, 137-178.	1.8	16
6211	Combination of optical coherence tomography (OCT) and OCT angiography increases diagnostic efficacy of Parkinson's disease. <i>Quantitative Imaging in Medicine and Surgery</i> , 2020, 10, 1930-1939.	1.1	27
6212	Responsiveness of Objective vs. Clinical Balance Domain Outcomes for Exercise Intervention in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 940.	1.1	19
6213	Differential Diagnosis of Multiple System Atrophy-Parkinsonism and Parkinson's Disease Using \pm -Synuclein and External Anal Sphincter Electromyography. <i>Frontiers in Neurology</i> , 2020, 11, 1043.	1.1	10
6214	Detection of Phosphorylated Alpha-Synuclein in the Muscularis Propria of the Gastrointestinal Tract Is a Sensitive Predictor for Parkinson's Disease. <i>Parkinson's Disease</i> , 2020, 2020, 1-8.	0.6	5
6215	N-terminal Pro-B-type Natriuretic Peptide Levels in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1886-1887.	2.2	2
6216	GraphNet-based imaging biomarker model to explain levodopa-induced dyskinesia in Parkinson's disease. <i>Computer Methods and Programs in Biomedicine</i> , 2020, 196, 105713.	2.6	1
6217	Theta and gamma connectivity is linked with affective and cognitive symptoms in Parkinson's disease. <i>Journal of Affective Disorders</i> , 2020, 277, 875-884.	2.0	11
6218	Cortical thinning pattern according to differential nigrosome involvement in patients with Parkinson's disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102382.	1.4	2
6219	Multimodal assessment of nigrosomal degeneration in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 102-107.	1.1	13

#	ARTICLE	IF	CITATIONS
6220	Serum TNF- α and neurodegeneration in isolated REM sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 1-7.	1.1	7
6221	A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 69-74.	1.1	15
6222	Classic and evolving animal models in Parkinson's disease. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 199, 173060.	1.3	19
6223	NREM sleep arousal-related disorders reflect cognitive impairment in Parkinson's disease. <i>Sleep Medicine</i> , 2020, 75, 491-496.	0.8	7
6224	Characterization of the intestinal microbiota during <i>Citrobacter rodentium</i> infection in a mouse model of infection-triggered Parkinson's disease. <i>Gut Microbes</i> , 2020, 12, 1830694.	4.3	14
6225	Dysautonomia Is Linked to Striatal Dopamine Deficits and Regional Cerebral Perfusion in Early Parkinson Disease. <i>Clinical Nuclear Medicine</i> , 2020, 45, e342-e348.	0.7	10
6226	Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson's disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study. <i>BMJ Open</i> , 2020, 10, e038911.	0.8	18
6227	Retinal Thickness and Microvascular Pattern in Early Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 533375.	1.1	26
6228	Diagnostic Ability of Radiofrequency Ultrasound in Parkinson's Disease Compared to Conventional Transcranial Sonography and Magnetic Resonance Imaging. <i>Diagnostics</i> , 2020, 10, 778.	1.3	0
6229	Visual hallucinations and inferior longitudinal fasciculus in Parkinson's disease. <i>Brain and Behavior</i> , 2020, 10, e01883.	1.0	8
6230	Radiocirugía estereotáctica con Gamma Knife® como tratamiento del temblor esencial y parkinsoniano: experiencia a largo plazo. <i>Neurología</i> , 2023, 38, 188-196.	0.3	3
6231	Determinants of Quality of Life According to Cognitive Status in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 269.	1.7	14
6232	Increased iron-deposition in lateral-ventral substantia nigra pars compacta: A promising neuroimaging marker for Parkinson's disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102391.	1.4	23
6233	Subthalamic deep brain stimulation identifies frontal networks supporting initiation, inhibition and strategy use in Parkinson's disease. <i>NeuroImage</i> , 2020, 223, 117352.	2.1	6
6234	The Impact of Amyloid-Beta Positivity with 18F-Florbetaben PET on Neuropsychological Aspects in Parkinson's Disease Dementia. <i>Metabolites</i> , 2020, 10, 380.	1.3	9
6235	A time-efficient screening tool for activities of daily living functions in Parkinson's disease dementia. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2020, 42, 867-879.	0.8	3
6236	Anti-Gravity Treadmill Training for Freezing of Gait in Parkinson's Disease. <i>Brain Sciences</i> , 2020, 10, 739.	1.1	5
6237	Immersive Virtual Reality to Restore Natural Long-Range Autocorrelations in Parkinson's Disease Patients' Gait During Treadmill Walking. <i>Frontiers in Physiology</i> , 2020, 11, 572063.	1.3	19

#	ARTICLE	IF	CITATIONS
6238	Boxing to Improve Sleep Quality and Daytime Sleepiness in Individuals With Parkinson Disease. <i>Topics in Geriatric Rehabilitation</i> , 2020, 36, 170-175.	0.2	3
6239	Dopamine effects on memory load and distraction during visuospatial working memory in cognitively normal Parkinson's disease. <i>Aging, Neuropsychology, and Cognition</i> , 2021, 28, 812-828.	0.7	3
6240	Contribution of functional dopamine D2 and D3 receptor variants to motor and non-motor symptoms of early onset Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2020, 199, 106257.	0.6	4
6241	Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1429-1442.	1.5	4
6242	Differential patterns of internally generated responses in parkinsonian disorders. <i>Neuropsychologia</i> , 2020, 146, 107569.	0.7	5
6243	Effectiveness of expiratory flow acceleration in patients with Parkinson's disease and swallowing deficiency: A preliminary study. <i>Clinical Neurology and Neurosurgery</i> , 2020, 199, 106249.	0.6	2
6244	Variability of Voluntary Cough Airflow in Healthy Adults and Parkinson's Disease. <i>Dysphagia</i> , 2020, 36, 700-706.	1.0	10
6245	Different patterns of short-term memory deficit in Alzheimer's disease, Parkinson's disease and subjective cognitive impairment. <i>Cortex</i> , 2020, 132, 41-50.	1.1	13
6246	Quantification of tremor severity with a mobile tremor pen. <i>Heliyon</i> , 2020, 6, e04702.	1.4	13
6247	Brain networks associated with anticipatory postural adjustments in Parkinson's disease patients with freezing of gait. <i>NeuroImage: Clinical</i> , 2020, 28, 102461.	1.4	10
6248	From discourse to pathology: Automatic identification of Parkinson's disease patients via morphological measures across three languages. <i>Cortex</i> , 2020, 132, 191-205.	1.1	24
6249	Neuroprotective potential of <i>Myrica esulenta</i> in Haloperidol induced Parkinson's disease. <i>Journal of Ayurveda and Integrative Medicine</i> , 2020, 11, 448-454.	0.9	11
6250	Movement disorders induced by psychiatric drugs that do not block dopamine receptors. <i>Parkinsonism and Related Disorders</i> , 2020, 79, 60-64.	1.1	20
6251	Tablet app-based dexterity-training in patients with Parkinson's disease: Pilot feasibility study. <i>Annals of Physical and Rehabilitation Medicine</i> , 2021, 64, 101419.	1.1	3
6252	Melatonin secretion in patients with Parkinson's disease receiving different-dose levodopa therapy. <i>Sleep Medicine</i> , 2020, 75, 309-314.	0.8	5
6253	Laterality of specific binding ratios on DAT-SPECT for differential diagnosis of degenerative parkinsonian syndromes. <i>Scientific Reports</i> , 2020, 10, 15761.	1.6	21
6254	Working memory training increases neural efficiency in Parkinson's disease: a randomized controlled trial. <i>Brain Communications</i> , 2020, 2, fcaa115.	1.5	5
6255	Lower Energy Intake among Advanced vs. Early Parkinson's Disease Patients and Healthy Controls in a Clinical Lunch Setting: A Cross-Sectional Study. <i>Nutrients</i> , 2020, 12, 2109.	1.7	8

#	ARTICLE	IF	CITATIONS
6256	Restâ€Activity Pattern Alterations in Idiopathic REM Sleep Behavior Disorder. <i>Annals of Neurology</i> , 2020, 88, 817-829.	2.8	19
6257	Quantitative assessment of posture in healthy controls and patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 76, 85-90.	1.1	18
6258	Value of Clinical Signs in Identifying Patients with Scans without Evidence of Dopaminergic Deficit (SWEDD). <i>Journal of Parkinson's Disease</i> , 2020, 10, 1561-1569.	1.5	4
6259	Role of Helicobacters in Neuropsychiatric Disease: A Systematic Review in Idiopathic Parkinsonism. <i>Journal of Clinical Medicine</i> , 2020, 9, 2159.	1.0	7
6260	Mutation Analysis of <sc><i>DNAJC</i></sc> Family for <sc>Earlyâ€Onset</sc> Parkinson's Disease in a Chinese Cohort. <i>Movement Disorders</i> , 2020, 35, 2068-2076.	2.2	21
6261	The effect of aging, Parkinson's disease, and exogenous dopamine on the neural response associated with auditory regularity processing. <i>Neurobiology of Aging</i> , 2020, 89, 71-82.	1.5	13
6262	Evaluating the Role of <sc><i>SNCA</i></sc>, <sc><i>LRRK2</i></sc>, and <sc><i>GBA</i></sc> in Chinese Patients With <sc>Earlyâ€Onset</sc> Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 2046-2055.	2.2	30
6263	Alterations of regional homogeneity in Parkinson's disease with â€pureâ€ apathy: A resting-state fMRI study. <i>Journal of Affective Disorders</i> , 2020, 274, 792-798.	2.0	14
6264	The Relationship between Side of Onset and Cerebral Regional Homogeneity in Parkinsonâ€™s Disease: A Resting-State fMRI Study. <i>Parkinson's Disease</i> , 2020, 2020, 1-8.	0.6	5
6265	Shared functional neural substrates in Parkinson's disease and drug-induced parkinsonism: association with dopaminergic depletion. <i>Scientific Reports</i> , 2020, 10, 11617.	1.6	5
6266	Changes of plasma cGP/IGFâ€1 molar ratio with age is associated with cognitive status of Parkinson disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12025.	1.2	5
6267	Identifying delirium in Parkinson disease: A pilot study. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 547-552.	1.3	14
6268	Aberrant Fiber Coherence of Amygdalaâ€Accumbensâ€Pallidum Pathway Is Associated With Disorganized Nigrostriatalâ€Nigropallidal Pathway in Parkinson's Disease. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 1799-1808.	1.9	9
6269	Glycopyrrolate Improves Disability From Sialorrhea in Parkinson's Disease: A <sc>12â€Week</sc> Controlled Trial. <i>Movement Disorders</i> , 2020, 35, 2319-2323.	2.2	10
6270	The cerebral blood flow deficits in Parkinsonâ€™s disease with mild cognitive impairment using arterial spin labeling MRI. <i>Journal of Neural Transmission</i> , 2020, 127, 1285-1294.	1.4	16
6271	High-Intensity Interval Cycle Ergometer Training in Parkinson's Disease: Protocol for Identifying Individual Response Patterns Using a Single-Subject Research Design. <i>Frontiers in Neurology</i> , 2020, 11, 569880.	1.1	4
6272	CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinsonâ€™s Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8519.	1.8	7
6273	High delta and gamma EEG power in resting state characterise dementia in Parkinsonâ€™s patients. <i>Biomarkers in Neuropsychiatry</i> , 2020, 3, 100027.	0.7	9

#	ARTICLE	IF	CITATIONS
6274	Dysfunction in superior frontal gyrus associated with diphasic dyskinesia in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2020, 6, 30.	2.5	12
6275	Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal fluid beta-amyloid levels in Parkinson disease. <i>Acta Neuropathologica Communications</i> , 2020, 8, 196.	2.4	8
6276	Corneal confocal microscopy detects small fibre neurodegeneration in Parkinson's disease using automated analysis. <i>Scientific Reports</i> , 2020, 10, 20147.	1.6	16
6277	Longitudinal Macro/Microstructural Alterations of Different Callosal Subsections in Parkinson's Disease Using Connectivity-Based Parcellation. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 572086.	1.7	6
6278	Association of Hippocampal Subfields, CSF Biomarkers, and Cognition in Patients With Parkinson Disease Without Dementia. <i>Neurology</i> , 2021, 96, e904-e915.	1.5	9
6279	Contributing Factors and Evolution of Impulse Control Disorder in the Luxembourg Parkinson Cohort. <i>Frontiers in Neurology</i> , 2020, 11, 578924.	1.1	1
6280	Distinct Changes in Global Brain Synchronization in Early-Onset vs. Late-Onset Parkinson Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 604995.	1.7	12
6281	Clinical and Epidemiological Aspects of Parkinson's Disease in the South of Western Siberia. <i>Frontiers in Neurology</i> , 2020, 11, 538782.	1.1	1
6282	Neurophthalmologic and Orthoptic Ambulatory Assessments Reveal Ocular and Visual Changes in Patients With Early Alzheimer and Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 577362.	1.1	6
6283	Longitudinal analysis of premotor anthropometric and serological markers of Parkinson's disease. <i>Scientific Reports</i> , 2020, 10, 20524.	1.6	0
6284	Plasma Total α -Synuclein and Neurofilament Light Chain: Clinical Validation for Discriminating Parkinson's Disease from Normal Control. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 401-409.	0.7	11
6285	A distinct neuromelanin magnetic resonance imaging pattern in parkinsonian multiple system atrophy. <i>BMC Neurology</i> , 2020, 20, 432.	0.8	15
6286	Association between freezing of gait and bone mineral density in patients with Parkinson's disease. <i>Neurological Sciences</i> , 2021, 42, 2921-2925.	0.9	5
6287	Histogram Analysis of Quantitative Susceptibility Mapping for the Diagnosis of Parkinson's Disease. <i>Academic Radiology</i> , 2022, 29, S71-S79.	1.3	6
6288	Effects of the agility boot camp with cognitive challenge (ABC-C) exercise program for Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2020, 6, 31.	2.5	25
6289	Invalid Self-Assessment of Olfactory Functioning in Parkinson's Disease Patients May Mislead the Neurologist. <i>Parkinson's Disease</i> , 2020, 2020, 1-5.	0.6	4
6290	Polymorphism of the Dopa-Decarboxylase Gene Modifies the Motor Response to Levodopa in Chinese Patients With Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 520934.	1.1	4
6291	MRI-Based Radiomics of Basal Nuclei in Differentiating Idiopathic Parkinson's Disease From Parkinsonian Variants of Multiple System Atrophy: A Susceptibility-Weighted Imaging Study. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 587250.	1.7	19

#	ARTICLE	IF	CITATIONS
6292	Validity and sensitivity of instrumented postural and gait assessment using low-cost devices in Parkinson's disease. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2020, 17, 149.	2.4	13
6293	Caregiver Burden in Late-Stage Parkinsonism and Its Associations. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2022, 35, 110-120.	1.2	18
6294	Abnormal Spontaneous Neural Activity in Parkinson's Disease With "Pure" Apathy. <i>Frontiers in Neuroscience</i> , 2020, 14, 830.	1.4	7
6295	Unsupervised clustering of dopamine transporter ¹⁸F PET imaging discovers heterogeneity of parkinsonism. <i>Human Brain Mapping</i> , 2020, 41, 4744-4752.	1.9	9
6296	Sexual Dysfunction in Parkinson Disease: A Multicenter Italian Cross-sectional Study on a Still Overlooked Problem. <i>Journal of Sexual Medicine</i> , 2020, 17, 1914-1925.	0.3	24
6297	Double-blind, Randomized, Placebo-controlled Trial of DA-9701 in Parkinson's Disease: PASS-GI Study. <i>Movement Disorders</i> , 2020, 35, 1966-1976.	2.2	7
6298	Suicidal and death ideation in patients with progressive supranuclear palsy and corticobasal syndrome. <i>Journal of Affective Disorders</i> , 2020, 276, 1061-1068.	2.0	8
6299	Primary Central Nervous System Lymphoma Presenting as Parkinsonism with Atypical MRI Findings and Elevated 14-3-3 Protein. <i>Journal of Neurosciences in Rural Practice</i> , 2020, 11, 492-494.	0.3	3
6300	Anterior insular network disconnection and cognitive impairment in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102364.	1.4	20
6301	Immunomodulatory effect and clinical outcome in Parkinson's disease patients on levodopa-pramipexole combo therapy: A two-year prospective study. <i>Journal of Neuroimmunology</i> , 2020, 347, 577328.	1.1	15
6302	Predictors of Time to Discontinuation of Levodopa-Carbidopa Intestinal Gel Infusion: A Retrospective Cohort Study. <i>Journal of Parkinson's Disease</i> , 2020, 10, 935-944.	1.5	8
6303	Motor/Nonmotor Symptoms and Progression in Patients with Parkinson's Disease: Prevalence and Risks in a Longitudinal Study. <i>Parkinson's Disease</i> , 2020, 2020, 1-13.	0.6	8
6304	GLP-1 receptor agonists for Parkinson's disease. <i>The Cochrane Library</i> , 2020, 2020, CD012990.	1.5	24
6305	Hand Resting Tremor Assessment of Healthy and Patients With Parkinson's Disease: An Exploratory Machine Learning Study. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 778.	2.0	19
6306	Structural Covariance Network Disruption and Functional Compensation in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 199.	1.7	13
6307	Exome Sequencing Reveals Signal Transduction Genes Involved in Impulse Control Disorders in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 641.	1.1	3
6308	Genetic and Phenotypic Basis of Autosomal Dominant Parkinson's Disease in a Large Multi-Center Cohort. <i>Frontiers in Neurology</i> , 2020, 11, 682.	1.1	28
6309	Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 2028-2037.	2.2	64

#	ARTICLE	IF	CITATIONS
6310	Fixel-based analysis reveals fiber-specific alterations during the progression of Parkinson's disease. <i>NeuroImage: Clinical</i> , 2020, 27, 102355.	1.4	21
6311	Abnormal Spontaneous Brain Activity in Left-Onset Parkinson Disease: A Resting-State Functional MRI Study. <i>Frontiers in Neurology</i> , 2020, 11, 727.	1.1	5
6312	Effectiveness of 6-Week Nordic Walking Training on Functional Performance, Gait Quality, and Quality of Life in Parkinson's Disease. <i>Medicina (Lithuania)</i> , 2020, 56, 356.	0.8	7
6313	Embarrassment and Shame in People With Parkinson's Disease: A New Tool for Self-Assessment. <i>Frontiers in Neurology</i> , 2020, 11, 779.	1.1	1
6314	The P2X7 Receptor: Central Hub of Brain Diseases. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 124.	1.4	87
6315	Multimodal Balance Training Supported by Rhythmic Auditory Stimuli in Parkinson Disease: Effects in Freezers and Nonfreezers. <i>Physical Therapy</i> , 2020, 100, 2023-2034.	1.1	16
6316	Vascular Inflammation Is a Risk Factor Associated with Brain Atrophy and Disease Severity in Parkinson's Disease: A Case-Control Study. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-12.	1.9	20
6317	GCH1 variants contribute to the risk and earlier age-at-onset of Parkinson's disease: a two-cohort case-control study. <i>Translational Neurodegeneration</i> , 2020, 9, 31.	3.6	30
6318	A Study of the Relationship Between Uric Acid and Substantia Nigra Brain Connectivity in Patients With REM Sleep Behavior Disorder and Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 815.	1.1	18
6319	Parkinsonism in Patients with Neuronopathic (Type 3) Gaucher Disease: A Case Series. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 834-837.	0.8	5
6320	Efficacy and Characteristics of the Stimuli of Action Observation Therapy in Subjects With Parkinson's Disease: A Systematic Review. <i>Frontiers in Neurology</i> , 2020, 11, 808.	1.1	15
6321	Sleep Disturbances and Sleep Disordered Breathing Impair Cognitive Performance in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2020, 14, 689.	1.4	14
6322	Effects of multimodal balance training supported by rhythmical auditory stimuli in people with advanced stages of Parkinson's disease: a pilot randomized clinical trial. <i>Journal of the Neurological Sciences</i> , 2020, 418, 117086.	0.3	13
6323	Intrinsic Auricular Muscle Zone Stimulation Improves Walking Parameters of Parkinson's Patients Faster Than Levodopa in the Motion Capture Analysis: A Pilot Study. <i>Frontiers in Neurology</i> , 2020, 11, 546123.	1.1	6
6324	The diagnostic potential of multimodal neuroimaging measures in Parkinson's disease and atypical parkinsonism. <i>Brain and Behavior</i> , 2020, 10, e01808.	1.0	9
6325	Cognitive Impairment, P300, and Transforming Growth Factor β 21 in Different Forms of Dementia. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 837-845.	1.2	11
6326	Dynamic posturography and posturographic training for Parkinson's disease in a routine clinical setting. <i>Gait and Posture</i> , 2020, 82, 281-286.	0.6	2
6327	STN Versus GPi Deep Brain Stimulation for Action and Rest Tremor in Parkinson's Disease. <i>Frontiers in Human Neuroscience</i> , 2020, 14, 578615.	1.0	22

#	ARTICLE	IF	CITATIONS
6328	The Role of Electrochemical Skin Conductance as a Screening Test of Cardiovascular Autonomic Neuropathy in Patients with Parkinson's Disease. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 7751.	1.2	9
6329	Screening non-MAPT genes of the Chr17q21 H1 haplotype in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 138-144.	1.1	12
6330	Relating Parkinson freezing and balance domains: A structural equation modeling approach. <i>Parkinsonism and Related Disorders</i> , 2020, 79, 73-78.	1.1	15
6331	The changes of exercise pattern and clinical symptoms in patients with Parkinson's disease in the era of COVID-19 pandemic. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 148-151.	1.1	45
6332	Machine learning discriminates a movement disorder in a zebrafish model of Parkinson's disease. <i>DMM Disease Models and Mechanisms</i> , 2020, 13, .	1.2	25
6333	Mapping the Interactive Effects of ApoE Gene Polymorphism on Caudate Functional Connectivity in Mild Cognitive Impairment Associated With Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2020, 14, 857.	1.4	5
6334	<p>Human Adipose Tissue-Derived Mesenchymal Stem Cells in Parkinson's Disease: Inhibition of T Helper 17 Cell Differentiation and Regulation of Immune Balance Towards a Regulatory T Cell Phenotype</p>. <i>Clinical Interventions in Aging</i> , 2020, Volume 15, 1383-1391.	1.3	22
6335	Rare and novel variants of <i>PRKN</i> and <i>PINK1</i> genes in Vietnamese patients with early-onset Parkinson's disease. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1463.	0.6	8
6336	Individual changes in visual performance in non-demented Parkinson's disease patients: a 1-year follow-up study. <i>Journal of Neural Transmission</i> , 2020, 127, 1387-1397.	1.4	3
6337	Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease. <i>Brain</i> , 2020, 143, 2757-2770.	3.7	61
6338	Striatal dopamine transporters and cognitive function in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 385-391.	1.0	3
6339	Predictors of Pharyngeal Dysphagia in Patients with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1727-1735.	1.5	9
6340	Tracking Cortical Changes Throughout Cognitive Decline in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1987-1998.	2.2	39
6341	Striatal asymmetry index and its correlation with the Hoehn & Yahr stage in Parkinson's disease. <i>International Journal of Neuroscience</i> , 2022, 132, 165-170.	0.8	4
6342	Differential Gait Decline in Parkinson's Disease Enhances Discrimination of Gait Freezers from Non-Freezers. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1657-1673.	1.5	7
6343	Sexual Dysfunction in Early-Onset Parkinson's Disease: A Cross-Sectional, Multicenter Study. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1621-1629.	1.5	20
6344	Squalamine Restores the Function of the Enteric Nervous System in Mouse Models of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1477-1491.	1.5	21
6345	Structural Network Analysis Using Diffusion MRI Tractography in Parkinson's Disease and Correlations With Motor Impairment. <i>Frontiers in Neurology</i> , 2020, 11, 841.	1.1	7

#	ARTICLE	IF	CITATIONS
6346	Plasma Exosomal Brain-Derived Neurotrophic Factor Correlated with the Postural Instability and Gait Disturbance-Related Motor Symptoms in Patients with Parkinson's Disease. <i>Diagnostics</i> , 2020, 10, 684.	1.3	17
6347	Vitamin B6 Deficiency in Patients With Parkinson Disease Treated With Levodopa/Carbidopa. <i>Clinical Neuropharmacology</i> , 2020, 43, 151-157.	0.2	19
6348	Exercise Therapies for Parkinson's Disease: A Systematic Review and Meta-Analysis. <i>Parkinson's Disease</i> , 2020, 2020, 1-22.	0.6	22
6349	Classifications of Neurodegenerative Disorders Using a Multiplex Blood Biomarkers-Based Machine Learning Model. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6914.	1.8	28
6350	Using IMU Sensors to Assess Motor Degradation of PD Patients by Modeling In-meal Plate-to-Mouth Movement Elongation. , 2020, 2020, 494-497.		4
6351	Speech task based automatic classification of ALS and Parkinson's Disease and their severity using log Mel spectrograms. , 2020, , .		9
6352	Theoretical and experimental research on the development of an analysis system of the hand tremor movement for patients with Parkinson's disease. <i>IOP Conference Series: Materials Science and Engineering</i> , 2020, 898, 012030.	0.3	0
6353	Writing errors in primary progressive aphasia. <i>Applied Neuropsychology Adult</i> , 2020, , 1-8.	0.7	0
6354	Comparisons of cardiovascular dysautonomia and cognitive impairment between de novo Parkinson's disease and de novo dementia with Lewy bodies. <i>BMC Neurology</i> , 2020, 20, 350.	0.8	19
6355	The Effect of a Secondary Task on Kinematics during Turning in Parkinson's Disease with Mild to Moderate Impairment. <i>Symmetry</i> , 2020, 12, 1284.	1.1	2
6356	The Effect of Conduction Exercise and Self-Acupressure in Treatment of Parkinson's Disease: A Pilot Study. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-9.	0.5	5
6357	Microglia Implicated in Tauopathy in the Striatum of Neurodegenerative Disease Patients from Genotype to Phenotype. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6047.	1.8	8
6358	Cerebrospinal fluid and blood levels of neurofilament light chain in Parkinson disease. <i>Medicine (United States)</i> , 2020, 99, e21458.	0.4	3
6359	Attentional Resource Associated With Visual Feedback on a Postural Dual Task in Parkinson's Disease. <i>Neurorehabilitation and Neural Repair</i> , 2020, 34, 891-903.	1.4	2
6360	Reliability, validity, and diagnostic accuracy of Parkinson's Disease-Cognitive Rating Scale in Iranian patients with idiopathic Parkinson's disease. <i>Disability and Rehabilitation</i> , 2022, 44, 2091-2098.	0.9	4
6361	Protein synthesis is suppressed in sporadic and familial Parkinson's disease by LRRK2. <i>FASEB Journal</i> , 2020, 34, 14217-14233.	0.2	17
6362	Motor Cerebellar Connectivity and Future Development of Freezing of Gait in De Novo Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 2240-2249.	2.2	17
6363	Decreased plasma α -synuclein in idiopathic Parkinson's disease patients after adjusting hemolysis factor. <i>Molecular and Cellular Toxicology</i> , 2020, 16, 477-484.	0.8	6

#	ARTICLE	IF	CITATIONS
6364	Jewels in the crown: a century of achievement for the Journal of Neurology, Neurosurgery & Psychiatry. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1-2.	0.9	5
6365	The Clinical Non-Motor Connectome in Early Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1797-1806.	1.5	3
6366	Does gender differences have a role in determining sleep quality in Parkinson's disease?. <i>Acta Neurologica Belgica</i> , 2021, 121, 1001-1007.	0.5	6
6367	Clinical Relevance of Standardized Mobile Gait Tests. Reliability Analysis Between Gait Recordings at Hospital and Home in Parkinson's Disease: A Pilot Study. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1763-1773.	1.5	18
6368	Pathophysiology of Swallowing Dysfunction in Parkinson Disease and Lack of Dopaminergic Impact on the Swallow Function and on the Effect of Thickening Agents. <i>Brain Sciences</i> , 2020, 10, 609.	1.1	16
6369	Cohort profile: the Oxford Parkinson's Disease Centre Discovery Cohort MRI substudy (OPDC-MRI). <i>BMJ Open</i> , 2020, 10, e034110.	0.8	11
6370	Immune profiling of plasma-derived extracellular vesicles identifies Parkinson disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	45
6371	Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson's Disease Patients and Is Present within Lewy Bodies. <i>Biomolecules</i> , 2020, 10, 1177.	1.8	14
6372	Does the Response to Morning Medication Predict the ADL-Level of the Day in Parkinson's Disease? <i>Parkinson's Disease</i> , 2020, 2020, 1-8.	0.6	7
6373	Can Samba and Forró Brazilian rhythmic dance be more effective than walking in improving functional mobility and spatiotemporal gait parameters in patients with Parkinson's disease?. <i>BMC Neurology</i> , 2020, 20, 305.	0.8	17
6374	Multicenter Validation of Metabolic Abnormalities Related to <sc>PSP</sc> According to the <sc>MDSâ€PSP</sc> Criteria. <i>Movement Disorders</i> , 2020, 35, 2009-2018.	2.2	18
6375	ATP13A2 Gene Variants in Patients with Parkinson's Disease in Xinjiang. <i>BioMed Research International</i> , 2020, 2020, 1-5.	0.9	2
6376	Classifying Parkinson's Disease Patients With Syntactic and Socio-emotional Verbal Measures. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 586233.	1.7	9
6377	Single Nucleotide Polymorphisms Associated With Gut Homeostasis Influence Risk and Age-at-Onset of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 603849.	1.7	16
6379	Neurofilament light chain level in plasma extracellular vesicles and Parkinson's disease. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642097591.	1.5	20
6380	Altered Insulin Receptor Substrate 1 Phosphorylation in Blood Neuron-Derived Extracellular Vesicles From Patients With Parkinson's Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 564641.	1.8	16
6381	Topological Abnormalities of Functional Brain Network in Early-Stage Parkinson's Disease Patients With Mild Cognitive Impairment. <i>Frontiers in Neuroscience</i> , 2020, 14, 616872.	1.4	11
6382	Screening Patients with Early Stage Parkinson's Disease Using a Machine Learning Technique: Measuring the Amount of Iron in the Basal Ganglia. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 8732.	1.3	0

#	ARTICLE	IF	CITATIONS
6383	Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson's Disease. <i>New England Journal of Medicine</i> , 2020, 383, 2501-2513.	13.9	111
6384	Quantification of Blood Caffeine Levels in Patients With Parkinson's Disease and Multiple System Atrophy by Caffeine ELISA. <i>Frontiers in Neurology</i> , 2020, 11, 580127.	1.1	7
6385	Influence of Autocorrelated Rhythmic Auditory Stimulations on Parkinson's Disease Gait Variability: Comparison With Other Auditory Rhythm Variabilities and Perspectives. <i>Frontiers in Physiology</i> , 2020, 11, 601721.	1.3	4
6386	Cardioselective peripheral noradrenergic deficiency in Lewy body synucleinopathies. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2450-2460.	1.7	16
6387	Mild and marked executive dysfunction and falls in people with Parkinson's disease. <i>Brazilian Journal of Physical Therapy</i> , 2021, 25, 437-443.	1.1	11
6388	Ten-Year Relative Survival From the Diagnosis of Parkinson's Disease: A Nationwide Database Study. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 1757-1761.	1.2	2
6389	Amyloid-beta uptake by blood monocytes is reduced with ageing and Alzheimer's disease. <i>Translational Psychiatry</i> , 2020, 10, 423.	2.4	35
6390	Association between positive history of essential tremor and disease progression in patients with Parkinson's disease. <i>Scientific Reports</i> , 2020, 10, 21749.	1.6	6
6391	Rare VPS35 A320V Variant in Taiwanese Parkinson's Disease Indicates Disrupted CI-MPR Sorting and Impaired Mitochondrial Morphology. <i>Brain Sciences</i> , 2020, 10, 783.	1.1	3
6392	Patients with Parkinson's Disease Show Alteration in their Visuospatial Abilities and in their Egocentric and Allocentric Spatial Orientation Measured by Card Placing Tests. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1807-1816.	1.5	7
6393	Objective measurement of limb bradykinesia using a marker-less tracking algorithm with 2D-video in PD patients. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 129-135.	1.1	11
6394	Corticospinal Tract Impairment of Patients With Parkinson's Disease: Triple Stimulation Technique Findings. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 588085.	1.7	5
6395	Iron deposition in Parkinsonisms: A Quantitative Susceptibility Mapping study in the deep grey matter. <i>European Journal of Radiology</i> , 2020, 133, 109394.	1.2	15
6396	People With Parkinson's Disease Exhibit Reduced Cognitive and Motor Cortical Activity When Undertaking Complex Stepping Tasks Requiring Inhibitory Control. <i>Neurorehabilitation and Neural Repair</i> , 2020, 34, 1088-1098.	1.4	21
6397	Association Between REM Sleep Behavior Disorder and Cognitive Dysfunctions in Parkinson's Disease: A Systematic Review and Meta-Analysis of Observational Studies. <i>Frontiers in Neurology</i> , 2020, 11, 577874.	1.1	10
6398	Elevated Serum Ceruloplasmin Levels Are Associated with Higher Impulsivity in People with Parkinson's Disease. <i>Parkinson's Disease</i> , 2020, 2020, 1-7.	0.6	2
6399	Forced exercise activates the Nrf2 pathway in the striatum and ameliorates motor and behavioral manifestations of Parkinson's disease in rotenone-treated rats. <i>Behavioral and Brain Functions</i> , 2020, 16, 9.	1.4	9
6400	Swallowing Assessment in Parkinson's Disease: Patient and Investigator Reported Outcome Measures are not Aligned. <i>Dysphagia</i> , 2021, 36, 864-874.	1.0	4

#	ARTICLE	IF	CITATIONS
6401	More Sensitive Identification for Bradykinesia Compared to Tremors in Parkinson's Disease Based on Parkinson's KinetiGraph (PKG). <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 594701.	1.7	14
6402	Rationale and Design of the PAIRED Trial: Partnered Dance Aerobic Exercise as a Neuroprotective, Motor, and Cognitive Intervention in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 943.	1.1	8
6403	The impact of distinct cognitive dual-tasks on gait in Parkinson's disease and the associations with the clinical features of Parkinson's disease. <i>Neurological Sciences</i> , 2021, 42, 2775-2783.	0.9	9
6404	Dementia with Lewy bodies and Parkinson disease dementia. <i>Neurology</i> , 2020, 94, 858-859.	1.5	4
6405	Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, e2076-e2087.	1.5	42
6406	Peripheral neuropathy in Parkinson's disease. <i>Neurological Sciences</i> , 2020, 41, 2691-2701.	0.9	26
6407	An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts. <i>Journal of Parkinson's Disease</i> , 2020, 10, 623-629.	1.5	36
6408	Trunk Range of Motion Is Related to Axial Rigidity, Functional Mobility and Quality of Life in Parkinson's Disease: An Exploratory Study. <i>Sensors</i> , 2020, 20, 2482.	2.1	18
6409	Longitudinal medication profile and cost savings in Parkinson's disease patients after bilateral subthalamic nucleus deep brain stimulation. <i>Journal of Neurology</i> , 2020, 267, 2443-2454.	1.8	5
6410	A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease: results at the 36-month follow-up. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 687-694.	0.9	36
6411	Olfaction in LRRK2 Linked Parkinson's Disease: Is It Different from Idiopathic Parkinson's Disease?. <i>Journal of Parkinson's Disease</i> , 2020, 10, 951-958.	1.5	7
6412	Melatonin supplementation and the effects on clinical and metabolic status in Parkinson's disease: A randomized, double-blind, placebo-controlled trial. <i>Clinical Neurology and Neurosurgery</i> , 2020, 195, 105878.	0.6	43
6413	Staging of cognitive impairment in Parkinson's disease: validity of Quick Dementia Rating System. <i>Disability and Rehabilitation</i> , 2022, 44, 44-51.	0.9	7
6414	Is There a Difference in Autonomic Dysfunction Between Multiple System Atrophy Subtypes?. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 405-412.	0.8	8
6415	Levodopa infusion in Parkinson's disease: Individual quality of life. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 248-254.	1.0	4
6416	Sharing our story individualized and triadic nurse meetings support couples adjustment to living with deep brain stimulation for Parkinson's disease. <i>International Journal of Qualitative Studies on Health and Well-being</i> , 2020, 15, 1748361.	0.6	6
6417	Development of a novel method for the quantification of tyrosine 39 phosphorylated α - and β -synuclein in human cerebrospinal fluid. <i>Clinical Proteomics</i> , 2020, 17, 13.	1.1	10
6418	Nonmotor Symptoms Affect Sleep Quality in Early-Stage Parkinson's Disease Patients With or Without Cognitive Dysfunction. <i>Frontiers in Neurology</i> , 2020, 11, 292.	1.1	9

#	ARTICLE	IF	CITATIONS
6419	Entropy of Real-World Gait in Parkinson's Disease Determined from Wearable Sensors as a Digital Marker of Altered Ambulatory Behavior. <i>Sensors</i> , 2020, 20, 2631.	2.1	23
6420	Motor Dysfunction as a Prodrome of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1067-1073.	1.5	6
6421	Psychosocial Adjustment of In-Home Caregivers of Family Members with Dementia and Parkinson's Disease: A Comparative Study. <i>Parkinson's Disease</i> , 2020, 2020, 1-10.	0.6	3
6422	Wearable haptic anklets for gait and freezing improvement in Parkinson's disease: a proof-of-concept study. <i>Neurological Sciences</i> , 2020, 41, 3643-3651.	0.9	12
6424	Plasma Levels of α -Synuclein, $\text{A}\beta$ -40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 112.	1.7	30
6425	EEG Slowing and Axial Motor Impairment Are Independent Predictors of Cognitive Worsening in a Three-Year Cohort of Patients With Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 171.	1.7	1
6426	Application of Machine Learning Technique to Distinguish Parkinson's Disease Dementia and Alzheimer's Dementia: Predictive Power of Parkinson's Disease-Related Non-Motor Symptoms and Neuropsychological Profile. <i>Journal of Personalized Medicine</i> , 2020, 10, 31.	1.1	11
6427	Motor symptom asymmetry in Parkinson's disease predicts emotional outcome following subthalamic nucleus deep brain stimulation. <i>Neuropsychologia</i> , 2020, 144, 107494.	0.7	12
6428	Oropharyngeal freezing and its relation to dysphagia – An analogy to freezing of gait. <i>Parkinsonism and Related Disorders</i> , 2020, 75, 1-6.	1.1	18
6429	DNA methylation of the 5'UTR DAT 1 gene in Parkinson's disease patients. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 275-280.	1.0	13
6430	Characterization of Recessive Parkinson Disease in a Large Multicenter Study. <i>Annals of Neurology</i> , 2020, 88, 843-850.	2.8	40
6431	Event-related potential changes due to early-onset Parkinson's disease in parkin (PARK2) gene mutation carriers and non-carriers. <i>Clinical Neurophysiology</i> , 2020, 131, 1444-1452.	0.7	7
6432	Pneumonia risk and its associated factors in Parkinson's disease: A National Database Study. <i>Journal of the Neurological Sciences</i> , 2020, 415, 116949.	0.3	14
6433	Essential tremor vs idiopathic Parkinson disease. <i>Medicine (United States)</i> , 2020, 99, e20028.	0.4	5
6434	Usability of the Experience Sampling Method in Parkinson's Disease on a Group and Individual Level. <i>Movement Disorders</i> , 2020, 35, 1145-1152.	2.2	2
6435	A novel multi-marker discovery approach identifies new serum biomarkers for Parkinson's disease in older people: an EXosomes in PARKinson Disease (EXPAND) ancillary study. <i>GeroScience</i> , 2020, 42, 1323-1334.	2.1	32
6436	Depressive symptoms effect subjective sleep quality in Chinese patients with Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2020, 195, 105950.	0.6	4
6437	Neurophysiological Biomarkers of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 471-480.	1.5	27

#	ARTICLE	IF	CITATIONS
6438	Brain Functional and Structural Signatures in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 125.	1.7	4
6439	Development of an assay of plasma neurofilament light chain utilizing immunomagnetic reduction technology. <i>PLoS ONE</i> , 2020, 15, e0234519.	1.1	12
6440	Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions. <i>BMC Biology</i> , 2020, 18, 62.	1.7	122
6441	Study protocol of the Dutch Parkinson Cohort (DUPARC): a prospective, observational study of de novo Parkinson's disease patients for the identification and validation of biomarkers for Parkinson's disease subtypes, progression and pathophysiology. <i>BMC Neurology</i> , 2020, 20, 245.	0.8	17
6442	Clinical Progression of Parkinson's Disease: Insights from the NINDS Common Data Elements. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1075-1085.	1.5	13
6443	The structural connectivity of subthalamic deep brain stimulation correlates with impulsivity in Parkinson's disease. <i>Brain</i> , 2020, 143, 2235-2254.	3.7	52
6444	Optimizing Treatment in Undertreated Late-Stage Parkinsonism: A Pragmatic Randomized Trial. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1171-1184.	1.5	6
6445	Parkinson's Disease, <i>NOTCH3</i> Genetic Variants, and White Matter Hyperintensities. <i>Movement Disorders</i> , 2020, 35, 2090-2095.	2.2	18
6446	Characterizing the heterogeneous metabolic progression in idiopathic REM sleep behavior disorder. <i>NeuroImage: Clinical</i> , 2020, 27, 102294.	1.4	10
6447	Cortical complexity and gyrification patterns in Parkinson's disease. <i>NeuroReport</i> , 2020, 31, 565-570.	0.6	12
6448	Common and unique connectivity at the interface of motor, neuropsychiatric, and cognitive symptoms in Parkinson's disease: A commonality analysis. <i>Human Brain Mapping</i> , 2020, 41, 3749-3764.	1.9	10
6449	Interaction between SNCA gene polymorphisms and T2DM with Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 443-448.	1.0	2
6450	Could ZI have a role in DBS for Parkinson's Disease? An observational study to optimize DBS target localization. <i>Journal of Clinical Neuroscience</i> , 2020, 77, 89-93.	0.8	3
6451	Smartphone-Based Estimation of Item 3.8 of the MDS-UPDRS-III for Assessing Leg Agility in People With Parkinson's Disease. <i>IEEE Open Journal of Engineering in Medicine and Biology</i> , 2020, 1, 140-147.	1.7	14
6452	Substantia Nigra Volumetry with 3-T MRI in De Novo and Advanced Parkinson Disease. <i>Radiology</i> , 2020, 296, 401-410.	3.6	18
6453	Genetic Architecture of Parkinson's Disease in the Indian Population: Harnessing Genetic Diversity to Address Critical Gaps in Parkinson's Disease Research. <i>Frontiers in Neurology</i> , 2020, 11, 524.	1.1	23
6454	Safety and immunogenicity of the α -synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. <i>Lancet Neurology</i> , The, 2020, 19, 591-600.	4.9	83
6455	The Nigeria Parkinson Disease Registry: Process, Profile, and Prospects of a Collaborative Project. <i>Movement Disorders</i> , 2020, 35, 1315-1322.	2.2	14

#	ARTICLE	IF	CITATIONS
6456	A Randomized, Controlled Trial of Exercise for Parkinsonian Individuals With Freezing of Gait. <i>Movement Disorders</i> , 2020, 35, 1607-1617.	2.2	39
6457	New insight into Parkinson's disease-related impairment of the automatic control of upright stance. <i>European Journal of Neuroscience</i> , 2020, 52, 4851-4862.	1.2	1
6458	Subjective Cognitive Complaint in Parkinson's Disease Patients With Normal Cognition: Canary in the Coal Mine?. <i>Movement Disorders</i> , 2020, 35, 1618-1625.	2.2	31
6459	Mutation screening and burden analysis of VPS13C in Chinese patients with early-onset Parkinson's disease. <i>Neurobiology of Aging</i> , 2020, 94, 311.e1-311.e4.	1.5	16
6460	Parkinson's Disease EMG Data Augmentation and Simulation with DCGANs and Style Transfer. <i>Sensors</i> , 2020, 20, 2605.	2.1	41
6461	Cognitive Function and Quality of Life in Parkinson's Disease: A Cross-Sectional Study. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1209-1216.	1.5	12
6462	Impact of Residual Drug in the Pharynx on the Delayed On Phenomenon in Parkinson's Disease Patients. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 273-278.	0.8	12
6463	Autonomic dysfunction is associated with neuropsychological impairment in Lewy body disease. <i>Journal of Neurology</i> , 2020, 267, 1941-1951.	1.8	16
6464	Video analysis of long-term effects of levodopa-carbidopa intestinal gel on gait and posture in advanced Parkinson's disease. <i>Neurological Sciences</i> , 2020, 41, 1927-1930.	0.9	6
6465	Hypermethylation of the Gene Coding for PGC-1 β in Peripheral Blood Leukocytes of Patients With Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2020, 14, 97.	1.4	17
6466	Association Between Stroke and Parkinson's Disease: a Meta-analysis. <i>Journal of Molecular Neuroscience</i> , 2020, 70, 1169-1176.	1.1	22
6467	Dysarthria enhancement mechanism under external clear speech instruction in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. <i>Journal of Neural Transmission</i> , 2020, 127, 905-914.	1.4	7
6468	Can the Executive Control Network be Used to Diagnose Parkinson's Disease and as an Efficacy Indicator of Deep Brain Stimulation?. <i>Parkinson's Disease</i> , 2020, 2020, 1-6.	0.6	12
6469	Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study. <i>Translational Neurodegeneration</i> , 2020, 9, 9.	3.6	35
6470	Plasma Short-Chain Fatty Acids in Patients With Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1021-1027.	2.2	65
6471	Dopamine Transporter, Age, and Motor Complications in Parkinson's Disease: A Clinical and Single-Photon Emission Computed Tomography Study. <i>Movement Disorders</i> , 2020, 35, 1028-1036.	2.2	17
6472	ALFF and ReHo Mapping Reveals Different Functional Patterns in Early- and Late-Onset Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2020, 14, 141.	1.4	29
6473	Optimizing future planning in Parkinson disease: suggestions for a comprehensive roadmap from patients and care partners. <i>Annals of Palliative Medicine</i> , 2020, 9, S63-S74.	0.5	27

#	ARTICLE	IF	CITATIONS
6474	CNTNAP4 deficiency in dopaminergic neurons initiates parkinsonian phenotypes. <i>Theranostics</i> , 2020, 10, 3000-3021.	4.6	21
6475	Autonomic dysfunction and phenoconversion in idiopathic REM sleep behavior disorder. <i>Clinical Autonomic Research</i> , 2020, 30, 207-213.	1.4	23
6476	Domain specific cognitive impairment in Parkinson's™ patients with mild cognitive impairment. <i>Journal of Clinical Neuroscience</i> , 2020, 75, 99-105.	0.8	13
6477	Brain morphological changes in hypokinetic dysarthria of Parkinson's disease and use of machine learning to predict severity. <i>CNS Neuroscience and Therapeutics</i> , 2020, 26, 711-719.	1.9	13
6478	Executive Function Is Related to the Urinary Urgency in Non-demented Patients With Parkinson's™ Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 55.	1.7	11
6479	A comparison of the relationship between manual dexterity and postural control in young and older individuals with Parkinson's™ disease. <i>Journal of Clinical Neuroscience</i> , 2020, 75, 89-93.	0.8	7
6480	Effect of Intestinal Levodopa-Carbidopa Infusion on Pharyngeal Dysphagia: Results from a Retrospective Pilot Study in Patients with Parkinson's™ Disease. <i>Parkinson's Disease</i> , 2020, 2020, 1-6.	0.6	14
6481	<p>Progressive Resistance Training Improves Bradykinesia, Motor Symptoms and Functional Performance in Patients with Parkinson's™ Disease</p>. <i>Clinical Interventions in Aging</i> , 2020, Volume 15, 87-95.	1.3	37
6482	Striatal Dopamine Denervation Impairs Gait Automaticity in Drug-naïve Parkinson's Disease Patients. <i>Movement Disorders</i> , 2020, 35, 1037-1045.	2.2	12
6483	Sexual dysfunction in male patients with Parkinson's™ disease: related factors and impact on quality of life. <i>Neurological Sciences</i> , 2020, 41, 2201-2206.	0.9	13
6484	Upper Limb Interactive Weightless Technology-Aided Intervention and Assessment Picks Out Motor Skills Improvement in Parkinson's Disease: A Pilot Study. <i>Frontiers in Neurology</i> , 2020, 11, 40.	1.1	3
6485	Three-Year Gait and Axial Outcomes of Bilateral STN and GPi Parkinson's™ Disease Deep Brain Stimulation. <i>Frontiers in Human Neuroscience</i> , 2020, 14, 1.	1.0	83
6486	Clinically relevant connectivity features define three subtypes of Parkinson's disease patients. <i>Human Brain Mapping</i> , 2020, 41, 4077-4092.	1.9	12
6487	Electrophysiological differences in cortical excitability in different forms of dementia: A transcranial magnetic stimulation and laboratory biomarkers study. <i>Neurophysiologie Clinique</i> , 2020, 50, 185-193.	1.0	12
6488	Integrated Care in Parkinson's Disease: A Systematic Review and <sc>Meta&Analysis</sc>. <i>Movement Disorders</i> , 2020, 35, 1509-1531.	2.2	71
6489	Relations of clinical symptoms with dopamine transporter imaging in drug-naïve Parkinson's™ disease. <i>Clinical Neurology and Neurosurgery</i> , 2020, 196, 105960.	0.6	3
6490	Assessment of Functional Activities in Individuals with Parkinson's™ Disease Using a Simple and Reliable Smartphone-Based Procedure. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 4123.	1.2	19
6491	Parkinson disease clinical subtypes: key features & clinical milestones. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1272-1283.	1.7	27

#	ARTICLE	IF	CITATIONS
6492	Genetic Analysis of <i>EGLN1</i> C127S Variant in Taiwanese Parkinson's Disease. <i>Parkinson's Disease</i> , 2020, 2020, 1-4.	0.6	1
6493	Phospho-HDAC6 Gathers Into Protein Aggregates in Parkinson's Disease and Atypical Parkinsonisms. <i>Frontiers in Neuroscience</i> , 2020, 14, 624.	1.4	17
6494	Quantifying Spatiotemporal Gait Parameters with HoloLens in Healthy Adults and People with Parkinson's Disease: Test-Retest Reliability, Concurrent Validity, and Face Validity. <i>Sensors</i> , 2020, 20, 3216.	2.1	19
6495	Levodopa Changes Functional Connectivity Patterns in Subregions of the Primary Motor Cortex in Patients With Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2020, 14, 647.	1.4	15
6496	Novel Nasal Epithelial Cell Markers of Parkinson's Disease Identified Using Cells Treated with α -Synuclein Preformed Fibrils. <i>Journal of Clinical Medicine</i> , 2020, 9, 2128.	1.0	3
6497	<i>Apkinson</i> : the smartphone application for telemonitoring Parkinson's patients through speech, gait and hands movement. <i>Neurodegenerative Disease Management</i> , 2020, 10, 137-157.	1.2	14
6498	A Virtual Cohort Study of Individuals at Genetic Risk for Parkinson's Disease: Study Protocol and Design. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1195-1207.	1.5	8
6499	Parkinson's Disease Multimodal Complex Treatment (PD-MCT): Analysis of Therapeutic Effects and Predictors for Improvement. <i>Journal of Clinical Medicine</i> , 2020, 9, 1874.	1.0	8
6500	Distinctive Pathophysiology Underlying Constipation in Parkinson's Disease: Implications for Cognitive Inefficiency. <i>Journal of Clinical Medicine</i> , 2020, 9, 1916.	1.0	6
6501	Speech disorder and vocal tremor in postural instability/gait difficulty and tremor dominant subtypes of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2020, 127, 1295-1304.	1.4	18
6502	Characterization of cognition in mild cognitive impairment with and without Parkinson's disease. <i>Clinical Parkinsonism & Related Disorders</i> , 2020, 3, 100034.	0.5	1
6503	Cognition, function and awareness of disease impact in early Parkinson's and Huntington's disease. <i>Disability and Rehabilitation</i> , 2022, 44, 920-938.	0.9	5
6504	Longitudinal Positron Emission Tomography of Dopamine Synthesis in Subjects with <i>GBA1</i> Mutations. <i>Annals of Neurology</i> , 2020, 87, 652-657.	2.8	12
6505	Subjects at risk of Parkinson's disease in health checkup examinees: cross-sectional analysis of baseline data of the NaT-PROBE study. <i>Journal of Neurology</i> , 2020, 267, 1516-1526.	1.8	15
6506	Phase I clinical study with different doses of ^{99m} Tc-TRODAT-1 in healthy adults. <i>Annals of Nuclear Medicine</i> , 2020, 34, 212-219.	1.2	1
6507	ReadySteady intervention to promote physical activity in older adults with Parkinson's disease: Study design and methods. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100513.	0.5	3
6508	Progression of Neuropsychiatric Symptoms over Time in an Incident Parkinson's Disease Cohort (ICICLE-PD). <i>Brain Sciences</i> , 2020, 10, 78.	1.1	20
6509	Comparison of Integrated Outpatient Palliative Care With Standard Care in Patients With Parkinson Disease and Related Disorders. <i>JAMA Neurology</i> , 2020, 77, 551.	4.5	107

#	ARTICLE	IF	CITATIONS
6510	Connectivity Patterns of Subthalamic Stimulation Influence Pain Outcomes in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 9.	1.1	16
6511	Identifying the Functional Brain Network of Motor Reserve in Early Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 577-586.	2.2	36
6512	Mitochondrial Signatures in Circulating Extracellular Vesicles of Older Adults with Parkinson's Disease: Results from the EXosomes in Parkinson's Disease (EXPAND) Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 504.	1.0	80
6513	Impaired context-sensitive adjustment of behaviour in Parkinson's disease patients tested on and off medication: An fMRI study. <i>NeuroImage</i> , 2020, 212, 116674.	2.1	3
6514	Cognitive training interventions for dementia and mild cognitive impairment in Parkinson's disease. <i>The Cochrane Library</i> , 2020, 2020, CD011961.	1.5	46
6515	Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease. <i>Journal of Proteome Research</i> , 2020, 19, 1310-1318.	1.8	43
6516	Sleep in Parkinson's disease: A systematic review and meta-analysis of polysomnographic findings. <i>Sleep Medicine Reviews</i> , 2020, 51, 101281.	3.8	76
6517	Effects of working memory training in patients with Parkinson's disease without cognitive impairment: A randomized controlled trial. <i>Parkinsonism and Related Disorders</i> , 2020, 72, 13-22.	1.1	14
6518	Does REM sleep behavior disorder change in the progression of Parkinson's disease?. <i>Sleep Medicine</i> , 2020, 68, 190-198.	0.8	29
6519	Goalkeeper Game: A New Assessment Tool for Prediction of Gait Performance Under Complex Condition in People With Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 50.	1.7	1
6520	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 421-441.	1.5	42
6521	Concordance of Mini-Mental State Examination, Montreal Cognitive Assessment and Parkinson Neuropsychometric Dementia Assessment in the classification of cognitive performance in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2020, 412, 116735.	0.3	13
6522	Subcortical atrophy and perfusion patterns in Parkinson disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2020, 72, 49-55.	1.1	12
6523	Tremorography in fragile X-associated tremor/ataxia syndrome, Parkinson's disease and essential tremor. <i>Clinical Parkinsonism & Related Disorders</i> , 2020, 3, 100040.	0.5	3
6524	When does cerebral β -amyloid deposition begin in Lewy body dementia?. <i>Neurology and Clinical Neuroscience</i> , 2020, 8, 362-371.	0.2	2
6525	Analyzing the co-localization of substantia nigra hyper-echogenicities and iron accumulation in Parkinson's disease: A multi-modal atlas study with transcranial ultrasound and MRI. <i>NeuroImage: Clinical</i> , 2020, 26, 102185.	1.4	18
6526	Rhythm disturbances as a potential early marker of Parkinson's disease in idiopathic REM sleep behavior disorder. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 280-287.	1.7	16
6527	Dementia in long-term Parkinson's disease patients: a multicentre retrospective study. <i>Npj Parkinson's Disease</i> , 2020, 6, 2.	2.5	32

#	ARTICLE	IF	CITATIONS
6528	Spectral domain OCT can differentiate the retinal morphological changes of patients with Parkinson's disease in clinical middle stages. <i>Neurological Sciences</i> , 2020, 41, 1909-1912.	0.9	4
6529	Patient perceptions and knowledge of Parkinson's disease and treatment (KnowPD). <i>Clinical Parkinsonism & Related Disorders</i> , 2020, 3, 100038.	0.5	8
6530	VCP expression decrease as a biomarker of preclinical and early clinical stages of Parkinson's disease. <i>Scientific Reports</i> , 2020, 10, 827.	1.6	15
6531	Fine-mapping of <i>SNCA</i> in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies. <i>Annals of Neurology</i> , 2020, 87, 584-598.	2.8	39
6532	Safinamide as an adjunct therapy in older patients with Parkinson's disease: a retrospective study. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 1369-1373.	1.4	4
6534	Hypomania and saccadic changes in Parkinson's disease: influence of D2 and D3 dopaminergic signalling. <i>Npj Parkinson's Disease</i> , 2020, 6, 5.	2.5	4
6535	Behavioral and Neuroanatomical Account of Impulsivity in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 1338.	1.1	20
6536	Brain connectivity markers for the identification of effective contacts in subthalamic nucleus deep brain stimulation. <i>Human Brain Mapping</i> , 2020, 41, 2028-2036.	1.9	12
6537	The Beneficial Effects of Computer-Based Cognitive Training in Parkinson's Disease: A Systematic Review. <i>Archives of Clinical Neuropsychology</i> , 2020, 35, 434-447.	0.3	13
6538	mHealth and wearable technology should replace motor diaries to track motor fluctuations in Parkinson's disease. <i>Npj Digital Medicine</i> , 2020, 3, 6.	5.7	83
6539	Sympathetic nervous activity and hemoglobin levels in de novo Parkinson's disease. <i>Clinical Autonomic Research</i> , 2020, 30, 273-278.	1.4	4
6540	Gastrointestinal dysfunction in Parkinson's disease. <i>Journal of Neurology</i> , 2020, 267, 1377-1388.	1.8	48
6541	Patterns of intrinsic brain activity in essential tremor with resting tremor and tremor-dominant Parkinson's disease. <i>Brain Imaging and Behavior</i> , 2020, 14, 2606-2617.	1.1	20
6542	Plasma prostaglandin D2 synthase levels in sleep and neurological diseases. <i>Journal of the Neurological Sciences</i> , 2020, 411, 116692.	0.3	6
6543	Effects of Home-Based Working Memory Training on Visuo-Spatial Working Memory in Parkinson's Disease: A Randomized Controlled Trial. <i>Journal of Central Nervous System Disease</i> , 2020, 12, 117957351989946.	0.7	8
6544	EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 543-558.	1.5	20
6545	The Levodopa Response Varies in Pathologically Confirmed Parkinson's Disease: A Systematic Review. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 218-222.	0.8	9
6546	Non-motor Symptoms in Parkinson's Disease Patients with Parkin Mutations: More Depression and Less Executive Dysfunction. <i>Journal of Molecular Neuroscience</i> , 2020, 70, 246-253.	1.1	25

#	ARTICLE	IF	CITATIONS
6547	Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations. <i>JAMA Neurology</i> , 2020, 77, 427.	4.5	213
6548	Is Parkinson's disease an unique clinical entity? Rigid or tremor dominant PD: Two faces of the same coin. <i>Journal of Clinical Neuroscience</i> , 2020, 74, 18-24.	0.8	1
6549	Axial perturbations evoke increased postural reflexes in Parkinson's disease with postural instability. <i>Clinical Neurophysiology</i> , 2020, 131, 928-935.	0.7	1
6550	<i>APOE</i> genotype regulates pathology and disease progression in synucleinopathy. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	102
6551	Simultaneously Improved Pulmonary and Cardiovascular Autonomic Function and Short-Term Functional Outcomes in Patients with Parkinson's Disease after Respiratory Muscle Training. <i>Journal of Clinical Medicine</i> , 2020, 9, 316.	1.0	8
6552	The morphology of thalamic subnuclei in Parkinson's disease and the effects of machine learning on disease diagnosis and clinical evaluation. <i>Journal of the Neurological Sciences</i> , 2020, 411, 116721.	0.3	21
6553	Association of GLP-1 receptor gene polymorphisms with sporadic Parkinson's disease in Chinese Han population. <i>Neuroscience Letters</i> , 2020, 728, 135004.	1.0	0
6554	Processing speed is related to striatal dopamine transporter availability in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2020, 26, 102257.	1.4	22
6555	Evaluation of the metric properties of the WHODAS 2.0, WHODAS-S, and RADS in the assessment of disability in Parkinsonian patients. <i>Clinical Neurology and Neurosurgery</i> , 2020, 194, 105872.	0.6	9
6556	Impaired topographic organization in Parkinson's disease with mild cognitive impairment. <i>Journal of the Neurological Sciences</i> , 2020, 414, 116861.	0.3	21
6557	Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: A preliminary finding. <i>Journal of the Neurological Sciences</i> , 2020, 415, 116869.	0.3	13
6558	Effects of a core stabilization training program on balance ability in persons with Parkinson's disease: a randomized controlled trial. <i>Clinical Rehabilitation</i> , 2020, 34, 764-772.	1.0	7
6559	Dissociable effects of subthalamic nucleus deep brain stimulation surgery and acute stimulation on verbal fluency in Parkinson's disease. <i>Behavioural Brain Research</i> , 2020, 388, 112621.	1.2	10
6560	Role of Alcohol Drinking in Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2316.	1.8	75
6561	A centrality based multi-objective approach to disease gene association. <i>BioSystems</i> , 2020, 193-194, 104133.	0.9	3
6562	Serum neuronal exosomes predict and differentiate Parkinson's disease from atypical parkinsonism. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 720-729.	0.9	148
6563	Low back pain in Parkinson's disease: A cross-sectional study of its prevalence, and implications on functional capacity and quality of life. <i>Clinical Neurology and Neurosurgery</i> , 2020, 194, 105787.	0.6	6
6564	NLRP3 inflammasome and glia maturation factor coordinately regulate neuroinflammation and neuronal loss in MPTP mouse model of Parkinson's disease. <i>International Immunopharmacology</i> , 2020, 83, 106441.	1.7	36

#	ARTICLE	IF	CITATIONS
6565	Genetic analysis of N6-methyladenosine modification genes in Parkinson's disease. <i>Neurobiology of Aging</i> , 2020, 93, 143.e9-143.e13.	1.5	35
6566	Enhanced Obstacle Contrast to Promote Visual Scanning in Fallers with Parkinson's Disease: Role of Executive Function. <i>Neuroscience</i> , 2020, 436, 82-92.	1.1	1
6567	Mild behavioral impairment in Parkinson's disease is associated with altered corticostriatal connectivity. <i>NeuroImage: Clinical</i> , 2020, 26, 102252.	1.4	25
6568	Positron emission tomography/computed tomography dual imaging using 18-fluorine fludeoxyglucose and 11C-labeled 2- β -carbomethoxy-3- β -(4-fluorophenyl) tropane for the severity assessment of Parkinson disease. <i>Medicine (United States)</i> , 2020, 99, e19662.	0.4	0
6569	Age at Onset of Parkinson's Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1123-1132.	1.5	21
6570	Detecting the Cognitive Prodrome of Dementia in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1033-1046.	1.5	8
6571	Parkinson's Disease Diagnosis Using Neostriatum Radiomic Features Based on T2-Weighted Magnetic Resonance Imaging. <i>Frontiers in Neurology</i> , 2020, 11, 248.	1.1	26
6572	Diffusion Kurtosis Imaging of Microstructural Changes in Gray Matter Nucleus in Parkinson Disease. <i>Frontiers in Neurology</i> , 2020, 11, 252.	1.1	10
6573	Applied strategy in the Iowa Gambling Task: Comparison of individuals with Parkinson's disease to healthy controls. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2020, 42, 425-435.	0.8	3
6574	Assessing the relationship between non-motor symptoms and health-related quality of life in Parkinson's disease: a retrospective observational cohort study. <i>Neurological Sciences</i> , 2020, 41, 2867-2873.	0.9	6
6575	Differential diagnosis of parkinsonian syndromes: a comparison of clinical and automated - metabolic brain patterns based approach. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2901-2910.	3.3	23
6576	Metabolic Fingerprinting on Synthetic Alloys for Medulloblastoma Diagnosis and Radiotherapy Evaluation. <i>Advanced Materials</i> , 2020, 32, e2000906.	11.1	93
6577	Initial motor reserve and long-term prognosis in Parkinson's disease. <i>Neurobiology of Aging</i> , 2020, 92, 1-6.	1.5	15
6578	Neuropathological correlates of parkinsonian disorders in a large Dutch autopsy series. <i>Acta Neuropathologica Communications</i> , 2020, 8, 39.	2.4	28
6579	The Impact of a Novel Immersive Virtual Reality Technology Associated with Serious Games in Parkinson's Disease Patients on Upper Limb Rehabilitation: A Mixed Methods Intervention Study. <i>Sensors</i> , 2020, 20, 2168.	2.1	36
6580	Construct validity and test-retest reliability of a free mobile application for spatio-temporal gait analysis in Parkinson's disease patients. <i>Gait and Posture</i> , 2020, 79, 86-91.	0.6	14
6581	Expanding the search for genetic biomarkers of Parkinson's disease into the living brain. <i>Neurobiology of Disease</i> , 2020, 140, 104872.	2.1	11
6582	Goal-directed behavior in individuals with mild Parkinson's disease: Role of self-efficacy and self-regulation. <i>Clinical Parkinsonism & Related Disorders</i> , 2020, 3, 100051.	0.5	2

#	ARTICLE	IF	CITATIONS
6583	Diagnosing REM sleep behavior disorder in Parkinson's disease without a gold standard: a latent-class model study. <i>Sleep</i> , 2020, 43, .	0.6	13
6584	Update on the Management of Parkinson's Disease for General Neurologists. <i>Parkinson's Disease</i> , 2020, 2020, 1-13.	0.6	33
6585	A different vision of translational research in biomarker discovery: a pilot study on circulatory mitochondrial proteins as Parkinson's disease potential biomarkers. <i>Translational Neurodegeneration</i> , 2020, 9, 11.	3.6	4
6586	Analysis of common and rare <i>VPS13C</i> variants in late-onset Parkinson disease. <i>Neurology: Genetics</i> , 2020, 6, 385.	0.9	19
6587	The clinical application of nigrosome 1 detection on high-resolution susceptibility-weighted imaging in the evaluation of suspected Parkinsonism: The real-world performance and pitfalls. <i>PLoS ONE</i> , 2020, 15, e0231010.	1.1	3
6588	The Dysfunctional Autonomic Function and "Dysfunctional" Fatigue in Drug Naïve Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 605-612.	1.5	7
6589	Parkinson's Disease in Kazakhstan: Clinico-Demographic Description of a Large Cohort. <i>Journal of Parkinson's Disease</i> , 2020, 10, 707-709.	1.5	1
6590	Can We Predict the Motor Performance of Patients With Parkinson's Disease Based on Their Symptomatology?. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 189.	2.0	2
6591	The Effects of Task Prioritization on Dual-Tasking Postural Control in Patients With Parkinson Disease Who Have Different Postural Impairments. <i>Archives of Physical Medicine and Rehabilitation</i> , 2020, 101, 1212-1219.	0.5	6
6592	Longitudinal analysis of functional disabilities, cognitive decline and risk of dementia in women with Parkinson's disease and detrusor overactivity. <i>Journal of Clinical Neuroscience</i> , 2020, 75, 85-88.	0.8	2
6593	High-Resolution Motor State Detection in Parkinson's Disease Using Convolutional Neural Networks. <i>Scientific Reports</i> , 2020, 10, 5860.	1.6	39
6594	Uso de la infusión intestinal continua de levodopa-carbidopa en pacientes con enfermedad de Parkinson avanzada en España. Subanálisis por comunidades autónomas. <i>Neurología</i> , 2021, 36, 101-111.	0.3	0
6595	REM sleep behaviour disorder in essential tremor: A polysomnographic study. <i>Journal of Sleep Research</i> , 2021, 30, e13050.	1.7	5
6596	Cognitive workload during verbal abstract reasoning in Parkinson's disease: a pilot study. <i>International Journal of Neuroscience</i> , 2021, 131, 504-510.	0.8	3
6597	SERIAL-ORDER recall in working memory across the cognitive spectrum of Parkinson's disease and neuroimaging correlates. <i>Journal of Neuropsychology</i> , 2021, 15, 88-111.	0.6	5
6598	Brief Cognitive Behavioral Therapy for Insomnia in Parkinson's Disease: A Case Series Study. <i>Japanese Psychological Research</i> , 2021, 63, 59-71.	0.4	4
6599	Gene Panel Sequencing Identifies Novel Pathogenic Mutations in Moroccan Patients with Familial Parkinson Disease. <i>Journal of Molecular Neuroscience</i> , 2021, 71, 142-152.	1.1	4
6600	Optimal target localisation and eight-year outcome for subthalamic stimulation in patients with Parkinson's disease. <i>British Journal of Neurosurgery</i> , 2021, 35, 151-156.	0.4	3

#	ARTICLE	IF	CITATIONS
6601	Association of SOD2 p.V16A polymorphism with Parkinson's disease: A meta-analysis in Han Chinese. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 501-507.	0.8	4
6602	Frameless stereotaxy in subthalamic deep brain stimulation: 3-year clinical outcome. <i>Neurological Sciences</i> , 2021, 42, 259-266.	0.9	5
6603	A Clinicopathologic Study of Movement Disorders in Frontotemporal Lobar Degeneration. <i>Movement Disorders</i> , 2021, 36, 632-641.	2.2	3
6604	Impact of depression on gait variability in Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2021, 200, 106324.	0.6	14
6605	Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 672-680.	2.2	8
6606	Accuracy of death certificates for recording parkinsonian syndromes and associated dementia. <i>Journal of Neurology</i> , 2021, 268, 140-146.	1.8	9
6607	Increased rapid eye movement density in Chinese patients with Parkinson's disease and RBD. <i>Neurological Sciences</i> , 2021, 42, 961-968.	0.9	4
6608	Motor asymmetry related cerebral perfusion patterns in Parkinson's disease: An arterial spin labeling study. <i>Human Brain Mapping</i> , 2021, 42, 298-309.	1.9	20
6609	Cerebrospinal Fluid Levels of Prodynorphin-Derived Peptides are Decreased in Huntington's Disease. <i>Movement Disorders</i> , 2021, 36, 492-497.	2.2	12
6610	Pallidal Connectivity Profiling of Stimulation-Induced Dyskinesia in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 380-388.	2.2	18
6611	Sarcopenia and frailty in individuals with dementia: A systematic review. <i>Archives of Gerontology and Geriatrics</i> , 2021, 92, 104268.	1.4	62
6612	Effect of different types of exercises on psychological and cognitive features in people with Parkinson's disease: A randomized controlled trial. <i>Annals of Physical and Rehabilitation Medicine</i> , 2021, 64, 101407.	1.1	10
6613	Utility of Imaging of Nigrosome-1 on 3T MRI and Its Comparison with 18F-DOPA PET in the Diagnosis of Idiopathic Parkinson Disease and Atypical Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 224-230.	0.8	12
6614	Brain $5\text{-HT}_1\text{A}$ Receptor Binding in Multiple System Atrophy: An [^{18}F]MPPF PET Study. <i>Movement Disorders</i> , 2021, 36, 246-251.	2.2	15
6615	Analysis of Heterozygous <i>PRKN</i> Variants and Copy Number Variations in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 178-187.	2.2	39
6616	The ability of the eating assessment tool-10 to detect penetration and aspiration in Parkinson's disease. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 1661-1668.	0.8	8
6617	Convergent patterns of structural brain changes in rapid eye movement sleep behavior disorder and Parkinson's disease on behalf of the German rapid eye movement sleep behavior disorder study group. <i>Sleep</i> , 2021, 44, .	0.6	26
6618	Highly challenging balance and gait training for individuals with Parkinson's disease improves pace, rhythm and variability domains of gait - A secondary analysis from a randomized controlled trial. <i>Clinical Rehabilitation</i> , 2021, 35, 200-212.	1.0	7

#	ARTICLE	IF	CITATIONS
6619	Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations. <i>Movement Disorders</i> , 2021, 36, 415-423.	2.2	24
6620	Study of EEG microstates in Parkinson's disease: a potential biomarker?. <i>Cognitive Neurodynamics</i> , 2021, 15, 463-471.	2.3	23
6621	Is freezing of gait correlated with postural control in patients with moderate-to-severe Parkinson's disease?. <i>European Journal of Neuroscience</i> , 2021, 53, 1189-1196.	1.2	5
6622	Effect of cognitive and motor dual-task on oropharyngeal swallowing in Parkinson's disease. <i>European Journal of Neurology</i> , 2021, 28, 754-762.	1.7	11
6623	Mutation analysis of LRP10 in a large Chinese familial Parkinson disease cohort. <i>Neurobiology of Aging</i> , 2021, 99, 99.e1-99.e6.	1.5	6
6624	Lack of PTRHD1 mutation in patients with young-onset and familial Parkinson's disease in a Taiwanese population. <i>Neurobiology of Aging</i> , 2021, 100, 118.e15-118.e16.	1.5	5
6625	Iron and inflammation: in vivo and post-mortem studies in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2021, 128, 15-25.	1.4	22
6626	Negative screening for 12 rare LRRK2 pathogenic variants in a cohort of Nigerians with Parkinson's disease. <i>Neurobiology of Aging</i> , 2021, 99, 101.e15-101.e19.	1.5	6
6627	No relationship between SRY variants and risk of Parkinson's disease in Chinese population. <i>Neurobiology of Aging</i> , 2021, 100, 119.e3-119.e6.	1.5	5
6628	Comparison of susceptibility-weighted imaging and susceptibility map-weighted imaging for the diagnosis of Parkinsonism with nigral hyperintensity. <i>European Journal of Radiology</i> , 2021, 134, 109398.	1.2	6
6629	Executive function network's white matter alterations relate to Parkinson's disease motor phenotype. <i>Neuroscience Letters</i> , 2021, 741, 135486.	1.0	4
6630	Reliability and Validity of Pupillary Response During Dual-Task Balance in Parkinson Disease. <i>Archives of Physical Medicine and Rehabilitation</i> , 2021, 102, 448-455.	0.5	9
6631	Gut microbiota-derived metabolite trimethylamine N-oxide as a biomarker in early Parkinson's disease. <i>Nutrition</i> , 2021, 83, 111090.	1.1	36
6632	Association of -94 ATG insertion/deletion NFkB1 and c.*126G>A NFkBIA genetic polymorphisms with oxidative and nitrosative stress biomarkers in Brazilian subjects with Parkinson's Disease. <i>Neuroscience Letters</i> , 2021, 740, 135487.	1.0	8
6633	Prolonged Standing Task Affects Adaptability of Postural Control in People With Parkinson's Disease. <i>Neurorehabilitation and Neural Repair</i> , 2021, 35, 58-67.	1.4	9
6634	Association analysis of <i>PSAP</i> variants in Parkinson's disease patients. <i>Brain</i> , 2021, 144, e9-e9.	3.7	6
6635	Mutation analysis of TMEM family members for early-onset Parkinson's disease in Chinese population. <i>Neurobiology of Aging</i> , 2021, 101, 299.e1-299.e6.	1.5	14
6636	Genetic Analysis of Prosaposin, the Lysosomal Storage Disorder Gene in Parkinson's Disease. <i>Molecular Neurobiology</i> , 2021, 58, 1583-1592.	1.9	14

#	ARTICLE	IF	CITATIONS
6637	Identification of BAG2 and Cathepsin D as Plasma Biomarkers for Parkinson's Disease. <i>Clinical and Translational Science</i> , 2021, 14, 606-616.	1.5	16
6638	Resting-State Functional Connectivity Predicts <scp>STN DBS</scp> Clinical Response. <i>Movement Disorders</i> , 2021, 36, 662-671.	2.2	28
6639	Neurophysiological correlates of dual tasking in people with Parkinson's disease and freezing of gait. <i>Experimental Brain Research</i> , 2021, 239, 175-187.	0.7	6
6640	Clinical Non-Motor Phenotyping of Black and Asian Minority Ethnic Compared to White Individuals with Parkinson's Disease Living in the United Kingdom. <i>Journal of Parkinson's Disease</i> , 2021, 11, 299-307.	1.5	15
6641	Investigating the 1-year decline in midbrain-to-pons ratio in the differential diagnosis of PSP and IPD. <i>Journal of Neurology</i> , 2021, 268, 1526-1532.	1.8	4
6642	Application of Remote Deep Brain Stimulation Programming for Parkinson's Disease Patients. <i>World Neurosurgery</i> , 2021, 147, e255-e261.	0.7	14
6643	Characterization of Gastrointestinal Symptom Type and Severity in Parkinson's Disease: A Case-Control Study in an Australian Cohort. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 245-253.	0.8	16
6644	Dysphagia Screening in Parkinson's Disease. A diagnostic accuracy cross-sectional study investigating the applicability of the Gugging Swallowing Screen (GUSS). <i>Neurogastroenterology and Motility</i> , 2021, 33, e14034.	1.6	7
6645	Dissonance in Music Impairs Spatial Gait Parameters in Patients with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 363-372.	1.5	1
6646	Delineation of Apathy Subgroups in Parkinson's Disease: Differences in Clinical Presentation, Functional Ability, Health-related Quality of Life, and Caregiver Burden. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 92-99.	0.8	6
6647	Imaging Cerebral Glucose Metabolism during Dual-Task Walking in Patients with Parkinson's disease. <i>Journal of Neuroimaging</i> , 2021, 31, 356-362.	1.0	4
6648	Neurodegenerative diseases among miners in Ontario, Canada, using a linked cohort. <i>Occupational and Environmental Medicine</i> , 2021, 78, 385-392.	1.3	4
6649	Predictors of Long-Term Outcome of Subthalamic Stimulation in Parkinson Disease. <i>Annals of Neurology</i> , 2021, 89, 587-597.	2.8	40
6650	Targeted sequencing of Parkinson's disease loci genes highlights <i>SYT11</i>, <i>FGF20</i> and other associations. <i>Brain</i> , 2021, 144, 462-472.	3.7	31
6651	Health-Related Quality of Life May Predict Disease Staging in 10 Years in Parkinson Disease With Hoehn-Yahr Stage III. <i>Neurology: Clinical Practice</i> , 2021, 11, e261-e266.	0.8	1
6652	Association of rare heterozygous PLA2G6 variants with the risk of Parkinson's disease. <i>Neurobiology of Aging</i> , 2021, 101, 297.e5-297.e8.	1.5	6
6653	Principal component analysis of routine blood test results with Parkinson's disease: A case-control study. <i>Experimental Gerontology</i> , 2021, 144, 111188.	1.2	14
6654	Increasing Contrast Improves Object Perception in Parkinson's Disease with Visual Hallucinations. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 51-59.	0.8	3

#	ARTICLE	IF	CITATIONS
6655	Magnetic resonance imaging evaluation of nigrosome 1 and neuromelanin can assist Parkinson's disease diagnosis, but requires an expert neuroradiologist. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 8-12.	1.1	5
6656	Disease Progression in Patients with <i>Parkin</i>â€Related Parkinson's Disease in a Longitudinal Cohort. <i>Movement Disorders</i> , 2021, 36, 442-448.	2.2	20
6657	Action fluency identifies different sex, age, global cognition, executive function and brain activation profile in non-demented patients with Parkinsonâ€™s disease. <i>Journal of Neurology</i> , 2021, 268, 1036-1049.	1.8	7
6658	Cortical thickness as predictor of response to exercise in people with Parkinson's disease. <i>Human Brain Mapping</i> , 2021, 42, 139-153.	1.9	11
6659	Clinical and laboratory measures of balance and comparison of balance performances according to postural instability and gait disorders in individuals with Parkinsonâ€™s disease. <i>Somatosensory & Motor Research</i> , 2021, 38, 34-40.	0.4	5
6660	Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 642-650.	2.2	41
6661	Microglia is associated with p-Tau aggregates in the olfactory bulb of patients with neurodegenerative diseases. <i>Neurological Sciences</i> , 2021, 42, 1473-1482.	0.9	8
6662	Dopaminergic Nigrostriatal Connectivity in Early Parkinson Disease: In Vivo Neuroimaging Study of ¹¹C-DTBZ PET Combined with Correlational Tractography. <i>Journal of Nuclear Medicine</i> , 2021, 62, 545-552.	2.8	19
6663	Longitudinal prediction of falls and near falls frequencies in Parkinsonâ€™s disease: a prospective cohort study. <i>Journal of Neurology</i> , 2021, 268, 997-1005.	1.8	6
6664	The Adapted Resistance Training with Instability Randomized Controlled Trial for Gait Automaticity. <i>Movement Disorders</i> , 2021, 36, 152-163.	2.2	9
6665	Parkinsonâ€™s disease laterality: a 11C-PE2I PET imaging study. <i>Journal of Neurology</i> , 2021, 268, 582-589.	1.8	3
6666	Non-invasive intervention for motor signs of Parkinsonâ€™s disease: the effect of vibratory stimuli. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 109-110.	0.9	3
6667	Conventional Magnetic Resonance Imaging in the Diagnosis of Parkinsonian Disorders: A <sc>Metaâ€™Analysis</sc>. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 217-223.	0.8	7
6668	Continuous intestinal infusion of levodopaâ€™carbidopa in patients with advanced Parkinson's disease in Spain: Subanalysis by autonomous community. <i>NeurologÃa (English Edition)</i> , 2021, 36, 101-111.	0.2	0
6669	Association of freezing of gait and clinical features in patients with Parkinsonâ€™s disease. <i>Acta Neurologica Belgica</i> , 2021, 121, 153-159.	0.5	5
6670	The motor prodromes of parkinsonâ€™s disease: from bedside observation to large-scale application. <i>Journal of Neurology</i> , 2021, 268, 2099-2108.	1.8	27
6671	Differential effects of sex on longitudinal patterns of cognitive decline in Parkinsonâ€™s disease. <i>Journal of Neurology</i> , 2021, 268, 1903-1912.	1.8	21
6673	Suicidal ideation in early-onset Parkinsonâ€™s disease. <i>Journal of Neurology</i> , 2021, 268, 1876-1884.	1.8	8

#	ARTICLE	IF	CITATIONS
6674	Possible role of glial cell line-derived neurotrophic factor for predicting cognitive impairment in Parkinson's disease: a case-control study. <i>Neural Regeneration Research</i> , 2021, 16, 885.	1.6	8
6675	Utility of objective gait measures in levodopa-unresponsive freezing in Parkinson's. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 1072-1077.	0.2	1
6676	Short-term Tolerance of Nasally-administered NeuroEPO in Patients with Parkinson Disease. <i>MEDICC Review</i> , 2021, 23, 49-54.	0.5	5
6677	Comprehensive functional evaluation of the spectrum of multi-system atrophy with ¹⁸ F-FDG PET/CT and ^{99m} Tc TRODAT-1 SPECT: 5 Year's experience from a tertiary care center. <i>Annals of Indian Academy of Neurology</i> , 2021, 24, 490.	0.2	3
6678	Diagnostic Validity of the Sleep Condition Indicator to Screen for Diagnostic and Statistical Manual-5 Insomnia Disorder in Patients with Parkinson's Disease. <i>European Neurology</i> , 2021, 84, 333-339.	0.6	3
6679	Leg Muscle Strength Correlates with Gait Performance in Advanced Parkinson Disease. <i>Internal Medicine</i> , 2021, , .	0.3	0
6680	Non-motor symptoms in essential tremor, akinetic rigid and tremor-dominant subtypes of Parkinson's disease. <i>PLoS ONE</i> , 2021, 16, e0245918.	1.1	10
6681	A Double-Blind, Randomized, Controlled Trial of Lovastatin in Early-Stage Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1229-1237.	2.2	22
6682	Can Plasma α -Synuclein Help Us to Differentiate Parkinson's Disease from Essential Tremor?. <i>Tremor and Other Hyperkinetic Movements</i> , 2021, 11, 20.	1.1	4
6683	Impulsivity Markers in Parkinsonian Subthalamic Single-Unit Activity. <i>Movement Disorders</i> , 2021, 36, 1435-1440.	2.2	5
6684	A compound heterozygous PINK1-associated juvenile Parkinson's disease with pregnancy in Chinese. <i>Journal of Neurology</i> , 2021, 268, 2223-2227.	1.8	2
6685	Etiology and pathogenesis of Parkinson disease. , 2021, , 121-163.e16.		2
6686	Evolution of Apathy in Early Parkinson's Disease: A 4-Years Prospective Cohort Study. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 620762.	1.7	11
6687	Role of sleep and sleep disorders on motor and nonmotor features of Parkinson's Disease. <i>Neurological Sciences and Neurophysiology</i> , 2021, 38, 20.	0.1	0
6688	Crucial Role of FABP3 in α -Syn-Induced Reduction of Septal GABAergic Neurons and Cognitive Decline in Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 400.	1.8	2
6689	Abnormal Topological Organization of Sulcal Depth-Based Structural Covariance Networks in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 575672.	1.7	6
6690	Determining the Degree of Dopaminergic Denervation Based on the Loss of Nigral Hyperintensity on SMWI in Parkinsonism. <i>American Journal of Neuroradiology</i> , 2021, 42, 681-687.	1.2	6
6691	Zonisamide effects on sleep problems and depressive symptoms in Parkinson's disease. <i>Brain and Behavior</i> , 2021, 11, e02026.	1.0	9

#	ARTICLE	IF	CITATIONS
6692	Alteration of mitochondrial function in oxidative stress in parkinsonian neurodegeneration: A cross-sectional study. <i>Annals of Indian Academy of Neurology</i> , 2021, 24, 506.	0.2	6
6693	Impact of sleep quality on cognitive functions in Parkinson's disease. <i>Annals of Movement Disorders</i> , 2021, 4, 28.	0.3	0
6694	Progressive Supranuclear Palsy and Corticobasal Degeneration. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1281, 151-176.	0.8	10
6696	Clinical Markers May Identify Patients at Risk for Early Parkinson's Disease Dementia: A Prospective Study. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2021, 36, 153331752110213.	0.9	2
6697	Advanced brain ageing in Parkinson's disease is related to disease duration and individual impairment. <i>Brain Communications</i> , 2021, 3, fcab191.	1.5	23
6698	Brain Motor Network Changes in Parkinson's Disease: Evidence from Meta-Analytic Modeling. <i>Movement Disorders</i> , 2021, 36, 1180-1190.	2.2	26
6699	Patterns of brain activity during a set-shifting task linked to mild behavioral impairment in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2021, 30, 102590.	1.4	10
6700	Applying Synthetic Minority Over-sampling Technique and Support Vector Machine to Develop a Classifier for Parkinson's disease. <i>International Journal of Advanced Computer Science and Applications</i> , 2021, 12, .	0.5	1
6702	Effectiveness of a Long-Term, Home-Based Aerobic Exercise Intervention on Slowing the Progression of Parkinson Disease: Design of the Cyclical Lower Extremity Exercise for Parkinson Disease II (CYCLE-II) Study. <i>Physical Therapy</i> , 2021, 101, .	1.1	5
6703	Functional connectivity of spoken language processing in early-stage Parkinson's disease: An MEG study. <i>NeuroImage: Clinical</i> , 2021, 32, 102718.	1.4	13
6704	Increased atrial fibrillation risk in Parkinson's disease: A nationwide population-based study. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 238-246.	1.7	9
6705	Electrophysiological evaluation of audiovestibular pathway dysfunction in parkinson's disease and its correlates: A case control study. <i>Annals of Indian Academy of Neurology</i> , 2021, 24, 531.	0.2	4
6706	Factors affecting adherence to pharmacotherapy in parkinson's disease. <i>Annals of Indian Academy of Neurology</i> , 2021, 24, 879.	0.2	5
6707	Expression Levels of an Alpha-Synuclein Transcript in Blood May Distinguish between Early Dementia with Lewy Bodies and Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 725.	1.8	7
6708	Putative second hit rare genetic variants in families with seemingly GBA-associated Parkinson's disease. <i>Npj Genomic Medicine</i> , 2021, 6, 2.	1.7	11
6709	Clinical overview and phenomenology of movement disorders. , 2021, , 1-51.e27.		3
6710	Automatic Resting Tremor Assessment in Parkinson's Disease Using Smartwatches and Multitask Convolutional Neural Networks. <i>Sensors</i> , 2021, 21, 291.	2.1	43
6712	Test-retest reproducibility of dopamine transporter density measured with [18F]FP-CIT PET in patients with essential tremor and Parkinson's disease. <i>Annals of Nuclear Medicine</i> , 2021, 35, 299-306.	1.2	6

#	ARTICLE	IF	CITATIONS
6713	Preliminary Study of hsa-mir-626 Change in the Cerebrospinal Fluid in Parkinson's Disease. <i>Neurology India</i> , 2021, 69, 115.	0.2	9
6714	Detecting Effect of Levodopa in Parkinson's Disease Patients Using Sustained Phonemes. <i>IEEE Journal of Translational Engineering in Health and Medicine</i> , 2021, 9, 1-9.	2.2	16
6715	Center of pressure responses to unpredictable external perturbations indicate low accuracy in predicting fall risk in people with Parkinson's disease. <i>European Journal of Neuroscience</i> , 2021, 53, 2901-2911.	1.2	7
6716	Role of Medicinal Plants against Neurodegenerative Diseases. <i>Current Pharmaceutical Biotechnology</i> , 2022, 23, 123-139.	0.9	18
6717	Abnormal Gray Matter Volume and Functional Connectivity in Parkinson's Disease with Rapid Eye Movement Sleep Behavior Disorder. <i>Parkinson's Disease</i> , 2021, 2021, 1-11.	0.6	9
6718	Associations between probable REM sleep behavior disorder, olfactory disturbance, and clinical symptoms in Parkinson's disease: A multicenter cross-sectional study. <i>PLoS ONE</i> , 2021, 16, e0247443.	1.1	13
6719	Peripheral blood lymphocyte phenotypes in Alzheimer and Parkinson's diseases. <i>Neurologia (English)</i> 2021, 36, 100-105.	0.2	5
6720	Dopaminergic and Metabolic Correlations With Cognitive Domains in Non-demented Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 627356.	1.7	9
6721	Facial tremor in patients with Parkinson's disease: prevalence, determinants and impacts on disease progression. <i>BMC Neurology</i> , 2021, 21, 86.	0.8	8
6722	Oral Levodopa Formulation Does Not Affect Progression of Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2021, 44, 47-52.	0.2	1
6723	Impact of the COVID-19 pandemic on physical activity, anxiety, and depression in patients with Parkinson's disease. <i>International Journal of Rehabilitation Research</i> , 2021, 44, 173-176.	0.7	23
6724	Olfactory Testing in Parkinson Disease and REM Behavior Disorder. <i>Neurology</i> , 2021, 96, e2016-e2027.	1.5	12
6725	APOE and MAPT Are Associated With Dementia in Neuropathologically Confirmed Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 631145.	1.1	30
6726	Physical interventions for people with Parkinson's disease: a systematic review and network meta-analysis. <i>The Cochrane Library</i> , 0, .	1.5	3
6727	Do Benzodiazepines Impair Motor and Nonmotor Symptoms in a Sample of Parkinson's Disease Patients?. <i>Cureus</i> , 2021, 13, e13220.	0.2	1
6728	Long-term safety and efficacy of opicapone in Japanese Parkinson's patients with motor fluctuations. <i>Journal of Neural Transmission</i> , 2021, 128, 337-344.	1.4	6
6729	Parkinson's Disease in Romania: A Scoping Review Protocol. <i>Brain Sciences</i> , 2021, 11, 251.	1.1	6
6730	Temporal orienting in Parkinson's disease. <i>European Journal of Neuroscience</i> , 2021, 53, 2713-2725.	1.2	7

#	ARTICLE	IF	CITATIONS
6731	Neurobehavioral Effects of LSVTÂ® LOUD on Auditory-Vocal Integration in Parkinsonâ€™s Disease: A Preliminary Study. <i>Frontiers in Neuroscience</i> , 2021, 15, 624801.	1.4	11
6732	Increased Plasma Heme Oxygenase-1 Levels in Patients With Early-Stage Parkinsonâ€™s Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 621508.	1.7	13
6733	An artificial neural network approach to detect presence and severity of Parkinsonâ€™s disease via gait parameters. <i>PLoS ONE</i> , 2021, 16, e0244396.	1.1	28
6734	A robust method for the detection of small changes in relaxation parameters and free water content in the vicinity of the substantia nigra in Parkinsonâ€™s disease patients. <i>PLoS ONE</i> , 2021, 16, e0247552.	1.1	3
6735	Utility of manual fractional anisotropy measurements in the management of patients with Parkinson disease: a feasibility study with a 1.5-T magnetic resonance imaging system. <i>Acta Radiologica Open</i> , 2021, 10, 205846012199347.	0.3	1
6736	Clinical and Neurophysiological Effects of the Therapeutic Combination of High-Frequency Rhythmic Transcranial Magnetic Stimulation of the Motor and Frontal Cortex in Parkinsonâ€™s Disease. <i>Neuroscience and Behavioral Physiology</i> , 2021, 51, 135-141.	0.2	3
6737	Revisiting the L-Dopa Response as a Predictor of Motor Outcomes After Deep Brain Stimulation in Parkinsonâ€™s Disease. <i>Frontiers in Human Neuroscience</i> , 2021, 15, 604433.	1.0	14
6738	Dopaminergic Treatment Effects on Dysarthric Speech: Acoustic Analysis in a Cohort of Patients With Advanced Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 616062.	1.1	19
6739	Bilingualism in Parkinsonâ€™s disease: Relationship to cognition and quality of life. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2021, 43, 199-212.	0.8	3
6740	Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinsonâ€™s disease patients. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 84-89.	0.4	3
6741	microRNA signatures in prodromal REM sleep behavior disorder and early Parkinson's disease as noninvasive biomarkers. <i>Sleep Medicine</i> , 2021, 78, 160-168.	0.8	6
6742	Reduced Regional NREM Sleep Slow-Wave Activity Is Associated With Cognitive Impairment in Parkinson Disease. <i>Frontiers in Neurology</i> , 2021, 12, 618101.	1.1	21
6743	Recognizing Parkinsonâ€™s disease gait patterns by vibes algorithm and Hilbert-Huang transform. <i>Engineering Science and Technology, an International Journal</i> , 2021, 24, 112-125.	2.0	9
6744	Profiling Inflammatory Extracellular Vesicles in Plasma and Cerebrospinal Fluid: An Optimized Diagnostic Model for Parkinsonâ€™s Disease. <i>Biomedicines</i> , 2021, 9, 230.	1.4	12
6745	A new quantitative index in the diagnosis of Parkinson syndrome by dopamine transporter single-photon emission computed tomography. <i>Annals of Nuclear Medicine</i> , 2021, 35, 504-513.	1.2	3
6746	Regional Gray Matter Volume Changes in Parkinsonâ€™s Disease with Orthostatic Hypotension. <i>Brain Sciences</i> , 2021, 11, 294.	1.1	3
6747	Bilateral subthalamic nucleus deep brain stimulation is an effective treatment for diphasic dyskinesia. <i>European Journal of Neurology</i> , 2021, 28, 1574-1580.	1.7	3
6748	LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease. <i>Neurobiology of Aging</i> , 2021, 103, 142.e1-142.e5.	1.5	11

#	ARTICLE	IF	CITATIONS
6749	Iron accumulation in the oculomotor nerve of the progressive supranuclear palsy brain. <i>Scientific Reports</i> , 2021, 11, 2950.	1.6	3
6750	Geospatial analysis of individual-based Parkinson's disease data supports a link with air pollution: A case-control study. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 41-48.	1.1	18
6751	Association study of MCCC1/LAMP3 and DGKQ variants with Parkinson's disease in patients of Malay ancestry. <i>Neurological Sciences</i> , 2021, 42, 4203-4207.	0.9	5
6752	Incidence of antidepressant use among community dwellers with and without Parkinson's disease – a nationwide cohort study. <i>BMC Geriatrics</i> , 2021, 21, 202.	1.1	11
6753	A Goal Intervention Improves Language Fluency: Evidence from Parkinson's Disease and Healthy Aging. <i>Medicines (Basel, Switzerland)</i> , 2021, 8, 15.	0.7	2
6754	Amyloid related cerebral microbleed and plasma A β 40 are associated with cognitive decline in Parkinson's disease. <i>Scientific Reports</i> , 2021, 11, 7115.	1.6	14
6755	Cytokine Profile in Plasma Extracellular Vesicles of Parkinson's Disease and the Association with Cognitive Function. <i>Cells</i> , 2021, 10, 604.	1.8	21
6756	Do indices of baroreflex failure and peripheral noradrenergic deficiency predict the magnitude of orthostatic hypotension in Lewy body diseases?. <i>Clinical Autonomic Research</i> , 2021, 31, 543-551.	1.4	5
6757	Cardiac ¹⁸ F- β -Dopamine PET Distinguishes PD with Orthostatic Hypotension from Parkinsonian MSA. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 582-586.	0.8	15
6758	Effect of diabetes control status on the progression of Parkinson's disease: A prospective study. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 887-897.	1.7	18
6760	Clinical Variability of SYNJ1-Associated Early-Onset Parkinsonism. <i>Frontiers in Neurology</i> , 2021, 12, 648457.	1.1	11
6761	Integrated 18F-T807 Tau PET, Structural MRI, and Plasma Tau in Tauopathy Neurodegenerative Disorders. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 646440.	1.7	13
6762	A Case-Control Study of the Effects of Chimarrão (Ilex paraguariensis) and Coffee on Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 619535.	1.1	5
6763	Exploratory pilot study of exogenous sustained-release melatonin on nocturia in Parkinson's disease. <i>European Journal of Neurology</i> , 2021, 28, 1884-1892.	1.7	19
6764	Tremor, Hallucinations, and Cognitive Decline. , 2021, , 109-111.		0
6765	Visual cues added to a virtual environment paradigm do not improve motor arrests in Parkinson's disease. <i>Journal of Neural Engineering</i> , 2021, 18, 046009.	1.8	0
6766	Genetic Analysis of ZNF Protein Family Members for Early-Onset Parkinson's Disease in Chinese Population. <i>Molecular Neurobiology</i> , 2021, 58, 3435-3442.	1.9	12
6767	Functional and Cognitive Improvement After an Intensive Inpatient Multidisciplinary Rehabilitation Program in Mild to Severe Parkinson's Disease: A Retrospective and Observational Study. <i>Frontiers in Neurology</i> , 2021, 12, 626041.	1.1	4

#	ARTICLE	IF	CITATIONS
6768	Poly (ADP-ribose) polymerase 1 and Parkinson's disease: A study in post-mortem human brain. <i>Neurochemistry International</i> , 2021, 144, 104978.	1.9	8
6769	Cross-sectional associations between cognition and mobility in Parkinson's disease. <i>Dementia & Neuropsychologia</i> , 2021, 15, 105-111.	0.3	9
6770	The Effect of Dopaminergic Replacement Therapy on Creative Thinking and Insight Problem-Solving in Parkinson's Disease Patients. <i>Frontiers in Psychology</i> , 2021, 12, 646448.	1.1	8
6771	Predicting the Severity of Parkinson's Disease Dementia by Assessing the Neuropsychiatric Symptoms with an SVM Regression Model. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2551.	1.2	10
6772	Association of Gyrfication Pattern, White Matter Changes, and Phenotypic Profile in Patients With Parkinson Disease. <i>Neurology</i> , 2021, 96, e2387-e2394.	1.5	11
6773	Extradural Motor Cortex Stimulation in Parkinson's Disease: Long-Term Clinical Outcome. <i>Brain Sciences</i> , 2021, 11, 416.	1.1	6
6775	Expiratory Muscle Strength Training for Therapy of Pharyngeal Dysphagia in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1815-1824.	2.2	33
6776	A Self-Reported Clinical Tool Predicts Falls in People with Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 427-434.	0.8	4
6777	Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker. <i>Movement Disorders</i> , 2021, 36, 1592-1602.	2.2	52
6778	Mutation analysis of seven SLC family transporters for early-onset Parkinson's disease in Chinese population. <i>Neurobiology of Aging</i> , 2021, 103, 152.e1-152.e6.	1.5	10
6779	Risk and mortality of aspiration pneumonia in Parkinson's disease: a nationwide database study. <i>Scientific Reports</i> , 2021, 11, 6597.	1.6	37
6780	The efficacy of repetitive transcranial magnetic stimulation on emotional processing in apathetic patients with Parkinson's disease: A Placebo-controlled ERP study. <i>Journal of Affective Disorders</i> , 2021, 282, 776-785.	2.0	6
6781	The TOMM40 523 polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson's disease. <i>Scientific Reports</i> , 2021, 11, 6363.	1.6	6
6782	Selegiline reduces daytime sleepiness in patients with Parkinson's disease. <i>Brain and Behavior</i> , 2021, 11, e01880.	1.0	11
6783	ALDH1A1 Genetic Variations May Modulate Risk of Parkinson's Disease in Han Chinese Population. <i>Frontiers in Neuroscience</i> , 2021, 15, 620929.	1.4	10
6784	Molecularly Imprinted Poly(2-phenylenediamine) Electrochemical Sensor for Entacapone. <i>Electroanalysis</i> , 2021, 33, 1578-1584.	1.5	6
6785	Global Variability in Deep Brain Stimulation Practices for Parkinson's Disease. <i>Frontiers in Human Neuroscience</i> , 2021, 15, 667035.	1.0	9
6786	Measurement and Correction of Stooped Posture during Gait Using Wearable Sensors in Patients with Parkinsonism: A Preliminary Study. <i>Sensors</i> , 2021, 21, 2379.	2.1	1

#	ARTICLE	IF	CITATIONS
6787	Sequential motion rate and oral reading rate: normative data for Greek and clinical implications. <i>Logopedics Phoniatrics Vocology</i> , 2022, 47, 177-182.	0.5	5
6788	Impaired Touchscreen Skills in Parkinson's Disease and Effects of Medication. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 546-554.	0.8	4
6789	The Lee Silverman Voice Treatment Improves Vocal Loudness in Early Persian-speaking Patients With Parkinson's Disease. <i>Iranian Rehabilitation Journal</i> , 2021, 19, 75-84.	0.1	1
6790	Closed-loop programming using external responses for deep brain stimulation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 84, 47-51.	1.1	23
6791	Memory enhancement by multidomain group cognitive training in patients with Parkinson's disease and mild cognitive impairment: long-term effects of a multicenter randomized controlled trial. <i>Journal of Neurology</i> , 2021, 268, 4655-4666.	1.8	8
6792	Kinesiophobia in Stroke Patients, Multiple Sclerosis and Parkinson's Disease. <i>Diagnostics</i> , 2021, 11, 796.	1.3	8
6793	Malnutrition and related factors in Filipino patients with Parkinson's disease: results from a pilot study. <i>Neurodegenerative Disease Management</i> , 2021, 11, 125-135.	1.2	0
6794	Corneal Confocal Microscopy Identifies Parkinson's Disease with More Rapid Motor Progression. <i>Movement Disorders</i> , 2021, 36, 1927-1934.	2.2	16
6795	Association study of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson's disease. <i>Neurobiology of Aging</i> , 2021, 100, 119.e7-119.e13.	1.5	19
6796	Disrupted morphological grey matter networks in early-stage Parkinson's disease. <i>Brain Structure and Function</i> , 2021, 226, 1389-1403.	1.2	16
6797	Regional cerebral cholinergic nerve terminal integrity and cardinal motor features in Parkinson's disease. <i>Brain Communications</i> , 2021, 3, fcb109.	1.5	21
6798	Fixation Duration and Pupil Size as Diagnostic Tools in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 865-875.	1.5	23
6799	Automatic classification of idiopathic Parkinson's disease and atypical Parkinsonian syndromes combining [¹¹ C]raclopride PET uptake and MRI grey matter morphometry. <i>Journal of Neural Engineering</i> , 2021, 18, 046037.	1.8	15
6800	Diagnostic criteria for Parkinson's disease. <i>Russian Journal of Geriatric Medicine</i> , 2021, , 92-96.	0.3	0
6801	Dual-Task Costs of Quantitative Gait Parameters While Walking and Turning in People with Parkinson's Disease: Beyond Gait Speed. <i>Journal of Parkinson's Disease</i> , 2021, 11, 653-664.	1.5	13
6802	Genetic Modifiers of Age at Onset for Parkinson's Disease in Asians: A Genome-Wide Association Study. <i>Movement Disorders</i> , 2021, 36, 2077-2084.	2.2	15
6803	Arithmetic Errors in Financial Contexts in Parkinson's Disease. <i>Frontiers in Psychology</i> , 2021, 12, 629984.	1.1	3
6804	BeatWalk: Personalized Music-Based Gait Rehabilitation in Parkinson's Disease. <i>Frontiers in Psychology</i> , 2021, 12, 655121.	1.1	22

#	ARTICLE	IF	CITATIONS
6805	Neuropathological correlation supports automated image-based differential diagnosis in parkinsonism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3522-3529.	3.3	9
6806	Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2085-2093.	2.2	23
6807	Interoception Primes Emotional Processing: Multimodal Evidence from Neurodegeneration. <i>Journal of Neuroscience</i> , 2021, 41, 4276-4292.	1.7	54
6808	Impact of Manual Coordination on Usability of Clothing Fasteners in People With Parkinson's Disease. <i>Ergonomics in Design</i> , 0, , 106480462110055.	0.4	1
6809	Comparing the Clinical and Neuropsychological Characteristics of Parkinson's Disease With and Without Freezing of Gait. <i>Frontiers in Neuroscience</i> , 2021, 15, 660340.	1.4	6
6810	Fibroblast Growth Factor 20 Gene Polymorphism in Parkinson's Disease in Asian Population: A Meta-Analysis. <i>Genes</i> , 2021, 12, 674.	1.0	1
6811	Validation of Î±-Synuclein in L1CAM-Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes. <i>Movement Disorders</i> , 2021, 36, 2663-2669.	2.2	62
6812	Impact of DaTscan Imaging on Clinical Decision Making in Clinically Uncertain Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 885-889.	1.5	8
6813	Synergistic Association between Plasma A β ₄₂ and p-tau in Alzheimer's Disease but Not in Parkinson's Disease or Frontotemporal Dementia. <i>ACS Chemical Neuroscience</i> , 2021, 12, 1376-1383.	1.7	9
6814	Preditor de qualidade de vida em indivíduos com doença de Parkinson moderada. <i>Revista Brasileira De EducaçãO Física E Esporte: RBEFE</i> , 2021, 35, 15-24.	0.1	1
6815	Pupillary Response to Postural Demand in Parkinson's Disease. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 617028.	2.0	6
6816	Utility of Multi-Modal MRI for Differentiating of Parkinson's Disease and Progressive Supranuclear Palsy Using Machine Learning. <i>Frontiers in Neurology</i> , 2021, 12, 648548.	1.1	25
6817	Oral Dysbiosis and Inflammation in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 619-631.	1.5	35
6818	Neuroprotective Effects of a GLP-2 Analogue in the MPTP Parkinson's Disease Mouse Model. <i>Journal of Parkinson's Disease</i> , 2021, 11, 529-543.	1.5	9
6819	Conveyance of cortical pacing for parkinsonian tremor-like hyperkinetic behavior by subthalamic dysrhythmia. <i>Cell Reports</i> , 2021, 35, 109007.	2.9	5
6820	Opposite effects of one session of 1ÂHz rTMS on functional connectivity between pre-supplementary motor area and putamen depending on the dyskinesia state in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2021, 132, 851-856.	0.7	9
6821	Probable REM Sleep Behavior Disorder Is a Risk Factor for Symptom Progression in Parkinson Disease. <i>Frontiers in Neurology</i> , 2021, 12, 651157.	1.1	8
6822	Altered Inhibitory Mechanisms in Parkinson's Disease: Evidence From Lexical Decision and Simple Reaction Time Tasks. <i>Frontiers in Human Neuroscience</i> , 2021, 15, 624026.	1.0	2

#	ARTICLE	IF	CITATIONS
6823	Perception of biological motion. No sensitivity differences between patients with Parkinson's disease and healthy observers. <i>Applied Neuropsychology Adult</i> , 2021, , 1-8.	0.7	2
6824	Spatial attention and spatial short term memory in PSP and Parkinson's disease. <i>Cortex</i> , 2021, 137, 49-60.	1.1	7
6825	DIAGNOSIS OF EARLY STAGE PARKINSON'S DISEASE ON QUANTITATIVE SUSCEPTIBILITY MAPPING USING COMPLEX NETWORK WITH ONE-WAY ANOVA F-TEST FEATURE SELECTION. <i>Journal of Mechanics in Medicine and Biology</i> , 2021, 21, 2140026.	0.3	8
6826	Dopaminergic Correlates of Orthostatic Hypotension in de novo Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 665-673.	1.5	1
6827	Psychometric Properties of the Clinical Dementia Rating Scale Sum of Boxes in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 737-745.	1.5	5
6828	Automated assessment of the substantia nigra on susceptibility map-weighted imaging using deep convolutional neural networks for diagnosis of Idiopathic Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 85, 84-90.	1.1	15
6829	Depression and Related Factors in Patients with Parkinson's Disease at High Altitude. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 1353-1362.	1.0	6
6830	Differences in Levodopa Response for Progressive and Non-Progressive Micrographia in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 665112.	1.1	6
6831	Aberrant Salient and Corticolimbic Connectivity in Hypersexual Parkinson's Disease. <i>Brain Connectivity</i> , 2021, 11, 639-650.	0.8	9
6832	Thalamic volume mediates associations between cardiorespiratory fitness (VO2max) and cognition in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 19-26.	1.1	5
6833	Binary dance rhythm or Quaternary dance rhythm which has the greatest effect on non-motor symptoms of individuals with Parkinson's disease?. <i>Complementary Therapies in Clinical Practice</i> , 2021, 43, 101348.	0.7	4
6834	Subthalamic deep brain stimulation induces finely-tuned gamma oscillations in the absence of levodopa. <i>Neurobiology of Disease</i> , 2021, 152, 105287.	2.1	27
6835	Molecular Imaging of Extrapyrmidal Movement Disorders With Dementia: The 4R Tauopathies. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 275-285.	2.5	3
6836	Linking Stage-Specific Plasma Biomarkers to Gray Matter Atrophy in Parkinson Disease. <i>American Journal of Neuroradiology</i> , 2021, 42, 1444-1451.	1.2	4
6837	Self-adjustment of deep brain stimulation delays optimization in Parkinson's disease. <i>Brain Stimulation</i> , 2021, 14, 676-681.	0.7	6
6838	Motor Symptom Lateralization Influences Cortico-Striatal Functional Connectivity in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 619631.	1.1	6
6839	Association Analyses of SNAP25, HNMT, FCHSD1, and DBH Single-Nucleotide Polymorphisms with Parkinson's Disease in a Northern Chinese Population. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 1689-1695.	1.0	3
6840	Recognition and Management of Antipsychotic-Induced Parkinsonism in Older Adults: A Narrative Review. <i>Medicines (Basel, Switzerland)</i> , 2021, 8, 24.	0.7	5

#	ARTICLE	IF	CITATIONS
6841	Regulatory rare variants of the dopaminergic gene ANKK1 as potential risk factors for Parkinson's disease. <i>Scientific Reports</i> , 2021, 11, 9879.	1.6	4
6842	The impact of Brazilian samba on balance and quality of life of individuals with Parkinson's disease. <i>Revista Brasileira De Atividade Física E Saude</i> , 0, 26, 1-7.	0.1	0
6843	α -Synuclein in Plasma-Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2508-2518.	2.2	47
6844	Oxygen uptake efficiency slope: A submaximal test evaluation tool that provides cardiopulmonary reserve data in individuals with Parkinson's disease. <i>Brazilian Journal of Physical Therapy</i> , 2021, 25, 641-647.	1.1	2
6845	Consistent skin α -synuclein positivity in REM sleep behavior disorder – A two center two-to-four-year follow-up study. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 108-113.	1.1	16
6846	The Contribution of Small Vessel Disease to Neurodegeneration: Focus on Alzheimer's Disease, Parkinson's Disease and Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4958.	1.8	28
6847	Association between Fatigue and Hoehn-Yahr Staging in Parkinson's Disease: Eight-Year Follow-Up Study. <i>Neurology International</i> , 2021, 13, 224-231.	1.3	4
6848	Radiomics on routine T1-weighted MRI can delineate Parkinson's disease from multiple system atrophy and progressive supranuclear palsy. <i>European Radiology</i> , 2021, 31, 8218-8227.	2.3	15
6849	Subthalamic nucleus deep brain stimulation and impulsivity in Parkinson's disease: a descriptive review. <i>Acta Neurologica Belgica</i> , 2021, 121, 837-847.	0.5	4
6850	Do peripheral immune and neurotrophic markers correlate with motor severity of Parkinson's disease?. <i>Journal of Neuroimmunology</i> , 2021, 354, 577545.	1.1	6
6851	Increased Added Sugar Consumption Is Common in Parkinson's Disease. <i>Frontiers in Nutrition</i> , 2021, 8, 628845.	1.6	23
6852	The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease. <i>Brain</i> , 2021, 144, 3114-3125.	3.7	65
6853	Serum Ceruloplasmin Depletion is Associated With Magnetic Resonance Evidence of Widespread Accumulation of Brain Iron in Parkinson's Disease. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 54, 1098-1106.	1.9	9
6854	Ability of a Set of Trunk Inertial Indexes of Gait to Identify Gait Instability and Recurrent Fallers in Parkinson's Disease. <i>Sensors</i> , 2021, 21, 3449.	2.1	13
6855	Desulfovibrio Bacteria Are Associated With Parkinson's Disease. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 652617.	1.8	82
6856	Cerebrospinal α -Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort. <i>Movement Disorders</i> , 2021, 36, 2048-2056.	2.2	21
6857	Decoupling of Global Brain Activity and Cerebrospinal Fluid Flow in Parkinson's Disease Cognitive Decline. <i>Movement Disorders</i> , 2021, 36, 2066-2076.	2.2	26
6858	Plasma Extracellular Vesicle α -Synuclein Level in Patients with Parkinson's Disease. <i>Biomolecules</i> , 2021, 11, 744.	1.8	16

#	ARTICLE	IF	CITATIONS
6859	Clinical Diagnostic Criteria Have a High Impact on the Frequency of Dementia in Late-Stage Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 652424.	1.1	2
6860	Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder. <i>Npj Parkinson's Disease</i> , 2021, 7, 40.	2.5	9
6861	Smartphone-Based Neuropsychological Assessment in Parkinson's Disease: Feasibility, Validity, and Contextually Driven Variability in Cognition. <i>Journal of the International Neuropsychological Society</i> , 2022, 28, 401-413.	1.2	15
6862	Baseline cognitive profile is closely associated with long-term motor prognosis in newly diagnosed Parkinson's disease. <i>Journal of Neurology</i> , 2021, 268, 4203-4212.	1.8	8
6863	Does Parkinson's Disease Increase the Risk of Atrial Fibrillation? Insights From Electrocardiogram and Risk Scores From a Case-Control Study. <i>Frontiers in Neurology</i> , 2021, 12, 633900.	1.1	5
6865	Patterns of Sulcal depth and cortical thickness in Parkinson's disease. <i>Brain Imaging and Behavior</i> , 2021, 15, 2340-2346.	1.1	6
6866	Mitochondrial D-Loop Region Methylation and Copy Number in Peripheral Blood DNA of Parkinson's Disease Patients. <i>Genes</i> , 2021, 12, 720.	1.0	14
6867	Challenges in the diagnosis of Parkinson's disease. <i>Lancet Neurology</i> , The, 2021, 20, 385-397.	4.9	468
6868	Brain connectivity markers in advanced Parkinson's disease for predicting mild cognitive impairment. <i>European Radiology</i> , 2021, 31, 9324-9334.	2.3	9
6869	Effect of orofacial physiotherapeutic and hygiene interventions on oral health-related quality of life in patients with Parkinson's disease: A randomised controlled trial. <i>Journal of Oral Rehabilitation</i> , 2021, 48, 1035-1043.	1.3	9
6870	Clinical and Genetic Analysis of Psychosis in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1973-1980.	1.5	4
6871	Protocol for the DeFOG trial: A randomized controlled trial on the effects of smartphone-based, on-demand cueing for freezing of gait in Parkinson's disease. <i>Contemporary Clinical Trials Communications</i> , 2021, 24, 100817.	0.5	11
6872	Deficits in or preservation of basic number processing in Parkinson's disease? A registered report. <i>Journal of Neuroscience Research</i> , 2021, 99, 2390-2405.	1.3	0
6873	R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils. <i>Acta Neuropathologica</i> , 2021, 142, 475-494.	3.9	44
6874	Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease: A Single-Center, Long-Term Follow-Up Study of the Causes for Discontinuation. <i>Journal of Personalized Medicine</i> , 2021, 11, 525.	1.1	7
6875	Polymorphisms of Interleukin-6 and Interleukin-8 Are Not Associated with Parkinson's Disease in Taiwan. <i>Brain Sciences</i> , 2021, 11, 768.	1.1	1
6876	Neuronal autophagy and mitophagy in Parkinson's disease. <i>Molecular Aspects of Medicine</i> , 2021, 82, 100972.	2.7	49
6877	Impaired dopamine metabolism is linked to fatigability in mice and fatigue in Parkinson's disease patients. <i>Brain Communications</i> , 2021, 3, fcab116.	1.5	5

#	ARTICLE	IF	CITATIONS
6878	Longitudinal changes in movement-related functional MRI activity in Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 61-69.	1.1	2
6879	Comparison of Laboratory and Daily-Life Gait Speed Assessment during ON and OFF States in Parkinson's Disease. <i>Sensors</i> , 2021, 21, 3974.	2.1	13
6880	Central Pain in Parkinson's Disease: Behavioral and Cognitive Characteristics. <i>Parkinson's Disease</i> , 2021, 2021, 1-7.	0.6	1
6881	Sensorimotor Cough Dysfunction Is Prevalent and Pervasive in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2021, 36, 2624-2633.	2.2	10
6882	Cardiovascular and cerebrovascular risk markers in Parkinson's disease: Results from a case-control study. <i>European Journal of Neurology</i> , 2021, 28, 2669-2679.	1.7	4
6883	Effects of resistance training on postural control in Parkinson's disease: a randomized controlled trial. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 511-520.	0.3	4
6884	Semantic verbal fluency: network analysis in Alzheimer's and Parkinson's disease. <i>Journal of Cognitive Psychology</i> , 2021, 33, 557-567.	0.4	2
6885	Study of cognitive impairment and genetic polymorphism of SLC41A1 (rs11240569 allele) in Parkinson's disease in Upper Egypt: case-control study. <i>Egyptian Journal of Neurology, Psychiatry and Neurosurgery</i> , 2021, 57, .	0.4	1
6886	Fields of Forel Brain Stimulation Improves Levodopa-Unresponsive Gait and Balance Disorders in Parkinson's Disease. <i>Neurosurgery</i> , 2021, 89, 450-459.	0.6	3
6887	Progressive microstructural alterations in subcortical nuclei in Parkinson's disease: A diffusion magnetic resonance imaging study. <i>Parkinsonism and Related Disorders</i> , 2021, 88, 82-89.	1.1	10
6888	The Impact of Dietary Intake and Physical Activity on Body Composition in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 896-903.	0.8	1
6889	Comparison between four published definitions of hyposmia in Parkinson's disease. <i>Brain and Behavior</i> , 2021, 11, e2258.	1.0	4
6890	Reasons for hospitalization and factors of mortality in patients with Parkinson's disease in the Philippines. <i>Neurodegenerative Disease Management</i> , 2021, 11, 229-238.	1.2	0
6891	Pragmatic abilities in early Parkinson's disease. <i>Brain and Cognition</i> , 2021, 150, 105706.	0.8	8
6892	Neuropsychiatric Burden Is a Predictor of Early Freezing and Motor Progression in Drug-Naïve Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1-10.	1.5	9
6893	The Genetics of Parkinson's Disease and Implications for Clinical Practice. <i>Genes</i> , 2021, 12, 1006.	1.0	81
6894	Validation of Blood Pressure Measurement Using a Smartwatch in Patients With Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 650929.	1.1	16
6895	RNA-sequencing of peripheral blood circular RNAs in Parkinson disease. <i>Medicine (United States)</i> , 2021, 100, e25888.	0.4	18

#	ARTICLE	IF	CITATIONS
6896	Long-term Outcomes (15 Years) After Subthalamic Nucleus Deep Brain Stimulation in Patients With Parkinson Disease. <i>Neurology</i> , 2021, 97, .	1.5	71
6897	Changes in Metabolic Activity and Gait Function by Dual-Task Cognitive Game-Based Treadmill System in Parkinsonâ€™s Disease: Protocol of a Randomized Controlled Trial. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 680270.	1.7	5
6898	The Cerebellum Is a Common Key for Visuospatial Execution and Attention in Parkinsonâ€™s Disease. <i>Diagnostics</i> , 2021, 11, 1042.	1.3	4
6899	Elevated HDL Levels Linked to Poorer Cognitive Ability in Females With Parkinsonâ€™s Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 656623.	1.7	7
6900	Pharmacokinetic Modeling of ¹⁸ F-FDOPA PET in the Human Brain for Early Parkinsonâ€™s Disease. <i>Molecular Imaging and Radionuclide Therapy</i> , 2021, 30, 69-78.	0.3	2
6901	Subjective organization in the episodic memory of individuals with Parkinsonâ€™s disease associated with mild cognitive impairment. <i>Journal of Neuropsychology</i> , 2021, , .	0.6	1
6902	Functional Connectivity of Vermis Correlates with Future Gait Impairments in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2559-2568.	2.2	13
6903	Slow Motion Analysis of Repetitive Tapping (SMART) Test: Measuring Bradykinesia in Recently Diagnosed Parkinsonâ€™s Disease and Idiopathic Anosmia. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1901-1915.	1.5	6
6904	<sc>HybraPD</sc> atlas: Towards precise subcortical nuclei segmentation using multimodality medical images in patients with Parkinson disease. <i>Human Brain Mapping</i> , 2021, 42, 4399-4421.	1.9	14
6905	Cholinergic basal forebrain and hippocampal structure influence visuospatial memory in Parkinsonâ€™s disease. <i>Brain Imaging and Behavior</i> , 2022, 16, 118-129.	1.1	7
6906	Investigation of Plasma PGC1-Î±, Irisin, BDNF, GAL, and GALP Levels in Parkinson's Disease. <i>Cumhuriyet Âœniversitesi SaÄŸlık Bilimleri Enstitüsü Dergisi</i> , 0, , .	0.0	0
6907	Parkinson's diseaseâ€™related changes in the behavioural synergy between eye movements and postural movements. <i>European Journal of Neuroscience</i> , 2021, 54, 5161-5172.	1.2	3
6908	Measuring the Effect of Rhythmic Auditory Stimuli on Parkinsonian Gait in Challenging Settings. , 2021, , .		0
6909	Longitudinal clinical, cognitive, and neuroanatomical changes over 5 years in GBA-positive Parkinsonâ€™s disease patients. <i>Journal of Neurology</i> , 2022, 269, 1485-1500.	1.8	24
6910	Case-control study of hypertension and Parkinsonâ€™s disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 63.	2.5	8
6911	Rare Variants Analysis of Lysosomal Related Genes in Early-Onset and Familial Parkinsonâ€™s Disease in a Chinese Cohort. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1845-1855.	1.5	6
6912	Computerized Dual-Task Testing of Gait Visuomotor and Cognitive Functions in Parkinsonâ€™s Disease: Test-Retest Reliability and Validity. <i>Frontiers in Human Neuroscience</i> , 2021, 15, 706230.	1.0	3
6913	Rivastigmine for minor visual hallucinations in Parkinson's disease: A randomized controlled trial with 24 months follow-up. <i>Brain and Behavior</i> , 2021, 11, e2257.	1.0	11

#	ARTICLE	IF	CITATIONS
6914	Clinical application of magnetic resonance-guided focused ultrasound in Parkinson's disease: a meta-analysis of randomized clinical trials. <i>Neurological Sciences</i> , 2021, 42, 3595-3604.	0.9	3
6915	Psycho-sensory modalities of visual hallucinations and illusions in Parkinson's disease. <i>Revue Neurologique</i> , 2021, 177, 1228-1236.	0.6	3
6916	Adult-onset mitochondrial movement disorders: a national picture from the Italian Network. <i>Journal of Neurology</i> , 2022, 269, 1413-1421.	1.8	10
6917	Multidimensional Factors Can Explain the Clinical Worsening in People With Parkinson's Disease During the COVID-19 Pandemic: A Multicenter Cross-Sectional Trial. <i>Frontiers in Neurology</i> , 2021, 12, 708433.	1.1	14
6918	Dual-task intervention based on trail making test: Effects on Parkinson's disease. <i>Journal of Bodywork and Movement Therapies</i> , 2021, 27, 628-633.	0.5	8
6920	Diagnostic performance of T2* gradient echo, susceptibility-weighted imaging, and quantitative susceptibility mapping for patients with multiple system atrophy parkinsonian type: a systematic review and meta-analysis. <i>European Radiology</i> , 2022, 32, 308-318.	2.3	6
6921	When fruits lose to animals: Disorganized search of semantic memory in Parkinson's disease. <i>Neuropsychology</i> , 2021, 35, 529-539.	1.0	3
6922	Attention switching deficit in patients of Parkinson's disease who experience freezing of gait. <i>Applied Neuropsychology Adult</i> , 2023, 30, 389-400.	0.7	1
6923	Cognition and transcranial sonography in Parkinson's disease patients with or without orthostatic hypotension. <i>Brain and Behavior</i> , 2021, 11, e2252.	1.0	2
6925	Genetic polymorphisms in the renin-angiotensin system and cognitive decline in Parkinson's disease. <i>Molecular Biology Reports</i> , 2021, 48, 5541-5548.	1.0	3
6926	Physical Activity in De Novo Parkinson Disease: Daily Step Recommendation and Effects of Treadmill Exercise on Physical Activity. <i>Physical Therapy</i> , 2021, 101, .	1.1	5
6927	Parkinson's disease multimodal imaging: F-DOPA PET, neuromelanin-sensitive and quantitative iron-sensitive MRI. <i>Npj Parkinson's Disease</i> , 2021, 7, 57.	2.5	31
6928	Normal-sized basal ganglia perivascular space related to motor phenotype in Parkinson freezers. <i>Aging</i> , 2021, 13, 18912-18923.	1.4	8
6929	Action Observation and Motor Imagery Improve Dual Task in Parkinson's Disease: A Clinical fMRI Study. <i>Movement Disorders</i> , 2021, 36, 2569-2582.	2.2	34
6930	Can Task Specificity Impact tDCS-Linked to Dual Task Training Gains in Parkinson's Disease? A Protocol for a Randomized Controlled Trial. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 684689.	1.7	2
6931	Diagnostic accuracy of dual-phase 18F-FP-CIT PET imaging for detection and differential diagnosis of Parkinsonism. <i>Scientific Reports</i> , 2021, 11, 14992.	1.6	14
6932	Prevalence and Cumulative Incidence of Caregiver-Reported Aggression in Advanced Parkinson Disease and Related Disorders. <i>Neurology: Clinical Practice</i> , 2021, 11, e826-e833.	0.8	4
6933	Striatal Acetylcholine Dopamine Imbalance in Parkinson Disease: In Vivo Neuroimaging Study with Dual-Tracer PET and Dopaminergic PET-Informed Correlational Tractography. <i>Journal of Nuclear Medicine</i> , 2022, 63, 438-445.	2.8	19

#	ARTICLE	IF	CITATIONS
6934	Longitudinal evolution of non-motor symptoms in early Parkinson's disease: a 3-year prospective cohort study. <i>Npj Parkinson's Disease</i> , 2021, 7, 58.	2.5	9
6935	Investigation of the peripheral inflammation (neutrophil-lymphocyte ratio) in two neurodegenerative diseases of the central nervous system. <i>Neurological Sciences</i> , 2022, 43, 1799-1807.	0.9	29
6936	Association of ITPKB, IL1R2 and COQ7 with Parkinson's disease in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2021, , .	0.8	5
6938	Hemodynamic response to exercise is impaired in individuals with Parkinson's disease. <i>Journal of Sports Medicine and Physical Fitness</i> , 2021, , .	0.4	0
6939	Identifying Mild Cognitive Impairment in Parkinson's Disease With Electroencephalogram Functional Connectivity. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 701499.	1.7	11
6940	Attenuated Postprandial GLP-1 Response in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2021, 15, 660942.	1.4	7
6941	Anxiety in Parkinson's Disease: A Systematic Review of Neuroimaging Studies. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2021, 33, 280-294.	0.9	6
6942	Short-term deceleration capacity of heart rate: a sensitive marker of cardiac autonomic dysfunction in idiopathic Parkinson's disease. <i>Clinical Autonomic Research</i> , 2021, 31, 729-736.	1.4	2
6943	Aberrant cerebral perfusion pattern in amnesic mild cognitive impairment and Parkinson's disease with mild cognitive impairment: a comparative arterial spin labeling study. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 3082-3097.	1.1	9
6944	Being physically active minimizes the effects of leg muscle fatigue on obstacle negotiation in people with Parkinson's disease. <i>Journal of Biomechanics</i> , 2021, 124, 110568.	0.9	1
6945	Global efficiency of the motor network is decreased in Parkinson's disease in comparison with essential tremor and healthy controls. <i>Brain and Behavior</i> , 2021, 11, e02178.	1.0	7
6946	Distinct progression patterns across Parkinson disease clinical subtypes. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1695-1708.	1.7	4
6947	Brain Atrophy Mediates the Relationship between Misfolded Proteins Deposition and Cognitive Impairment in Parkinson's Disease. <i>Journal of Personalized Medicine</i> , 2021, 11, 702.	1.1	4
6948	Semantic Memory and Lexical Availability in Parkinson's Disease: A Statistical Learning Study. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 697065.	1.7	4
6949	Drooling, Swallowing Difficulties and Health Related Quality of Life in Parkinson's Disease Patients. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8138.	1.2	7
6950	The Effect of Deep Brain Stimulation of the Subthalamic Nucleus on Language Function in Parkinson's Disease: A Systematic Review. <i>Journal of Speech, Language, and Hearing Research</i> , 2021, 64, 2794-2810.	0.7	8
6951	<sc><i>ANXA1</i></sc> with Anti-inflammatory Properties Might Contribute to Parkinsonism. <i>Annals of Neurology</i> , 2021, 90, 319-323.	2.8	7
6952	Rekindling Action Language: A Neuromodulatory Study on Parkinson's Disease Patients. <i>Brain Sciences</i> , 2021, 11, 887.	1.1	7

#	ARTICLE	IF	CITATIONS
6953	Characteristics of sagittal spinopelvic alignment in patients with Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2022, 145, 53-62.	1.0	3
6954	Abnormal Topological Network in Parkinson's Disease With Impulse Control Disorders: A Resting-State Functional Magnetic Resonance Imaging Study. <i>Frontiers in Neuroscience</i> , 2021, 15, 651710.	1.4	1
6955	Deconstructing Apathy in Parkinson's Disease: Challenges in Isolating Core Components of Apathy From Depression, Anxiety, and Fatigue. <i>Frontiers in Neurology</i> , 2021, 12, 720921.	1.1	5
6956	Cognitive Determinants of Dysarthria in Parkinson's Disease: An Automated Machine Learning Approach. <i>Movement Disorders</i> , 2021, 36, 2862-2873.	2.2	36
6957	Does antiretroviral therapy alter the course of Parkinson's disease in people living with HIV?. <i>Journal of NeuroVirology</i> , 2021, 27, 595-600.	1.0	3
6958	The Impact of Non-dopaminergic Medication on Quality of Life in Parkinson's Disease. <i>Clinical Drug Investigation</i> , 2021, 41, 809-816.	1.1	1
6959	Disrupted functional brain network topology in Parkinson's disease patients with freezing of gait. <i>Neuroscience Letters</i> , 2021, 759, 135970.	1.0	10
6960	Structural Connectivity Patterns of Side Effects Induced by Subthalamic Deep Brain Stimulation for Parkinson's Disease. <i>Brain Connectivity</i> , 2022, 12, 374-384.	0.8	4
6961	Housekeeping Genes for Parkinson's Disease in Humans and Mice. <i>Cells</i> , 2021, 10, 2252.	1.8	6
6962	Neural networks associated with quality of life in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 89, 6-12.	1.1	8
6963	Impact of social and mobility restrictions in Parkinson's disease during COVID-19 lockdown. <i>BMC Neurology</i> , 2021, 21, 332.	0.8	25
6964	Regional Neural Activity Changes in Parkinson's Disease-Associated Mild Cognitive Impairment and Cognitively Normal Patients. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 2697-2706.	1.0	9
6965	Low serum uric acid levels are associated with the nonmotor symptoms and brain gray matter volume in Parkinson's disease. <i>Neurological Sciences</i> , 2022, 43, 1747-1754.	0.9	9
6966	Qualitative Deficits in Verbal Fluency in Parkinson's Disease with Mild Cognitive Impairment: A Clinical and Neuroimaging Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 2005-2016.	1.5	2
6967	Voice Analysis for Diagnosis and Monitoring Parkinson's Disease. <i>Series in Bioengineering</i> , 2022, , 119-133.	0.3	3
6968	Olfactory Deficits in the Freezing of Gait Phenotype of Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 656379.	1.1	7
6969	A prospective pilot study of the effects of deep brain stimulation on olfaction and constipation in Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2021, 207, 106774.	0.6	5
6970	Quantitative Gait Analysis Using a Pose-Estimation Algorithm with a Single 2D-Video of Parkinson's Disease Patients. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1271-1283.	1.5	22

#	ARTICLE	IF	CITATIONS
6971	Evaluation of the Sensitivity and Reproducibility of Targeted Proteomic Analysis Using Data-Independent Acquisition for Serum and Cerebrospinal Fluid Proteins. <i>Journal of Proteome Research</i> , 2021, 20, 4284-4291.	1.8	6
6972	Long-term clinical outcomes of bilateral GPi deep brain stimulation in advanced Parkinson's disease: 5 years and beyond. <i>Journal of Neurosurgery</i> , 2020, , 1-10.	0.9	8
6973	Connectivity of EEG synchronization networks increases for Parkinson's disease patients with freezing of gait. <i>Communications Biology</i> , 2021, 4, 1017.	2.0	24
6974	Enrichment of rare variants in E3 ubiquitin ligase genes in Early onset Parkinson's disease. <i>Neurobiology of Aging</i> , 2022, 109, 273-278.	1.5	6
6975	Serum fractalkine and 3-nitrotyrosine levels correlate with disease severity in Parkinson's disease: a pilot study. <i>Metabolic Brain Disease</i> , 2022, 37, 209-217.	1.4	11
6976	The dynamics of nigrostriatal system damage and neurobehavioral changes in the rotenone rat model of Parkinson's disease. <i>Brain Research Bulletin</i> , 2021, 173, 1-13.	1.4	9
6977	Structural network topology and microstructural alterations of the anterior insula associate with cognitive and affective impairment in Parkinson's disease. <i>Scientific Reports</i> , 2021, 11, 16021.	1.6	10
6978	Preexisting Bipolar Disorder Influences the Subsequent Phenotype of Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2840-2852.	2.2	8
6979	Six-Month Community-Based Brisk Walking and Balance Exercise Alleviates Motor Symptoms and Promotes Functions in People with Parkinson's Disease: A Randomized Controlled Trial. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1431-1441.	1.5	22
6980	Quality Improvement in Neurology. <i>Neurology</i> , 2021, 97, 239-245.	1.5	10
6981	Neural signatures of predictive language processing in Parkinson's disease with and without mild cognitive impairment. <i>Cortex</i> , 2021, 141, 112-127.	1.1	4
6982	Family history of hand tremor in patients with early Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2021, 90, 161-164.	0.8	0
6983	Serum levels of lipocalin-2 in patients with Parkinson's disease. <i>Neurological Sciences</i> , 2021, , 1.	0.9	4
6984	Systematic quantitative assessment of motor function in clinically isolated REM sleep behaviour disorder: A diagnostic window into early alpha-synucleinopathies. <i>Journal of Sleep Research</i> , 2022, 31, e13459.	1.7	3
6985	Evaluating the role of ARSA in Chinese patients with Parkinson's disease. <i>Neurobiology of Aging</i> , 2022, 109, 269-272.	1.5	5
6986	Development of parkinsonism after long-standing cervical dystonia " A cohort. <i>Journal of the Neurological Sciences</i> , 2021, 427, 117477.	0.3	10
6987	Safety and Tolerability of Active Immunotherapy Targeting α -Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1079-1089.	1.5	29
6988	Subthalamic Nucleus Stimulation Impairs Sequence Processing in Patients with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1869-1879.	1.5	2

#	ARTICLE	IF	CITATIONS
6989	Conflict adaptation and related neuronal processing in Parkinson's disease. <i>Brain Imaging and Behavior</i> , 2021, , 1.	1.1	4
6990	Aberrant Neurogliovascular Unit Dynamics in Cerebral Small Vessel Disease: A Rheological Clue to Vascular Parkinsonism. <i>Pharmaceutics</i> , 2021, 13, 1207.	2.0	6
6991	Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 68-74.	0.9	39
6992	Plasma Lipopolysaccharide-Binding Protein Reflects Risk and Progression of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1129-1139.	1.5	10
6993	Which Neuropsychological Tests? Predicting Cognitive Decline and Dementia in Parkinson's Disease in the ICICLE-PD Cohort. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1297-1308.	1.5	11
6994	The Potential Effects of Oxidative Stress-Related Plasma Abnormal Protein Aggregate Levels on Brain Volume and Its Neuropsychiatric Consequences in Parkinson's Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-10.	1.9	2
6995	Long-term effect of bilateral STN-DBS on non-motor symptoms in Parkinson's disease: A four-year observational, prospective study. <i>Parkinsonism and Related Disorders</i> , 2021, 89, 13-16.	1.1	21
6996	Role of LRP10 in Parkinson's disease in a Taiwanese cohort. <i>Parkinsonism and Related Disorders</i> , 2021, 89, 79-83.	1.1	3
6997	Intrasubject relationship between striatal 18F-FP-CIT uptake and cardiac 123I-MIBG uptake differs by motor subtype in early Parkinson disease. <i>Medicine (United States)</i> , 2021, 100, e26995.	0.4	2
6998	Impulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson's disease: A [11C]-PHNO PET study. <i>Parkinsonism and Related Disorders</i> , 2021, 90, 52-56.	1.1	4
6999	Changes in efficiencies and interactions of attentional networks in Parkinson's disease with sleep disturbance. <i>Neuroscience Research</i> , 2021, 170, 236-244.	1.0	2
7000	Short- and long-term motor outcome of STN-DBS in Parkinson's Disease: focus on sex differences. <i>Neurological Sciences</i> , 2022, 43, 1769-1781.	0.9	15
7001	Altered Cortical Cholinergic Network in Parkinson's Disease at Different Stage: A Resting-State fMRI Study. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 723948.	1.7	4
7002	A Comparison of Functional Abilities in Individuals with Mild Cognitive Impairment and Parkinson's Disease with Mild Cognitive Impairment Using Multiple Assessment Methods. <i>Journal of the International Neuropsychological Society</i> , 2022, 28, 798-809.	1.2	4
7003	Curcuma longa extract ameliorates motor and cognitive deficits of 6-hydroxydopamine-infused Parkinson's disease model rats. <i>Advances in Traditional Medicine</i> , 2022, 22, 773-787.	1.0	3
7004	Diffusion tensor imaging-based pontine damage as a degeneration marker in synucleinopathy. <i>Journal of Neuroscience Research</i> , 2021, 99, 2922-2931.	1.3	1
7005	Tipping the scales: how clinical assessment shapes the neural correlates of Parkinson's disease mild cognitive impairment. <i>Brain Imaging and Behavior</i> , 2022, 16, 761-772.	1.1	4
7006	Cognitive Correlates of Instrumental Activities of Daily Living Performance in Parkinson Disease Without Dementia. <i>Archives of Rehabilitation Research and Clinical Translation</i> , 2021, 3, 100138.	0.5	8

#	ARTICLE	IF	CITATIONS
7007	Multimodal mechanisms of human socially reinforced learning across neurodegenerative diseases. <i>Brain</i> , 2022, 145, 1052-1068.	3.7	24
7008	Depressive symptoms in elderly patients with Parkinson's disease: frequency and associated factors. <i>International Journal of Therapy and Rehabilitation</i> , 2021, 28, 1-9.	0.1	0
7009	Theta Burst Magnetic Stimulation Improves Parkinson's-Related Cognitive Impairment: A Randomised Controlled Study. <i>Neurorehabilitation and Neural Repair</i> , 2021, 35, 986-995.	1.4	9
7010	Cross-Sectional Design: Link Between Parkinson's Pain and Restless Leg Syndrome. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2022, 35, 622-626.	1.2	1
7011	A transcriptome-wide association study identifies susceptibility genes for Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 79.	2.5	32
7012	King's Parkinson's Disease Pain Scale (KPPS): Cross-cultural adaptation to Brazilian Portuguese and content validity. <i>Clinical Neurology and Neurosurgery</i> , 2021, 208, 106815.	0.6	5
7013	Axial Impairment Following Deep Brain Stimulation in Parkinson's Disease: A Surgicogenomic Approach. <i>Journal of Parkinson's Disease</i> , 2022, 12, 117-128.	1.5	5
7014	Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice. <i>Neurologia</i> , 2021, , .	0.3	4
7015	A Parkinson's disease patient displaying increased neuromelanin-sensitive areas in the substantia nigra after rehabilitation with tDCS: a case report. <i>Neurocase</i> , 2021, 27, 407-414.	0.2	3
7016	Parkinson's disease-related pattern (PDRP) identified using resting-state functional MRI: Validation study. <i>NeuroImage Reports</i> , 2021, 1, 100026.	0.5	8
7017	Correlation of active contact location with weight gain after subthalamic nucleus deep brain stimulation: a case series. <i>BMC Neurology</i> , 2021, 21, 351.	0.8	3
7018	Clinical features and related factors of freezing of gait in patients with Parkinson's disease. <i>Brain and Behavior</i> , 2021, 11, e2359.	1.0	10
7019	Plasma acyl-carnitines, bilirubin, tyramine and tetrahydro-21-deoxycortisol in Parkinson's disease and essential tremor. A case control biomarker study. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 167-172.	1.1	6
7020	Association between heart rate variability and striatal dopamine depletion in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2021, 128, 1835-1840.	1.4	5
7021	Subthalamic Peak Beta Ratio Is Asymmetric in Glucocerebrosidase Mutation Carriers With Parkinson's Disease: A Pilot Study. <i>Frontiers in Neurology</i> , 2021, 12, 723476.	1.1	5
7022	Parkinson's disease diagnosis using convolutional neural networks and figure-copying tasks. <i>Neural Computing and Applications</i> , 2022, 34, 1433-1453.	3.2	19
7023	Detection of visual and frontoparietal network perfusion deficits in Parkinson's disease dementia. <i>European Journal of Radiology</i> , 2021, 144, 109985.	1.2	7
7024	Use of machine learning method on automatic classification of motor subtype of Parkinson's disease based on multilevel indices of rs-fMRI. <i>Parkinsonism and Related Disorders</i> , 2021, 90, 65-72.	1.1	23

#	ARTICLE	IF	CITATIONS
7025	A new CERAD total score with equally weighted z-scores and additional executive and non-amnesic â€œCERAD-Plusâ€œ tests enhances cognitive diagnosis in patients with Parkinson's disease: Evidence from the LANDSCAPE study. <i>Parkinsonism and Related Disorders</i> , 2021, 90, 90-97.	1.1	5
7026	Altered Regional Homogeneity and Functional Connectivity during Microlesion Period after Deep Brain Stimulation in Parkinsonâ€™s Disease. <i>Parkinson's Disease</i> , 2021, 2021, 1-10.	0.6	1
7027	Plasma neurofilament light chain level and orthostatic hypotension in early Parkinsonâ€™s disease. <i>Journal of Neural Transmission</i> , 2021, 128, 1853-1861.	1.4	9
7028	Circadian activity rhythm in Parkinson's disease: findings from the PHASE study. <i>Sleep Medicine</i> , 2021, 85, 8-14.	0.8	15
7029	Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications. <i>Pharmaceutics</i> , 2021, 13, 1395.	2.0	4
7030	Predicting Motor Outcome of Subthalamic Nucleus Deep Brain Stimulation for Parkinsonâ€™s Disease Using Quantitative Susceptibility Mapping and Radiomics: A Pilot Study. <i>Frontiers in Neuroscience</i> , 2021, 15, 731109.	1.4	5
7031	Disorganized restingâ€state functional connectivity between the dorsal attention network and intrinsic networks in Parkinson's disease with freezing of gait. <i>European Journal of Neuroscience</i> , 2021, 54, 6633-6645.	1.2	15
7032	Neurosurgeons perspective on the shift towards earlier use of deep brain stimulation for Parkinson disease. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2021, 25, 101224.	0.2	0
7034	The impact of dopaminergic treatment over cognitive networks in Parkinson's disease: Stemming the tide?. <i>Human Brain Mapping</i> , 2021, 42, 5736-5746.	1.9	8
7035	Intestinal Decontamination Therapy for Dyskinesia and Motor Fluctuations in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 729961.	1.1	7
7036	Outer Retinal Layer Thickness Changes in White Matter Hyperintensity and Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2021, 15, 741651.	1.4	4
7037	Genetic analysis of TRIM family genes for early-onset Parkinson's disease in Chinese population. <i>Parkinsonism and Related Disorders</i> , 2021, 90, 105-113.	1.1	2
7038	Heterogeneity by global and textural feature analysis in F-18 FP-CIT brain PET images for diagnosis of Parkinson's disease. <i>Medicine (United States)</i> , 2021, 100, e26961.	0.4	3
7039	Assessment of Force Production in Parkinsonâ€™s Disease Subtypes. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10044.	1.2	3
7040	The Metabolomic Approach Reveals the Alteration in Human Serum and Cerebrospinal Fluid Composition in Parkinsonâ€™s Disease Patients. <i>Pharmaceutics</i> , 2021, 14, 935.	1.7	13
7041	Plasma extracellular vesicles tau and Î²â€amyloid as biomarkers of cognitive dysfunction of Parkinson's disease. <i>FASEB Journal</i> , 2021, 35, e21895.	0.2	23
7042	Odor Identification and Regional Gray Matter Atrophy in Patients with Alzheimerâ€™s Disease, Parkinsonâ€™s Disease, and the Healthy Elderly: A Cross-Sectional Structural MRI Study. <i>Brain Sciences</i> , 2021, 11, 1296.	1.1	2
7043	Abnormally reduced frontal cortex activity during Trail-Making-Test in prodromal parkinson's diseaseâ€a fNIRS study. <i>Neurobiology of Aging</i> , 2021, 105, 148-158.	1.5	6

#	ARTICLE	IF	CITATIONS
7044	Longitudinal, Interdisciplinary Home Visits Versus Usual Care for Homebound People With Advanced Parkinson Disease: Protocol for a Controlled Trial. <i>JMIR Research Protocols</i> , 2021, 10, e31690.	0.5	8
7045	Screening of <i>GBA</i> Mutations in Nigerian Patients with Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2971-2973.	2.2	4
7046	Development of α -Synuclein Real-Time Quaking-Induced Conversion as a Diagnostic Method for α -Synucleinopathies. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 703984.	1.7	12
7047	Abnormal Intracortical Functions in Parkinson's Disease with Rapid Eye Movement Sleep Behaviour Disorder. <i>Canadian Journal of Neurological Sciences</i> , 2022, 49, 672-677.	0.3	5
7048	LncRNA HOXA-AS2 regulates microglial polarization via recruitment of PRC2 and epigenetic modification of PGC-1 α expression. <i>Journal of Neuroinflammation</i> , 2021, 18, 197.	3.1	15
7049	Translation, adaptation and validation of the Bulgarian version of the King's Parkinson's Disease Pain Scale. <i>BMC Neurology</i> , 2021, 21, 357.	0.8	6
7050	Platelet miRNA Biosignature Discriminates between Dementia with Lewy Bodies and Alzheimer's Disease. <i>Biomedicines</i> , 2021, 9, 1272.	1.4	8
7051	Narcolepsy genetic marker HLA DQB1*06:02 and excessive daytime sleepiness in Parkinson disease patients treated with dopaminergic agents. <i>Journal of Neurology</i> , 2021, , 1.	1.8	3
7052	Effect of Resistance Exercise on Body Structure and Function, Activity, and Participation in Individuals With Parkinson Disease: A Systematic Review. <i>Archives of Physical Medicine and Rehabilitation</i> , 2021, 102, 1998-2011.	0.5	10
7053	Statistical shape analysis of putamen in early-onset Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2021, 209, 106936.	0.6	7
7054	Neuroprotective effect of <i>Lactobacillus plantarum</i> DP189 on MPTP-induced Parkinson's disease model mice. <i>Journal of Functional Foods</i> , 2021, 85, 104635.	1.6	15
7055	ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 139-145.	1.1	27
7056	Parkinsonism and cerebrospinal fluid disorders. <i>Journal of the Neurological Sciences</i> , 2022, 433, 120019.	0.3	6
7057	Virtual functional mobility test: A potential novel tool for assessing mobility of individuals with Parkinson's disease in a multitask condition. <i>Journal of Clinical Neuroscience</i> , 2021, 93, 17-22.	0.8	1
7058	Transcutaneous vagus nerve stimulation (tVNS) as a potential therapeutic application for neurodegenerative disorders – A focus on dysautonomia in Parkinson's disease. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2021, 235, 102858.	1.4	2
7059	Neurogenic and anti-inflammatory effects of probiotics in Parkinson's disease: A systematic review of preclinical and clinical evidence. <i>Brain, Behavior, and Immunity</i> , 2021, 98, 59-73.	2.0	35
7060	Frontal lobe dysfunction is associated with reduced DAT-SPECT accumulation in Lewy body disease. <i>Journal of the Neurological Sciences</i> , 2021, 430, 119998.	0.3	3
7061	Striatal oxidative damages and neuroinflammation correlate with progression and survival of Lewy body and Alzheimer diseases. <i>Neural Regeneration Research</i> , 2022, 17, 867.	1.6	8

#	ARTICLE	IF	CITATIONS
7062	A Patient With Gait Difficulty. , 2022, , 133-141.		0
7063	Changes in facial expressions in patients with Parkinson's disease during the phonation test and their correlation with disease severity. Computer Speech and Language, 2022, 72, 101286.	2.9	5
7064	Assessment of myocardial sympathetic innervation with 18F-FDOPA-PET/CT in patients with autonomic dysfunction: feasibility study in IPD patients. Journal of Nuclear Cardiology, 2022, 29, 1280-1290.	1.4	6
7065	Development and Validation of a New Wearable Mobile Device for the Automated Detection of Resting Tremor in Parkinsonâ€™s Disease and Essential Tremor. Diagnostics, 2021, 11, 200.	1.3	16
7066	Predicting Working Memory Training Responsiveness in Parkinsonâ€™s Disease: Both â€œSystem Hardwareâ€• and Room for Improvement Are Needed. Neurorehabilitation and Neural Repair, 2021, 35, 117-130.	1.4	3
7067	Health-Related Quality of Life for Parkinsonâ€™s Disease Patients and Their Caregivers. Journal of Movement Disorders, 2021, 14, 42-52.	0.7	22
7068	Components determining the slowness of information processing in parkinsonâ€™s disease. Brain and Behavior, 2021, 11, e02031.	1.0	10
7069	Smartphone Speech Testing for Symptom Assessment in Rapid Eye Movement Sleep Behavior Disorder and Parkinsonâ€™s Disease. IEEE Access, 2021, 9, 44813-44824.	2.6	19
7070	Cognitive profiles of patients with mild cognitive impairment due to Alzheimer's versus Parkinson's disease defined using a base rate approach: Implications for neuropsychological assessments. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12223.	1.2	4
7071	Predicting Long-Term Outcome of Patients of Early Parkinsonism with Acute Levodopa Challenge Test. Neurology India, 2021, 69, 430.	0.2	0
7072	Idiopathic Parkinson Disease : The Prevalence of in Edirne and Its Counties and Concomitant Non Motor Symptoms Determination of Feature.. Noropsikiyatri Arsivi, 2021, , .	0.2	0
7073	Motor Asymmetry and Interocular Retinal Thickness in Parkinson's Disease. Journal of Korean Medical Science, 2021, 36, e50.	1.1	2
7074	Fearing Parkinsonâ€™s Disease: Relationships Between Cognition and Emotion. , 2021, , 419-430.		0
7075	Artificial intelligence applied to neuroimaging data in Parkinsonian syndromes: Actuality and expectations. Mathematical Biosciences and Engineering, 2021, 18, 1753-1773.	1.0	8
7078	Video-based Parkinsonâ€™s disease assessments in a nationwide cohort of Fox Insight participants. Clinical Parkinsonism & Related Disorders, 2021, 4, 100094.	0.5	18
7079	From the nose to the brain, nanomedicine drug delivery. , 2021, , 153-180.		2
7080	Does the Personality of Patients with Parkinsonâ€™s Disease Affect the Decision to Perform Deep Brain Stimulation Surgery? A Cross-Sectional Study in a Chinese Cohort. Behavioural Neurology, 2021, 2021, 1-6.	1.1	1
7081	Hypomimia in Parkinson's Disease: What Is It Telling Us?. Frontiers in Neurology, 2020, 11, 603582.	1.1	11

#	ARTICLE	IF	CITATIONS
7082	Dopaminergic Basis of Spatial Deficits in Early Parkinsonâ€™s Disease. <i>Cerebral Cortex Communications</i> , 2021, 2, tgab042.	0.7	1
7083	T2-Hyperintense Lateral Rim and Hypointense Putamen Are Typical but Not Exclusive of Multiple System Atrophy. <i>Archives of Neurology</i> , 2001, 58, 1024-a-1026.	4.9	25
7084	Dysautonomic (Orthostatic) Syncope. , 0, , 72-91.		11
7085	Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 611-621.	2.2	25
7086	BewegungsstÃ¶rungen. , 2006, , 846-940.		2
7087	High-Field Neuroimaging in Parkinsonâ€™s Disease. , 2006, , 194-200.		3
7088	Modelling and Simulation of Brain Energy Metabolism: Energy and Parkinsonâ€™s Disease. , 2012, , 19-38.		4
7089	Postural Tremors. , 2013, , 133-150.		3
7090	Indices of Oxidative Stress in the Peripheral Blood of De Novo Patients With Parkinsonâ€™s Disease. <i>Advances in Behavioral Biology</i> , 1998, , 779-785.	0.2	1
7091	Different Cognitive Profiles on Memory Tests in Parkinsonâ€™s Disease and Alzheimerâ€™s Disease. <i>Advances in Behavioral Biology</i> , 1998, , 265-270.	0.2	2
7092	Manganese-Induced Neurotoxicity. , 1994, , 53-62.		3
7093	Clinical Features of Parkinsonâ€™s Disease. , 2000, , 71-84.		5
7094	Dual-Radionuclide Brain SPECT for the Differential Diagnosis of Parkinsonism. <i>Methods in Molecular Biology</i> , 2011, 680, 237-246.	0.4	3
7095	Magnetic Resonance Spectroscopy in Parkinsonian Disorders. <i>Contemporary Clinical Neuroscience</i> , 2016, , 71-102.	0.3	1
7096	PET and SPECT Imaging in Parkinsonian Syndromes. , 2014, , 619-638.		1
7097	Neurovegetative Regulation of the Vascular System. , 2002, , 175-187.		1
7098	Transdermal lisuride delivery in the treatment of Parkinsonâ€™s disease. <i>Journal of Neural Transmission Supplementum</i> , 2004, , 89-95.	0.5	38
7099	Simple movement sequences better correlate to levodopa plasma levels than complex ones. <i>Journal of Neural Transmission Supplementum</i> , 2004, , 53-60.	0.5	2

#	ARTICLE	IF	CITATIONS
7100	Clinical effects of repetitive transcranial magnetic stimulation versus acute levodopa challenge in Parkinson's disease. <i>Journal of Neural Transmission Supplementum</i> , 2004, , 61-67.	0.5	30
7101	The Natural History of Parkinson's Disease. , 2017, , 129-137.		1
7102	Dementia with Lewy bodies: prevalence, clinical spectrum and natural history. , 2000, , 303-314.		10
7103	PET studies in progressive supranuclear palsy. <i>Journal of Neural Transmission Supplementum</i> , 1994, 42, 119-134.	0.5	21
7104	Clinical diagnosis and diagnostic criteria of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). <i>Journal of Neural Transmission Supplementum</i> , 1994, 42, 15-31.	0.5	52
7105	Measurement of the dopaminergic degeneration in Parkinson's disease with [¹²³ I]β-CIT and SPECT. <i>Journal of Neural Transmission Supplementum</i> , 1997, , 9-24.	0.5	143
7106	IBZM- and CIT-SPECT of the dopaminergic system in parkinsonism. <i>Journal of Neural Transmission Supplementum</i> , 1997, 50, 31-37.	0.5	18
7107	Pathology of familial Alzheimer's disease with Lewy bodies. <i>Journal of Neural Transmission Supplementum</i> , 1997, 51, 121-135.	0.5	22
7108	Apolipoprotein E gene in Parkinson's disease, Lewy body dementia and Alzheimer's disease. <i>Journal of Neural Transmission Supplementum</i> , 1997, 51, 161-165.	0.5	11
7109	Treatment of behavioural disturbances in Parkinson's disease. <i>Journal of Neural Transmission Supplementum</i> , 1997, 51, 175-204.	0.5	18
7110	Morphological substrates of dementia in parkinsonism A critical update. <i>Journal of Neural Transmission Supplementum</i> , 1997, 51, 57-82.	0.5	61
7111	Structural basis of dementia in neurodegenerative disorders. <i>Journal of Neural Transmission Supplementum</i> , 1996, 47, 1-29.	0.5	45
7112	Functional imaging techniques in the diagnosis of non-Alzheimer dementias. <i>Journal of Neural Transmission Supplementum</i> , 1996, 47, 155-167.	0.5	8
7113	What are the relations between Lewy body disease and AD?. <i>Journal of Neural Transmission Supplementum</i> , 1998, 54, 107-116.	0.5	17
7114	Modifying the Progression of Parkinson's Disease. , 1995, , 179-188.		1
7115	Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease. <i>Acta Neuropathologica</i> , 1994, 87, 269-276.	3.9	14
7116	Diagnosing mild cognitive impairment in Parkinson's disease: which tests perform best in the Italian population?. <i>Neurological Sciences</i> , 2017, 38, 1461-1468.	0.9	4
7118	Striatonigral Degeneration. , 2010, , 183-186.		1

#	ARTICLE	IF	CITATIONS
7119	Restoring dopamine levels in Parkinson's disease: neuronal pathways, agonists and antiinflammatory agents. , 2020, , 479-493.		1
7120	Autonomic dysfunction. , 2003, , 1453-1477.		1
7121	Neurobiology of Disorders with Lewy Bodies. , 2001, , 173-182.		2
7122	Parkinson-Syndrom. , 2013, , 207-233.		1
7123	Levodopa has primarily negative influences on postural control in patients with Parkinson's disease. Behavioural Brain Research, 2017, 331, 67-75.	1.2	12
7124	Disrupted interhemispheric coordination with unaffected lateralization of global eigenvector centrality characterizes hemiparkinsonism. Brain Research, 2020, 1742, 146888.	1.1	2
7125	Relationships of drooling with motor symptoms and dopamine transporter imaging in drug-naïve Parkinson's disease. Clinical Neurology and Neurosurgery, 2020, 195, 105951.	0.6	4
7126	Precuneus degeneration and isolated apathy in patients with Parkinson's disease. Neuroscience Letters, 2017, 653, 250-257.	1.0	25
7127	Reproducible metabolic topographies associated with multiple system atrophy: Network and regional analyses in Chinese and American patient cohorts. NeuroImage: Clinical, 2020, 28, 102416.	1.4	12
7128	The distribution and risk effect of GBA variants in a large cohort of PD patients from Colombia and Peru. Parkinsonism and Related Disorders, 2019, 63, 204-208.	1.1	31
7129	Prolonged-release melatonin in Parkinson's disease patients with a poor sleep quality: A randomized trial. Parkinsonism and Related Disorders, 2020, 75, 50-54.	1.1	31
7130	Progressive supranuclear palsy: Advances in diagnosis and management. Parkinsonism and Related Disorders, 2020, 73, 105-116.	1.1	55
7131	Parkinson's disease motor subtypes and bilateral GPi deep brain stimulation: One-year outcomes. Parkinsonism and Related Disorders, 2020, 75, 7-13.	1.1	15
7132	The late stage of Parkinson's "results of a large multinational study on motor and non-motor complications. Parkinsonism and Related Disorders, 2020, 75, 91-96.	1.1	25
7133	Hair glucocorticoid levels in Parkinson's disease. Psychoneuroendocrinology, 2020, 117, 104704.	1.3	16
7134	The influence of sleep disordered breathing in REM sleep behavior disorder. Sleep Medicine, 2017, 37, 210-215.	0.8	22
7135	Movement Disorders in Geriatric Rehabilitation. Clinics in Geriatric Medicine, 1993, 9, 765-781.	1.0	1
7137	Parkinson's disease and parkinsonism in the elderly. , 2000, , 22-63.		8

#	ARTICLE	IF	CITATIONS
7138	Deep Brain Stimulation Management. , 2010, , .		9
7141	Spatial judgment in Parkinsonâ€™s disease: Contributions of attentional and executive dysfunction.. Behavioral Neuroscience, 2019, 133, 350-360.	0.6	6
7142	The relation of anxiety and cognition in Parkinsonâ€™s disease.. Neuropsychology, 2017, 31, 596-604.	1.0	33
7143	The effects of integrated single- and dual-task training on automaticity and attention allocation in Parkinsonâ€™s disease: A secondary analysis from a randomized trial.. Neuropsychology, 2019, 33, 147-156.	1.0	19
7144	Memory impairment in Parkinsonâ€™s disease: The retrieval versus associative deficit hypothesis revisited and reconciled.. Neuropsychology, 2019, 33, 391-405.	1.0	20
7145	Multimethod assessment of everyday functioning and memory abilities in Parkinsonâ€™s disease.. Neuropsychology, 2019, 33, 169-177.	1.0	11
7146	Dopaminergic medication improves cognitive control under low cognitive demand in Parkinsonâ€™s disease.. Neuropsychology, 2020, 34, 551-559.	1.0	3
7147	The role of interaction and predictability in the spontaneous entrainment of movement.. Journal of Experimental Psychology: General, 2019, 148, 1041-1057.	1.5	26
7148	Optogenetic investigation of neural circuits underlying brain disease in animal models. , 0, .		1
7149	Cognitive function in people with and without freezing of gait in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2020, 6, 9.	2.5	31
7150	Pretreatment brain volumes can affect the effectiveness of deep brain stimulation in Parkinson's disease patients. Scientific Reports, 2020, 10, 22065.	1.6	8
7151	Cortical thickness and gyrification index measuring cognition in Parkinsonâ€™s disease. International Journal of Neuroscience, 2021, 131, 984-993.	0.8	17
7152	Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain, 2002, 125, 789-800.	3.7	24
7153	Neuronal Laterality in Parkinson's Disease With Unilateral Symptom by In Vivo 1H Magnetic Resonance Spectroscopy. Investigative Radiology, 1998, 33, 450-455.	3.5	52
7154	VOIDING DYSFUNCTION AND PARKINSON??S DISEASE: URODYNAMIC ABNORMALITIES AND URINARY SYMPTOMS. Journal of Urology, 2000, , 1640-1643.	0.2	3
7155	The Results, Indications, and Physiology of Posteroventral Pallidotomy for Patients with Parkinson??s Disease. Neurosurgery, 1995, 36, 1118-1127.	0.6	18
7156	Differential Dynamic of Action on Cortical and Subcortical Structures of Anesthetic Agents during Induction of Anesthesia. Anesthesiology, 2007, 107, 202-212.	1.3	220
7168	Efforts of subthalamic nucleus deep brain stimulation on cognitive spectrum: From explicit to implicit changes in the patients with Parkinson's disease for 1Â½year. CNS Neuroscience and Therapeutics, 2020, 26, 972-980.	1.9	14

#	ARTICLE	IF	CITATIONS
7169	The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson's disease. <i>European Journal of Neurology</i> , 2021, 28, 1557-1565.	1.7	12
7170	Loss of presynaptic inhibition for step initiation in parkinsonian individuals with freezing of gait. <i>Journal of Physiology</i> , 2020, 598, 1611-1624.	1.3	21
7172	Apathy in corticobasal degeneration: possible parietal involvement. <i>Functional Neurology</i> , 2017, 32, 201.	1.3	6
7173	High-Intensity Interval Versus Moderate-Intensity Continuous Training in Individuals With Parkinson's Disease: Hemodynamic and Functional Adaptation. <i>Journal of Physical Activity and Health</i> , 2020, 17, 85-91.	1.0	25
7174	Severe depression masquerading as Creutzfeldt-Jakob disease. <i>BMJ Case Reports</i> , 2014, 2014, bcr2013203352-bcr2013203352.	0.2	3
7175	G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. <i>BMJ Case Reports</i> , 2009, 2009, bcr0820080632-bcr0820080632.	0.2	11
7176	Recent Advances: Neurology. <i>BMJ: British Medical Journal</i> , 1994, 309, 392-5.	2.4	5
7177	Fortnightly Review: Parkinsonism—recognition and differential diagnosis. <i>BMJ: British Medical Journal</i> , 1995, 310, 447-452.	2.4	169
7178	Parkinson's disease is rarely a primary cause of death. <i>BMJ: British Medical Journal</i> , 1996, 312, 703-703.	2.4	8
7179	Protocol for PD SENSORS: Parkinson's Disease Symptom Evaluation in a Naturalistic Setting producing Outcome measures using SPHERE technology. An observational feasibility study of multi-modal multi-sensor technology to measure symptoms and activities of daily living in Parkinson's disease. <i>BMI Open</i> , 2020, 10, e041303.	0.8	15
7180	Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 349-356.	0.9	31
7181	Visual hallucinations in Parkinson's disease: their nature, frequency, and origins. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 70, 719a-720.	0.9	2
7182	Ambulatory Activity Components Deteriorate Differently across Neurodegenerative Diseases: A Cross-Sectional Sensor-Based Study. <i>Neurodegenerative Diseases</i> , 2016, 16, 317-323.	0.8	11
7183	Neurological Signs and Frontal White Matter Lesions in Vascular Parkinsonism. <i>Stroke</i> , 1997, 28, 965-969.	1.0	128
7184	Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia. <i>JCI Insight</i> , 2016, 1, e86615.	2.3	28
7185	Increased putamen hypercapnic vasoreactivity in levodopa-induced dyskinesia. <i>JCI Insight</i> , 2017, 2, .	2.3	15
7186	Series Introduction: Neurodegeneration: What is it and where are we?. <i>Journal of Clinical Investigation</i> , 2003, 111, 3-10.	3.9	161
7187	Series Introduction: Neurodegeneration: What is it and where are we?. <i>Journal of Clinical Investigation</i> , 2003, 111, 3-10.	3.9	327

#	ARTICLE	IF	CITATIONS
7188	Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. <i>Journal of Clinical Investigation</i> , 2010, 120, 2745-2754.	3.9	359
7189	Cerebrospinal fluid-based kinetic biomarkers of axonal transport in monitoring neurodegeneration. <i>Journal of Clinical Investigation</i> , 2012, 122, 3159-3169.	3.9	51
7190	The Parkinsonian Personality and Concomitant Depression. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, 48-55.	0.9	14
7191	Binge Eating in Parkinson's Disease: Prevalence, Correlates and the Contribution of Deep Brain Stimulation. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, 56-62.	0.9	62
7193	EMPOWER-PD - A physical therapy intervention to empower the individuals with Parkinson's disease: a study protocol for a feasibility randomized controlled trial. <i>Pilot and Feasibility Studies</i> , 2019, 5, 19.	0.5	1
7194	Pathogenesis, diagnosis and treatment. , 2005, , 1-17.		16
7195	Diagnosing Parkinson Disease. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2016, 22, 1047-1063.	0.4	18
7196	Lewy Body Dementias. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 128-146.	0.4	16
7197	Parkinson Disease. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 896-918.	0.4	34
7199	Cohort Study in Parkinsonism. <i>Neurology: Clinical Practice</i> , 2021, 11, e407-e413.	0.8	9
7200	The SPID-GBA study. <i>Neurology: Genetics</i> , 2020, 6, e523.	0.9	37
7201	Î± ₁ -Antichymotrypsin gene polymorphism and susceptibility to Parkinson's disease. <i>Neurology</i> , 1999, 52, 297-297.	1.5	18
7202	Changing epidemiology of Parkinson's disease in southwestern Finland. <i>Neurology</i> , 1999, 52, 302-302.	1.5	106
7203	Risk of Alzheimer's disease in relatives of Parkinson's disease patients with and without dementia. <i>Neurology</i> , 1999, 52, 719-719.	1.5	51
7204	Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. <i>Neurology</i> , 1999, 53, 85-85.	1.5	366
7205	Cardiac uptake of [¹²³ I]MIBG separates Parkinson's disease from multiple system atrophy. <i>Neurology</i> , 1999, 53, 1020-1020.	1.5	293
7206	Autopsy patterns for Parkinson's disease and related disorders in Olmsted County, Minnesota. <i>Neurology</i> , 1999, 53, 1342-1342.	1.5	28
7207	A multi-incident, Old-Order Amish family with PD. <i>Neurology</i> , 2002, 58, 568-574.	1.5	10

#	ARTICLE	IF	CITATIONS
7208	Movement disorders. <i>Neurology</i> , 2004, 62, S9-16.	1.5	17
7209	CD200 Inhibits Inflammatory Response by Promoting KATP Channel Opening in Microglia Cells in Parkinson's Disease. <i>Medical Science Monitor</i> , 2016, 22, 1733-1741.	0.5	30
7210	Genome-Scale Expression Pattern of Long Non-Coding RNAs in Chinese Uyghur Patients with Parkinson's Disease. <i>Medical Science Monitor</i> , 2020, 26, e925888.	0.5	1
7211	A protocol to examine vision and gait in Parkinson's disease: impact of cognition and response to visual cues. <i>F1000Research</i> , 2015, 4, 1379.	0.8	7
7212	A protocol to examine vision and gait in Parkinson's disease: impact of cognition and response to visual cues. <i>F1000Research</i> , 2015, 4, 1379.	0.8	10
7213	Prevalence of hippocampal sclerosis in a clinicopathologically characterized cohort. <i>Clinical and Experimental Medical Sciences</i> , 2013, 1, 317-327.	0.4	7
7214	Neither Replication nor Simulation Supports a Role for the Axon Guidance Pathway in the Genetics of Parkinson's Disease. <i>PLoS ONE</i> , 2008, 3, e2707.	1.1	17
7215	SRRM2, a Potential Blood Biomarker Revealing High Alternative Splicing in Parkinson's Disease. <i>PLoS ONE</i> , 2010, 5, e9104.	1.1	97
7216	Subthalamic Nucleus Stimulation Affects Theory of Mind Network: A PET Study in Parkinson's Disease. <i>PLoS ONE</i> , 2010, 5, e9919.	1.1	52
7217	Colonic Biopsies to Assess the Neuropathology of Parkinson's Disease and Its Relationship with Symptoms. <i>PLoS ONE</i> , 2010, 5, e12728.	1.1	355
7218	The Combination of Homocysteine and C-Reactive Protein Predicts the Outcomes of Chinese Patients with Parkinson's Disease and Vascular Parkinsonism. <i>PLoS ONE</i> , 2011, 6, e19333.	1.1	29
7219	Comparison of Endothelial Progenitor Cells in Parkinson's Disease Patients Treated with Levodopa and Levodopa/COMT Inhibitor. <i>PLoS ONE</i> , 2011, 6, e21536.	1.1	5
7220	Convergence of miRNA Expression Profiling, α -Synuclein Interacton and GWAS in Parkinson's Disease. <i>PLoS ONE</i> , 2011, 6, e25443.	1.1	235
7221	Increased Intestinal Permeability Correlates with Sigmoid Mucosa alpha-Synuclein Staining and Endotoxin Exposure Markers in Early Parkinson's Disease. <i>PLoS ONE</i> , 2011, 6, e28032.	1.1	689
7222	Impaired Trunk Stability in Individuals at High Risk for Parkinson's Disease. <i>PLoS ONE</i> , 2012, 7, e32240.	1.1	79
7223	The Five-Point Test: Reliability, Validity and Normative Data for Children and Adults. <i>PLoS ONE</i> , 2012, 7, e46080.	1.1	62
7224	Automatic Classification of Early Parkinson's Disease with Multi-Modal MR Imaging. <i>PLoS ONE</i> , 2012, 7, e47714.	1.1	124
7225	Dissociation between Active and Observational Learning from Positive and Negative Feedback in Parkinsonism. <i>PLoS ONE</i> , 2012, 7, e50250.	1.1	24

#	ARTICLE	IF	CITATIONS
7226	Binding of the Radioligand SIL23 to α -Synuclein Fibrils in Parkinson Disease Brain Tissue Establishes Feasibility and Screening Approaches for Developing a Parkinson Disease Imaging Agent. PLoS ONE, 2013, 8, e55031.	1.1	97
7227	Diminished Activation of Motor Working-Memory Networks in Parkinson's Disease. PLoS ONE, 2013, 8, e61786.	1.1	29
7228	Diagnostic Value of the Impairment of Olfaction in Parkinson's Disease. PLoS ONE, 2013, 8, e64735.	1.1	39
7229	The Heterogeneity of Early Parkinson's Disease: A Cluster Analysis on Newly Diagnosed Untreated Patients. PLoS ONE, 2013, 8, e70244.	1.1	150
7230	Association Studies of MMP-9 in Parkinson's Disease and Amyotrophic Lateral Sclerosis. PLoS ONE, 2013, 8, e73777.	1.1	46
7231	Basal Ganglia Neuronal Activity during Scanning Eye Movements in Parkinson's Disease. PLoS ONE, 2013, 8, e78581.	1.1	13
7232	Genetic Association Study between STK39 and CCDC62/HIP1R and Parkinson's Disease. PLoS ONE, 2013, 8, e79211.	1.1	16
7233	Niemann-Pick C Disease Gene Mutations and Age-Related Neurodegenerative Disorders. PLoS ONE, 2013, 8, e82879.	1.1	50
7234	Influence of Perturbation Velocity on Balance Control in Parkinson's Disease. PLoS ONE, 2014, 9, e86650.	1.1	22
7235	Changes in Topological Organization of Functional PET Brain Network with Normal Aging. PLoS ONE, 2014, 9, e88690.	1.1	37
7236	Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients. PLoS ONE, 2014, 9, e89741.	1.1	407
7237	Effect of Dopamine Therapy on Nonverbal Affect Burst Recognition in Parkinson's Disease. PLoS ONE, 2014, 9, e90092.	1.1	18
7238	Gait-Related Brain Activity in People with Parkinson Disease with Freezing of Gait. PLoS ONE, 2014, 9, e90634.	1.1	88
7239	Motor, Psychiatric and Fatigue Features Associated with Nutritional Status and Its Effects on Quality of Life in Parkinson's Disease Patients. PLoS ONE, 2014, 9, e91153.	1.1	48
7240	Specific Changes of Serum Proteins in Parkinson's Disease Patients. PLoS ONE, 2014, 9, e95684.	1.1	17
7241	Standardized Handwriting to Assess Bradykinesia, Micrographia and Tremor in Parkinson's Disease. PLoS ONE, 2014, 9, e97614.	1.1	91
7242	Initial Medication in Patients of Newly Diagnosed Parkinson's Disease in Taiwan. PLoS ONE, 2014, 9, e107465.	1.1	14
7243	Parkin (PARK 2) Mutations Are Rare in Czech Patients with Early-Onset Parkinson's Disease. PLoS ONE, 2014, 9, e107585.	1.1	14

#	ARTICLE	IF	CITATIONS
7244	Abnormal Pulmonary Function and Respiratory Muscle Strength Findings in Chinese Patients with Parkinsonâ€™s Disease and Multiple System Atrophyâ€“Comparison with Normal Elderly. PLoS ONE, 2014, 9, e116123.	1.1	51
7245	Effects of Aging and Idiopathic Parkinsonâ€™s Disease on Tactile Temporal Order Judgment. PLoS ONE, 2015, 10, e0118331.	1.1	12
7246	Effectiveness of Traditional Chinese Medicine as an Adjunct Therapy for Parkinsonâ€™s Disease: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0118498.	1.1	45
7247	Assessment of Brainstem Function with Auricular Branch of Vagus Nerve Stimulation in Parkinsonâ€™s Disease. PLoS ONE, 2015, 10, e0120786.	1.1	36
7248	StartReact Effects Support Different Pathophysiological Mechanisms Underlying Freezing of Gait and Postural Instability in Parkinsonâ€™s Disease. PLoS ONE, 2015, 10, e0122064.	1.1	27
7249	Feasibility of Computed Tomography-Guided Methods for Spatial Normalization of Dopamine Transporter Positron Emission Tomography Image. PLoS ONE, 2015, 10, e0132585.	1.1	25
7250	Motivational Modulation of Self-Initiated and Externally Triggered Movement Speed Induced by Threat of Shock: Experimental Evidence for Paradoxical Kinesis in Parkinsonâ€™s Disease. PLoS ONE, 2015, 10, e0135149.	1.1	10
7251	Accelerometer Cut Points for Physical Activity Assessment of Older Adults with Parkinsonâ€™s Disease. PLoS ONE, 2015, 10, e0135899.	1.1	33
7252	Comparative Incidence of Conformational, Neurodegenerative Disorders. PLoS ONE, 2015, 10, e0137342.	1.1	21
7253	Alteration of Brain Functional Networks in Early-Stage Parkinsonâ€™s Disease: A Resting-State fMRI Study. PLoS ONE, 2015, 10, e0141815.	1.1	63
7254	Amplitude Manipulation Evokes Upper Limb Freezing during Handwriting in Patients with Parkinsonâ€™s Disease with Freezing of Gait. PLoS ONE, 2015, 10, e0142874.	1.1	24
7255	Tracking Parkinsonâ€™s Disease over One Year with Multimodal Magnetic Resonance Imaging in a Group of Older Patients with Moderate Disease. PLoS ONE, 2015, 10, e0143923.	1.1	21
7256	Serum Insulin-Like Growth Factor-1 in Patients with De Novo, Drug Naïve Parkinsonâ€™s Disease: A Meta-Analysis. PLoS ONE, 2015, 10, e0144755.	1.1	13
7257	Serum Levels of Coenzyme Q10 in Patients with Multiple System Atrophy. PLoS ONE, 2016, 11, e0147574.	1.1	39
7258	Impaired Retention of Motor Learning of Writing Skills in Patients with Parkinsonâ€™s Disease with Freezing of Gait. PLoS ONE, 2016, 11, e0148933.	1.1	32
7259	GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinsonâ€™s Disease and Lewy Body Dementia. PLoS ONE, 2016, 11, e0149349.	1.1	29
7260	Principal Component Analysis of Multimodal Neuromelanin MRI and Dopamine Transporter PET Data Provides a Specific Metric for the Nigral Dopaminergic Neuronal Density. PLoS ONE, 2016, 11, e0151191.	1.1	27
7261	Contribution of Step Length to Increase Walking and Turning Speed as a Marker of Parkinsonâ€™s Disease Progression. PLoS ONE, 2016, 11, e0152469.	1.1	31

#	ARTICLE	IF	CITATIONS
7262	On the Utility of MIBG SPECT/CT in Evaluating Cardiac Sympathetic Dysfunction in Lewy Body Diseases. PLoS ONE, 2016, 11, e0152746.	1.1	18
7263	Screening for Cognitive Impairment in Parkinson's Disease: Improving the Diagnostic Utility of the MoCA through Subtest Weighting. PLoS ONE, 2016, 11, e0159318.	1.1	24
7264	Correlation of Quantitative Motor State Assessment Using a Kinetograph and Patient Diaries in Advanced PD: Data from an Observational Study. PLoS ONE, 2016, 11, e0161559.	1.1	52
7265	Weight Change Is a Characteristic Non-Motor Symptom in Drug-Naïve Parkinson's Disease Patients with Non-Tremor Dominant Subtype: A Nation-Wide Observational Study. PLoS ONE, 2016, 11, e0162254.	1.1	10
7266	Quantitative Susceptibility Mapping in Parkinson's Disease. PLoS ONE, 2016, 11, e0162460.	1.1	184
7267	Alterations of Myelin Content in Parkinson's Disease: A Cross-Sectional Neuroimaging Study. PLoS ONE, 2016, 11, e0163774.	1.1	63
7268	Brain Connectivity Changes in Autosomal Recessive Parkinson Disease: A Model for the Sporadic Form. PLoS ONE, 2016, 11, e0163980.	1.1	10
7269	Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson's Disease and Atypical Parkinsonian Syndromes. PLoS ONE, 2016, 11, e0165869.	1.1	26
7270	Facial Emotion Recognition and Expression in Parkinson's Disease: An Emotional Mirror Mechanism?. PLoS ONE, 2017, 12, e0169110.	1.1	83
7271	Home detection of freezing of gait using support vector machines through a single waist-worn triaxial accelerometer. PLoS ONE, 2017, 12, e0171764.	1.1	135
7272	DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers. PLoS ONE, 2017, 12, e0175424.	1.1	27
7273	Impact of Sjogren's syndrome on Parkinson's disease: A nationwide case-control study. PLoS ONE, 2017, 12, e0175836.	1.1	13
7274	Comparison of T2*-weighted and QSM contrasts in Parkinson's disease to visualize the STN with MRI. PLoS ONE, 2017, 12, e0176130.	1.1	58
7275	Determinants of generic and specific health-related quality of life in patients with Parkinson's disease. PLoS ONE, 2017, 12, e0178896.	1.1	22
7276	The variability of the steps preceding obstacle avoidance (approach phase) is dependent on the height of the obstacle in people with Parkinson's disease. PLoS ONE, 2017, 12, e0184134.	1.1	11
7277	The absence of orthostatic heart rate increase is associated with cognitive impairment in Parkinson's disease. PLoS ONE, 2020, 15, e0240491.	1.1	10
7278	A compound downregulation of SRRM2 and miR-27a-3p with upregulation of miR-27b-3p in PBMCs of Parkinson's patients is associated with the early stage onset of disease. PLoS ONE, 2020, 15, e0240855.	1.1	18
7279	Effect of family history, occupation and diet on the risk of Parkinson disease: A case-control study. PLoS ONE, 2020, 15, e0243612.	1.1	10

#	ARTICLE	IF	CITATIONS
7280	Multi-strain probiotics (Hexbio) containing MCP BCMC strains improved constipation and gut motility in Parkinson's disease: A randomised controlled trial. PLoS ONE, 2020, 15, e0244680.	1.1	79
7281	Effect of a Leucine-rich Repeat Kinase 2 Variant on Motor and Non-motor Symptoms in Chinese Parkinson's Disease Patients. , 2016, 7, 230.		27
7282	Six Visual Rating Scales as A Biomarker for Monitoring Atrophied Brain Volume in Parkinson's Disease. , 2020, 11, 1082.		7
7283	Transcranial Sonography in Parkinson's Disease and Parkinsonism. Journal of Movement Disorders, 2008, 1, 6-12.	0.7	1
7284	Gait Analysis in Patients With Parkinson's Disease: Relationship to Clinical Features and Freezing. Journal of Movement Disorders, 2008, 1, 59-64.	0.7	15
7285	One View of the Current State of Understanding in Basal Ganglia Pathophysiology and What is Needed for the Future. Journal of Movement Disorders, 2011, 4, 13-20.	0.7	4
7286	Orthostatic Hypotension in Drug-Naïve Patients with Parkinson's Disease. Journal of Movement Disorders, 2011, 4, 33-37.	0.7	16
7287	Putaminal Hypointensity in the Parkinsonian Variant of Multiple System Atrophy: Simple Visual Assessment Using Susceptibility-Weighted Imaging. Journal of Movement Disorders, 2011, 4, 60-63.	0.7	26
7288	Analysis of the Substantia Innominata Volume in Patients with Parkinson's Disease with Dementia, Dementia with Lewy Bodies, and Alzheimer's Disease. Journal of Movement Disorders, 2011, 4, 68-72.	0.7	18
7289	Can Postural Instability Respond to Galvanic Vestibular Stimulation in Patients with Parkinson's Disease?. Journal of Movement Disorders, 2016, 9, 40-43.	0.7	33
7290	Cognition and Visit-to-Visit Variability of Blood Pressure and Heart Rate in De Novo Patients with Parkinson's Disease. Journal of Movement Disorders, 2016, 9, 144-151.	0.7	8
7291	Sleepiness and Depression in Parkinson's Disease Patients Treated with Ropinirole and Levodopa. Journal of Movement Disorders, 2017, 10, 123-129.	0.7	13
7292	Clinical and Imaging Features of Multiple System Atrophy: Challenges for an Early and Clinically Definitive Diagnosis. Journal of Movement Disorders, 2018, 11, 107-120.	0.7	28
7293	Cognition, Olfaction and Uric Acid in Early de novo Parkinson's Disease. Journal of Movement Disorders, 2018, 11, 139-144.	0.7	6
7294	Clinical Characteristics of Involuntary Movement in Hospitalized Patients. Journal of Movement Disorders, 2019, 12, 31-36.	0.7	2
7295	Immunotherapy Targeting Neurodegenerative Proteinopathies: Î±-Synucleinopathies and Tauopathies. Journal of Movement Disorders, 2020, 13, 11-19.	0.7	20
7296	Emerging Concepts of Motor Reserve in Parkinson's Disease. Journal of Movement Disorders, 2020, 13, 171-184.	0.7	30
7297	Is the timed up and go (TUG) sensitive to differentiating patients with mild to moderate PD compared to age matched controls: a descriptive pilot study. International Physical Medicine & Rehabilitation Journal, 2018, 3, .	0.1	2

#	ARTICLE	IF	CITATIONS
7298	Effect of Capicor on the Parkinson's disease pathogenic links. <i>Fiziologichnyi Zhurnal (Kiev, Ukraine:)</i> 2000, 4, 0.1	0.1	4
7299	Tribute to Professor Andrew J. Lees. <i>Arquivos De Neuro-Psiquiatria</i> , 2020, 78, 307-310.	0.3	1
7300	Validation of 19-items wearing-off (WOQ-19) questionnaire to Portuguese. <i>Arquivos De Neuro-Psiquiatria</i> , 2020, 78, 624-628.	0.3	1
7301	Validation of the Brazilian Portuguese version of the Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire (RBDSQ-BR). <i>Arquivos De Neuro-Psiquiatria</i> , 2020, 78, 629-637.	0.3	8
7302	THE IMPACT OF BRAZILIAN SAMBA ON PARKINSON'S DISEASE: ANALYSIS BY THE DISEASE SUBTYPES. <i>Revista Brasileira De Medicina Do Esporte</i> , 2020, 26, 25-29.	0.1	7
7303	Exercícios terapêuticos domiciliares na doença de Parkinson: uma revisão integrativa. <i>Revista Brasileira De Geriatria E Gerontologia</i> , 2016, 19, 349-364.	0.1	10
7304	Relationship between cognitive performance and mobility in patients with Parkinson's disease: A cross-sectional study. <i>Dementia E Neuropsychologia</i> , 2019, 13, 403-409.	0.3	8
7306	Instrumentos de avaliação clínica para disfagia orofaríngea na doença de Parkinson: revisão sistemática. <i>Audiology: Communication Research</i> , 2017, 22, .	0.1	4
7307	Estudio caso-control de marcadores de estrés oxidativo y metabolismo del hierro plasmático en la enfermedad de Parkinson. <i>Revista Espanola De Salud Publica</i> , 2001, 75, .	0.3	11
7308	The perception of apathy by caregivers of patients with dementia in Parkinson's disease. <i>Dementia E Neuropsychologia</i> , 2016, 10, 339-343.	0.3	2
7309	Investigating the role of 99mTc-TRODAT-1 SPECT imaging in idiopathic Parkinson's disease. <i>Journal of Zhejiang University Science B</i> , 2005, 6B, 22-27.	0.4	17
7310	Subjective visual vertical perception and sense of smell in Parkinson disease. <i>Journal of Rehabilitation Research and Development</i> , 2012, 49, 961.	1.6	11
7314	Altered oxidative stress levels in Indian Parkinson's disease patients with PARK2 mutations.. <i>Acta Biochimica Polonica</i> , 2011, 58, .	0.3	31
7315	The increased gray matter volumes of precentral gyri in Parkinson's disease patients with diphasic dyskinesia. <i>Aging</i> , 2019, 11, 9661-9671.	1.4	7
7316	Asymmetrical nigral iron accumulation in Parkinson's disease with motor asymmetry: an explorative, longitudinal and test-retest study. <i>Aging</i> , 2020, 12, 18622-18634.	1.4	10
7317	Altered putamen functional connectivity is associated with anxiety disorder in Parkinson's disease. <i>Oncotarget</i> , 2017, 8, 81377-81386.	0.8	21
7318	NFE2L2 variations reduce antioxidant response in patients with Parkinson disease. <i>Oncotarget</i> , 2016, 7, 10756-10764.	0.8	17
7319	Association between carotid plaque and Parkinson's disease. <i>Annals of Translational Medicine</i> , 2019, 7, 94-94.	0.7	6

#	ARTICLE	IF	CITATIONS
7320	Prodromal non-motor symptoms of Parkinson's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2007, 3, 145-151.	1.0	83
7321	Analysis of PRKN Variants and Clinical Features in Polish Patients with Parkinson's Disease. <i>Current Genomics</i> , 2015, 16, 215-223.	0.7	6
7322	Recent Progress of Imaging Agents for Parkinson's Disease. <i>Current Neuropharmacology</i> , 2015, 12, 551-563.	1.4	11
7323	Cerebral and Extracranial Neurodegeneration are Strongly Coupled in Parkinson's Disease. <i>The Open Neurology Journal</i> , 2007, 1, 1-4.	0.4	11
7324	The Insertion/Deletion Polymorphism of the Angiotensin Converting Enzyme (ACE) in Parkinson's Disease. <i>The Open Neurology Journal</i> , 2008, 2, 66-70.	0.4	3
7325	Validation of a Portable Device for Mapping Motor and Gait Disturbances in Parkinson's Disease. <i>JMIR MHealth and UHealth</i> , 2015, 3, e9.	1.8	49
7326	Brazilian Samba Protocol for Individuals With Parkinson's Disease: A Clinical Non-Randomized Study. <i>JMIR Research Protocols</i> , 2017, 6, e129.	0.5	14
7327	Tc-TRODAT-1 SPECT Imaging in Early and Late Onset Parkinson's Disease. <i>Asia Oceania Journal of Nuclear Medicine and Biology</i> , 2017, 5, 114-119.	0.1	18
7328	Parkinson disease-related cortical and striatal cognitive patterns in dual time F-18 FP CIT: evidence for neural correlates between the caudate and the frontal lobe. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 379-386.	0.4	8
7329	Automatic Extraction of the Cingulum Bundle in Diffusion Tensor Tract-specific Analysis: Feasibility Study in Parkinson's Disease with and without Dementia. <i>Magnetic Resonance in Medical Sciences</i> , 2013, 12, 201-213.	1.1	3
7330	Genitourinary Dysfunction Prevalence in Parkinson Disease Patients. <i>ARS Medica Tomitana</i> , 2019, 25, 6-10.	0.0	2
7331	ASSOCIATIONS BETWEEN OLFACTORY IMPAIRMENT AND COGNITIVE FUNCTIONS IN PATIENTS WITH PARKINSON DISEASE. <i>Noropsikiyatri Arsivi</i> , 2018, 57, 216-221.	0.2	4
7333	Comparing two randomized deep brain stimulation trials for Parkinson's disease. <i>Journal of Neurosurgery</i> , 2020, 132, 1376-1384.	0.9	18
7334	Hemispheric Network Expression in Parkinson's Disease: Relationship to Dopaminergic Asymmetries. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1737-1749.	1.5	8
7335	Dysarthria and Speech Intelligibility Following Parkinson's Disease Globus Pallidus Internus Deep Brain Stimulation. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1493-1502.	1.5	8
7336	The Association Between Balance, Fear of Falling and Daily Activities in Drug Phases and Different Levels of Disease Severity in Patients With Parkinson's Disease. <i>Basic and Clinical Neuroscience</i> , 2019, 10, 355-362.	0.3	11
7338	Chemically Induced Models of Parkinson's Disease: History and Perspectives for the Involvement of Ferroptosis. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 581191.	1.8	27
7339	Theta-Burst Stimulation for Cognitive Enhancement in Parkinson's Disease With Mild Cognitive Impairment: A Randomized, Double-Blind, Sham-Controlled Trial. <i>Frontiers in Neurology</i> , 2020, 11, 584374.	1.1	19

#	ARTICLE	IF	CITATIONS
7340	Time Series Analysis Applied to EEG Shows Increased Global Connectivity during Motor Activation Detected in PD Patients Compared to Controls. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 15.	1.3	5
7341	Complexity Measures of Voice Recordings as a Discriminative Tool for Parkinson's Disease. <i>Biosensors</i> , 2020, 10, 1.	2.3	25
7342	Doença de Parkinson. <i>Revista Neurociencias</i> , 2005, 13, 158-165.	0.0	6
7344	Evaluation of abnormal iron distribution in specific regions in the brains of patients with Parkinson's disease using quantitative susceptibility mapping and R2* mapping. <i>Experimental and Therapeutic Medicine</i> , 2020, 19, 3778-3786.	0.8	8
7345	The effect of REM sleep behaviour disorder on clinical severity in Parkinson's disease. <i>Turkish Journal of Medical Sciences</i> , 0, , .	0.4	2
7346	Association of Nurr1 gene mutations with Parkinson's disease in the Han population living in the Hubei province of China. <i>Neural Regeneration Research</i> , 2012, 7, 1791-6.	1.6	6
7347	A Cortical Substrate for Square-Wave Jerks in Progressive Supranuclear Palsy. <i>Journal of Clinical</i>		

#	ARTICLE	IF	CITATIONS
7359	Auditory and vestibular dysfunction in patients with Parkinson's disease. The Egyptian Journal of Otolaryngology, 2019, 35, 313-321.	0.1	5
7360	Quality of life in patients with Parkinson's disease after subthalamic stimulation: An observational cohort study for outcome prediction. Tzu Chi Medical Journal, 2019, 31, 107.	0.4	5
7361	Is "Frequency Distribution" Enough to Detect Tremor in PD Patients Using a Wrist Worn Accelerometer?. , 2014, , .		6
7362	Orthostatic Hypotension and its Relationship to the Clinical Course of Patients with Parkinson's Disease. , 2014, 04, .		1
7363	Apathy and Emotional Blunting in Parkinson's Disease. Brain Disorders & Therapy, 2014, 03, .	0.1	3
7364	The effects of a supervised Pilates training program on balance in Parkinson's disease. Advances in Parkinson S Disease, 2013, 02, 58-61.	0.2	17
7365	Potential of a planarian model to study certain aspects of anti-Parkinsonism drugs. Advances in Parkinson S Disease, 2013, 02, 70-74.	0.2	2
7366	Effectiveness of Istradefylline for Fatigue and Quality of Life in Parkinson's Disease Patients and of Their Caregivers. Advances in Parkinson S Disease, 2016, 05, 24-28.	0.2	10
7367	Levodopa/Carbidopa Intestinal Gel for Treatment of Advanced Parkinson's Disease: An Update on the Effects of Cognitive Functions. Advances in Parkinson S Disease, 2017, 06, 13-23.	0.2	7
7368	Differences between Istradefylline Responders and Non-Responders in Parkinson's Disease. Advances in Parkinson S Disease, 2017, 06, 45-51.	0.2	2
7369	Evaluation of Clinical Utility of the Personal KinetiGraph [®] in the Management of Parkinson Disease. Advances in Parkinson S Disease, 2019, 08, 42-61.	0.2	6
7370	Effects of Physical Activity Levels on Fatigue Perception in Patients with Parkinson's Disease and Neurologically Healthy Individuals. Health, 2014, 06, 2927-2933.	0.1	4
7371	Polymorphisms in the SNCA Gene: Association with the Risk of Development of the Sporadic Form of Parkinson's Disease and the Level of SNCA Gene Expression in Peripheral Blood of Patients from Russia. Neuroscience and Medicine, 2013, 04, 208-214.	0.2	5
7372	Related factors and prevalence of Parkinson's disease among Uygur residents in Hetian, Xinjiang Uygur Autonomous Region. Genetics and Molecular Research, 2015, 14, 8539-8546.	0.3	6
7373	Validity and Reliability of the Turkish Version of the 8-Item Parkinson's Disease Questionnaire. Noropsikiyatri Arsivi, 2018, 55, 337-340.	0.7	5
7374	Occupational history of night shift work and Parkinson's disease in Denmark. Scandinavian Journal of Work, Environment and Health, 2015, 41, 377-383.	1.7	9
7375	Occupational and recreational physical activity and Parkinson's disease in Denmark. Scandinavian Journal of Work, Environment and Health, 2017, 43, 210-216.	1.7	6
7376	Parkinsonian Symptoms, Not Dyskinesia, Negatively Affect Active Life Participation of Dyskinetic Patients with Parkinson's Disease. Tremor and Other Hyperkinetic Movements, 2020, 10, 20.	1.1	4

#	ARTICLE	IF	CITATIONS
7377	Correlation of Age and Severity of Clinical Manifestation Assessed by UPDRS in Patients with Idiopathic Parkinson's Disease. <i>Medicinski Arhiv = Medical Archives = Archives De MÃ©decine</i> , 2014, 68, 44.	0.4	1
7378	Development of a depression in Parkinson's disease prediction model using machine learning. <i>World Journal of Psychiatry</i> , 2020, 10, 234-244.	1.3	20
7379	Best early-onset Parkinson dementia predictor using ensemble learning among Parkinson's symptoms, rapid eye movement sleep disorder, and neuropsychological profile. <i>World Journal of Psychiatry</i> , 2020, 10, 245-259.	1.3	7
7380	Handwriting Rehabilitation in Parkinson Disease: A Pilot Study. <i>Annals of Rehabilitation Medicine</i> , 2015, 39, 586.	0.6	13
7381	Factors Influencing the Presentation of REM Sleep Behavior Disorder: The Relative Importance of Sex, Associated Neurological Disorder, and Context of Referral to Polysomnography. <i>Journal of Clinical Sleep Medicine</i> , 2019, 15, 1789-1798.	1.4	14
7382	Simulating Idiopathic Parkinson's Disease by In Vitro and Computational Models. , 0, , .		1
7383	Quantitative Evaluation of Movement Disorders by Specified Analysis According to Actigraphy Records. <i>International Journal of Integrative Medicine</i> , 2013, , 1.	0.7	6
7384	The Current Status of Integrative Therapies in Treating Parkinson's Disease in Six General Hospitals in Shanghai. <i>International Journal of Integrative Medicine</i> , 2013, , 1.	0.7	10
7385	Towards New Therapies for Parkinson's Disease. , 2011, , .		10
7386	Effects of Alexander-Based Corrective Techniques on Forward Flexed Posture, Risk of Fall, and Fear of Falling in Idiopathic Parkinson's Disease. <i>Archives of Neuroscience</i> , 2018, 5, .	0.1	6
7387	A study on risk factors for Parkinson's disease in Indian population. <i>Bioinformation</i> , 2014, 10, 342-346.	0.2	7
7388	State transitions in the substantia nigra reticulata predict the onset of motor deficits in models of progressive dopamine depletion in mice. <i>ELife</i> , 2019, 8, .	2.8	46
7389	Subjective poor sleep quality in Chinese patients with Parkinson's disease without dementia. <i>Journal of Biomedical Research</i> , 2013, 27, 291-5.	0.7	7
7390	Transcranial sonography findings related to depression in parkinsonian disorders: cross-sectional study in 126 patients. <i>PeerJ</i> , 2016, 4, e2037.	0.9	5
7391	Eye movement control during visual pursuit in Parkinson's disease. <i>PeerJ</i> , 2018, 6, e5442.	0.9	16
7392	Efficacy and Safety of Deep Brain Stimulation in the Treatment of Parkinson's Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Cureus</i> , 2018, 10, e3474.	0.2	31
7393	Serological Analysis of Alpha-synuclein and NF- κ B in Parkinson's Disease Patients. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2015, 9, BC01-4.	0.8	9
7394	Comparison of VIM and STN DBS for Parkinsonian Resting and Postural/Action Tremor. <i>Tremor and Other Hyperkinetic Movements</i> , 2015, 5, 321.	1.1	20

#	ARTICLE	IF	CITATIONS
7395	Change in Non-motor Symptoms in Parkinson's Disease and Essential Tremor Patients: A One-year Follow-up Study. Tremor and Other Hyperkinetic Movements, 2014, 4, 216.	1.1	8
7396	A Comparison Study of Cognitive and Neuropsychiatric Features of Essential Tremor and Parkinson's Disease. Tremor and Other Hyperkinetic Movements, 2016, 6, 431.	1.1	17
7397	Genetic Analysis of Leucin-Rich Repeat Kinase 2 (LRRK2) G2019S Mutation in a Sample of Egyptian Patients with Parkinson's Disease, a Pilot Study. British Journal of Medicine and Medical Research, 2015, 5, 404-408.	0.2	4
7398	Distinguishing Between Parkinson's Disease and Essential Tremor Through Video Analytics Using Machine Learning: A Pilot Study. IEEE Sensors Journal, 2021, 21, 11916-11925.	2.4	11
7399	Constipation Predicts Cognitive Decline in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group. Journal of Parkinson's Disease, 2022, 12, 315-331.	1.5	10
7400	Prevalence and Risk Factors for Minor Hallucinations in Patients with Parkinson's Disease. Behavioural Neurology, 2021, 2021, 1-10.	1.1	12
7401	Analysing the reasons for rejection of neurosurgery intervention in patients with Parkinson's disease referred to an extrapyramidal movement disorders clinic. Annals of Clinical and Experimental Neurology, 2021, 15, 43-53.	0.1	1
7403	Brain network topology and future development of freezing of gait in Parkinson's disease: a longitudinal study. Journal of Neurology, 2022, 269, 2503-2512.	1.8	8
7404	Assessing Parkinson's Disease at Scale Using Telephone-Recorded Speech: Insights from the Parkinson's Voice Initiative. Diagnostics, 2021, 11, 1892.	1.3	12
7405	Safety and efficacy of amprelosetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial. Clinical Autonomic Research, 2021, 31, 699-711.	1.4	11
7406	The end of the affair?. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1249-1250.	0.9	0
7407	A pathophysiological model of gait captures the details of the impairment of pace/rhythm, variability and asymmetry in Parkinsonian patients at distinct stages of the disease. Scientific Reports, 2021, 11, 21143.	1.6	7
7408	First delirium episode in Parkinson's disease and parkinsonism: incidence, predictors, and outcomes. Npj Parkinson's Disease, 2021, 7, 92.	2.5	7
7409	Parkinson's disease: the nutrition perspective. Proceedings of the Nutrition Society, 2022, 81, 12-26.	0.4	9
7410	Hybrid PET-MRI for early detection of dopaminergic dysfunction and microstructural degradation involved in Parkinson's disease. Communications Biology, 2021, 4, 1162.	2.0	11
7411	Progression of Fatigue in Early Parkinson's Disease: A 3-Year Prospective Cohort Study. Frontiers in Aging Neuroscience, 2021, 13, 701906.	1.7	5
7412	Relationship Between Brain Volumes and Objective Balance and Gait Measures in Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 283-294.	1.5	5
7413	Istradefylline Versus Opicapone for 'Off' Episodes in Parkinson's Disease: A Systematic Review and Meta-Analysis. Annals of Neurosciences, 2021, 28, 65-73.	0.9	3

#	ARTICLE	IF	CITATIONS
7414	Macular microcirculation characteristics in Parkinson's disease evaluated by OCT-Angiography: a literature review. <i>Seminars in Ophthalmology</i> , 2021, , 1-9.	0.8	4
7415	Sleep Disturbances and Phenoconversion in Patients with REM Sleep Behavior Disorder. <i>Journal of Clinical Medicine</i> , 2021, 10, 4709.	1.0	2
7416	Detraining Effect on Pulmonary and Cardiovascular Autonomic Function and Functional Outcomes in Patients With Parkinson's Disease After Respiratory Muscle Training: An 18-Month Follow-Up Study. <i>Frontiers in Neurology</i> , 2021, 12, 735847.	1.1	1
7417	Impact of Mild Cognitive Impairment on Quality of Life in Young and Typical Onset Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 69-75.	0.8	2
7418	Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection. <i>Pharmacological Reviews</i> , 2021, 73, 1204-1268.	7.1	11
7419	A six-metabolite panel as potential blood-based biomarkers for Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 94.	2.5	19
7420	The Parkinson's Disease-Cognitive Rating Scale: Greek Normative Data, Clinical Utility and Cultural Considerations. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2021, , 089198872110491.	1.2	0
7421	Surrogates for rigidity and PIGD MDS-UPDRS subscores using wearable sensors. <i>Gait and Posture</i> , 2022, 91, 186-191.	0.6	10
7422	More Than Just Static: Dynamic Functional Connectivity Changes of the Thalamic Nuclei to Cortex in Parkinson's Disease With Freezing of Gait. <i>Frontiers in Neurology</i> , 2021, 12, 735999.	1.1	9
7423	Comprehensive Analysis of LIN28A in Chinese Patients With Early Onset Parkinson's Disease. <i>Frontiers in Genetics</i> , 2021, 12, 740096.	1.1	2
7424	Decreased frontotemporal connectivity in patients with parkinson's disease experiencing face pareidolia. <i>Npj Parkinson's Disease</i> , 2021, 7, 90.	2.5	9
7425	Validation of the Korean version of the composite autonomic symptom scale 31 in patients with Parkinson's disease. <i>PLoS ONE</i> , 2021, 16, e0258897.	1.1	0
7426	Prescribing considerations in the use of oral medication in Parkinson's disease. <i>Journal of Prescribing Practice</i> , 2021, 3, 396-403.	0.1	0
7427	Differential Effect of Iron and Myelin on Susceptibility MRI in the Substantia Nigra. <i>Radiology</i> , 2021, 301, 682-691.	3.6	6
7428	A novel approach to understanding Parkinsonian cognitive decline using minimum spanning trees, edge cutting, and magnetoencephalography. <i>Scientific Reports</i> , 2021, 11, 19704.	1.6	2
7429	Off Time Independently Affects Quality of Life in Advanced Parkinson's Disease (APD) Patients but Not in Non-APD Patients: Results from the Self-Reported Japanese Quality-of-Life Survey of Parkinson's Disease (JAQPAD) Study. <i>Parkinson's Disease</i> , 2021, 2021, 1-9.	0.6	3
7430	The amplitude of low-frequency fluctuation predicts levodopa treatment response in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 92, 26-32.	1.1	10
7431	The starting distance of obstacle circumvention did not affect intersegmental coordination in individuals with Parkinson's disease. <i>Human Movement Science</i> , 2021, 80, 102878.	0.6	0

#	ARTICLE	IF	CITATIONS
7432	Monitoring neuroprotection and restorative therapies in Parkinson's disease with PET. , 2000, , 125-137.		12
7433	Movement Disorders: Other Hypokinetic Disorders. , 2000, , 263-284.		2
7434	Parkinson's Disease: Outcome Variables and Clinical Scales. , 2001, , 299-310.		0
7435	Parkinson's Disease: Experience with Large Multicentre Trials. , 2001, , 325-337.		0
7436	Tricks that relieve camptocormia during gait in Parkinson's disease patients. Revista Neurociencias, 2012, 20, 236-239.	0.0	0
7438	Familial Variants of Parkinson's Disease. Advances in Behavioral Biology, 2002, , 281-284.	0.2	0
7439	Parkinson-Syndrom und zerebrovaskuläre Morbidität. , 2002, , 61-68.		0
7440	Parkinson's Disease: Recognition, Diagnosis, and Measurement. , 2003, , 740-743.		0
7446	Histopathologie de la maladie de Parkinson. Bulletin De L'Academie Nationale De Medecine, 2003, 187, 259-276.	0.0	1
7449	MR Imaging of Parkinsonism. , 2004, , .		0
7451	The treatment of patients with Parkinson's disease: who cares?. Practical Neurology, 2005, 5, 66-67.	0.5	0
7453	Parkinsonism and tremor disorders. A clinical approach. Libyan Journal of Medicine, 2007, 2, 66-72.	0.8	0
7455	LRRK2-Associated Parkinsonism. , 2007, , 45-59.		0
7456	Drug Treatment of Motor Symptoms in Parkinson's Disease. , 2007, , 103-121.		0
7459	Entscheiden bei Morbus Parkinson " eine "bersicht. Zeitschrift für Neuropsychologie = Journal of Neuropsychology, 2008, 19, 235-251.	0.2	0
7460	Tomografia por emisiã de fotã de nico. , 2008, , 127-154.		0
7461	Deep Brain Stimulation in Atypical Parkinsonism. , 2008, , 291-303.		0
7462	The Shaking Palsy - Advances in Our Understanding of Parkinson's Disease. Opticon1826, 2008, , .	0.0	0

#	ARTICLE	IF	CITATIONS
7463	The Relationship Between Plasma Homocysteine Level and C677T MTHFR Genotype in Drug-Naive Patients With Idiopathic Parkinson's Disease. <i>Journal of Movement Disorders</i> , 2008, 1, 71-74.	0.7	0
7464	â€˜Here Comes the Judgeâ€™ (with absent left arm swing). , 2008, , 365-368.		0
7465	Parkinsonism with dysautonomia. , 2008, , 163-166.		0
7466	Role of Imaging Techniques in Discerning Neurobehavioral Changes in Ischemic, Neurodegenerative and Demyelinating Disorders. , 2009, , 17-54.		0
7467	Clinica e terapia della malattia di Parkinson. , 2009, , 1-22.		0
7468	PET and SPECT in the Evaluation of Patients with Central Motor Disorders. , 2009, , 67-92.		0
7469	Diagnostic PET in Image Guided Neurosurgery. , 2009, , 307-323.		0
7472	Parkinsonkrankheit und Dystonie. , 2010, , 711-738.		0
7473	Managing Parkinson's disease in primary care. <i>Independent Nurse</i> , 2010, 2010, .	0.0	0
7475	FREEZING OF GAIT IN PARKINSON'S DISEASE: IMPACT ON FALLS RISK, WALKING AIDS UTILIZATION, AND ASSISTANCE-SEEKING BEHAVIOUR. <i>European Journal of Adapted Physical Activity</i> , 2010, 3, 49-59.	0.5	1
7476	Criteria for the diagnosis of dementia. , 2010, , 31-37.		0
7477	CritÃ©res diagnostiques. , 2011, , 111-117.		0
7478	The Influence of Errors Inherent in Genome Wide Association Studies(GWAS) in Relation To Single Gene Models. <i>Journal of Proteomics and Bioinformatics</i> , 2011, 04, .	0.4	2
7479	Elicitation of Neurological Knowledge with ABML. <i>Lecture Notes in Computer Science</i> , 2011, , 14-23.	1.0	2
7480	A young adult with progressive limb shaking and slowness. <i>Journal of Postgraduate Medicine</i> , 2011, 57, 231-236.	0.2	0
7481	BewegungsstÃ¶rungen. , 2011, , 955-1054.		0
7485	CFS Biomarkers in Parkinson's Disease. , 0, , .		0
7486	Clinical and Genetic Aspects in Patients with Idiopathic Parkinson Disease. , 0, , .		0

#	ARTICLE	IF	CITATIONS
7487	Cognitive Rehabilitation in Parkinson's Disease Using Neuropsychological Training, Transfer Training and Sports Therapy. , 0, , .		0
7488	A semi-quantitative evaluation of substantia nigra hyperechogenicity in Parkinson's disease and Parkinsonian syndrome using the Gray Scale Median ultrasound analysis. Neurosonology, 2012, 25, 7-12.	0.0	0
7489	Modeling Protein and Oxidative Metabolism in Parkinson's Disease. , 2012, , 131-150.		0
7490	Dementia in Parkinson's disease. , 2012, , 368-371.		0
7491	Role of 123I-Metaiodobenzylguanidine Myocardial Scintigraphy in Parkinsonian Disorders. , 0, , .		0
7493	Early Computer Aided Diagnosis of Parkinson's Disease Based on Nearest Neighbor Strategy and striatum Activation Threshold. Lecture Notes in Computer Science, 2013, , 258-265.	1.0	0
7495	Neuropathology of parkinsonism. , 2013, , 239-257.		0
7498	Arm Swing Asymmetry and Effect of Auditory Cues on Amplitude in the Patients with Parkinson's Disease. Journal of the Korea Academia-Industrial Cooperation Society, 2013, 14, 344-350.	0.0	1
7499	Morbus Parkinson und verwandte Demenzen. , 2013, , 186-203.		0
7500	The Role of Neuroimaging in the Diagnosis of Parkinson's Disease. International Journal of Integrative Medicine, 2013, , 1.	0.7	1
7502	Rheumatoid Arthritis and Coexisting Parkinson's Disease a Report of 5 Cases. Electronic Journal of General Medicine, 2013, 10, .	0.3	0
7504	Cardiovascular Proteomic Analysis. , 2013, , 81-98.		0
7505	Seria a Doenãsa de Parkinson Fator Protetor da Enxaqueca?. Revista Neurociencias, 2013, 21, 455-460.	0.0	0
7506	Seria a Doenãsa de Parkinson Fator Protetor da Enxaqueca?. Revista Neurociencias, 2013, 21, 455-460.	0.0	0
7508	Immediate positive effects of physical therapy on gait disturbance in patients with parkinson's disease. Physical Therapy and Rehabilitation, 2014, 1, 5.	0.3	0
7509	SPECT Imaging for Idiopathic M. Parkinson and Parkinsonian Syndromes: Guidelines and Comparison with PET and Recent Developments. , 2014, , 605-617.		0
7511	Personality and Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease. International Neuropsychiatric Disease Journal, 2014, 2, 356-367.	0.1	2
7512	Epidermal Growth Factor (EGF) is Associated with Memory and Executive Functioning in Progressed Parkinson's Disease. , 2014, 04, .		0

#	ARTICLE	IF	CITATIONS
7513	Klinische Differentialdiagnose der Parkinson-Syndrome. , 1993, , 48-53.		0
7515	Neuroepidemiology of Parkinsonâ€™s Disease: Environmental Influences. , 1994, , 35-44.		0
7517	SPECT-Darstellung der Dopamin-D2-Rezeptoren. , 1995, , 174-191.		0
7518	Parkinson's disease: moving forward. Medical Journal of Australia, 1995, 163, 287-288.	0.8	0
7519	Die Bewegungsstörungen im höheren Lebensalter. , 1996, , 202-290.		2
7520	Parkinsonâ€™s disease: an update. Primary Health Care, 1996, 6, 17-21.	0.0	0
7521	Cognitive Impairment in Patients with Parkinsonism. Advances in Behavioral Biology, 1998, , 337-341.	0.2	1
7522	A Review of Parkinsonâ€™s Disease and Related Disorders. , 1998, , .		0
7523	Bewegungsstörungen. , 1999, , 857-953.		0
7524	Exkurs: Multisystematrophie. , 1999, , 416-421.		0
7525	Exkurs: Begleitende Behandlung von psychiatrischen Symptomen bei Morbus Parkinson. , 1999, , 316-334.		0
7526	Quality of life in patients with Parkinsonâ€™s Disease and their caregiversâ€™ stress levels. Revista Neurociencias, 2008, 16, 113-117.	0.0	3
7527	loflupane I123 Injection (DaTscanTM) SPECT Brain Imaging in Patients with Movement Disorders and/or Dementia: Preliminary Report. Journal of Neurology & Stroke, 2014, 1, .	0.0	0
7528	Update on Transcranial Sonography Applications in Movement Disorders. Journal of Diagnostic Imaging in Therapy, 2014, 1, 110-128.	0.2	3
7529	Characteristics of Dysarthria and Cognitive Functions in Patients with Parkinsonâ€™s Disease and Parkinson-plus Syndrome. Communication Sciences and Disorders, 2014, 19, 551-557.	0.1	3
7530	Methods (1): Participants and Test Methods. , 2015, , 19-44.		0
7532	Development, Debugging, and Assessment of ParkinsonCheck Attributes Through Visualisation. , 2015, , 47-71.		0
7533	Parkinson-Syndrom. , 2015, , 77-102.		3

#	ARTICLE	IF	CITATIONS
7534	Concurrent and Discriminative Validity of the Mini Balance Evaluation Systems Test (miniBESTest) in People with Parkinson's Disease. Indian Journal of Physical Medicine and Rehabilitation, 2015, 26, 43-48.	0.1	0
7536	The Effect of Sleep and Wakefulness Disorders on Cognitive Function in Parkinson's Disease. European Journal of Medicine Series B, 2015, 2, 18-23.	0.0	0
7538	Exonic Re-Sequencing of the Chromosome 2q24.3 Parkinson's Disease Locus. PLoS ONE, 2015, 10, e0128586.	1.1	0
7539	Effectiveness of Gastric Levodopa Infusion on Motor Fluctuations in a Series of Advanced Parkinson's Disease Cases. , 2015, 1, 1-5.		0
7540	Poverty and Slowness of Voluntary Movement. , 2016, , 1-47.		0
7541	Common Neurologic Issues. , 2016, , 97-123.		0
7542	Morphological changes of the visual analyzer and disturbance of visual-spatial perception in Parkinson's disease. Vestnik of Saint Petersburg University Medicine, 2016, 11, 35-48.	0.0	1
7543	Wirelessly programmed deep brain stimulation of the bilateral subthalamic nucleus for the treatment of primary Parkinson's disease: study protocol for a multicenter, randomized, parallel-controlled optimal-efficiency trial. Clinical and Translational Degenerative Diseases, 2016, 1, 107.	0.0	0
7544	Motor Patterns Recognition in Parkinson's Disease. , 2016, , 1-16.		0
7545	Novel Therapeutic Approach for Parkinson Disease during REM Sleep. Journal of Health Education Research & Development, 2016, 04, .	0.1	0
7547	Nuclear Imaging of Movement Disorders. , 2016, , 241-248.		0
7548	Is Parkinson's Disease with History of Agent Orange Exposure Different from Idiopathic Parkinson's Disease?. Dementia and Neurocognitive Disorders, 2016, 15, 75.	0.4	6
7549	What Should Constitute a Health Related Quality of Life Scale for Parkinson's Disease?. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, OC35-OC39.	0.8	2
7550	Cortical physiology as a therapeutic target in Parkinson's disease related dementia and cognitive dysfunction: study protocol for a randomized controlled trial. Clinical and Translational Degenerative Diseases, 2016, 1, 91.	0.0	1
7551	Tremor Differentiation on Surface Electromyography. IOSR Journal of Dental and Medical Sciences, 2016, 15, 23-29.	0.0	0
7552	Impact of levodopa/carbidopa intestinal gel treatment on the quality of life and ability. Neurologie Pro Praxi, 2016, 17, 323-327.	0.0	1
7553	Determination of Cd, Cr, Pb and Ni contents among Parkinson's disease individuals: a case-control study. International Journal of Neuroscience, 2017, 127, 770-775.	0.8	4
7554	An Autopsy Case of Sporadic Parkinson's Disease that Died of Pneumonia. Journal of the Nihon University Medical Association, 2017, 76, 209-213.	0.0	0

#	ARTICLE	IF	CITATIONS
7557	Biobanks as Producers of Reference Materials. , 2017, , 85-98.		0
7558	Combining Multitask Learning and Short Time Series Analysis in Parkinsonâ€™s Disease Patients Stratification. Lecture Notes in Computer Science, 2017, , 116-125.	1.0	1
7559	Ziekte van Parkinson. , 2017, , 181-194.		0
7560	Neuropsychiatric Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson Disease in China: A Prospectively Controlled Study. Neuropsychiatry, 2017, 07, .	0.4	0
7561	Dynamic Dopamine Transporter Imaging For Detecting Cortical Perfusion Patterns in Parkinsonism. MOJ Clinical & Medical Case Reports, 2017, 6, .	0.0	0
7562	Quasicrystal: A Beautiful Morphology and Diffraction Pattern. Material Science & Engineering International Journal, 2017, 1, .	0.0	1
7564	The pattern of verbal, visuospatial and procedural learning in Richardson variant of progressive supranuclear palsy in comparison to Parkinsonâ€™s disease. Psychiatria Polska, 2017, 51, 647-659.	0.2	6
7565	Parkinson's Disease in the Very Old - Clinicopathological Observations. Journal of Neuroscience and Neuropsychology, 0, , .	0.2	0
7566	Effect of clinical autonomic dysfunction on cognitive functions in Parkinsonâ€™s disease. Dicle Medical Journal, 0, , 225-230.	0.2	3
7567	Serum Levels of Melatonin and Sleep Evaluation Scales in the Diagnosis of Sleep Disorders in Patients with Idiopathic Parkinsonâ€™s Disease. Noropsikiyatri Arsivi, 2019, 56, 264-268.	0.2	2
7570	Gambling Habits of People With Parkinsonâ€™s Disease: An Exploratory Study. Journal of Gambling Issues, 2017, , .	0.3	0
7571	Idiopatisches Parkinson-Syndrom (IPS). Springer Reference Medizin, 2018, , 1-32.	0.0	0
7573	Motor Patterns Recognition in Parkinsonâ€™s Disease. , 2018, , 1237-1252.		0
7575	Frequency of Low Vitamin D3 Levels in Subjects with Parkinsonâ€™s Disease. A Study Conducted at PMCH, a Tertiary Care Hospital, Nawabshah. Advances in Parkinson S Disease, 2018, 07, 7-18.	0.2	2
7576	Cognitive Function in Early and Advanced Parkinsonâ€™s disease. Neuropsychiatry, 2018, 08, .	0.4	0
7581	Application of an Artificial Neural Network for The Early and Accurate Diagnosis of Parkinson's Disease. Transactions on Machine Learning and Artificial Intelligence, 2018, 6, .	0.3	0
7584	Motivation of elderly with Parkinson's disease submitted to functional training, aerobic exercise and exergame. Acta FisiÅ¡trica, 2018, 25, .	0.0	3
7585	Turkish version of Parkinson Fatigue Scale: Validity and reliability study of binary scoring method. Turkish Journal of Physical Medicine and Rehabilitation, 2018, 64, 253-260.	1.1	0

#	ARTICLE	IF	CITATIONS
7586	Case-Control Study of Idiopathic Parkinson's Disease in Japan. <i>Current Topics in Environmental Health and Preventive Medicine</i> , 2019, , 61-81.	0.1	0
7587	Maladie de Parkinson. , 2018, , 650-665.		0
7589	Indications for Deep Brain Stimulation Therapy in Parkinson's Disease. , 2019, , 3-19.		0
7590	Study protocol for a randomised pilot study of a computer-based, non-pharmacological cognitive intervention for motor slowing and motor fatigue in Parkinson's disease. <i>Pilot and Feasibility Studies</i> , 2018, 4, 190.	0.5	0
7591	Validation of Transcranial Sonographic Measurement of the Brainstem Raphe in Korean Patients with Parkinson's Disease. <i>Journal of Neurosonology and Neuroimaging</i> , 2018, 10, 133-137.	0.0	1
7592	Deep Parkinson Disease Diagnosis: Stacked Auto-encoder. <i>Advances in Intelligent Systems and Computing</i> , 2019, , 577-585.	0.5	0
7593	Frailty in Patients with Parkinson's Disease: Associations with Disability and Timed Up and Go. <i>Noropsikiyatri Arsivi</i> , 2019, 58, 206-212.	0.2	4
7594	Is dementia in Parkinson' disease related to chronic stress, anxiety, and depression?. <i>Annals of Indian Academy of Neurology</i> , 2019, 22, 409.	0.2	1
7595	The Relationship between Pain, and Freezing of Gait and Falls in Parkinson's Disease. <i>Noropsikiyatri Arsivi</i> , 2019, 57, 56-60.	0.2	3
7596	Abnormal subcortical volumes and cortical thickness in Parkinson's disease with impulse control disorders. <i>Annals of Indian Academy of Neurology</i> , 2019, 22, 426.	0.2	3
7597	Methods (1): Participants and Test Methods. , 2019, , 21-49.		0
7598	Gray matter correlates of progression of motor symptoms in patients with Parkinson's disease. <i>Annals of Movement Disorders</i> , 2019, 2, 58.	0.3	0
7599	Treatment of Parkinson's Disease: Early, Late, and Combined. , 2019, , 1-26.		0
7600	Change in non-motor symptoms after deep brain stimulation of bilateral subthalamic nuclei in patients with Parkinson's disease. <i>Annals of Movement Disorders</i> , 2019, 2, 65.	0.3	1
7601	Development and validation of quality of life in Parkinson's disease instrument. <i>Annals of Indian Academy of Neurology</i> , 2020, 23, 59.	0.2	1
7602	Neuroinflammation mediators are reduced in sera of Parkinson's disease patients with mild cognitive impairment. <i>Noropsikiyatri Arsivi</i> , 2019, 57, 15-17.	0.2	4
7603	SEMIQUANTITATIVE EVALUATION OF 99MTCTRODAT1 BINDING POTENTIAL BY TWO METHODS OF SPECT IMAGE RECONSTRUCTION.. <i>Brazilian Journal of Radiation Sciences</i> , 2019, 7, .	0.0	0
7604	The Relation Between Type 2 Diabetes Mellitus and Parkinson Disease Up to Date. <i>Romanian Journal of Diabetes Nutrition and Metabolic Diseases</i> , 2019, 26, 79-84.	0.3	0

#	ARTICLE	IF	CITATIONS
7605	Parkon as a treatment of the Parkinsonâ€™s disease. , 0, , 001-005.		3
7607	Frequency of Cognitive Impairment in Patients with Parkinsonâ€™s Disease. Cureus, 2019, 11, e4733.	0.2	1
7611	Parkinsonism and Related Disorders. , 0, , .		0
7615	Therapeutic Approaches to Dysphagia Treatment in Parkinson Disease: A Review. Archives of Neuroscience, 2019, 6, .	0.1	0
7618	The SleepFit Tablet Application for Home-Based Clinical Data Collection in Parkinson Disease: User-Centric Development and Usability Study. JMIR MHealth and UHealth, 2021, 9, e16304.	1.8	5
7619	Allelic variant in SLC6A3 rs393795 affects cerebral regional homogeneity and gait dysfunction in patients with Parkinsonâ€™s disease. PeerJ, 2019, 7, e7957.	0.9	1
7620	Parkinson HastalarÄ±nda Halusinasyon ve Risk Faktörleri. Kâ±rÄ±kkale Ä±niversitesi TÄ±p Fakültesi Dergisi, 0, , 388-394.	0.0	0
7622	Diagnostic value of transcranial sonography for patients with Parkinsonâ€™s disease in the chinese population: A meta and meta-regression analysis. Journal of Systems and Integrative Neuroscience, 2020, 6, .	0.6	0
7626	Flanker Task-Elicited Event-Related Potential Sources Reflect Human Recombinant Erythropoietin Differential Effects on Parkinsonâ€™s Patients. Parkinson's Disease, 2020, 2020, 1-10.	0.6	1
7628	Vitamin D status in idiopathic Parkinsonâ€™s disease: an Egyptian study. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2020, 56, .	0.4	2
7629	Cerebral hemodynamic monitoring of Parkinsonâ€™s disease patients with orthostatic intolerance during head-up tilt test. Neurophotonics, 2020, 7, 1.	1.7	5
7631	Sex-specific association of urate and levodopa-induced dyskinesia in Parkinsonâ€™s disease. European Journal of Neurology, 2020, 27, 1948-1956.	1.7	5
7632	Direct and indirect assessment of functional abilities in patients with Parkinsonâ€™s disease transitioning to dementia. Dementia E Neuropsychologia, 2020, 14, 171-177.	0.3	4
7634	Factors Predicting Falls in Parkinsonâ€™s Disease: Investigation of Motor, Non-motor Findings and Different Dual Task Activities. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2020, 26, 126-132.	0.1	1
7635	ROLE OF REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION IN TREATMENT OF COGNITIVE MANIFESTATIONS IN PARKINSON'S DISEASE. Ain Shams Medical Journal, 2020, 71, 281-292.	0.0	0
7637	Virtual Rehabilitation in Parkinson Disease. American Journal of Physical Medicine and Rehabilitation, 2021, 100, 359-366.	0.7	3
7638	Differential functional dysconnectivity of caudate nucleus subdivisions in Parkinsonâ€™s disease. Aging, 2020, 12, 16183-16194.	1.4	10
7639	for Cognitive Impairment and Dementia in Parkinsonâ€™s. Neuromethods, 2021, , 193-225.	0.2	0

#	ARTICLE	IF	CITATIONS
7640	for , , , and in Parkinsonâ€™s. <i>Neuromethods</i> , 2021, , 227-269.	0.2	0
7641	A Review of Randomized Pharmacological for in Parkinsonâ€™s Patients and Recommendations. <i>Neuromethods</i> , 2021, , 87-108.	0.2	0
7642	Đ;ÑfÑ†Đ°ÑĐ½Đ,Đ¹ Đ;Đ¾Đ³Đ»ÑĐ´ Đ½Đ° Đ°Đ¾Ñ€ĐµĐ°Ñ†Ñ–ÑŽ Đ;Đ¾ÑÑ,ÑfÑ€Đ°Đ»Ñ€Đ½Đ¾Ñ– Đ½ĐµÑÑ,Ñ€Đ½Đ°Đ¾ÑÑ,Ñ– Đ		
7644	AI-based multimodal data management and intelligent analysis system for Parkinson's disease. , 2020, , .		0
7645	Dopamine denervation in the functional territories of the striatum: a new MR and atlas-based 123I-FP-CIT SPECT quantification method. <i>Journal of Neural Transmission</i> , 2021, 128, 1841-1852.	1.4	3
7646	Determinants of quality of life in Parkinsonâ€™s disease: a perspective of novel clinical subtypes. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2174-2183.	1.7	1
7647	Cortical activation during gait adaptability in people with Parkinsonâ€™s disease. <i>Gait and Posture</i> , 2022, 91, 247-253.	0.6	8
7648	Pareidolia in Parkinsonâ€™s Disease and Multiple System Atrophy. <i>Parkinson's Disease</i> , 2021, 2021, 1-6.	0.6	3
7649	Changes in the Gut Microbiome and Predicted Functional Metabolic Effects in an Australian Parkinsonâ€™s Disease Cohort. <i>Frontiers in Neuroscience</i> , 2021, 15, 756951.	1.4	15
7650	MRI of nigrosomeâ€¹: A potential triage tool for patients with suspected parkinsonism. <i>Journal of Neuroimaging</i> , 2021, , .	1.0	3
7651	Adherence to treatment in Parkinson's disease: A multicenter exploratory study with patients from six Latin American countries. <i>Parkinsonism and Related Disorders</i> , 2021, 93, 1-7.	1.1	3
7652	Feasibility of a Brazilian samba protocol for patients with Parkinson's disease: a clinical non-randomized study. <i>Arquivos De Neuro-Psiquiatria</i> , 2020, 78, 13-20.	0.3	8
7653	Action programming disorders associated with Parkinson's disease. , 2020, , 377-393.		0
7654	Analyses of Visuospatial and Visuoperceptual Errors as Predictors of Dementia in Parkinsonâ€™s Disease Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 722-732.	1.2	6
7655	Relating Response Inhibition, Brain Connectivity, and Freezing of Gait in People with Parkinsonâ€™s Disease. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 733-743.	1.2	1
7657	Effect of Motor State on Postactivation Depression of the Soleus H-Reflex in Parkinson's Disease During Deep Brain Stimulation and Dopaminergic Medication Treatment. <i>Journal of Clinical Neurophysiology</i> , 2020, Publish Ahead of Print, .	0.9	1
7658	Fatigue correlates with sleep disturbances in Parkinson disease. <i>Chinese Medical Journal</i> , 2021, 134, 668-674.	0.9	4
7659	Global Functional Network Connectivity Disturbances in Parkinsonâ€™s Disease with Mild Cognitive Impairment by Resting-State Functional MRI. <i>Current Medical Science</i> , 2020, 40, 1057-1066.	0.7	3

#	ARTICLE	IF	CITATIONS
7660	Pharmacotherapy of Psychosis in Parkinsonâ€™s Disease. , 2021, , 1-39.		1
7661	Multimodal neurocognitive markers of naturalistic discourse typify diverse neurodegenerative diseases. <i>Cerebral Cortex</i> , 2022, 32, 3377-3391.	1.6	22
7662	DÄ°YABETÄ°N PARKÄ°NSON HASTALIÄžINDA NON-MOTOR SEMPTOMLAR ÄœZERÄ°NE ETKÄ°SÄ°. <i>Acta Medica Alanya</i> , 0, , . 0		0
7663	Idiopathisches Parkinson-Syndrom (IPS). <i>Springer Reference Medizin</i> , 2020, , 1293-1324.	0.0	0
7664	Approaches to Evaluate Parkinsonian Speech Using Artificial Models. <i>Communications in Computer and Information Science</i> , 2020, , 77-99.	0.4	1
7665	Pain assessment in Indian Parkinson's Disease patients using King's Parkinson's Disease pain scale. <i>Annals of Indian Academy of Neurology</i> , 2020, 23, 774.	0.2	11
7666	Does quality of sleep differ in familial and sporadic Parkinsonâ€™s disease?. <i>Annals of Movement Disorders</i> , 2020, 3, 167.	0.3	0
7667	Symbiotic Relationship with Gut Microbiomes and Parkinson Disease. <i>Asian Journal of Basic Science & Research</i> , 2020, 02, 75-79.	0.1	0
7668	StÄ¶rungen der Basalganglienfunktion. , 2020, , 179-203.		0
7669	A Glance into Regional Parkinsonâ€™s Disease Characteristics: What Differs from Northwest to Southeast of Turkey?. <i>Neuroscience and Medicine</i> , 2020, 11, 63-73.	0.2	0
7670	Can fatigue predict walking capacity of patients with Parkinsonâ€™s disease?. <i>Arquivos De Neuro-Psiquiatria</i> , 2020, 78, 70-75.	0.3	7
7672	Locus coeruleus degeneration is associated with disorganized functional topology in Parkinsonâ€™s disease. <i>NeuroImage: Clinical</i> , 2021, 32, 102873.	1.4	8
7675	Can Levodopa Challenge Testing Predict the Effect of Deep Brain Stimulation? One-Year Outcomes in a Chinese Cohort. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 764308.	1.7	2
7676	D ₂ -Like Receptor Expression in the Hippocampus and Amygdala Informs Performance on the Stop-Signal Task in Parkinson's Disease. <i>Journal of Neuroscience</i> , 2021, 41, 10023-10030.	1.7	4
7677	Assessing Plasma Levels of Î±-Synuclein and Neurofilament Light Chain by Different Blood Preparation Methods. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 759182.	1.7	3
7678	Structural and Functional Correlates of Hallucinations and Illusions in Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2021, , 1-13.	1.5	9
7679	Ultrasensitive detection of blood biomarkers of Alzheimer's and Parkinson's diseases: a systematic review. <i>Biomarkers in Medicine</i> , 2021, 15, 1693-1708.	0.6	2
7682	Association of the serum microRNA-29 family with cognitive impairment in Parkinson's disease. <i>Aging</i> , 2020, 12, 13518-13528.	1.4	20

#	ARTICLE	IF	CITATIONS
7685	Cardiovagal Baroreflex Sensitivity in Parkinson's Disease and Multiple-System Atrophy. Journal of		



#	ARTICLE	IF	CITATIONS
7708	Cognitive impairment and dementia in patients with Parkinson disease. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 903-12.	1.0	58
7709	Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease. <i>Core Evidence</i> , 2010, 5, 1-10.	4.7	7
7710	Behind the mask : a study on the clinical course, psychopathology and impact on quality of life in idiopathic Parkinson's disease. <i>Indian Journal of Psychiatry</i> , 2004, 46, 354-60.	0.4	1
7711	Parkinsonism and tremor disorders. A clinical approach. <i>Libyan Journal of Medicine</i> , 2007, 2, 66-72.	0.8	0
7712	Aging, Angiotensin system and dopaminergic degeneration in the substantia nigra. , 2011, 2, 257-74.		23
7714	Functional brain imaging: an evidence-based analysis. <i>Ontario Health Technology Assessment Series</i> , 2006, 6, 1-79.	3.0	6
7716	Validation of hospital register-based diagnosis of Parkinson's disease. <i>Danish Medical Journal</i> , 2012, 59, A4391.	0.5	42
7717	Transcranial sonography on Parkinson's disease and essential tremor. <i>Journal of Research in Medical Sciences</i> , 2013, 18, S28-31.	0.4	6
7718	Alexithymia may modulate decision making in patients with de novo Parkinson's disease. <i>Functional Neurology</i> , 2011, 26, 127-31.	1.3	9
7719	Alexithymia and apathy in Parkinson's disease: neurocognitive correlates. <i>Behavioural Neurology</i> , 2013, 27, 535-45.	1.1	5
7720	Demographic study of parkinson's disease in Iran: Data on 1656 cases. <i>Iranian Journal of Neurology</i> , 2011, 10, 19-21.	0.5	5
7721	Alternative normalization methods demonstrate widespread cortical hypometabolism in untreated de novo Parkinson's disease. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 56, 299-308.	0.4	13
7722	A cross-sectional study investigating clinical predictors and physical experiences of pain in Parkinson's disease. <i>Functional Neurology</i> , 2013, 28, 297-304.	1.3	15
7724	Mutant of leucine-rich repeat kinase 2 is not associated with non-motor symptoms in Chinese Parkinson's disease patients. <i>International Journal of Clinical and Experimental Medicine</i> , 2014, 7, 2253-7.	1.3	2
7725	Parkinsonism associated with multiple sclerosis: A report of eight new cases and a review on the literature. <i>Iranian Journal of Neurology</i> , 2014, 13, 88-93.	0.5	6
7727	Dispositional optimism, depression, disability and quality of life in Parkinson's disease. <i>Functional Neurology</i> , 2014, 29, 113-9.	1.3	19
7728	"Masters and servants" in parkinsonian gait: a three-dimensional analysis of biomechanical changes sensitive to disease progression. <i>Functional Neurology</i> , 2014, 29, 99-105.	1.3	14
7729	Stem cell-based approach for the treatment of Parkinson's disease. <i>Medical Journal of the Islamic Republic of Iran</i> , 2015, 29, 168.	0.9	39

#	ARTICLE	IF	CITATIONS
7730	Clinical characteristics and peripheral T cell subsets in Parkinson's disease patients with constipation. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 2495-504.	0.5	17
7731	Vascular risk factors aggravate the progression of Parkinson's disease: a five-year follow-up study in Chinese patients. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 9897-903.	1.3	5
7732	Association study between SMPD1 p.L302P and sporadic Parkinson's disease in ethnic Chinese population. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 13869-73.	1.3	1
7733	Analysis of the LRRK2 p.G2019S mutation in Colombian Parkinson's Disease Patients. <i>Colombia Medica</i> , 2015, 46, 117-21.	0.7	14
7734	Association analysis of HLA-DRA in Chinese patients with sporadic Parkinson's disease. <i>International Journal of Physiology, Pathophysiology and Pharmacology</i> , 2015, 7, 185-94.	0.8	2
7736	Can levodopa prevent cognitive decline in patients with Parkinson's disease?. <i>American Journal of Neurodegenerative Disease</i> , 2017, 6, 9-14.	0.1	11
7737	Serum leptin levels in Iranian patients with Parkinson's disease. <i>Iranian Journal of Neurology</i> , 2018, 17, 71-77.	0.5	2
7738	A Comparative Study of Early and Late Onset Freezing of Gait in Parkinson's Disease. <i>Annals of Indian Academy of Neurology</i> , 2018, 21, 256-262.	0.2	7
7739	Lee Silverman voice treatment (LSVT) mitigates voice difficulties in mild Parkinson's disease. <i>Medical Journal of the Islamic Republic of Iran</i> , 2019, 33, 5.	0.9	2
7740	Effects of Low-Volume Resistance Training on Muscle Strength and Functionality of People with Parkinson's Disease. <i>International Journal of Exercise Science</i> , 2019, 12, 567-580.	0.5	2
7741	Association of Cardinal Motor Symptoms with Region-Specific Dopamine Transporter Activity in Mild to Moderate Parkinson's Disease. <i>European Neurological Journal</i> , 2013, 4, 1-7.	0.0	1
7742	Dopamine Transporter Density in Parkinson's Disease Does Not Relate to the Development of Levodopa-Induced Dyskinesias. , 2019, 3, 10000.		1
7743	Selective Neuronal Death in Neurodegenerative Diseases: The Ongoing Mystery. <i>Yale Journal of Biology and Medicine</i> , 2019, 92, 695-705.	0.2	15
7744	Alpha-synuclein oligomerization increases its effect on promoting NMDA receptor internalization. <i>International Journal of Clinical and Experimental Pathology</i> , 2019, 12, 87-100.	0.5	2
7745	Î±-Syn oligomers incubated with Parkinson's disease plasma promote neuron damage. <i>International Journal of Clinical and Experimental Pathology</i> , 2020, 13, 1995-2008.	0.5	2
7746	Multicentre, randomised, single-blind, parallel group trial to compare the effectiveness of a Holter for Parkinson's symptoms against other clinical monitoring methods: study protocol. <i>BMJ Open</i> , 2021, 11, e045272.	0.8	0
7747	Clinical Diagnostic Accuracy of Early/Advanced Parkinson Disease: An Updated Clinicopathologic Study. <i>Neurology: Clinical Practice</i> , 2021, 11, e414-e421.	0.8	1
7748	Advances in dementia with Lewy bodies. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110576.	1.5	14

#	ARTICLE	IF	CITATIONS
7749	PINK1: Multiple mechanisms of neuroprotection. <i>International Review of Movement Disorders</i> , 2021, , 193-219.	0.1	1
7750	High frequency of psychosis in late-stage Parkinson's disease. <i>Clinical Parkinsonism & Related Disorders</i> , 2021, 5, 100119.	0.5	4
7751	Temporal dynamics of cortical activity and postural control in response to the first levodopa dose of the day in people with Parkinson's disease. <i>Brain Research</i> , 2022, 1775, 147727.	1.1	4
7752	Comparisons of vesicular monoamine transporter type 2 signals in Parkinson's disease and parkinsonism secondary to carbon monoxide poisoning. <i>NeuroToxicology</i> , 2022, 88, 178-186.	1.4	4
7753	SNCA 3' UTR Genetic Variants in Patients with Parkinson's Disease. <i>Biomolecules</i> , 2021, 11, 1799.	1.8	3
7754	Autonomic Symptoms in Older Adults Are Common and Associated With Health-Related Quality of Life. <i>Frontiers in Neurology</i> , 2021, 12, 757748.	1.1	2
7755	Comparison of Transcranial Sonography and [¹⁸ F]Fluorodopa PET Imaging in GBA1 Mutation Carriers. <i>Movement Disorders</i> , 2022, 37, 629-634.	2.2	5
7756	Constipation is Associated With Mild Cognitive Impairment in Patients With de novo Parkinson's Disease. <i>Journal of Movement Disorders</i> , 2022, 15, 38-42.	0.7	2
7757	Acute improvement in the attention network with repetitive transcranial magnetic stimulation in Parkinson's disease. <i>Disability and Rehabilitation</i> , 2022, 44, 7958-7966.	0.9	1
7758	Clinical Usefulness of Retropulsion Tests in Persons with Mild to Moderate Parkinson's Disease. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12325.	1.2	1
7759	Corticobasal Degeneration. , 2022, , 373-386.		0
7760	The prevalence of impulsive compulsive behaviors in patients treated with apomorphine infusion: a retrospective analysis. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, , .	0.3	0
7761	Independent effect of neurogenic orthostatic hypotension on mild cognitive impairment in Parkinson's disease. <i>Clinical Autonomic Research</i> , 2022, 32, 43-50.	1.4	6
7762	Validation of a Sensor-Based Gait Analysis System with a Gold-Standard Motion Capture System in Patients with Parkinson's Disease. <i>Sensors</i> , 2021, 21, 7680.	2.1	26
7763	Estimation of Severity in Parkinson's Disease Using Acoustic Features of Phonatory Tasks. <i>IETE Journal of Research</i> , 2023, 69, 6292-6303.	1.8	0
7764	Plasma proteome profiling using tandem mass tag labeling technology reveals potential biomarkers for Parkinson's disease: a preliminary study. <i>Proteomics - Clinical Applications</i> , 2022, 16, e2100010.	0.8	3
7765	Motor and Non-motor Symptoms Associated With Exercise Behavior in Parkinson's Disease Patients: Factors Differ Between Patients With and Without Postural Instability. <i>Frontiers in Neurology</i> , 2021, 12, 772391.	1.1	3
7766	Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach. <i>Npj Parkinson's Disease</i> , 2021, 7, 107.	2.5	11

#	ARTICLE	IF	CITATIONS
7767	Cerebrospinal fluid biomarkers in Parkinsonâ€™s disease with freezing of gait: an exploratory analysis. <i>Npj Parkinson's Disease</i> , 2021, 7, 105.	2.5	13
7768	24-hour ambulatory blood pressure alterations in patients with Parkinson's disease. <i>Brain and Behavior</i> , 2022, 12, e2428.	1.0	5
7769	Association Analysis of WNT3, HLA-DRB5 and IL1R2 Polymorphisms in Chinese Patients With Parkinsonâ€™s Disease and Multiple System Atrophy. <i>Frontiers in Genetics</i> , 2021, 12, 765833.	1.1	5
7770	Association of AXIN1 With Parkinsonâ€™s Disease in a Taiwanese Population. <i>Journal of Movement Disorders</i> , 2022, 15, 33-37.	0.7	1
7771	Theta Burst Magnetic Stimulation Improves Parkinsonâ€™s-Related Cognitive Impairment: A Randomised Controlled Study. <i>Neurorehabilitation and Neural Repair</i> , 2021, 35, 986-995.	1.4	7
7772	PET-CT in brain disorders: The South African context. <i>South African Journal of Radiology</i> , 2021, 25, 2201.	0.1	1
7773	It Is Time to Study Overlapping Molecular and Circuit Pathophysiologies in Alzheimerâ€™s and Lewy Body Disease Spectra. <i>Frontiers in Systems Neuroscience</i> , 2021, 15, 777706.	1.2	8
7774	Segmental Alterations of the Corpus Callosum in Progressive Supranuclear Palsy: A Multiparametric Magnetic Resonance Imaging Study. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 720634.	1.7	2
7775	Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinsonâ€™s disease trial. <i>BMC Neurology</i> , 2021, 21, 459.	0.8	9
7776	Stability of AI-Enabled Diagnosis of Parkinsonâ€™s Disease: A Study Targeting Substantia Nigra in Quantitative Susceptibility Mapping Imaging. <i>Frontiers in Neuroscience</i> , 2021, 15, 760975.	1.4	3
7777	Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinsonâ€™s disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 108.	2.5	8
7778	Imaging of the nigrostriatal system for evaluating the preclinical phase of Parkinsonâ€™s disease development: the utility of neuromelanin, diffusion MRI, and DAT-SPECT. <i>British Journal of Radiology</i> , 2022, 95, 20210837.	1.0	6
7779	The Association Between Lysosomal Storage Disorder Genes and Parkinsonâ€™s Disease: A Large Cohort Study in Chinese Mainland Population. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 749109.	1.7	11
7780	Region-Specific Neurovascular Decoupling Associated With Cognitive Decline in Parkinsonâ€™s Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 770528.	1.7	15
7781	Evaluation of Bedside Tests of Attention and Arousal Assessing Delirium in Parkinsonâ€™s Disease, Dementia, and Older Adults. <i>Journal of Parkinson's Disease</i> , 2022, 12, 655-665.	1.5	0
7782	White matter connectivity networks predict levodopa-induced dyskinesia in Parkinsonâ€™s disease. <i>Journal of Neurology</i> , 2022, 269, 2948-2960.	1.8	3
7783	Cognitive Influences in Parkinson's Disease Patients and Their Caregivers: Perspectives From an Australian Cohort. <i>Frontiers in Neurology</i> , 2021, 12, 673816.	1.1	3
7784	Alterations of Plasma Galectin-3 and C3 Levels in Patients with Parkinsonâ€™s Disease. <i>Brain Sciences</i> , 2021, 11, 1515.	1.1	6

#	ARTICLE	IF	CITATIONS
7785	Gamified Dual-Task Training for Individuals with Parkinson Disease: An Exploratory Study on Feasibility, Safety, and Efficacy. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12384.	1.2	5
7786	Combining Repetitive Transcranial Magnetic Stimulation and Video Game-Based Training to Improve Dexterity in Parkinson's Disease: Study Protocol of a Randomized Controlled Trial. <i>Frontiers in Rehabilitation Sciences</i> , 2021, 2, .	0.5	1
7787	Cross-cultural adaptation of the Activities of Daily Living Questionnaire-Brazil in Parkinsonâ€™s disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 1101-1108.	0.3	2
7788	Clinical long-term nocturnal sleeping disturbances and excessive daytime sleepiness in Parkinsonâ€™s disease. <i>PLoS ONE</i> , 2021, 16, e0259935.	1.1	3
7789	Neuropsychiatric Symptoms and Caregiver's Burden in Parkinson's Disease Patients in a Tertiary Care Teaching Hospital in South India: A Cross-Sectional Study. <i>Neurology India</i> , 2021, 69, 1706.	0.2	2
7790	Heterozygous <i>PRKN</i> mutations are common but do not increase the risk of Parkinsonâ€™s disease. <i>Brain</i> , 2022, 145, 2077-2091.	3.7	26
7791	A Panel of Plasma Biomarkers for Differential Diagnosis of Parkinsonian Syndromes. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
7792	Reliability and validity study of a Turkish version of the Sialorrhea Clinical Scale for Parkinsonâ€™s disease (SCS-TR). <i>Noropsikiyatri Arsivi</i> , 2021, , .	0.2	1
7793	Neurodegenerative changes of retina in Parkinson disease. <i>Russian Neurological Journal</i> , 2022, 26, 29-34.	0.1	0
7794	Holocue: A Wearable Holographic Cueing Application for Alleviating Freezing of Gait in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 628388.	1.1	9
7795	Parkinson's Disease With Visual Hallucinations Is Associated With Epileptiform Activity on EEG. <i>Frontiers in Neurology</i> , 2021, 12, 788632.	1.1	2
7796	Motorâ€™Cognitive Treadmill Training With Virtual Reality in Parkinsonâ€™s Disease: The Effect of Training Duration. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 753381.	1.7	9
7797	Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease. <i>Neurology</i> , 2022, 98, .	1.5	90
7798	Cortical excitability changes as a marker of cognitive impairment in Parkinsonâ€™s disease. <i>Behavioural Brain Research</i> , 2022, 422, 113733.	1.2	2
7799	Prevalence of parkinsonism and Parkinson disease in urban and rural populations from Latin America: A community based study. <i>The Lancet Regional Health Americas</i> , 2022, 7, 100136.	1.5	6
7800	Clinical Diagnostic Accuracy of Early/Advanced Parkinson Disease. <i>Neurology: Clinical Practice</i> , 2021, 11, e414-e421.	0.8	16
7801	Deep nasal sinus cavity microbiota dysbiosis in Parkinsonâ€™s disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 111.	2.5	11
7802	Microarray Genotyping Identifies New Loci Associated with Dementia in Parkinsonâ€™s Disease. <i>Genes</i> , 2021, 12, 1975.	1.0	6

#	ARTICLE	IF	CITATIONS
7803	Development and validation of a nomogram for freezing of gait in patients with Parkinson's Disease. <i>Acta Neurologica Scandinavica</i> , 2022, 145, 658-668.	1.0	2
7804	Brain volume patterns in corticobasal syndrome versus idiopathic Parkinson's disease. <i>Journal of Neuroimaging</i> , 2022, , .	1.0	1
7805	Lower GDNF Serum Level Is a Possible Risk Factor for Constipation in Patients With Parkinson Disease: A Caseâ€“Control Study. <i>Frontiers in Neurology</i> , 2021, 12, 777591.	1.1	5
7806	Evolution of Prodromal Multiple System Atrophy from REM Sleep Behavior Disorder: A Descriptive Study. <i>Journal of Parkinson's Disease</i> , 2022, 12, 983-991.	1.5	3
7807	Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson's Disease Using Gait Parameters. <i>Movement Disorders</i> , 2022, 37, 842-846.	2.2	6
7808	Factors Contributing to the Severity and Laterality of Pisa Syndrome in Parkinsonâ€™s Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 716990.	1.7	0
7809	Effects of task prioritization on a postural-motor task in early-stage Parkinsonâ€™s disease: EEG connectivity and clinical implication. <i>GeroScience</i> , 2022, 44, 2061-2075.	2.1	5
7810	Systematic review and meta-analysis of clinical effectiveness of self-management interventions in Parkinsonâ€™s disease. <i>BMC Geriatrics</i> , 2022, 22, 45.	1.1	18
7811	The motor inhibitory network in patients with asymmetrical Parkinsonâ€™s disease: An fMRI study. <i>Brain Imaging and Behavior</i> , 2022, , 1.	1.1	2
7812	Evaluation of rest tremor in different positions in Parkinsonâ€™s disease and essential tremor plus. <i>Neurological Sciences</i> , 2022, 43, 3621-3627.	0.9	8
7813	PEG-J replacement for duodenal levodopa infusion in Parkinsonâ€™s disease patients: a retrospective study. <i>BMC Neurology</i> , 2022, 22, 25.	0.8	7
7814	Differential Phosphoâ€“Signatures in Blood Cells Identify <i>LRRK2</i> G2019S Carriers in Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 1004-1015.	2.2	9
7815	Current Status of Acceptance of Disability and the Correlation With the Life Quality in Parkinson's Disease in Southwest China. <i>Frontiers in Medicine</i> , 2021, 8, 767215.	1.2	1
7816	Analysis of mRNA and Protein Levels of CAP2, DLG1 and ADAM10 Genes in Post-Mortem Brain of Schizophrenia, Parkinsonâ€™s and Alzheimerâ€™s Disease Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1539.	1.8	10
7817	Peripheral neuropathy in Parkinsonâ€™s disease: prevalence and functional impact on gait and balance. <i>Brain</i> , 2023, 146, 225-236.	3.7	11
7818	Identification of an early-stage Parkinsonâ€™s disease neuromarker using event-related potentials, brain network analytics and machine-learning. <i>PLoS ONE</i> , 2022, 17, e0261947.	1.1	12
7819	Cholinergic relevant functional reactivity is associated with dopamine responsiveness of tremor in Parkinsonâ€™s disease. <i>Brain Imaging and Behavior</i> , 2022, 16, 1234-1245.	1.1	2
7820	Where Do Parkinson's Disease Patients Look while Walking?. <i>Movement Disorders</i> , 2022, , .	2.2	4

#	ARTICLE	IF	CITATIONS
7821	Profiling Parkinson's disease cognitive phenotypes via resting-state magnetoencephalography. <i>Journal of Neurophysiology</i> , 2022, 127, 279-289.	0.9	7
7822	Normalization effect of levodopa on hierarchical brain function in Parkinson's disease. <i>Network Neuroscience</i> , 2022, 6, 552-569.	1.4	3
7823	Functional MAOB Gene Intron 13 Polymorphism Predicts Dyskinesia in Parkinson's Disease. <i>Parkinson's Disease</i> , 2022, 2022, 1-6.	0.6	0
7824	Developing and assessing a new web-based tapping test for measuring distal movement in Parkinson's disease: a Distal Finger Tapping test. <i>Scientific Reports</i> , 2022, 12, 386.	1.6	22
7825	Automatic Measurement of Postural Abnormalities With a Pose Estimation Algorithm in Parkinson's Disease. <i>Journal of Movement Disorders</i> , 2022, 15, 140-145.	0.7	4
7826	^{99m} Tc-TRODAT-1 SPECT Revealed That Striatal Dopamine Transport Availability Significantly Decreases in Late Mid-Aged Healthy Taiwanese and Then Remains Stable. <i>Clinical Nuclear Medicine</i> , 2022, 47, 201-208.	0.7	3
7827	Disease-Modifying Antirheumatic Drugs and Risk of Parkinson Disease. <i>Neurology</i> , 2022, 98, .	1.5	10
7828	Quantifying regional β -synuclein, amyloid β , and tau accumulation in lewy body dementia. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 106-121.	1.7	21
7829	Lewy body disease or diseases with Lewy bodies?. <i>Npj Parkinson's Disease</i> , 2022, 8, 3.	2.5	26
7831	Anxiety in Parkinson's disease: A resting-state high density EEG study. <i>Neurophysiologie Clinique</i> , 2022, 52, 202-211.	1.0	8
7832	Correlation Analysis of Lower-Limb Muscle Function With Clinical Status, Balance Tests, and Quality of Life in People With Parkinson Disease. <i>Topics in Geriatric Rehabilitation</i> , 2022, 38, 56-64.	0.2	1
7833	Association of plasma β -synuclein with cardiac ¹²³ I-MIBG scintigraphy in early Parkinson's disease. <i>Neuroscience Letters</i> , 2022, 770, 136399.	1.0	5
7834	Serum NFL discriminates Parkinson disease from essential tremor and reflect motor and cognition severity. <i>BMC Neurology</i> , 2022, 22, 39.	0.8	19
7835	Alterations of Sphingolipid and Phospholipid Pathways and Ornithine Level in the Plasma as Biomarkers of Parkinson's Disease. <i>Cells</i> , 2022, 11, 395.	1.8	11
7836	Automated text-level semantic markers of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12276.	1.2	6
7837	Parkinson Hastalığı'nda Kognitif İşlevler ile Fiziksel Fonksiyon Arasındaki İlişki. , 0, , 115-122.		0
7838	Force Platform-Based Intervention Program for Individuals Suffering with Neurodegenerative Diseases like Parkinson. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-11.	0.7	2
7839	Gender differences in motor and non-motor symptoms in early Parkinson disease. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT /Over</i>	0.4	10

#	ARTICLE	IF	CITATIONS
7840	A prospective multi-centre study of susceptibility map-weighted MRI for the diagnosis of neurodegenerative parkinsonism. <i>European Radiology</i> , 2022, 32, 3597-3608.	2.3	7
7841	Predict initial subthalamic nucleus stimulation outcome in Parkinson's disease with brain morphology. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 667-676.	1.9	7
7842	Factors Influencing Habitual Physical Activity in Parkinson's Disease: Considering the Psychosocial State and Wellbeing of People with Parkinson's and Their Carers. <i>Sensors</i> , 2022, 22, 871.	2.1	5
7844	Clinical Disease Severity Mediates the Relationship between Stride Length and Speed and the Risk of Falling in Parkinson's Disease. <i>Journal of Personalized Medicine</i> , 2022, 12, 192.	1.1	9
7845	Transcranial Direct Current Stimulation (tDCS) as a Useful Rehabilitation Strategy to Improve Cognition in Patients With Alzheimer's Disease and Parkinson's Disease: An Updated Systematic Review of Randomized Controlled Trials. <i>Frontiers in Neurology</i> , 2021, 12, 798191.	1.1	13
7846	Deep Learning-Based Neuromelanin MRI Changes of Isolated REM Sleep Behavior Disorder. <i>Movement Disorders</i> , 2022, 37, 1064-1069.	2.2	13
7847	Computer-Aided Classification Framework of Parkinsonian Disorders Using 11C-CFT PET Imaging. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 792951.	1.7	6
7848	Early Detection of Parkinson's Disease by Neural Network Models. <i>IEEE Access</i> , 2022, 10, 19033-19044.	2.6	13
7849	Caring for a loved one with Parkinson's disease: the role of coping styles and relationship quality. <i>International Psychogeriatrics</i> , 2022, 34, 637-644.	0.6	5
7850	Decision Making Under Uncertainty In Parkinson's Disease With Rem Sleep Behavior Disorder. <i>Sleep Medicine</i> , 2022, 90, 214-221.	0.8	1
7851	Graded peak cycle ergometer test for cognitively impaired patients with Parkinson's disease: a pilot study. <i>Physiotherapy Theory and Practice</i> , 2023, 39, 1249-1256.	0.6	1
7853	Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies. <i>Parkinsonism and Related Disorders</i> , 2022, 96, 65-73.	1.1	8
7854	Magnetoencephalography detects phase-amplitude coupling in Parkinson's disease. <i>Scientific Reports</i> , 2022, 12, 1835.	1.6	3
7855	Mechanisms of motor symptom improvement by long-term Tai Chi training in Parkinson's disease patients. <i>Translational Neurodegeneration</i> , 2022, 11, 6.	3.6	21
7856	The role of <i>NOTCH2NL</i> in Parkinson's disease: A clinical, neuroimaging, and pathological study. <i>European Journal of Neurology</i> , 2022, 29, 1610-1618.	1.7	6
7857	Fluid markers of synapse degeneration in synucleinopathies. <i>Journal of Neural Transmission</i> , 2022, 129, 187-206.	1.4	4
7858	Self-Stigma in Parkinson's Disease: A 3-Year Prospective Cohort Study. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 790897.	1.7	5
7859	Retrograde Procedural Memory in Parkinson's Disease: A Cross-Sectional, Case-Control Study. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1013-1022.	1.5	1

#	ARTICLE	IF	CITATIONS
7861	Computerised analysis of writing and drawing by essential tremor phenotype. <i>BMJ Neurology Open</i> , 2021, 3, e000212.	0.7	1
7862	Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. <i>Brain</i> , 2022, 145, 584-595.	3.7	65
7863	Do P1 and N1 evoked by the ERP task reflect primary visual processing in Parkinson's disease?. <i>Documenta Ophthalmologica</i> , 2001, 102, 83-93.	1.0	8
7864	Advances in the discovery of genetic risk factors for complex forms of neurodegenerative disorders: contemporary approaches, success, challenges and prospects. <i>Journal of Genetics</i> , 2018, 97, 625-648.	0.4	1
7866	Application of random forest in detection of Parkinson's disease. , 2022, , 125-133.		0
7867	Contribution and Clinical Significance of 3D and 2D Deep Learning and Radimoics Features Based on MR-T1W Images in Joint Diagnosis of Parkinson's Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
7868	Detection of neuron-derived pathological α -synuclein in blood. <i>Brain</i> , 2022, 145, 3058-3071.	3.7	82
7869	Movement disorders and translational research. , 2022, , 155-178.		0
7870	Neurofeedback-guided kinesthetic motor imagery training in Parkinsonâ€™s disease: Randomized trial. <i>NeuroImage: Clinical</i> , 2022, 34, 102980.	1.4	9
7871	Prologue. <i>International Review of Neurobiology</i> , 2022, 162, xi-xiv.	0.9	0
7872	CSF and Serum Levels of Inflammatory Markers in PD: Sparse Correlation, Sex Differences and Association With Neurodegenerative Biomarkers. <i>Frontiers in Neurology</i> , 2022, 13, 834580.	1.1	17
7873	Goal management training and psychoeducation / mindfulness for treatment of executive dysfunction in Parkinsonâ€™s disease: A feasibility pilot trial. <i>PLoS ONE</i> , 2022, 17, e0263108.	1.1	6
7874	Presence of Skin α -Synuclein Deposits Discriminates Parkinsonâ€™s Disease from Progressive Supranuclear Palsy and Corticobasal Syndrome. <i>Journal of Parkinson's Disease</i> , 2022, 12, 585-591.	1.5	9
7875	Role of Specialized Pro-resolving Mediators in Reducing Neuroinflammation in Neurodegenerative Disorders. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 780811.	1.7	13
7876	Hand Pronationâ€™Supination Movement as a Proxy for Remotely Monitoring Gait and Posture Stability in Parkinsonâ€™s Disease. <i>Sensors</i> , 2022, 22, 1827.	2.1	1
7877	The psychometric properties of the figure-of-eight walk test in people with Parkinson's disease. <i>Disability and Rehabilitation</i> , 2023, 45, 301-309.	0.9	3
7878	Astrocytes expressing Vitamin Dâ€™activating enzyme identify Parkinsonâ€™s disease. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 703-713.	1.9	10
7879	Cytokines, miRNAs, and Antioxidants as Combined Non-invasive Biomarkers for Parkinsonâ€™s Disease. <i>Journal of Molecular Neuroscience</i> , 2022, 72, 1133-1140.	1.1	8

#	ARTICLE	IF	CITATIONS
7880	Brain Morphometry Associated With Response to Levodopa and Deep Brain Stimulation in Parkinson Disease. <i>Neuromodulation</i> , 2023, 26, 340-347.	0.4	6
7881	Integration of Virtual Reality into Transcranial Magnetic Stimulation Improves Cognitive Function in Patients with Parkinson's Disease with Cognitive Impairment: A Proof-of-Concept Study. <i>Journal of Parkinson's Disease</i> , 2022, 12, 723-736.	1.5	6
7882	Safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease—Results of a multicenter open trial. <i>Neuropsychopharmacology Reports</i> , 2022, 42, 135-141.	1.1	4
7883	Differentiating Parkinson's Disease from Essential Tremor Using Transcranial Sonography: A Systematic Review and Meta-Analysis. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1115-1123.	1.5	7
7884	A Randomized, Double-Blind, Controlled Phase II Study of Foliqlurax in Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 1088-1093.	2.2	17
7885	A replication study, systematic review and meta-analysis of automated image-based diagnosis in parkinsonism. <i>Scientific Reports</i> , 2022, 12, 2763.	1.6	8
7886	Effect of vitamin D and other indicators of phosphorus-calcium metabolism on cognitive functions and quality of life in patients with Parkinson's disease. <i>Nevrologiya, Neuropsikhiatriya, Psikhosomatika</i> , 2022, 14, 38-44.	0.2	0
7887	Serum NfL and CHI3L1 for ALS and parkinsonian disorders in the process of diagnosis. <i>Journal of Neural Transmission</i> , 2022, 129, 301-309.	1.4	6
7888	Multimodal Brain Connectomics-Based Prediction of Parkinson's Disease Using Graph Attention Networks. <i>Frontiers in Neuroscience</i> , 2021, 15, 741489.	1.4	4
7889	Effectiveness of Different Methods for Baroreflex Sensitivity Assessment in Determining the Severity of Cardiovascular Autonomic Neuropathy in Patients With Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2022, 16, 833344.	1.4	1
7890	Telling functional networks apart using ranked network features stability. <i>Scientific Reports</i> , 2022, 12, 2562.	1.6	0
7891	Effect of Intensive Rehabilitation Program in Thermal Water on a Group of People with Parkinson's Disease: A Retrospective Longitudinal Study. <i>Healthcare (Switzerland)</i> , 2022, 10, 368.	1.0	4
7892	A Panel of Plasma Biomarkers for Differential Diagnosis of Parkinsonian Syndromes. <i>Frontiers in Neuroscience</i> , 2022, 16, 805953.	1.4	13
7893	Significant modulations of linc001128 and linc0938 with miR-24-3p and miR-30c-5p in Parkinson disease. <i>Scientific Reports</i> , 2022, 12, 2569.	1.6	12
7894	Altered Dynamic Functional Connectivity in de novo Parkinson's Disease Patients With Depression. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 789785.	1.7	11
7895	Computer Aided Written Character Feature Extraction in Progressive Supranuclear Palsy and Parkinson's Disease. <i>Sensors</i> , 2022, 22, 1688.	2.1	1
7896	Profile of cognitive impairment in late-stage Parkinson's disease. <i>Brain and Behavior</i> , 2022, 12, e32537.	1.0	5
7897	Alterations in Proteostasis System Components in Peripheral Blood Mononuclear Cells in Parkinson Disease: Focusing on the HSP70 and p62 Levels. <i>Biomolecules</i> , 2022, 12, 493.	1.8	4

#	ARTICLE	IF	CITATIONS
7898	The Effects of Action Observation Therapy as a Rehabilitation Tool in Parkinson's Disease Patients: A Systematic Review. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3311.	1.2	3
7899	Two-year longitudinal follow-up of visual illusions and hallucinations in Parkinson's disease. <i>Journal of Neurology</i> , 2022, , 1.	1.8	0
7900	Relationship between Plasma Level of Beta-amyloid, Alpha-synuclein, and Tau Protein with Cognitive Impairment in Parkinson Disease. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2022, 10, 663-667.	0.1	2
7901	Altered Neural Network Connectivity Predicts Depression in de novo Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2022, 16, 828651.	1.4	6
7902	The coin rotation test: a reliable and valid test in people with Parkinson's disease. <i>Disability and Rehabilitation</i> , 2022, , 1-10.	0.9	1
7903	Shared Molecular Targets in Parkinson's Disease and Arterial Hypertension: A Systematic Review. <i>Biomedicines</i> , 2022, 10, 653.	1.4	3
7904	Novel insights into the effects of levodopa on the up- and downstrokes of writing sequences. <i>Journal of Neural Transmission</i> , 2022, 129, 379-386.	1.4	1
7905	The incidence, baseline predictors, and outcomes of dementia in an incident cohort of Parkinson's disease and controls. <i>Journal of Neurology</i> , 2022, 269, 4288-4298.	1.8	3
7906	Differential diagnosis of parkinsonism based on deep metabolic imaging indices. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.121.263029.	2.8	9
7907	Large-scale network dysfunction in α -Synucleinopathy: A meta-analysis of resting-state functional connectivity. <i>EBioMedicine</i> , 2022, 77, 103915.	2.7	14
7908	Gait-Related Metabolic Covariance Networks at Rest in Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 1222-1234.	2.2	5
7909	Fear of Falling Avoidance Behavior Assessment and Intervention in Parkinson's Disease: A Scoping Review. <i>Research and Reviews in Parkinsonism</i> , 0, Volume 12, 1-17.	0.5	5
7910	Characterization of advanced Parkinson's disease in Germany: results of the non-interventional OBSERVE-PD study. <i>Neurological Research and Practice</i> , 2022, 4, 9.	1.0	4
7911	Evaluation of Brain SPECT with ^{99m}Tc -TRODAT-1 in the Differential Diagnosis of Parkinsonism. <i>Parkinson's Disease</i> , 2022, 2022, 1-10.	0.6	1
7912	Neuroinflammation Upregulated Neuronal Toll-Like Receptors 2 and 4 to Drive Synucleinopathy in Neurodegeneration. <i>Frontiers in Pharmacology</i> , 2022, 13, 845930.	1.6	10
7913	Seed-Based Connectivity Prediction of Initial Outcome of Subthalamic Nuclei Deep Brain Stimulation. <i>Neurotherapeutics</i> , 2022, 19, 608-615.	2.1	3
7914	Adaptive and pathological connectivity responses in Parkinson's disease brain networks. <i>Cerebral Cortex</i> , 2023, 33, 917-932.	1.6	7
7915	Amplitude setting and dopamine response of finger tapping and gait are related in Parkinson's disease. <i>Scientific Reports</i> , 2022, 12, 4180.	1.6	5

#	ARTICLE	IF	CITATIONS
7916	Autoimmune Disease Associated CLEC16A Variants Convey Risk of Parkinsonâ€™s Disease in Han Chinese. <i>Frontiers in Genetics</i> , 2022, 13, 856493.	1.1	6
7917	No Dopamine Agonist Modulation of Brain [¹⁸ F]FEOBV Binding in Parkinsonâ€™s Disease. <i>Molecular Pharmaceutics</i> , 2022, 19, 1176-1182.	2.3	1
7918	RNA-seq analysis of gene expression profiles in posttraumatic stress disorder, Parkinsonâ€™s disease and schizophrenia identifies roles for common and distinct biological pathways. <i>Discover Mental Health</i> , 2022, 2, .	1.0	4
7919	Opicapone Improves Global Non-Motor Symptoms Burden in Parkinsonâ€™s Disease: An Open-Label Prospective Study. <i>Brain Sciences</i> , 2022, 12, 383.	1.1	7
7920	The Reliability and Validity of the Manual Ability Measure-36 in Patients with Parkinsonâ€™s Disease. <i>Turk Noroloji Dergisi = Turkish Journal of Neurology</i> , 2022, 28, 84-90.	0.1	1
7921	Factors Contributing to Malnutrition in Parkinson's Disease Patients With Freezing of Gait. <i>Frontiers in Neurology</i> , 2022, 13, 816315.	1.1	2
7923	Cortical oscillatory dysfunction in Parkinson disease during movement activation and inhibition. <i>PLoS ONE</i> , 2022, 17, e0257711.	1.1	2
7924	Role of Lysosomal Gene Variants in Modulating <i>GBA1</i> -Associated Parkinson's Disease Risk. <i>Movement Disorders</i> , 2022, 37, 1202-1210.	2.2	17
7925	A Multimodal Omics Exploration of the Motor and Non-Motor Symptoms of Parkinsonâ€™s Disease. <i>International Journal of Translational Medicine</i> , 2022, 2, 97-112.	0.1	1
7926	Does transcranial direct current stimulation enhance cognitive performance in Parkinsonâ€™s disease mild cognitive impairment? An event-related potentials and neuropsychological assessment study. <i>Neurological Sciences</i> , 2022, 43, 4029-4044.	0.9	3
7927	Automated Differentiation of Atypical Parkinsonian Syndromes Using Brain Iron Patterns in Susceptibility Weighted Imaging. <i>Diagnostics</i> , 2022, 12, 637.	1.3	2
7928	Crocin Protects Malathion-Induced Striatal Biochemical Deficits by Inhibiting Apoptosis and Increasing β -Synuclein in Ratsâ€™ Striatum. <i>Journal of Molecular Neuroscience</i> , 2022, 72, 983-993.	1.1	8
7929	Hyperhidrosis in Parkinson's disease: a 3â€year prospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, , .	1.3	2
7930	Elevation of Plasma Homocysteine and Minor Hallucinations in Parkinsonâ€™s Disease: A Cross-Sectional Study. <i>Behavioural Neurology</i> , 2022, 2022, 1-10.	1.1	5
7931	Characteristics of the Ontario Neurodegenerative Disease Research Initiative cohort. <i>Alzheimer's and Dementia</i> , 2023, 19, 226-243.	0.4	15
7932	The Effect of a Structured Medication Review on Quality of Life in Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1295-1306.	1.5	2
7933	Motion characteristics of subclinical tremors in Parkinsonâ€™s disease and normal subjects. <i>Scientific Reports</i> , 2022, 12, 4021.	1.6	8
7934	Gamma Knife [®] stereotactic radiosurgery as a treatment for essential and parkinsonian tremor: long-term experience. <i>Neurologia (English Edition)</i> , 2023, 38, 188-196.	0.2	3

#	ARTICLE	IF	CITATIONS
7935	A modified version of the interlocking finger test as a bedside screening test for visuospatial deficits and dementia in Parkinson's disease. <i>Brain and Behavior</i> , 2022, , e2516.	1.0	2
7936	The Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinsonâ€™s Disease on Associative Learning of Verbal and Non-Verbal Information by Trial and Error or with Corrective Feedback. <i>Journal of Parkinson's Disease</i> , 2022, 12, 885-896.	1.5	1
7937	Striatal dopamine transporter imaging in Parkinsonâ€™s disease drug-naïve patients: focus on sexual dysfunction. <i>Neurological Sciences</i> , 2022, 43, 4769-4776.	0.9	6
7938	Association Study of TAF1 Variants in Parkinsonâ€™s Disease. <i>Frontiers in Neuroscience</i> , 2022, 16, 846095.	1.4	2
7939	Parkinsonâ€™s Disease Progression and Statins: Hydrophobicity Matters. <i>Journal of Parkinson's Disease</i> , 2022, 12, 821-830.	1.5	6
7940	Poly (ADP-Ribose) and Î±-synuclein extracellular vesicles in patients with Parkinson disease: A possible biomarker of disease severity. <i>PLoS ONE</i> , 2022, 17, e0264446.	1.1	6
7941	Dopaminergic medication reduces interhemispheric hyper-synchronization in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2022, 97, 39-46.	1.1	3
7942	A Novel Way of Measuring Dual-Task Interference: The Reliability and Construct Validity of the Dual-Task Effect Battery in Neurodegenerative Disease. <i>Neurorehabilitation and Neural Repair</i> , 2022, 36, 346-359.	1.4	10
7943	Altered Functional Connectivity of Ventral Striatum Subregions in De-novo Parkinsonâ€™s Disease with Depression. <i>Neuroscience</i> , 2022, 491, 13-22.	1.1	4
7944	Classification of healthy, Alzheimer and Parkinson populations with a multi-branch neural network. <i>Biomedical Signal Processing and Control</i> , 2022, 75, 103617.	3.5	5
7945	Effects on intermittent postural control in people with Parkinson's due to a dual task.. <i>Human Movement Science</i> , 2022, 83, 102947.	0.6	1
7946	Dual tasking reduces gait asymmetry of trajectory deviation during obstacle circumvention in people with Parkinson's disease. <i>Human Movement Science</i> , 2022, 83, 102938.	0.6	2
7947	Utility of 18F FDG-PET in Parkinsonism in an African population. <i>ENeurologicalSci</i> , 2022, 27, 100399.	0.5	1
7948	Longitudinal White Matter Damage Evolution in Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 315-324.	2.2	16
7949	Risk of falls using the Biodex Balance System in non-faller patients with Parkinson Disease. <i>Somatosensory & Motor Research</i> , 2021, , 1-5.	0.4	1
7950	Profiling the most elderly parkinsonâ€™s disease patients: Does age or disease duration matter?. <i>PLoS ONE</i> , 2021, 16, e0261302.	1.1	7
7951	Phosphorylated Î±-synuclein in diluted human serum as a biomarker for Parkinson's disease. <i>Biomedical Journal</i> , 2022, 45, 914-922.	1.4	8
7952	Identifying a whole-brain connectome-based model in drug-naïve Parkinson's disease for predicting motor impairment. <i>Human Brain Mapping</i> , 2022, 43, 1984-1996.	1.9	6

#	ARTICLE	IF	CITATIONS
7953	Cognitive Correlates of Visual and Minor Hallucinations in Parkinson's Disease. Canadian Journal of Neurological Sciences, 2023, 50, 44-48.	0.3	3
7954	The Parkinson's Disease Progression Neuroimaging Initiative. Behavioural Neurology, 2021, 2021, 1-8.	1.1	3
7955	Neuroimaging cerebrovascular biomarkers in Parkinson's disease. Neuroradiology Journal, 2022, 35, 490-496.	0.6	1
7957	Akathisia in Parkinson's Disease: A Comparative Cross-Sectional Study. Turk Noroloji Dergisi = Turkish Journal of Neurology, 0, , .	0.1	0
7958	Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?. Nature Reviews Neuroscience, 2022, 23, 115-128.	4.9	92
7959	Prevalence and incidence of Parkinson's disease and other forms of parkinsonism in a cohort of elderly individuals in Southern Brazil: protocol for a population-based study. BMJ Open, 2021, 11, e054423.	0.8	0
7960	Cognition and driving ability in isolated and symptomatic REM sleep behavior disorder. Sleep, 2022, 45, .	0.6	1
7961	Alpha-synuclein oligomers and small nerve fiber pathology in skin are potential biomarkers of Parkinson's disease. Npj Parkinson's Disease, 2021, 7, 119.	2.5	19
7962	Amphetamine-induced dopamine release and impulsivity in Parkinson's disease. Brain, 2022, 145, 3488-3499.	3.7	6
7963	Multimodality Anatomic and Molecular Imaging of Parkinson Disease and Atypical Parkinson Syndromes with MRI, Iodine 123 N-(2-Fluoropropyl)-2-(4-Iodobenzyloxy)-3-(4-Iodophenyl) Nortropane SPECT (Dopamine Transporter SPECT), Iodine 123 Metaiodobenzylguanidine Cardiac Scintigraphy, and [¹⁸ F] FDG-PET. Neurographics, 2021, 11, 259-274.	0.0	0
7964	Transcriptome Analysis of Induced Pluripotent Stem Cells and Neuronal Progenitor Cells, Derived from Discordant Monozygotic Twins with Parkinson's Disease. Cells, 2021, 10, 3478.	1.8	4
7965	Sleep Disturbances and Associated Factors in Drug-Naïve Patients with Parkinson's Disease. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 3499-3508.	1.0	2
7966	Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinson's Disease: A Single-Center, Randomized, Placebo-Controlled Trial. Biomedicines, 2021, 9, 1881.	1.4	6
7967	The Hopkins Symptom Checklist (SCL-90-R): A Patient-Reported Outcome Measure in Parkinson's Disease. Journal of Geriatric Psychiatry and Neurology, 2021, , 089198872110600.	1.2	0
7968	Associations between resting-state functional connectivity changes and prolonged benefits of writing training in Parkinson's disease. Journal of Neurology, 2022, 269, 4696-4707.	1.8	1
7969	Structural Connectivity of Subthalamic Nucleus Stimulation for Improving Freezing of Gait. Journal of Parkinson's Disease, 2022, 12, 1251-1267.	1.5	5
7970	Small and Large Magnetic Resonance Imaging-Visible Perivascular Spaces in the Basal Ganglia of Parkinson's Disease Patients. Movement Disorders, 2022, 37, 1304-1309.	2.2	11
7971	Brain pathological changes during neurodegenerative diseases and their identification methods: How does QSM perform in detecting this process?. Insights Into Imaging, 2022, 13, 74.	1.6	9

#	ARTICLE	IF	CITATIONS
7972	Proteinopathy and Longitudinal Cognitive Decline in Parkinson Disease. <i>Neurology</i> , 2022, 99, .	1.5	8
7973	Does Prefrontal Glutamate Index Cognitive Changes in Parkinsonâ€™s Disease?. <i>Frontiers in Human Neuroscience</i> , 2022, 16, 809905.	1.0	3
7974	Impact of Visual Impairment on Vision-Related Quality of Life in Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1633-1643.	1.5	2
7975	Prediction of Quality of Life in Patients With Parkinsonâ€™s Disease With and Without Excessive Daytime Sleepiness: A Longitudinal Study. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 846563.	1.7	1
7976	Arterial spin labeling imaging for the detection of cerebral blood flow asymmetry in patients with corticobasal syndrome. <i>Neuroradiology</i> , 2022, , 1.	1.1	1
7977	Continuous Dopaminergic Stimulation Improves Cortical Maladaptive Changes in Advanced <scp>Parkinson's Disease</scp>. <i>Movement Disorders</i> , 2022, , .	2.2	1
7978	Gender gap in deep brain stimulation for Parkinsonâ€™s disease. <i>Npj Parkinson's Disease</i> , 2022, 8, 47.	2.5	22
7979	Intraoperative Quantification of MDS-UPDRS Tremor Measurements Using 3D Accelerometry: A Pilot Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2275.	1.0	8
7980	Differential diagnosis between Parkinson's disease and atypical parkinsonism based on gait and postural instability: Artificial intelligence using an enhanced weight voting ensemble model. <i>Parkinsonism and Related Disorders</i> , 2022, 98, 32-37.	1.1	3
7981	Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study. <i>Lancet Neurology</i> , The, 2022, 21, 428-437.	4.9	31
7982	The association between LIN28A gene rare variants and Parkinsonâ€™s disease in Chinese population. <i>Gene</i> , 2022, 829, 146515.	1.0	2
7985	Do P1 and N1 evoked by the ERP task reflect primary visual processing in Parkinson's disease?. <i>Documenta Ophthalmologica</i> , 2001, 102, 83-93.	1.0	2
8168	Antagonistic network signature of motor function in Parkinsonâ€™s disease revealed by connectome-based predictive modeling. <i>Npj Parkinson's Disease</i> , 2022, 8, 49.	2.5	8
8170	Multicentre, randomised, single-blind, parallel group trial to compare the effectiveness of a Holter for Parkinsonâ€™s symptoms against other clinical monitoring methods: study protocol. <i>BMJ Open</i> , 2021, 11, e045272.	0.8	5
8171	A composite clinical motor score as a comprehensive and sensitive outcome measure for Parkinsonâ€™s disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 617-624.	0.9	7
8174	SPECT findings in Alzheimer's disease and Parkinson's disease with dementia. <i>Behavioural Neurology</i> , 1997, 10, 121-7.	1.1	1
8175	Effect of Theta Burst Stimulation-Patterned rTMS on Motor and Nonmotor Dysfunction of Parkinson's Disease: A Systematic Review and Metaanalysis. <i>Frontiers in Neurology</i> , 2021, 12, 762100.	1.1	8
8176	Subthalamic Beta Activity in Parkinson's Disease May Be Linked to Dorsal Striatum Gray Matter Volume and Prefrontal Cortical Thickness: A Pilot Study. <i>Frontiers in Neurology</i> , 2022, 13, 799696.	1.1	3

#	ARTICLE	IF	CITATIONS
8178	A comparative study of early and late onset freezing of gait in Parkinson's disease. <i>Annals of Indian Academy of Neurology</i> , 2018, 21, 256.	0.2	10
8180	Advanced diffusion imaging to track progression in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. <i>NeuroImage: Clinical</i> , 2022, 34, 103022.	1.4	12
8181	Effect of <i>Lactobacillus Paracasei</i> Strain Shirota Supplementation on Clinical Responses, Gut Microbiota and Faecal Metabolites in Patients with Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
8182	Adaptation and validation of a sinhala version of the radboud oral motor inventory (ROMP) for parkinson's disease. <i>Annals of Indian Academy of Neurology</i> , 2022, 25, 688.	0.2	0
8183	How does prosodic deficit impact naïve listeners recognition of emotion? An analysis with speakers affected by Parkinson's disease. <i>Psychology of Language and Communication</i> , 2022, 26, 102-125.	0.2	2
8184	Elevated α -synuclein and NfL levels in tear fluids and decreased retinal microvascular densities in patients with Parkinson's disease. <i>GeroScience</i> , 2022, 44, 1551-1562.	2.1	9
8185	Non-motor symptoms fluctuations in patients with Parkinson's disease at the Clinical Hospital of Salvador, Bahia. <i>Dementia E Neuropsychologia</i> , 2022, 16, 213-219.	0.3	1
8187	Aberrant changes of dynamic global synchronization in patients with Parkinson's disease. <i>Acta Radiologica</i> , 2022, , 028418512210949.	0.5	1
8188	Exploring Perceptions of Cross-Sectoral Data Sharing with People with Parkinson's. , 2022, , .		2
8189	Free-water imaging of the cholinergic basal forebrain and pedunculopontine nucleus in Parkinson's disease. <i>Brain</i> , 2023, 146, 1053-1064.	3.7	7
8190	Tau protein quantification in skin biopsies differentiates tauopathies from alpha-synucleinopathies. <i>Brain</i> , 2022, 145, 2755-2768.	3.7	8
8191	Polymorphisms of Cytochromes P450 and Glutathione S-Transferases Synergistically Modulate Risk for Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 888942.	1.7	4
8192	From Perceived Stress to Demoralization in Parkinson Disease: A Path Analysis. <i>Frontiers in Psychiatry</i> , 2022, 13, .	1.3	3
8193	Nutritional Intake and Gut Microbiome Composition Predict Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, .	1.7	10
8194	Success of home-to-home tele-neuropsychology (TeleNP) in deep brain stimulation (DBS) candidacy assessments: COVID-19 and beyond. <i>Parkinsonism and Related Disorders</i> , 2022, 98, 56-61.	1.1	4
8195	The Atrophy of the Vagus Nerve Correlated With Gastrointestinal Non-Motor Symptoms Scores, in Parkinson's Disease: A Sonography Research Study. <i>Journal of Diagnostic Medical Sonography</i> , 2022, 38, 498-505.	0.1	1
8196	Caregiving concerns and clinical characteristics across neurodegenerative and cerebrovascular disorders in the Ontario neurodegenerative disease research initiative. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	3
8197	Pallidal Structural Changes Related to Levodopa-induced Dyskinesia in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, .	1.7	0

#	ARTICLE	IF	CITATIONS
8198	Deep Brain Stimulation and Levodopa Affect Gait Variability in Parkinson Disease Differently. <i>Neuromodulation</i> , 2023, 26, 382-393.	0.4	5
8199	Deficits in Emotion Recognition and Theory of Mind in Parkinson's Disease Patients With and Without Cognitive Impairments. <i>Frontiers in Psychology</i> , 2022, 13, .	1.1	9
8200	Unilateral GPI-DBS Improves Ipsilateral and Axial Motor Symptoms in Parkinson's Disease as Evidenced by a Brain Perfusion Single Photon Emission Computed Tomography Study. <i>Frontiers in Human Neuroscience</i> , 2022, 16, .	1.0	0
8201	Sleep disturbance and health-related quality of life in Parkinson's disease: A clear correlation between health-related quality of life and subjective sleep quality. <i>Parkinsonism and Related Disorders</i> , 2022, 98, 86-91.	1.1	2
8202	Machine Learning Approach to Support the Detection of Parkinson's Disease in IMU-Based Gait Analysis. <i>Sensors</i> , 2022, 22, 3700.	2.1	29
8203	Improving Upper Extremity Bradykinesia in Parkinson's Disease: A Randomized Clinical Trial on the Use of Gravity-Supporting Exoskeletons. <i>Journal of Clinical Medicine</i> , 2022, 11, 2543.	1.0	5
8204	EEG Abnormalities During Delirium as a Prodromal Feature of Dementia with Lewy Bodies: A Case Report. <i>Journal of Alzheimer's Disease Reports</i> , 2022, 6, 223-228.	1.2	1
8205	Parkinson's disease clinical milestones and mortality. <i>Npj Parkinson's Disease</i> , 2022, 8, 58.	2.5	23
8206	Depotiation of associative plasticity is intact in Parkinson's disease with mild dyskinesia. <i>Parkinsonism and Related Disorders</i> , 2022, 99, 16-22.	1.1	1
8207	Abnormal metabolic covariance patterns associated with multiple system atrophy and progressive supranuclear palsy. <i>Physica Medica</i> , 2022, 98, 131-138.	0.4	9
8208	The Potential Circular RNAs Biomarker Panel and Regulatory Networks of Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2022, 16, .	1.4	4
8210	Comparison of the Results of a Parkinson's Holter Monitor With Patient Diaries, in Real Conditions of Use: A Sub-analysis of the MoMoPa-EC Clinical Trial. <i>Frontiers in Neurology</i> , 2022, 13, .	1.1	7
8212	The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, .	1.7	15
8213	Parkinson's Disease-Specific Autoantibodies against the Neuroprotective Co-Chaperone STIP1. <i>Cells</i> , 2022, 11, 1649.	1.8	4
8214	An antisense Alu transposon insertion/deletion polymorphism of ALDH1A1 may functionally associate with Parkinson's disease. <i>BMC Geriatrics</i> , 2022, 22, 427.	1.1	2
8215	Predictors of the change in burden, strain, mood, and quality of life among caregivers of Parkinson's disease patients. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	7
8216	Evolution of Prodromal REM Sleep Behavior Disorder to Neurodegeneration. <i>Neurology</i> , 2022, 99, .	1.5	9

#	ARTICLE	IF	CITATIONS
8217	Clinical Aspects of the Differential Diagnosis of Parkinson's Disease and Parkinsonism. Journal of		



#	ARTICLE	IF	CITATIONS
8237	Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson's disease. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 537-546.	1.5	5
8238	Relationship between motor learning and gambling propensity in Parkinson's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2022, 44, 50-61.	0.8	1
8242	Interactions Across Emotional, Cognitive and Subcortical Motor Networks Underlying Freezing of Gait. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
8243	Objective Quantification of Responses to the Clinical Pull-Test in People with Parkinson's Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
8244	Which Test Is the Best to Assess Visuo-Cognitive Impairment in Patients with Parkinson's Disease with Mild Cognitive Impairment and Dementia? A Systematic Review and Meta-Analysis. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1749-1782.	1.5	3
8245	Mass Spectrometry-Based Analysis of Serum N-Glycosylation Changes in Patients with Parkinson's Disease. <i>ACS Chemical Neuroscience</i> , 2022, 13, 1719-1726.	1.7	18
8246	The Weekly Calendar Planning Activity to Assess Functional Cognition in Parkinson Disease. <i>OTJR Occupation, Participation and Health</i> , 2022, 42, 315-323.	0.4	3
8247	Interventions for preventing falls in Parkinson's disease. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	19
8248	Association of Structural Measurements of Brain Reserve With Motor Progression in Patients With Parkinson Disease. <i>Neurology</i> , 2022, 99, .	1.5	5
8249	The Effect of Cannabidiol for Restless Legs Syndrome/Willis-Ekbom Disease in Parkinson's Disease Patients with REM Sleep Behavior Disorder: A Post Hoc Exploratory Analysis of Phase 2/3 Clinical Trial. <i>Cannabis and Cannabinoid Research</i> , 0, , .	1.5	4
8250	Identifying Depression in Parkinson's Disease by Using Combined Diffusion Tensor Imaging and Support Vector Machine. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	2
8251	Gray and white matter alterations in different predominant side and type of motor symptom in Parkinson's disease. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 1372-1379.	1.9	6
8252	GuitarPD: A Randomized Pilot Study on the Impact of Nontraditional Guitar Instruction on Functional Movement and Well-Being in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 2022, 1-12.	0.6	2
8253	Polymorphism of neurodegeneration-related genes associated with Parkinson's disease risk. <i>Neurological Sciences</i> , 2022, 43, 5301-5312.	0.9	2
8254	Deficiency in endocannabinoid synthase DAGLB contributes to early onset Parkinsonism and murine nigral dopaminergic neuron dysfunction. <i>Nature Communications</i> , 2022, 13, .	5.8	22
8255	Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	13
8256	The Instrumental Activities of Daily Living in Parkinson's Disease Patients Treated by Subthalamic Deep Brain Stimulation. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	2
8257	Implementing Deep Brain Stimulation into Practice. , 2022, , 4-16.		0

#	ARTICLE	IF	CITATIONS
8258	Reference Values for Dopamine Transporter Imaging With 99mTc-TRODAT-1 in Healthy Subjects and Parkinsonâ€™s Disease Patients. <i>Clinical Nuclear Medicine</i> , 0, Publish Ahead of Print, .	0.7	0
8259	Lifeâ€™space mobility, balance and selfâ€™efficacy in Parkinson's disease: a crossâ€™sectional study. <i>PM and R</i> , 0, , .	0.9	0
8260	Cerebral blood flow alterations specific to freezing of gait in Parkinsonâ€™s disease. <i>Neurological Sciences</i> , 2022, 43, 5323-5331.	0.9	2
8261	A 10â€™Year Communityâ€™Based Study of <scp>Leucineâ€™Rich Repeat Kinase 2 G2385R</scp> Carriers' Conversion to Parkinson's Disease. <i>Movement Disorders</i> , 0, , .	2.2	2
8262	Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntingtonâ€™s and Parkinsonâ€™s disease. <i>Journal of Neurology</i> , 2022, 269, 5136-5143.	1.8	6
8263	Diagnostic Performance for Differential Diagnosis of Atypical Parkinsonian Syndromes from Parkinsonâ€™s Disease Using Quantitative Indices of 18F-FP-CIT PET/CT. <i>Diagnostics</i> , 2022, 12, 1402.	1.3	4
8264	Attentional focus effect on dual-task walking in Parkinsonâ€™s disease with and without freezing of gait. <i>GeroScience</i> , 0, , .	2.1	0
8265	Insulin-like growth factor in Parkinsonâ€™s disease is related to nonmotor symptoms and the volume of specific brain areas. <i>Neuroscience Letters</i> , 2022, 783, 136735.	1.0	5
8266	Ketogenic therapy for Parkinson's disease: A systematic review and synthesis without meta-analysis of animal and human trials. <i>Maturitas</i> , 2022, 163, 46-61.	1.0	8
8267	Polysomnographic and Clinical Parameters before and after Zonisamide Therapy for Parkinson's Disease. <i>Internal Medicine</i> , 2023, 62, 527-531.	0.3	2
8268	Functional training versus Mat Pilates in motor and non-motor symptoms of individuals with Parkinson's disease: study protocol for a randomized controlled trial. <i>Motriz Revista De Educacao Fisica</i> , 0, 28, .	0.3	0
8269	Evaluation of the Dementia Apraxia Test in Parkinsonâ€™s Disease Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2022, 51, 271-278.	0.7	1
8270	Neural correlates of working memory and compensation at different stages of cognitive impairment in Parkinsonâ€™s disease. <i>NeuroImage: Clinical</i> , 2022, 35, 103100.	1.4	6
8271	Simulating the progression of brain structural alterations in Parkinsonâ€™s disease. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	3
8272	Advanced radiological investigation of levodopa- induced dyskinesia in Parkinsonâ€™s disease patients: assessment of blood brain barrier function. <i>Neurology Asia</i> , 2022, 27, 353-362.	0.1	0
8273	Parametric analysis of pilot voice signals in Parkinson's disease diagnostics. <i>Journal of Automation Electronics and Electrical Engineering</i> , 2022, 4, 21-28.	0.2	1
8274	Parkinsonian Syndromes in Motor Neuron Disease: A Clinical Study. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	7
8275	Documentation and diagnosis of delirium in Parkinson's disease. <i>Acta Psychiatrica Scandinavica</i> , 2023, 147, 527-535.	2.2	4

#	ARTICLE	IF	CITATIONS
8276	Yerbamate Tea Consumption: A Protective Factor in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2022, 45, 79-83.	0.2	0
8277	STN-DBS does not increase the risk of sialorrhea in patients with advanced Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	1
8278	Cholinergic brain network deficits associated with vestibular sensory conflict deficits in Parkinson's disease: correlation with postural and gait deficits. <i>Journal of Neural Transmission</i> , 2022, 129, 1001-1009.	1.4	8
8279	Use of deep learning-based radiomics to differentiate Parkinson's disease patients from normal controls: a study based on [18F]FDG PET imaging. <i>European Radiology</i> , 2022, 32, 8008-8018.	2.3	9
8280	Automated volumetric determination of high R^2 regions in substantia nigra: A feasibility study of quantifying substantia nigra atrophy in progressive supranuclear palsy. <i>NMR in Biomedicine</i> , 2022, 35, .	1.6	1
8281	Oral and gut dysbiosis leads to functional alterations in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	15
8282	Dual task effect on upper and lower extremity skills in different stages of Parkinson's disease. <i>Acta Neurologica Belgica</i> , 2023, 123, 865-872.	0.5	2
8283	Association between Baseline Cognitive Score and Postoperative Delirium in Parkinson's Disease Patients following Deep Brain Stimulation Surgery. <i>Parkinson's Disease</i> , 2022, 2022, 1-8.	0.6	0
8284	Association of Plasma and Electroencephalography Markers With Motor Subtypes of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	2
8285	Predictors of health-related quality of life in Parkinson's disease: the impact of overlap between health-related quality of life and clinical measures. <i>Quality of Life Research</i> , 2022, 31, 3241-3252.	1.5	2
8287	The Role of Parkinson Nurses for Personalizing Care in Parkinson's Disease: A Systematic Review and Meta-Analysis. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1807-1831.	1.5	3
8288	A Critical Analysis of Intestinal Enteric Neuron Loss and Constipation in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1841-1861.	1.5	6
8289	Novel inflammasome and oxidative modulators in Parkinson's disease: A prospective study. <i>Neuroscience Letters</i> , 2022, 786, 136768.	1.0	5
8290	Evaluation of iron overload in nigrosome 1 via quantitative susceptibility mapping as a progression biomarker in prodromal stages of synucleinopathies. <i>NeuroImage</i> , 2022, 260, 119454.	2.1	8
8293	Identification of metabolic correlates of mild cognitive impairment in Parkinson's disease using magnetic resonance spectroscopic imaging and machine learning. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 0, , .	1.1	0
8294	Evaluation of the visual system with visual evoked potential and optical coherence tomography in patients with idiopathic Parkinson's disease and with multiple system atrophy. <i>Documenta Ophthalmologica</i> , 2022, 145, 99-112.	1.0	2
8295	Rare variant screening and burden analysis of <i>PLXNA1</i> in Parkinson's Disease. <i>European Journal of Neurology</i> , 0, , .	1.7	0
8297	Harmonic ratio is the most responsive trunk-acceleration derived gait index to rehabilitation in people with Parkinson's disease at moderate disease stages. <i>Gait and Posture</i> , 2022, 97, 152-158.	0.6	7

#	ARTICLE	IF	CITATIONS
8298	New Targets and New Technologies in the Treatment of Parkinson's Disease: A Narrative Review. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8799.	1.2	10
8299	Gait alterations in Parkinson's disease at the stage of hemiparkinsonism—A longitudinal study. <i>PLoS ONE</i> , 2022, 17, e0269886.	1.1	1
8300	Intermediate and Expanded <i>HTT</i> Alleles and the Risk for α -Synucleinopathies. <i>Movement Disorders</i> , 2022, 37, 1841-1849.	2.2	5
8301	A multiple domain postural control assessment in people with Parkinson's disease: traditional, non-linear, and rambling and trembling trajectories analysis. <i>Gait and Posture</i> , 2022, 97, 130-136.	0.6	3
8302	Sleep spindle and slow wave activity in Parkinson disease with excessive daytime sleepiness. <i>Sleep</i> , 2023, 46, .	0.6	7
8303	The structural changes of gray matter in Parkinson disease patients with mild cognitive impairments. <i>PLoS ONE</i> , 2022, 17, e0269787.	1.1	7
8304	Is peripheral alpha synuclein a marker for gait velocity in Parkinson's disease?. <i>Neuroscience Letters</i> , 2022, 786, 136819.	1.0	2
8308	Spectrum of cardiovascular autonomic dysfunction and 24-hour blood pressure variability in idiopathic Parkinson's disease. <i>Annals of Indian Academy of Neurology</i> , 2022, 25, 902.	0.2	1
8309	Differential diagnosis of secondary parkinsonism in a complex clinical case in the city of Vladikavkaz. <i>Vestnik Nevrologii, Psihiatrii I Nejrohirurgii</i> , 2022, , 535-538.	0.0	0
8310	Identifying and validating subtypes of Parkinson's disease based on multimodal MRI data via hierarchical clustering analysis. <i>Frontiers in Human Neuroscience</i> , 0, 16, .	1.0	4
8311	Assessment of Vestibular-Evoked Myogenic Potentials in Parkinson's Disease: A Systematic Review and Meta-Analysis. <i>Brain Sciences</i> , 2022, 12, 956.	1.1	0
8312	Feasibility and positive effects of scalp acupuncture for modulating motor and cerebral activity in Parkinson's disease: A pilot study. <i>NeuroRehabilitation</i> , 2022, , 1-13.	0.5	2
8313	Evaluation of the PREDIGT score's performance in identifying newly diagnosed Parkinson's patients without motor examination. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	1
8314	Decreased soluble Nogo-B in serum as a promising biomarker for Parkinson's disease. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	1
8315	Adverse effects of levodopa/carbidopa intrajejunal gel treatment: A single-center long-term follow-up study. <i>Acta Neurologica Scandinavica</i> , 2022, 146, 537-544.	1.0	8
8316	First Two-Year Observational Exploratory Real Life Clinical Phenotyping, and Societal Impact Study of Parkinson's Disease in Emiratis and Expatriate Population of United Arab Emirates 2019–2021: The EmPark Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 1300.	1.1	1
8317	Essential tremor-Parkinson's disease syndrome: clinical characteristics and subtypes using cluster analysis. <i>Chinese Medical Journal</i> , 0, Publish Ahead of Print, .	0.9	0
8318	A Mini-Mental State Examination Formula May Help to Distinguish Alzheimer's Disease from Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2022, 89, 1119-1129.	1.2	1

#	ARTICLE	IF	CITATIONS
8319	Association between <i>LAG3/CD4</i> gene variants and risk of Parkinson's disease. <i>European Journal of Clinical Investigation</i> , 2022, 52, .	1.7	6
8320	CSF levels of SNAP-25 are increased early in Creutzfeldt-Jakob and Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 1059-1065.	0.9	13
8321	Increased phospho-AKT in blood cells from <i>LRRK2</i> G2019S mutation carriers. <i>Annals of Neurology</i> , 0, , .	2.8	0
8322	Vestibular Sensory Conflict During Postural Control, Freezing of Gait, and Falls in Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 2257-2262.	2.2	5
8323	Continuous theta burst stimulation over left supplementary motor area facilitates auditory-vocal integration in individuals with Parkinson's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	5
8324	Usability of Two New Interactive Game Sensor-Based Hand Training Devices in Parkinson's Disease. <i>Sensors</i> , 2022, 22, 6278.	2.1	0
8325	Stereotyped Relationship Between Motor and Cognitive Metabolic Networks in Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 2247-2256.	2.2	5
8326	Astrogliosis in aging and Parkinson's disease dementia: a new clinical study with 11C-BU99008 PET. <i>Brain Communications</i> , 2022, 4, .	1.5	6
8327	Striatal Hand Deformities in Parkinson's Disease: Hand Surgical Perspectives. <i>Movement Disorders Clinical Practice</i> , 0, , .	0.8	0
8328	Serum metabolomic characterization of PLA2G6-associated dystonia-parkinsonism: A case-control biomarker study. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	2
8329	Immediate Effect of Augmented Reality, Virtual Reality, and Neurofunctional Physiotherapy on Postural Control and Executive Function of Individuals with Parkinson's Disease. <i>Games for Health Journal</i> , 2023, 12, 211-219.	1.1	3
8330	A task-specific cognitive domain decline is correlated with plasma and neuroimaging markers in patients with Parkinson's disease. <i>Journal of Neurology</i> , 0, , .	1.8	0
8331	Validation of STOP, STOP-BANG, STOP-BAG, STOP-B28, and GOAL screening tools for identification of obstructive sleep apnea in patients with Parkinson disease. <i>Journal of Clinical Sleep Medicine</i> , 2023, 19, 45-54.	1.4	1
8332	Epigenetic Clock Acceleration Is Linked to Age at Onset of Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 1831-1840.	2.2	11
8333	Seasonal variations of nonmotor symptoms in patients with Parkinson's disease in Southeast China. <i>Chinese Medical Journal</i> , 0, Publish Ahead of Print, .	0.9	2
8334	Phase 1/1b Studies of UCB0599, an Oral Inhibitor of Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 2045-2056.	2.2	18
8335	Predicting Impulse Control Disorders in Parkinson Disease through Incentive Biomarkers. <i>Annals of Neurology</i> , 2022, 92, 974-984.	2.8	5
8336	The mutation spectrum of Parkinson's disease-related genes in early-onset Parkinson's disease in ethnic Chinese. <i>European Journal of Neurology</i> , 2022, 29, 3218-3228.	1.7	12

#	ARTICLE	IF	CITATIONS
8337	Prediction of Cognitive Degeneration in Parkinson's Disease Patients Using a Machine Learning Method. <i>Brain Sciences</i> , 2022, 12, 1048.	1.1	0
8338	A Remote Longitudinal Observational Study of Individuals at Genetic Risk for Parkinson Disease. <i>Neurology: Genetics</i> , 2022, 8, .	0.9	4
8340	Can the prediction model using regression with optimal scale improve the power to predict the Parkinson's dementia?. <i>World Journal of Psychiatry</i> , 2022, 12, 1031-1043.	1.3	1
8341	Altered Medial Prefrontal Connectivity in Parkinson's Disease Patients with Somatic Symptoms. <i>Movement Disorders</i> , 0, , .	2.2	1
8342	Balance Training Modulates Cortical Inhibition in Individuals with Parkinson's Disease: A Randomized Controlled Trial. <i>Neurorehabilitation and Neural Repair</i> , 2022, 36, 613-620.	1.4	3
8343	Prospective predictors of care partner burden and depression in Parkinson's disease. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	1
8344	The ability of patients with Parkinson's disease to recognize masked faces during the COVID-19 pandemic. <i>Dementia E Neuropsychologia</i> , 0, , .	0.3	0
8345	Oculomotor deficits in Parkinson's disease: Increasing sensitivity using multivariate approaches. <i>Frontiers in Digital Health</i> , 0, 4, .	1.5	3
8346	Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2022, 17, .	4.4	17
8347	IN-HOME-PD: The effects of longitudinal telehealth-enhanced interdisciplinary home visits on care and quality of life for homebound individuals with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2022, 102, 68-76.	1.1	9
8348	Decreased vestibular efficacy contributes to abnormal balance in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2022, 440, 120357.	0.3	4
8349	Identifying the white matter structural network of motor reserve in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2022, 102, 108-114.	1.1	6
8350	Finger dexterity measured by the Grooved Pegboard test indexes Parkinson's motor severity in a tremor-independent manner. <i>Journal of Electromyography and Kinesiology</i> , 2022, 66, 102695.	0.7	1
8351	The effect of age and disease duration on the efficacy of subthalamic nuclei deep brain stimulation in Parkinson's disease patients. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 2163-2171.	1.9	3
8352	Alterations of structure and functional connectivity of visual brain network in patients with freezing of gait in Parkinson's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	1
8353	Disease-Associated α -Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage. <i>Neurology</i> , 2022, 99, .	1.5	20
8354	Incidental neuroimaging findings in South African adult research participants with and without neuropsychiatric disorders. <i>NeuroImage Reports</i> , 2022, 2, 100130.	0.5	0
8355	Sex modulates the outcome of subthalamic nucleus deep brain stimulation in patients with Parkinson's disease. <i>Neural Regeneration Research</i> , 2023, 18, 901.	1.6	5

#	ARTICLE	IF	CITATIONS
8356	Translation, Cross-Cultural Adaptation, and Validation of the Physical Activity Scale for Individuals With Physical Disabilities for Brazilian Individuals With Parkinson's Disease. <i>Journal of Aging and Physical Activity</i> , 2023, 31, 223-229.	0.5	1
8357	Parkinson's Disease Detection Using Smartphone Recorded Phonemes in Real World Conditions. <i>IEEE Access</i> , 2022, 10, 97600-97609.	2.6	5
8358	Time Taken for and Causes of a Decline to Hoehn and Yahr Stage 5 in Patients with Parkinson's Disease. <i>Internal Medicine</i> , 2022, , .	0.3	0
8359	Vitamin D and other indicators of calcium-phosphorus metabolism as possible predictors of Parkinson's disease. <i>Zhurnal Nevrologii I Psikhatrii Imeni S S Korsakova</i> , 2022, 122, 56.	0.1	0
8360	Stress system and related biomarkers in Parkinson's disease. <i>Advances in Clinical Chemistry</i> , 2022, , .	1.8	1
8361	Cognitive correlates of dual tasking costs on the timed up and go test in Parkinson disease. <i>Clinical Parkinsonism & Related Disorders</i> , 2022, 7, 100158.	0.5	3
8362	Breathing disorders in neurodegenerative diseases. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2022, , 223-239.	1.0	0
8363	Widening spectrum of neuroleptic malignant syndrome: Case series. <i>Journal of Anaesthesiology Clinical Pharmacology</i> , 2022, 38, 309.	0.2	0
8364	Effects of Health Qigong Exercise on Depression and Anxiety in Patients with Parkinson's Disease. <i>International Journal of Mental Health Promotion</i> , 2022, 24, 855-867.	0.4	3
8365	Is fatigue associated with balance in Parkinson's disease?. <i>Motriz Revista De Educacao Fisica</i> , 0, 28, .	0.3	0
8366	The effects of an individualized smartphone-based exercise program on self-defined motor tasks in Parkinson's disease: A pilot interventional study Bradykinesia and rigidity are prototypical motor impairments of Parkinson's disease (PD) highly influencing everyday life. Exercise training is an effective treatment alternative for motor symptoms, complementing dopaminergic medication. High frequency training is necessary to yield clinically relevant improvements. Exercise programs need to be tailored to indivi. <i>JMIR Rehabilitation and Assistive Technologies</i> , 0, , .	1.1	3
8367	Predicting cognitive decline in Parkinson's disease using FDG-PET-based supervised learning. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	9
8368	Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 2272-2283.	2.2	9
8369	Correlation of Serum Uric Acid with Cognition, Severity, and Stage of Disease in Patients with Idiopathic Parkinson's Disease and Vascular Parkinsonism: A Cross-Sectional Study. <i>The Open Neurology Journal</i> , 2022, 16, .	0.4	0
8370	Medication adversely impacts visually-guided eye movements in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2022, 143, 145-153.	0.7	5
8371	Diet quality, sleep and quality of life in Parkinson's disease: a cross-sectional study. <i>Irish Journal of Medical Science</i> , 0, , .	0.8	3
8372	Prevalence of lower urinary tract symptoms, urinary incontinence and retention in Parkinson's disease: A systematic review and meta-analysis. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	5
8373	The effects of surface electrical stimulation plus voice therapy in Parkinson disease. <i>Journal of Laryngology and Otology</i> , 0, , 1-24.	0.4	0

#	ARTICLE	IF	CITATIONS
8374	Prevalence of axial postural abnormalities and their subtypes in Parkinson's disease: a systematic review and meta-analysis. <i>Journal of Neurology</i> , 2023, 270, 139-151.	1.8	6
8375	Aberrant gray matter volume and functional connectivity in Parkinson's disease with minor hallucination. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	5
8376	Blood based biomarkers for movement disorders. <i>Acta Neurologica Scandinavica</i> , 2022, 146, 353-361.	1.0	9
8377	Freezing of Gait in Parkinson's Disease Patients Treated with Bilateral Subthalamic Nucleus Deep Brain Stimulation: A Long-Term Overview. <i>Biomedicines</i> , 2022, 10, 2214.	1.4	4
8378	Multimodal striatal neuromarkers in distinguishing parkinsonian variant of multiple system atrophy from idiopathic Parkinson's disease. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 2172-2182.	1.9	4
8379	Abnormal Cross Frequency Coupling of Brain Electroencephalographic Oscillations Related to Visual Oddball Task in Parkinson's Disease with Mild Cognitive Impairment. <i>Clinical EEG and Neuroscience</i> , 2023, 54, 379-390.	0.9	4
8380	The Forward and Lateral Tilt Angle of the Neck and Trunk Measured by Three-Dimensional Gait and Motion Analysis as a Candidate for a Severity Index in Patients with Parkinson's Disease. <i>Neurology International</i> , 2022, 14, 727-737.	1.3	2
8381	Initiating dopamine agonists rather than levodopa in early Parkinson's disease does not delay the need for deep brain stimulation. <i>European Journal of Neurology</i> , 0, , .	1.7	0
8382	Combination of Quantitative Susceptibility Mapping and Diffusion Kurtosis Imaging Provides Potential Biomarkers for Early-Stage Parkinson's Disease. <i>ACS Chemical Neuroscience</i> , 2022, 13, 2699-2708.	1.7	2
8383	Survival in patients with Parkinson's disease: a ten-year follow-up study in northern China. <i>BMC Neurology</i> , 2022, 22, .	0.8	2
8384	Global Alterations of Whole Brain Structural Connectome in Parkinson's Disease: A Meta-analysis. <i>Neuropsychology Review</i> , 2023, 33, 783-802.	2.5	5
8385	Impaired dynamic cerebral autoregulation: A potential mechanism of orthostatic hypotension and dementia in Parkinson's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	4
8387	Relationship between Substantia Nigra Neuromelanin Imaging and Dual Alpha-Synuclein Labeling of Labial Minor in Salivary Glands in Isolated Rapid Eye Movement Sleep Behavior Disorder and Parkinson's Disease. <i>Genes</i> , 2022, 13, 1715.	1.0	5
8388	<i>Agathobaculum butyriciproducens</i> Shows Neuroprotective Effects in a 6-OHDA-Induced Mouse Model of Parkinson's Disease. <i>Journal of Microbiology and Biotechnology</i> , 2022, 32, 1168-1177.	0.9	6
8389	Parkinsonics: A Randomized, Blinded, Cross-Over Trial of Group Singing for Motor and Nonmotor Symptoms in Idiopathic Parkinson Disease. <i>Parkinson's Disease</i> , 2022, 2022, 1-14.	0.6	7
8390	Effect of cerebral small vessel disease on cognitive impairment in Parkinson's disease. <i>Acta Neurologica Belgica</i> , 2023, 123, 487-495.	0.5	2
8391	Cognitive Performance and Learning Parameters Predict Response to Working Memory Training in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, , 1-13.	1.5	1
8392	A literature review of online handwriting analysis to detect Parkinson's disease at an early stage. <i>Multimedia Tools and Applications</i> , 2023, 82, 11923-11948.	2.6	8

#	ARTICLE	IF	CITATIONS
8393	Serotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 2301-2307.	2.2	7
8394	Effects of LSVT-BIG via telerehabilitation on non-motor and motor symptoms and quality of life in Parkinson's disease. <i>Acta Neurologica Belgica</i> , 2023, 123, 207-214.	0.5	4
8395	Early Dysbiosis and Dampened Gut Microbe Oscillation Precede Motor Dysfunction and Neuropathology in Animal Models of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 2423-2440.	1.5	5
8396	Action observation and motor imagery have no effect on balance and freezing of gait in Parkinson's disease: a randomized controlled trial. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2022, 58, .	1.1	2
8397	Resistance Training Combined with Balance or Gait Training for Patients with Parkinson's Disease: A Randomized Controlled Pilot Study. <i>Parkinson's Disease</i> , 2022, 2022, 1-7.	0.6	0
8398	From anticipation to impulsivity in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	1
8399	Immune system disruptions implicated in whole blood epigenome-wide association study of depression among Parkinson's disease patients. <i>Brain, Behavior, & Immunity - Health</i> , 2022, , 100530.	1.3	2
8400	The prevalence and associated factors of dysphagia in Parkinson's disease: A systematic review and meta-analysis. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	10
8402	Actigraphy Enables Home Screening of Rapid Eye Movement Behavior Disorder in Parkinson's Disease. <i>Annals of Neurology</i> , 2023, 93, 317-329.	2.8	9
8403	Mild cognitive impairment is associated with poor gait performance in patients with Parkinson's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	1
8404	Attentional Demand of Motor Speech Encoding: Evidence From Parkinson's Disease. <i>Journal of Speech, Language, and Hearing Research</i> , 2022, 65, 3758-3775.	0.7	2
8405	Physical activity intensity is associated with cognition and functional connectivity in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2022, 104, 7-14.	1.1	4
8406	Computerized analysis of speech and voice for Parkinson's disease: A systematic review. <i>Computer Methods and Programs in Biomedicine</i> , 2022, 226, 107133.	2.6	14
8408	Analysis of rs34637584 polymorphism in the LRRK2 gene in patients with Parkinson's disease. <i>Medicinski Podmladak</i> , 2022, 73, 33-37.	0.2	0
8409	NigraNet: An automatic framework to assess nigral neuromelanin content in early Parkinson's disease using convolutional neural network. <i>NeuroImage: Clinical</i> , 2022, 36, 103250.	1.4	2
8410	Encoding type, medication, and deep brain stimulation differentially affect memory-guided sequential reaching movements in Parkinson's disease. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	0
8411	Relevance of plasma biomarkers to pathologies in Alzheimer's disease, Parkinson's disease and frontotemporal dementia. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
8412	Dual-phase ¹⁸ F-FPET positron emission tomography and cardiac ¹²³ I-MIBG scintigraphy of Parkinson's disease patients with GBA mutations: evidence of the body-first type?. <i>European Journal of Neurology</i> , 2023, 30, 344-352.	1.7	7

#	ARTICLE	IF	CITATIONS
8413	Surgical Therapies for Parkinson Disease. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 1301-1313.	0.4	0
8414	Topological patterns of motor networks in Parkinson's disease with different sides of onset: A resting-state-informed structural connectome study. Frontiers in Aging Neuroscience, 0, 14, .	1.7	0
8415	Nigral Iron Deposition Influences Disease Severity by Modulating the Effect of Parkinson's Disease on Brain Networks. Journal of Parkinson's Disease, 2022, 12, 2479-2492.	1.5	2
8416	Differential cholinergic systems' changes in progressive supranuclear palsy versus Parkinson's disease: an exploratory analysis. Journal of Neural Transmission, 2022, 129, 1469-1479.	1.4	2
8417	Identification of cholinergic centro-cingulate topography as main contributor to cognitive functioning in Parkinson's disease: Results from a data-driven approach. Frontiers in Aging Neuroscience, 0, 14, .	1.7	2
8418	Reduced power and phase-locking values were accompanied by thalamus, putamen, and hippocampus atrophy in Parkinson's disease with mild cognitive impairment: an event-related oscillation study. Neurobiology of Aging, 2023, 121, 88-106.	1.5	5
8419	Abnormal brain activities in multiple frequency bands in Parkinson's disease with apathy. Frontiers in Neuroscience, 0, 16, .	1.4	4
8420	Altered dynamic functional network connectivity in levodopa-induced dyskinesia of Parkinson's disease. CNS Neuroscience and Therapeutics, 2023, 29, 192-201.	1.9	8
8421	A pilot trial of dopamine replacement for dynamic facial expressions in Parkinson's disease. Movement Disorders Clinical Practice, 0, , .	0.8	1
8422	Specific pattern of linguistic impairment in Parkinson's disease patients with subjective cognitive decline and mild cognitive impairment predicts dementia. Journal of the International Neuropsychological Society, 2023, 29, 632-640.	1.2	5
8423	Disrupted topological organization of resting-state functional brain networks in Parkinson's disease patients with glucocerebrosidase gene mutations. Neuroradiology, 2023, 65, 361-370.	1.1	2
8424	Activities of Daily Living in Parkinson Disease. Topics in Geriatric Rehabilitation, 2022, 38, 285-295.	0.2	0
8425	Shrinkage of olfactory amygdala connotes cognitive impairment in patients with Parkinson's disease. Cognitive Neurodynamics, 2023, 17, 1309-1320.	2.3	2
8426	<sc>Splitâ€Belt</sc> Treadmill Training to Improve Gait Adaptation in Parkinson's Disease. Movement Disorders, 2023, 38, 92-103.	2.2	3
8427	Telehealth Transdiagnostic Cognitive Behavioral Therapy for Depression in Parkinson's Disease: A Pilot Randomized Controlled Trial. Movement Disorders Clinical Practice, 2023, 10, 79-85.	0.8	7
8428	Motor progression marker for newly diagnosed drug-naïve patients with Parkinson's disease: A resting-state functional <sc>MRI</sc> study. Human Brain Mapping, 0, , .	1.9	3
8429	Reproductive Lifespan and Motor Progression of Parkinson's Disease. Journal of Clinical Medicine, 2022, 11, 6163.	1.0	1
8430	Global, in situ analysis of the structural proteome in individuals with Parkinson's disease to identify a new class of biomarker. Nature Structural and Molecular Biology, 2022, 29, 978-989.	3.6	16

#	ARTICLE	IF	CITATIONS
8431	Levodopa alters resting-state functional connectivity more selectively in Parkinson's disease with freezing of gait. <i>European Journal of Neuroscience</i> , 2023, 57, 163-177.	1.2	2
8433	Human Induced Pluripotent Stem Cell Phenotyping and Preclinical Modeling of Familial Parkinson's Disease. <i>Genes</i> , 2022, 13, 1937.	1.0	4
8434	An integrated biometric voice and facial features for early detection of Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	8
8435	High frequency of Depressive Disorders and Suicidal Phenomena in Late-Stage Parkinson's Disease – A Cross-Sectional Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2023, 36, 336-346.	1.2	2
8436	Identification of Drugs Associated with Lower Risk of Parkinson's Disease Using a Systematic Screening Approach in a Nationwide Nested Case-Control Study. <i>Clinical Epidemiology</i> , 0, Volume 14, 1217-1227.	1.5	5
8437	The relationship between meaning in life and apathy in people with Parkinson's disease: a cross-sectional analysis. <i>Aging Clinical and Experimental Research</i> , 2023, 35, 91-99.	1.4	2
8438	Diagnostic value of α -synuclein seeding amplification assays in α -synucleinopathies: A systematic review and meta-analysis. <i>Parkinsonism and Related Disorders</i> , 2022, 104, 99-109.	1.1	21
8439	Muscle Strength and Power in People With Parkinson Disease: A Systematic Review and Meta-analysis. <i>Journal of Neurologic Physical Therapy</i> , 2023, 47, 3-15.	0.7	10
8440	Putamen Atrophy Is a Possible Clinical Evaluation Index for Parkinson's Disease Using Human Brain Magnetic Resonance Imaging. <i>Journal of Imaging</i> , 2022, 8, 299.	1.7	1
8441	Brain network characteristics and cognitive performance in motor subtypes of Parkinson's disease: A resting state fMRI study. <i>Parkinsonism and Related Disorders</i> , 2022, 105, 32-38.	1.1	2
8442	Altered brain iron depositions from aging to Parkinson's disease and Alzheimer's disease: A quantitative susceptibility mapping study. <i>NeuroImage</i> , 2022, 264, 119683.	2.1	13
8443	The c-Abl/p73 pathway induces neurodegeneration in a Parkinson's disease model. <i>IBRO Neuroscience Reports</i> , 2022, 13, 378-387.	0.7	2
8444	Incidence of cataract surgeries in relation to diagnosis of Parkinson's disease. <i>Archives of Gerontology and Geriatrics</i> , 2023, 104, 104842.	1.4	3
8445	The MIT Encyclopedia of Communication Disorders. , 2003, , .		28
8446	Neurogenic supine hypertension and cardiovascular autonomic dysfunction in patients with parkinson's disease. <i>Annals of Indian Academy of Neurology</i> , 2023, 26, 33.	0.2	0
8447	Treatment of Parkinson's Disease: Early, Late, and Combined. , 2022, , 2891-2915.		0
8448	Pharmacotherapy of Psychosis in Parkinson's Disease. , 2022, , 4231-4269.		0
8449	Objective and self-perceived lower limb weakness in Parkinson's disease. <i>Therapeutic Advances in Neurological Disorders</i> , 2022, 15, 175628642211369.	1.5	3

#	ARTICLE	IF	CITATIONS
8450	Molecular imaging evidence in favor or against PDD and DLB overlap. , 2023, , 275-295.		1
8451	Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson's disease. Npj Parkinson's Disease, 2022, 8, .	2.5	17
8452	APDM gait and balance measures fail to predict symptom progression rate in Parkinson's disease. Frontiers in Neurology, 0, 13, .	1.1	0
8453	The mechanism of exercise for pain management in Parkinson's disease. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	2
8454	APOE E4 is associated with impaired self-declared cognition but not disease risk or age of onset in Nigerians with Parkinson's disease. Npj Parkinson's Disease, 2022, 8, .	2.5	4
8455	Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease. Annals of Internal Medicine, 2022, 175, 1666-1674.	2.0	20
8456	Correlation between serum IGF-1 and EGF levels and neuropsychiatric and cognitive in Parkinson's disease patients. Neurological Sciences, 2023, 44, 881-887.	0.9	4
8457	Multimodal visual system analysis as a biomarker of visual hallucinations in Parkinson's disease. Journal of Neurology, 2023, 270, 519-529.	1.8	2
8458	Attentional impairment in Parkinson's disease is modulated by side of onset: neurophysiological evidence. Clinical Neurophysiology, 2022, , .	0.7	0
8459	Socially Assistive Robots for Parkinson's Disease: Needs, Attitudes and Specific Applications as Identified by Healthcare Professionals. ACM Transactions on Human-Robot Interaction, 2023, 12, 1-25.	3.2	2
8460	Microstructural but not macrostructural cortical degeneration occurs in Parkinson's disease with mild cognitive impairment. Npj Parkinson's Disease, 2022, 8, .	2.5	6
8461	Quantitative Susceptibility Mapping and Free Water Imaging of Substantia Nigra in Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 2469-2478.	1.5	4
8462	Cognitive Digital Intervention for Older Patients with Parkinson's Disease during COVID-19: A Mixed-Method Pilot Study. International Journal of Environmental Research and Public Health, 2022, 19, 14844.	1.2	3
8463	Machine learning based risk prediction for Parkinson's disease with nationwide health screening data. Scientific Reports, 2022, 12, .	1.6	2
8464	Preliminary Effects of Osteopathic Manipulative Medicine on Reactive Oxygen Species in Parkinson's Disease: A Randomized Controlled Pilot Study. Cureus, 2022, , .	0.2	0
8465	The Thr105Ile Variant (rs11558538) in the Histamine N-Methyltransferase Gene May Be Associated with Reduced Risk of Parkinson's Disease: A Meta-analysis. Genetic Testing and Molecular Biomarkers, 0, , .	0.3	0
8466	Analysis of handgrip strength, pulling force using the upper limbs, and ground reaction forces in the task of boarding a bus between healthy elderly individuals and those with Parkinson's disease. Physiotherapy Theory and Practice, 0, , 1-10.	0.6	1
8467	Dysphagia for medication in Parkinson's disease. Npj Parkinson's Disease, 2022, 8, .	2.5	6

#	ARTICLE	IF	CITATIONS
8468	Deep learning signature of brain [18F]FDG PET associated with cognitive outcome of rapid eye movement sleep behavior disorder. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
8471	Mass Spectrometry-Based Proteomics Analysis of Human Substantia Nigra From Parkinson's Disease Patients Identifies Multiple Pathways Potentially Involved in the Disease. <i>Molecular and Cellular Proteomics</i> , 2023, 22, 100452.	2.5	15
8472	Speech temporal organization in three basal ganglia-related neurological conditions. <i>DELTA Documentacao De Estudos Em Linguistica Teorica E Aplicada</i> , 2022, 38, .	0.0	0
8473	Severity of depressive and motor symptoms impacts quality of life in Parkinson's disease patients at an academic movement clinic: A cross-sectional study. <i>Clinical Parkinsonism & Related Disorders</i> , 2023, 8, 100180.	0.5	4
8474	Impact of long-term care insurance on medical costs and utilization by patients with Parkinson's disease. <i>Social Science and Medicine</i> , 2023, 317, 115563.	1.8	0
8475	White matter hyperintensity presence, quantity, and location exhibits no association with motor and non-motor manifestations of PD. <i>Parkinsonism and Related Disorders</i> , 2023, 106, 105245.	1.1	0
8476	Proximity to residential and workplace pesticides application and the risk of progression of Parkinson's diseases in Central California. <i>Science of the Total Environment</i> , 2023, 864, 160851.	3.9	6
8477	Parkinson's disease: Pathology and treatment. <i>AIP Conference Proceedings</i> , 2022, , .	0.3	0
8478	Leczenie zaawansowanej choroby Parkinsona - rekomendacje Polskiego Towarzystwa Choroby Parkinsona i Innych Zaburzeni Ruchowych. , 2022, 18, 61-84.	0.1	0
8479	Tratamento da demência: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. <i>Dementia E Neuropsychologia</i> , 2022, 16, 88-100.	0.3	2
8480	Diagnóstico e manejo da demência da doença de Parkinson e demência com corpos de Lewy: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. <i>Dementia E Neuropsychologia</i> , 2022, 16, 73-87.	0.3	1
8481	Diagnosis and management of Parkinson's disease dementia and dementia with Lewy bodies: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. <i>Dementia E Neuropsychologia</i> , 2022, 16, 73-87.	0.3	0
8482	Treatment of dementia: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. <i>Dementia E Neuropsychologia</i> , 2022, 16, 88-100.	0.3	1
8483	A Case Report of a Patient with Parkinson's Disease Treated with Acupuncture and Exercise Therapy. <i>The Journal of Internal Korean Medicine</i> , 2022, 43, 1018-1028.	0.0	1
8484	Test-Retest Reliability and Criterion Validity of the Spanish Version of Two Motor Imagery Questionnaires in People With Parkinson Disease. <i>Journal of Neurologic Physical Therapy</i> , 2023, 47, 35-43.	0.7	2
8485	Dual-task walking improvement with enhanced kinesthetic awareness in Parkinson's disease with mild gait impairment: EEG connectivity and clinical implication. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	3
8486	Progression of regional cortical cholinergic denervation in Parkinson's disease. <i>Brain Communications</i> , 2022, 4, .	1.5	9
8487	Visinin-like protein 1 levels in blood and CSF as emerging markers for Alzheimer's and other neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	5

#	ARTICLE	IF	CITATIONS
8488	Early Diagnosis of Parkinson's Disease: Utility of Animal Models. , 0, , .		0
8490	A Novel Trial of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO). Cureus, 2022, , .	0.2	0
8492	Mental imagery content is associated with disease severity and specific brain functional connectivity changes in patients with Parkinson's disease. Brain Imaging and Behavior, 2023, 17, 161-171.	1.1	1
8493	A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson's disease. Npj Parkinson's Disease, 2022, 8, .	2.5	4
8495	Impact of Gastrointestinal Symptoms on Health-Related Quality of Life in an Australian Parkinson's Disease Cohort. Parkinson's Disease, 2022, 2022, 1-8.	0.6	0
8496	Detecting Parkinson's disease and its cognitive phenotypes via automated semantic analyses of action stories. Npj Parkinson's Disease, 2022, 8, .	2.5	8
8497	Early-Onset Parkinson's Disease: Creating the Right Environment for a Genetic Disorder. Journal of Parkinson's Disease, 2022, 12, 2353-2367.	1.5	6
8499	Association of Depression With Early Occurrence of Postural Instability in Parkinson's Disease. Journal of Movement Disorders, 2023, 16, 68-78.	0.7	0
8500	Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects. Nature Communications, 2022, 13, .	5.8	21
8501	Chronic Pain And Levodopa Therapy in Parkinson's Disease Patients. The Open Neurology Journal, 2022, 16, .	0.4	0
8502	Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials. European Journal of Neurology, 2023, 30, 1118-1134.	1.7	5
8503	Identification and prediction of Parkinson's disease subtypes and progression using machine learning in two cohorts. Npj Parkinson's Disease, 2022, 8, .	2.5	14
8504	Cortical and subcortical morphological alterations in motor subtypes of Parkinson's disease. Npj Parkinson's Disease, 2022, 8, .	2.5	4
8505	Feasibility of a Novel Therapist-Assisted Feedback System for Gait Training in Parkinson's Disease. Sensors, 2023, 23, 128.	2.1	1
8506	Predictors of Falls with Injuries in People with Parkinson's Disease. Movement Disorders Clinical Practice, 0, , .	0.8	0
8507	Alterations of Regional Homogeneity in Parkinson's Disease with Rapid Eye Movement Sleep Behavior Disorder. Neuropsychiatric Disease and Treatment, 0, Volume 18, 2967-2978.	1.0	0
8508	Hippocampal, basal ganglia and olfactory connectivity contribute to cognitive impairments in Parkinson's disease. European Journal of Neuroscience, 2023, 57, 511-526.	1.2	4
8509	UQCRC1 variants in early-onset and familial Parkinson's disease in a Taiwanese cohort. Frontiers in Neurology, 0, 13, .	1.1	1

#	ARTICLE	IF	CITATIONS
8510	Association between NOTCH3 gene and Parkinson's disease based on whole-exome sequencing. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	1
8511	Recent hospitalization and risk of antidepressant initiation in people with Parkinson's disease. <i>BMC Geriatrics</i> , 2022, 22, .	1.1	0
8512	Brain and Cerebrospinal Fluid α -Synuclein Real-Time Quaking-Induced Conversion Identifies Lewy Body Pathology in α -LRRK2 α -PD. <i>Movement Disorders</i> , 2023, 38, 333-338.	2.2	10
8513	Telehealth For Individuals with Parkinson's Disease During Covid-19 In Brazil: A Prospective Case Series. <i>International Journal of Telerehabilitation</i> , 2022, 14, .	0.7	1
8514	Experience of diagnosis and managements for patients with primary progressive freezing of gait. <i>Journal of Neurorestoratology</i> , 2023, 11, 100039.	1.1	1
8515	Telerehabilitation during social distancing for people with Parkinson's disease: a retrospective study. <i>Acta Neurologica Belgica</i> , 2023, 123, 1267-1277.	0.5	4
8516	Effect of Upper Limb Motor Rehabilitation on Cognition in Parkinson's Disease: An Observational Study. <i>Brain Sciences</i> , 2022, 12, 1684.	1.1	2
8517	The mortality of patients with Parkinson's disease with deep brain stimulation. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	1
8518	Atrophy of the Cholinergic Basal Forebrain can Detect Presynaptic Cholinergic Loss in Parkinson's Disease. <i>Annals of Neurology</i> , 2023, 93, 991-998.	2.8	5
8519	Feasibility of a combined intermittent theta-burst stimulation and video game-based dexterity training in Parkinson's disease. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2023, 20, .	2.4	0
8521	Clinical determinants of apathy and its impact on health-related quality of life in early Parkinson disease. <i>Medicine (United States)</i> , 2023, 102, e32674.	0.4	0
8522	Faecal metabolite deficit, gut inflammation and diet in Parkinson's disease: Integrative analysis indicates inflammatory response syndrome. <i>Clinical and Translational Medicine</i> , 2023, 13, .	1.7	4
8523	Neuropsychological Changes in Isolated REM Sleep Behavior Disorder: A Systematic Review and Meta-analysis of Cross-sectional and Longitudinal Studies. <i>Neuropsychology Review</i> , 2024, 34, 41-66.	2.5	2
8524	Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	13
8525	Ultrasound of the Biceps Muscle in Idiopathic Parkinson's Disease with Deep Brain Stimulation: Rigidity Can Be Quantified by Shear Wave Elastography. <i>Diagnostics</i> , 2023, 13, 213.	1.3	2
8526	Role of serotonin in modulation of decision-making in Parkinson's disease. <i>Journal of Psychopharmacology</i> , 0, , 026988112211446.	2.0	0
8527	The effects of synbiotic supplementation on oxidative stress markers, mental status, and quality of life in patients with Parkinson's disease: A double-blind, placebo-controlled, randomized controlled trial. <i>Journal of Functional Foods</i> , 2023, 100, 105397.	1.6	2
8528	Changes in Principal Caregiver Mood Affects the Mood of the Parkinson's Disease Patient: The Vicious Cycle of Illness. <i>Journal of Parkinson's Disease</i> , 2023, , 1-13.	1.5	1

#	ARTICLE	IF	CITATIONS
8529	Quality of life: Seasonal fluctuation in Parkinson's disease. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	0
8530	Parkinson's <scp>Diseaseâ€Cognitive</scp> Rating Scale (<scp>PDâ€CRS</scp>): normative data and mild cognitive impairment assessment in Brazil. <i>Movement Disorders Clinical Practice</i> , 0, , .	0.8	0
8531	Understanding the Impact of Occupational Stress on the Home Environment: Evidence from Oman. <i>FIIB Business Review</i> , 2023, 12, 263-278.	2.2	1
8532	Effect of aquatic exercise programs according to the International Classification of Functionality, Disability and Health domains in individuals with Parkinsonâ€™s disease: a systematic review and meta-analysis with GRADE quality assessment. <i>Disability and Rehabilitation</i> , 2024, 46, 429-442.	0.9	3
8534	Electroacupuncture for motor dysfunction and constipation inÂpatients with Parkinson's disease: a randomised controlled multi-centre trial. <i>EClinicalMedicine</i> , 2023, 56, 101814.	3.2	10
8535	Cross-sectional proteomic expression in Parkinson's disease-related proteins in drug-naïve patients vs healthy controls with longitudinal clinical follow-up. <i>Neurobiology of Disease</i> , 2023, 177, 105997.	2.1	7
8536	Structural and metabolic correlates of neuropsychological profiles in multiple system atrophy and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2023, 107, 105277.	1.1	3
8537	Nitric Oxide Synthase Inhibition Protects Against RotenoneInduced Neurodegeneration in vivo. <i>Journal of Neurology and Epidemiology</i> , 0, 7, 9-18.	0.0	0
8539	Factors Influencing Driving following DBS Surgery in Parkinsonâ€™s Disease: A Single UK Centre Experience and Review of the Literature. <i>Journal of Clinical Medicine</i> , 2023, 12, 166.	1.0	0
8540	Impact of LSVT-BIG Â® on functional mobility, walking, dexterity, and quality of life in Parkinson's disease. <i>Cukurova Medical Journal</i> , 2022, 47, 1738-1745.	0.1	0
8541	Cross-cultural validation of the Cebuano version of a screening questionnaire for Parkinson's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2022, 80, 1239-1245.	0.3	0
8542	Striatal Dopaminergic Loss and Dysphagia in Parkinson Disease. <i>Clinical Nuclear Medicine</i> , 2023, 48, 143-149.	0.7	1
8543	Feasibility of Combining Disease-Specific and Balance-Related Measures as Risk Predictors of Future Falls in Patients with Parkinsonâ€™s Disease. <i>Journal of Clinical Medicine</i> , 2023, 12, 127.	1.0	0
8544	Parkinson's disease fluid biomarkers for differential diagnosis of atypical parkinsonian syndromes. <i>Clinical and Translational Discovery</i> , 2023, 3, .	0.2	3
8545	Parkinson disease. , 2023, , 549-552.		0
8546	Risk of Cognitive Impairment in Patients With Parkinsonâ€™s Disease With Visual Hallucinations and		

#	ARTICLE	IF	CITATIONS
8549	Levodopa-induced Dyskinesia in Parkinson's Disease: Plausible Inflammatory and Oxidative Stress Biomarkers. <i>Canadian Journal of Neurological Sciences</i> , 2024, 51, 104-109.	0.3	1
8550	ANXA1 mutation analysis in Italian patients with early onset PD. <i>Neurobiology of Aging</i> , 2023, , .	1.5	0
8551	Interactions across emotional, cognitive and subcortical motor networks underlying freezing of gait. <i>NeuroImage: Clinical</i> , 2023, 37, 103342.	1.4	3
8552	Low Levels of Adenosine and GDNF Are Potential Risk Factors for Parkinson's Disease with Sleep Disorders. <i>Brain Sciences</i> , 2023, 13, 200.	1.1	8
8553	Dopamine transporter SPECT imaging in Parkinson's disease and atypical Parkinsonism: a study of 137 patients. <i>Neurological Sciences</i> , 2023, 44, 1613-1623.	0.9	2
8554	Altered gut microbiota in patients with idiopathic Parkinson's disease: an age- and sex matched case-control study. <i>Acta Neurologica Belgica</i> , 2023, 123, 999-1009.	0.5	1
8555	Characteristics of behavioural addiction in Parkinson's disease patients with self-reported impulse control disorder and controls matched for levodopa equivalent dose: a matched case-control study. <i>Journal of Neural Transmission</i> , 2023, 130, 125-133.	1.4	1
8556	Plasma extracellular vesicle tau, β -amyloid, and α -synuclein and the progression of Parkinson's disease: a follow-up study. <i>Therapeutic Advances in Neurological Disorders</i> , 2023, 16, 175628642211503.	1.5	5
8557	Stroke in Parkinson's disease: a review of epidemiological studies and potential pathophysiological mechanisms. <i>Acta Neurologica Belgica</i> , 2023, 123, 773-783.	0.5	4
8558	Technology-Assisted Cognitive Motor Dual-Task Rehabilitation in Chronic Age-Related Conditions: Systematic Review. <i>Journal of Medical Internet Research</i> , 0, 25, e44484.	2.1	5
8559	Sequential production of motor-action verb subtypes in Parkinson's disease patients. <i>Dementia E Neuropsychologia</i> , 0, 17, .	0.3	0
8560	The theoretical problems of "prodrome" and "phenocconversion" in neurodegeneration. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2023, , 155-167.	1.0	0
8561	Influence of cognitive reserve on cognitive and motor function in α -synucleinopathies: A systematic review protocol. <i>Annals of the New York Academy of Sciences</i> , 2023, 1522, 15-23.	1.8	0
8562	Acute effects of transcranial direct current stimulation combined with physical therapy on the balance and gait in individuals with Parkinson's disease: A randomized controlled trial. <i>Clinical Neurology and Neurosurgery</i> , 2023, 226, 107604.	0.6	0
8563	Transcranial direct current stimulation enhances motor learning in Parkinson's disease: a randomized controlled trial. <i>Journal of Neurology</i> , 0, , .	1.8	2
8564	Brainstem neuromelanin and iron MRI reveals a precise signature for idiopathic and LRRK2 Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2023, 9, .	2.5	5
8565	Non-motor effects of deep brain stimulation in Parkinson's disease motor subtypes. <i>Parkinsonism and Related Disorders</i> , 2023, 109, 105318.	1.1	5
8566	Levodopa responsive freezing of gait is associated with reduced norepinephrine transporter binding in Parkinson's disease. <i>Neurobiology of Disease</i> , 2023, 179, 106048.	2.1	3

#	ARTICLE	IF	CITATIONS
8567	Cortical connectivity of cholinergic basal forebrain in Parkinson's disease with mild cognitive impairment. <i>Quantitative Imaging in Medicine and Surgery</i> , 2023, 13, 2167-2182.	1.1	3
8568	Presence but not the timing of onset of REM sleep behavior disorder distinguishes evolution patterns in Parkinson's disease. <i>Neurobiology of Disease</i> , 2023, 180, 106084.	2.1	3
8569	(A)symmetry during gait initiation in people with Parkinson's disease: A motor and cortical activity exploratory study. <i>Frontiers in Aging Neuroscience</i> , 0, 15, .	1.7	0
8571	Evoked resonant neural activity in subthalamic local field potentials reflects basal ganglia network dynamics. <i>Neurobiology of Disease</i> , 2023, 178, 106019.	2.1	7
8572	Aberrant inter-network functional connectivity in drug-naïve Parkinson's disease patients with tremor dominant and postural instability and gait difficulty. <i>Frontiers in Human Neuroscience</i> , 0, 17, .	1.0	2
8573	Differential serum microRNAs in premotor LRRK2 G2019S carriers from Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2023, 9, .	2.5	2
8574	Fluphenazine-Induced Neurotoxicity with Acute Almost Transient Parkinsonism and Permanent Memory Loss: Lessons from a Case Report. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2968.	1.8	4
8575	Safety and tolerability of adjunct non-invasive vagus nerve stimulation in people with parkinson's: a study protocol. <i>BMC Neurology</i> , 2023, 23, .	0.8	3
8576	The Lived Experience of Caregiving and Perception of Service Provision among Family-Caregivers of People with Late-Stage Parkinson's: A Qualitative Study. <i>Parkinson's Disease</i> , 2023, 2023, 1-12.	0.6	1
8577	An Explainable Spatial-Temporal Graphical Convolutional Network to Score Freezing of Gait in Parkinsonian Patients. <i>Sensors</i> , 2023, 23, 1766.	2.1	3
8578	Ambiental Factors in Parkinson's Disease Progression: A Systematic Review. <i>Medicina (Lithuania)</i> , 2023, 59, 294.	0.8	1
8579	At-home assessment of postural stability in parkinson's disease: a vision-based approach. <i>Journal of Ambient Intelligence and Humanized Computing</i> , 0, , .	3.3	0
8580	Gut microbiota of Parkinson's disease in an appendectomy cohort: a preliminary study. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
8581	Classification and staging of Parkinson's disease using video-based eye tracking. <i>Parkinsonism and Related Disorders</i> , 2023, 110, 105316.	1.1	14
8582	Orthostatic Hypotension Is a Predictor of Fatigue in Drug-Naïve Parkinson's Disease. <i>Parkinson's Disease</i> , 2023, 2023, 1-6.	0.6	0
8583	Genome-wide association study using whole-genome sequencing identifies risk loci for Parkinson's disease in Chinese population. <i>Npj Parkinson's Disease</i> , 2023, 9, .	2.5	11
8584	Quantifying Impairments in Swallowing Safety and Efficiency in Progressive Supranuclear Palsy and Parkinson's Disease. <i>Dysphagia</i> , 0, , .	1.0	0
8585	Cerebral Small Vessel Disease Progression Increases Risk of Incident Parkinsonism. <i>Annals of Neurology</i> , 2023, 93, 1130-1141.	2.8	4

#	ARTICLE	IF	CITATIONS
8586	Plasma GFAP in Parkinson's disease with cognitive impairment and its potential to predict conversion to dementia. <i>Npj Parkinson's Disease</i> , 2023, 9, .	2.5	14
8587	The challenging quest of neuroimaging: From clinical to molecular-based subtyping of Parkinson disease and atypical parkinsonisms. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2023, , 231-258.	1.0	0
8588	Can we add whey protein supplementation in patients with Parkinson's disease without interfering with levodopa response?. <i>International Journal of Neuroscience</i> , 0, , 1-5.	0.8	0
8589	Detection of <i>ATXN2</i> Expansions in an Exome Dataset: An Underdiagnosed Cause of Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 2023, 10, 664-669.	0.8	2
8590	Healthy lifestyles and wellbeing reduce neuroinflammation and prevent neurodegenerative and psychiatric disorders. <i>Frontiers in Neuroscience</i> , 0, 17, .	1.4	11
8591	Dopamine transporter single photon emission computed tomography (DaT-SPECT) use in the diagnosis and clinical management of parkinsonism: an 8-year retrospective study. <i>Journal of Neurology</i> , 2023, 270, 2550-2558.	1.8	1
8592	Leveraging the regulatory framework to facilitate drug development in Parkinson's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2023, , 347-360.	1.0	1
8593	Quantitative Seed Amplification Assay: A Proof-of-Principle Study. <i>Journal of Physical Chemistry B</i> , 2023, 127, 1735-1743.	1.2	5
8594	Imaging in Movement Disorders. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2023, 29, 194-218.	0.4	0
8595	An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson's disease participants. <i>Nature Communications</i> , 2023, 14, .	5.8	15
8596	Differing Patterns of Diurnal Variation and Impact of Antacids on Levodopa Pharmacokinetics in Patients with Parkinson's Disease. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2023, 54, 3-8.	0.1	1
8597	Functional and structural alterations as diagnostic imaging markers for depression in de novo Parkinson's disease. <i>Frontiers in Neuroscience</i> , 0, 17, .	1.4	2
8598	The Relationship between Visual-Evoked Potential and Optic Coherence Tomography and Clinical Findings in Parkinson Patients. <i>Parkinson's Disease</i> , 2023, 2023, 1-11.	0.6	2
8599	Evaluating the association between DNM1L variants and Parkinson's disease in the Chinese population. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	0
8600	Home calligraphic exercises as manual dexterity training in patients with Parkinson's disease: a pilot feasibility study. <i>Disability and Rehabilitation</i> , 2024, 46, 870-874.	0.9	1
8601	Is Disrupted Mitophagy a Central Player to Parkinson's Disease Pathology?. <i>Cureus</i> , 2023, , .	0.2	1
8602	Relationship between [123I]FP-CIT SPECT data and peripheral CD4 ⁺ T cell profile in newly-diagnosed drug-naïve Parkinson's disease patients. <i>Journal of Neurology</i> , 0, , .	1.8	0
8603	Multiple system atrophy. <i>Zhurnal Nevrologii I Psikiatrii Imeni S S Korsakova</i> , 2023, 123, 144.	0.1	0

#	ARTICLE	IF	CITATIONS
8604	Efficacy of herbal medicine treatment based on syndrome differentiation for Parkinson's disease: A systematic review and meta-analysis of randomized placebo-controlled clinical trials. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
8605	Brain and Systemic Inflammation in De Novo Parkinson's Disease. <i>Movement Disorders</i> , 2023, 38, 743-754.	2.2	12
8606	The FACE test: a new neuropsychological task to assess the recognition of complex mental states from faces. <i>Neurological Sciences</i> , 2023, 44, 2339-2347.	0.9	2
8607	Sex differences in gastrointestinal dysfunction among patients with Parkinson's disease. <i>Neurological Sciences</i> , 0, , .	0.9	0
8608	Comparative validation of AI and non-AI methods in MRI volumetry to diagnose Parkinsonian syndromes. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
8609	Fecal microbiota transplantation in Parkinson's disease—A randomized repeat-dose, placebo-controlled clinical pilot study. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	16
8610	α-Synuclein Seed Amplification Assays in the Diagnosis of Synucleinopathies Using Cerebrospinal Fluid—A Systematic Review and Meta-Analysis. <i>Movement Disorders Clinical Practice</i> , 2023, 10, 737-747.	0.8	9
8611	Whole-genome sequencing reveals an association between small genomic deletions and an increased risk of developing Parkinson's disease. <i>Experimental and Molecular Medicine</i> , 2023, 55, 555-564.	3.2	1
8612	Genetic impacts on nigral iron deposition in Parkinson's disease: A preliminary quantitative susceptibility mapping study. <i>CNS Neuroscience and Therapeutics</i> , 2023, 29, 1776-1784.	1.9	4
8613	Correlations between cerebrospinal fluid homovanillic acid and dopamine transporter SPECT in degenerative parkinsonian syndromes. <i>Journal of Neural Transmission</i> , 2023, 130, 513-520.	1.4	0
8614	Quantitative and causal analysis for inflammatory genes and the risk of Parkinson's disease. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
8615	Amplitude of low-frequency fluctuation-based regional radiomics similarity network: Biomarker for Parkinson's disease. <i>Heliyon</i> , 2023, 9, e14325.	1.4	2
8616	Gene-wide significant association analyses of DNMT1 genetic variants with Parkinson's disease. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	1
8617	Muscle shape changes in Parkinson's disease impair function during rapid contractions. <i>Acta Physiologica</i> , 2023, 238, .	1.8	2
8618	Staging Parkinson's Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life. <i>Journal of Parkinson's Disease</i> , 2023, 13, 379-402.	1.5	0
8620	Central retinal microvasculature damage is associated with orthostatic hypotension in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2023, 9, .	2.5	1
8621	Imagined Timed Up and Go test (iTUG) in people with Parkinson's Disease: test-retest reliability and validity. <i>Disability and Rehabilitation</i> , 2024, 46, 1005-1015.	0.9	0
8622	First Longitudinal Study Using Binaural Beats on Parkinson Disease. <i>International Journal of Neural Systems</i> , 2023, 33, .	3.2	2

#	ARTICLE	IF	CITATIONS
8623	Cytokine profiles of plasma extracellular vesicles as progression biomarkers in Parkinson's disease. <i>Aging</i> , 0, , .	1.4	2
8624	Incidence and outcomes of head injuries in people with and without Parkinson disease. <i>European Journal of Neurology</i> , 0, , .	1.7	0
8625	Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2023, 81, 040-046.	0.3	1
8626	Pharmacological and Behavioral Interventions for Fatigue in Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Geriatric Psychiatry and Neurology</i> , 0, , 089198872311632.	1.2	0
8627	The Assessment of the Diagnostic Delay in Japanese People with Parkinson's Disease Using a Web-based Survey of Patients and Physicians. <i>Internal Medicine</i> , 2023, 62, 839-847.	0.3	1
8628	Mobile Applications for Resting Tremor Assessment in Parkinson's Disease: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2023, 12, 2334.	1.0	1
8630	Clinical Utility of Plantar Pressure Measurements as Screening in Patients With Parkinson Disease With and Without Freezing of Gait History. <i>Archives of Physical Medicine and Rehabilitation</i> , 2023, 104, 1091-1098.	0.5	2
8631	Cognitive evaluation in Parkinson's disease: applying the Movement Disorder Society recommendations in a population with a low level of formal education. <i>Arquivos De Neuro-Psiquiatria</i> , 2023, 81, 119-127.	0.3	1
8632	Long-Term Effects of Subthalamic Stimulation on Motor Symptoms and Quality of Life in Patients with Parkinson's Disease. <i>Healthcare (Switzerland)</i> , 2023, 11, 920.	1.0	1
8633	Increased depressive symptoms in Parkinson's disease during the COVID-19 pandemic: Preliminary findings from longitudinal analysis of the PHASE study. <i>Clinical Parkinsonism & Related Disorders</i> , 2023, 8, 100194.	0.5	0
8634	Quick computer aided differential diagnostics based on repetitive finger tapping in Parkinson's disease and atypical parkinsonisms. <i>Heliyon</i> , 2023, 9, e14824.	1.4	1
8635	Neuropsychological evaluation of phenoconversion risk in REM sleep behaviour disorder: A scoping review. <i>Journal of Sleep Research</i> , 0, , .	1.7	2
8637	The evolution of diagnosis from symptom onset to death in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) compared to Parkinson's disease (PD). <i>Journal of Neurology</i> , 2023, 270, 3464-3474.	1.8	2
8638	Interplay between speech and gait variables in Parkinson's disease patients treated with subthalamic nucleus deep brain stimulation: A long-term instrumental assessment. <i>European Journal of Neurology</i> , 2023, 30, 1963-1972.	1.7	1
8639	Dietary and environmental risk factors in Parkinson's and Alzheimer's disease: A semi-quantitative pilot study. <i>Annals of Indian Academy of Neurology</i> , 2023, 26, 174.	0.2	1
8640	Impulse-control disorders and restless leg syndrome in Parkinson's Disease: Association or coexistence. <i>Annals of Indian Academy of Neurology</i> , 2023, 26, 161.	0.2	4
8641	Severity of REM sleep without atonia correlates with measures of cognitive impairment and depressive symptoms in REM sleep behaviour disorder. <i>Journal of Sleep Research</i> , 2023, 32, .	1.7	4
8643	Prevalence and Factors Associated with Drooling in Parkinson's Disease: Results from a Longitudinal Prospective Cohort and Comparison with a Control Group. <i>Parkinson's Disease</i> , 2023, 2023, 1-18.	0.6	1

#	ARTICLE	IF	CITATIONS
8644	Association between Cognitive Impairment and Freezing of Gait in Patients with Parkinson's Disease. <i>Journal of Clinical Medicine</i> , 2023, 12, 2799.	1.0	6
8645	Association of dysphagia with altered brain glucose metabolism in Parkinson's disease. <i>CNS Neuroscience and Therapeutics</i> , 2023, 29, 2498-2507.	1.9	0
8646	Upregulation of APAF1 and CSF1R in Peripheral Blood Mononuclear Cells of Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7095.	1.8	0
8647	The impact of the COVID-19 pandemic on neuropsychiatric and sleep disorders, and quality of life in individuals with neurodegenerative and demyelinating diseases: a systematic review and meta-analysis of observational studies. <i>BMC Neurology</i> , 2023, 23, .	0.8	0
8648	Comparison of resting tremor at the upper limb joints between patients with Parkinson's disease and scans without evidence of dopaminergic deficit. <i>Technology and Health Care</i> , 2023, 31, 515-523.	0.5	2
8649	The Clinical Diagnosis of Parkinson's Disease "We Are Getting Better. <i>Movement Disorders</i> , 2023, 38, 515-517.	2.2	1
8651	A non-expensive bidimensional assessment can detect subtle alterations in gait performance in people in the early stages of Parkinson's disease. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	1
8652	Visual dysfunction is a better predictor than retinal thickness for dementia in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2023, 94, 742-750.	0.9	6
8653	Effectiveness of Center of Pressure Trajectory as Anticipatory Postural Adjustment Measurement in Parkinson's Disease With Freezing of Gait History. <i>Neurorehabilitation and Neural Repair</i> , 2023, 37, 240-250.	1.4	1
8654	Validation of Commercial Activity Trackers in Everyday Life of People with Parkinson's Disease. <i>Sensors</i> , 2023, 23, 4156.	2.1	3
8684	The Colossal Impact of Machine Learning Models on Parkinson's Disorder: A Comparative Analysis. <i>Cognitive Technologies</i> , 2023, , 215-223.	0.5	0
8693	MetaViT: Metabolism-Aware Vision Transformer for Differential Diagnosis of Parkinsonism with ¹⁸ F-FDG PET. <i>Lecture Notes in Computer Science</i> , 2023, , 132-144.	1.0	1
8734	Extrapyramidale Störungen und neurodegenerative Erkrankungen. , 2023, , 127-174.		0
8740	Neuroprotective effects of saponins on neurodegenerative diseases. , 2023, , 259-282.		0
8744	Depressive symptoms in Parkinson's disease are insufficiently but more often treated than in other chronic conditions. <i>Npj Parkinson's Disease</i> , 2023, 9, .	2.5	1
8755	Capsaicin, The Vanilloid Receptor TRPV1 Agonist in Neuroprotection: Mechanisms Involved and Significance. <i>Neurochemical Research</i> , 2023, 48, 3296-3315.	1.6	9
8758	Graph and Handwriting Signals-Based Machine Learning Models Development in Parkinson's Screening and Telemonitoring. , 2023, , .		2
8764	Pharmacological Treatments of Parkinson's Disease. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2023, , 220-232.	0.1	0

#	ARTICLE	IF	CITATIONS
8766	Autonomic failure: Clinicopathologic, physiologic, and genetic aspects. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 55-102.	1.0	0
8771	Cognitive impairment and dementia in young onset Parkinsonâ€™s disease. Journal of Neurology, 2023, 270, 5793-5812.	1.8	2
8778	Photobiomodulation Therapy for Parkinsonâ€™s Disease. Synthesis Lectures on Biomedical Engineering, 2023, , 191-219.	0.1	0
8790	Volumetric changes and clinical trajectories in Parkinsonâ€™s disease: a prospective multicentric study. Journal of Neurology, 0, , .	1.8	0
8799	Diagnosing Methods of Parkinson's Disease. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 46-63.	0.1	0
8809	Symptomatology and Clinical Features of Parkinson's Disease. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 14-24.	0.1	1
8814	Molecular Imaging of Parkinsonâ€™s Disease. , 0, , .		0
8816	The effects of exercise dose on patients with Parkinsonâ€™s disease: a systematic review and meta-analysis of randomized controlled trials. Journal of Neurology, 2023, 270, 5327-5343.	1.8	4
8820	Synucleinopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 175-202.	1.0	0
8832	Diagnostic value of plasma SIRT1 levels and whole-brain gray matter volume in Parkinsonâ€™s disease patients with cognitive impairment. Neurological Sciences, 0, , .	0.9	0
8848	Video-Based Hand Pose Estimation for Remote Assessment of Bradykinesia in Parkinsonâ€™s Disease. Lecture Notes in Computer Science, 2023, , 241-252.	1.0	0
8861	Postural Tremors. Contemporary Clinical Neuroscience, 2023, , 125-150.	0.3	0
8877	Differentiation of speech in Parkinsonâ€™s disease and spinocerebellar degeneration using deep neural networks. Journal of Neurology, 2024, 271, 1004-1012.	1.8	0
8976	Selection of Gait Parameters for Differential Diagnostics of Patients With De Novo Parkinson's Disease. Advances in Medical Technologies and Clinical Practice Book Series, 2024, , 276-287.	0.3	0